,pubmed_id,title,abstract,keywords,journal,publication_date,authors,methods,conclusions,results,copyrights,doi,xml
0,"38261034
23307732
34922231
36316366
36302379
31257151
33269775
12684452
31531390
24828040
34916524
8787820
18786563
33653950
12498954
35723106
34442795
36741393
19558211
35144890
34216264
11413243
28713158
29467962
22050439
32170061
18692159
34694344
28226226
11160388
8346443
35951647
30182919
10568882
11271377
25561720
25015508
36639608
29775591
26990767
25522431
29540778
27888296
35493431
7886816
36549577
16436595
33264547
22007767
4594185
19290934
1848677
8833434
35447986
25015505
34372568
29196460
33980968
22383755
18828417
33132005
17961138
35668422
27248826
30258234
35782132
2899295
32357266
12846989
28899018
35139081
12666098
33679311
27006278
32375809
10787036
27497484
28765170
22994491
1649907
18981147
18760350
19667183
22302798
1641138
21442038
19404653
34704923
27107797
28602351
10934283
28092376
11478426
12111466
28524175
35925897
37165453
36036863
36669485
29151590
35040520
36598534
20849883
29414327
20205644
31635156
25833819
32577796
35032223
8232937
12707851
11444798
15109580
17850169
18044695
16914866
3399080
17986224
36354180
34355492
25146924
11930028
8015728
7700568
7478158
8888015
35618889
33248159
37046272
36726198
37638996
28921554
21772278
9223513
25800044
36768596
34505378
35458506
11106303
35605280
35364661
35172843
34551810
31585077
32211826
15051507
16816350
35077495
29784049
11444794
31923845
31484320
31240402
34636961
37062012
17478722
22579772
10454636
34058792
33065077
26197842
8798567
12760396
11459001
34015428
36943516
34001896
24509812
34860005
31212939
21777559
33803185
33658354
32823544
32815036
33361610
35579496
22024597
15269317
37023787
27288982
15285801
34116706
35396576
36976485
35892669
20573913
10507986
31089059
19913097
27367905
35740467
36639783
37141688
29049127
32413185
22731384
35918171
27959620
35328814
36853618
27861127
31264132
35208467
23941863
32116554",Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view.,"Fascinatingly, an abundance of recent studies has subscribed to the importance of cytotoxic immune mechanisms that appear to increase the risk/trigger for many progressive neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis, and multiple sclerosis. Events associated with the neuroinflammatory cascades, such as ageing, immunologic dysfunction, and eventually disruption of the blood-brain barrier and the ""cytokine storm"", appear to be orchestrated mainly through the activation of microglial cells and communication with the neurons. The inflammatory processes prompt cellular protein dyshomeostasis. Parkinson's and Alzheimer's disease share a common feature marked by characteristic pathological hallmarks of abnormal neuronal protein accumulation. These Lewy bodies contain misfolded α-synuclein aggregates in PD or in the case of AD, they are Aβ deposits and tau-containing neurofibrillary tangles. Subsequently, these abnormal protein aggregates further elicit neurotoxic processes and events which contribute to the onset of neurodegeneration and to its progression including aggravation of neuroinflammation. However, there is a caveat for exclusively linking neuroinflammation with neurodegeneration, since it's highly unlikely that immune dysregulation is the only factor that contributes to the manifestation of many of these neurodegenerative disorders. It is unquestionably a complex interaction with other factors such as genetics, age, and environment. This endorses the ""multiple hit hypothesis"". Consequently, if the host has a genetic susceptibility coupled to an age-related weakened immune system, this makes them more susceptible to the virus/bacteria-related infection. This may trigger the onset of chronic cytotoxic neuroinflammatory processes leading to protein dyshomeostasis and accumulation, and finally, these events lead to neuronal destruction. Here, we differentiate ""neuroinflammation"" and ""inflammation"" with regard to the involvement of the blood-brain barrier, which seems to be intact in the case of neuroinflammation but defect in the case of inflammation. There is a neuroinflammation-inflammation continuum with regard to virus-induced brain affection. Therefore, we propose a staging of this process, which might be further developed by adding blood- and CSF parameters, their stage-dependent composition and stage-dependent severeness grade. If so, this might be suitable to optimise therapeutic strategies to fight brain neuroinflammation in its beginning and avoid inflammation at all.","['Alzheimer’s disease', 'Cytotoxicity', 'Immunology', 'Inflammation', 'Microglia and neuroinflammation', 'Neurodegeneration', 'Parkinson’s disease', 'Viruses']","Journal of neural transmission (Vienna, Austria : 1996)",2024-01-23,"[{'lastname': 'Sian-Hulsmann', 'firstname': 'Jeswinder', 'initials': 'J', 'affiliation': 'Department of Human Anatomy and Medical Physiology, University of Nairobi, P.O. Box 30197, Nairobi, 00100, Kenya.'}, {'lastname': 'Riederer', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'University Hospital Wuerzburg, Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy Margarete-Höppel-Platz 1, 97080, Würzburg, Germany. jntspringer@web.de.\nDepartment of Psychiatry, University of Southern Denmark, Winslows Vey 18, 5000, Odense, J.B, Denmark. jntspringer@web.de.'}]",,,,© 2024. The Author(s).,"10.1007/s00702-023-02723-5
10.1126/science.1227901.PMID:23307732;PMCID:PMC4431634
10.1016/j.ajem.2021.02.050
10.1038/s41380-022-01831-0
10.1177/1535370215619707
10.1002/ca.980080612
10.3389/fimmu.2018.02379
10.3390/ijms24031869
10.1155/2013/683920
10.1515/revneuro-2022-0087
10.1016/j.cmet.2019.06.005
10.4103/1673-5374.300437
10.1523/jneurosci.23-07-02665.2003
10.1038/s41531-019-0090-8
10.1128/jvi.02949-15
10.1016/j.jadr.2023.100521
10.1038/nature13324
10.1038/s41467-021-27737-z
10.3389/fnagi.2022.879021
10.1016/0304-3940(95)12192-7
10.1016/j.pharmthera.2008.08.002
10.1073/pnas.2009579118
10.1016/s0197-4580(02)00065-9
10.3233/JAD-220361
10.3390/microorganisms9081716.PMID:34442795;PMCID:PMC8398509
10.3389/fimmu.2022.856376.PMID:35558075;PMCID:PMC9086828
10.3233/jad-220287
10.1089/ars.2009.2721
10.1016/j.tim.2022.01.004
10.1007/s00415-021-10694-4
10.1046/j.1471-4159.2001.00374.x
10.1038/aps.2017.28
10.18632/oncotarget.23208
10.3389/fphys.2020.00598
10.1111/j.1471-4159.2011.07572.x
10.1038/s41467-020-15119-w.PMID:32170061;PMCID:PMC7069981
10.1016/j.arr.2008.07.002
10.1007/s00018-020-03656-y
10.3389/fimmu.2017.00782.PMID:28740490;PMCID:PMC5502347
10.1001/jamaneurol.2021.3895
10.1146/annurev-immunol-051116-052358
10.1523/jneurosci.21-04-01179.2001
10.1007/s11356-021-16737-7
10.1126/science.8346443
10.1073/pnas.2200960119.PMID:35951647;PMCID:PMC9436354
10.4269/ajtmh.18-0420
10.3109/13550289909045374
10.1007/s004010000313
10.3389/fmicb.2022.789882.PMID:35222327;PMCID:PMC8870622
10.1101/cshperspect.a020412
10.1016/B978-0-444-53488-0.00030-4
10.1038/s41579-022-00846-2
10.1016/j.cell.2018.05.003
10.1111/jnc.13607
10.1093/ijnp/pyu103.PMID:25522431;PMCID:PMC4438545
10.1038/s41419-018-0437-9
10.1007/s00401-016-1648-8
10.3892/etm.2022.11290
10.1016/0165-6147(94)90057-4
10.1016/j.bbi.2022.12.013
10.1523/jneurosci.3863-05.2006
10.1056/NEJMra2026131.PMID:33264547;PMCID:PMC7727315
10.1111/j.1471-4159.2011.07541.x
10.3389/fimmu.2019.01412
10.1073/pnas.1604032113
10.1111/j.1600-065x.2008.00754.x
10.1002/mds.870060103
10.1146/annurev.ne.19.030196.000245
10.3390/brainsci12040456
10.1016/B978-0-444-53488-0.00027-4
10.3390/v13071362.PMID:34372568;PMCID:PMC8310017
10.1007/s00281-017-0636-y
10.1083/jcb.201709069
10.1038/s41598-021-89586-6.PMID:33980968;PMCID:PMC8115602
10.1101/cshperspect.a011205
10.1177/003335490812300512
10.1016/j.it.2020.10.004
10.1111/j.1365-2990.2007.00874.x
10.1186/s12974-022-02496-w
10.18632/oncotarget.9633
10.1038/s41593-018-0242-x
10.3389/fcimb.2022.887800
10.1038/334345a0
10.1002/mds.28075
10.1111/j.1749-6632.2003.tb07478.x
10.1093/brain/awx177
10.1371/journal.pntd.0010118
10.1002/ana.10481
10.3389/fnins.2021.630502
10.3389/fcimb.2023.1181315.PMID:37197200;PMCID:PMC10183572
10.1016/j.bbi.2016.03.014
10.1186/s12974-020-01820-6.PMID:32375809;PMCID:PMC7203856
10.1007/s004010051139
10.3233/JAD-160607
10.1096/fj.201700360
10.1146/annurev-micro-092611-150203.PMID:22994491;PMCID:PMC3549330
10.1016/b978-0-444-53488-0.00029-8
10.1002/jmv.1890330403
10.4049/jimmunol.181.10.7254
10.1016/j.bbadis.2008.08.001
10.1073/pnas.0900096106
10.1523/JNEUROSCI.5123-11.2012.PMID:22302798;PMCID:PMC3307392
10.1136/jnnp-2019-322338
10.1212/WNL.42.8.1472
10.1177/1947601910397187
10.1007/s00401-009-0537-9
10.1099/jgv.0.001667.PMID:34704923;PMCID:PMC8604193
10.1016/j.pneurobio.2016.04.006
10.1016/j.molmed.2007.09.002
10.1016/j.cell.2017.05.018
10.1523/JNEUROSCI.20-16-06309.2000.PMID:10934283;PMCID:PMC6772569
10.1038/ni.3656
10.1007/s007020170051
10.1007/s007020200063
10.3389/fnagi.2017.00365
10.1038/nrneurol.2017.69
10.1371/journal.ppat.1010670
10.1186/s40478-023-01566-1.PMID:37165453;PMCID:PMC10170054
10.1007/s00702-022-02536-y
10.1016/j.neuron.2022.12.029
10.1038/nri.2017.125
10.3389/fneur.2019.00652.PMID:31275235;PMCID:PMC6593078
10.1002/mds.28925
10.1007/s00011-022-01676-x
10.1016/j.bbamcr.2010.09.004
10.1016/j.cyto.2018.01.025
10.2174/187152710791012071
10.3390/v11100966
10.1093/brain/awv081
10.1007/s00018-020-03561-4
10.1186/s13244-021-01144-w.PMID:35032223;PMCID:PMC8760871
10.1212/wnl.43.11.2245
10.1080/13550280390194109
10.1093/jnen/60.7.696
10.1016/j.parkreldis.2004.01.005
10.2165/00023210-200721100-00001
10.1002/mds.21751
10.3233/jad-2006-9s330
10.1212/wnl.38.8.1285
10.1155/2008/517162
10.1111/j.1471-4159.2007.05007.x
10.1021/acs.jpclett.2c02278
10.1111/acel.13440
10.1038/cdd.2014.123
10.1136/pmj.78.918.238
10.1016/0304-3940(94)90746-3
10.1016/0304-3940(94)90508-8
10.1016/0304-3940(95)11686-Q
10.1007/BF02252965
10.1016/0304-3940(95)11686-Q
10.1016/0304-3940(96)12961-X
10.1038/s41380-022-01619-2
10.1016/j.neulet.2020.135528
10.1186/s12979-023-00341-z
10.1080/17512433.2023.2176301
10.1007/s00702-023-02617-6
10.1111/jnc.14222
10.1038/ni.2065
10.1128/JVI.71.8.6179-6182.1997.PMID:9223513;PMCID:PMC191879
10.1111/bph.13139
10.3390/ijms24032272
10.1002/wps.20913
10.3390/v14040776
10.1177/026988110001400309
10.3389/fphar.2014.00097.PMID:24847267;PMCID:PMC4019841
10.1152/physrev.00005.2022
10.31083/j.jin2102073
10.1186/s12974-022-02410-4.PMID:35172843;PMCID:PMC8848816
10.1186/s12974-021-02252-6.PMID:34551810;PMCID:PMC8459490
10.1016/j.jns.2022.120162
10.1016/j.cell.2019.08.053
10.1084/jem.20190062.PMID:32211826;PMCID:PMC7144528
10.1016/j.brainres.2007.09.063
10.1016/j.yexcr.2004.01.002
10.1183/09031936.06.00053805
10.1371/journal.pone.0262438.PMID:35077495;PMCID:PMC8789122
10.1186/s13024-018-0254-8.PMID:29784049;PMCID:PMC5963076
10.3389/fcell.2021.673395
10.1093/jnen/60.7.663
10.1016/j.biomaterials.2019.119752
10.3390/jcm8091377
10.1007/s00702-019-02025-9
10.1007/s00702-021-02414-z
10.1007/s00702-023-02630-9
10.1126/science.1141736
10.1016/j.nbd.2012.04.014
10.1093/nar/27.16.3291
10.1053/spid.2003.127223
10.1002/glia.24033
10.1016/j.expneurol.2020.113506
10.1093/cid/civ606
10.1002/lary.29286
10.1074/jbc.271.38.23572
10.1007/s11910-003-0087-9
10.1007/s007020070012
10.1016/j.bbi.2021.05.013
10.1007/s00415-023-11661-x
10.1038/s41467-021-23088-x.PMID:34001896;PMCID:PMC8129091
10.3390/v6020606
10.1021/acschemneuro.1c00666
10.3390/v11060560
10.1016/j.ajpath.2011.05.047
10.3390/cells10030598.PMID:33803185;PMCID:PMC8000327
10.1126/scitranslmed.aaz4564.PMID:33658354;PMCID:PMC8218593
10.3389/fncel.2013.00006
10.3390/antiox9080743
10.1007/s00428-020-02903-8
10.3233/JPD-202279.PMID:33361610;PMCID:PMC7990414
10.1002/mds.29116
10.1016/j.brainresbull.2011.10.004
10.1056/nejmra030476
10.1055/s-0043-1767716
10.1016/j.neuropharm.2016.06.009
10.1007/s10875-014-0034-3
10.1186/1742-2094-1-14
10.1038/s41531-020-00123-0.PMID:32885037;PMCID:PMC7441399
10.1186/s12974-021-02182-3.PMID:34116706;PMCID:PMC8196535
10.1038/s12276-022-00755-7
10.1007/s10787-023-01197-x
10.3390/biomedicines10081769.PMID:35892669;PMCID:PMC9331936
10.1523/JNEUROSCI.1860-10.2010.PMID:20573913;PMCID:PMC2902258
10.7883/yoken.52.89
10.4103/1673-5374.255975
10.1016/j.nbd.2009.11.004
10.2174/1570159x18666200429001549
10.3389/fcimb.2017.00276.PMID:28676848;PMCID:PMC5476750
10.1001/jamaneurol.2016.1043
10.3390/biomedicines10061446.PMID:35740467;PMCID:PMC9221078
10.1186/s12977-023-00616-9.PMID:36639783;PMCID:PMC9840342
10.1016/j.parkreldis.2023.105433
10.3389/fnagi.2022.1102613.PMID:36570539;PMCID:PMC9782399
10.1097/MEG.0000000000000991
10.1002/mds.28015
10.1186/1742-2094-9-143
10.1212/WNL.0000000000201095
10.1146/annurev-physiol-022516-034406
10.1111/jvh.12392
10.3390/ijms23063394.PMID:35328814;PMCID:PMC8949667
10.1002/mds.29363
10.15252/emmm.201606566.PMID:27861127;PMCID:PMC5210088
10.1007/s10787-019-00613-5
10.1111/febs.16344
10.3390/medicina58020144.PMID:35208467;PMCID:PMC8876409
10.1159/000351221
10.1155/2019/1409582
10.3389/fncel.2018.00531",<Element 'PubmedArticle' at 0x7f05df3838b0>
1,38246483,Alzheimer's disease biomarker analysis using targeted mass spectrometry.,"Alzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.",[],Molecular & cellular proteomics : MCP,2024-01-22,"[{'lastname': 'Gobom', 'firstname': 'Johan', 'initials': 'J', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. Electronic address: johan.gobom@neuro.gu.se.'}, {'lastname': 'Brinkmalm', 'firstname': 'Ann', 'initials': 'A', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'lastname': 'Brinkmalm', 'firstname': 'Gunnar', 'initials': 'G', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': ""Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: henrik.zetterberg@gu.se.""}]",,,,Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.mcpro.2024.100721,<Element 'PubmedArticle' at 0x7f05df38a450>
2,"38228892
27012484
12399581
1789684
8811505
23432720
33307047
33459642
31779518
22006270
12740129
36692274
35397615
28367951
34772450
34120905
30237073
21889116
36092715
28283575
22568827
34487044
22035587
15232109
11572944
27466341
15465911
17610578
16959793
22848456
26084473
11016969
15564582
22375104
2360787
25851548
25394486
26696824
17360908
29843241
37192625
28696204
28123806
31161981
35690535
34556565
2269883
9396008
15803158
19809472
20875798
25533203
26366630
26373605
26136856
26092348
27018940
27531278
29580670
31097472
28170377
29177427
26250687
24439167
24987465
24392009
30055132
21757905
30826968
33579836
36451155
37052206
37186338
26402751
11173883
18703769
27068280
21823155
23800322
26836160
25867677
22357717
24598588
31939203
27716408
27047369
25418885
30846386
36964594
24647228
9023877
30321501
34460014
28440221
32807227
37345460
21983241
28135241
11986126
35573314
33891195
30014145
31468182
31728839
30084043
24412275
35606871
27601437
29025866
32801201
32350238
36504237
36045450
37550416
37177386
32365890
29630555",Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives.,"Alzheimer's disease (AD) is currently constrained by limited clinical treatment options. The initial pathophysiological event, which can be traced back to decades before the clinical symptoms become apparent, involves the excessive accumulation of amyloid-beta (Aβ), a peptide comprised of 40-42 amino acids, in extraneuronal plaques within the brain. Biochemical and histological studies have shown that overaccumulation of Aβ instigates an aberrant escalation in the phosphorylation and secretion of tau, a microtubule-binding axonal protein. The accumulation of hyperphosphorylated tau into intraneuronal neurofibrillary tangles is in turn correlated with microglial dysfunction and reactive astrocytosis, culminating in synaptic dysfunction and neurodegeneration. As neurodegeneration progresses, it gives rise to mild clinical symptoms of AD, which may eventually evolve into overt dementia. Synaptic loss in AD may develop even before tau alteration and in response to possible elevations in soluble oligomeric forms of Aβ associated with early AD. These findings largely rely on post-mortem autopsy examinations, which typically involve a limited number of patients. Over the past decade, a range of fluid biomarkers such as neurogranin, α-synuclein, visinin-like protein 1 (VILIP-1), neuronal pentraxin 2, and β-synuclein, along with positron emission tomography (PET) markers like synaptic vesicle glycoprotein 2A, have been developed. These advancements have facilitated the exploration of how synaptic markers in AD patients correlate with cognitive impairment. However, fluid biomarkers indicating synaptic loss have only been validated in cerebrospinal fluid (CSF), not in plasma, with the exception of VILIP-1. The most promising PET radiotracer, [",[],Molecular psychiatry,2024-01-17,"[{'lastname': 'Lista', 'firstname': 'Simone', 'initials': 'S', 'affiliation': 'i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012, Valladolid, Spain. slista@uemc.es.'}, {'lastname': 'Santos-Lozano', 'firstname': 'Alejandro', 'initials': 'A', 'affiliation': ""i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012, Valladolid, Spain.\nPhysical Activity and Health Research Group (PaHerg), Research Institute of the Hospital 12 de Octubre ('imas12'), 28041, Madrid, Spain.""}, {'lastname': 'Emanuele', 'firstname': 'Enzo', 'initials': 'E', 'affiliation': '2E Science, 27038, Robbio, Italy.'}, {'lastname': 'Mercuri', 'firstname': 'Nicola B', 'initials': 'NB', 'affiliation': 'Experimental Neurology Laboratory, IRCCS Santa Lucia Foundation, 00143, Rome, Italy.\nDepartment of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.'}, {'lastname': 'Gabelle', 'firstname': 'Audrey', 'initials': 'A', 'affiliation': 'CMRR, Memory Resources and Research Center, Montpellier University of Excellence i-site, 34295, Montpellier, France.'}, {'lastname': 'López-Ortiz', 'firstname': 'Susana', 'initials': 'S', 'affiliation': 'i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012, Valladolid, Spain.'}, {'lastname': 'Martín-Hernández', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012, Valladolid, Spain.'}, {'lastname': 'Maisto', 'firstname': 'Nunzia', 'initials': 'N', 'affiliation': 'Laboratory of Pharmacology of Synaptic Plasticity, EBRI Rita Levi-Montalcini Foundation, 00143, Rome, Italy.\nDepartment of Physiology and Pharmacology ""V. Erspamer"", Sapienza University of Rome, 00185, Rome, Italy.'}, {'lastname': 'Imbimbo', 'firstname': 'Camillo', 'initials': 'C', 'affiliation': 'Department of Brain and Behavioral Sciences, University of Pavia, 27100, Pavia, Italy.'}, {'lastname': 'Caraci', 'firstname': 'Filippo', 'initials': 'F', 'affiliation': 'Department of Drug and Health Sciences, University of Catania, 95125, Catania, Italy.\nNeuropharmacology and Translational Neurosciences Research Unit, Oasi Research Institute-IRCCS, 94018, Troina, Italy.'}, {'lastname': 'Imbimbo', 'firstname': 'Bruno P', 'initials': 'BP', 'affiliation': 'Department of Research and Development, Chiesi Farmaceutici, 43122, Parma, Italy.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': ""Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, 431 80, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 80, Mölndal, Sweden.\nDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, WC1N, London, UK.\nUK Dementia Research Institute at UCL, WC1E 6BT, London, UK.\nHong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.\nWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, 53726, WI, USA.""}, {'lastname': 'Nisticò', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Laboratory of Pharmacology of Synaptic Plasticity, EBRI Rita Levi-Montalcini Foundation, 00143, Rome, Italy. robert.nistico@uniroma2.it.\nSchool of Pharmacy, University of Rome ""Tor Vergata"", 00133, Rome, Italy. robert.nistico@uniroma2.it.'}]",,,,"© 2024. The Author(s), under exclusive licence to Springer Nature Limited.","10.1038/s41380-023-02376-6
10.1016/j.jalz.2016.02.002
10.1126/science.1074069
10.1002/ana.410300410
10.1007/BF01273157
10.2174/1381612811319360001
10.3389/fphar.2019.00778
10.1016/j.neubiorev.2020.12.003
10.3233/JAD-201178
10.1177/1073858419882619
10.1007/s00221-011-2894-6
10.1098/rstb.2002.1240
10.1111/ene.15691
10.1038/s41398-022-01901-5
10.1038/ncomms14727
10.1186/s13195-021-00925-1
10.3233/JAD-210171
10.1016/j.neurobiolaging.2018.08.012
10.1016/j.jalz.2011.05.2410
10.3389/fcell.2022.964075
10.1074/jbc.M116.761189
10.1021/pr300021e
10.3233/JAD-210585
10.1016/j.neurobiolaging.2011.09.021
10.1126/science.1098180
10.1073/pnas.211412398
10.1523/JNEUROSCI.0775-16.2016
10.1073/pnas.0406283101
10.1111/j.1460-9568.2007.05569.x
10.1093/hmg/ddl242
10.1074/mcp.RA118.001290
10.1371/journal.pone.0041275
10.1038/srep11135
10.1073/pnas.210184697
10.1523/JNEUROSCI.2213-04.2004
10.3389/fnmol.2012.00020
10.1002/ana.410270502
10.1186/s13195-020-00588-4
10.1177/1177271920950319
10.1017/S1041610215000447
10.1186/1750-1326-9-48
10.3389/fncel.2015.00464
10.1523/JNEUROSCI.4970-06.2007
10.3233/JAD-179941
10.1016/j.neuron.2023.04.020
10.7554/eLife.26991
10.1515/tnsci-2015-0023
10.2174/1570159X17666190603170511
10.1016/j.semcdb.2022.05.028
10.1212/WNL.0000000000012853
10.1523/JNEUROSCI.10-12-03782.1990
10.1007/BF02740632
10.1038/nrn1647
10.1038/emboj.2009.273
10.1016/j.brainres.2010.09.073
10.1016/j.jalz.2014.10.009
10.1001/jamaneurol.2015.1867
10.1093/brain/awv267
10.1186/s13195-015-0124-3
10.1016/j.jalz.2015.05.012
10.1001/jamaneurol.2016.0086
10.1007/s00702-016-1597-3
10.3233/JAD-170368
10.1016/j.jalz.2018.01.012
10.1136/jnnp-2018-320155
10.1038/nm.4269
10.1093/brain/awx275
10.1126/science.1255555
10.1016/j.jalz.2013.10.004
10.1186/alzrt255
10.1371/journal.pone.0085443
10.1016/j.jalz.2018.06.3053
10.1159/000329763
10.1007/s12035-019-1531-4
10.3233/JAD-201038
10.1074/mcp.M116.059915
10.1186/s13195-022-01125-1
10.1002/alz.13046
10.1002/alz.13103
10.3233/JAD-150060
10.1159/000051244
10.1373/clinchem.2008.104497
10.1016/S1474-4422(16)00070-3
10.1002/ana.22448
10.1111/jnc.12331
10.3233/JAD-150705
10.1001/jamaneurol.2015.0202
10.1212/WNL.0b013e318248e568
10.1126/scitranslmed.3007901
10.1007/s40520-019-01458-2
10.1186/s13195-016-0208-8
10.3389/fnsyn.2016.00007
10.1186/1750-1326-9-53
10.1186/s13195-018-0407-6
10.1016/j.jalz.2018.12.019
10.1186/s13195-023-01212-x
10.1371/journal.pone.0092624
10.1016/S0166-2236(96)10072-2
10.1016/j.jalz.2018.08.006
10.1007/s00702-021-02411-2
10.7554/eLife.23798
10.1186/s13024-020-00398-0
10.1002/ana.26725
10.1016/j.neurobiolaging.2011.09.007
10.1038/nn.4492
10.1176/appi.ajp.159.5.738
10.3389/fnins.2022.864514
10.1186/s40658-021-00384-5
10.1001/jamaneurol.2018.1836
10.1007/s00259-019-04461-x
10.1007/s11307-019-01428-0
10.1007/s11307-018-1260-5
10.1016/j.bcp.2013.12.028
10.1186/s13195-022-01014-7
10.1096/fj.201600816R
10.1096/fj.201700731R
10.1136/bmjopen-2020-036990
10.1038/s41398-020-0801-2
10.1002/mds.29287
10.1186/s13195-022-01042-3
10.1016/j.mcpro.2023.100542
10.1038/s41591-023-02476-4
10.3390/s23094184
10.3390/jpm10020034
10.3233/JAD-180063",<Element 'PubmedArticle' at 0x7f05df3a0950>
3,38176932,The Pathogenesis in Alzheimer's Disease: TREM2 as a Potential Target.,"Alzheimer's disease (AD) is ranked as the third-most expensive illness and sixth leading cause of mortality. It is associated with the deposition of extracellular amyloid-β (Aβ) in neural plaques (NPs), as well as intracellular hyperphosphorylated tau proteins that form neurofibrillary tangles (NFTs). As a new target in regulating neuroinflammation in AD, triggering receptor expressed on myeloid cells 2 (TREM2) is highly and exclusively expressed on the microglial surface. TREM2 interacts with adaptor protein DAP12 to initiate signal pathways that mainly dominant microglia phenotype and phagocytosis mobility. Furthermore, ","['AD', 'TREM2', 'neuroinflammation', 'pathogenesis']",Journal of integrative neuroscience,2024-01-05,"[{'lastname': 'Liu', 'firstname': 'Guangtong', 'initials': 'G', 'affiliation': 'Department of Physical Education, Henan Normal University, 453007 Xinxiang, Henan, China.'}, {'lastname': 'Zhang', 'firstname': 'Linlin', 'initials': 'L', 'affiliation': 'Department of Physical Education, Henan Normal University, 453007 Xinxiang, Henan, China.'}, {'lastname': 'Fan', 'firstname': 'Yongzhao', 'initials': 'Y', 'affiliation': 'Department of Physical Education, Henan Normal University, 453007 Xinxiang, Henan, China.'}, {'lastname': 'Ji', 'firstname': 'Wenliang', 'initials': 'W', 'affiliation': 'College of Chemistry, Beijing Normal University, 100875 Beijing, China.'}]",,,,© 2023 The Author(s). Published by IMR Press.,10.31083/j.jin2206150,<Element 'PubmedArticle' at 0x7f05df8b9a90>
4,"38167557
31375134
27540968
10220456
2011243
35392986
9224523
35895141
26638867
26057852
29880901
28814675
20550967
36773106
28774322
30593285
23300938
36480077
36076283
31551688
33606195
31914225
19624097
23397619
26074756
26807101
32799317
28926133
1759558
31884473
24728269
9100663
26436904
22057275
25130657
28662669
27377630
35431903",The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer's disease patients and App,"Amyloid beta (Aβ) deposits and hyperphosphorylated tau (p-tau) accumulation have been identified in the retina of Alzheimer's disease (AD) patients and transgenic AD mice. Previous studies have shown that retinal microglia engulf Aβ, but this property decreases in AD patients. Whether retinal microglia also take up p-tau and if this event is affected in AD is yet not described. In the current study, we use the p-tau-specific thiophene-based ligand bTVBT2 to investigate the relationship between disease progression and p-tau uptake by microglia in the retina of AD patients and App
Evaluation of bTVBT2 specificity and its presence within microglia was assessed by immunofluorescent staining of hippocampal sections and flat-mount retina samples from non-demented controls, AD patients, 3-, 9-, and 12-month-old App
Confocal imaging analysis showed that bTVBT2 binds to PHF-1- and AT8-positive aggregates inside retinal microglia, and not to Aβ, pTDP-43, or IAPP. The density of bTVBT2-positive microglia was higher in cases with a high Aβ load compared to those with a low Aβ load. This density correlated with the neurofibrillary tangle load in the brain, but not with retinal levels of high molecular weight (aggregated) Aβ40 or Aβ42. Analysis of App
Our study suggests that the microglial capability to uptake p-tau in the retina persists and intensifies with AD progression. These results also highlight bTVBT2 as a ligand of interest in future monitoring of retinal AD pathology.","['Alzheimer’s disease', 'Retina', 'Tauopathy', 'Thiophene-based ligands']",Alzheimer's research & therapy,2024-01-04,"[{'lastname': 'Nuñez-Diaz', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.'}, {'lastname': 'Andersson', 'firstname': 'Emelie', 'initials': 'E', 'affiliation': 'Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.'}, {'lastname': 'Schultz', 'firstname': 'Nina', 'initials': 'N', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.\nClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.'}, {'lastname': 'Pocevičiūtė', 'firstname': 'Dovilė', 'initials': 'D', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.'}, {'lastname': 'Hansson', 'firstname': 'Oskar', 'initials': 'O', 'affiliation': 'Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.\nMemory Clinic, Skåne University Hospital, Malmö, Sweden.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Nilsson', 'firstname': 'K Peter R', 'initials': 'KPR', 'affiliation': 'Department of Physics, Chemistry and Biology IFM, Linköping University, 581 83, Linköping, Sweden.'}, {'lastname': 'Wennström', 'firstname': 'Malin', 'initials': 'M', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. malin.wennstrom@med.lu.se.'}]",,Our study suggests that the microglial capability to uptake p-tau in the retina persists and intensifies with AD progression. These results also highlight bTVBT2 as a ligand of interest in future monitoring of retinal AD pathology.,"Confocal imaging analysis showed that bTVBT2 binds to PHF-1- and AT8-positive aggregates inside retinal microglia, and not to Aβ, pTDP-43, or IAPP. The density of bTVBT2-positive microglia was higher in cases with a high Aβ load compared to those with a low Aβ load. This density correlated with the neurofibrillary tangle load in the brain, but not with retinal levels of high molecular weight (aggregated) Aβ40 or Aβ42. Analysis of App",© 2023. The Author(s).,"10.1186/s13195-023-01375-7
10.1186/s13024-019-0333-5
10.3233/JAD-160365
10.1073/pnas.96.9.5274
10.1186/s13024-022-00533-z
10.1007/s004010050664
10.1007/s00401-022-02469-6
10.3233/JAD-150704
10.1038/srep11161
10.1038/s41419-018-0740-5
10.1016/j.neuroimage.2010.06.020
10.1007/s00401-023-02548-2
10.1186/s13024-017-0199-3
10.1186/s40478-018-0650-x
10.1371/journal.pone.0053547
10.1186/s40478-022-01439-z
10.3389/fnins.2019.00925
10.1007/s12035-021-02316-x
10.1002/alz.12006
10.1021/cb900112v
10.1007/978-1-4614-4711-5_3
10.3389/fnins.2015.00184
10.4103/1673-5374.165298
10.1111/jnc.15148
10.1002/chem.201703846
10.1007/BF00308809
10.3233/JAD-190868
10.1038/nn.3697
10.1097/00005072-199704000-00001
10.1038/nn.4132
10.1074/jbc.M111.277061
10.1186/s13024-017-0192-x
10.1016/j.nlm.2016.07.001
10.3389/fnagi.2022.868448",<Element 'PubmedArticle' at 0x7f05df8a22c0>
5,38043010,Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer's Disease.,"Alzheimer's disease is a pervasive neurodegenerative disease that is estimated to represent approximately 70% of dementia cases worldwide, and the molecular complexity that has been highlighted remains poorly understood. The accumulation of extracellular amyloid-β (Aβ), intracellular neurofibrillary tangles formed by tau hyperphosphorylation, and neuroinflammation are the major pathological features of Alzheimer's disease (AD). Over the years, there has been no apparent breakthrough in drug discovery based on the Aβ and tau hypotheses. Neuroinflammation has gradually become a hot spot in AD treatment research. As the primary cells of innate immunity in the central nervous system, microglia play a key role in neuroinflammation. Toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain-like receptor 3 (NLRP3) inflammasomes are vital molecules in neuroinflammation. In the pathological context of AD, the complex interplay between TLR4 and the NLRP3 inflammasomes in microglia influences AD pathology via neuroinflammation. In this review, the effect of the activation and inhibition of TLR4 and NLRP3 in microglia on AD pathology, as well as the cross-talk between TLR4 and the NLRP3 inflammasome, and the influence of essential molecules in the relevant signaling pathway on AD pathology, were expounded. In addition, the feasibility of these factors in representing a potential treatment option for AD has been clarified.","['Alzheimer’s disease', 'NLRP3 inflammasomes', 'TLR4', 'microglia']",Journal of Alzheimer's disease : JAD,2023-12-03,"[{'lastname': 'Li', 'firstname': 'Yunfeng', 'initials': 'Y', 'affiliation': 'Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.\nDepartment of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.'}, {'lastname': 'Chen', 'firstname': 'Xiongjin', 'initials': 'X', 'affiliation': 'Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.\nDepartment of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.'}, {'lastname': 'Zhou', 'firstname': 'Mulan', 'initials': 'M', 'affiliation': ""Department of Pharmacy, The People's Hospital of Gaozhou, Maoming, China.""}, {'lastname': 'Feng', 'firstname': 'Sifan', 'initials': 'S', 'affiliation': 'Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.\nDepartment of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.'}, {'lastname': 'Peng', 'firstname': 'Xiaoping', 'initials': 'X', 'affiliation': 'Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.\nDepartment of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.'}, {'lastname': 'Wang', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.'}]",,,,,10.3233/JAD-230273,<Element 'PubmedArticle' at 0x7f05df2b7e00>
6,"38036535
31564456
26871627
29653606
27025652
35379992
30617256
30820047
28097204
29632380
32341526
29785013
36749789
28099414
36732642
31157827
30857563
28441426
25495832
32844198
34446931
34160128
25188341
34002480
32568366
29340569
23708142
21391232
30992433
30689776
27385740
29592889
31078131
34308291
27422368
32994401
32464432
29865057
24648338
30992449
31324783
31042697
8532113
22229116
22265587
22655212
19381658
33742668
30679421
17886233
24886908
35649652
32772265
37336975
35165441
22054870
17568013
12552039
15023815
9330978
32250387
37458272
16906426
26505746
30084846
17701901
16862161
27694958
27571263
27548312
26432245
20811451
25722852
34475573
28506277
28645171",Cell-type-specific Alzheimer's disease polygenic risk scores are associated with distinct disease processes in Alzheimer's disease.,"Many of the Alzheimer's disease (AD) risk genes are specifically expressed in microglia and astrocytes, but how and when the genetic risk localizing to these cell types contributes to AD pathophysiology remains unclear. Here, we derive cell-type-specific AD polygenic risk scores (ADPRS) from two extensively characterized datasets and uncover the impact of cell-type-specific genetic risk on AD endophenotypes. In an autopsy dataset spanning all stages of AD (n = 1457), the astrocytic ADPRS affected diffuse and neuritic plaques (amyloid-β), while microglial ADPRS affected neuritic plaques, microglial activation, neurofibrillary tangles (tau), and cognitive decline. In an independent neuroimaging dataset of cognitively unimpaired elderly (n = 2921), astrocytic ADPRS was associated with amyloid-β, and microglial ADPRS was associated with amyloid-β and tau, connecting cell-type-specific genetic risk with AD pathology even before symptom onset. Together, our study provides human genetic evidence implicating multiple glial cell types in AD pathophysiology, starting from the preclinical stage.",[],Nature communications,2023-12-01,"[{'lastname': 'Yang', 'firstname': 'Hyun-Sik', 'initials': 'HS', 'affiliation': ""Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA. hyang18@bwh.harvard.edu.\nDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA. hyang18@bwh.harvard.edu.\nHarvard Medical School, Boston, MA, USA. hyang18@bwh.harvard.edu.\nBroad Institute of MIT and Harvard, Cambridge, MA, USA. hyang18@bwh.harvard.edu.""}, {'lastname': 'Teng', 'firstname': 'Ling', 'initials': 'L', 'affiliation': ""Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.\nBroad Institute of MIT and Harvard, Cambridge, MA, USA.""}, {'lastname': 'Kang', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'lastname': 'Menon', 'firstname': 'Vilas', 'initials': 'V', 'affiliation': ""Center for Translational & Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.\nDepartment of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'Ge', 'firstname': 'Tian', 'initials': 'T', 'affiliation': 'Harvard Medical School, Boston, MA, USA.\nBroad Institute of MIT and Harvard, Cambridge, MA, USA.\nPsychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.\nCenter for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.'}, {'lastname': 'Finucane', 'firstname': 'Hilary K', 'initials': 'HK', 'affiliation': 'Harvard Medical School, Boston, MA, USA.\nBroad Institute of MIT and Harvard, Cambridge, MA, USA.\nDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.'}, {'lastname': 'Schultz', 'firstname': 'Aaron P', 'initials': 'AP', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.\nHarvard Medical School, Boston, MA, USA.'}, {'lastname': 'Properzi', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.'}, {'lastname': 'Klein', 'firstname': 'Hans-Ulrich', 'initials': 'HU', 'affiliation': ""Center for Translational & Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.\nDepartment of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'Chibnik', 'firstname': 'Lori B', 'initials': 'LB', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.\nBroad Institute of MIT and Harvard, Cambridge, MA, USA.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'lastname': 'Schneider', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.""}, {'lastname': 'Bennett', 'firstname': 'David A', 'initials': 'DA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.""}, {'lastname': 'Hohman', 'firstname': 'Timothy J', 'initials': 'TJ', 'affiliation': 'Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'lastname': 'Mayeux', 'firstname': 'Richard P', 'initials': 'RP', 'affiliation': ""Department of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'Johnson', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': ""Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.\nDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.\nHarvard Medical School, Boston, MA, USA.\nDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.""}, {'lastname': 'De Jager', 'firstname': 'Philip L', 'initials': 'PL', 'affiliation': ""Center for Translational & Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.\nDepartment of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'Sperling', 'firstname': 'Reisa A', 'initials': 'RA', 'affiliation': ""Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.\nDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.\nHarvard Medical School, Boston, MA, USA.""}]",,,,© 2023. The Author(s).,"10.1038/s41467-023-43132-2
10.1016/j.cell.2019.09.001
10.1016/j.cell.2015.12.056
10.1016/j.jalz.2018.02.018
10.15252/emmm.201606210
10.1038/s41588-022-01024-z
10.1038/s41588-018-0311-9
10.1038/s41588-019-0358-2
10.1002/acn3.369
10.1038/s41588-018-0081-4
10.1038/s41588-020-0610-9
10.1038/s41588-018-0129-5
10.1038/nature21029
10.1001/jamaneurol.2019.1424
10.1186/s13195-019-0479-y
10.1371/journal.pmed.1002287
10.1037/neu0000159
10.1093/brain/awaa209
10.1038/s41591-021-01456-w
10.1002/alz.12399
10.1371/journal.pgen.1004606
10.1002/alz.12333
10.1001/jamaneurol.2020.1760
10.1001/jamaneurol.2017.4198
10.1038/nn.3435
10.1002/ana.22277
10.1038/s41467-019-09564-5
10.1093/brain/awy327
10.1212/WNL.0000000000002922
10.1212/WNL.0000000000005415
10.1038/s41386-019-0410-z
10.1016/j.isci.2021.102785
10.1016/j.biopsych.2016.04.017
10.1038/s41398-020-01018-7
10.1016/j.neurobiolaging.2020.04.024
10.3233/JAD-179939
10.1126/scitranslmed.3007941
10.1038/s41467-019-09718-5
10.1038/s41467-019-11181-1
10.1038/s41586-019-1195-2
10.1016/0197-4580(95)00092-S
10.1101/cshperspect.a006189
10.1016/j.jalz.2011.10.007
10.1007/s00401-009-0532-1
10.1093/brain/awab092
10.1038/s41467-018-08279-3
10.1002/sim.3034
10.1001/jamaneurol.2014.803
10.2967/jnumed.121.263195
10.1007/s00401-020-02175-1
10.1038/s41593-023-01356-x
10.1038/s41586-021-04369-3
10.1016/j.neurobiolaging.2011.09.033
10.1212/01.wnl.0000271090.28148.24
10.1212/01.WNL.0000042478.08543.F7
10.1001/archneur.61.3.378
10.1001/jamaneurol.2020.0387
10.1007/s00401-006-0127-z
10.1002/ana.24546
10.1038/sdata.2018.142
10.1086/519795
10.1038/ng1847
10.1038/ng.3679
10.1038/ng.3656
10.1038/ng.3643
10.1038/nature15393
10.1038/nature09298
10.1186/s13742-015-0047-8
10.1038/s41588-021-00913-z
10.1186/s13059-017-1216-0
10.1093/bioinformatics/btx364",<Element 'PubmedArticle' at 0x7f05df2cb680>
7,"38010651
12243634
12473759
25585033
31799369
35171235
33789730
31914223
33816761
33318676
32380523
35260470
28454915
22008728
22968319
34446931
25840980
18313558
24605806
21514250
11001602
27697430
32737243
33443136
32671408
30064520
25766898
19457380
23227001
30027214
26472628
34595576
36323521
25589671
35113011
35741458
15070770
25938726
31164641
29089479
34099005
34500400
23418130
25406711
15956266
17299264
24635665
22261729
30123816",Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease.,"Neuropsychiatric symptoms are commonly encountered and are highly debilitating in patients with Alzheimer disease. Understanding their underpinnings has implications for identifying biomarkers and treatment for these symptoms.
To evaluate whether glial markers are associated with neuropsychiatric symptoms in individuals across the Alzheimer disease continuum.
This cross-sectional study was conducted from January to June 2023, leveraging data from the Translational Biomarkers in Aging and Dementia cohort at McGill University, Canada. Recruitment was based on referrals of individuals from the community or from outpatient clinics. Exclusion criteria included active substance abuse, major surgery, recent head trauma, safety contraindications for positron emission tomography (PET) or magnetic resonance imaging, being currently enrolled in other studies, and having inadequately treated systemic conditions.
All individuals underwent assessment for neuropsychiatric symptoms (Neuropsychiatry Inventory Questionnaire [NPI-Q]), and imaging for microglial activation ([11C]PBR28 PET), amyloid-β ([18F]AZD4694 PET), and tau tangles ([18F]MK6240 PET).
Of the 109 participants, 72 (66%) were women and 37 (34%) were men; the median age was 71.8 years (range, 38.0-86.5 years). Overall, 70 had no cognitive impairment and 39 had cognitive impairment (25 mild; 14 Alzheimer disease dementia). Amyloid-β PET positivity was present in 21 cognitively unimpaired individuals (30%) and in 31 cognitively impaired individuals (79%). The NPI-Q severity score was associated with microglial activation in the frontal, temporal, and parietal cortices (β = 7.37; 95% CI, 1.34-13.41; P = .01). A leave-one-out approach revealed that irritability was the NPI-Q domain most closely associated with the presence of brain microglial activation (β = 6.86; 95% CI, 1.77-11.95; P = .008). Furthermore, we found that microglia-associated irritability was associated with study partner burden measured by NPI-Q distress score (β = 5.72; 95% CI, 0.33-11.10; P = .03).
In this cross-sectional study of 109 individuals across the AD continuum, microglial activation was associated with and a potential biomarker of neuropsychiatric symptoms in Alzheimer disease. Moreover, our findings suggest that the combination of amyloid-β- and microglia-targeted therapies could have an impact on relieving these symptoms.",[],JAMA network open,2023-11-27,"[{'lastname': 'Schaffer Aguzzoli', 'firstname': 'Cristiano', 'initials': 'C', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nBrain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.\nGlobal Brain Health Institute, University of California, San Francisco.'}, {'lastname': 'Ferreira', 'firstname': 'Pâmela C L', 'initials': 'PCL', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'lastname': 'Povala', 'firstname': 'Guilherme', 'initials': 'G', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Ferrari-Souza', 'firstname': 'João Pedro', 'initials': 'JP', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'lastname': 'Bellaver', 'firstname': 'Bruna', 'initials': 'B', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Soares Katz', 'firstname': 'Carolina', 'initials': 'C', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'lastname': 'Zalzale', 'firstname': 'Hussein', 'initials': 'H', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Lussier', 'firstname': 'Firoza Z', 'initials': 'FZ', 'affiliation': ""Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Rohden', 'firstname': 'Francieli', 'initials': 'F', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'lastname': 'Abbas', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Leffa', 'firstname': 'Douglas T', 'initials': 'DT', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Scop Medeiros', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Therriault', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.\nMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Benedet', 'firstname': 'Andréa L', 'initials': 'AL', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Tissot', 'firstname': 'Cécile', 'initials': 'C', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.\nMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Servaes', 'firstname': 'Stijn', 'initials': 'S', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Rahmouni', 'firstname': 'Nesrine', 'initials': 'N', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Cassa Macedo', 'firstname': 'Arthur', 'initials': 'A', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Bezgin', 'firstname': 'Gleb', 'initials': 'G', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Kang', 'firstname': 'Min Su', 'initials': 'MS', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Stevenson', 'firstname': 'Jenna', 'initials': 'J', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Pallen', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Cohen', 'firstname': 'Ann', 'initials': 'A', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Lopez', 'firstname': 'Oscar L', 'initials': 'OL', 'affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Tudorascu', 'firstname': 'Dana L', 'initials': 'DL', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Klunk', 'firstname': 'William E', 'initials': 'WE', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Villemagne', 'firstname': 'Victor L', 'initials': 'VL', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Soucy', 'firstname': 'Jean Paul', 'initials': 'JP', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Zimmer', 'firstname': 'Eduardo R', 'initials': 'ER', 'affiliation': 'Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.\nDepartment of Pharmacology, Graduate Program in Biological Sciences: Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.\nBrain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'lastname': 'Schilling', 'firstname': 'Lucas P', 'initials': 'LP', 'affiliation': 'Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.\nDepartment of Neurology, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.'}, {'lastname': 'Karikari', 'firstname': 'Thomas K', 'initials': 'TK', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Ashton', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': ""Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.\nDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom.\nUK Dementia Research Institute at UCL, London, United Kingdom.\nHong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.\nWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison.""}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Gauthier', 'firstname': 'Serge', 'initials': 'S', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Valcour', 'firstname': 'Victor', 'initials': 'V', 'affiliation': 'Global Brain Health Institute, University of California, San Francisco.\nDepartment of Neurology, University of California, San Francisco.'}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': 'Global Brain Health Institute, University of California, San Francisco.\nDepartment of Neurology, University of California, San Francisco.'}, {'lastname': 'Rosa-Neto', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.\nMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Pascoal', 'firstname': 'Tharick A', 'initials': 'TA', 'affiliation': 'Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.\nDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.'}]",,,"Of the 109 participants, 72 (66%) were women and 37 (34%) were men; the median age was 71.8 years (range, 38.0-86.5 years). Overall, 70 had no cognitive impairment and 39 had cognitive impairment (25 mild; 14 Alzheimer disease dementia). Amyloid-β PET positivity was present in 21 cognitively unimpaired individuals (30%) and in 31 cognitively impaired individuals (79%). The NPI-Q severity score was associated with microglial activation in the frontal, temporal, and parietal cortices (β = 7.37; 95% CI, 1.34-13.41; P = .01). A leave-one-out approach revealed that irritability was the NPI-Q domain most closely associated with the presence of brain microglial activation (β = 6.86; 95% CI, 1.77-11.95; P = .008). Furthermore, we found that microglia-associated irritability was associated with study partner burden measured by NPI-Q distress score (β = 5.72; 95% CI, 0.33-11.10; P = .03).",,"10.1001/jamanetworkopen.2023.45175
10.1001/jama.288.12.1475
10.1212/01.WNL.0000036904.73393.E4
10.1176/appi.ajp.2014.14040480
10.1016/j.trci.2019.10.004
10.1001/jamapsychiatry.2021.4363
10.1186/s40035-021-00236-3
10.1002/alz.12007
10.1002/trc2.12154
10.1038/s41582-020-00435-y
10.1093/brain/awaa088
10.1212/NXI.0000000000001152
10.1016/S2215-0366(17)30101-3
10.1038/jcbfm.2011.147
10.1038/jcbfm.2012.131
10.1101/2022.07.12.22277556
10.1038/s41591-021-01456-w
10.2967/jnumed.114.149443
10.1016/j.jclinepi.2007.11.008
10.1111/joim.12190
10.1016/j.jalz.2011.03.005
10.1176/jnp.12.2.233
10.1016/j.jalz.2016.08.005
10.2967/jnumed.120.245209
10.1212/WNL.0000000000011416
10.1093/brain/awaa180
10.1186/s13195-018-0402-y
10.2967/jnumed.114.146027
10.1016/j.neuroimage.2009.01.045
10.3389/fnins.2012.00171
10.1001/jamapsychiatry.2018.1877
10.1086/701235
10.1176/appi.ajp.2015.14101358
10.1007/s00406-021-01334-z
10.1212/WNL.0000000000201517
10.1212/WNL.0000000000001238
10.17305/bjbms.2021.6825
10.3390/biology11060938
10.1073/pnas.0308627101
10.1146/annurev-neuro-071013-014030
10.1038/s41467-019-10217-w
10.1038/s41467-017-01150-x
10.1186/s13024-021-00456-1
10.1016/j.smrv.2021.101541
10.1002/hbm.22248
10.1038/nrn3857
10.1097/00019442-200506000-00005
10.1159/000099472
10.1111/jgs.12730
10.1097/WAD.0b013e3182471c54
10.1016/j.cobeha.2017.12.007",<Element 'PubmedArticle' at 0x7f05df8d68b0>
8,37874085,Fibrin-Targeting Immunotherapy for Dementia.,"Blood-brain barrier (BBB) disruption is an early event in the development of Alzheimer's disease. It precedes extracellular deposition of amyloid-β in senile plaques and blood vessel walls, the intracellular accumulation of neurofibrillary tangles containing phosphorylated tau protein, microglial activation, and neuronal cell death. BBB disruption allows the coagulation protein fibrinogen to leak from the blood into the brain, where it is converted by thrombin cleavage into fibrin and deposits in the parenchyma and CNS vessels. Fibrinogen cleavage by thrombin exposes a cryptic epitope termed P2 which can bind CD11b and CD11c on microglia, macrophages and dendritic cells and trigger an inflammatory response toxic to neurons. Indeed, genetic and pharmacological evidence demonstrates a causal role for fibrin in innate immune cell activation and the development of neurodegenerative diseases. The P2 inflammatory epitope is spatially and compositionally distinct from the coagulation epitope on fibrin. Mouse monoclonal antibody 5B8, which targets the P2 epitope without interfering with the clotting process, has been shown to reduce neurodegeneration and neuroinflammation in animal models of Alzheimer's disease and multiple sclerosis. The selectivity and efficacy of this anti-human fibrin-P2 antibody in animal models supports the development of a monoclonal antibody drug targeting fibrin P2 for the treatment of neurodegenerative diseases. THN391 is a humanized, affinity-matured antibody which has a 100-fold greater affinity for fibrin P2 and improved development properties compared to the parental 5B8 antibody. It is currently in a Phase 1 clinical trial.","['Alzheimer’s disease', 'Fibrinogen', 'fibrin', 'microglia', 'neurodegeneration', 'neuroinflammation']",The journal of prevention of Alzheimer's disease,2023-10-24,"[{'lastname': 'Kantor', 'firstname': 'A B', 'initials': 'AB', 'affiliation': 'Jeffrey Stavenhagen, PhD, Therini Bio, Inc, Sacramento, CA, USA, Email: Jstavenhagen@therinibio.com.'}, {'lastname': 'Akassoglou', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Stavenhagen', 'firstname': 'J B', 'initials': 'JB', 'affiliation': None}]",,,,,10.14283/jpad.2023.105,<Element 'PubmedArticle' at 0x7f05df197590>
9,"37753266
31638686
29433981
30503937
30605887
31564456
32462551
32425941
28226226
30258234
33239064
29196460
27004698
34460037
17180163
33242662
35248147
36062448
25598354
34646113
26556658
30546389
20303880
30138572
31487775
31264132
32973484
33065077
31283973
33083018
33712031
33402181
31649508
21670502
31214192
36055034
37401041
35953545
29263232
32129117
31800167
28575151
26510952
33261147
31392693
27751869
31319868
30802950
34970114
25257319
27091974
31923845
30042659
35427810
22397366
20920788
28367114
25833819
33831349
34769495
28803064
33585492
30651105
27444227
29327503
31838836
31136989
29170536
28248199
29074454
26077373
31133802
29982332
27197967
25027649
32022336
31300734
32846274
22510765
27826912
24244499
24990149
30684217
33240878
22709905
29408500
27027823
30208760
32341353
33279663
33754051
26376347
26971344
27423553
36379282
32251872
33624913
30412727
29705945
34815784
34818971
30510257
36092798
27277332
23613494
32135232
28912849
29174617
26552593
32950103
30016687
29108992
29209166
33711331
32987149
17242365
19890474
23762086
30951849
21652514
31456514
33694209
32582192
18801740
19021527
33185814
31707205
23952003
28737113
26410391
29857185
28912710
31734880
26968890
28404732
34776873
24293102
29559383
32676990
34843004
32513933
30549219
32286945
31605772
30328681
35783137
23783805
24212398
35659599
34710587
34540002
34533063
25545945
23650073
31092279
35532940
26794445
24139697
28731435
30706990
27235580
36038535
32014577
31957613
28114268
33542630
30328325
32222058
34151409
35563107
23001356
31244932
27031810
32711535
27786595
35620289
29324907
33500732
24336080
25019481
25723469
27693495
31614121
36638942
25725784
34241565
34371179
32463968
22653784
35011699
34279788
31801298
33343808
32779043
27797173
31783671
25862375
34523719
23399684
31395983
28080204
26861625
27892769
31659415
28535767
25921068
32966858
33396004
35637250
34920022
33002329
33952191
35366241
35887031
36409993
30259371
35060046
30742923
35167942
35246267
35982472
36362022
21890647
24936207
26041786
25642422
26721498
35860297
34455059
29666475
35087519
33410377
32976819
35442818
34955647
29956723
31743528
34017373
26880762
28808113
35592641
32470877
31434993
36195691
34718247
31985016
33341564
29307821
28630232
29636074
32648622
29844328
32972446
29631367
31286366
35949493
32140098
32602030
29944870
35026768
33013268
36734383
28215748
31778769
30026327
35098860
30038357
33234729
28476620
31863767
32234564
30569101
30961627
33359189
32307615
33407665
32826878
31551710
31462285
35714586
33464299
34050133
27459405
35805174
36327895
30728477
37253858",Non-Coding RNA in Microglia Activation and Neuroinflammation in Alzheimer's Disease.,"Alzheimer's disease (AD) is a neurodegenerative disorder characterized by complex pathophysiological features. Amyloid plaques resulting from extracellular amyloid deposition and neurofibrillary tangles formed by intracellular hyperphosphorylated tau accumulation serve as primary neuropathological criteria for AD diagnosis. The activation of microglia has been closely associated with these pathological manifestations. Non-coding RNA (ncRNA), a versatile molecule involved in various cellular functions such as genetic information storage and transport, as well as catalysis of biochemical reactions, plays a crucial role in microglial activation. This review aims to investigate the regulatory role of ncRNAs in protein expression by directly targeting genes, proteins, and interactions. Furthermore, it explores the ability of ncRNAs to modulate inflammatory pathways, influence the expression of inflammatory factors, and regulate microglia activation, all of which contribute to neuroinflammation and AD. However, there are still significant controversies surrounding microglial activation and polarization. The categorization into M1 and M2 phenotypes may oversimplify the intricate and multifaceted regulatory processes in microglial response to neuroinflammation. Limited research has been conducted on the role of ncRNAs in regulating microglial activation and inducing distinct polarization states in the context of neuroinflammation. Moreover, the regulatory mechanisms through which ncRNAs govern microglial function continue to be refined. The current understanding of ncRNA regulatory pathways involved in microglial activation remains incomplete and may be influenced by spatial, temporal, and tissue-specific factors. Therefore, further in-depth investigations are warranted. In conclusion, there are ongoing debates and uncertainties regarding the activation and polarization of microglial cells, particularly concerning the categorization into M1 and M2 phenotypes. The study of ncRNA regulation in microglial activation and polarization, as well as its mechanisms, is still in its early stages and requires further investigation. However, this review offers new insights and opportunities for therapeutic approaches in AD. The development of ncRNA-based drugs may hold promise as a new direction in AD treatment.","['Alzheimer’s disease', 'circRNA', 'lncRNA', 'miRNA', 'microglia activation', 'neuroinflammation', 'non-coding RNA']",Journal of inflammation research,2023-09-27,"[{'lastname': 'He', 'firstname': 'Chunxiang', 'initials': 'C', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Ze', 'initials': 'Z', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Yang', 'firstname': 'Miao', 'initials': 'M', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Yu', 'firstname': 'Wenjing', 'initials': 'W', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Luo', 'firstname': 'Rongsiqing', 'initials': 'R', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Zhou', 'firstname': 'Jinyong', 'initials': 'J', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'He', 'firstname': 'Jiawei', 'initials': 'J', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Chen', 'firstname': 'Qi', 'initials': 'Q', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Song', 'firstname': 'Zhenyan', 'initials': 'Z', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}, {'lastname': 'Cheng', 'firstname': 'Shaowu', 'initials': 'S', 'affiliation': ""School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.\nKey Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.""}]",,,,© 2023 He et al.,"10.2147/JIR.S422114
10.1001/jama.2019.4782
10.1016/j.jalz.2017.12.006
10.1016/j.ejmech.2018.11.049
10.1016/j.bioorg.2018.12.017
10.1016/j.cell.2019.09.001
10.1007/s12035-020-01945-y
10.3389/fimmu.2020.00754
10.1146/annurev-immunol-051116-052358
10.1038/s41593-018-0242-x
10.1186/s40035-020-00221-2
10.1083/jcb.201709069
10.1016/j.tcb.2016.02.006
10.1007/s10571-021-01145-9
10.1038/nrn2038
10.1016/j.parkreldis.2020.11.011
10.1186/s13024-022-00522-2
10.1002/ptr.7597
10.1007/s12035-014-9070-5
10.3389/fnins.2021.689629
10.1016/j.bcp.2015.11.003
10.1111/cen3.12475
10.1016/j.cell.2010.02.016
10.1080/14728222.2018.1515917
10.3390/molecules24183207
10.1007/s10787-019-00613-5
10.3389/fnagi.2020.00219
10.1016/j.expneurol.2020.113506
10.1016/j.bbi.2019.07.004
10.1038/s41420-020-00333-8
10.1186/s12974-021-02120-3
10.1186/s12974-020-02041-7
10.3389/fncel.2019.00430
10.1172/JCI45444
10.3389/fimmu.2019.01241
10.1016/j.intimp.2022.109191
10.1111/cns.14333
10.1038/s41593-022-01131-4
10.1126/scitranslmed.aai7635
10.1080/14728222.2020.1738391
10.1111/acel.13078
10.1093/brain/awx120
10.1093/brain/awv288
10.3390/ijms21239036
10.1007/978-1-4939-9658-2_21
10.1016/j.bbi.2016.10.012
10.1186/s12974-019-1538-9
10.1111/jnc.14687
10.3389/fnins.2021.777347
10.1186/s40478-014-0142-6
10.1073/pnas.1604032113
10.1016/j.biomaterials.2019.119752
10.3389/fncel.2018.00172
10.1016/j.arr.2022.101622
10.1186/1742-2094-9-47
10.1016/j.neuron.2010.08.023
10.3389/fnmol.2017.00069
10.1093/brain/awv081
10.1016/j.neuron.2021.03.024
10.3390/ijms222112063
10.1016/j.yexcr.2017.07.032
10.3389/fcell.2021.635636
10.1186/s12974-019-1398-3
10.1038/nrd.2016.117
10.1002/wrna.1463
10.14348/molcells.2019.0241
10.2741/4789
10.1038/nrc.2017.99
10.1172/JCI84424
10.1016/j.jaci.2017.08.034
10.1038/nrg3965
10.3389/fnmol.2019.00125
10.1093/bib/bby054
10.1186/s12967-016-0893-x
10.1038/nrm3838
10.1111/ejn.14695
10.1038/s41423-019-0257-6
10.1016/j.neurobiolaging.2020.07.023
10.1038/nrg3198
10.1007/978-1-4939-6524-3_1
10.1371/journal.pone.0079416
10.1093/hmg/ddu348
10.1007/s12035-019-1487-4
10.3389/fcell.2020.566530
10.1186/1742-2094-9-131
10.1016/j.brainres.2018.01.032
10.1002/cbf.3184
10.1080/15548627.2018.1522467
10.1038/s41419-020-2490-4
10.1016/j.exger.2020.111180
10.7150/thno.53418
10.1111/jnc.13364
10.1007/s10571-016-0361-4
10.1016/j.jns.2016.05.038
10.1016/j.ijbiomac.2022.11.078
10.1016/j.jns.2020.116793
10.1002/cbin.11576
10.1016/j.ejphar.2018.11.004
10.1007/s12035-018-1092-y
10.7150/thno.67227
10.1080/21655979.2021.2008638
10.1038/s41591-018-0223-3
10.3389/fnagi.2022.955461
10.3892/mmr.2016.5369
10.1161/STROKEAHA.111.000504
10.1016/j.neuroscience.2020.02.044
10.3892/etm.2017.4874
10.1016/j.mcn.2017.11.012
10.1186/s12974-015-0424-3
10.1016/j.ymthe.2020.09.006
10.1016/j.neuint.2018.07.003
10.1016/j.bbrc.2017.11.013
10.3389/fnmol.2017.00383
10.1016/j.imlet.2021.03.004
10.1016/j.bbagrm.2020.194639
10.1073/pnas.0610731104
10.1002/emmm.200900028
10.1155/2013/186872
10.1016/j.nbd.2019.02.015
10.1093/intimm/dxr034
10.2174/1567205016666190503145207
10.1002/glia.23988
10.3389/fimmu.2020.01110
10.1074/jbc.M805371200
10.1042/BST0361211
10.1007/s12031-020-01750-1
10.1016/j.omtn.2019.10.002
10.1111/jnc.12400
10.1177/1073858417721150
10.1016/j.coph.2015.09.001
10.1016/j.biochi.2018.05.015
10.3389/fnagi.2017.00277
10.1007/s12035-019-01819-y
10.1016/j.gene.2016.03.008
10.1073/pnas.1702367114
10.3389/fncel.2021.785433
10.1007/s12035-013-8595-3
10.1016/j.neuroscience.2018.03.016
10.1007/s12035-020-02013-1
10.1007/s11064-021-03490-z
10.1038/s41419-020-2583-0
10.1111/acel.12886
10.2174/1567202617666200414142637
10.1016/j.neulet.2019.134541
10.1002/mnfr.201800621
10.3389/fnagi.2022.909222
10.3892/mmr.2013.1534
10.1212/01.wnl.0000437306.37850.22
10.1186/s12883-022-02728-9
10.1016/j.arr.2021.101497
10.1177/09603271211041996
10.1111/jnc.13021
10.1002/glia.22483
10.1186/s13195-019-0501-4
10.1093/gerona/glac106
10.1038/cdd.2015.153
10.1016/j.jns.2013.10.002
10.3233/JAD-170156
10.1111/acel.12902
10.1016/j.neulet.2016.05.049
10.1038/s41398-022-02108-4
10.1016/j.bbi.2020.01.025
10.2174/1567202617666200117103931
10.12659/msm.898788
10.2147/NDT.S290925
10.3349/ymj.2018.59.9.1096
10.1111/acel.13144
10.1007/s12031-021-01862-2
10.3390/ijms23094718
10.18632/aging.100486
10.7150/thno.30879
10.1016/j.biomaterials.2016.03.025
10.1186/s12951-020-00665-8
10.1080/15592294.2016.1232233
10.3389/fphar.2022.833066
10.1371/journal.pone.0191382
10.7150/thno.47408
10.1038/cddis.2013.486
10.1038/ncomms5386
10.1016/j.molimm.2015.01.019
10.1016/j.yexcr.2016.09.020
10.1016/j.expneurol.2019.113076
10.1016/j.actbio.2023.01.014
10.1007/s12031-015-0526-5
10.1080/15476286.2021.1940697
10.1016/j.ymthe.2021.08.008
10.1002/glia.23846
10.1002/glia.22363
10.3390/cells11010137
10.1007/s12017-021-08676-w
10.3390/ijms20236055
10.1155/2020/6038919
10.1007/s11010-020-03852-1
10.1021/acschemneuro.6b00250
10.3390/pathogens8040268
10.1007/s12035-015-9142-1
10.1111/imr.13024
10.1016/j.brainres.2013.01.052
10.1038/s41576-019-0158-7
10.1080/15476286.2017.1279788
10.1093/nar/gkw027
10.1080/15476286.2016.1255398
10.1007/s00018-019-03345-5
10.1186/s12943-017-0663-2
10.1016/j.molcel.2015.03.027
10.1016/j.ygeno.2020.09.042
10.1016/j.ecoenv.2020.111672
10.1038/s41388-022-02360-4
10.1016/j.neuroscience.2021.12.012
10.1111/jcmm.15894
10.1186/s10020-021-00305-3
10.18632/aging.203989
10.3390/ijms23147682
10.1093/jnen/nlac108
10.1007/978-981-13-1426-1_19
10.1007/s11356-021-17478-3
10.1016/j.ijbiomac.2019.02.041
10.1016/j.neulet.2022.136531
10.1186/s40478-022-01328-5
10.1186/s40364-022-00405-0
10.3390/ijms232113232
10.1101/gad.17446611
10.3389/fgene.2014.00164
10.1093/bib/bbv031
10.3389/fbioe.2014.00088
10.1007/978-1-4939-3378-5_21
10.3389/fnins.2022.903472
10.1016/j.bbi.2021.08.230
10.1038/s41418-018-0105-8
10.3389/fimmu.2021.790750
10.1080/15384101.2020.1863681
10.1016/j.yexmp.2020.104545
10.1177/15333175221091424
10.2147/JIR.S343575
10.3892/ijmm.2018.3736
10.1002/cbin.11263
10.4049/jimmunol.1502146
10.15252/embr.201643668
10.2147/CIA.S363116
10.1016/j.intimp.2020.106614
10.1038/s41598-019-48759-0
10.1007/s12035-022-03045-5
10.1097/WNR.0000000000001730
10.3892/ijmm.2020.4471
10.1016/j.jstrokecerebrovasdis.2020.105550
10.1016/j.bbrc.2018.01.022
10.1161/STROKEAHA.117.017387
10.1186/s12974-018-1139-z
10.1111/cpr.12856
10.1038/s41598-018-26421-5
10.1186/s13041-020-00656-8
10.1152/ajpcell.00278.2017
10.1007/s11626-019-00375-y
10.17179/excli2022-4764
10.3389/fncel.2020.00028
10.1007/s12031-020-01623-7
10.1016/j.bcp.2018.06.028
10.1159/000521014
10.17179/excli2020-2286
10.5114/fn.2022.118961
10.1016/j.neuroscience.2017.02.002
10.1016/j.neulet.2019.134649
10.1158/0008-5472.CAN-18-1102
10.1080/01677063.2022.2028784
10.1038/s41419-018-0821-5
10.18632/aging.104079
10.1016/j.bbrc.2017.05.005
10.1016/j.ejphar.2019.172880
10.1016/j.mcp.2020.101565
10.3892/mmr.2018.9748
10.1186/s12974-019-1464-x
10.1016/j.neuint.2020.104929
10.1007/s10753-020-01230-z
10.1186/s13018-020-02041-6
10.1038/s41419-020-02824-z
10.3389/fnmol.2019.00215
10.1186/s13046-019-1371-0
10.1016/j.molcel.2022.05.027
10.1083/jcb.202009045
10.1038/s41419-021-03821-6
10.1038/nn.4338
10.3390/cells11132091
10.1016/j.neuron.2022.10.020
10.1038/s41580-019-0106-6
10.1038/s41573-023-00704-7",<Element 'PubmedArticle' at 0x7f05df18ce00>
10,"37587511
27546235
24833586
30471926
26786204
28732515
34107254
33214681
35228310
23273845
28122230
31493147
35260865
30783653
19910308
27508061
16199517
35589920
24994846
21369534
35974106
28602351
30082275
37393197
17969104
28863860
16626397
12670482
25896511
21490621
21642987
17851529
32848093
28970783
36617879
23545502
25666439
34530748
26235985
35177477
30944478
34140954
31959936
25309543
24963278
22198949
18981147
31324751
35487953
28245991
30782788
15833363
34294785
33301878
19689368
34281564
23965734
32379705
27374120
24162652
31018141
28930663
36747024
35181976
11322887
26354916
24019961
35922662
33732142
32589933
28340339
18256700
28928743
28665028
22171895
22036569
24411104
15728241
19503107
20484116
27091843
36257314
33008530
36449413
36624497",Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer's disease.,"Microglia, the brain's principal immune cells, have been implicated in the pathogenesis of Alzheimer's disease (AD), a condition shown to affect more females than males. Although sex differences in microglial function and transcriptomic programming have been described across development and in disease models of AD, no studies have comprehensively identified the sex divergences that emerge in the aging mouse hippocampus. Further, existing models of AD generally develop pathology (amyloid plaques and tau tangles) early in life and fail to recapitulate the aged brain environment associated with late-onset AD. Here, we examined and compared transcriptomic and translatomic sex effects in young and old murine hippocampal microglia.
Hippocampal tissue from C57BL6/N and microglial NuTRAP mice of both sexes were collected at young (5-6 month-old [mo]) and old (22-25 mo) ages. Cell sorting and affinity purification techniques were used to isolate the microglial transcriptome and translatome for RNA-sequencing and differential expression analyses. Flow cytometry, qPCR, and imaging approaches were used to confirm the transcriptomic and translatomic findings.
There were marginal sex differences identified in the young hippocampal microglia, with most differentially expressed genes (DEGs) restricted to the sex chromosomes. Both sex chromosomally and autosomally encoded sex differences emerged with aging. These sex DEGs identified at old age were primarily female-biased and enriched in senescent and disease-associated microglial signatures. Normalized gene expression values can be accessed through a searchable web interface ( https://neuroepigenomics.omrf.org/ ). Pathway analyses identified upstream regulators induced to a greater extent in females than in males, including inflammatory mediators IFNG, TNF, and IL1B, as well as AD-risk genes TREM2 and APP.
These data suggest that female microglia adopt disease-associated and senescent phenotypes in the aging mouse hippocampus, even in the absence of disease pathology, to a greater extent than males. This sexually divergent microglial phenotype may explain the difference in susceptibility and disease progression in the case of AD pathology. Future studies will need to explore sex differences in microglial heterogeneity in response to AD pathology and determine how sex-specific regulators (i.e., sex chromosomal or hormonal) elicit these sex effects.","['Alzheimer’s disease', 'Brain aging', 'Disease-associated microglia', 'Hippocampus', 'Microglia', 'Neuroinflammation', 'Senescence', 'Sex divergence', 'Sex effects', 'Transcriptomics']",Journal of neuroinflammation,2023-08-17,"[{'lastname': 'Ocañas', 'firstname': 'Sarah R', 'initials': 'SR', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Pham', 'firstname': 'Kevin D', 'initials': 'KD', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Cox', 'firstname': 'Jillian E J', 'initials': 'JEJ', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nGraduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Keck', 'firstname': 'Alex W', 'initials': 'AW', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Ko', 'firstname': 'Sunghwan', 'initials': 'S', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nGraduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Ampadu', 'firstname': 'Felix A', 'initials': 'FA', 'affiliation': 'Graduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Porter', 'firstname': 'Hunter L', 'initials': 'HL', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Ansere', 'firstname': 'Victor A', 'initials': 'VA', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Kulpa', 'firstname': 'Adam', 'initials': 'A', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Kellogg', 'firstname': 'Collyn M', 'initials': 'CM', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nDepartment of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Machalinski', 'firstname': 'Adeline H', 'initials': 'AH', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Thomas', 'firstname': 'Manu A', 'initials': 'MA', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Wright', 'firstname': 'Zsabre', 'initials': 'Z', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Chucair-Elliott', 'firstname': 'Ana J', 'initials': 'AJ', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Freeman', 'firstname': 'Willard M', 'initials': 'WM', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA. bill-freeman@omrf.org.\nDepartment of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. bill-freeman@omrf.org.\nOklahoma City Veterans Affairs Medical Center, Oklahoma City, OK, USA. bill-freeman@omrf.org.'}]",,,"There were marginal sex differences identified in the young hippocampal microglia, with most differentially expressed genes (DEGs) restricted to the sex chromosomes. Both sex chromosomally and autosomally encoded sex differences emerged with aging. These sex DEGs identified at old age were primarily female-biased and enriched in senescent and disease-associated microglial signatures. Normalized gene expression values can be accessed through a searchable web interface ( https://neuroepigenomics.omrf.org/ ). Pathway analyses identified upstream regulators induced to a greater extent in females than in males, including inflammatory mediators IFNG, TNF, and IL1B, as well as AD-risk genes TREM2 and APP.","© 2023. BioMed Central Ltd., part of Springer Nature.",10.1186/s12974-023-02870-2,<Element 'PubmedArticle' at 0x7f05df1f0400>
11,"37546928
31375134
22471863
15639312
19661626
19376612
29865057
16330558
1307688
5707082
21222594
21557722
2011243
1759558
35332316
33185603
18520776
22640423
23824488
17599696
30336198
36776048
34052751
29200205
27373369
27196974
34100905
35164877
35816404
24607960
19587326
2422580
30819250
35764973
35320002
36344699
25261551
33667711
33859405
35731195
26018760
31847365
31434879
32479996
33563332
34655981
23050084
21047142
21666499
24159335
16406150
30872998
32855357
35296031
33517893
29967008
37191183
36583547
17245426
15751225
32994401
31703599
33627135
31242692
31410926
36653245
20061647
34599967
34687956
20121465
16148231
10683279
25630253
35348636
23656989
35351465
36704504
36376530
30942936
33926499
20705452
26834588
23577177
30029608
33094279
33324642
20088812
27629719
36264429
35307206",Enhanced microglial dynamics and paucity of tau seeding in the amyloid plaque microenvironment contributes to cognitive resilience in Alzheimer's disease.,"Asymptomatic Alzheimer's disease (AsymAD) describes the status of subjects with preserved cognition but with identifiable Alzheimer's disease (AD) brain pathology (i.e. Aβ-amyloid deposits, neuritic plaques, and neurofibrillary tangles) at autopsy. In this study, we investigated the postmortem brains of a cohort of AsymAD cases to gain insight into the underlying mechanisms of resilience to AD pathology and cognitive decline. Our results showed that AsymAD cases exhibit an enrichment of core plaques and decreased filamentous plaque accumulation, as well as an increase in microglia surrounding this last type. In AsymAD cases we found less pathological tau aggregation in dystrophic neurites compared to AD and tau seeding activity comparable to healthy control subjects. We used spatial transcriptomics to further characterize the plaque niche and found autophagy, endocytosis, and phagocytosis within the top upregulated pathways in the AsymAD plaque niche, but not in AD. Furthermore, we found ARP2, an actin-based motility protein crucial to initiate the formation of new actin filaments, increased within microglia in the proximity of amyloid plaques in AsymAD. Our findings support that the amyloid-plaque microenvironment in AsymAD cases is characterized by microglia with highly efficient actin-based cell motility mechanisms and decreased tau seeding compared to AD. These two mechanisms can potentially provide protection against the toxic cascade initiated by Aβ that preserves brain health and slows down the progression of AD pathology.","['Alzheimer disease', 'Amyloid plaques', 'Cognitive reserve', 'Microglia motility', 'Resilience', 'Tau', 'autophagy', 'dystrophic neurites']",bioRxiv : the preprint server for biology,2023-08-07,"[{'lastname': 'Jury-Garfe', 'firstname': 'Nur', 'initials': 'N', 'affiliation': 'Stark Neuroscience Research Institute, Indiana University, Indianapolis, USA.\nDepartment of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'lastname': 'You', 'firstname': 'Yanwen', 'initials': 'Y', 'affiliation': 'Stark Neuroscience Research Institute, Indiana University, Indianapolis, USA.\nDepartment of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'lastname': 'Martínez', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': 'Stark Neuroscience Research Institute, Indiana University, Indianapolis, USA.\nDepartment of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'lastname': 'Redding-Ochoa', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Departments of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.'}, {'lastname': 'Karahan', 'firstname': 'Hande', 'initials': 'H', 'affiliation': 'Stark Neuroscience Research Institute, Indiana University, Indianapolis, USA.\nDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.'}, {'lastname': 'Johnson', 'firstname': 'Travis S', 'initials': 'TS', 'affiliation': 'Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, USA.'}, {'lastname': 'Zhang', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.\nCenter for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA.'}, {'lastname': 'Kim', 'firstname': 'Jungsu', 'initials': 'J', 'affiliation': 'Stark Neuroscience Research Institute, Indiana University, Indianapolis, USA.\nDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.'}, {'lastname': 'Troncoso', 'firstname': 'Juan C', 'initials': 'JC', 'affiliation': 'Departments of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.\nDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA.'}, {'lastname': 'Lasagna-Reeves', 'firstname': 'Cristian A', 'initials': 'CA', 'affiliation': 'Stark Neuroscience Research Institute, Indiana University, Indianapolis, USA.\nDepartment of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.\nCenter for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA.'}]",,,,,"10.1101/2023.07.27.550884
10.1002/alz.13074
10.1002/alz.12899
10.1101/2020.05.31.124941
10.1101/2020.05.31.124941",<Element 'PubmedArticle' at 0x7f05df81f0e0>
12,"37511507
31587896
33587917
11154927
30068016
11016935
21988719
16547218
31551714
14715932
9885283
24470356
22394324
15640761
12551918
21088470
30098011
32825423
9354812
9263190
29934546
31031598
17086106
34391810
34516970
29225193
34708251
24928329
15123679
12586825
20360457
26188005
11150303
15972634
12431909
11943260
12404161
25456845
23303206
35887215
32116543
21081501
22891241
21651910
22048123
32811520
37287063
18604209
23254930
14741428
25948251
19299738
29673550
27723233
27818384
9665462
19729478
26511387
11549724
19014371
16600437
28747389
28747388
27858314
30074479
22467178
30691318
21821797
20007545
23562658
36449279
12068068
16338906
30098388
32581707
22966146
22382341
26197451
10860929
21536754
35770396
33889073
36299894
36224611","The P2X7 Receptor, a Multifaceted Receptor in Alzheimer's Disease.","Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by impaired episodic memory and two pathological lesions: amyloid plaques and neurofibrillary tangles. In AD, damaged neurons and the accumulation of amyloid β (Aβ) peptides cause a significant release of high amounts of extracellular ATP, which acts as a danger signal. The purinergic receptor P2X7 is the main sensor of high concentrations of ATP, and P2X7 has been shown to be upregulated in the brains of AD patients, contributing to the disease's pathological processes. Further, there are many polymorphisms of the ","['Alzheimer’s disease', 'chemokines', 'cytokines', 'inflammation', 'microglia', 'purinergic receptor']",International journal of molecular sciences,2023-07-29,"[{'lastname': 'Ronning', 'firstname': 'Kaitryn E', 'initials': 'KE', 'affiliation': 'INSERM, CNRS, Institut de la Vision, Sorbonne University, F-75012 Paris, France.'}, {'lastname': 'Déchelle-Marquet', 'firstname': 'Paul-Alexandre', 'initials': 'PA', 'affiliation': 'INSERM, CNRS, Institut de la Vision, Sorbonne University, F-75012 Paris, France.'}, {'lastname': 'Che', 'firstname': 'Yueshen', 'initials': 'Y', 'affiliation': 'INSERM, CNRS, Institut de la Vision, Sorbonne University, F-75012 Paris, France.'}, {'lastname': 'Guillonneau', 'firstname': 'Xavier', 'initials': 'X', 'affiliation': 'INSERM, CNRS, Institut de la Vision, Sorbonne University, F-75012 Paris, France.'}, {'lastname': 'Sennlaub', 'firstname': 'Florian', 'initials': 'F', 'affiliation': 'INSERM, CNRS, Institut de la Vision, Sorbonne University, F-75012 Paris, France.'}, {'lastname': 'Delarasse', 'firstname': 'Cécile', 'initials': 'C', 'affiliation': 'INSERM, CNRS, Institut de la Vision, Sorbonne University, F-75012 Paris, France.'}]",,,,,"10.3390/ijms241411747
10.1016/j.cell.2019.09.017
10.1016/j.bcp.2021.114472
10.1016/S0952-7915(00)00191-6
10.1002/stem.2894
10.1074/jbc.M006781200
10.1111/j.1399-0039.2011.01780.x
10.4049/jimmunol.176.7.3877
10.3389/fncel.2019.00401
10.1523/JNEUROSCI.3792-03.2004
10.1242/jcs.112.3.297
10.1002/glia.22628
10.1111/j.1476-5381.2012.01932.x
10.1097/00001756-200410250-00017
10.1074/jbc.M209478200
10.3858/emm.2011.43.1.001
10.1111/bph.14470
10.3390/ijms21175996
10.1152/physrev.1997.77.4.1081
10.1016/S0197-4580(97)80306-5
10.1038/s41380-018-0108-3
10.3389/fncel.2019.00143
10.1097/01.jnen.0000240470.97295.d3
10.1016/j.pneurobio.2021.102139
10.1016/j.pneurobio.2021.102173
10.1016/j.ejphar.2017.12.006
10.1007/s00018-021-03986-5
10.1124/pr.113.008003
10.1074/jbc.M313902200
10.1074/jbc.M212759200
10.1096/fj.09-150862
10.1093/hmg/ddv278
10.1074/jbc.M010353200
10.4049/jimmunol.175.1.82
10.1152/ajpcell.00042.2002
10.1016/S0140-6736(02)08156-4
10.1086/344351
10.1016/j.exger.2014.10.009
10.1096/fj.12-215368
10.3390/ijms23147867
10.3389/fnmol.2020.00008
10.1074/jbc.M110.200618
10.1074/jbc.M112.400010
10.1016/j.febslet.2011.05.048
10.1016/j.neurobiolaging.2011.09.040
10.1186/s13024-020-00396-2
10.1186/s13195-023-01258-x
10.1038/ni.1636
10.1038/nature11729
10.1016/j.jneuroim.2003.10.014
10.1523/JNEUROSCI.3955-14.2015
10.4049/jimmunol.0803612
10.1016/j.bj.2018.01.002
10.1111/acel.12522
10.1093/brain/aww270
10.1016/S0002-9440(10)65542-3
10.2353/ajpath.2009.081113
10.1038/srep15862
10.1523/JNEUROSCI.21-18-07135.2001
10.1111/j.1471-4159.2008.05744.x
10.1016/j.neurobiolaging.2006.02.013
10.1523/JNEUROSCI.3104-16.2017
10.1523/JNEUROSCI.3103-16.2017
10.1007/s11302-016-9546-z
10.7554/eLife.36217
10.1007/s12035-012-8263-z
10.1080/14728222.2019.1575811
10.4049/jimmunol.1101178
10.1182/blood-2009-11-251744
10.1016/j.bbrc.2013.03.079
10.1042/EBC20220079
10.1046/j.1471-4159.2002.00920.x
10.1074/jbc.M510679200
10.1016/j.brainresbull.2018.07.016
10.3389/fnmol.2020.00094
10.1136/annrheumdis-2011-143578
10.3899/jrheum.110874
10.1097/MIB.0000000000000514
10.1124/mol.58.1.82
10.1124/mol.110.070276
10.2174/0929867329666220629141418
10.3389/fncel.2021.617036
10.3389/fphar.2022.1029236
10.1186/s12974-022-02601-z",<Element 'PubmedArticle' at 0x7f05df3c46d0>
13,"37461318
26871627
30643230
22229116
21777559
23656989
23602650
26687817
22637583
25623662
36199750
33771840
31042697
31768052
31932797
32989152
33432193
33609158
35381189
32702314
36732642
31350575
36544231
21514250
22265587
22101365
27312411
23104886
24227677
20196867
24485249
25605792
26687838
16199517
21546393
28602351
28930663
31018141
33347974
33665258
34297416
32736565
31612919
35531351
35000600
20709693
33780170
27141961
22805771
2808689
28628103
33301878
25681350
12374847
22049429
35346299
9525997
15930395
19164506
31875547
36385529
33482083
25453105
28959956
31601677
36368315
32804935
32660529
33558695
36216958","Distinct transcriptomic responses to Aβ plaques, neurofibrillary tangles, and APOE in Alzheimer's disease.","Omics studies have revealed that various brain cell types undergo profound molecular changes in Alzheimer's disease (AD) but the spatial relationships with plaques and tangles and APOE-linked differences remain unclear.
We performed laser capture microdissection of amyloid beta (Aβ) plaques, the 50 μm halo around them, tangles with the 50 μm halo around them, and areas distant (> 50 μm) from plaques and tangles in the temporal cortex of AD and control donors, followed by RNA-sequencing.
Aβ plaques exhibited upregulated microglial (neuroinflammation/phagocytosis) and downregulated neuronal (neurotransmission/energy metabolism) genes, whereas tangles had mostly downregulated neuronal genes. Aβ plaques had more differentially expressed genes than tangles. We identified a gradient Aβ plaque > peri-plaque > tangle > distant for these changes. AD APOE ε4 homozygotes had greater changes than APOE ε3 across locations, especially within Aβ plaques.
Transcriptomic changes in AD consist primarily of neuroinflammation and neuronal dysfunction, are spatially associated mainly with Aβ plaques, and are exacerbated by the APOE ε4 allele.","['APOE', ""Alzheimer's disease"", 'RNA-sequencing', 'amyloid-β plaques', 'laser capture microdissection', 'neurofibrillary tangles']",Alzheimer's & dementia : the journal of the Alzheimer's Association,2023-07-18,"[{'lastname': 'Das', 'firstname': 'Sudeshna', 'initials': 'S', 'affiliation': ""Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, Massachusetts, USA.\nHarvard Medical School, Boston, Massachusetts, USA.""}, {'lastname': 'Li', 'firstname': 'Zhaozhi', 'initials': 'Z', 'affiliation': ""Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, Massachusetts, USA.""}, {'lastname': 'Wachter', 'firstname': 'Astrid', 'initials': 'A', 'affiliation': 'AbbVie Deutschland GmbH & Co. KG, Genomics Research Center, Ludwigshafen, Germany.'}, {'lastname': 'Alla', 'firstname': 'Srinija', 'initials': 'S', 'affiliation': 'Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'lastname': 'Noori', 'firstname': 'Ayush', 'initials': 'A', 'affiliation': 'Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'lastname': 'Abdourahman', 'firstname': 'Aicha', 'initials': 'A', 'affiliation': 'AbbVie, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Tamm', 'firstname': 'Joseph A', 'initials': 'JA', 'affiliation': 'AbbVie, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Woodbury', 'firstname': 'Maya E', 'initials': 'ME', 'affiliation': 'AbbVie, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Talanian', 'firstname': 'Robert V', 'initials': 'RV', 'affiliation': 'AbbVie, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Biber', 'firstname': 'Knut', 'initials': 'K', 'affiliation': 'AbbVie Deutschland GmbH & Co. KG, Neuroscience Research Center, Ludwigshafen, Germany.'}, {'lastname': 'Karran', 'firstname': 'Eric H', 'initials': 'EH', 'affiliation': 'AbbVie, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Hyman', 'firstname': 'Bradley T', 'initials': 'BT', 'affiliation': ""Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, Massachusetts, USA.\nHarvard Medical School, Boston, Massachusetts, USA.""}, {'lastname': 'Serrano-Pozo', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, Massachusetts, USA.\nHarvard Medical School, Boston, Massachusetts, USA.""}]",,,"Aβ plaques exhibited upregulated microglial (neuroinflammation/phagocytosis) and downregulated neuronal (neurotransmission/energy metabolism) genes, whereas tangles had mostly downregulated neuronal genes. Aβ plaques had more differentially expressed genes than tangles. We identified a gradient Aβ plaque > peri-plaque > tangle > distant for these changes. AD APOE ε4 homozygotes had greater changes than APOE ε3 across locations, especially within Aβ plaques.",© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.,"10.1002/alz.13387
10.1016/j.cell.2015.12.056
10.1038/s41583-018-0113-1
10.1101/cshperspect.a006189
10.1016/j.ajpath.2011.05.047
10.1097/NEN.0b013e3182933788
10.1016/j.ajpath.2013.02.031
10.1016/j.ajpath.2015.10.010
10.1093/brain/aws127
10.1002/ana.24369
10.1038/s43587-021-00123-6
10.1212/WNL.0000000000011883
10.1038/s41586-019-1195-2
10.1038/s41593-019-0539-4
10.1038/s41591-019-0695-9
10.1073/pnas2008762117
10.1038/s41593-020-00764-7
10.1007/s00401-021-02263-w
10.1016/j.neuron.2022.03.008
10.1016/j.cell.2020.06.038
10.1038/s41593-022-01251-x
10.1007/s00401-019-02048-2
10.1186/s40478-022-01494-6
10.1016/j.jalz.2011.03.005
10.1016/j.jalz.2011.10.007
10.1007/s00401-011-0910-3
10.1093/bioinformatics/btw354
10.1093/bioinformatics/bts635
10.1093/bioinformatics/btt656
10.1186/gb-2010-11-3-r25
10.1186/gb-2014-15-2-r29
10.1093/nar/gkv007
10.1016/j.neuron.2015.11.013
10.1073/pnas.0506580102
10.1093/bioinformatics/btr260
10.1016/j.cell.2017.05.018
10.1016/j.immuni.2017.08.008
10.1016/j.celrep.2019.03.099
10.1101/2020.05.11.088591
10.1016/j.nbd.2020.105225
10.1016/j.dib.2021.106863
10.1111/nan.12753
10.1186/s12974-020-01898-y
10.1093/nar/gkz879
10.1038/s43587-021-00142-3
10.1186/s13024-021-00507-7
10.1093/bioinformatics/btq466
10.1002/cpz1.90
10.1093/nar/gkw377
10.1097/NEN.0b013e31825e77de
10.1016/0165-5728(89)90115-x
10.1038/nn.4587
10.1016/j.nbd.2020.105217
10.4049/jimmunol.1400874
10.1073/pnas.222433299
10.1523/JNEUROSCI.3272-11.2011
10.1186/s13024-022-00521-3
10.1523/JNEUROSCI.18-08-02801.1998
10.1523/JNEUROSCI.4637-04.2005
10.2353/ajpath.2009.080583
10.1016/j.celrep.2019.11.093
10.1038/s41586-022-05439-w
10.1016/j.cell.2020.12.025
10.1073/pnas.1419083111
10.1038/nature24016
10.1084/jem.20190980
10.1016/j.neuron.2022.10.022
10.1371/journal.pcbi.1008120
10.1186/s13024-020-00392-6
10.1038/s41593-020-00787-0
10.1038/s41592-022-01604-1",<Element 'PubmedArticle' at 0x7f05df5682c0>
14,37437821,LPS priming before plaque deposition impedes microglial activation and restrains Aβ pathology in the 5xFAD mouse model of Alzheimer's disease.,"Microglia have an innate immunity memory (IIM) with divergent functions in different animal models of neurodegenerative diseases, including Alzheimer's disease (AD). AD is characterized by chronic neuroinflammation, neurodegeneration, tau tangles and β-amyloid (Aβ) deposition. Systemic inflammation has been implicated in contributing to the progression of AD. Multiple reports have demonstrated unique microglial signatures in AD mouse models and patients. However, the proteomic profiles of microglia modified by IIM have not been well-documented in an AD model. Therefore, in the present study, we investigate whether lipopolysaccharide (LPS)-induced IIM in the pre-clinical stage of AD alters the microglial responses and shapes the neuropathology. We accomplished this by priming 5xFAD and wild-type (WT) mice with an LPS injection at 6 weeks (before the robust development of plaques). 140 days later, we evaluated microglial morphology, activation, the microglial barrier around Aβ, and Aβ deposition in both 5xFAD primed and unprimed mice. Priming induced decreased soma size of microglia and reduced colocalization of PSD95 and Synaptophysin in the retrosplenial cortex. Priming appeared to increase phagocytosis of Aβ, resulting in fewer Thioflavin S","['Innate immune memory', 'LPS', 'Long-term effects', 'Microglia', 'Neuroinflammation', 'Priming', 'Proteomics', 'Systemic inflammation', 'β-amyloid pathology']","Brain, behavior, and immunity",2023-07-13,"[{'lastname': 'Yang', 'firstname': 'Yiyi', 'initials': 'Y', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden. Electronic address: yiyi.yang@med.lu.se.'}, {'lastname': 'García-Cruzado', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden.'}, {'lastname': 'Zeng', 'firstname': 'Hairuo', 'initials': 'H', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden.'}, {'lastname': 'Camprubí-Ferrer', 'firstname': 'Lluís', 'initials': 'L', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden.'}, {'lastname': 'Bahatyrevich-Kharitonik', 'firstname': 'Bazhena', 'initials': 'B', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden; Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, Spain; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Seville, Seville, Spain.'}, {'lastname': 'Bachiller', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden; Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, Spain; Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Seville, Spain.'}, {'lastname': 'Deierborg', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Sweden. Electronic address: tomas.deierborg@med.lu.se.'}]",,,,Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.bbi.2023.07.006,<Element 'PubmedArticle' at 0x7f05df353130>
15,37419407,"DpdtpA, A Multi-metal Ion Chelator, Attenuates Tau Phosphorylation and Microglial Inflammatory Response via Regulating the PI3K/AKT/GSK-3β Signal Pathways.","Tau protein hyperphosphorylation and formation of intracellular neurofibrillary tangles (NFTs) are one of the histopathological hallmarks of Alzheimer's disease (AD) and positively correlated with the severity of AD symptoms. NFTs contain a large number of metal ions that play an important role in regulating tau protein phosphorylation and AD progression. Extracellular tau induces primary phagocytosis of stressed neurons and neuronal loss by activating microglia. Here, we studied the effects of a multi-metal ion chelator, DpdtpA, on tau-induced microglial activation and inflammatory responses and the underlying mechanisms. Treatment with DpdtpA attenuated the increase in the expression of NF-κB and production of inflammatory cytokines, IL-1β, IL-6 and IL-10, in rat microglial cells induced by expression of human tau40 proteins. Treatment with DpdtpA also suppressed tau protein expression and phosphorylation. Moreover, treatment with DpdtpA prevented tau-induced activation of glycogen synthase kinase-3β (GSK-3β) and inhibition of phosphatidylinositol-3-hydroxy kinase (PI3K)/AKT. Collectively, these results show that DpdtpA can attenuate tau phosphorylation and inflammatory responses of microglia by regulating the PI3K/AKT/GSK-3β signal pathways, providing a new option to alleviate neuroinflammation for the treatment of AD.","[""Alzheimer's disease"", 'DpdtpA', 'microglia', 'neuroinflammation', 'tau']",Neuroscience,2023-07-08,"[{'lastname': 'Wang', 'firstname': 'Lu', 'initials': 'L', 'affiliation': 'Henan Key Laboratory of Neurorestoratology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang, China. Electronic address: wllisa2004@126.com.'}, {'lastname': 'Wei', 'firstname': 'Yingjuan', 'initials': 'Y', 'affiliation': 'Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Sun', 'firstname': 'Zhenzhou', 'initials': 'Z', 'affiliation': 'Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Jiang', 'firstname': 'Lin-Hua', 'initials': 'LH', 'affiliation': 'Sino-UK Joint Laboratory of Brain Function and Injury of Henan Province, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Yin', 'firstname': 'Yaling', 'initials': 'Y', 'affiliation': 'Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Zheng', 'firstname': 'Panpan', 'initials': 'P', 'affiliation': 'Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Fu', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': 'Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Wang', 'firstname': 'Hongwei', 'initials': 'H', 'affiliation': 'Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Li', 'firstname': 'Changzheng', 'initials': 'C', 'affiliation': 'Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, China.'}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': 'Henan Key Laboratory of Neurorestoratology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Key Laboratory of Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}]",,,,Copyright © 2023 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2023.07.004,<Element 'PubmedArticle' at 0x7f05df347c70>
16,37341833,Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases.,"Microglia, the resident immune cells of the central nervous system, play a critical role in maintaining brain homeostasis. However, in neurodegenerative conditions, microglial cells undergo metabolic reprogramming in response to pathological stimuli, including Aβ plaques, Tau tangles, and α-synuclein aggregates. This metabolic shift is characterized by a transition from oxidative phosphorylation (OXPHOS) to glycolysis, increased glucose uptake, enhanced production of lactate, lipids, and succinate, and upregulation of glycolytic enzymes. These metabolic adaptations result in altered microglial functions, such as amplified inflammatory responses and diminished phagocytic capacity, which exacerbate neurodegeneration. This review highlights recent advances in understanding the molecular mechanisms underlying microglial metabolic reprogramming in neurodegenerative diseases and discusses potential therapeutic strategies targeting microglial metabolism to mitigate neuroinflammation and promote brain health. Microglial Metabolic Reprogramming in Neurodegenerative Diseases This graphical abstract illustrates the metabolic shift in microglial cells in response to pathological stimuli and highlights potential therapeutic strategies targeting microglial metabolism for improved brain health.","[""Alzheimer's disease"", 'Metabolic reprogramming', 'Microglia', 'Multiple sclerosis', ""Parkinson's disease""]",Cellular and molecular neurobiology,2023-06-21,"[{'lastname': 'Miao', 'firstname': 'Jifei', 'initials': 'J', 'affiliation': ""Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China.\nSchool of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.""}, {'lastname': 'Chen', 'firstname': 'Lihua', 'initials': 'L', 'affiliation': ""Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China.""}, {'lastname': 'Pan', 'firstname': 'Xiaojin', 'initials': 'X', 'affiliation': ""Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China.""}, {'lastname': 'Li', 'firstname': 'Liqing', 'initials': 'L', 'affiliation': ""Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China.""}, {'lastname': 'Zhao', 'firstname': 'Beibei', 'initials': 'B', 'affiliation': ""Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China. zhaobeibei@szbazyy.net.""}, {'lastname': 'Lan', 'firstname': 'Jiao', 'initials': 'J', 'affiliation': ""Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China. lanjiao@szbazyy.net.""}]",,,,"© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s10571-023-01376-y
10.1016/j.cmet.2019.06.005
10.1021/acs.jmedchem.5b01091
10.1371/journal.pone.0159381
10.1002/glia.22979
10.1016/j.yjmcc.2014.09.023
10.1016/j.celrep.2019.05.010
10.1038/s41467-020-15267-z
10.1016/j.tins.2020.08.008
10.1038/nrn2038
10.1016/S0140-6736(21)00218-X
10.1007/s00401-014-1310-2
10.1126/science.1123511
10.2174/1381612043452910
10.1038/nn.3599
10.3389/fimmu.2022.856376
10.3389/fncel.2014.00152
10.1126/science.aan4183
10.2174/1389450117666160401120514
10.1159/000516926
10.1073/pnas.95.20.11715
10.1186/s12974-015-0244-5
10.1002/glia.22282
10.3969/j.issn.1673-5374.2012.05.009
10.1186/1742-2094-11-98
10.3390/ijms22083907
10.1146/annurev-immunol-051116-052358
10.4103/1673-5374.322423
10.1007/s12192-014-0552-1
10.1007/s13277-015-4671-9
10.3233/JPD-130230
10.1007/s12035-016-0245-0
10.1016/j.neulet.2015.08.033
10.1016/j.mcn.2017.02.004
10.1523/JNEUROSCI.23-13-05928.2003
10.1111/dom.12608
10.1016/s0301-0082(02)00019-9
10.1186/1742-2094-4-9
10.1073/pnas.1807958115
10.1002/glia.10301
10.1016/j.pneurobio.2011.03.005
10.1016/j.tips.2012.03.008
10.1002/glia.22580
10.1097/00005072-199509000-00010
10.1038/ncb2012
10.3389/fnagi.2017.00242
10.1002/glia.23271
10.1002/jnr.23356
10.1016/j.cell.2010.02.016
10.1038/nature13989
10.1126/scitranslmed.aah4066
10.1016/j.nbd.2006.12.019
10.1007/s12031-007-0050-3
10.1016/j.immuni.2018.11.004
10.1186/s13073-021-00863-5
10.1038/nrm.2017.107
10.1083/jcb.201709069
10.1523/JNEUROSCI.5610-12.2013
10.1111/acel.12149
10.1038/nature11729
10.1016/S1474-4422(15)70016-5
10.1016/j.neuroscience.2014.09.007
10.1038/nrneurol.2014.207
10.1371/journal.pone.0052728
10.1523/JNEUROSCI.2051-11.2011
10.1038/s41593-018-0090-8
10.1038/nm.2399
10.1084/jem.20142322
10.1016/j.immuni.2015.02.005
10.1177/1073858418783959
10.1523/JNEUROSCI.2778-14.2015
10.1016/j.freeradbiomed.2013.04.016
10.1038/s41593-019-0486-0
10.1038/cr.2015.68
10.1016/j.lfs.2011.12.011
10.1111/jnc.12979
10.1186/1742-2094-10-114
10.1016/j.ijdevneu.2018.09.009
10.1007/s00406-016-0750-1
10.1186/s40035-020-00221-2
10.1038/ng.2802
10.1016/j.exger.2016.07.011
10.1016/j.cell.2012.03.017
10.3389/fimmu.2020.00493
10.1016/j.cell.2014.11.018
10.1186/1742-2094-10-119
10.1016/j.molimm.2021.10.017
10.1016/j.jpeds.2015.12.061
10.1016/j.expneurol.2015.08.018
10.1016/j.cmet.2013.12.008
10.1146/annurev.immunol.15.1.323
10.3390/ijms24031861
10.1523/JNEUROSCI.3944-09.2010
10.1073/pnas.1113421108
10.1097/01.mol.0000226119.20307.2b
10.1016/j.intimp.2020.107064
10.1111/bpa.12704
10.1074/jbc.M115.676817
10.1073/pnas.1002396107
10.1016/j.tins.2013.07.001
10.1016/j.cell.2016.08.064
10.1038/nn.3469
10.1016/j.plefa.2011.04.007
10.1523/JNEUROSCI.5321-06.2007
10.1016/j.plefa.2018.07.006
10.1038/ni.1980
10.1186/1742-2094-5-13
10.1016/j.plipres.2009.01.001
10.1038/nri.2016.70
10.1016/j.cmet.2016.11.009
10.3389/fnagi.2015.00057
10.1126/science.164.3880.719
10.1111/bph.13139
10.1016/j.immuni.2014.09.008
10.1007/s40259-017-0248-z
10.1111/jnc.12361
10.1111/jnc.12984
10.1016/j.neuroscience.2014.07.046
10.1007/s11064-015-1665-3
10.1016/j.expneurol.2014.05.015
10.1016/j.neuron.2014.12.007
10.1096/fj.201902447R
10.1111/j.1742-4658.2010.07754.x
10.3389/fchem.2014.00061
10.1172/JCI77983
10.1007/s12264-019-00388-3
10.1038/aps.2010.174
10.2174/1567205020666230203112351
10.1523/JNEUROSCI.0983-17.2017
10.1016/j.cell.2017.02.004
10.1016/j.freeradbiomed.2008.04.029
10.1016/j.cell.2012.01.021
10.3390/cells10061547
10.1038/nrneurol.2017.13
10.1371/journal.pbio.1002279
10.1111/febs.15327
10.1016/j.bbi.2012.09.013
10.1007/s00401-021-02384-2
10.1111/brv.12140
10.1016/j.tins.2006.07.001
10.1016/s0197-0186(02)00033-5
10.3389/fnagi.2017.00176
10.1007/s12035-014-9070-5
10.1038/nature11986
10.1152/ajpendo.00712.2009
10.1186/s12974-019-1659-1
10.1038/s41582-018-0072-1
10.1016/j.cell.2017.07.023
10.2174/157015909787602823
10.1016/j.celrep.2016.09.008
10.1126/science.1160809
10.1038/nature25158
10.1186/1742-2094-11-58
10.1007/s11064-015-1804-x
10.1016/j.febslet.2013.01.067
10.1016/j.neuropharm.2015.10.026
10.1017/S0007114511002868
10.1016/j.cell.2015.01.049
10.1084/jem.20151948
10.3390/metabo11120854
10.1016/j.biopha.2022.113412
10.1016/j.intimp.2023.109691
10.1016/j.neurobiolaging.2015.04.008
10.3389/fnagi.2016.00274
10.3390/cells11132091
10.1038/nrm3013
10.1016/j.bbi.2010.05.011
10.1016/s0197-0186(03)00013-5
10.2147/RRBC.S58057
10.1016/j.bbi.2016.01.001
10.3389/fcvm.2021.745810
10.1523/JNEUROSCI.1569-12.2012
10.1038/jcbfm.2013.242
10.1016/j.nbd.2021.105290
10.1016/j.neuron.2016.06.015
10.1016/s0304-3940(00)01724-9
10.1126/science.1219855
10.1002/wsbm.1483
10.1096/fj.03-0983fje
10.4161/auto.7.4.14541
10.1523/JNEUROSCI.1860-14.2014
10.1159/000373972
10.1016/j.placenta.2021.02.014
10.1002/dneu.22862
10.1186/s13024-022-00541-z
10.1002/jcp.27261",<Element 'PubmedArticle' at 0x7f05df3405e0>
17,"37297653
35913583
29143189
30103351
32508326
26963387
34501210
31076670
34657515
26923007
29311898
29249963
1759558
22002422
7217992
7198741
2883954
1449247
32651317
28974926
486847
17229089
10858586
12476347
25792098
15063099
23548902
16452658
35573291
21740813
1081052
6838727
2451684
2453254
1385201
2795482
11073068
23035667
20547177
30746447
31921707
20940357
7049316
16861296
15853938
19141730
11075904
15064399
9841671
9495612
19832799
20195365
19060153
19493340
20007650
16887619
3013780
11553560
15060736
16385121
7018907
11782116
14532000
3166451
2404867
7543886
8945563
9234775
11257008
18647113
15845495
10722578
4200775
3539799
2824585
1938897
16291643
14596901
16552080
17533151
2254019
7049315
6183890
7000302
4892124
1092423
10506508
15476920
11890454
12399581
29196460
30392797
31433986
31893014
31518519
34705082
28099414
27033548
17101650
18602340
301546
5813010
22371503
23808705
21414084
15495265
15582397
15853935
12002822
15155678
17868382
16495573
15056218
11312269
21901132
19862699
7642269
16730956
19657041
19951898
19828789
19880746
1382871
7538359
16406469
17392473
19377471
18202255
17190808
12428805
19747973
18074639
19095717
19081372
17188795
15340079
18337408
11163132
9813097
11901170
15615646
16344479
12695498
21816039
11929559
9228664
27372648
26432822
27223408
23125205
29144467
34542071
16704339
35954742
36673763
33731966
34346717",,"Alzheimer's disease (AD) is a neurodegenerative disease and the most common example of dementia. The neuropathological features of AD are the abnormal deposition of extracellular amyloid-β (Aβ) and intraneuronal neurofibrillary tangles with hyperphosphorylated tau protein. It is recognized that AD starts in the frontal cerebral cortex, and then it progresses to the entorhinal cortex, the hippocampus, and the rest of the brain. However, some studies on animals suggest that AD could also progress in the reverse order starting from the midbrain and then spreading to the frontal cortex. Spirochetes are neurotrophic: From a peripheral route of infection, they can reach the brain via the midbrain. Their direct and indirect effect via the interaction of their virulence factors and the microglia potentially leads to the host peripheral nerve, the midbrain (especially the locus coeruleus), and cortical damage. On this basis, this review aims to discuss the hypothesis of the ability of ","['Alzheimer’s disease', 'Treponema denticola', 'axonal transport', 'cytoskeletal impairment', 'mitochondrial docking', 'neurodegeneration', 'periodontal disease', 'peripheral nerve']",International journal of environmental research and public health,2023-06-10,"[{'lastname': 'Pisani', 'firstname': 'Flavio', 'initials': 'F', 'affiliation': 'Faculty of Clinical and Biomedical Sciences, School of Dentistry, University of Central Lancashire, Preston PR1 2HE, UK.'}, {'lastname': 'Pisani', 'firstname': 'Valerio', 'initials': 'V', 'affiliation': 'IRCCS, ""Santa Lucia"" Foundation, Neurology and Neurorehabilitation Unit, Via Ardeatina, 306, 00179 Rome, Italy.'}, {'lastname': 'Arcangeli', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Azienda Sanitaria Locale ASLRM1, Nuovo Regina Margherita Hospital, Geriatric Department, Advanced Centre for Dementia and Cognitive Disorders, Via Emilio Morosini, 30, 00153 Rome, Italy.'}, {'lastname': 'Harding', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Dementia and Neurodegenerative Disease Research Group, Faculty of Clinical and Biomedical Sciences, School of Dentistry, University of Central Lancashire, Preston PR1 2HE, UK.'}, {'lastname': 'Singhrao', 'firstname': 'Simarjit Kaur', 'initials': 'SK', 'affiliation': 'Dementia and Neurodegenerative Disease Research Group, Faculty of Clinical and Biomedical Sciences, School of Dentistry, University of Central Lancashire, Preston PR1 2HE, UK.'}]",,,,,"10.3390/ijerph20116049
10.1111/prd.12452
10.1007/s00784-017-2264-2
10.3233/JPD-181367
10.3233/JAD-200385
10.1371/journal.pone.0151081
10.3390/jcm10173763
10.1038/s41415-019-0309-4
10.1177/00220345211043461
10.3233/JAD150690
10.3389/fnagi.2017.00408
10.3389/fnagi.2017.00398
10.1007/BF00308809
10.1097/NEN.0b013e318232a379
10.1016/0022-510X(81)90031-9
10.1212/WNL.32.2.164
10.1001/archpsyc.1987.01800170026005
10.1002/ana.410320510
10.3233/JAD-200257
10.3389/fnana.2017.00080
10.1192/bjp.135.3.216
10.1111/j.1460-9568.2006.05223.x
10.1016/S0197-4580(00)00124-X
10.1080/13550280290100969
10.1016/S1474-4422(15)70016-5
10.1016/j.brainresrev.2004.02.002
10.1074/jbc.M113.458901
10.1523/JNEUROSCI.4236-05.2006
10.3389/fnins.2022.839622
10.1007/BF00235459
10.1037/0735-7044.97.1.62
10.1002/cne.902680403
10.1016/0006-8993(88)91206-1
10.1007/BF00230940
10.1113/jphysiol.1989.sp017519
10.1679/aohc.63.369
10.1111/j.1532-5415.2012.04154.x
10.1016/j.neubiorev.2010.06.002
10.1126/sciadv.aau3333
10.35702/nrj.10003
10.3389/fcimb.2019.00432
10.1177/0022034510385242
10.1136/sti.58.4.220
10.1177/154405910608500814
10.1111/j.1600-0757.2005.00113.x
10.1099/jmm.0.003517-0
10.1073/pnas.0307639101
10.1128/MMBR.62.4.1244-1263.1998
10.1111/j.1600-051X.1998.tb02419.x
10.1111/j.1399-302X.2009.00544.x
10.1371/journal.pone.0009321
10.1128/JB.01465-08
10.1186/1745-6150-4-19
10.1099/mic.0.033654-0
10.1006/anae.1997.0131
10.1128/iai.53.1.213-220.1986
10.1128/IAI.69.10.6193-6200.2001
10.1007/s00284-003-4168-4
10.1099/mic.0.28317-0
10.1111/j.1432-1033.1981.tb05338.x
10.1006/mpat.2001.0474
10.1016/S0092-8674(03)00754-2
10.1128/iai.56.10.2717-2722.1988
10.1128/iai.58.2.347-351.1990
10.1128/iai.63.9.3567-3575.1995
10.1128/iai.64.12.5178-5186.1996
10.1128/iai.65.8.3199-3202.1997
10.1128/AAC.45.4.999-1007.2001
10.1146/annurev.bioeng.10.061807.160536
10.1128/IAI.73.5.2891-2898.2005
10.1128/IAI.68.4.1884-1892.2000
10.1084/jem.138.5.1156
10.1128/iai.55.1.111-117.1987
10.1177/00220345870660120601
10.1128/jb.173.21.6935-6947.1991
10.1101/gad.1299905
10.1016/j.resmic.2003.08.001
10.1128/IAI.74.4.2462-2467.2006
10.1016/j.micinf.2007.03.009
10.1128/iai.58.12.3924-3928.1990
10.1136/sti.58.4.211
10.1136/sti.56.3.137
10.1136/sti.45.2.87
10.1136/sti.51.1.10
10.1006/exnr.1999.7170
10.1016/j.molimm.2004.06.011
10.1385/MN:25:1:001
10.1126/science.1074069
10.1083/jcb.201709069
10.1016/j.neuron.2018.10.014
10.1016/j.celrep.2019.07.060
10.1080/20002297.2019.1676486
10.1146/annurev-genet-112618-043515
10.1007/s00281-021-00895-4
10.1038/nature21029
10.1126/science.aad8373
10.1128/IAI.01458-06
10.1016/j.it.2008.04.008
10.1084/jem.146.1.257
10.4049/jimmunol.102.3.533
10.1074/jbc.M112.339721
10.1111/mmi.12311
10.1111/j.1469-0691.2011.03460.x
10.1002/path.1638
10.1016/j.sbi.2004.09.011
10.1111/j.1600-0757.2005.00108.x
10.1177/10454411010120050301
10.1128/IAI.72.6.3650-3654.2004
10.1111/j.1462-5822.2007.01045.x
10.1128/IAI.74.3.1954-1957.2006
10.1111/j.1462-5822.2004.00377.x
10.1074/jbc.M011735200
10.1371/journal.pone.0023736
10.1002/jcb.22372
10.1128/iai.63.9.3401-3410.1995
10.1016/j.bbadis.2006.04.002
10.1523/JNEUROSCI.0813-09.2009
10.1083/jcb.200908164
10.1523/JNEUROSCI.3463-09.2009
10.1073/pnas.0902949106
10.1002/cm.970230104
10.1091/mbc.6.1.21
10.1016/j.ijdevneu.2005.11.013
10.1523/JNEUROSCI.0037-07.2007
10.1038/nn.2314
10.1126/science.1152993
10.1073/pnas.0607919104
10.1385/NMM:2:2:089
10.1016/j.bbadis.2009.09.005
10.1002/9780470725207.ch13
10.1093/hmg/ddn437
10.1016/j.neuron.2008.10.010
10.1016/j.pneurobio.2006.09.003
10.1016/B978-0-12-374947-5.00008-0
10.1128/MCB.24.18.8195-8209.2004
10.1523/JNEUROSCI.0106-08.2008
10.1016/S0955-0674(00)00172-1
10.1083/jcb.143.3.777
10.1083/jcb.200108057
10.1016/j.bbadis.2004.06.017
10.1073/pnas.0508254102
10.1083/jcb.200207030
10.1186/1753-6561-2-s1-p43
10.1046/j.0902-0055.2001.00100.x
10.3233/JAD-160388
10.1093/femsre/fuv038
10.1016/j.cbi.2016.05.028
10.1101/cshperspect.a012427
10.1038/nature24624
10.3233/JAD-210429
10.1146/annurev.micro.60.080805.142106
10.3390/ijerph19159386
10.3390/ijerph20021007
10.1267/ahc.20-00036
10.1128/JCM.02385-20",<Element 'PubmedArticle' at 0x7f05df94b5e0>
18,"37287063
9759494
18834306
25766616
29401585
24885455
22559833
22270043
33414510
11520930
12358741
20478262
31332267
12641733
10854289
30003951
8180825
14962978
30721769
17429044
27468270
29934546
31031598
17086106
34391810
34516970
29225193
32811520
25193238
26852943
27768902
18987356
15466467
10692467
10802622
11375494
22048123
19682070
21651910
18550525
28104575
24383989
28747389
18266959
30074479
23604491
32159362
18506388
24193664
14685250
11182078
17270732
18353281
16723119
21245377
17823202
28887195
33279620
26886723
19171786
33122998
14684867
30839208
30021169
28355566",P2X7 receptor inhibition ameliorates ubiquitin-proteasome system dysfunction associated with Alzheimer's disease.,"Over recent years, increasing evidence suggests a causal relationship between neurofibrillary tangles (NFTs) formation, the main histopathological hallmark of tauopathies, including Alzheimer's disease (AD), and the ubiquitin-proteasome system (UPS) dysfunction detected in these patients. Nevertheless, the mechanisms underlying UPS failure and the factors involved remain poorly understood. Given that AD and tauopathies are associated with chronic neuroinflammation, here, we explore if ATP, one of the danger-associated molecules patterns (DAMPs) associated with neuroinflammation, impacts on AD-associated UPS dysfunction.
To evaluate if ATP may modulate the UPS via its selective P2X7 receptor, we combined in vitro and in vivo approaches using both pharmacological and genetic tools. We analyze postmortem samples from human AD patients and P301S mice, a mouse model that mimics pathology observed in AD patients, and those from the new transgenic mouse lines generated, such as P301S mice expressing the UPS reporter Ub
We describe for the first time that extracellular ATP-induced activation of the purinergic P2X7 receptor (P2X7R) downregulates the transcription of β5 and β1 proteasomal catalytic subunits via the PI3K/Akt/GSK3/Nfr2 pathway, leading to their deficient assembly into the 20S core proteasomal complex, resulting in a reduced proteasomal chymotrypsin-like and postglutamyl-like activities. Using UPS-reported mice (UbGFP mice), we identified neurons and microglial cells as the most sensitive cell linages to a P2X7R-mediated UPS regulation. In vivo pharmacological or genetic P2X7R blockade reverted the proteasomal impairment developed by P301S mice, which mimics that were detected in AD patients. Finally, the generation of P301S;UbGFP mice allowed us to identify those hippocampal cells more sensitive to UPS impairment and demonstrate that the pharmacological or genetic blockade of P2X7R promotes their survival.
Our work demonstrates the sustained and aberrant activation of P2X7R caused by Tau-induced neuroinflammation contributes to the UPS dysfunction and subsequent neuronal death associated with AD, especially in the hippocampus.","['Alzheimer’s disease', 'P2X7 receptor', 'Ubiquitin–proteasome system']",Alzheimer's research & therapy,2023-06-08,"[{'lastname': 'Bianchi', 'firstname': 'Carolina', 'initials': 'C', 'affiliation': 'Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Avda. Puerta de Hierro S/N, 28040, Madrid, Spain.\nInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.'}, {'lastname': 'Alvarez-Castelao', 'firstname': 'Beatriz', 'initials': 'B', 'affiliation': 'Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Avda. Puerta de Hierro S/N, 28040, Madrid, Spain.\nInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.'}, {'lastname': 'Sebastián-Serrano', 'firstname': 'Álvaro', 'initials': 'Á', 'affiliation': 'Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Avda. Puerta de Hierro S/N, 28040, Madrid, Spain.\nInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.'}, {'lastname': 'Di Lauro', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': 'Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Avda. Puerta de Hierro S/N, 28040, Madrid, Spain.\nInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.'}, {'lastname': 'Soria-Tobar', 'firstname': 'Lucia', 'initials': 'L', 'affiliation': 'Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Avda. Puerta de Hierro S/N, 28040, Madrid, Spain.\nInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.'}, {'lastname': 'Nicke', 'firstname': 'Annette', 'initials': 'A', 'affiliation': 'Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.'}, {'lastname': 'Engel', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'Department of Physiology and Medical Physics, RCSI, University of Medicine and Health Sciences, Dublin, D02 YN77, Ireland.\nFutureNeuro, SFI Research Centre for Chronic and Rare Neurological Diseases, RCSI, University of Medicine and Health Sciences, Dublin, D02 YN77, Ireland.'}, {'lastname': 'Díaz-Hernández', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': 'Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Avda. Puerta de Hierro S/N, 28040, Madrid, Spain. migueldiaz@ucm.es.\nInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain. migueldiaz@ucm.es.'}]",,,"We describe for the first time that extracellular ATP-induced activation of the purinergic P2X7 receptor (P2X7R) downregulates the transcription of β5 and β1 proteasomal catalytic subunits via the PI3K/Akt/GSK3/Nfr2 pathway, leading to their deficient assembly into the 20S core proteasomal complex, resulting in a reduced proteasomal chymotrypsin-like and postglutamyl-like activities. Using UPS-reported mice (UbGFP mice), we identified neurons and microglial cells as the most sensitive cell linages to a P2X7R-mediated UPS regulation. In vivo pharmacological or genetic P2X7R blockade reverted the proteasomal impairment developed by P301S mice, which mimics that were detected in AD patients. Finally, the generation of P301S;UbGFP mice allowed us to identify those hippocampal cells more sensitive to UPS impairment and demonstrate that the pharmacological or genetic blockade of P2X7R promotes their survival.",© 2023. The Author(s).,"10.1186/s13195-023-01258-x
10.1146/annurev.biochem.67.1.425
10.1146/annurev.pharmtox.051208.165340
10.1038/emm.2014.117
10.1096/fj.201701064RR
10.1186/1471-2474-15-166
10.1186/1742-2094-9-87
10.1016/j.pneurobio.2012.01.003
10.1038/s41418-020-00706-7
10.1146/annurev.neuro.24.1.1121
10.1046/j.1471-4159.2002.01137.x
10.1016/j.abb.2010.05.008
10.1038/s41598-019-47033-7
10.1046/j.1471-4159.2003.01642.x
10.1046/j.1471-4159.2000.0750436.x
10.1016/j.nbd.2018.07.006
10.1016/0006-8993(94)91757-4
10.1093/hmg/ddh083
10.1016/j.brainresbull.2019.01.031
10.1152/physrev.00043.2006
10.3389/fphys.2016.00294
10.1038/s41380-018-0108-3
10.3389/fncel.2019.00143
10.1097/01.jnen.0000240470.97295.d3
10.1016/j.pneurobio.2021.102139
10.1016/j.pneurobio.2021.102173
10.1016/j.ejphar.2017.12.006
10.1186/s13024-020-00396-2
10.1016/j.neuroscience.2014.08.036
10.2174/1567205013666160208142456
10.1016/j.bbadis.2016.10.012
10.1242/jcs.034082
10.1074/jbc.M409028200
10.1074/jbc.275.9.6592
10.1038/75406
10.1126/science.292.5521.1552
10.1016/j.neurobiolaging.2011.09.040
10.1111/j.1742-4658.2009.07228.x
10.1016/j.febslet.2011.05.048
10.1074/jbc.M802481200
10.1016/j.redox.2017.01.006
10.1111/jnc.12647
10.1523/JNEUROSCI.3104-16.2017
10.1111/j.1582-4934.2008.00276.x
10.7554/eLife.36217
10.1093/brain/awt083
10.1152/ajpcell.00053.2020
10.1007/s00702-008-0067-y
10.1007/s12035-013-8577-5
10.1038/nature02263
10.1016/S0896-6273(01)00177-5
10.1016/j.neuron.2007.01.010
10.1016/j.brainres.2008.02.030
10.1016/j.bbrc.2006.05.043
10.1128/MCB.01204-10
10.1093/hmg/ddm249
10.1016/j.bbr.2017.09.011
10.1016/j.freeradbiomed.2020.11.038
10.1089/ars.2015.6494
10.1096/fj.08-122275
10.3389/fnmol.2020.567430
10.1523/JNEUROSCI.23-37-11653.2003
10.1021/acs.jmedchem.9b00101
10.1016/j.celrep.2018.06.058
10.1016/j.celrep.2017.03.010",<Element 'PubmedArticle' at 0x7f05df7ddb80>
19,"37190116
33667416
31339847
27583652
31476157
31654430
34292312
33096024
32253358
34950148
31940023
33065974
29420261
33328899
35805174
36017697
29038483
29493017
34354209
31040847
33608912
33181238
30548343
34331705
32990808
36721258
30738892
31171767
25186741
33679311
7920638
8346443
31434879
7478253
8089103
26374899
24904407
34643971
12776204
33516818
12472885
23150934
23150908
27477018
25186950
25047746
27051467
36306735
33539598
30323814
31649511
36257314
26941262
28671693
22352893
21460840
23623698
26851150
33278431
28713158
34254984
34650610
33847763
26207229
29587871
31410002
30523761
32840654
31019207
34779509
31795604
11160388
11114266
15347683
1745413
12933918
32203525
11222634
32142677
36283867
34853891
18026096
21813677
24210819
26458768
33066368
30605723
18855662
8393323
34753506
17270732
25833819
31915009
30042659
9650583
29017970
28810892
33713018
33167838
18378084
29416128
27160163
28586818
30543173
31337809
31486140
29406043
26731277
25788560
30666612
32072098
30223011
26813032
30949019
27574286
27175012
31694670
36593507
16022602
27267247
22854119
29094305
31847911
12423672
21525267
20064241
25598354
36327895
32023447
31042697
28602351
29775591
28930663
32610143
32318054
18386786
25471735
21076838
24666681
35357926
27425031
16864778
28434692
30687013
21872563
28638339
16944320
22796213
27902447
32006534
35273075
20495845
34146512
31884472
24491678
34990615
36329553
23906616
29454265
31217968
35307206
31462511
35799899
34266459
9422548
23560052
24641683
32745992
35031916
34066847",The Functions and Phenotypes of Microglia in Alzheimer's Disease.,"Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide, but therapeutic strategies to slow down AD pathology and symptoms have not yet been successful. While attention has been focused on neurodegeneration in AD pathogenesis, recent decades have provided evidence of the importance of microglia, and resident immune cells in the central nervous system. In addition, new technologies, including single-cell RNA sequencing, have revealed heterogeneous cell states of microglia in AD. In this review, we systematically summarize the microglial response to amyloid-β and tau tangles, and the risk factor genes expressed in microglia. Furthermore, we discuss the characteristics of protective microglia that appear during AD pathology and the relationship between AD and microglia-induced inflammation during chronic pain. Understanding the diverse roles of microglia will help identify new therapeutic strategies for AD.","['Alzheimer’s disease', 'ApoE', 'CD11c', 'DAMs', 'TREM2', 'amyloid beta', 'brain', 'microglia', 'monocyte', 'pain', 'spinal cord', 'tau']",Cells,2023-05-16,"[{'lastname': 'Fujikawa', 'firstname': 'Risako', 'initials': 'R', 'affiliation': 'Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.'}, {'lastname': 'Tsuda', 'firstname': 'Makoto', 'initials': 'M', 'affiliation': 'Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.\nKyushu University Institute for Advanced Study, Fukuoka 819-0395, Japan.'}]",,,,,"10.3390/cells12081207
10.1016/S0140-6736(20)32205-4
10.1136/bmj.l94
10.1016/j.jalz.2016.07.150
10.3233/JAD-190507
10.1111/imcb.12301
10.1084/jem.20202717
10.1016/j.neuron.2020.09.029
10.1523/JNEUROSCI.2339-19.2020
10.3389/fimmu.2021.787307
10.1084/jem.20190290
10.3390/cells9102277
10.1126/science.aal3589
10.3389/fncel.2020.608073
10.3390/cells11132091
10.1111/ejn.15812
10.1038/s41598-017-13581-z
10.1002/glia.23318
10.1038/s41598-021-95535-0
10.3389/fimmu.2019.00790
10.1111/jnc.15327
10.1016/j.neuint.2020.104901
10.1002/glia.23571
10.1111/cei.13649
10.1186/s13550-020-00699-x
10.1186/s12974-023-02708-x
10.1016/j.jmb.2019.01.045
10.1038/s41398-019-0498-2
10.1523/JNEUROSCI.1860-14.2014
10.3389/fnins.2021.630502
10.1038/ng0694-180
10.1126/science.8346443
10.1038/s41467-019-11674-z
10.1016/0304-3940(95)11763-M
10.1016/S0021-9258(17)31529-6
10.1074/jbc.M115.679043
10.3389/fnagi.2014.00093
10.1002/glia.24105
10.1038/nri1106
10.1016/j.mad.2021.111438
10.1046/j.1471-4159.2002.01243.x
10.1056/NEJMoa1211851
10.1056/NEJMoa1211103
10.1016/j.neuron.2016.06.015
10.1111/bpa.12190
10.1038/npp.2014.164
10.1186/s13148-016-0202-9
10.1016/j.cell.2022.09.033
10.1002/glia.23968
10.3389/fimmu.2018.02235
10.3389/fncel.2019.00457
10.1016/j.cell.2022.09.030
10.15252/emmm.201506123
10.1038/nn.4597
10.1111/j.1749-6632.2011.06449.x
10.1038/ng.803
10.1016/j.neuron.2013.04.014
10.1016/j.proghi.2016.01.001
10.1016/j.ijbiomac.2020.11.192
10.1038/aps.2017.28
10.1001/jamainternmed.2021.4607
10.7573/dic.2021-7-3
10.1007/s00018-021-03810-0
10.1186/s13024-018-0247-7
10.2147/IJN.S200490
10.1080/15548627.2018.1556946
10.1007/s00401-020-02200-3
10.1038/s41598-019-42931-2
10.1111/ane.13551
10.5213/inj.1938184.092
10.1523/JNEUROSCI.21-04-01179.2001
10.1006/nbdi.2000.0321
10.1074/jbc.M402034200
10.1016/0304-3940(91)90490-K
10.1136/jnnp.74.9.1200
10.1371/journal.pone.0229819
10.1523/JNEUROSCI.21-05-01444.2001
10.1016/j.cell.2020.02.013
10.1016/j.tins.2022.10.007
10.1007/s00401-021-02384-2
10.1038/nn2015
10.1523/JNEUROSCI.6209-10.2011
10.1016/j.celrep.2013.10.010
10.1084/jem.20150479
10.3390/biom10101439
10.1016/j.pneurobio.2018.12.005
10.2174/092986708785909111
10.1016/0896-6273(93)90279-Z
10.1186/s40035-021-00270-1
10.1016/j.neuron.2007.01.010
10.1093/brain/awv081
10.1186/s12974-019-1694-y
10.3389/fncel.2018.00172
10.1016/S0014-5793(98)00583-3
10.1016/j.bbi.2017.10.002
10.1186/s13024-017-0200-1
10.1007/s12035-021-02348-3
10.2174/1567205017666201109095657
10.1016/j.neulet.2008.03.019
10.1038/nrn.2018.2
10.1159/000444791
10.1001/jamainternmed.2017.1622
10.2174/1567205016666181212162424
10.1038/s41598-019-47005-x
10.1002/gps.5180
10.1016/j.amjms.2017.09.002
10.1371/journal.pone.0144589
10.1212/WNL.0000000000001465
10.1007/s40122-019-0111-7
10.1097/PR9.0000000000000803
10.1016/j.bbi.2018.09.018
10.1111/jdi.12379
10.3389/fnins.2019.00213
10.1002/jnr.23883
10.1177/1744806916646784
10.1186/s12974-019-1608-z
10.1186/s13041-022-00986-9
10.1146/annurev.neuro.28.061604.135709
10.1016/j.neuroscience.2016.05.057
10.1016/j.biopsych.2012.06.033
10.1007/s00429-017-1543-7
10.1186/s12974-019-1632-z
10.1016/S0028-3908(02)00211-3
10.1523/JNEUROSCI.0450-11.2011
10.1186/1742-2094-7-2
10.1007/s12035-014-9070-5
10.1016/j.neuron.2022.10.020
10.1016/j.celrep.2020.01.010
10.1038/s41586-019-1195-2
10.1016/j.cell.2017.05.018
10.1016/j.cell.2018.05.003
10.1016/j.immuni.2017.08.008
10.1016/j.celrep.2020.107843
10.3389/fimmu.2020.00430
10.1002/cne.21668
10.1002/glia.22771
10.1007/s00401-010-0774-y
10.1186/1742-2094-11-57
10.1126/science.abf6805
10.1016/j.bbadis.2016.07.007
10.1073/pnas.0604681103
10.1016/j.neurobiolaging.2017.03.021
10.3389/fncel.2018.00523
10.1016/j.ajpath.2011.06.011
10.3389/fnagi.2017.00175
10.1007/s11064-006-9128-5
10.1016/j.neuint.2012.07.003
10.1126/scisignal.aah7102
10.1016/j.bbamcr.2020.118664
10.1101/gad.349232.121
10.1007/s00011-010-0203-7
10.1016/S1474-4422(21)00043-0
10.3233/JAD-190864
10.1016/j.cbi.2014.01.012
10.1016/j.neuropharm.2021.108941
10.1186/s13195-022-01097-2
10.1016/j.neurobiolaging.2013.06.020
10.1016/j.jnutbio.2018.01.009
10.1017/jns.2019.16
10.1016/j.tins.2022.02.005
10.1126/scitranslmed.aav6221
10.3389/fnmol.2022.912995
10.1186/s13024-021-00457-0
10.1371/journal.pone.0059586
10.1111/acel.12210
10.1016/j.ebiom.2020.102919
10.1007/s12035-021-02613-5
10.3390/cells10051138",<Element 'PubmedArticle' at 0x7f05df24cbd0>
20,"37182879
22675658
28872215
1566067
12130773
11520988
18055549
30599077
28500862
24076100
20802182
11520987
15664690
25853174
20936700
24604080
18258852
8878531
8742040
24904272
17239007
17997701
17059563
19477245
19782073
21421841
19940172
24269021
27190008
31591472
11160831
15044677
17183532
8245963
7898684
19183272
8809831
8287279
22787440
19695252
22337826
29562522
21061060
3084478
3088567
2427509
3099793
1899488
8849730
7507619
7566346
1284442
1587865
9771888
14713290
16803897
7515946
10450875
19816983
17047304
18690834
16529745
18855662
2874414
8360683
8202528
11381127
16735465
30584140
26192747
18052981
17241267
17237805
28251650
30349462
26969409
30445661
30796139
24962261
27179961
27060942
26984188
7849528
15639313
10858586
23392676
16960575
17222916
31960800
8751442
19688332
28049142
11526957
12379901
17979699
16977605
23650361
28607354
18186084
14581618
18757884
22056384
28469641
24062644
28431620
28928740
28744452
12700599
15212825
16814429
10534257
15944180
11406822
15788705
20887954
14668448
26311768
8742267
16399667
18467361
11596125
10668987
12700753
12465047
12235363
12161747
12202033
10995547
11070094
9326667
9398456
30391355
34531807
33071951
33806259
30538622
31973106
17917161
27090093
26797041
23656989
3196922
26515274
19057621
28805002
29237809
24462092
33589835
26671410
31165009
12571445
20880504
28607171
26546579
29178139
22896675
18071147
10377448
23630193
15800046
28619259
23898238
8581317
23599891
28152040
11986659
22983209
15707899
20124433
14684875
16846377
26606999
33318676
33239064
28127589
20303880
20846376
24973918
23690607
25730668
28515434
16212664
35714860
31960800
1759558
9330961
16906426
22002422
21170538
25920101
26283673
15063099
16254995
19506723
19190638
22717696
1336586
17140156
25359108
27878366
19503072
22365544
19282288
21372138
22312444
6363926
11016541
33061903
31686182
28408124
30040731
24075978
29590627
23898162
25261551
20805224
28610892
22496370
25869641
27351289
26458742
29258615
27497324
27810929
28587664
31064413
25406315
24857020
23690619
24531916
24479894
26150341
25220759
9144589
34395435
26224867
28424326
29509544
24971751
29768203
30463001
28086931
27715442
27809932
31312118
26436904
22138183
27567840
27030011
22057275
25130657
29495441
27408937
23395797
25981034
24362441
23188818
27760323
28527044
24005412
18359772
29988016
27322420
26988744
26576562
33913022
25833819
30227881
26659578
7479786
9082959
33169029
29298427
21917794
31118883
30874605
26057852
25217135
29054878
27580631
7898168
2537480
22675301
6756551
29752551
30349969
24362760
21331296
12625464
2913203
10985279
18313770
18551518
8126576
7890828
25032492
27084356
12619779
15851853
30532084
690285
7240454
33163897
4090943
11517260
16254185
15755543
19252922
20525067
20071537
22867732
22940906
22492306
22215607
26384869
31978364
30820459
22842902
20943911
19951691
31186040
29632371
31782760
19230552
21325651
12053130
26141491
29070667
20061618
18991338
21705422
23358601
26962052
30266970
16120771
19211893
26037224
25405944
21185234
31672482
33246962
32047067
32201044
31657834
33429401
21802369
36376963
31476153
33305264
33262228
28241163
30549156
28747523
28394771
29451323
28754841
29497818
33927414
35393555
29323751
26936940
23239642
21596277
20403963
30344489
31275097
25936874
30550812
12453618
15917746
19325641
27496030
12447935
14550778
16775151
30028510
16210404
26091041
31199935
17537967
25957904
20452319
30837840
9133393
16168988
16611826
27597527
17042797
19118585
19699201
23986699
22192775
21395858
29217824
21382546
22583753
16341203
19553437
20801218
21395851
12244210
17760871
21149712
26682682
12764034
14702635
16251967
18852283
30190379
27298190
26879907
23773067
17639447
16814555
16938507
15207348
17070803
21323664
15340159
25348064
30465754
25778618
5707082
9546293
26597697
22802095
7566337
23208308
13812088
4729191
1759563
10442557
17143242
15987548
20032774
19535999
20720505
20587081
21074091
21074089
21074078
21696410
22035690
22593173
22017610
23458973
20851190
26667418
28347679
19909815
11484824
24366527
30314800
24656052
1649907
22899188
25157230
24429902
25932012
20209079
27225182
24988208
25376108
26836158
30001512
24847267
30863282
26967229
18973185
25043910
18982063
23261465
24072067
9014911
9649761
18599953
19221424
24296813
28251511
7116237
3998736
8936355
9643802
14686902
17994434
18852062
1328575
30870531
27357149
25031345
16036791
26246389
15731073
23382563
16963740
24807365
23748078
31381841
33551741
29435558
27454922
28097205
28253546
29912295
29403032
29449700
27413148
28232190
23683827
19201065
17940008
26134318
30250262
26746185
31392412
29922148
12711363
28397252
12031273
23563788
26417888
19801098
14973487
11333968
12627226
9809557
31271749
29681514",The Adult Neurogenesis Theory of Alzheimer's Disease.,"Alzheimer's disease starts in neural stem cells (NSCs) in the niches of adult neurogenesis. All primary factors responsible for pathological tau hyperphosphorylation are inherent to adult neurogenesis and migration. However, when amyloid pathology is present, it strongly amplifies tau pathogenesis. Indeed, the progressive accumulation of extracellular amyloid-β deposits in the brain triggers a state of chronic inflammation by microglia. Microglial activation has a significant pro-neurogenic effect that fosters the process of adult neurogenesis and supports neuronal migration. Unfortunately, this ""reactive"" pro-neurogenic activity ultimately perturbs homeostatic equilibrium in the niches of adult neurogenesis by amplifying tau pathogenesis in AD. This scenario involves NSCs in the subgranular zone of the hippocampal dentate gyrus in late-onset AD (LOAD) and NSCs in the ventricular-subventricular zone along the lateral ventricles in early-onset AD (EOAD), including familial AD (FAD). Neuroblasts carrying the initial seed of tau pathology travel throughout the brain via neuronal migration driven by complex signals and convey the disease from the niches of adult neurogenesis to near (LOAD) or distant (EOAD) brain regions. In these locations, or in close proximity, a focus of degeneration begins to develop. Then, tau pathology spreads from the initial foci to large neuronal networks along neural connections through neuron-to-neuron transmission.","['Amyloid', 'microglia', 'neurofibrillary tangles', 'neurogenesis', 'tauopathies']",Journal of Alzheimer's disease : JAD,2023-05-15,"[{'lastname': 'Abbate', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': 'IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy.'}]",,,,,10.3233/JAD-221279,<Element 'PubmedArticle' at 0x7f05df85b1d0>
21,"37131588
27763252
25534619
30611442
31841704
32238454
29196460
29790571
24786080
33720902
32576641
28067908
30820047
34493866
27863251
22492648
17701901
24733291
29335400
29846171
26414676
34493870
34873335
31701892
31604244
32499647
34002096
30718901
35396580
33277387
21187437
30518596
26414614
34795257
33712570
28263993
32103677
31824296
30872998
11533682
31002701
33298560
29881546
31543810
33693659
22442384
34561436
28867419
29986021
28322246
35668160
33446646",Genetic insights into the association between inflammatory bowel disease and Alzheimer's disease.,"Myeloid cells, including monocytes, macrophages, microglia, dendritic cells and neutrophils are a part of innate immunity, playing a major role in orchestrating innate and adaptive immune responses. Microglia are the resident myeloid cells of the central nervous system, and many Alzheimer's disease (AD) risk loci are found in or near genes that are highly or sometimes uniquely expressed in myeloid cells. Similarly, inflammatory bowel disease (IBD) loci are also enriched for genes expressed by myeloid cells. However, the extent to which there is overlap between the effects of AD and IBD susceptibility loci in myeloid cells remains poorly described, and the substantial IBD genetic maps may help to accelerate AD research.
Here, we leveraged summary statistics from large-scale genome-wide association studies (GWAS) to investigate the causal effect of IBD (including ulcerative colitis and Crohn's disease) variants on AD and AD endophenotypes. Microglia and monocyte expression Quantitative Trait Locus (eQTLs) were used to examine the functional consequences of IBD and AD risk variants enrichment in two different myeloid cell subtypes.
Our results showed that, while 
To our knowledge, this is the first study to systematically contrast the genetic association between IBD and AD, our findings highlight a possible genetically protective effect of IBD on AD even if the majority of effects on myeloid cell gene expression by the two sets of disease variants are distinct. Thus, IBD myeloid studies may not help to accelerate AD functional studies, but our observation reinforces the role of myeloid cells in the accumulation of tau proteinopathy and provides a new avenue for discovering a protective factor.","['AD endophenotypes', 'Alzheimer’s disease', 'GWAS', 'Inflammatory bowel disease', 'Mendelian randomization', 'PheWAS', 'eQTL']",medRxiv : the preprint server for health sciences,2023-05-03,"[{'lastname': 'Zeng', 'firstname': 'Lu', 'initials': 'L', 'affiliation': ""Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'White', 'firstname': 'Charles C', 'initials': 'CC', 'affiliation': ""Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'Bennett', 'firstname': 'David A', 'initials': 'DA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.""}, {'lastname': 'Klein', 'firstname': 'Hans-Ulrich', 'initials': 'HU', 'affiliation': ""Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.""}, {'lastname': 'De Jager', 'firstname': 'Philip L', 'initials': 'PL', 'affiliation': ""Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.""}]",,"To our knowledge, this is the first study to systematically contrast the genetic association between IBD and AD, our findings highlight a possible genetically protective effect of IBD on AD even if the majority of effects on myeloid cell gene expression by the two sets of disease variants are distinct. Thus, IBD myeloid studies may not help to accelerate AD functional studies, but our observation reinforces the role of myeloid cells in the accumulation of tau proteinopathy and provides a new avenue for discovering a protective factor.","Our results showed that, while ",,10.1101/2023.04.17.23286845,<Element 'PubmedArticle' at 0x7f05df6ab8b0>
22,"37018391
29242522
33986301
33318676
25792098
31748742
30227881
34446931
1759558
9330961
16906426
22002422
32380523
31320450
12383924
15681802
24052108
21777559
28575151
30052812
9343467
21556001
24162737
8346443
22393530
28959956
31367008
21907569
29861287
24948358
36871219
28602351
35232622
23150908
23150934
30140051
28768545
28930663
31601677
32460813
33550655
33831349
31504240
10563634
23152815
20541611
31860000
32251378
29230021
18800007
22875916
31479168
31276244
26936941
34593971
35717526
15324362
21514250
31698286
31139959
30610927
26194313
35948658
30064520
22323782
32671408
23227001
27697430
26938442
34515754
25857759
22996553
29723639
32333900",,Animal studies suggest that the apolipoprotein E ε4 (,[],Science advances,2023-04-06,"[{'lastname': 'Ferrari-Souza', 'firstname': 'João Pedro', 'initials': 'JP', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'lastname': 'Lussier', 'firstname': 'Firoza Z', 'initials': 'FZ', 'affiliation': ""Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Leffa', 'firstname': 'Douglas T', 'initials': 'DT', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nADHD Outpatient Program and Development Psychiatry Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'lastname': 'Therriault', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Tissot', 'firstname': 'Cécile', 'initials': 'C', 'affiliation': ""Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Bellaver', 'firstname': 'Bruna', 'initials': 'B', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'lastname': 'Ferreira', 'firstname': 'Pâmela C L', 'initials': 'PCL', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Malpetti', 'firstname': 'Maura', 'initials': 'M', 'affiliation': 'Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Wang', 'firstname': 'Yi-Ting', 'initials': 'YT', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Povala', 'firstname': 'Guilherme', 'initials': 'G', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'lastname': 'Benedet', 'firstname': 'Andréa L', 'initials': 'AL', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.\nDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.""}, {'lastname': 'Ashton', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': ""Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nCentre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.\nDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'lastname': 'Chamoun', 'firstname': 'Mira', 'initials': 'M', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Servaes', 'firstname': 'Stijn', 'initials': 'S', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Bezgin', 'firstname': 'Gleb', 'initials': 'G', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.\nMontreal Neurological Institute, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Kang', 'firstname': 'Min Su', 'initials': 'MS', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.\nArtificial Intelligence and Computational Neurosciences lab, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.\nLC Campbell Cognitive Neurology Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.""}, {'lastname': 'Stevenson', 'firstname': 'Jenna', 'initials': 'J', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Rahmouni', 'firstname': 'Nesrine', 'initials': 'N', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Pallen', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Poltronetti', 'firstname': 'Nina Margherita', 'initials': 'NM', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': ""O'Brien"", 'firstname': 'John T', 'initials': 'JT', 'affiliation': 'Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.\nDepartment of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.\nMRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Cohen', 'firstname': 'Ann D', 'initials': 'AD', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Lopez', 'firstname': 'Oscar L', 'initials': 'OL', 'affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Tudorascu', 'firstname': 'Dana L', 'initials': 'DL', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Karikari', 'firstname': 'Thomas K', 'initials': 'TK', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'lastname': 'Klunk', 'firstname': 'William E', 'initials': 'WE', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Villemagne', 'firstname': 'Victor L', 'initials': 'VL', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Soucy', 'firstname': 'Jean-Paul', 'initials': 'JP', 'affiliation': 'Montreal Neurological Institute, McGill University, Montreal, QC, Canada.'}, {'lastname': 'Gauthier', 'firstname': 'Serge', 'initials': 'S', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Souza', 'firstname': 'Diogo O', 'initials': 'DO', 'affiliation': 'Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.\nDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.\nUK Dementia Research Institute at UCL, London, UK.\nHong Kong Center for Neurodegenerative Diseases, Hong Kong, China.'}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'lastname': 'Zimmer', 'firstname': 'Eduardo R', 'initials': 'ER', 'affiliation': 'Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.\nDepartment of Pharmacology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.\nGraduate Program in Biological Sciences: Pharmacology and Therapeuctis, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'lastname': 'Rosa-Neto', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.""}, {'lastname': 'Pascoal', 'firstname': 'Tharick A', 'initials': 'TA', 'affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.\nDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.'}]",,,,,"10.1126/sciadv.ade1474
10.1101/2022.05.17.492361
10.1101/2022.01.20.22269607",<Element 'PubmedArticle' at 0x7f05df6476d0>
23,"36945656
27546235
24833586
30471926
26786204
28732515
34107254
33214681
35228310
23273845
28122230
31493147
35260865
30783653
19910308
27508061
16199517
35589920
24994846
21369534
35974106
28602351
30082275
17969104
28863860
16626397
12670482
25896511
21490621
21642987
17851529
32848093
28970783
36617879
23545502
25666439
34530748
26235985
35177477
30944478
34140954
31959936
25309543
24963278
22198949
18981147
31324751
35487953
28245991
30782788
15833363
34294785
33301878
19689368
34281564
23965734
32379705
24162652
31018141
28930663
36747024
35181976
11322887
26354916
24019961
18256700
28928743
28665028
15728241
19503107
20484116
27091843
36257314
33008530
36449413
36624497",Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer's disease.,"Microglia, the brain's principal immune cells, have been implicated in the pathogenesis of Alzheimer's disease (AD), a condition shown to affect more females than males. Although sex differences in microglial function and transcriptomic programming have been described across development and in disease models of AD, no studies have comprehensively identified the sex divergences that emerge in the aging mouse hippocampus. Further, existing models of AD generally develop pathology (amyloid plaques and tau tangles) early in life and fail to recapitulate the aged brain environment associated with late-onset AD. Here, we examined and compared transcriptomic and translatomic sex effects in young and old murine hippocampal microglia.
Hippocampal tissue from C57BL6/N and microglial NuTRAP mice of both sexes were collected at young (5-6 month-old [mo]) and old (22-25 mo) ages. Cell sorting and affinity purification techniques were used to isolate the microglial transcriptome and translatome for RNA-sequencing and differential expression analyses. Flow cytometry, qPCR, and imaging approaches were used to confirm the transcriptomic and translatomic findings.
There were marginal sex differences identified in the young hippocampal microglia, with most differentially expressed genes (DEGs) restricted to the sex chromosomes. Both sex chromosomally-and autosomally-encoded sex differences emerged with aging. These sex DEGs identified at old age were primarily female-biased and enriched in senescent and disease-associated microglial signatures. Normalized gene expression values can be accessed through a searchable web interface ( https://neuroepigenomics.omrf.org/ ). Pathway analyses identified upstream regulators induced to a greater extent in females than in males, including inflammatory mediators IFNG, TNF, and IL1B, as well as AD-risk genes TREM2 and APP.
These data suggest that female microglia adopt disease-associated and senescent phenotypes in the aging mouse hippocampus, even in the absence of disease pathology, to a greater extent than males. This sexually divergent microglial phenotype may explain the difference in susceptibility and disease progression in the case of AD pathology. Future studies will need to explore sex differences in microglial heterogeneity in response to AD pathology and determine how sex-specific regulators (i.e., sex chromosomal or hormonal) elicit these sex effects.",[],bioRxiv : the preprint server for biology,2023-03-23,"[{'lastname': 'Ocañas', 'firstname': 'Sarah R', 'initials': 'SR', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.\nDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.'}, {'lastname': 'Pham', 'firstname': 'Kevin D', 'initials': 'KD', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.'}, {'lastname': 'Cox', 'firstname': 'Jillian E J', 'initials': 'JEJ', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.\nGraduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'lastname': 'Keck', 'firstname': 'Alex W', 'initials': 'AW', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.'}, {'lastname': 'Ko', 'firstname': 'Sunghwan', 'initials': 'S', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.\nGraduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'lastname': 'Ampadu', 'firstname': 'Felix A', 'initials': 'FA', 'affiliation': 'Graduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'lastname': 'Porter', 'firstname': 'Hunter L', 'initials': 'HL', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.'}, {'lastname': 'Ansere', 'firstname': 'Victor A', 'initials': 'VA', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.\nDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.'}, {'lastname': 'Kulpa', 'firstname': 'Adam', 'initials': 'A', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.'}, {'lastname': 'Kellogg', 'firstname': 'Collyn M', 'initials': 'CM', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.\nDepartment of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.'}, {'lastname': 'Machalinski', 'firstname': 'Adeline H', 'initials': 'AH', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.'}, {'lastname': 'Chucair-Elliott', 'firstname': 'Ana J', 'initials': 'AJ', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.'}, {'lastname': 'Freeman', 'firstname': 'Willard M', 'initials': 'WM', 'affiliation': 'Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK USA.\nDepartment of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.\nOklahoma City Veterans Affairs Medical Center, Oklahoma City, OK USA.'}]",,,"There were marginal sex differences identified in the young hippocampal microglia, with most differentially expressed genes (DEGs) restricted to the sex chromosomes. Both sex chromosomally-and autosomally-encoded sex differences emerged with aging. These sex DEGs identified at old age were primarily female-biased and enriched in senescent and disease-associated microglial signatures. Normalized gene expression values can be accessed through a searchable web interface ( https://neuroepigenomics.omrf.org/ ). Pathway analyses identified upstream regulators induced to a greater extent in females than in males, including inflammatory mediators IFNG, TNF, and IL1B, as well as AD-risk genes TREM2 and APP.",,10.1101/2023.03.07.531562,<Element 'PubmedArticle' at 0x7f05df61b4f0>
24,36889338,Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment.,"The pathophysiological processes of dementia and cognitive impairment are linked to advanced glycation end products (AGEs) and their receptor (RAGE).The neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau protein and senile plaques (SPs), which are brought on by amyloid beta (Aβ) deposition, are the hallmarks of Alzheimer's disease (AD), a progressive neurodegenerative condition. Advanced glycation end products that are produced as a result of vascular dysfunction are bound by the receptor for advanced glycation end products (RAGE). Dementia and cognitive impairment could develop when RAGE binds to Aβ and produces reactive oxygen species, aggravating Aβ buildup and ultimately resulting in SPs and NFTs. RAGE could be a more powerful biomarker than Aβ because it is implicated in early AD. The resident immune cells in the brain known as microglia are essential for healthy brain function. Microglia is prominent in the amyloid plaques' outside border as well as their central region in Alzheimer's disease. Microglial cells, in the opinion of some authors, actively contribute to the formation of amyloid plaques. In this review, we first discuss the early diagnosis of dementia and cognitive impairment, and then detail the interaction between RAGE and Aβ and Tau that is necessary to cause dementia and cognitive impairment pathology, and it is anticipated that the creation of RAGE probes will help in the diagnosis and treatment of dementia and cognitive impairment.",[],Drug research,2023-03-09,"[{'lastname': 'Singh', 'firstname': 'Aditya', 'initials': 'A', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Ansari', 'firstname': 'Vaseem Ahamad', 'initials': 'VA', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Mahmood', 'firstname': 'Tarique', 'initials': 'T', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Ahsan', 'firstname': 'Farogh', 'initials': 'F', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Wasim', 'firstname': 'Rufaida', 'initials': 'R', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Shariq', 'firstname': 'Mohammad', 'initials': 'M', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Parveen', 'firstname': 'Saba', 'initials': 'S', 'affiliation': 'Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, India.'}, {'lastname': 'Maheshwari', 'firstname': 'Shubhrat', 'initials': 'S', 'affiliation': 'Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Rama University, Mandhana, Bithoor Road, Kanpur, Uttar Pradesh, India.'}]",,,,Thieme. All rights reserved.,10.1055/a-2015-8041,<Element 'PubmedArticle' at 0x7f05df5c8720>
25,36740796,Roles of Microglia in AD Pathology.,"Amyloid plaques and neurofibrillary tangles are two main characteristics of Alzheimer's disease (AD). As cerebral resident phagocytes, microglia have different roles in Aβ pathology and tau pathology. In this review, we discuss microglial functions in the formation, clearance, and spread of Aβ and tau. Many receptors and enzymes, which are related to microglia, participate in AD pathologies and thus are thought to be potential targets of AD. So, making use of microglia can be beneficial to confine AD pathologies. To sum up, this article review the roles of microglia in AD pathology and possible corresponding treatments.","['Alzheimer’s disease', 'amyloid β', 'microglia', 'neurofibrillary tangles', 'phagocytes', 'tau']",Current Alzheimer research,2023-02-07,"[{'lastname': 'Rong', 'firstname': 'Gao', 'initials': 'G', 'affiliation': 'Department of Physiology, Hengyang Medical School, University of South China, Hengyang, P.R. China.'}, {'lastname': 'Hongrong', 'firstname': 'Wu', 'initials': 'W', 'affiliation': 'Institute of Pathogenic Biology, Hengyang Medical School, University of South China, Hengyang, P.R. China.'}, {'lastname': 'Qingqi', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Institute of Neuroscience, Hengyang Medical School, University of South China, Hengyang, P.R. China.'}, {'lastname': 'Jianfeng', 'firstname': 'Zhao', 'initials': 'Z', 'affiliation': 'Department of Physiology, Hengyang Medical School, University of South China, Hengyang, P.R. China.\nInstitute of Neuroscience, Hengyang Medical School, University of South China, Hengyang, P.R. China.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1567205020666230203112351,<Element 'PubmedArticle' at 0x7f05df5cfd10>
26,36641613,"Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis.","Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, amyloid-β (Aβ) plaques and the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. Increasing evidence has demonstrated that the damage of cell plays an important role in AD. Cell death is a critical phenomenon for physiological functions, which promotes AD pathogenesis. Programmed cell death, including necroptosis, pyroptosis, autophagy, and ferroptosis, have been discovered that have unique biological functions and pathophysiological characteristics. Here, we review the available evidence detailing the mechanisms of programmed microglial death, including pyroptosis, autophagy, and ferroptosis. We also highlight the role of programmed death of microglia during the process of AD and focus on the connection between the disease and cell death.","['Alzheimer’s disease', 'autophagy', 'cell death', 'ferroptosis', 'microglia', 'pyroptosis']",The journal of prevention of Alzheimer's disease,2023-01-16,"[{'lastname': 'Qiu', 'firstname': 'Z', 'initials': 'Z', 'affiliation': 'Changhong Miao, Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China, miaochangh@163.com.'}, {'lastname': 'Zhang', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Xia', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gu', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Guo', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Miao', 'firstname': 'C', 'initials': 'C', 'affiliation': None}]",,,,,10.14283/jpad.2023.3,<Element 'PubmedArticle' at 0x7f05df5d9c70>
27,36370050,Total alkaloids from the seed embryo of ,The seed embryo of ,"['APP/PS1 mice', 'Alkaloids', ""Alzheimer's disease"", 'PC12 cells', 'Seed embryo of Nelumbo nucifera Gaertn', 'Tau phosphorylation', '\u200cAmyloid-β', '\u200cCaM', '\u200cMicroglia']",Nutritional neuroscience,2022-11-13,"[{'lastname': 'Meng', 'firstname': 'Xue-Lian', 'initials': 'XL', 'affiliation': ""School of Pharmaceutical Science, Liaoning University, Shenyang, People's Republic of China.\nResearch Center for Natural Product Pharmacy of Liaoning Province, Shenyang, People's Republic of China.""}, {'lastname': 'Xue', 'firstname': 'Jing-Su', 'initials': 'JS', 'affiliation': ""School of Pharmaceutical Science, Liaoning University, Shenyang, People's Republic of China.""}, {'lastname': 'Su', 'firstname': 'Shu-Jie', 'initials': 'SJ', 'affiliation': ""School of Pharmaceutical Science, Liaoning University, Shenyang, People's Republic of China.""}, {'lastname': 'Gou', 'firstname': 'Jiang-Min', 'initials': 'JM', 'affiliation': ""School of Pharmaceutical Science, Liaoning University, Shenyang, People's Republic of China.""}, {'lastname': 'Lu', 'firstname': 'Jing', 'initials': 'J', 'affiliation': ""School of Pharmaceutical Science, Liaoning University, Shenyang, People's Republic of China.\nResearch Center for Natural Product Pharmacy of Liaoning Province, Shenyang, People's Republic of China.""}, {'lastname': 'Chen', 'firstname': 'Chang-Lan', 'initials': 'CL', 'affiliation': ""School of Pharmaceutical Science, Liaoning University, Shenyang, People's Republic of China.""}, {'lastname': 'Xu', 'firstname': 'Cheng-Bin', 'initials': 'CB', 'affiliation': ""School of Environmental Science, Liaoning University, Shenyang, People's Republic of China.""}]",,,,,10.1080/1028415X.2022.2145426,<Element 'PubmedArticle' at 0x7f05df5e34f0>
28,36302379,Dysfunctional microglia and tau pathology in Alzheimer's disease.,"Extensive human studies and animal models show that chronic immune system stimulation involving microglia, inflammasome, complement activation, synthesis of cytokines, and reactive oxygen species exacerbates neurodegeneration in Alzheimer's disease (AD) and other tauopathies. Abnormalities in tau, Aβ, and microglial activation are frequently observed in dementia patients and indicate that these elements may work in concert to cause cognitive impairment. Contradicting reports from postmortem studies demonstrating the presence of Aβ aggregates in the brains of cognitively healthy individuals, as well as other investigations, show that tau aggregation is more strongly associated with synapse loss, neurodegeneration, and cognitive decline than amyloid pathology. Tau association with microtubules' surface promotes their growth and maintains their assembly, dynamicity, and stability. In contrast, the reduced affinity of hyperphosphorylated and mislocalized tau to microtubules leads to axonal deficits and neurofibrillary tangles (NFTs). Loss of microglial neuroprotective and phagocytic functions, as indicated by the faulty clearance of amyloid plaques, as well as correlations between microglial activation and tau tangle spread, all demonstrate the critical involvement of malfunctioning microglia in driving tau propagation. This review discusses the recent reports on the contribution of microglial cells to the development and progression of tau pathology. The detailed study of pathogenic mechanisms involved in interactions between neuroinflammation and tau spread is critical in identifying the targets for efficacious treatment strategies in AD.","['Alzheimer’s disease', 'endolysosomal degradation', 'microglia', 'neurofibrillary tangles', 'tau protein']",Reviews in the neurosciences,2022-10-28,"[{'lastname': 'Ayyubova', 'firstname': 'Gunel', 'initials': 'G', 'affiliation': 'Department of Cytology, Embryology and Histology, Azerbaijan Medical University, S. Vurgun Street, Baku 1102, Azerbaijan.'}]",,,,"© 2022 Walter de Gruyter GmbH, Berlin/Boston.","10.1515/revneuro-2022-0087
10.1016/j.neurobiolaging.2014.05.005
10.1016/j.expneurol.2021.113756
10.1038/nn.4132
10.1186/s13195-020-00596-4
10.1186/s13024-017-0216-6
10.1016/s1474-4422(03)00530-1
10.1016/j.jneumeth.2018.09.030
10.1093/cercor/bhy152
10.1126/sciadv.abg4980
10.1038/srep30498
10.1007/s00018-019-03349-1
10.1038/343461a0
10.1016/j.celrep.2016.09.063
10.1038/nn1715
10.1038/nrn4056
10.3390/cells10040957
10.1038/s41593-021-00963-w
10.1186/s13578-020-00474-4
10.3389/fphar.2021.766082
10.1016/j.parkreldis.2020.04.014
10.1002/alz.12233
10.1038/s41598-019-45676-0
10.1007/978-981-32-9358-8_26
10.1038/s41593-021-00951-0
10.1371/journal.pone.0100760
10.1007/s00401-017-1722-x
10.1016/j.ebiom.2015.09.053
10.1523/jneurosci.2393-17.2017
10.26508/lsa.201900453
10.1016/j.exger.2009.10.010
10.1093/jnen/nlw105
10.1073/pnas.95.18.10896
10.1038/nature11729
10.1016/s1474-4422(15)70016-5
10.1038/s41593-018-0242-x
10.1073/pnas.1411649111
10.1016/j.neuron.2010.11.030
10.1038/s41586-019-1769-z
10.1038/s41467-020-15436-0
10.1001/jamaneurol.2020.4201
10.1038/s41588-018-0311-9
10.1007/s00401-018-1937-5
10.1038/nature12481
10.1186/s12974-022-02532-9
10.1083/jcb.151.6.1257
10.1007/s00401-020-02196-w
10.1016/j.cell.2017.05.018
10.1098/rstb.2013.0144
10.1196/annals.1332.006
10.1038/ng.2802
10.1016/j.bj.2018.01.003
10.3389/fnins.2020.00285
10.3389/fnins.2020.00285
10.1523/jneurosci.23-05-01605.2003
10.1523/jneurosci.4105-11.2011
10.1186/s40478-021-01204-8
10.1016/j.cell.2019.09.001
10.1111/j.1471-4159.2009.06253.x
10.1093/brain/awv081
10.1084/jem.20161731
10.1007/s13311-021-01179-3
10.1038/s41467-022-30461-x
10.1002/alz.12239
10.1093/rheumatology/kez545
10.1038/s41467-017-02533-w
10.1038/nm.4011
10.1016/j.neurobiolaging.2006.08.014
10.1038/s41591-021-01456-w
10.1007/s12035-021-02715-0
10.3389/fnins.2019.00649
10.3389/fncel.2015.00498
10.1074/jbc.ra120.013553
10.1038/embor.2013.15
10.1038/s41586-020-2156-5
10.1111/jnc.13994
10.1158/0008-5472.can-17-3175
10.1074/jbc.m111.277061
10.1038/onc.2009.503
10.1016/j.ajpath.2011.05.047
10.1084/jem.20190980
10.3390/ijms21218067
10.1042/BCJ20190506
10.1007/s12035-018-1102-0
10.3390/biomedicines9020190
10.1007/s00401-018-01957-y
10.1002/jev2.12089
10.1186/s40478-020-01047-9
10.1038/cdd.2016.90
10.1172/jci59903
10.1186/s40478-016-0386-4
10.1038/s41380-020-0688-6
10.1016/j.cell.2021.12.041
10.1016/j.celrep.2016.04.045
10.15252/embj.201899084
10.1038/nature25158
10.1016/j.ijbiomac.2019.04.120
10.1038/nrn.2015.1
10.1084/jem.20200785
10.1038/s41467-022-29552-6
10.3390/cells9092022
10.1038/s41593-021-00931-4
10.1186/s40478-020-00967-w
10.1038/s41421-018-0012-7
10.1186/s12974-016-0772-7
10.1016/j.neuron.2007.01.010
10.1016/j.neuron.2016.05.003
10.1038/emboj.2013.207
10.1523/jneurosci.1860-14.2014
10.1016/j.neuron.2015.11.013
10.7554/eLife.43584
10.1016/j.jbc.2022.102132",<Element 'PubmedArticle' at 0x7f05df5efcc0>
29,"36153580
32840331
1566067
22553493
7895820
29447116
31753135
8269082
22762014
26631930
30356756
32601397
32508595
30724769
29850777
30569080
31976781
29936690
33075193
29241829
33225065
26312828
1671712
23948899
7596406
7638621
7651536
21911656
27016693
33464407
29478590
9585365
33148290
31367008
18416843
30140051
30385170
30804776
30394574
32968074
27940516
30820047
29878075
17265535
4067419
28596079
31722659
28647612
20868222
23112842
21958003
15101252
24690272
22555407
8154371
11553788
28683096
28031319
10986041
20368805
3922972
33176118
24115173
6277903
17854398
11950276
26556230
28389477
20734437
18430993
33679311
30884759
25609095
31686034
3038959
2831187
33095930
34586832
29516132
3166458
3932467
15837562
20034483
16687490
20595630
17660382
28929132
32787955
33519371
31616924
28555747
33361391
31417573
29323721
32366277
24833295
31988486
31298602
30924124
17430243
33562440
22993429
31641056
27174096
19166509
25358504
27683909
32119690
20170744
23376685
17916878
31058310
10995233
32882843
22393530
17457719
28434655
15863833
19339974
30304853
32604886
10571240
21554715
30581971
34586066
33979165
21322570
21219628
15485881
29933361
33930462
34058468
33836655
35351864
31888770
34099706
8702576
21114327
23413428
28559318
10526164
18507396
15583000
7683668
12588864
9869645
30619849
20053627
24398134
8245966
21289173
27030596
25186741
10375696
25482438
17685481
16376010
15456862
8398148
16463279
18466341
20637285
32457076
28606304
20967887
33383106
26772978
34180138
25242217
28802038
21956652
28547529
15356140
17693552
10471645
10552997
29861287
32457210
32152337
27570072
33010423
31331998
33139712
24907980
25131449
27277824
18987181
19577821
16291938
15026113
35418601
23601557
2056122
19018038
31623648
17430597
24633805
32054532
27793990
22918225
32561398
30674067
22821396
28137305
33814450
28774656
32808727
31524156
22675504
26990767
30874626
30276315
31291966
32246400
33166661
31572186
27412492
26207229
33239064
15831717
24162652
31896673
21778362
31058364
24722525
26215806
31772305
31627485
32928017
22024597
21385991
19955384
22228589
29483128
33556209
22903150
10744782
12807485
1985096
16208376
34705495
34588955
17553793
31915375
30206328
33972475
29151590
29422891
29230021
29020624
30139626
25017883
30266932
29775591
29735982
31373067
27459405
30572908
27051467
28546318
23150934
23150908
31006066
28768545
28602351
33314529
28930663
28209725
27196974
29037207
29073081
30617257
31235932
32514138
31902528
33097708
30711010
20218969
25309543
30290215
33390886
30872118
32552741
11452127
27049947
25194421
33859405
29216448
7969426
27280679
27931217
27400748
30746765
19586665
32572761
22632727
22957298
30692699
32023447
30618635
32757416
30760929
29881376
28484229
30108586
31018141
29309541
30894627
33606969
20820167
31575706
28235680
25896511
33282858
29210074
30703614
30471926
31959936
3115992
25682154
12042316
28444230
35750033
33658354
31130380
33406436
28965825
23921897
28366720
28697336
23044265
26451484
32709881
31931141
34488832
8346443
15184600
8415756
10694577
10611368
9354781
15772340
29499171
20186853
19346482
15522251
29216449
8823200
7977635
7534068
16207713
16207708
2029618
10623648
24154541
17428983
28111074
26195256
24559670
10655101
9830016
18549781
17021406
12507914
23132858
15195085
22130662
22383525
23620513
19033669
28994390
30340601
32376954
22622580
21471207
21715678
22002422
26938442
29053874
11447277
15014128
22902767
19284597
29021756
33927414
33472953
16906426
33129364
24199961
29874566
29323751
32457389
31601677
31780819
28959956
33831349
33564035
33895869
33550655
29632371
30840313
33831349
31903524
24312462
32886451
26505746
33521872
31860000
32096038
31642932
32929366
23554593
28247064
31918679
33746700
29062035
30610252
32291510
20980669
28062720
33287896
30348994
21917794
32296178
34157306
2360787
1789684
16289476
12399581
9629521
15851848
16120771
19228947
22491782
9600986
25394486
28287086
12414533
32362813
11701931
12861382
23296339
23217737
33503410
8171342
11844476
10582625
15686968
24328732
20547867
15570172
19725929
15464259
23592036
20943911
18572260
22637583
34621153
31108099
33631652
34910503
30375977
12167620
30124770
24035364
24395130
31262433
26923027
31159836
23155049
26338325
25126727
28663518
24330807
28748360
33161129
18337753
32621514
10880397
24162737
18032783
23499462
29353455
31306119
29311783
31975051
28945989
23115165
26372964
29852219
32006858
24064186
26923592
29078414
20178983
28626421
17053810
24252508
31228807
27385004
26721390
32173556
30674654
23305670
32493451
24052255
32632205
19474305
23060451
7654074
23771217
10702411
27087442
11997703
29311783
31501588
33502634
24094294
20879692
32817639
28161508
33292860
29357308
30554190
23636330
33479445
33074098
32199103
16141197
16987932
33436375
33014432
31478208
28379162
27604565
28251674
31954398
30370589
34043283
30010124
24470773
34108509
29801024
28673336
34488804
29754747
33712031
33731174
34720875
29275859
30227622
21745355
32517777
32370112
31766592
32791113
31753762
30949921
33374235
30823925
20413858
29950970
21818468
27445800
29377010
32730766
26800892
29896424
29311965
31978603
28740125
29967007
26346625
28088659
28957663
34537055
33921683
32211501
34300094
30671455
33627859
24885250
27422439
24721528
24604561
23623982
31630687
30787164
18094335
16239176
29363108
30233156
29154278
29113943
32780691
22329653
31324021
31815693
12417353
34211387
32299450
32961338
33403644
15781953
27911292
22517108
31011620
33331535
18395955
30700591
33427740
29215900
31028125
32110803
28089676
24795624
33509035
22232206
27643858
32520736
30980923
24044641
26512759
29899525
32867607
31798373
28642251
23385659
33340485
22323736
29067298
26822146
25871773
29409358
22305802
33072846
29600961
23129750
24849360
33597265
12511579
33775891
26509334
21633390
20070435
12067447
31159836
32840654
33432241
26190401
30605594
29048372
33219714
31331333
16956959
17250686
26921451
30272057
31270237
12498954
30925619
30665447
25178429
22349451
12270650
10746597
11807891
33111402
28332488
28930663
32170061
30405900
30143564
32024798
32024799
32948752
24639435
23407718
29442376
32024799
32024798
30477568
31186026
28390509
25702206
27599555
29389151
32323483
18373478
30848161
25752446
30711612
31875163
33199792
32973558
32848858
29618365
35291561
28751738
28557010
25943889
28900205
12743231
29396300
25770439
2191084
17420316
33148816
19342825
26806700
31381519
32070225
32070224
31619479
26751679
16926844
30679481
33412903
27612206
32513932
27090751
27567871
17322072
25672924
32086779
31185581
23345638
30410094
29982983
33419478
24100629
28871262
32457070
32848579
20880000
15657798
30240096
24918518
28283675
28244008
32221024
31019485
33051352
27811233
31406145
31316211
22972946
11552016
22165672
32818802
10888365
32178676
31586799
28273782
16955483
33927692
14664465
29867440
32358224
17294608
26200258
33593693
28007993
31998844
32772264
35639372
25469919
28086184
27641441
15111582
35251042
34572041
34210002",APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.,"ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer's disease (AD). Neuroinflammation has become the third hallmark of AD, together with Amyloid-β plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein. This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE's single-nucleotide polymorphisms affect its structure, function, and involvement during health and disease. This review reflects on how APOE's polymorphisms impact critical aspects of AD pathology, such as the neuroinflammatory response, particularly the effect of APOE on astrocytic and microglial function and microglial dynamics, synaptic function, amyloid-β load, tau pathology, autophagy, and cell-cell communication. We discuss influential factors affecting AD pathology combined with the APOE genotype, such as sex, age, diet, physical exercise, current therapies and clinical trials in the AD field. The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation, e.g., alpha- synucleinopathies and Parkinson's disease, traumatic brain injury, stroke, amyotrophic lateral sclerosis, and multiple sclerosis, is also addressed. Therefore, this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field.","['Alzheimer’s disease', 'Apolipoprotein E', 'Neurodegeneration', 'Neuroinflammation']",Molecular neurodegeneration,2022-09-25,"[{'lastname': 'Fernández-Calle', 'firstname': 'Rosalía', 'initials': 'R', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden. rosalia.fernandez_calle@med.lu.se.'}, {'lastname': 'Konings', 'firstname': 'Sabine C', 'initials': 'SC', 'affiliation': 'Department of Experimental Medical Science, Experimental Dementia Research Unit, Lund University, Lund, Sweden.'}, {'lastname': 'Frontiñán-Rubio', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Oxidative Stress and Neurodegeneration Group, Faculty of Medicine, Universidad de Castilla-La Mancha, Ciudad Real, Spain.'}, {'lastname': 'García-Revilla', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden.\nDepartamento de Bioquímica Y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.'}, {'lastname': 'Camprubí-Ferrer', 'firstname': 'Lluís', 'initials': 'L', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden.'}, {'lastname': 'Svensson', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden.'}, {'lastname': 'Martinson', 'firstname': 'Isak', 'initials': 'I', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden.'}, {'lastname': 'Boza-Serrano', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden.\nDepartamento de Bioquímica Y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.'}, {'lastname': 'Venero', 'firstname': 'José Luís', 'initials': 'JL', 'affiliation': 'Departamento de Bioquímica Y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.'}, {'lastname': 'Nielsen', 'firstname': 'Henrietta M', 'initials': 'HM', 'affiliation': 'Department of Biochemistry and Biophysics at, Stockholm University, Stockholm, Sweden.'}, {'lastname': 'Gouras', 'firstname': 'Gunnar K', 'initials': 'GK', 'affiliation': 'Department of Experimental Medical Science, Experimental Dementia Research Unit, Lund University, Lund, Sweden.'}, {'lastname': 'Deierborg', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, Lund, Sweden. tomas.deierborg@med.lu.se.'}]",,,,© 2022. The Author(s).,"10.1186/s13024-022-00566-4
10.1126/science.1566067
10.1101/cshperspect.a006270
10.1016/0014-4886(95)90041-1
10.1515/revneuro-2017-0063
10.1016/B978-0-12-804766-8.00013-3
10.1111/j.1750-3639.1993.tb00724.x
10.1101/cshperspect.a006247
10.1038/nrn.2015.1
10.3389/fncel.2018.00338
10.1038/s41583-020-0325-z
10.3389/fncel.2020.00129
10.1097/WCO.0000000000000672
10.1093/brain/awy132
10.1080/14740338.2020.1721456
10.1007/s12035-018-1188-4
10.1002/alz.12192
10.1016/j.jalz.2017.11.005
10.1212/NXG.0000000000000512
10.1038/gim.2015.117
10.1038/349704a0
10.3233/JAD-130746
10.1038/375754a0
10.1126/science.7638621
10.1038/376775a0
10.1001/archneurol.2011.221
10.1016/j.jalz.2016.01.012
10.1007/s11910-020-01090-y
10.1016/B978-0-444-64076-5.00026-0
10.1002/ana.410430519
10.1186/s13024-020-00413-4
10.1038/s41582-019-0228-7
10.1186/1471-2377-8-9
10.1038/s41577-018-0051-1
10.1016/j.jocn.2018.10.034
10.3389/fnagi.2019.00014
10.1111/nan.12529
10.1038/s41467-020-18534-1
10.1101/cshperspect.a023705
10.1038/s41588-019-0358-2
10.1093/brain/awy146
10.1002/cbf.1396
10.1016/S0022-2275(20)34273-5
10.1016/j.ygcen.2017.05.023
10.1186/s12862-019-1519-8
10.1016/j.arr.2017.06.002
10.1515/bc.2010.129
10.1371/journal.pone.0047760
10.1089/rej.2011.1169
10.1086/381662
10.1016/j.tins.2014.03.001
10.1007/s00109-012-0901-4
10.1016/S0065-3233(08)60642-7
10.1073/pnas.201279298
10.1371/journal.pone.0179497
10.1096/fj.201601084R
10.1086/303070
10.1371/journal.pone.0010022
10.1016/S0021-9258(18)88963-3
10.1016/j.neuron.2020.10.008
10.1002/pro.2379
10.1016/S0021-9258(18)34954-8
10.1111/j.1471-4159.2007.04831.x
10.1006/nbdi.2002.0483
10.1186/s40478-015-0250-y
10.1194/jlr.R076315
10.1002/ajpa.21298
10.3233/JAD-2008-13303
10.3389/fnins.2021.630502
10.3390/genes10030222
10.1093/aje/kwu442
10.1038/s41591-019-0611-3
10.1172/JCI113096
10.1016/S0021-9258(18)68957-4
10.1126/scitranslmed.abc9375
10.1007/s00109-018-1632-y
10.1016/S0021-9258(18)37710-X
10.1172/JCI112130
10.1016/j.nbd.2004.11.005
10.1016/j.brainres.2009.12.039
10.1523/JNEUROSCI.5476-05.2006
10.2353/ajpath.2010.090973
10.1161/CIRCRESAHA.107.157198
10.1126/sciadv.1601576
10.1186/s13195-020-00664-9
10.3389/fnins.2020.625348
10.1093/glycob/cwz084
10.1002/1873-3468.12702
10.3389/fimmu.2019.01811
10.1002/jcp.26480
10.1186/s13041-020-00609-1
10.1038/nrd4280
10.1038/s41582-020-0315-9
10.1080/13543776.2019.1643322
10.1111/bph.14668
10.2174/156720507780362227
10.3390/ijms22041593
10.1523/JNEUROSCI.1937-12.2012
10.1523/JNEUROSCI.1400-19.2019
10.1161/ATVBAHA.116.307023
10.1111/j.1471-4159.2009.05917.x
10.14348/molcells.2014.0248
10.1523/JNEUROSCI.1054-16.2016
10.1371/journal.pone.0229240
10.1016/j.bbalip.2010.02.007
10.1016/j.nbd.2013.01.018
10.1194/jlr.M700364-JLR200
10.1002/1873-3468.13428
10.1021/bi000099m
10.3390/ijms21176336
10.1101/cshperspect.a006312
10.1080/07853890701214881
10.1016/j.biopsych.2017.03.003
10.1194/jlr.M500114-JLR200
10.1038/nrn2620
10.3390/ijms19103090
10.3390/biom10060964
10.1016/S0896-6273(00)80860-0
10.1186/1750-1326-6-30
10.20517/2347-8659.2018.26
10.1016/j.dadm.2018.10.005
10.7554/eLife.68231
10.1021/acs.jpcb.1c03011
10.1021/bi1020106
10.1186/1423-0127-18-4
10.1074/jbc.M409324200
10.1371/journal.pcbi.1006165
10.1016/j.jbc.2021.100715
10.1016/j.atherosclerosis.2021.05.007
10.1186/s12863-021-00968-1
10.1038/s41398-022-01881-6
10.1186/s13195-019-0558-0
10.1038/s41467-021-23762-0
10.1074/jbc.271.32.19053
10.1021/bi1017655
10.1161/ATVBAHA.112.301193
10.1073/pnas.1705080114
10.1016/S0014-5793(99)01285-5
10.1021/bi8003999
10.1074/jbc.M411719200
10.1016/S0021-9258(18)82186-X
10.1074/jbc.M213207200
10.1016/S0022-2275(20)33334-4
10.3389/fcell.2018.00163
10.1093/glycob/cwp205
10.1016/j.matbio.2013.12.009
10.1111/j.1471-4159.1993.tb07453.x
10.1523/JNEUROSCI.5491-10.2011
10.1126/scitranslmed.aad3650
10.1523/JNEUROSCI.1860-14.2014
10.1016/S0006-8993(99)01542-5
10.1016/j.bbrc.2014.11.111
10.1002/dvdy.21283
10.1016/j.biochi.2005.10.007
10.1128/MCB.24.20.8872-8883.2004
10.1016/0896-6273(93)90070-8
10.1002/jnr.20774
10.1111/j.1471-4159.2008.05462.x
10.1016/j.mcn.2010.07.005
10.1523/JNEUROSCI.0250-20.2020
10.7554/eLife.27347
10.1002/glia.21081
10.1016/j.pneurobio.2020.101937
10.1186/s13041-015-0183-1
10.1002/advs.202004993
10.1016/j.neuron.2014.08.048
10.1016/j.cell.2017.07.023
10.1002/eji.201141679
10.4049/jimmunol.173.6.3916
10.1073/pnas.0702553104
10.1093/clinchem/45.9.1431
10.1016/S0022-2275(20)32417-2
10.1016/j.neuron.2018.05.008
10.1212/WNL.0000000000009582
10.1038/s41598-020-61142-8
10.1016/j.molcel.2016.07.016
10.1016/j.phrs.2020.105211
10.1523/JNEUROSCI.2994-18.2019
10.1038/s41467-020-19264-0
10.1093/cvr/cvu148
10.1016/j.nbd.2014.07.015
10.1007/s00109-016-1427-y
10.1523/JNEUROSCI.1972-08.2008
10.1016/j.neurobiolaging.2009.05.011
10.1523/JNEUROSCI.1922-05.2005
10.1016/j.neuroscience.2003.10.011
10.1186/1750-1326-8-13
10.1172/JCI115288
10.1194/jlr.R800058-JLR200
10.1186/s13024-019-0337-1
10.1186/1750-1326-2-7
10.1007/s00401-014-1266-2
10.1186/s13195-020-00585-7
10.1074/jbc.M116.721779
10.1074/mcp.M112.018861
10.1016/j.exger.2020.111004
10.1093/hmg/dds296
10.1186/s13195-016-0231-9
10.3233/JAD-210065
10.1016/j.jalz.2017.05.006
10.1002/alz.12165
10.3233/JAD-190175
10.1371/journal.pone.0038013
10.1111/jnc.13607
10.1038/s41423-019-0223-3
10.4103/bc.bc_18_17
10.1186/s12974-019-1516-2
10.1007/s40263-020-00721-9
10.1016/j.bbi.2020.11.013
10.3389/fphar.2019.01008
10.1080/00207454.2016.1212854
10.1186/s40035-020-00221-2
10.1126/science.1110647
10.1038/nn.3554
10.1523/JNEUROSCI.0993-19.2019
10.1126/science.1202529
10.1002/glia.23637
10.1177/1073858414530512
10.1186/s40635-015-0039-0
10.1038/s41380-019-0609-8
10.3390/jcm8101719
10.1177/0271678X20951995
10.1016/j.brainresbull.2011.10.004
10.1096/fj.10-176891
10.1523/JNEUROSCI.4026-09.2009
10.1002/glia.22289
10.1084/jem.20171265
10.1002/glia.23974
10.1038/nri3265
10.1016/S0022-2275(20)32409-3
10.1046/j.1365-2567.2003.01665.x
10.1172/JCI114971
10.1038/nature04001
10.1126/sciadv.abh0050
10.3389/fncel.2021.661838
10.1074/jbc.M611422200
10.1038/s41586-019-1895-7
10.1038/s41583-018-0057-5
10.14348/molcells.2021.0060
10.1038/nri.2017.125
10.3389/fimmu.2017.01905
10.1038/mp.2017.246
10.1016/j.celrep.2017.09.039
10.1016/j.ebiom.2018.08.026
10.1016/j.expneurol.2014.01.001
10.1038/s41582-018-0072-1
10.1016/j.cell.2018.05.003
10.1038/s41593-018-0145-x
10.15252/embj.2019101997
10.1038/nn.4338
10.1186/s13024-018-0298-9
10.1186/s13148-016-0202-9
10.1126/science.aal3222
10.1056/NEJMoa1211851
10.1056/NEJMoa1211103
10.1007/s00401-019-02013-z
10.1186/s13024-017-0197-5
10.1016/j.cell.2017.05.018
10.1016/j.immuni.2017.08.008
10.1084/jem.20160844
10.1016/j.neuron.2016.05.003
10.1186/s13024-017-0216-6
10.1073/pnas.1710311114
10.1038/s41593-018-0296-9
10.1038/s41593-019-0433-0
10.1038/s41593-020-0650-6
10.1016/j.neuron.2019.12.007
10.1038/s41467-020-19227-5
10.1186/s13195-019-0469-0
10.1042/BJ20100016
10.3389/fimmu.2014.00461
10.1016/j.pneurobio.2018.09.007
10.3389/fnins.2020.602508
10.1016/j.jaci.2019.02.027
10.1186/s12974-020-01869-3
10.1126/science.1061663
10.1038/nature17630
10.1038/ni.2986
10.1038/s41590-021-00913-5
10.1016/j.neuron.2017.11.014
10.1038/372092a0
10.1371/journal.pone.0155878
10.1186/s12974-016-0772-7
10.1186/s40478-016-0343-2
10.1002/glia.23599
10.1016/j.jneuroim.2009.06.010
10.1007/s12035-020-01982-7
10.1016/j.neuron.2012.03.026
10.1038/s41591-018-0336-8
10.1016/j.celrep.2020.01.010
10.3389/fncel.2018.00488
10.1038/s41586-019-0924-x
10.3389/fimmu.2018.01014
10.1038/s41598-017-01747-8
10.3389/fimmu.2018.01753
10.1016/j.celrep.2019.03.099
10.1093/brain/awx355
10.1038/s41598-019-41363-2
10.1016/j.neuron.2021.01.027
10.1038/mp.2010.90
10.1212/WNL.0000000000008377
10.1016/j.neurobiolaging.2017.01.014
10.15252/embj.201490791
10.3389/fcell.2020.564351
10.1111/jnc.14271
10.1016/j.redox.2019.101121
10.1016/j.immuni.2018.11.004
10.1038/s41593-019-0566-1
10.1016/S0021-9258(18)47945-8
10.1007/s13238-014-0131-3
10.1074/jbc.M203934200
10.1093/hmg/ddx155
10.1016/j.cell.2022.05.017
10.1126/scitranslmed.aaz4564
10.1016/j.cell.2019.04.001
10.1016/j.celrep.2020.108572
10.1016/j.cmet.2017.08.024
10.1038/jcbfm.2013.128
10.1016/j.neuint.2017.03.018
10.1016/j.devcel.2017.06.003
10.1016/j.freeradbiomed.2012.09.027
10.1016/j.cell.2015.09.020
10.1038/s41419-020-02776-4
10.1016/j.nbd.2020.104742
10.1186/s13024-021-00483-y
10.1126/science.8346443
10.1212/01.WNL.0000128091.92139.0F
10.1073/pnas.90.20.9649
10.1073/pnas.050004797
10.1073/pnas.96.26.15233
10.1038/ng1197-263
10.1523/JNEUROSCI.5170-04.2005
10.1016/j.jalz.2018.01.010
10.1002/ana.21843
10.1073/pnas.0900345106
10.1016/j.biopsych.2004.07.021
10.1016/j.neuron.2017.11.013
10.1021/bi961074j
10.1042/bj3060599
10.1074/jbc.M504513200
10.1074/jbc.M508780200
10.1016/0006-8993(91)91092-F
10.1016/S0002-9440(10)64700-1
10.1093/hmg/ddt525
10.1523/JNEUROSCI.3993-06.2007
10.1016/j.cell.2016.12.044
10.1038/nrneurol.2015.119
10.1016/j.neuron.2014.01.045
10.1038/72237
10.1074/jbc.273.49.32730
10.1016/j.neuron.2008.04.010
10.1097/01.jnen.0000240463.87886.9a
10.1016/S0002-9440(10)63822-9
10.1074/jbc.M112.420224
10.1038/nm1058
10.1074/jbc.M111.295451
10.1074/jbc.M111.288746
10.1073/pnas.1220484110
10.1172/JCI36663
10.7554/eLife.29595
10.1186/s13024-018-0286-0
10.1038/s41586-020-2247-3
10.1038/nature11087
10.1074/jbc.M111.225532
10.1126/scitranslmed.3002156
10.1097/NEN.0b013e318232a379
10.1016/j.neuron.2016.01.028
10.1093/brain/awx243
10.1073/pnas.151254698
10.1523/JNEUROSCI.4315-03.2004
10.1016/j.brainres.2012.08.003
10.1186/1750-1326-4-13
10.3389/fnagi.2017.00311
10.1038/s41591-021-01309-6
10.1126/scitranslmed.abc0655
10.1007/s00401-006-0127-z
10.1186/s13195-020-00710-6
10.1016/j.neurobiolaging.2013.10.074
10.1016/j.cmet.2018.05.011
10.1002/ana.25142
10.1038/s41467-020-15701-2
10.1084/jem.20190980
10.1038/s41583-019-0240-3
10.1038/nature24016
10.1016/j.neuron.2021.03.024
10.1038/s41598-021-82901-1
10.1007/s00401-021-02315-1
10.1002/ana.26043
10.1038/s41591-018-0004-z
10.1002/ana.25455
10.1016/j.neuron.2021.03.024
10.1007/s12035-019-01859-4
10.1371/journal.pone.0080180
10.1002/alz.12173
10.1002/ana.24546
10.1007/s00259-021-05192-8
10.1001/jamaneurol.2019.4421
10.1007/978-981-32-9358-8_15
10.1001/jamanetworkopen.2019.13909
10.7150/thno.48522
10.3389/fnagi.2013.00011
10.1007/s00401-017-1685-y
10.1186/s12883-019-1591-0
10.3389/fnins.2021.633576
10.1038/s41598-017-14204-3
10.1007/s00259-018-4242-6
10.1007/s00259-020-04758-2
10.1212/WNL.0b013e3181ffe4d1
10.1212/WNL.0000000000003585
10.1186/s40478-020-01095-1
10.1038/s41467-018-06783-0
10.1523/JNEUROSCI.2569-11.2011
10.1038/s41586-020-2156-5
10.1016/j.neuron.2021.05.034
10.1002/ana.410270502
10.1002/ana.410300410
10.1016/j.neurobiolaging.2005.09.012
10.1126/science.1074069
10.1017/S1041610298005110
10.3233/JAD-2005-7203
10.1523/JNEUROSCI.2177-05.2005
10.1073/pnas.0811698106
10.1101/cshperspect.a005777
10.1073/pnas.95.11.6448
10.1186/1750-1326-9-48
10.1038/ncomms14726
10.1016/S0002-9440(10)64463-X
10.3389/fncel.2020.00072
10.1126/science.294.5545.1354
10.1007/s00018-003-3018-7
10.1038/nrneurol.2012.263
10.1016/j.neuron.2012.11.020
10.1016/j.neuron.2021.01.005
10.1126/science.8171342
10.1016/S0006-8993(01)03367-4
10.1046/j.1471-4159.1999.0732613.x
10.1016/j.nbd.2004.10.013
10.1073/pnas.0914984107
10.1097/00001756-200412030-00020
10.1186/1750-1326-4-21
10.1016/j.neulet.2004.07.084
10.1101/lm.030031.112
10.1523/JNEUROSCI.4040-10.2010
10.1016/j.bbr.2008.05.008
10.1093/brain/aws127
10.3389/fnins.2021.734001
10.1016/j.ajpath.2019.04.010
10.1016/j.biomaterials.2021.120700
10.1126/sciadv.abk0473
10.7554/eLife.40048
10.1074/jbc.M205147200
10.1093/brain/awy197
10.1016/j.immuni.2013.08.026
10.1007/s12035-013-8620-6
10.1016/j.biopsych.2019.05.008
10.3233/JAD-151101
10.1186/s13024-019-0323-7
10.1074/jbc.M112.409250
10.1523/JNEUROSCI.0705-15.2015
10.4161/auto.29647
10.1096/fj.201700359
10.1186/1742-2094-10-151
10.1186/s40169-017-0154-5
10.1016/j.arr.2020.101202
10.1038/emboj.2008.31
10.1111/bph.15192
10.1016/S0002-9440(10)64538-5
10.1038/ng.2802
10.1242/jcs.019265
10.1016/j.ajpath.2013.01.034
10.1007/s12035-018-0892-4
10.3233/JAD-190074
10.3389/fnins.2017.00702
10.1007/s11357-020-00161-9
10.1016/j.jalz.2017.07.754
10.1523/JNEUROSCI.2034-12.2012
10.1073/pnas.1510011112
10.1016/j.nbd.2018.05.012
10.1016/j.bioelechem.2019.107447
10.1016/j.neurobiolaging.2013.08.003
10.1016/j.celrep.2016.02.006
10.1073/pnas.1716173114
10.1074/jbc.M110.100420
10.3389/fnagi.2017.00173
10.1038/nrn2009
10.1186/2051-5960-1-3
10.1016/j.envres.2019.108537
10.18632/oncotarget.10349
10.1177/0271678X15621575
10.1016/j.nbd.2020.104834
10.1126/scitranslmed.aar4289
10.1016/j.cub.2012.10.041
10.1186/s40478-020-00954-1
10.1074/jbc.M113.504365
10.1523/JNEUROSCI.0887-09.2009
10.1074/jbc.M112.407957
10.1002/ana.410380219
10.1097/NEN.0b013e31829a25b9
10.1016/S0002-9440(10)64963-2
10.2174/1567205013666160415154550
10.1097/00001756-200205070-00026
10.3389/fnins.2017.00702
10.1038/s41582-019-0244-7
10.1007/s10522-021-09910-5
10.1016/j.cger.2013.07.002
10.1515/REVNEURO.2010.21.3.187
10.1371/journal.pmed.1003289
10.1016/j.neubiorev.2017.01.044
10.1186/s41232-020-00137-4
10.1016/j.neuroimage.2017.12.027
10.18632/aging.101704
10.1038/nature12143
10.1038/s41598-021-81705-7
10.7554/eLife.62199
10.1016/j.neuron.2020.02.034
10.1074/jbc.M505598200
10.1093/brain/awl255
10.1212/NXI.0000000000000941
10.1038/s41420-020-00325-8
10.1111/jnc.14860
10.3390/ijms18040769
10.1038/npp.2016.185
10.1002/glia.23135
10.1186/s12974-019-1678-y
10.1002/glia.23477
10.1002/alz.12362
10.3233/JAD-180141
10.2147/CLEP.S37929
10.1038/s41598-021-90084-y
10.1001/jamaneurol.2018.0821
10.1186/s13195-017-0271-9
10.1186/s12974-021-02235-7
10.1016/j.neurobiolaging.2018.04.004
10.1186/s12974-021-02120-3
10.1186/s12974-021-02124-z
10.3389/fnmol.2021.753946
10.1016/j.cell.2017.11.042
10.3390/ijms19092793
10.1186/2042-6410-2-7
10.1186/s13024-020-00382-8
10.3390/ijms21093219
10.3390/nu11122862
10.1016/j.chom.2020.06.008
10.1016/S1474-4422(19)30356-4
10.1007/s13668-019-0271-4
10.3390/nu13010037
10.1186/s12974-019-1434-3
10.3233/JAD-2010-100012
10.3389/fnins.2018.00383
10.1039/C1CS15112F
10.3389/fnagi.2016.00159
10.1038/nrneurol.2017.185
10.1016/S1474-4422(20)30231-3
10.1186/s12933-016-0329-1
10.14336/AD.2017.0715
10.3389/fphys.2017.01031
10.1016/j.nbd.2020.104755
10.1038/s41598-017-05802-2
10.1523/JNEUROSCI.2262-17.2018
10.1038/srep13842
10.1016/j.psyneuen.2016.11.028
10.1016/j.neuron.2017.09.003
10.1186/s12974-021-02256-2
10.3390/nu13041362
10.3390/ijerph18147643
10.1155/2018/4840531
10.1038/d41586-021-00419-y
10.1186/1471-2458-14-510
10.1016/j.jalz.2014.01.008
10.1093/brain/awu041
10.1016/j.neubiorev.2013.04.005
10.1186/s13195-019-0538-4
10.1212/WNL.0000000000007021
10.1212/01.wnl.0000296276.50595.86
10.1016/S1474-4422(05)70198-8
10.1111/jgs.15241
10.2147/CIA.S169565
10.3233/JAD-170567
10.1016/j.neuroimage.2017.11.007
10.1016/j.jshs.2020.01.004
10.2174/156720512799015019
10.3390/cells8070691
10.3233/JAD-190654
10.1016/S0022-510X(02)00256-3
10.3389/fnagi.2021.653334
10.1186/s12974-020-01771-y
10.1016/j.arr.2020.101173
10.1007/s40119-020-00209-z
10.1093/aje/kwi092
10.3233/JAD-160424
10.1212/WNL.0b013e3182535d35
10.1016/j.trci.2019.02.007
10.1590/1414-431x202010098
10.1016/j.biopsycho.2008.02.007
10.1212/WNL.0000000000007003
10.3233/JAD-201090
10.1037/hea0000515
10.1212/WNL.0000000000007551
10.1093/gerona/glaa054
10.1016/j.neuroimage.2016.12.023
10.3389/fnagi.2014.00061
10.1177/0271678X21990342
10.1001/archneurol.2011.845
10.1159/000449408
10.1097/WAD.0000000000000385
10.1016/j.exger.2019.04.003
10.1186/1742-2094-10-114
10.1371/journal.pbio.1002279
10.1038/s41366-018-0120-3
10.1007/s10433-019-00513-1
10.1136/bmj.j2709
10.1007/s10654-013-9773-3
10.1016/S1474-4422(20)30412-9
10.1126/science.1217697
10.1016/j.trci.2016.06.001
10.1186/s13195-016-0173-2
10.1186/s13024-015-0001-3
10.1089/humc.2017.231
10.1016/S1474-4422(12)70015-7
10.1172/JCI96429
10.1084/jem.20121274
10.1523/JNEUROSCI.0646-14.2014
10.1126/scitranslmed.abd7522
10.1172/JCI200317522
10.1016/j.arr.2021.101336
10.1111/jnc.13411
10.1038/cddis.2011.50
10.1111/j.1582-4934.2001.tb00134.x
10.1186/s13024-019-0323-7
10.1007/s00401-020-02200-3
10.1038/s41583-020-00416-6
10.1111/jnc.13249
10.1021/acschemneuro.8b00579
10.3390/molecules22101769
10.1002/mds.28396
10.1186/s12974-019-1532-2
10.1097/01.JGP.0000225088.29353.08
10.1111/j.1471-4159.2006.04348.x
10.1016/j.neulet.2016.02.042
10.1073/pnas.1821409116
10.1016/S0197-4580(02)00065-9
10.1055/s-0039-1678579
10.1186/s13024-019-0306-8
10.1001/jamaneurol.2014.1455
10.1016/j.nbd.2012.02.002
10.1016/S0304-3940(02)00819-4
10.1212/WNL.54.6.1272
10.1002/ajmg.10111
10.1002/mds.28342
10.1038/nrdp.2017.13
10.1016/j.immuni.2017.08.008
10.1038/s41467-020-15119-w
10.1212/WNL.0000000000006212
10.1126/scitranslmed.aay1809
10.1038/s41467-020-18198-x
10.1136/jnnp-2013-307228
10.1001/jamaneurol.2013.600
10.1002/mds.27297
10.1126/scitranslmed.aay3069
10.1126/scitranslmed.aay1809
10.1186/s40478-018-0624-z
10.1186/s13024-019-0320-x
10.1016/j.pmr.2016.12.001
10.1016/B978-0-444-52892-6.00001-5
10.2217/nmt-2016-0017
10.1037/neu0000423
10.1002/alz.12080
10.1089/neu.2007.0489
10.1089/neu.2018.6052
10.1111/bph.13125
10.1016/j.neuroscience.2019.01.049
10.7717/peerj.8324
10.1038/s41598-020-76849-x
10.3389/fphys.2020.01030
10.3389/fphys.2020.00914
10.1186/s13024-018-0249-5
10.1038/s43587-021-00073-z
10.1038/s41598-017-06932-3
10.1111/bpa.12532
10.1007/s00401-015-1435-y
10.1038/s41598-017-11654-7
10.1212/01.WNL.0000063313.57292.00
10.1016/j.ebiom.2018.01.021
10.1016/j.mcn.2015.03.012
10.1136/jnnp.53.5.373
10.1001/archneur.64.4.541
10.1159/000210432
10.1016/j.bbadis.2016.01.015
10.3233/JAD-190566
10.1161/STROKEAHA.119.028814
10.1161/STROKEAHA.119.026927
10.1212/WNL.0000000000008459
10.1159/000442678
10.1038/sj.jcbfm.9600385
10.1038/s41598-018-36598-4
10.1161/STROKEAHA.120.032402
10.1038/srep32893
10.1038/s41398-020-00864-9
10.1016/j.pneurobio.2016.04.005
10.3233/JAD-160527
10.1161/01.STR.0000259816.31370.44
10.1212/WNL.0000000000001379
10.1007/s12975-020-00786-0
10.3390/ijms20112818
10.1212/WNL.0b013e318281cc1b
10.1038/s41598-018-34510-8
10.1007/s12035-018-1218-2
10.1186/s40035-020-00228-9
10.1007/s00018-013-1480-4
10.3389/fimmu.2017.01005
10.1523/JNEUROSCI.0536-20.2020
10.3389/fnins.2020.00824
10.1111/j.1468-1331.2010.03225.x
10.1007/s10048-004-0193-0
10.1111/ene.13812
10.3109/21678421.2014.918149
10.18632/aging.101195
10.1007/s12035-017-0453-2
10.1212/WNL.0000000000009322
10.3389/fneur.2019.00284
10.1523/JNEUROSCI.1388-20.2020
10.1194/jlr.P071639
10.1038/s41598-019-48059-7
10.1038/s41586-019-1404-z
10.1136/jmedgenet-2012-101175
10.1212/WNL.57.5.853
10.1016/j.ebiom.2020.102954
10.1093/jnen/59.5.361
10.1186/s12944-020-01221-x
10.1016/j.msard.2019.101415
10.1177/1352458517696595
10.1002/jnr.21038
10.3389/fendo.2021.639757
10.1191/1352458503ms965oa
10.3389/fnagi.2018.00129
10.1177/1352458506070682
10.1111/nyas.12841
10.1016/j.it.2021.01.005
10.1093/brain/aww298
10.1126/sciadv.aay6324
10.1007/s00401-020-02193-z
10.1001/jamaneurol.2022.1166
10.1002/ana.24326
10.1016/j.cortex.2016.12.016
10.1113/JP273106
10.1167/iovs.03-1121
10.3389/fimmu.2022.843558
10.3390/cells10092394",<Element 'PubmedArticle' at 0x7f05df5a3900>
30,"36112222
23359374
1759558
7566337
23686809
29315334
24535663
30594046
28259709
32531244
24849862
29142083
21325651
32544086
23150934
33887187
22014136
24355566
17963732
33429401
24899047
23150908
34663480
27148593
26076170
28130640
33675684
33732320
30219939
25027412
28592453
22101365
21802369
28747523
31039256
32840654
26141491
26962052
28365005
31250152
29105977
31350575
24131186
21810890
26058841
25499537
28886007
29552443
27911311
28714976
27591113
25160042
27520774
25596843
23978324
34854996
34604500
25114068",TREM2 risk variants are associated with atypical Alzheimer's disease.,"Alzheimer's disease (AD) has multiple clinically and pathologically defined subtypes where the underlying causes of such heterogeneity are not well established. Rare TREM2 variants confer significantly increased risk for clinical AD in addition to other neurodegenerative disease clinical phenotypes. Whether TREM2 variants are associated with atypical clinical or pathologically defined subtypes of AD is not known. We studied here the clinical and pathological features associated with TREM2 risk variants in an autopsy-confirmed cohort. TREM2 variant cases were more frequently associated with non-amnestic clinical syndromes. Pathologically, TREM2 variant cases were associated with an atypical distribution of neurofibrillary tangle density with significantly lower hippocampal NFT burden relative to neocortical NFT accumulation. In addition, NFT density but not amyloid burden was associated with an increase of dystrophic microglia. TREM2 variant cases were not associated with an increased prevalence, extent, or severity of co-pathologies. These clinicopathological features suggest that TREM2 variants contribute to clinical and pathologic AD heterogeneity by altering the distribution of neurofibrillary degeneration and tau-dependent microglial dystrophy, resulting in hippocampal-sparing and non-amnestic AD phenotypes.","['Behavioral variant', 'Comorbidity', 'Dementia', 'Primary progressive aphasia', 'TREM2', 'Tau']",Acta neuropathologica,2022-09-17,"[{'lastname': 'Kim', 'firstname': 'Boram', 'initials': 'B', 'affiliation': 'Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.'}, {'lastname': 'Suh', 'firstname': 'EunRan', 'initials': 'E', 'affiliation': 'Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Nguyen', 'firstname': 'Aivi T', 'initials': 'AT', 'affiliation': 'Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.'}, {'lastname': 'Prokop', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': 'Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Mikytuck', 'firstname': 'Bailey', 'initials': 'B', 'affiliation': 'Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.'}, {'lastname': 'Olatunji', 'firstname': 'Olamide A', 'initials': 'OA', 'affiliation': 'Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA.'}, {'lastname': 'Robinson', 'firstname': 'John L', 'initials': 'JL', 'affiliation': 'Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Phillips', 'firstname': 'Jeffrey S', 'initials': 'JS', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Mechanic-Hamilton', 'firstname': 'Dawn', 'initials': 'D', 'affiliation': 'Department of Neurology, Penn Memory Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Wolk', 'firstname': 'David A', 'initials': 'DA', 'affiliation': 'Department of Neurology, Penn Memory Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': 'Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'McMillan', 'firstname': 'Corey T', 'initials': 'CT', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': 'Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Lee', 'firstname': 'Edward B', 'initials': 'EB', 'affiliation': 'Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 613A Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA. edward.lee@pennmedicine.upenn.edu.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.","10.1007/s00401-022-02495-4
10.1212/WNL.0b013e31827f0fd1
10.1007/bf00308809
10.1016/0197-4580(95)00021-6
10.1002/ana.23937
10.1371/journal.pmed.1002487
10.1001/jamaneurol.2013.6237
10.1016/j.neurobiolaging.2018.11.017
10.1016/j.jalz.2017.01.014
10.1016/j.cell.2020.05.003
10.1016/S1474-4422(14)70090-0
10.1212/wnl.0000000000004747
10.1212/WNL.0b013e31821103e6
10.1172/jci138179
10.1056/NEJMoa1211851
10.1016/j.neuron.2021.03.029
10.1586/ern.11.153
10.1016/j.bcp.2013.11.021
10.1016/j.brainres.2007.09.048
10.1159/000508625
10.1093/hmg/ddu277
10.1056/NEJMoa1211103
10.1186/s40478-021-01263-x
10.1038/npjparkd.2015.2
10.1001/jamaneurol.2015.0979
10.1007/s00401-017-1679-9
10.1016/j.neuron.2021.02.010
10.3892/etm.2021.9778
10.1007/s00401-018-1908-x
10.1016/j.neurobiolaging.2014.06.007
10.1212/WNL.0000000000004058
10.1007/s00401-011-0910-3
10.1016/S1474-4422(11)70156-9
10.2967/jnumed.117.194282
10.1093/brain/awz099
10.1007/s00401-020-02200-3
10.1093/brain/awv191
10.1093/brain/aww027
10.1016/j.neurobiolaging.2017.02.012
10.1007/s00401-019-02036-6
10.1002/hbm.23874
10.1007/s00401-019-02048-2
10.1056/NEJMc1306509
10.1093/brain/awr179
10.1016/j.neurobiolaging.2015.04.012
10.1016/j.jalz.2014.10.013
10.1038/nm.4397
10.5582/irdr.2017.01088
10.3233/JAD-160780
10.1038/ng.3916
10.1093/brain/aww214
10.1016/j.jalz.2014.05.1751
10.1016/j.jalz.2016.07.004
10.1007/s00702-015-1369-5
10.1016/j.jalz.2013.06.003
10.1007/s00401-021-02383-3
10.1002/trc2.12201
10.3233/jad-140729",<Element 'PubmedArticle' at 0x7f05df1d0860>
31,36053756,Microglial Activation and Connectivity in Alzheimer Disease and Aging.,"Alzheimer disease (AD) is characterized by amyloid β (Aβ) plaques and neurofibrillary tau tangles, but increasing evidence suggests that neuroinflammation also plays a key role, driven by the activation of microglia. Aβ and tau pathology appear to spread along pathways of highly connected brain regions, but it remains elusive whether microglial activation follows a similar distribution pattern. Here, we assess whether connectivity is associated with microglia activation patterns.
We included 32 Aβ-positive early AD subjects (18 women, 14 men) and 18 Aβ-negative age-matched healthy controls (10 women, 8 men) from the prospective ActiGliA (Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease) study. All participants underwent microglial activation positron emission tomography (PET) with the third-generation mitochondrial 18 kDa translocator protein (TSPO) ligand [
We found that inter-regional covariance in TSPO-PET and standardized uptake value ratio was preferentially distributed along functionally highly connected brain regions, with MRI structural connectivity showing a weaker association with microglial activation. AD patients showed increased TSPO-PET tracer uptake bilaterally in the anterior medial temporal lobe compared to controls, and higher TSPO-PET uptake was associated with cognitive impairment and dementia severity in a disease stage-dependent manner.
Microglial activation distributes preferentially along highly connected brain regions, similar to tau pathology. These findings support the important role of microglia in neurodegeneration, and we speculate that pathology spreads throughout the brain along vulnerable connectivity pathways. ANN NEUROL 2022;92:768-781.",[],Annals of neurology,2022-09-03,"[{'lastname': 'Rauchmann', 'firstname': 'Boris-Stephan', 'initials': 'BS', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nGerman Center for Neurodegenerative Diseases, Munich, Germany.\nSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield.\nDepartment of Neuroradiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Brendel', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nMunich Cluster for Systems Neurology, Munich, Germany.'}, {'lastname': 'Franzmeier', 'firstname': 'Nicolai', 'initials': 'N', 'affiliation': 'Institute for Stroke and Dementia Research, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Trappmann', 'firstname': 'Lena', 'initials': 'L', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Zaganjori', 'firstname': 'Mirlind', 'initials': 'M', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Ersoezlue', 'firstname': 'Ersin', 'initials': 'E', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Morenas-Rodriguez', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': 'German Center for Neurodegenerative Diseases, Munich, Germany.\nChair of Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Guersel', 'firstname': 'Selim', 'initials': 'S', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nGerman Center for Neurodegenerative Diseases, Munich, Germany.'}, {'lastname': 'Burow', 'firstname': 'Lena', 'initials': 'L', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Kurz', 'firstname': 'Carolin', 'initials': 'C', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Haeckert', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nDepartment of Psychiatry, Psychotherapy, and Psychosomatics, University of Augsburg, Augsburg, Germany.'}, {'lastname': 'Tatò', 'firstname': 'Maia', 'initials': 'M', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Utecht', 'firstname': 'Julia', 'initials': 'J', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Papazov', 'firstname': 'Boris', 'initials': 'B', 'affiliation': 'Department of Radiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Pogarell', 'firstname': 'Oliver', 'initials': 'O', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Janowitz', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Institute for Stroke and Dementia Research, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Buerger', 'firstname': 'Katharina', 'initials': 'K', 'affiliation': 'German Center for Neurodegenerative Diseases, Munich, Germany.\nInstitute for Stroke and Dementia Research, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Ewers', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Institute for Stroke and Dementia Research, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Palleis', 'firstname': 'Carla', 'initials': 'C', 'affiliation': 'German Center for Neurodegenerative Diseases, Munich, Germany.\nMunich Cluster for Systems Neurology, Munich, Germany.\nDepartment of Neurology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Weidinger', 'firstname': 'Endy', 'initials': 'E', 'affiliation': 'Department of Neurology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Biechele', 'firstname': 'Gloria', 'initials': 'G', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Schuster', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Finze', 'firstname': 'Anika', 'initials': 'A', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Eckenweber', 'firstname': 'Florian', 'initials': 'F', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Rupprecht', 'firstname': 'Rainer', 'initials': 'R', 'affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.'}, {'lastname': 'Rominger', 'firstname': 'Axel', 'initials': 'A', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nDepartment of Nuclear Medicine, University of Bern, Inselspital, Bern, Switzerland.'}, {'lastname': 'Goldhardt', 'firstname': 'Oliver', 'initials': 'O', 'affiliation': 'Department of Psychiatry and Psychotherapy, Rechts der Isar Hospital, Technical University of Munich, Munich, Germany.'}, {'lastname': 'Grimmer', 'firstname': 'Timo', 'initials': 'T', 'affiliation': 'Department of Psychiatry and Psychotherapy, Rechts der Isar Hospital, Technical University of Munich, Munich, Germany.'}, {'lastname': 'Keeser', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nDepartment of Neuroradiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nDepartment of Radiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Stoecklein', 'firstname': 'Sophia', 'initials': 'S', 'affiliation': 'Department of Radiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Dietrich', 'firstname': 'Olaf', 'initials': 'O', 'affiliation': 'Department of Radiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Bartenstein', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nMunich Cluster for Systems Neurology, Munich, Germany.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'German Center for Neurodegenerative Diseases, Munich, Germany.\nMunich Cluster for Systems Neurology, Munich, Germany.\nDepartment of Neurology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'lastname': 'Höglinger', 'firstname': 'Günter', 'initials': 'G', 'affiliation': 'German Center for Neurodegenerative Diseases, Munich, Germany.\nDepartment of Neurology, Hannover Medical School, Hannover, Germany.'}, {'lastname': 'Perneczky', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nGerman Center for Neurodegenerative Diseases, Munich, Germany.\nSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield.\nDepartment of Neuroradiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.\nMunich Cluster for Systems Neurology, Munich, Germany.\nAgeing Epidemiology Research Unit, School of Public Health, Imperial College London, London.'}]",,,"We found that inter-regional covariance in TSPO-PET and standardized uptake value ratio was preferentially distributed along functionally highly connected brain regions, with MRI structural connectivity showing a weaker association with microglial activation. AD patients showed increased TSPO-PET tracer uptake bilaterally in the anterior medial temporal lobe compared to controls, and higher TSPO-PET uptake was associated with cognitive impairment and dementia severity in a disease stage-dependent manner.",© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.,10.1002/ana.26465,<Element 'PubmedArticle' at 0x7f05df1441d0>
32,"36042131
31532495
31795604
21456963
30897251
27878186
23816568
1311804
30874945
22683129
30022099
30684443
35073330
22662249
22064493
26131326
23393665
23393697
15451897
21931106
16886099
10599761
25061284
31428627
32730766
31213970
26159189
27567931
12761548
16399206
25043908
16216936
12084635
12006603
29966615
33240260
30090655
31953127
28942458
28676377
23894546
25938784
32417750
10783895
16191393
18473845
9881236
25400546
23252647
30618559
30249283
30696869
2089275
25470051
20966214
22927325
18026097
24742461
20234358
19302036
28238188
29361314
30707122
8816495
15530839
23813380
25598354
27558646
32808923
23525041
24360280
25206041
34129917
19286560
22441246
25308331
19783993
21072242
22632727
19339593
19705460
29219210
23395614
30634998
27687525
15488021
10657232
15356189
19107988
10975910
24845678
16132232
35431894
18599959
15831717
27988872
34067173
20107219
21293471
17180163
34279193
17538955
34356130
28284330
19221555
26121197
12137925
30766472
33754353
17639599
16365156
27406855
25452175
29413961
20552050
27156888
15998743
12845153
29204450
2463334
2941683
21612515
19464758
11520119
24503708
11150482
18657529
19906677
9846883
21209080
8734442
12603271
20813920
26646186
27829145
33127514
31283973
20554604
25818332
30597356
20418720
31876682
22406537
24696507
25586103",Contribution of hyperglycemia-induced changes in microglia to Alzheimer's disease pathology.,"Alzheimer's disease (AD) is a neurodegenerative condition characterized by cognitive and functional impairments. The investigation of AD has focused on the formation of senile plaques, composed mainly by amyloid β (Aβ) peptide, and neurofibrillary tangles (NFTs) in the brain. Senile plaques and NFTs cause the excessive recruitment and activation of microglia, thus generating neuroinflammation and neuronal damage. Among the risk factors for the development of AD, diabetes has increasingly attracted attention. Hyperglycemia, the fundamental characteristic of diabetes, is involved in several mechanisms that give rise to microglial overactivation, resulting in neuronal damage and cognitive impairment. Indeed, various studies have identified the correlation between diabetes and AD. The aim of this review is to describe various mechanisms of the hyperglycemia-induced overactivation of microglia, which leads to neuroinflammation and neuronal damage and consequently contributes to the pathology of AD. The disruption of the regulation of microglial activity by hyperglycemia occurs through many mechanisms, including a greater production of reactive oxygen species (ROS) and glycation end products (AGEs), and a decrease in the elimination of Aβ. The future direction of research on the relation between hyperglycemia and AD is addressed, such as the importance of determining whether the hyperglycemia-induced harmful effects on microglial activity can be reversed or attenuated if blood glucose returns to a normal level.","['Alzheimer’s disease', 'Amyloid beta', 'Diabetes', 'Hyperglycemia', 'Microglia', 'Tau protein']",Pharmacological reports : PR,2022-08-31,"[{'lastname': 'Hernández-Rodríguez', 'firstname': 'Maricarmen', 'initials': 'M', 'affiliation': 'Laboratorio de Cultivo Celular, Sección de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón S/N, 11340, Mexico City, Mexico. dra.hernandez.ipn@gmail.com.'}, {'lastname': 'Clemente', 'firstname': 'Cecilia Flores', 'initials': 'CF', 'affiliation': 'Laboratorio de Cultivo Celular, Sección de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón S/N, 11340, Mexico City, Mexico.'}, {'lastname': 'Macías-Pérez', 'firstname': 'Martha Edith', 'initials': 'ME', 'affiliation': 'Unidad de Investigación Biomédica de Zacatecas (UIBMZ) del Instituto Mexicano del Seguro Social (IMSS), Alameda Trinidad García de La Cadena, 98000, Zacatecas, Mexico.'}, {'lastname': 'Rodríguez-Fonseca', 'firstname': 'Rolando Alberto', 'initials': 'RA', 'affiliation': 'Unidad de Investigación Biomédica de Zacatecas (UIBMZ) del Instituto Mexicano del Seguro Social (IMSS), Alameda Trinidad García de La Cadena, 98000, Zacatecas, Mexico.'}, {'lastname': 'Vázquez', 'firstname': 'M Inés Nicolás', 'initials': 'MIN', 'affiliation': 'Química Inorgánica-Orgánica del Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Av. Primero de Mayo S/N, 54740, Estado de México, Mexico.'}, {'lastname': 'Martínez', 'firstname': 'Joel', 'initials': 'J', 'affiliation': 'Química Inorgánica-Orgánica del Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Av. Primero de Mayo S/N, 54740, Estado de México, Mexico.\nFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Salvador Nava 6, 78210, San Luis Potosí, Mexico.'}, {'lastname': 'Ruvalcaba', 'firstname': 'Rene Miranda', 'initials': 'RM', 'affiliation': 'Química Inorgánica-Orgánica del Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Av. Primero de Mayo S/N, 54740, Estado de México, Mexico.'}, {'lastname': 'Rosas', 'firstname': 'Martín Martínez', 'initials': 'MM', 'affiliation': 'Departamento de Fisiología, Instituto Nacional de Cardiología ""Ignacio Chávez"", Juan Badiano 1, 14080, Mexico City, Mexico.'}, {'lastname': 'Jiménez', 'firstname': 'Elvia Mera', 'initials': 'EM', 'affiliation': 'Laboratorio de Cultivo Celular, Sección de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón S/N, 11340, Mexico City, Mexico. elviamj@gmail.com.'}]",,,,© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.,10.1007/s43440-022-00405-9,<Element 'PubmedArticle' at 0x7f05df1634a0>
33,35978514,Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease.,"Alzheimer's disease (AD) manifests as progressive deterioration in multiple cognitive and information processing domains, including memory and executive functions. Although AD's cause and cure remain elusive, increasing evidence supports a key role for microglial cells in AD pathogenesis via diverse mechanisms. β-Amyloid (Aβ) and tau triggered proteopathic and immunopathic processes are key contributors to AD pathology. These proteins aggregate into oligomers and fibrils, which eventually deposit in the central nervous system (CNS) as plaques and tangles. Aβ and tau are directly synaptotoxic and neurotoxic, but also concomitantly induce neuroinflammation. As a central player in CNS immunity, microglia recognize different forms of misfolded proteins and initiate subsequent immune responses, mediating neuroinflammation and neuron-glia crosstalk. Microglia phagocytose debris and release cytokines to maintain brain homeostasis and synaptic integrity. However, microglia also exhibit harmful effects when subject to prolonged activation. This review describes the role of microglia in the proteopathic-immunopathic pathogeneses of AD. We summarize the microglial receptors involved in Aβ recognition, and the role played by this interaction in explaining the interplay between Aβ accumulation and AD progression through microglia-mediated neuroinflammation. Based on the dual proteopathic and immunopathic roles of microglia, we also review putative drug candidates targeting microglial receptors.","['Alzheimer’s disease', 'Cytokine', 'Innate immunity', 'Microglia', 'Neuroinflammation', 'β-amyloid']",International immunopharmacology,2022-08-19,"[{'lastname': 'Wang', 'firstname': 'Zhiyu', 'initials': 'Z', 'affiliation': 'Krembil Research Institute, Toronto M5T 0S8, Canada; Department of Pharmaceutical Sciences, University of Toronto, Toronto M5S 3M2, Canada.'}, {'lastname': 'Weaver', 'firstname': 'Donald F', 'initials': 'DF', 'affiliation': 'Krembil Research Institute, Toronto M5T 0S8, Canada; Department of Chemistry, University of Toronto, Toronto M5S 3H6, Canada; Department of Medicine, University of Toronto, Toronto M5S 1A8, Canada; Department of Pharmaceutical Sciences, University of Toronto, Toronto M5S 3M2, Canada. Electronic address: Donald.Weaver@uhnresearch.ca.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.intimp.2022.109070,<Element 'PubmedArticle' at 0x7f05df12d4a0>
34,"35974399
27497324
15023815
1759558
25630253
29253129
30392797
32660541
17029828
31481130
27890650
29200205
21172610
10804202
34641980
31235932
31673052
16990547
22487856
15372280
24076336
16906128
17478722
27743026
12399581
23036017
24853936
19513731
1789684
30599077
25677332",Pathological changes induced by Alzheimer's brain inoculation in amyloid-beta plaque-bearing mice.,"Alzheimer's disease (AD) is characterized by intracerebral accumulations of extracellular amyloid-β (Aβ) plaques and intracellular tau pathology that spread in the brain. Three types of tau lesions occur in the form of neuropil threads, neurofibrillary tangles, and neuritic plaques i.e. tau aggregates within neurites surrounding Aβ deposits. The cascade of events linking these lesions and synaptic or memory impairments are still debated. Intracerebral infusion of human AD brain extracts in Aβ plaque-bearing mice that do not overexpress pathological tau proteins induces tau pathologies following heterotopic seeding of mouse tau protein. There is however little information regarding the downstream events including synaptic or cognitive repercussions of tau pathology induction in these models. In the present study, human AD brain extracts (AD","[""Alzheimer's disease"", 'Amyloid-β', 'Memory', 'Microglia', 'Synapses', 'Tau', 'Transmission']",Acta neuropathologica communications,2022-08-17,"[{'lastname': 'Lam', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': ""CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.\nDirection de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Hérard', 'firstname': 'Anne-Sophie', 'initials': 'AS', 'affiliation': ""CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.\nDirection de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Boluda', 'firstname': 'Susana', 'initials': 'S', 'affiliation': ""ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.\nBrainbank NeuroCEB Neuropathology Network: Plate-Forme de Ressources Biologiques, Bâtiment Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.""}, {'lastname': 'Petit', 'firstname': 'Fanny', 'initials': 'F', 'affiliation': ""CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.\nDirection de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Eddarkaoui', 'firstname': 'Sabiha', 'initials': 'S', 'affiliation': 'Inserm, CHU-Lille, Lille Neuroscience & Cognition, Alzheimer & Tauopathies, LabEx DISTALZ, Université de Lille, Rue Polonovski, 59045, Lille, France.'}, {'lastname': 'Cambon', 'firstname': 'Karine', 'initials': 'K', 'affiliation': ""CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.\nDirection de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.""}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Picq', 'firstname': 'Jean-Luc', 'initials': 'JL', 'affiliation': ""CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.\nDirection de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.\nLaboratory of Cognitive Functioning and Dysfunctioning (DysCo), University Paris 8, 93526, Saint-Denis Cedex, France.""}, {'lastname': 'Buée', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'Inserm, CHU-Lille, Lille Neuroscience & Cognition, Alzheimer & Tauopathies, LabEx DISTALZ, Université de Lille, Rue Polonovski, 59045, Lille, France.'}, {'lastname': 'Duyckaerts', 'firstname': 'Charles', 'initials': 'C', 'affiliation': ""ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.\nBrainbank NeuroCEB Neuropathology Network: Plate-Forme de Ressources Biologiques, Bâtiment Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.""}, {'lastname': 'Haïk', 'firstname': 'Stéphane', 'initials': 'S', 'affiliation': ""ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.\nBrainbank NeuroCEB Neuropathology Network: Plate-Forme de Ressources Biologiques, Bâtiment Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.""}, {'lastname': 'Dhenain', 'firstname': 'Marc', 'initials': 'M', 'affiliation': ""CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France. Marc.Dhenain@cnrs.fr.\nDirection de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France. Marc.Dhenain@cnrs.fr.""}]",,,,© 2022. The Author(s).,"10.1186/s40478-022-01410-y
10.1016/j.ajpath.2016.06.008
10.1001/archneur.61.3.378
10.1007/BF00308809
10.1038/ncomms7176
10.1093/brain/awx342
10.1016/j.neuron.2018.10.014
10.1186/s12917-020-02451-y
10.1016/j.nbd.2006.08.017
10.1186/s40478-019-0771-x
10.1016/j.ymeth.2016.11.016
10.1038/nm.4443
10.1016/j.neuron.2010.11.030
10.1523/JNEUROSCI.20-10-03606.2000
10.1186/s40478-021-01266-8
10.1038/s41593-019-0433-0
10.1038/S41598-019-52357-5
10.1126/science.1131864
10.1097/NEN.0b013e31825018f7
10.1007/s00401-004-0907-2
10.1016/j.neuropharm.2013.09.018
10.1038/sj.embor.7400784
10.1126/science.1141736
10.1007/s00401-016-1630-5
10.1126/science.1074069
10.2174/1567205011310030011
10.1016/j.neuron.2014.05.004
10.1007/s00401-009-0556-6
10.1002/ana.410300410
10.1007/s00401-018-1953-5
10.1111/bpa.12252",<Element 'PubmedArticle' at 0x7f05df0b6180>
35,"35962936
20303880
29513402
23717262
28062563
28127589
16972896
32779097
17965659
31077796
34097990
24669294
27459405
32780691
30954437
23337815
26207229
32736085
22315722
29883227
31208286
32047471
31981631
27438996
24659507
31073303
30832464
23732506
26354893
33562601
19763574
27959620
26957147
33925154
33239064
25598354
31585077
23386811
28730967
30258234
31583594
21467220
29892066
29140923
30564548
28939262
25576658
25340046
21296109
12857678
17027275
1566067
27213058
26973475
27021169
33809300
32434194
25792098
28479898
29232315
22876726
33414714
27016501
30980923
12776204
29562537
31631455
28936761
31606860
25969543
27888296
23054368
28104909
27107797
27412492
27816415
28062370
26209418
23041759
22636255
31823227
26448816
12531233
32489563
30652256
20851176
24930517
28527958
11929132
20713051
22947253
32853910
27843334
29113750
31628652
29463708
9202291
21375602
21282661",Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer's and Parkinson's Diseases.,"Neuroinflammation is an inflammatory process in the central nervous system (CNS), in addition to being one of the main features of Alzheimer's disease (AD) and Parkinson's disease (PD). Microglia are known for their immune functions and have multiple reactive phenotypes related to the types of stages involving neurodegenerative diseases. Depending on the state of activation of microglia in the CNS, it can be neuroprotective or neurotoxic. In this context, AD is a neurodegenerative and neuroinflammatory disease characterized by the deposition of beta-amyloid plaques, formation of fibrillar tangles of tau protein, and loss of neurons due to neurotoxic activation of microglia. However, PD is characterized by the loss of dopaminergic neurons in the substantia nigra and accumulation of alpha-synuclein in the cortical regions, spinal cord, and brain stem, which occurs by microglial activation, contributing to the neuroinflammatory process. In this aspect, the activation of microglia in both pathologies triggers high levels of inflammatory markers, such as interleukins, and causes the neuroinflammatory process of the diseases. Thus, physical exercise is pointed out as neuroprotective, as it can act to strengthen neurogenesis and reduce the inflammatory process. Therefore, the present review addresses the neuroprotective effect of microglia after different types of physical exercise protocols and evaluates the activity and effects of inflammatory and anti-inflammatory parameters and mechanisms of AD and PD. This review will discuss the anti-inflammatory effects of physical exercise through microglia activation with neuroprotective activity and the role of pro-and anti-inflammatory cytokines in AD and PD.","[""Alzheimer's disease"", 'Anti-inflammatory', 'Cytokines', 'Neuroinflammation', ""Parkinson's disease"", 'Physical exercise']",Neurochemical research,2022-08-14,"[{'lastname': 'de Almeida', 'firstname': 'Erin John Rieger', 'initials': 'EJR', 'affiliation': 'Graduate Program in Physical Education From Federal University of Santa Maria, Santa Maria, RS, Brazil.'}, {'lastname': 'Ibrahim', 'firstname': 'Hélio Jungkenn', 'initials': 'HJ', 'affiliation': 'Federal University of Fronteira Sul, Fronteira Sul, SC, Brazil.'}, {'lastname': 'Chitolina Schetinger', 'firstname': 'Maria Rosa', 'initials': 'MR', 'affiliation': 'Department of Biochemistry and Molecular Biology, UFSM, Santa Maria, RS, Brazil.'}, {'lastname': 'de Andrade', 'firstname': 'Cinthia Melazzo', 'initials': 'CM', 'affiliation': 'Department of Small Animal Clinic, Center of Rural Sciences, Federal University of Santa Maria-RS, Room 121, Veterinary Hospital Building, Avenue Roraima No. 1000, Santa Maria, RS, 97105-900, Brazil.'}, {'lastname': 'Cardoso', 'firstname': 'Andréia Machado', 'initials': 'AM', 'affiliation': 'Graduate Program in Physical Education From Federal University of Santa Maria, Santa Maria, RS, Brazil. deiaa.mc@gmail.com.\nGraduate Program in Biomedical Sciences From Federal University of Fronteira Sul, Campus Chapecó, Rodovia SC 484 - Km 02, Fronteira Sul, SC, 89815-899, Brazil. deiaa.mc@gmail.com.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s11064-022-03713-x
10.1016/j.cell.2010.02.016
10.1111/imm.12922
10.3389/fncel.2013.00065
10.1101/cshperspect.a028035
10.1111/j.1600-065X.2006.00441.x
10.1007/s11064-020-03105-z
10.1038/nn1997
10.1016/j.semcdb.2019.05.004
10.1016/j.neuint.2021.105094
10.12703/P6-13
10.1038/nn.4338
10.1007/s00702-017-1795-7
10.1016/j.jshs.2020.01.004
10.1016/j.clinbiochem.2019.04.001
10.1186/s12974-018-1313-3
10.1016/j.nbd.2020.105028
10.1101/cshperspect.a009381
10.1080/00207454.2018.1486837
10.1177/1545968319856893
10.3389/fneur.2019.01389
10.1016/j.lfs.2020.117345
10.1002/hipo.22620
10.1136/bjsports-2013-093224
10.1155/2019/8215017
10.5213/inj.1938038.019
10.1007/s00281-013-0382-8
10.1101/cshperspect.a020560
10.3390/ijms22041605
10.1007/s00281-009-0180-5
10.1146/annurev-physiol-022516-034406
10.1038/srep22490
10.3390/ijms22094676
10.1186/s40035-020-00221-2
10.1007/s12035-014-9070-5
10.1016/j.cell.2019.08.053
10.3389/fncel.2013.00006
10.2174/1570159X15666170720095240
10.1038/s41593-018-0242-x
10.1007/978-981-13-9913-8_13
10.1073/pnas.1017820108
10.1038/s41591-018-0051-5
10.3390/cells8070691
10.1097/j.pain.0000000000001109
10.3233/BPL-180074
10.1016/j.bjpt.2017.09.004
10.1016/j.intimp.2014.12.035
10.3389/fped.2014.00108
10.1016/j.bbamcr.2011.01.034
10.1152/ajpendo.00074.2003
10.3233/JAD-160869
10.1016/j.nbd.2006.08.019
10.1126/science.1566067
10.1155/2016/6362707
10.3389/fnint.2016.00007
10.1016/j.brainresbull.2016.03.012
10.3390/ijms22062897
10.1159/000507285
10.1016/S1474-4422(15)70016-5
10.4314/ahs.v16i4.22
10.1249/MSS.0000000000001519
10.3233/JAD-190729
10.3389/fnagi.2020.588958
10.1016/j.bbamcr.2016.03.018
10.1016/j.exger.2019.04.003
10.1038/nri1106
10.3233/JAD-170819
10.1126/science.aan8821
10.1111/ene.14108
10.1007/s12264-017-0183-5
10.1007/s40520-019-01353-w
10.1126/scisignal.2005965
10.1007/s00401-016-1648-8
10.1007/s11481-012-9401-0
10.1038/nrn.2016.178
10.1016/j.pneurobio.2016.04.006
10.1080/00207454.2016.1212854
10.1016/j.brainres.2016.10.029
10.1016/j.exger.2017.01.001
10.1016/j.mehy.2015.07.011
10.1016/j.neuroscience.2012.09.063
10.1113/expphysiol.2012.066720
10.1007/s00702-006-0575-6
10.1007/s12640-019-00147-2
10.1155/2015/261809
10.1016/S0301-0082(02)00127-2
10.1007/s11011-018-0379-z
10.3390/jcm9010184
10.1016/j.bbi.2010.09.006
10.1016/j.neuroscience.2017.05.016
10.1016/S1471-4906(01)02149-4
10.1016/j.expneurol.2010.08.016
10.1186/1742-2094-9-210
10.3390/ijms19082155
10.1016/j.biopha.2020.110660
10.2147/JIR.S86958
10.1016/j.bbadis.2017.11.004
10.1007/978-981-13-9367-9_4
10.1073/pnas.1718435115
10.1046/j.1471-4159.1997.69010034.x
10.1007/s00441-017-2782-x
10.1111/j.1460-9568.2011.07626.x
10.1073/pnas.1015950108",<Element 'PubmedArticle' at 0x7f05df0dcc20>
36,"35897046
29653606
30897353
30406177
29196460
28549481
28714976
30326945
34493870
10978530
11956071
29259854
34004146
22485184
11140685
23825679
31261380
23104886
23950696
25516281
25186741
32702314
29346778
30471926
28602351
28930663
31018141
19114008
23050260
20132535
30392797
27115769
30084846
32668255
31561642
30042661
23354023
28099414
29126445
31932797
23622250
30758077
33734581
26428302
17804420
34731000
29037207
30232263
29073081
33675684
32483373
26030851
9286705
30283031
30283032
31980586
30617257
25732305
20368278
26156074
17549256
23486975
32681824
20920788
20864679
26984188
28122877
34128045
28921611
19825975
25492702
23158496
21035623
33328329
30711010
27104977
22496823
31301936
10995551",Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways.,"The S209F variant of Abelson Interactor Protein 3 (ABI3) increases risk for Alzheimer's disease (AD), but little is known about its function in relation to AD pathogenesis.
Here, we use a mouse model that is deficient in Abi3 locus to study how the loss of function of Abi3 impacts two cardinal neuropathological hallmarks of AD-amyloid β plaques and tau pathology. Our study employs extensive neuropathological and transcriptomic characterization using transgenic mouse models and adeno-associated virus-mediated gene targeting strategies.
Analysis of bulk RNAseq data confirmed age-progressive increase in Abi3 levels in rodent models of AD-type amyloidosis and upregulation in AD patients relative to healthy controls. Using RNAscope in situ hybridization, we localized the cellular distribution of Abi3 in mouse and human brains, finding that Abi3 is expressed in both microglial and non-microglial cells. Next, we evaluated Abi3
These data provide an important experimental framework for understanding the role of Abi3-Gngt2 function and early inflammatory gliosis in AD. Our studies also demonstrate that inflammatory gliosis could have opposing effects on amyloid and tau pathology, highlighting the unpredictability of targeting immune pathways in AD.","['Alzheimer’s disease', 'Disease signature', 'Gene dose', 'Neurofibrillary tangle', 'Plaque burden', 'Risk factor']",Alzheimer's research & therapy,2022-07-28,"[{'lastname': 'Ibanez', 'firstname': 'Kristen R', 'initials': 'KR', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'McFarland', 'firstname': 'Karen N', 'initials': 'KN', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.\nDepartment of Neurology, University of Florida, Gainesville, FL, 32610, USA.'}, {'lastname': 'Phillips', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'Allen', 'firstname': 'Mariet', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Lessard', 'firstname': 'Christian B', 'initials': 'CB', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'Zobel', 'firstname': 'Lillian', 'initials': 'L', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'De La Cruz', 'firstname': 'Elsa Gonzalez', 'initials': 'EG', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'Shah', 'firstname': 'Shivani', 'initials': 'S', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'Vo', 'firstname': 'Quan', 'initials': 'Q', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'Wang', 'firstname': 'Xue', 'initials': 'X', 'affiliation': 'Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Quicksall', 'firstname': 'Zachary', 'initials': 'Z', 'affiliation': 'Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Ryu', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.'}, {'lastname': 'Funk', 'firstname': 'Cory', 'initials': 'C', 'affiliation': 'Institute for Systems Biology, Seattle, WA, 98109, USA.'}, {'lastname': 'Ertekin-Taner', 'firstname': 'Nilüfer', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.\nDepartment of Neurology, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Prokop', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.\nDepartment of Pathology, University of Florida, Gainesville, FL, 32610, USA.\nMcKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA.'}, {'lastname': 'Golde', 'firstname': 'Todd E', 'initials': 'TE', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.\nMcKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA.\nDepartment of Neuroscience, University of Florida, Gainesville, FL, 32610, USA.'}, {'lastname': 'Chakrabarty', 'firstname': 'Paramita', 'initials': 'P', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.\nMcKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.\nDepartment of Neuroscience, University of Florida, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.'}]",,,"Analysis of bulk RNAseq data confirmed age-progressive increase in Abi3 levels in rodent models of AD-type amyloidosis and upregulation in AD patients relative to healthy controls. Using RNAscope in situ hybridization, we localized the cellular distribution of Abi3 in mouse and human brains, finding that Abi3 is expressed in both microglial and non-microglial cells. Next, we evaluated Abi3",© 2022. The Author(s).,"10.1186/s13195-022-01044-1
10.1016/j.neuron.2019.02.027
10.1186/s13024-018-0289-x
10.1016/j.cell.2021.04.021
10.1371/journal.pone.0034677
10.1371/journal.pone.0067680
10.1093/hmg/ddz151
10.1093/bioinformatics/bts635
10.1371/journal.pcbi.1003118
10.1186/s13059-014-0550-8
10.1523/JNEUROSCI.1860-14.2014
10.1016/j.immuni.2018.11.004
10.1016/j.immuni.2017.08.008
10.1186/1471-2105-9-559
10.18637/jss.v046.i11
10.1186/gb-2010-11-2-r14
10.1016/j.neuron.2018.10.014
10.1007/s00401-016-1576-7
10.3390/genes10100759
10.1016/j.semcdb.2013.01.007
10.1038/nature21029
10.1186/s13024-017-0226-4
10.1186/s12964-015-0119-5
10.1074/jbc.M702583200
10.1101/2021.03.19.436147v1
10.1186/s13024-017-0216-6
10.1073/pnas.1811411115
10.1073/pnas.1710311114
10.1016/j.neuron.2021.02.010
10.1038/s41586-020-2288-7
10.1038/nn.4030
10.1006/geno.1997.4814
10.1038/s41593-018-0296-9
10.4049/jimmunol.0903382
10.1096/fj.15-275834
10.1172/JCI31450
10.1016/j.neuron.2020.06.021
10.1016/j.neuron.2010.08.023
10.1096/fj.09-141754
10.1007/s00401-014-1371-2
10.1186/1742-2094-9-250
10.1016/j.cell.2016.03.014
10.1371/journal.pone.0034514
10.1006/mcne.2000.0865",<Element 'PubmedArticle' at 0x7f05df09cef0>
37,"35883667
24471431
31654430
31699331
15509534
18457819
20122289
20971854
21777559
31636558
30755589
33328952
34782623
18201950
17270732
25598354
30136683
30536167
30536165
31036962
29158945
16123779
25744023
15277226
17392160
29031088
18604209
21946017
23254930
25144717
29293211
29273951
31748742
31111399
32564756
32032696
32768944
17164409
30105072
34106880
33542629
33574670
6610841
2011243
2422580
9067838
2358525
24162652
24093676
26847266
33410748
35273086
17349957
10964481
18988639
12484566
12849422
33927414
31023342
32276587
34250722
35072836
31843293
31611248
33761363
23486975
30467171
11069945
11355301
18487604
10438520
23402898
33649324
24265764
12528818
32372343
33980303
24413155
19649251
23238751
32592441
23318584
23160153
26751493
30721409
33262692
34920732
15652989
26001591
27256292
28601280
28445885
30189209
35379992
34107254
30069930",NLRP1 Inflammasome Activation in the Hippocampal Formation in Alzheimer's Disease: Correlation with Neuropathological Changes and Unbiasedly Estimated Neuronal Loss.,"Neuroinflammation is one of the core pathological features of Alzheimer's disease (AD) as both amyloid β (Aβ) and tau monomers and oligomers can trigger the long-term pro-inflammatory phenotype of microglial cells with consequent overactivation of the inflammasomes. To investigate the NLRP1 inflammasome activation in AD, we analyzed the expression of NLRP1, ASC, cleaved gasdermin (cGSDMD), and active caspase-6 (CASP-6) proteins in each hippocampal subdivision (hilar part of CA3, CA2/3, CA1, subiculum) of postmortem tissue of 9 cognitively healthy controls (HC) and 11 AD patients whose disease duration varied from 3 to 7 years after the clinical diagnosis. The total number of neurons, along with the total number of neurofibrillary tangles (NFTs), were estimated in Nissl- and adjacent modified Bielschowsky-stained sections, respectively, using the optical disector method. The same 9 HC and 11 AD cases were additionally semiquantitatively analyzed for expression of IBA1, HLA-DR, and CD68 microglial markers. Our results show that the expression of NLRP1, ASC, and CASP-6 is present in a significantly greater number of hippocampal formation neurons in AD brains compared to controls, suggesting that the NLRP1 inflammasome is more active in the AD brain. None of the investigated inflammasome and microglial markers were found to correlate with the age of the subjects or the duration of AD. However, besides positive correlations with microglial IBA1 expression in the subiculum and with microglial CD68 expression in the CA1 field and subiculum in the AD group, the overall NLRP1 expression in the hippocampal formation was positively correlated with the number of NFTs, thus providing a causal link between neuroinflammation and neurofibrillary degeneration. The accumulation of AT8-immunoreactive phosphorylated tau proteins that we observed at nuclear pores of large pyramidal neurons of the Ammon's horn further supports their role in the extent of neuronal dysfunction and degeneration in AD. This is important because unlike fibrillar amyloid-β deposits that are not related to dementia severity, total NFTs and neuron numbers in the hippocampal formation, especially in the CA1 field, are the best correlates of cognitive deterioration in both human brain aging and AD. Our findings also support the notion that the CA2 field vulnerability is strongly linked to specific susceptibilities to different tauopathies, including primary age-related tauopathy. Altogether, these findings contrast with reports of nonsignificant microglial activation in aged nonhuman primates and indicate that susceptibility to inflammasome activation may render the human brain comparatively more vulnerable to neurodegenerative changes and AD. In conclusion, our results confirm a key role of NLRP1 inflammasome in AD pathogenesis and suggest NLRP1 as a potential diagnostic marker and therapeutic target to slow or prevent AD progression.","['Alzheimer’s disease', 'NLRP3', 'hippocampus', 'inflammasome', 'microglia', 'neurofibrillary pathology', 'tau protein']",Cells,2022-07-28,"[{'lastname': 'Španić', 'firstname': 'Ena', 'initials': 'E', 'affiliation': 'Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Šalata 12, 10000 Zagreb, Croatia.'}, {'lastname': 'Langer Horvat', 'firstname': 'Lea', 'initials': 'L', 'affiliation': 'Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Šalata 12, 10000 Zagreb, Croatia.'}, {'lastname': 'Ilić', 'firstname': 'Katarina', 'initials': 'K', 'affiliation': ""Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Šalata 12, 10000 Zagreb, Croatia.\nBRAIN Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London WC2R 2LS, UK.""}, {'lastname': 'Hof', 'firstname': 'Patrick R', 'initials': 'PR', 'affiliation': ""Nash Family Department of Neuroscience, Friedman Brain Institute, and Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.""}, {'lastname': 'Šimić', 'firstname': 'Goran', 'initials': 'G', 'affiliation': 'Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Šalata 12, 10000 Zagreb, Croatia.'}]",,,,,"10.3390/cells11142223
10.1146/annurev-immunol-032713-120240
10.1111/imcb.12301
10.1016/S0002-9440(10)63421-9
10.1016/j.brainres.2008.02.084
10.1186/alzrt24
10.1074/jbc.M110.135244
10.1016/j.ajpath.2011.05.047
10.3389/fnagi.2019.00271
10.1038/s41419-019-1413-8
10.3389/fnagi.2020.512097
10.1038/s41467-021-26851-2
10.1007/BF03033906
10.1016/j.neuron.2007.01.010
10.1007/s12035-014-9070-5
10.4103/1673-5374.238608
10.15419/bmrat.v5i8.464
10.1038/s41577-019-0165-0
10.1038/sigtrans.2017.23
10.1038/sj.cdd.4401753
10.1038/cdd.2015.16
10.1016/S0002-9440(10)63317-2
10.2353/ajpath.2007.060974
10.1016/j.neurobiolaging.2017.09.007
10.1038/ni.1636
10.1097/WAD.0b013e318231a8ac
10.1038/nature11729
10.1038/cddis.2014.348
10.1038/nature25158
10.1007/s00702-017-1831-7
10.1038/s41586-019-1769-z
10.1007/s12035-019-1638-7
10.2174/1570159X18666200621204546
10.1016/j.pnpbp.2020.109884
10.1016/j.biopha.2020.110449
10.1369/jhc.6A7101.2006
10.1155/2018/8296824
10.18632/aging.203125
10.2147/NDT.S279147
10.2147/NDT.S279304
10.1212/WNL.34.7.939
10.1212/WNL.41.4.479
10.1111/j.1365-2990.1986.tb00677.x
10.1002/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z
10.1002/cne.902960102
10.1038/nn.3554
10.1016/j.cmet.2013.09.010
10.2139/ssrn.4065080
10.1002/glia.22966
10.7554/eLife.60609
10.1016/j.molcel.2007.01.032
10.1006/exnr.2000.7448
10.1093/brain/awn280
10.1093/jnen/61.12.1040
10.1016/S1474-4422(02)00130-8
10.1038/s41591-021-01309-6
10.1186/s40478-019-0717-3
10.1186/s13024-020-00374-8
10.1111/jcmm.16787
10.1007/s11033-022-07177-8
10.1016/j.tins.2019.11.005
10.1084/jem.20190314
10.1016/j.celrep.2021.108887
10.1523/JNEUROSCI.4361-12.2013
10.1126/science.aar7607
10.1523/JNEUROSCI.20-22-08384.2000
10.1007/s004010100378
10.1074/mcp.M800007-MCP200
10.1074/jbc.274.33.23426
10.1016/j.neurobiolaging.2013.01.007
10.1038/s41419-021-03506-0
10.1371/journal.pone.0079313
10.1093/jnen/62.1.55
10.1007/s12031-020-01573-0
10.1186/s40478-021-01189-4
10.1038/cdd.2013.194
10.1371/journal.pone.0006486
10.1038/ni.2493
10.1096/fj.202000734R
10.1038/cr.2013.6
10.1038/ni.2474
10.3390/biom6010006
10.1007/s00401-018-01957-y
10.1186/s12993-021-00185-x
10.1016/j.neuroscience.2004.09.040
10.1186/s40478-015-0209-z
10.1186/s12974-016-0601-z
10.1016/j.jneuroim.2017.04.007
10.1159/000457127
10.1016/j.neuron.2018.07.039
10.1038/s41588-022-01024-z
10.1016/j.celrep.2021.109228
10.1002/cne.24484",<Element 'PubmedArticle' at 0x7f05df05acc0>
38,"35807370
31375134
35000160
15709478
16472958
12130773
12544843
18771816
17117171
19302036
20303880
23616747
29196460
20966214
24316888
24742461
24471431
28226226
22632727
27004698
15831717
28522972
28659790
27862631
26847266
29493017
27743026
29867449
24033473
27404378
19513731
28434692
27696527
19917131
26556658
25598354
27288982
27091843
29198280
30191777
28588356
29935546
27848250
29895249
32792944
34450170
34532504
33100197
33622399
33490374
33679375
32048763
28164764
20577641
19747160
29080524
20061647
21214928
31440798
32147039
19339593
11596125
18662748
22741103
24360280
20193723
21527731
16355225
22167804
22223464
18432411
14730714
16859761
19389585
17203473
21665818
18495785
17951027
34899188
31924219
32840654
22406537
23799536
28894284
28802038
23454195
31690660
21771791
23254930
33065077
31235932
28959956
31659342
31504240
31100304
23178247
28959184
25499735
24813611
27732836
15485493
29623063
16720574
21106831
22666621
17351623
16639431
21839061
24008733
17130689
21531375
32929691
32564756
12933918
23560052
30104698
20303873
26091541
26939933
18604209
15285801
21889505
24742453
18602982
15959904
15489356
22912745
20133628
21946271
23732506
12399581
18359495
26257642
11513911
15954124
17023659
15095274
20083042
28099414
26436904
29490706
31434879
32479996
31019207
25847999
26163224
28255908
31872431
30051350
30022810
17086106
18852683
20837824
12930788
19923038
29599291
32795308
32579671
32154671
28005991
31369984
27668937
28528700
28591653
23049854
23623603
26086962
26293123
31324781
26163371
25728668
30541012
10908610
15817521
20696495
27885860
30696107
30502599
28003153
31738372
28977782
21088470
29573818
28636962
32923843
31543810",Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules.,"Alzheimer's disease (AD) is a common, progressive, and devastating neurodegenerative disorder that mainly affects the elderly. Microglial dysregulation, amyloid-beta (Aβ) plaques, and intracellular neurofibrillary tangles play crucial roles in the pathogenesis of AD. In the brain, microglia play roles as immune cells to provide protection against virus injuries and diseases. They have significant contributions in the development of the brain, cognition, homeostasis of the brain, and plasticity. Multiple studies have confirmed that uncontrolled microglial function can result in impaired microglial mitophagy, induced Aβ accumulation and tau pathology, and a chronic neuroinflammatory environment. In the brain, most of the genes that are associated with AD risk are highly expressed by microglia. Although it was initially regarded that microglia reaction is incidental and induced by dystrophic neurites and Aβ plaques. Nonetheless, it has been reported by genome-wide association studies that most of the risk loci for AD are located in genes that are occasionally uniquely and highly expressed in microglia. This finding further suggests that microglia play significant roles in early AD stages and they be targeted for the development of novel therapeutics. In this review, we have summarized the molecular pathogenesis of AD, microglial activities in the adult brain, the role of microglia in the aging brain, and the role of microglia in AD. We have also particularly focused on the significance of targeting microglia for the treatment of AD.","['Alzheimer’s disease', 'amyloid-beta', 'microglia', 'neuroinflammation', 'pathogenesis', 'tau']","Molecules (Basel, Switzerland)",2022-07-10,"[{'lastname': 'Althafar', 'firstname': 'Ziyad M', 'initials': 'ZM', 'affiliation': 'Department of Medical Laboratories Sciences, College of Applied Medical Sciences in Alquwayiyah, Shaqra University, Riyadh 11961, Saudi Arabia.'}]",,,,,"10.3390/molecules27134124
10.1186/s13024-019-0333-5
10.1007/s11356-021-17830-7
10.1007/0-387-23226-5_8
10.1016/j.ijdevneu.2005.11.014
10.1126/science.1072994
10.1097/00001756-200301200-00023
10.1016/j.neurobiolaging.2008.07.021
10.1038/ncpneuro0355
10.1146/annurev.immunol.021908.132528
10.1016/j.cell.2010.02.016
10.3389/fncel.2013.00045
10.1083/jcb.201709069
10.1126/science.1194637
10.1038/nn.3599
10.1016/j.neuron.2014.02.040
10.1146/annurev-immunol-032713-120240
10.1146/annurev-immunol-051116-052358
10.1016/j.neuron.2012.03.026
10.1016/j.tcb.2016.02.006
10.1126/science.1110647
10.3389/fnagi.2017.00128
10.3389/fnagi.2017.00194
10.1111/bpa.12456
10.1002/glia.22966
10.1002/glia.23318
10.1007/s00401-016-1630-5
10.3389/fnagi.2018.00140
10.1111/bpa.12088
10.1002/glia.23024
10.1007/s00401-009-0556-6
10.1016/j.neurobiolaging.2017.03.021
10.1002/glia.23078
10.1186/1750-1326-4-47
10.1016/j.bcp.2015.11.003
10.1007/s12035-014-9070-5
10.1016/j.neuropharm.2016.06.009
10.1084/jem.20151948
10.1017/S135561771700100X
10.2174/0929867323666161213101126
10.1159/000464422
10.1186/s13195-018-0394-7
10.1142/S0192415X16500853
10.2174/1567205015666180613112040
10.3389/fphar.2020.01097
10.1016/j.lfs.2021.119899
10.1155/2021/7396580
10.2174/1381612826666201023144836
10.1186/s13195-021-00788-6
10.3934/Neuroscience.2021005
10.3389/fnagi.2021.617588
10.1111/and.13535
10.2174/1567205014666170203141717
10.3389/fnagi.2010.00022
10.2174/156720509790147179
10.1016/j.redox.2017.10.014
10.3233/JAD-2010-1221
10.1186/1756-6606-4-3
10.1007/s00204-019-02538-y
10.1016/j.ctim.2019.102294
10.1523/JNEUROSCI.4363-08.2009
10.1002/glia.1106
10.1016/j.neuroscience.2008.06.052
10.1002/brb3.51
10.1016/j.cell.2013.11.030
10.1016/j.neuint.2010.02.013
10.1152/physrev.00011.2010
10.1038/nature04223
10.1073/pnas.1111098109
10.1002/glia.22287
10.1080/08916930802024889
10.1002/glia.10319
10.1016/j.tins.2006.07.001
10.1016/j.iac.2009.02.007
10.1002/glia.20468
10.1093/icb/icp009
10.1189/jlb.0208108
10.1016/j.bbi.2007.08.014
10.3389/fncel.2021.749587
10.1186/s12974-019-1673-3
10.1007/s00401-020-02200-3
10.1172/JCI58642
10.1038/ncomms3030
10.1038/s41598-017-11634-x
10.1016/j.cell.2017.07.023
10.1016/j.nbd.2013.02.003
10.1073/pnas.1908529116
10.1074/jbc.M111.254268
10.1038/nature11729
10.1016/j.expneurol.2020.113506
10.1038/s41593-019-0433-0
10.1038/nature24016
10.1038/s41593-019-0525-x
10.1093/brain/awz241
10.1016/j.neuint.2019.104469
10.1038/nm.2965
10.3389/fnmol.2017.00291
10.1016/j.tcb.2014.11.002
10.1016/j.cell.2014.03.026
10.1016/j.cmet.2016.09.004
10.1111/j.1471-4159.2004.02765.x
10.3389/fneur.2018.00169
10.1074/jbc.M600504200
10.1523/JNEUROSCI.3021-10.2010
10.1155/2012/489456
10.1038/nm1555
10.1038/nri1843
10.1016/j.ajpath.2011.06.025
10.1038/cddis.2013.325
10.1097/01.ede.0000248202.83695.4e
10.1016/j.ajpath.2011.02.012
10.1007/s11064-020-03121-z
10.2174/1570159X18666200621204546
10.1136/jnnp.74.9.1200
10.1371/journal.pone.0059586
10.1038/s41598-018-30487-6
10.1016/j.cell.2010.01.040
10.1371/journal.pone.0130624
10.1186/s13024-016-0088-1
10.1038/ni.1636
10.1186/1742-2094-1-14
10.1016/j.febslet.2011.08.033
10.1111/j.1468-0297.2012.02549.x
10.1016/j.neuron.2014.04.010
10.1016/j.exger.2008.06.004
10.1002/jnr.20488
10.1128/CMR.17.4.942-964.2004
10.1371/journal.pone.0042823
10.1073/pnas.0912245107
10.1016/j.expneurol.2011.09.016
10.1007/s00281-013-0382-8
10.1126/science.1074069
10.1016/j.neuropharm.2008.01.012
10.3389/fnagi.2015.00124
10.1016/S0140-6736(01)05625-2
10.1002/jnr.20562
10.1126/science.1134108
10.1002/path.1538
10.1016/S1474-4422(09)70299-6
10.1038/nature21029
10.1038/nn.4132
10.1186/s13024-018-0244-x
10.1038/s41467-019-11674-z
10.1016/j.nbd.2020.104956
10.1038/s41598-019-42931-2
10.1073/pnas.1422998112
10.1007/s10072-015-2314-y
10.1007/s12035-017-0467-9
10.1111/jnc.14945
10.1007/s12035-018-1211-9
10.2147/DDDT.S161944
10.1097/01.jnen.0000240470.97295.d3
10.1097/WNR.0b013e3283179333
10.1001/archneurol.2010.229
10.1523/JNEUROSCI.23-20-07504.2003
10.1016/j.neurobiolaging.2009.10.009
10.1074/jbc.RA118.001848
10.1186/s12974-020-01915-0
10.1084/jem.20200785
10.15252/emmm.201911227
10.1371/journal.pone.0168812
10.1016/j.isci.2019.07.023
10.1038/nm.4189
10.1016/j.stemcr.2017.04.023
10.1016/j.stemcr.2017.05.017
10.1371/journal.pone.0045757
10.1016/j.neurobiolaging.2013.03.029
10.1038/cddis.2015.138
10.1186/s13024-015-0035-6
10.1038/s41467-019-11053-8
10.1016/j.immuni.2015.06.012
10.1016/j.cell.2015.01.049
10.1159/000492596
10.1523/JNEUROSCI.20-15-05709.2000
10.1093/brain/awh452
10.1016/j.neurobiolaging.2010.06.014
10.1080/13543784.2017.1265504
10.3390/ijms20030558
10.1016/j.jneuroim.2018.11.010
10.1016/j.bbi.2016.12.014
10.1001/jamaneurol.2019.3762
10.1159/000481753
10.3858/emm.2011.43.1.001
10.1016/j.tig.2018.02.007
10.1016/j.immuni.2017.06.006
10.1063/5.0013178
10.3389/fnagi.2019.00233",<Element 'PubmedArticle' at 0x7f05df0212c0>
39,"35693341
8202528
32514138
28522972
35309305
33314529
28131016
26001591
2495152
1849776
31447664
10932230
24952504
29053874
26884166
26393402
22473769
1759558
29223680
9748670
16341139
19794442
17185504
29616709
32778792
19300564
30886620
9285591
21841002
20368278
21324189
19825975
25619653
22838967
1663599
28713158
32702314
29859094
24889886
18057827
29437957
19503072
28226226
29895964
30326945
17474819
11786404
17035538
29695589
22674585
21108733
11207825
15895084
27862631
22365544
31375134
32253358
30069930
23316765
15148142
1745413
34099706
21403390
24952505
23799536
29346778
20133839
28671693
33609158
26870803
20966214
33501429
15919760
26251237
21525931
10623648
31301936
23623698
16981890
7876895
32341542
25792098
23254930
34643971
18814846
30995916
18701698
24162652
30826549
32894243
29365294
17682126
22397651
31906949
28111074
29216448
18270819
2874414
31748742
28165122
28100745
25732305
18987201
17047368
22766509
34731000
24951455
28602351
21527731
11861655
29656362
19679070
16876915
30127720
28930663
17551515
17008526
24162737
29518357
23481567
33318676
17293054
29951498
30606613
21543591
28099414
6425287
20721346
24833613
16437436
24630722
10487842
11424194
23210447
25052481
30711010
34254352
22762014
20610346
32840330
30760929
10567338
29020624
22173340
21911734
20061650
10589538
31980586
15258207
21956108
35320002
29867449
22487856
15831717
23039106
30569088
31902528
17021169
7566636
15548589
33257666
32894242
29221491
32238175
25331948
34446931
31780579
25092575
24638131
8423063
21651394
23276979
22837131
18316756
27540165
27459405
17934472
8398148
21084593
12672860
30630900
20189881
24874542
31822279
19908146
8712790
33065077
24728269
31018141
24450891
19923038
29259854
8350998
16877359
18378357
26428302
31138932
27582220
23812099
26238576
17203473
28714976
28714976
33402227
28659790
32610143
20037584
19513731
29794134
22262900
17011668
31036962
32917267
20947502
25452009
27334934
25598354
24830807
33631273
17197236
34366341
21989322
29935546
29293211
32197217
34385305
25728668
25728668
27091843
12572918
31283900
33539598
22233753
26294005
27710785
27196974
31932797
23111107",Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer's Disease.,"Alzheimer's disease (AD) is a progressive neurodegenerative disease and is closely associated with the accumulation of β-amyloid (Aβ) and neurofibrillary tangles (NFTs). Apart from Aβ and NFT pathologies, AD patients also exhibit a widespread microglial activation in various brain regions with elevated production of pro-inflammatory cytokines, a phenomenon known as neuroinflammation. In healthy central nervous system, microglia adopt ramified, ""surveying"" phenotype with compact cell bodies and elongated processes. In AD, the presence of pathogenic proteins such as extracellular Aβ plaques and hyperphosphorylated tau, induce the transformation of ramified microglia into amoeboid microglia. Ameboid microglia are highly phagocytic immune cells and actively secrete a cascade of pro-inflammatory cytokines and chemokines. However, the phagocytic ability of microglia gradually declines with age, and thus the clearance of pathogenic proteins becomes highly ineffective, leading to the accumulation of Aβ plaques and hyperphosphorylated tau in the aging brain. The accumulation of pathogenic proteins further augments the neuroinflammatory responses and sustains the activation of microglia. The excessive production of pro-inflammatory cytokines induces a massive loss of functional synapses and neurons, further worsening the disease condition of AD. More recently, the identification of a subset of microglia by transcriptomic studies, namely disease-associated microglia (DAM), the progressive transition from homeostatic microglia to DAM is TREM2-dependent and the homeostatic microglia gradually acquire the state of DAM during the disease progression of AD. Recent in-depth transcriptomic analysis identifies ApoE and Trem2 from microglia as the major risk factors for AD pathogenesis. In this review, we summarize current understandings of the functional roles of age-dependent microglial activation and neuroinflammation in the pathogenesis of AD. To this end, the exponential growth in transcriptomic data provides a solid foundation for ","['Alzheimer’s disease', 'beta-amyloid', 'bipolar/rod-shaped microglia', 'disease-associated microglia (DAM)', 'neurofibrillary tangles', 'neuroinflammation', 'single-cell RNA-seq (scRNA-seq)']",Frontiers in aging neuroscience,2022-06-14,"[{'lastname': 'Xu', 'firstname': 'Yi-Jun', 'initials': 'YJ', 'affiliation': 'Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China.'}, {'lastname': 'Au', 'firstname': 'Ngan Pan Bennett', 'initials': 'NPB', 'affiliation': 'Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China.'}, {'lastname': 'Ma', 'firstname': 'Chi Him Eddie', 'initials': 'CHE', 'affiliation': 'Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China.\nCity University of Hong Kong Shenzhen Research Institute, Shenzhen, China.'}]",,,,"Copyright © 2022 Xu, Au and Ma.","10.3389/fnagi.2022.896852
10.1073/pnas.91.12.5562
10.1016/j.jalz.2019.01.010
10.1038/s41593-020-0650-6
10.3389/fnagi.2017.00128
10.3389/fimmu.2022.860070
10.1002/alz.12256
10.1016/j.neurobiolaging.2016.12.028
10.1186/s40478-015-0209-z
10.1016/0006-8993(89)91396-6
10.1016/0006-8993(91)90681-k
10.3389/fnagi.2019.00204
10.1038/78682
10.1038/ni.2919
10.1093/brain/awx243
10.1073/pnas.1525528113
10.1001/archneurol.2012.90
10.1007/BF00308809
10.1016/j.neurobiolaging.2017.11.009
10.1038/nri1745
10.1038/nrd2959
10.1196/annals.1377.005
10.14283/jpad.2018.18
10.1038/s41593-020-0687-6
10.3389/fimmu.2019.00362
10.1038/42030
10.1074/jbc.M111.229633
10.4049/jimmunol.0903382
10.1096/fj.09-141754
10.1016/j.neuron.2014.11.020
10.1186/1750-1326-7-36
10.1016/0306-4522(91)90267-r
10.1038/aps.2017.28
10.1016/j.cell.2020.06.038
10.1186/s13024-018-0262-8
10.1186/1742-2094-11-98
10.1292/jvms.69.1131
10.1073/pnas.1800165115
10.1038/ncb1901
10.1146/annurev-immunol-051116-052358
10.1038/s41582-018-0013-z
10.1186/s13024-018-0289-x
10.4088/jcp.v68n0419
10.1016/s0002-9440(10)64354-4
10.1523/JNEUROSCI.3133-06.2006
10.1212/WNL.0000000000005550
10.1002/glia.22350
10.1111/j.1474-9726.2010.00660.x
10.1046/j.1365-2559.2001.01082.x
10.1038/nn1472
10.1111/bpa.12456
10.1016/j.neuron.2011.11.033
10.1523/JNEUROSCI.2339-19.2020
10.1002/cne.24484
10.1186/1750-1326-8-2
10.1001/archneur.61.5.668
10.1016/0304-3940(91)90490-k
10.1038/s41467-021-23762-0
10.3233/JAD-2011-101014
10.1038/ni.2913
10.1038/ncomms3030
10.1016/j.celrep.2017.12.066
10.1073/pnas.0904532106
10.1038/nn.4597
10.1007/s00401-021-02263-w
10.1016/j.ebiom.2015.09.053
10.1126/science.1194637
10.1093/braincomms/fcaa227
10.1096/fj.05-3776fje
10.1007/s00281-015-0518-0
10.1038/nature10071
10.1016/s0002-9440(10)64700-1
10.1016/j.neuron.2019.06.010
10.1016/j.neuron.2013.04.014
10.1111/j.1471-4159.2006.04165.x
10.1097/00005072-199503000-00014
10.1038/s41593-020-0624-8
10.1038/nature11729
10.1002/glia.24105
10.1016/j.bbi.2008.09.002
10.1186/s12974-019-1478-4
10.1523/JNEUROSCI.0616-08.2008
10.1038/nn.3554
10.1016/j.semcdb.2019.02.005
10.3233/JAD-200098
10.1056/NEJMoa1705971
10.1182/blood-2007-02-073874
10.1016/j.cell.2016.12.044
10.1016/j.neuron.2017.11.014
10.1007/s11064-007-9584-6
10.1016/s0140-6736(86)92134-3
10.1038/s41586-019-1769-z
10.1093/hmg/ddx043
10.1523/JNEUROSCI.2110-16.2016
10.1084/jem.20142322
10.1523/JNEUROSCI.3024-08.2008
10.1159/000095267
10.1210/er.2011-1049
10.1126/sciadv.abe3954
10.1016/j.biopsych.2014.05.006
10.1016/j.cell.2017.05.018
10.1074/jbc.M200887200
10.1007/s12035-018-1036-6
10.1016/j.neurobiolaging.2006.06.019
10.3389/fncel.2018.00206
10.1016/j.immuni.2017.08.008
10.1126/science.1132939
10.1038/ng.2802
10.1016/j.neuron.2018.02.002
10.1016/j.neurobiolaging.2012.12.014
10.1038/s41582-020-00435-y
10.1016/j.neuroscience.2007.01.004
10.1016/j.neuron.2018.12.006
10.1523/JNEUROSCI.0203-11.2011
10.1038/nature21029
10.1016/s0021-9258(17)42989-9
10.4061/2010/587463
10.1093/glycob/cwu044
10.1016/j.cell.2014.02.008
10.1016/s0002-9440(10)65184-x
10.1002/glia.1072
10.1186/2047-9158-1-9
10.1007/s12035-014-8811-9
10.1186/s13195-019-0469-0
10.15252/embj.2020105603
10.1101/cshperspect.a006247
10.37765/ajmc.2020.88481
10.1038/s41586-019-0924-x
10.1074/jbc.274.48.33835
10.1016/j.celrep.2017.09.039
10.1007/s11481-011-9331-2
10.1212/wnl.0b013e31822e145d
10.3233/JAD-2010-1219
10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
10.1523/JNEUROSCI.1871-19.2019
10.1136/jnnp.2003.025858
10.1074/jbc.M111.280495
10.1126/scitranslmed.abl7634
10.3389/fnagi.2018.00140
10.1097/NEN.0b013e31825018f7
10.1126/science.1110647
10.1111/j.1365-2990.2012.01306.x
10.14283/jpad.2018.45
10.1016/j.neuron.2019.12.007
10.1523/JNEUROSCI.1202-06.2006
10.1016/0304-3940(95)11595-n
10.1096/fj.04-2637fje
10.1038/s41467-020-19737-2
10.3233/JAD-200019
10.1186/s12974-020-01774-9
10.1074/jbc.M114.608091
10.1038/s41591-021-01456-w
10.1242/jcs.238030
10.1016/j.nbd.2014.07.011
10.1038/nrneurol.2014.38
10.1002/glia.440070111
10.2741/e605
10.7326/0003-4819-148-5-200803040-00009
10.1126/science.aag2590
10.1038/nn.4338
10.1038/nm1653
10.1016/0896-6273(93)90070-8
10.1523/JNEUROSCI.2637-10.2010
10.1016/S1474-4422(10)70043-0
10.1016/j.nbd.2014.05.018
10.1186/s12974-019-1645-7
10.1007/s11065-009-9118-x
10.1146/annurev.med.47.1.387
10.1016/j.expneurol.2020.113506
10.1038/nn.3697
10.1016/j.celrep.2019.03.099
10.1016/j.neurobiolaging.2009.10.009
10.5582/irdr.2017.01073
10.1212/wnl.43.8.1467
10.2353/ajpath.2006.060002
10.1016/j.neurobiolaging.2008.01.014
10.1186/s12964-015-0119-5
10.1038/s41582-019-0205-1
10.1038/ni.2639
10.1016/j.jalz.2015.06.1893
10.1002/glia.20468
10.1186/s40478-020-01099-x
10.1007/978-3-642-50703-8_1
10.3389/fnagi.2017.00194
10.1016/j.celrep.2020.107843
10.1038/ni.1836
10.1007/s00401-009-0556-6
10.1074/jbc.RA118.002352
10.1523/JNEUROSCI.5177-11.2012
10.1016/j.neurobiolaging.2006.08.013
10.1038/s41577-019-0165-0
10.1186/s13024-020-00402-7
10.1074/jbc.M110.142356
10.1038/srep07279
10.1038/srep28580
10.1007/s12035-014-9070-5
10.1371/journal.pone.0097096
10.1016/j.nbd.2021.105303
10.1016/j.it.2006.12.004
10.3233/JAD-210268
10.1186/1742-2094-8-138
10.1186/s13195-018-0394-7
10.1038/nature25158
10.1016/j.conb.2020.02.003
10.1073/pnas.2102191118
10.1084/jem.20151948
10.1146/annurev-neuro-070918-050306
10.1002/glia.23968
10.1016/j.pharmthera.2011.12.008
10.1136/jnnp-2015-310548
10.1016/j.neuron.2016.09.016
10.1016/j.neuron.2016.05.003
10.1186/1742-2094-9-247",<Element 'PubmedArticle' at 0x7f05def967c0>
40,35636493,Traumatic brain injury alterations in the functional connectome are associated with neuroinflammation but not tau in a P30IL tauopathy mouse model.,"Traumatic Brain Injury (TBI) is often associated with long-term cognitive deficits and altered brain networks which have been linked with accumulation of neurofibrillary tau tangles and neuroinflammation. In this work, we investigated the changes in the brain post-TBI in an Alzheimer's disease pR5 tauopathy model and evaluated the contribution of tauopathy and neuroinflammation to connectivity alterations using resting-state functional Magnetic Resonance Imaging (rs-fMRI).
26 P301L tau transgenic mice of 8-9 months of age (21-35 g) expressing the human tau isoform carrying the pathogenic P301L mutation were used for the study. Animals were assessed at day 1 and 7 post-injury/craniotomy and were randomly divided into four groups. All animals underwent an MRI scan on a 9.4T Bruker system where rsfMRI was acquired. Following imaging, brains were stained with pSer (396 + 404), glial fibrillary acidic protein (GFAP), and ionised calcium-binding adaptor molecule-1 (Iba-1). Group-information-guided Independent Component Analysis (GIG-ICA) and region-of-interest (ROI)-based network connectivity approaches were applied. Principal Component Regression was applied to predict connectivity network strength from the corresponding ROIs.
TBI mice showed decreased functional connectivity in the dentate gyrus, thalamus, and other areas compared to sham animals at day 1 post-injury with the majority of changes resolving at day 7. Principal Component Regression showed only the contralateral CA1 network strength was correlated with the CA1's astrocyte and microglia cell density and the ipsilateral thalamus network strength was correlated with the ipsilateral thalamus' astrocyte and microglia cell density.
We present the first report on the temporal alterations in functional connectivity in a P30IL mouse model following TBI. Connectivity between key regions known to be affected in Alzheimer's disease were short-term and reversible following injury. Connectivity strength in CA1 and thalamus showed significant correlation with astrocyte and microglial cell density but not tau density.","['Alzheimer’s disease', 'Neuroinflammation', 'Phosphorylated tau', 'Resting state functional connectivity', 'Tau']",Brain research,2022-06-01,"[{'lastname': 'Vinh To', 'firstname': 'Xuan', 'initials': 'X', 'affiliation': 'The Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia.'}, {'lastname': 'Soni', 'firstname': 'Neha', 'initials': 'N', 'affiliation': 'The Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia.'}, {'lastname': 'Medeiros', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'The Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia.'}, {'lastname': 'Alateeq', 'firstname': 'Khawlah', 'initials': 'K', 'affiliation': 'The Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia.'}, {'lastname': 'Nasrallah', 'firstname': 'Fatima A', 'initials': 'FA', 'affiliation': 'The Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia; The University of California, Irvine, United States. Electronic address: f.nasrallah@uq.edu.au.'}]","26 P301L tau transgenic mice of 8-9 months of age (21-35 g) expressing the human tau isoform carrying the pathogenic P301L mutation were used for the study. Animals were assessed at day 1 and 7 post-injury/craniotomy and were randomly divided into four groups. All animals underwent an MRI scan on a 9.4T Bruker system where rsfMRI was acquired. Following imaging, brains were stained with pSer (396 + 404), glial fibrillary acidic protein (GFAP), and ionised calcium-binding adaptor molecule-1 (Iba-1). Group-information-guided Independent Component Analysis (GIG-ICA) and region-of-interest (ROI)-based network connectivity approaches were applied. Principal Component Regression was applied to predict connectivity network strength from the corresponding ROIs.",We present the first report on the temporal alterations in functional connectivity in a P30IL mouse model following TBI. Connectivity between key regions known to be affected in Alzheimer's disease were short-term and reversible following injury. Connectivity strength in CA1 and thalamus showed significant correlation with astrocyte and microglial cell density but not tau density.,"TBI mice showed decreased functional connectivity in the dentate gyrus, thalamus, and other areas compared to sham animals at day 1 post-injury with the majority of changes resolving at day 7. Principal Component Regression showed only the contralateral CA1 network strength was correlated with the CA1's astrocyte and microglia cell density and the ipsilateral thalamus network strength was correlated with the ipsilateral thalamus' astrocyte and microglia cell density.",Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2022.147955,<Element 'PubmedArticle' at 0x7f05def20040>
41,"35558075
21371747
19330877
21706152
28930663
28800454
31759806
29386065
22700814
17409229
18786637
33196457
28099414
20610346
29669582
29196460
23644076
26163371
22632727
17965659
15831717
21778362
9724801
29181126
20336135
2976393
2465626
25792098
21527731
12684452
18701698
22710659
25653382
9626999
28948967
28963396
30706162
16148231
17724122
30923023
31257151
28602351
29784049
33424025
31932797
32610143
30796139
32535152
33257666
21324189
16085473
12191486
22430786
18604209
23254930
22898493
31872431
30721409
29107864
33257576
31594217
28255908
18849965
30617086
33708103
8346443
8398148
26933942
20547867
28546318
29953873
28959956
33032659
32675407
33831349
33473210
25485684
11700559
29247995
2529544
17977705
31463498
29803222
31822279
15051507
23136552
32142677
32652855
34015428
31991850
32514180
32579116
22047170
31128596
28799796
33927630
25728668
32579671
24990881
28947091
33097708
25732305
29518356
8350391
28003243
26912648
25882245
25035950
30705627
26538310
32528242
2531194
24260222
24216477
34275478
30291029
27091974
20081870
30043220
24316888
21684012
21879289
18356065
20429874
34243602
218198
21220023
29246456
20424635
29627764
30686764
28483986
20037584
23197723
24702189
33036632
28760504
32046119
33396372
28284330
28205565
30898012
29740932
33144123
32111854
31257024
32009952
31089059
34025399
29132916
15039230
14687544
11349148
20876579
27579517
32425881
32377293
32508567
28268115
32630597
30914921
29666569
33153476
32323368
33600815
32280102
31618623",Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets.,"Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide, characterized by progressive neuron degeneration or loss due to excessive accumulation of β-amyloid (Aβ) peptides, formation of neurofibrillary tangles (NFTs), and hyperphosphorylated tau. The treatment of AD has been only partially successful as the majority of the pharmacotherapies on the market may alleviate some of the symptoms. In the occurrence of AD, increasing attention has been paid to neurodegeneration, while the resident glial cells, like microglia are also observed. Microglia, a kind of crucial glial cells associated with the innate immune response, functions as double-edge sword role in CNS. They exert a beneficial or detrimental influence on the adjacent neurons through secretion of both pro-inflammatory cytokines as well as neurotrophic factors. In addition, their endocytosis of debris and toxic protein like Aβ and tau ensures homeostasis of the neuronal microenvironment. In this review, we will systematically summarize recent research regarding the roles of microglia in AD pathology and latest microglia-associated therapeutic targets mainly including pro-inflammatory genes, anti-inflammatory genes and phagocytosis at length, some of which are contradictory and controversial and warrant to further be investigated.","['alzheimer’s disease', 'anti-neuroinflammation', 'microglial cells', 'molecular therapy', 'neuroinflammation']",Frontiers in immunology,2022-05-14,"[{'lastname': 'Cai', 'firstname': 'Yongle', 'initials': 'Y', 'affiliation': 'Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}, {'lastname': 'Liu', 'firstname': 'Jingliu', 'initials': 'J', 'affiliation': 'Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}, {'lastname': 'Wang', 'firstname': 'Bin', 'initials': 'B', 'affiliation': 'Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}, {'lastname': 'Sun', 'firstname': 'Miao', 'initials': 'M', 'affiliation': 'Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}, {'lastname': 'Yang', 'firstname': 'Hao', 'initials': 'H', 'affiliation': 'Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}]",,,,"Copyright © 2022 Cai, Liu, Wang, Sun and Yang.","10.3389/fimmu.2022.856376
10.1016/S0140-6736(10)61349-9
10.1002/anie.200802808
10.1007/s00415-011-6145-3
10.1016/j.immuni.2017.08.008
10.1016/j.ejmech.2017.07.070
10.1016/j.neuron.2019.10.010
10.1186/s13195-018-0341-7
10.1212/WNL.0b013e31825fdf18
10.1523/JNEUROSCI.0587-07.2007
10.1016/j.nbd.2008.08.001
10.18632/aging.103663
10.1038/nature21029
10.1016/S1474-4422(10)70119-8
10.1186/s12974-018-1141-5
10.1083/jcb.201709069
10.1016/j.pharmthera.2013.04.013
10.1016/j.immuni.2015.06.012
10.1016/j.neuron.2012.03.026
10.1038/nn1997
10.1126/science.1110647
10.1126/science.1202529
10.1073/pnas.95.18.10896
10.1155/2017/5414297
10.1038/nature08983
10.1002/glia.440010502
10.1016/0166-2236(88)90110-5
10.1016/S1474-4422(15)70016-5
10.1152/physrev.00011.2010
10.1523/JNEUROSCI.23-07-02665.2003
10.1523/JNEUROSCI.0616-08.2008
10.1007/s00005-012-0181-2
10.1523/JNEUROSCI.3751-14.2015
10.1016/s0165-5728(97)00251-8
10.1038/mp.2017.180
10.15252/embj.201696056
10.1007/s00429-019-01834-8
10.1523/JNEUROSCI.1808-05.2005
10.1083/jcb.200705042
10.1016/j.pneurobio.2019.03.003
10.1016/j.cmet.2019.06.005
10.1016/j.cell.2017.05.018
10.1186/s13024-018-0254-8
10.1038/s41596-020-00447-4
10.1038/s41591-019-0695-9
10.1016/j.celrep.2020.107843
10.1212/WNL.0000000000007133
10.1016/j.nbd.2020.104962
10.1038/s41467-020-19737-2
10.1186/1750-1326-6-16
10.1016/j.cub.2005.07.049
10.1016/s1097-2765(02)00599-3
10.1038/ni.2237
10.1038/ni.1636
10.1038/nature11729
10.1186/1742-2094-9-199
10.1111/jnc.14945
10.1007/s00401-018-01957-y
10.1016/j.intimp.2017.10.024
10.1073/pnas.2009680117
10.3233/JAD-181259
10.1007/s12035-017-0467-9
10.1038/nature07383
10.15252/embj.201899430
10.3389/fnagi.2021.629891
10.1126/science.8346443
10.1016/0896-6273(93)90070-8
10.1002/ana.24628
10.1073/pnas.0914984107
10.1126/science.aal3222
10.1016/j.neuron.2018.05.008
10.1038/nature24016
10.1186/s13024-020-00407-2
10.3233/JAD-190588
10.1016/j.neuron.2021.03.024
10.1038/s41586-020-03160-0
10.1172/JCI77487
10.1038/35102591
10.1111/imr.12621
10.1073/pnas.86.19.7611
10.1016/j.coi.2007.09.002
10.1039/c9fo00058e
10.1186/s12974-018-1205-6
10.1186/s12974-019-1645-7
10.1016/j.yexcr.2004.01.002
10.7150/ijbs.4989
10.1016/j.cell.2020.02.013
10.1002/glia.23878
10.1016/j.bbi.2021.05.013
10.3390/ijms21030804
10.1038/s41419-020-2644-4
10.7554/eLife.57513
10.1186/1742-2094-8-150
10.1186/s12974-019-1492-6
10.1080/10408398.2017.1358139
10.3389/fphar.2021.654489
10.1016/j.cell.2015.01.049
10.1084/jem.20200785
10.1126/scitranslmed.3009093
10.1016/j.tibs.2017.09.002
10.1038/s41467-020-19227-5
10.1084/jem.20142322
10.1016/j.neuron.2018.01.031
10.1002/jnr.490350310
10.1093/brain/aww330
10.1093/brain/awv408
10.1038/nri3823
10.1016/j.immuni.2014.06.008
10.3389/fnagi.2018.00439
10.1186/s12974-015-0411-8
10.3389/fnins.2020.00441
10.1084/jem.170.6.2081
10.1371/journal.pone.0079445
10.1172/JCI65180
10.1186/s12974-021-02211-1
10.1016/j.immuni.2018.07.015
10.1073/pnas.1604032113
10.1038/nri2692
10.1007/s11684-018-0646-8
10.1038/nn.3599
10.1016/j.jad.2011.05.047
10.1007/s00441-011-1230-6
10.1016/j.nbd.2008.01.007
10.1186/1742-2094-7-28
10.1016/j.biopha.2021.111651
10.1073/pnas.76.1.333
10.1016/j.nbd.2011.01.005
10.1016/j.bbi.2017.12.007
10.1038/jcbfm.2010.59
10.1194/jlr.R082933
10.1016/j.stem.2018.12.013
10.4049/jimmunol.1700373
10.1038/ni.1836
10.1523/JNEUROSCI.1569-12.2012
10.1089/ars.2014.5845
10.1186/s12974-020-01973-4
10.1016/j.bbi.2017.07.158
10.3390/cells9020383
10.3390/ijms22010361
10.1016/j.jneuroim.2017.02.010
10.1038/srep42370
10.1080/15548627.2019.1596488
10.1111/acel.12774
10.1016/j.arr.2020.101207
10.1038/s41598-020-59930-3
10.1016/j.cell.2019.05.056
10.3389/fphar.2019.01529
10.4103/1673-5374.255975
10.3389/fphar.2021.612981
10.1016/j.tips.2017.10.008
10.1016/s0002-9440(10)63229-4
10.1016/s0896-6273(03)00787-6
10.1126/science.1059344
10.1074/jbc.M110.149468
10.1111/febs.13841
10.3389/fendo.2020.00191
10.1155/2020/2315106
10.3389/fnins.2020.00444
10.1016/j.bbi.2017.03.003
10.3390/ijms21124532
10.3389/fnmol.2019.00058
10.3389/fnmol.2018.00098
10.1186/s12974-020-01987-y
10.1111/jpi.12660
10.1016/j.expneurol.2021.113645
10.3233/JAD-200099
10.1016/j.bbr.2019.112296",<Element 'PubmedArticle' at 0x7f05def2a720>
42,35316021,"Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress.","Alzheimer's disease is identified by pathological hallmarks such as intracellular neurofibrillary tangles (NFTs) and extracellular amyloid β plaques. Several hypotheses exist to define the neurodegeneration including microglial activation associated with neuroinflammatory processes. Recently, pharmacological inhibition of endocannabinoid (eCB)-degrading enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), is being investigated to modulate the pathology of Alzheimer's disease. While MAGL inhibitors upregulate 2-acyl glycerol (2-AG) levels and reduce neuroinflammation, FAAH inhibitors elevate anandamide (AEA) levels and prevent the degradation of HSP-70, thereby preventing the phosphorylation of tau protein and formation of NFTs in neural cells. We investigated the possible neuroprotective potential of the dual MAGL/FAAH inhibitor JZL-195 (20 mg/kg) against ICV-STZ-induced sporadic Alzheimer's disease (SAD) in Swiss albino mice using donepezil (5 mg/kg) as the standard. The protective effects of JZL-195 were observed by the reversal of altered levels of Aβ","['Aβ1−42', 'HSP-70', 'JZL-195', 'Morris water maze', 'endocannabinoid', 'sporadic Alzheimer’s disease (SAD)']",ACS chemical neuroscience,2022-03-23,"[{'lastname': 'Bajaj', 'firstname': 'Shivanshu', 'initials': 'S', 'affiliation': 'Neurobehavioral Pharmacological Laboratory, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Zameer', 'firstname': 'Saima', 'initials': 'S', 'affiliation': 'Neurobehavioral Pharmacological Laboratory, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Jain', 'firstname': 'Shreshta', 'initials': 'S', 'affiliation': 'Neurobehavioral Pharmacological Laboratory, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Yadav', 'firstname': 'Vaishali', 'initials': 'V', 'affiliation': 'Neurobehavioral Pharmacological Laboratory, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Vohora', 'firstname': 'Divya', 'initials': 'D', 'affiliation': 'Neurobehavioral Pharmacological Laboratory, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}]",,,,,10.1021/acschemneuro.1c00699,<Element 'PubmedArticle' at 0x7f05dee96cc0>
43,"35265207
33756057
32028456
29232315
31637009
27567878
32475349
20698820
20101723
11904757
31835422
30614456
29440986
30501591
29333532
30194347
34493703
34219711
28070154
30044464
31363464
33953158
29131369
26989758
23575824
33859360
27815990
23380713
33391534
30652418
30032397
33654837
32628986
28157094
31515743
27520275
23868073
15723970
31470002
34262178
33318676
27459405
25598354
28409745
33796100
29327206
33859360
26347062
22028832
21116053
28735143
20662021
27929004
33935090
32612506
29706957
30498474
23708142
27030596
20205644
24395130
21158978
31822279
30820451
30072722
31264132
29437957
31551688
27497943
32471464
32017944
28973308
33488521
21157025
19116637
26824991
29498007
32448557
27199640
24889886
22697066
31507384
12417755",Non-invasive photobiomodulation treatment in an Alzheimer Disease-like transgenic rat model.,"Alzheimer's disease (AD) is the most common form of dementia in the elderly, causing neuronal degeneration and cognitive deficits that significantly impair independence and quality of life for those affected and their families. Though AD is a major neurodegenerative disease with vast avenues of investigation, there is no effective treatment to cure AD or slow disease progression. The present work evaluated the therapeutic effect of long-term photobiomodulation (PBM) treatment with continuous-wave low-level laser on AD and its underlying mechanism. ","['Microglia recruitment', 'Mitochondria', 'Neuronal hemoglobin', 'Photobiomodulation', 'TgF344 rats']",Theranostics,2022-03-11,"[{'lastname': 'Yang', 'firstname': 'Luodan', 'initials': 'L', 'affiliation': 'Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, LA, 1501 Kings Highway, LA 71103 USA.\nMedical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Wu', 'firstname': 'Chongyun', 'initials': 'C', 'affiliation': 'Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Parker', 'firstname': 'Emily', 'initials': 'E', 'affiliation': 'Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Li', 'firstname': 'Yong', 'initials': 'Y', 'affiliation': 'Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Dong', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Tucker', 'firstname': 'Lorelei', 'initials': 'L', 'affiliation': 'Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Brann', 'firstname': 'Darrell W', 'initials': 'DW', 'affiliation': 'Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912 USA.'}, {'lastname': 'Lin', 'firstname': 'Hung Wen', 'initials': 'HW', 'affiliation': 'Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, LA, 1501 Kings Highway, LA 71103 USA.'}, {'lastname': 'Zhang', 'firstname': 'Quanguang', 'initials': 'Q', 'affiliation': 'Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, LA, 1501 Kings Highway, LA 71103 USA.'}]",,,,© The author(s).,10.7150/thno.70756,<Element 'PubmedArticle' at 0x7f05deea1810>
44,"35232622
8446617
7920638
33176118
8346443
8415756
33074098
12130773
28666525
28602351
28930663
3932467
3283935
16207708
16207707
20005821
19339974
19765634
2050696
8044413
2280190
23217737
8040342
8367470
34586832
31686034
14987560
19679070
10694577
21715678
21349439
27683850
22018896
20186853
7969426
1625800
7534068
22993429
7721816
10816430
23620513
23100439
25207746
29216449
28794245
22633529
9354781
11045665
10079115
10852539
11950276
15772340
19474305
19357304
23771217
11425936
8596645
9173910
7586507
18549781
11078212
27477018
29483128
16364896
14523085
21755005
16236385
16373604
18202749
16207713
24849360
29600961
23129750
33597265
28246336
26481403
33129364
10563634
31860000
20541611
29723639
28241163
1759558
26962052
29801024
28959956
31601677
34157306
33550655
33831349
33139712
30283141
27793990
2056122
27683909
25319693
27931262
11547323
30646251
18155324
14507923
22730380
30958695
32819810
12612547
15195085
19033669
26923027
28275161
25082552
19606063
22553043
32341542
31042697
33589835
28099414
34616039
31623648
33432193
33658354
33406436
29861287
31902528
18256671
30617257
34446931
27540165
24948358
31113487
23656989
31434879
34100905
27196974
34643971
31504240
24742461
26921617
33054973
30140051
33301878
33665345
15181253
14741101
17973979
33246484
28701379
31469155
26871627
29643512
28746864
28846081
28414331
26780511",APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease.,"Neuroinflammation is a central mechanism involved in neurodegeneration as observed in Alzheimer's disease (AD), the most prevalent form of neurodegenerative disease. Apolipoprotein E4 (APOE4), the strongest genetic risk factor for AD, directly influences disease onset and progression by interacting with the major pathological hallmarks of AD including amyloid-β plaques, neurofibrillary tau tangles, as well as neuroinflammation. Microglia and astrocytes, the two major immune cells in the brain, exist in an immune-vigilant state providing immunological defense as well as housekeeping functions that promote neuronal well-being. It is becoming increasingly evident that under disease conditions, these immune cells become progressively dysfunctional in regulating metabolic and immunoregulatory pathways, thereby promoting chronic inflammation-induced neurodegeneration. Here, we review and discuss how APOE and specifically APOE4 directly influences amyloid-β and tau pathology, and disrupts microglial as well as astroglial immunomodulating functions leading to chronic inflammation that contributes to neurodegeneration in AD.","['Alzheimer’s disease', 'Apolipoprotein E', 'Astrocytes', 'Inflammation', 'Microglia', 'Neurodegeneration']",Seminars in immunology,2022-03-03,"[{'lastname': 'Parhizkar', 'firstname': 'Samira', 'initials': 'S', 'affiliation': 'Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO, 63110, USA.'}, {'lastname': 'Holtzman', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO, 63110, USA. Electronic address: holtzman@wustl.edu.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.,"10.1016/j.smim.2022.101594
10.1073/PNAS.90.5.1977
10.1038/NG0694-180
10.1016/J.NEURON.2020.10.008
10.1126/SCIENCE.8346443
10.1073/PNAS.90.20.9649
10.7554/eLife.62199
10.1126/science.1072994
10.1016/J.BIOPSYCH.2017.05.014
10.1016/j.cell.2017.05.018
10.1016/J.IMMUNI.2017.08.008
10.1172/JCI112130
10.1074/jbc.M508780200
10.1074/jbc.M508781200
10.1016/J.NEURON.2009.11.013
10.1038/NRN2620
10.1016/J.NEULET.2009.09.017
10.1097/00041433-199404000-00007
10.1016/J.NEURON.2012.11.020
10.1172/JCI117407
10.1073/pnas.90.17.8098
10.1126/SCITRANSLMED.ABC9375/SUPPL_FILE/SCITRANSLMED.ABC9375_DATA_FILE_S1.ZIP
10.1038/S41591-019-0611-3
10.1016/S1050-1738(98)00017-6
10.1016/J.NEURON.2009.06.026
10.1073/pnas.050004797
10.1126/scitranslmed.3002156
10.1016/S1474-4422(10)70325-2
10.1212/WNL.0000000000003234
10.1016/J.NEUROBIOLAGING.2011.09.024
10.1002/ana.21843
10.1038/372092a0
10.1016/0304-3940(92)90444-C
10.1042/bj3060599
10.1523/JNEUROSCI.1937-12.2012
10.1074/jbc.270.16.9039
10.1073/pnas.1220484110
10.1523/JNEUROSCI.1542-12.2012
10.1021/bi5008172
10.1016/J.NEURON.2017.11.013
10.1212/WNL.0000000000004336
10.1016/J.NEUROBIOLAGING.2012.04.017
10.1038/NG1197-263
10.1007/S004010000263
10.1172/JCI6179
10.1006/nbdi.2002.0483
10.1523/JNEUROSCI.5170-04.2005
10.1523/JNEUROSCI.0887-09.2009
10.1073/PNAS.0811879106
10.1097/NEN.0B013E31829A25B9
10.1212/WNL.56.12.1696
10.1016/0306-4522(95)00331-C
10.1006/NBDI.1996.0003
10.1016/0165-3806(95)00066-M
10.1016/J.NEURON.2008.04.010
10.1007/S004010000242
10.1016/J.NEURON.2016.06.015
10.1084/JEM.20171265
10.1016/J.NEURON.2005.10.028
10.1523/JNEUROSCI.23-26-08844.2003
10.1371/journal.pone.0021880
10.1016/J.NEUROBIOLAGING.2005.09.011
10.1161/01.ATV.0000201282.64751.47
10.1172/JCI33622
10.1074/JBC.M504513200
10.1523/JNEUROSCI.0646-14.2014
10.1172/JCI96429
10.1084/JEM.20121274
10.1126/scitranslmed.abd7522
10.1194/JLR.R075481
10.1016/j.neurobiolaging.2015.09.011
10.1186/S13195-020-007106/FIGURES/5
10.1212/WNL.53.8.1825
10.1001/JAMANEUROL.2019.4421
10.1016/J.NEUROIMAGE.2010.06.009
10.1016/J.NEUROIMAGE.2018.04.068
10.1093/BRAIN/AWW027
10.1001/jamaneurol.2018.0821
10.1038/nature24016
10.1084/jem.20190980
10.1016/J.NEURON.2021.05.034
10.1002/ANA.26043
10.1016/J.NEURON.2021.03.024
10.1038/s41467-020-19264-0
10.1038/s41586-018-0590-4
10.1074/jbc.M116.721779
10.1172/JCI115288
10.1523/JNEUROSCI.1054-16.2016
10.1523/JNEUROSCI.0684-14.2014
10.1186/s13024-016-0138-8
10.1067/MTC.2001.115152
10.1001/jamanetworkopen.2018.3597
10.1016/j.neurobiolaging.2007.11.014
10.1074/jbc.M306923200
10.1074/jbc.M112.377549
10.1096/fj.201900071R
10.1016/J.IT.2020.07.004
10.1038/NM838
10.1038/NM1058
10.1172/JCI36663
10.3233/JAD-151101
10.1523/JNEUROSCI.3442-16.2017
10.1179/1743132814Y.0000000434
10.1097/NEN.0B013E3181AFE475
10.1523/JNEUROSCI.6221-11.2012
10.1038/s41593-020-0624-8
10.1038/S41586-019-1195-2
10.1038/s41593-020-00783-4
10.1038/NATURE21029
10.1038/s41586-021-03960-y
10.1186/S13024-019-0337-1
10.1038/S41593-020-00764-7
10.1126/scitranslmed.aaz4564
10.1016/j.celrep.2020.108572
10.1101/713362
10.1016/J.NEURON.2018.05.008
10.1016/j.neuron.2019.12.007
10.1038/NATURE06616
10.1038/s41593-018-0296-9
10.1038/s41591-021-01456-w
10.1126/SCIENCE.AAG2590
10.1186/1742-2094-11-111
10.1186/S40478-019-0729-Z/FIGURES/5
10.1097/NEN.0B013E3182933788
10.1038/s41467-019-11674-z
10.1084/JEM.20210542
10.1016/j.neuron.2016.05.003
10.1002/GLIA.24105
10.1093/BRAIN/AWZ241
10.1016/j.neuron.2014.02.040
10.1093/brain/aww016
10.7554/ELIFE.51796
10.1038/s41577-018-0051-1
10.1016/J.NBD.2020.105217
10.1002/DAD2.12155
10.1385/JMN:23:3:247
10.1016/S0896-6273(03)00850-X
10.1111/J.1471-4159.2007.05099.X
10.1186/s13024-020-00416-1
10.1073/pnas.1701137114
10.1590/1678-4685-GMB-2018-0320
10.1016/J.CELL.2015.12.056
10.1038/s41586-018-0023-4
10.1016/j.celrep.2017.07.004
10.1038/nn.4631
10.1038/nn.4547
10.1038/nn.4222",<Element 'PubmedArticle' at 0x7f05dee4d2c0>
45,"35109872
22229116
21777559
23656989
23602650
26687817
29922147
34297416
31042697
31768052
31932797
33257666
33432193
32989152
33609158
33558695
34050164
21514250
22265587
22101365
25242720
26399630
27925668
29993362
22743772
29187165
31534232
15700280
24464287
0
27620283
29230021
7636630
31276244
33589835
26884166
28602351
18442088
18586353
29755340
29374250
30779205
23824488
30336198
30406865
31494186
31982467
34592173
33337377
34267628
25745860
32198485",Cyclic multiplex fluorescent immunohistochemistry and machine learning reveal distinct states of astrocytes and microglia in normal aging and Alzheimer's disease.,"Astrocytes and microglia react to Aβ plaques, neurofibrillary tangles, and neurodegeneration in the Alzheimer's disease (AD) brain. Single-nuclei and single-cell RNA-seq have revealed multiple states or subpopulations of these glial cells but lack spatial information. We have developed a methodology of cyclic multiplex fluorescent immunohistochemistry on human postmortem brains and image analysis that enables a comprehensive morphological quantitative characterization of astrocytes and microglia in the context of their spatial relationships with plaques and tangles.
Single FFPE sections from the temporal association cortex of control and AD subjects were subjected to 8 cycles of multiplex fluorescent immunohistochemistry, including 7 astroglial, 6 microglial, 1 neuronal, Aβ, and phospho-tau markers. Our analysis pipeline consisted of: (1) image alignment across cycles; (2) background subtraction; (3) manual annotation of 5172 ALDH1L1+ astrocytic and 6226 IBA1+ microglial profiles; (4) local thresholding and segmentation of profiles; (5) machine learning on marker intensity data; and (6) deep learning on image features.
Spectral clustering identified three phenotypes of astrocytes and microglia, which we termed ""homeostatic,"" ""intermediate,"" and ""reactive."" Reactive and, to a lesser extent, intermediate astrocytes and microglia were closely associated with AD pathology (≤ 50 µm). Compared to homeostatic, reactive astrocytes contained substantially higher GFAP and YKL-40, modestly elevated vimentin and TSPO as well as EAAT1, and reduced GS. Intermediate astrocytes had markedly increased EAAT2, moderately increased GS, and intermediate GFAP and YKL-40 levels. Relative to homeostatic, reactive microglia showed increased expression of all markers (CD68, ferritin, MHC2, TMEM119, TSPO), whereas intermediate microglia exhibited increased ferritin and TMEM119 as well as intermediate CD68 levels. Machine learning models applied on either high-plex signal intensity data (gradient boosting machines) or directly on image features (convolutional neural networks) accurately discriminated control vs. AD diagnoses at the single-cell level.
Cyclic multiplex fluorescent immunohistochemistry combined with machine learning models holds promise to advance our understanding of the complexity and heterogeneity of glial responses as well as inform transcriptomics studies. Three distinct phenotypes emerged with our combination of markers, thus expanding the classic binary ""homeostatic vs. reactive"" classification to a third state, which could represent ""transitional"" or ""resilient"" glia.","['Alzheimer’s disease', 'Amyloid plaques', 'Astrocytes', 'Immunohistochemistry', 'Microglia', 'Neurofibrillary tangles', 'Neuropathology', 'Tau']",Journal of neuroinflammation,2022-02-04,"[{'lastname': 'Muñoz-Castro', 'firstname': 'Clara', 'initials': 'C', 'affiliation': ""Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, 41012, Sevilla, Spain.\nInstituto de Biomedicina de Sevilla (IBiS)-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013, Sevilla, Spain.\nDepartment of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.\nHarvard Medical School, Boston, MA, 02115, USA.""}, {'lastname': 'Noori', 'firstname': 'Ayush', 'initials': 'A', 'affiliation': ""Harvard College, Boston, MA, 02138, USA.\nDepartment of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.""}, {'lastname': 'Magdamo', 'firstname': 'Colin G', 'initials': 'CG', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.""}, {'lastname': 'Li', 'firstname': 'Zhaozhi', 'initials': 'Z', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.""}, {'lastname': 'Marks', 'firstname': 'Jordan D', 'initials': 'JD', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.'}, {'lastname': 'Frosch', 'firstname': 'Matthew P', 'initials': 'MP', 'affiliation': ""Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.\nHarvard Medical School, Boston, MA, 02115, USA.""}, {'lastname': 'Das', 'firstname': 'Sudeshna', 'initials': 'S', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.\nHarvard Medical School, Boston, MA, 02115, USA.""}, {'lastname': 'Hyman', 'firstname': 'Bradley T', 'initials': 'BT', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA.\nHarvard Medical School, Boston, MA, 02115, USA.""}, {'lastname': 'Serrano-Pozo', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA. aserrano1@mgh.harvard.edu.\nMassGeneral Institute for Neurodegenerative Disease, 114 16th Street, Charlestown, MA, 02129, USA. aserrano1@mgh.harvard.edu.\nMassachusetts Alzheimer's Disease Research Center, Charlestown, MA, 02129, USA. aserrano1@mgh.harvard.edu.\nHarvard Medical School, Boston, MA, 02115, USA. aserrano1@mgh.harvard.edu.""}]",,,"Spectral clustering identified three phenotypes of astrocytes and microglia, which we termed ""homeostatic,"" ""intermediate,"" and ""reactive."" Reactive and, to a lesser extent, intermediate astrocytes and microglia were closely associated with AD pathology (≤ 50 µm). Compared to homeostatic, reactive astrocytes contained substantially higher GFAP and YKL-40, modestly elevated vimentin and TSPO as well as EAAT1, and reduced GS. Intermediate astrocytes had markedly increased EAAT2, moderately increased GS, and intermediate GFAP and YKL-40 levels. Relative to homeostatic, reactive microglia showed increased expression of all markers (CD68, ferritin, MHC2, TMEM119, TSPO), whereas intermediate microglia exhibited increased ferritin and TMEM119 as well as intermediate CD68 levels. Machine learning models applied on either high-plex signal intensity data (gradient boosting machines) or directly on image features (convolutional neural networks) accurately discriminated control vs. AD diagnoses at the single-cell level.",© 2022. The Author(s).,"10.1186/s12974-022-02383-4
10.1111/nan.12753
10.1186/s12859-017-1934-z",<Element 'PubmedArticle' at 0x7f05dedb66d0>
46,"34820873
22101365
24162737
31159836
33177989
23188818
27760323
31578281
12621426
19696796
28387218
24067654
12086608
9714795
7593326
12036598
27989508
32357373
30297968
23589030
19240038
31748784
30040735
30682540
29186589
26001591
28281308
15473838
17035630
20603002
24186068
15292237
17986441
16227583
32323475
29937276
32612231
25061211
32743075
31430451",Alpha adaptins show isoform-specific association with neurofibrillary tangles in Alzheimer's disease.,"The heterotetrameric assembly protein complex 2 (AP-2) is a central hub for clathrin-dependent endocytosis. The AP-2 α-adaptin subunit has two major isoforms, encoded by two separate genes: AP2A1 and AP2A2. Endocytosis has been implicated in the pathogenesis of neurodegenerative disease, and recent studies linked α-adaptins (gene variants, splicing defects and altered expression) with late-onset Alzheimer's disease (LOAD) risk. Here, we used multiple antibodies to investigate α-adaptin isoforms and their localization in human brains.
The specificities of 10 different α-adaptin antibodies were evaluated using immunoblots after human AP2A1 and AP2A2 plasmid transfection in cultured cells. Additional immunoblot analyses were then performed on protein homogenates from control and LOAD subjects. Formalin-fixed, paraffin-embedded brain sections from control and LOAD subjects were immunohistochemically stained, and immunofluorescence experiments were performed for quantitation of colocalisation with digital image analysis.
Eight of the 10 evaluated antibodies recognised transfected α-adaptin proteins on immunoblots. The α-adaptin subspecies were relatively uniformly expressed in five different human brain regions. The α-adaptins were present in the detergent-insoluble fraction from cognitively impaired, but less so in control, brains. Immunohistochemical analyses showed colocalisation of AP2A1 with tau pathology in LOAD brains. By contrast, AP2A2 colocalised with microglial cells.
These observations provide evidence of isoform-specific changes of α-adaptins in the brains of LOAD subjects. Antibodies that were verified to recognise AP2A1, but not AP2A2, labelled neurofibrillary tangles of LOAD patients. The findings extend our understanding of AP-2 proteins in the human brain in healthy and diseased states.","['CCV', 'endolysosomal', 'human genetics', 'microglia', 'neuropathology', 'tau', 'tauopathy']",Neuropathology and applied neurobiology,2021-11-26,"[{'lastname': 'Srinivasan', 'firstname': 'Sukanya', 'initials': 'S', 'affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.'}, {'lastname': 'Gal', 'firstname': 'Jozsef', 'initials': 'J', 'affiliation': 'Spinal Cord and Brain Injury Research Center (SCoBIRC), University of Kentucky, Lexington, Kentucky, USA.\nDepartment of Neuroscience, University of Kentucky, Lexington, Kentucky, USA.'}, {'lastname': 'Bachstetter', 'firstname': 'Adam', 'initials': 'A', 'affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.\nSpinal Cord and Brain Injury Research Center (SCoBIRC), University of Kentucky, Lexington, Kentucky, USA.\nDepartment of Neuroscience, University of Kentucky, Lexington, Kentucky, USA.'}, {'lastname': 'Nelson', 'firstname': 'Peter T', 'initials': 'PT', 'affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.\nDepartment of Pathology, University of Kentucky, Lexington, Kentucky, USA.'}]",,,"Eight of the 10 evaluated antibodies recognised transfected α-adaptin proteins on immunoblots. The α-adaptin subspecies were relatively uniformly expressed in five different human brain regions. The α-adaptins were present in the detergent-insoluble fraction from cognitively impaired, but less so in control, brains. Immunohistochemical analyses showed colocalisation of AP2A1 with tau pathology in LOAD brains. By contrast, AP2A2 colocalised with microglial cells.",© 2021 British Neuropathological Society.,10.1111/nan.12776,<Element 'PubmedArticle' at 0x7f05dede3720>
47,"34819850
10567732
14620878
27979768
27760324
16183991
30417362
17005052
11160388
10430470
30396067
31915009
29973370
32209097
28549481
24742461
22046273
31215797
32919870
28504723
25511390
20966214
20303880
1424778
32803224
31301936
23623698
27567845
18604209
29896413
30995916
26048578
24412678
28466999
29472620
29882480
31748742
18974297
31010119
27067662
18987201
30515090
23150908
27425031
24951455
30498474
25716838
21527731
23334579
29248892
24990881
19596372
33239064
28830445
2089275
23481567
21088470
28662669
12629164
26758846
32150150
31110178
22198949
27028176
27887626
15708447
31031598
19808651
29876879
24838382
30791945
29416036
30477578
31191253
30907316
3895031
27144978
30031930
29784049
27459405
27296494
29861718
9636227
31077796
30711675
10600748
25598354
24212761
11121537
30686764
29422898
26286145
32909149
25728668
31001073
30626751
30778288
31659561
23733958
11943805
16512913
28434692
24911496
31024293
31774629
32296063
29621548
28963052
30541012
30820829
32112058",Microglia Polarization in Alzheimer's Disease: Mechanisms and a Potential Therapeutic Target.,Neuroinflammation regulated by microglia is one of the important factors involved in the pathogenesis of Alzheimer's disease (AD). Activated microglia exhibited phenotypes termed as M1 and M2 phenotypes separately. M1 microglia contribute to the development of inflammation ,"['Alzheimer’s disease', 'M1 microglia', 'M2 microglia', 'microglia activation', 'neuroinflammation']",Frontiers in aging neuroscience,2021-11-26,"[{'lastname': 'Wang', 'firstname': 'Qinqin', 'initials': 'Q', 'affiliation': 'Shandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, China.'}, {'lastname': 'Yao', 'firstname': 'Hongmei', 'initials': 'H', 'affiliation': 'Affiliated Hospital of Jining Medical University, Jining, China.'}, {'lastname': 'Liu', 'firstname': 'Wenyan', 'initials': 'W', 'affiliation': 'Department of Physiology, College of Basic Medicine, Jining Medical University, Jining, China.'}, {'lastname': 'Ya', 'firstname': 'Bailiu', 'initials': 'B', 'affiliation': 'Department of Physiology, College of Basic Medicine, Jining Medical University, Jining, China.'}, {'lastname': 'Cheng', 'firstname': 'Hongju', 'initials': 'H', 'affiliation': 'Department of Physiology, College of Basic Medicine, Jining Medical University, Jining, China.'}, {'lastname': 'Xing', 'firstname': 'Zhenkai', 'initials': 'Z', 'affiliation': 'Shandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, China.'}, {'lastname': 'Wu', 'firstname': 'Yili', 'initials': 'Y', 'affiliation': ""The Affiliated Kangning Hospital, Wenzhou Medical University, Wenzhou, China.\nKey Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, School of Mental Health, Wenzhou Medical University, Wenzhou, China.\nOujiang Laboratory, Wenzhou, China.""}]",,,,"Copyright © 2021 Wang, Yao, Liu, Ya, Cheng, Xing and Wu.","10.3389/fnagi.2021.772717
10.1002/hipo.10135
10.1016/j.exger.2016.12.006
10.1016/j.celrep.2016.09.075
10.1074/jbc.M509329200
10.1002/jcp.27659
10.1186/1742-2094-3-27
10.1523/JNEUROSCI.21-04-01179.2001
10.1016/s0306-4522(99)00100-1
10.1016/j.biopha.2018.10.053
10.1186/s12974-019-1694-y
10.1242/dev.152306
10.1186/s12974-020-01742-3
10.1186/s13024-017-0184-x
10.1016/j.neuron.2014.02.040
10.1371/journal.pone.0026317
10.1089/dna.2018.4308
10.1016/j.pscychresns.2020.111181
10.1038/nm.4340
10.1111/ggi.12425
10.1126/science.1194637
10.1016/j.cell.2010.02.016
10.1093/hmg/ddaa179
10.1016/j.neuron.2019.06.010
10.1016/j.neuron.2013.04.014
10.3233/JAD-160394
10.1038/ni.1636
10.14336/AD.2017.0328
10.1186/s12974-019-1478-4
10.1186/s12974-015-0332-6
10.1016/j.neulet.2014.01.004
10.1111/cns.12697
10.1038/s41593-018-0090-8
10.1177/1744806918781733
10.1038/s41586-019-1769-z
10.2353/ajpath.2008.080528
10.3390/ijms20081927
10.1016/j.neurobiolaging.2016.02.023
10.1523/JNEUROSCI.3024-08.2008
10.3389/fnagi.2018.00378
10.1056/NEJMoa1211103
10.1016/j.bbadis.2016.07.007
10.1016/j.biopsych.2014.05.006
10.3389/fneur.2018.00978
10.1523/JNEUROSCI.2620-14.2015
10.1152/physrev.00011.2010
10.1038/nn.3318
10.1136/jnnp-2017-317134
10.1126/scitranslmed.3009093
10.1016/j.neuro.2009.07.001
10.1186/s40035-020-00221-2
10.1186/s12974-017-0941-3
10.1016/0306-4522(90)90229-w
10.1016/j.neurobiolaging.2012.12.014
10.3858/emm.2011.43.1.001
10.1186/s13024-017-0192-x
10.1523/JNEUROSCI.23-05-01605.2003
10.1523/JNEUROSCI.2117-15.2016
10.1097/WNR.0000000000001429
10.1038/s41467-019-10152-w
10.4049/jimmunol.1101121
10.1186/s13024-016-0137-9
10.1016/j.neurobiolaging.2004.07.002
10.3389/fncel.2019.00143
10.2353/ajpath.2009.090059
10.1007/s12035-018-1135-4
10.1007/s12031-014-0315-6
10.1186/s12974-019-1399-2
10.1038/s41467-018-02926-5
10.1186/s40478-018-0636-8
10.3389/fncel.2019.00227
10.2174/1567205016666190321154618
10.1371/journal.pone.0154721
10.1016/j.neurobiolaging.2018.06.020
10.1186/s13024-018-0254-8
10.1038/nn.4338
10.1016/j.nrl.2016.03.013
10.1155/2018/8430123
10.1073/pnas.95.13.7778
10.1016/j.semcdb.2019.05.004
10.1016/j.neurobiolaging.2018.12.019
10.1126/science.286.5448.2352
10.1007/s12035-014-9070-5
10.1038/cdd.2013.159
10.1016/s0006-8993(00)02984-x
10.1016/j.stem.2018.12.013
10.3389/fimmu.2018.00050
10.1186/s13195-015-0139-9
10.1007/s12035-020-02107-w
10.1016/j.cell.2015.01.049
10.3389/fnins.2019.00291
10.1172/jci.insight.123431
10.3389/fncel.2019.00019
10.1007/s10571-019-00745-w
10.1073/pnas.1222895110
10.1523/JNEUROSCI.22-08-03025.2002
10.1186/1471-2377-6-12
10.1016/j.neurobiolaging.2017.03.021
10.1038/nbt.2929
10.3389/fnagi.2019.00078
10.1111/cns.13271
10.1038/s41392-020-0145-7
10.1016/j.bbrc.2018.03.226
10.1016/j.brainres.2017.09.019
10.1159/000492596
10.1007/s12264-019-00345-0
10.1038/s41593-020-0597-7",<Element 'PubmedArticle' at 0x7f05ded7edb0>
48,"34685737
32643143
2470173
24398425
21304480
10681074
28930663
9118312
32460886
32362813
25365775
17724290
8742039
10197733
30266932
23150908
20061651
32679025
33783469
31564456
32165850
24149893
32612165
29102593
26196079
28833933
26316079
31129766
30147644
23036020
23682015
19654931
15985565
33200854
27352075
26758846
26818951
22633273
30453390
31680874
31951107
30687017
31726033
20830611
25623948
20153405
29067757
28293167
32985471
29731895
12133838
17638387
17643073
18497889
25596736
18497881
28806762
31640096
11520976
30630874
29443039
27498145
25039425
30500334
17581964
17629417
32951598
24037032
31503421
30710571
24627329
31834353
11208906
23501261
29656013
32117672
26293123
20014009
29441009
28279350
28138112
30104698
19161426
25619654
30087595
30802950
28502705
27716675
32635578
25526861
31907987
33176649
26250788
31888724
29740932
28963052
18973185
15665404
26468932
31914220
30480234
32284616
32918696
12218646
26414614
12897209
33097708
27456198
26918424
26884167
32019561
29063348
32111146
30958382
31042564
32540373
23122960
28635355
29240990
32149777
31987051
23951173
24817672
31295540
24594369
26590375
25302802
29625119
33300254
32496649",Novel Balance Mechanism Participates in Stem Cell Therapy to Alleviate Neuropathology and Cognitive Impairment in Animal Models with Alzheimer's Disease.,"Stem cell therapy improves memory loss and cognitive deficits in animal models with Alzheimer's disease. The underlying mechanism remains to be determined, but it may involve the interaction of stem cells with hippocampal cells. The transplantation of stem cells alters the pathological state and establishes a novel balance based on multiple signaling pathways. The new balance mechanism is regulated by various autocrine and paracrine cytokines, including signal molecules that target (a) cell growth and death. Stem cell treatment stimulates neurogenesis and inhibits apoptosis, which is regulated by the crosstalk between apoptosis and autophagy-(b) Aβ and tau pathology. Aberrant Aβ plaques and neurofibrillary tau tangles are mitigated subsequent to stem cell intervention-(c) inflammation. Neuroinflammation in the lesion is relieved, which may be related to the microglial M1/M2 polarization-(d) immunoregulation. The transplanted stem cells modulate immune cells and shape the pathophysiological roles of immune-related genes such as TREM2, CR1, and CD33-(e) synaptogenesis. The functional reconstruction of synaptic connections can be promoted by stem cell therapy through multi-level signaling, such as autophagy, microglial activity, and remyelination. The regulation of new balance mechanism provides perspective and challenge for the treatment of Alzheimer's disease.","['Alzheimer’s disease', 'apoptosis', 'astrocyte', 'autophagy', 'immunoregulation', 'microglia', 'neurogenesis', 'neuroinflammation', 'stem cell therapy', 'synaptogenesis']",Cells,2021-10-24,"[{'lastname': 'Qin', 'firstname': 'Chuan', 'initials': 'C', 'affiliation': 'Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medical Center, Peking Union Medical College, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, 5 Panjiayuan Nanli St., Beijing 100021, China.'}, {'lastname': 'Li', 'firstname': 'Yongning', 'initials': 'Y', 'affiliation': 'Departments of International Medical Service and of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Shuaifuyuan 1, Dong Cheng District, Beijing 100730, China.'}, {'lastname': 'Wang', 'firstname': 'Kewei', 'initials': 'K', 'affiliation': 'Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medical Center, Peking Union Medical College, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, 5 Panjiayuan Nanli St., Beijing 100021, China.'}]",,,,,"10.3390/cells10102757
10.1111/nan.12642
10.1016/0166-2236(89)90055-6
10.1016/j.bcp.2013.12.024
10.1038/nrneurol.2011.2
10.1001/archneur.57.2.176
10.1016/j.immuni.2017.08.008
10.1186/s40035-020-00199-x
10.3389/fncel.2020.00072
10.1001/jamaneurol.2014.3049
10.1212/01.wnl.0000277657.95487.1c
10.1016/0304-3940(95)12256-7
10.1016/S0531-5565(98)00017-5
10.1038/s41582-018-0072-1
10.1056/NEJMoa1211103
10.3233/JAD-2010-1239
10.2174/1871527319666200717091513
10.1001/jama.2021.3854
10.1016/j.cell.2019.09.001
10.1177/1179573520907397
10.4161/auto.26508
10.1038/s41598-020-67460-1
10.1016/j.bbr.2017.10.032
10.1016/j.expneurol.2015.07.008
10.1002/hipo.22794
10.1159/000430356
10.1007/s11011-019-00421-4
10.3389/fnmol.2018.00261
10.2174/15672050113109990027
10.1002/cne.23463
10.3346/jkms.2009.24.4.547
10.1212/01.WNL.0000166914.38327.BB
10.1002/cbin.11500
10.1007/s11481-016-9694-5
10.1523/JNEUROSCI.2117-15.2016
10.1186/s12974-016-0477-y
10.1016/j.jneuroim.2012.04.018
10.1002/glia.23534
10.3389/fncel.2019.00466
10.15252/emmm.201910606
10.3389/fncel.2018.00531
10.1016/j.neuroscience.2019.10.048
10.1007/s12015-010-9190-x
10.1038/mp.2014.176
10.1016/j.neuroscience.2010.01.057
10.1002/stem.2727
10.3389/fnmol.2017.00049
10.4103/1673-5374.293138
10.3892/ol.2017.7543
10.1074/jbc.M205797200
10.1002/dneu.20506
10.4161/auto.4713
10.1172/JCI33585
10.18632/oncotarget.2733
10.1172/JCI35662
10.1371/journal.pgen.1006962
10.3233/JAD-190562
10.1126/science.1064638
10.1126/science.aaw0930
10.3791/56795
10.1016/j.bbr.2016.08.002
10.1111/jnc.12828
10.1016/j.physbeh.2018.11.034
10.1523/JNEUROSCI.5564-06.2007
10.1016/j.psyneuen.2007.04.014
10.1186/s40035-020-00214-1
10.3233/JAD-130632
10.1111/cns.13216
10.1016/j.neuropharm.2019.01.030
10.1007/s12264-013-1415-y
10.1093/brain/awz381
10.1046/j.1471-4159.2001.00046.x
10.1016/j.exger.2013.03.001
10.1016/j.neurobiolaging.2018.03.011
10.1007/s13205-020-2103-z
10.1186/s13024-015-0035-6
10.1002/stem.277
10.3389/fnagi.2018.00004
10.1016/j.neuron.2017.01.022
10.9758/cpn.2017.15.1.59
10.1038/s41598-018-30487-6
10.1111/j.1600-065X.2008.00706.x
10.1016/j.neuron.2014.12.068
10.3389/fncel.2018.00215
10.1111/jnc.14687
10.1016/j.bbadis.2017.05.014
10.3233/JAD-160912
10.3390/cells9071618
10.1007/s12035-014-9051-8
10.1096/fj.201902447R
10.2174/1567205017666201111120919
10.1111/neup.12235
10.1186/s12974-019-1658-2
10.1111/acel.12774
10.1016/j.brainres.2017.09.019
10.1002/path.2449
10.3233/JAD-2004-6608
10.1038/srep15015
10.1002/alz.12008
10.3233/ADR-170017
10.1038/s41591-020-0822-7
10.1007/s40520-020-01676-z
10.1097/00002093-200207000-00005
10.1038/nn.4126
10.1172/JCI200318104
10.1038/s41467-020-19227-5
10.1038/srep30459
10.1111/nan.12319
10.1073/pnas.1525466113
10.1186/s12974-020-1726-7
10.1007/s00702-017-1795-7
10.1089/scd.2019.0235
10.3233/JAD-190150
10.1016/j.phrs.2019.04.033
10.1016/j.gene.2020.144904
10.1016/j.celrep.2012.09.026
10.1080/01677063.2017.1338696
10.1111/jnc.14278
10.1097/ALN.0000000000003224
10.1186/s12929-020-0622-x
10.1371/journal.pone.0071479
10.1007/s12015-014-9512-5
10.1016/j.neulet.2019.134372
10.3727/096368914X679354
10.12659/MSM.894567
10.3727/096368914X684970
10.1016/j.brainres.2018.03.034
10.1002/cbin.11522
10.1002/sctm.19-0327",<Element 'PubmedArticle' at 0x7f05ded490e0>
49,"34593951
32129164
29391234
29477284
30717814
9803423
12859348
20026186
2908095
2870131
17182012
19204262
7991116
9267971
8727172
14557565
19752301
23023095
29630556
21696925
32281119
30222946
28086229
23242137
31810491
28367951
33150709
34286270
27344237
24844690
22286308
23884018
24144550
24374506
20471965
25486177
18729626
17251414
14643377
12895417
25309431
34286270
31354471
8742039
8489408
27233824
29265497
25076876
15866053
26104289
27693549
15533323
24463000
30322407
29246683
8102851
23473324
27103531
31346000
24746486
25446741
20558146
27696155",Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer's disease.,"Alzheimer's disease (AD) is characterized by amyloid (Aβ) protein aggregation and neurofibrillary tangles accumulation, accompanied by neuroinflammation. With all the therapeutic attempts targeting these biomarkers having been unsuccessful, the understanding of early mechanisms involved in the pathology is of paramount importance. Dopaminergic system involvement in AD has been suggested, particularly through the appearance of dopaminergic dysfunction-related neuropsychiatric symptoms and an overall worsening of cognitive and behavioral symptoms. In this study, we reported an early dopaminergic dysfunction in a mouse model presenting both amyloid and Tau pathology. 3xTg-AD mice showed an increase of postsynaptic D",[],Scientific reports,2021-10-02,"[{'lastname': 'Gloria', 'firstname': 'Yesica', 'initials': 'Y', 'affiliation': 'Department of Psychiatry, University Hospitals of Geneva, Avenue de la Roseraie, 64, 1206, Geneva, Switzerland.\nDepartment of Psychiatry, University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Ceyzériat', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': 'Department of Psychiatry, University Hospitals of Geneva, Avenue de la Roseraie, 64, 1206, Geneva, Switzerland.\nDepartment of Psychiatry, University of Geneva, Geneva, Switzerland.\nDivision of Nuclear Medicine, Diagnostic Department, University Hospitals of Geneva, Geneva, Switzerland.\nDivision of Radiation Oncology, Department of Oncology, University Hospitals of Geneva, Geneva, Switzerland.'}, {'lastname': 'Tsartsalis', 'firstname': 'Stergios', 'initials': 'S', 'affiliation': 'Department of Psychiatry, University Hospitals of Geneva, Avenue de la Roseraie, 64, 1206, Geneva, Switzerland.\nDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.'}, {'lastname': 'Millet', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Department of Psychiatry, University Hospitals of Geneva, Avenue de la Roseraie, 64, 1206, Geneva, Switzerland.\nDepartment of Psychiatry, University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Tournier', 'firstname': 'Benjamin B', 'initials': 'BB', 'affiliation': 'Department of Psychiatry, University Hospitals of Geneva, Avenue de la Roseraie, 64, 1206, Geneva, Switzerland. benjamin.tournier@hcuge.ch.\nDepartment of Psychiatry, University of Geneva, Geneva, Switzerland. benjamin.tournier@hcuge.ch.'}]",,,,© 2021. The Author(s).,"10.1038/s41598-021-99025-1
10.2174/1567205017666200304085513
10.1016/j.phrs.2018.01.016
10.1016/j.jalz.2018.01.002
10.1186/s13195-019-0468-1
10.1016/S0893-133X(98)00044-X
10.1046/j.1460-9568.2003.02716.x
10.1016/j.neubiorev.2009.12.008
10.1016/0893-133X(87)90004-2
10.1007/BF01249611
10.1016/j.brainres.2006.10.049
10.1212/01.wnl.0000341932.21961.f3
10.1212/WNL.44.12.2300
10.1001/archneur.1997.00550200033007
10.1097/00002093-199601020-00008
10.1212/WNL.61.7.944
10.1001/archneurol.2009.196
10.1097/WAD.0b013e31826f040d
10.3233/JAD-180094
10.1016/j.eurpsy.2011.04.006
10.1002/gps.5308
10.1016/j.jalz.2018.06.3054
10.18632/oncotarget.14601
10.1038/nature11748
10.1186/s12974-019-1652-8
10.1038/ncomms14727
10.1111/gbb.12712
10.1016/j.bbadis.2016.06.016
10.3233/JAD-131961
10.1038/nm.2613
10.4161/mabs.25424
10.1016/j.bbr.2013.10.017
10.1007/s00429-013-0693-5
10.1016/j.brainres.2010.05.013
10.1016/j.bbr.2014.11.046
10.1037/a0012520
10.1523/JNEUROSCI.4800-06.2007
10.1016/j.neurobiolaging.2003.08.012
10.1016/S0896-6273(03)00434-3
10.3389/fnagi.2014.00252
10.3389/fnagi.2019.00175
10.1016/0304-3940(95)12256-7
10.1001/archneur.1993.00540050059016
10.1016/j.bbr.2016.05.045
10.1002/syn.22023
10.3389/fnint.2014.00056
10.1016/j.mcn.2005.01.003
10.1038/jcbfm.2015.128
10.1016/j.neuropharm.2016.09.028
10.1016/j.brainres.2004.09.014
10.1016/j.neuroscience.2014.01.025
10.1186/s40478-018-0606-1
10.1016/j.neures.2017.12.002
10.1016/0166-4328(93)90121-6
10.1016/j.neuron.2012.12.038
10.1016/j.neurobiolaging.2016.02.021
10.1523/ENEURO.0035-19.2019
10.1016/j.bbr.2014.04.008
10.1016/j.bbr.2014.11.004
10.1016/j.brainres.2010.06.011
10.1007/s00429-016-1316-8",<Element 'PubmedArticle' at 0x7f05ded15e50>
50,"34566422
20107219
27777020
30980800
25069841
30725250
20463393
33271006
31639691
34053209
29663387
31053120
29154274
31622640
30426182
29625119
26414627
25739415
28170178
26196079
28643422
26918424
23036020
29067112
30471926
31023504
32460886
25302802
29102593
26316079
31129766
25698614
28056358
19654931
31009502
24005862
15690083
31858380
30377672
20030561
25110277
19397469
30143052
23809154
25356526
32977984
9626137
30542456
21512135
22570192
25030047
20673001
28420460
30875363
24855521
19819721
19717647
20014009
22809070
12050269
31726033
32496649
30500334
29392844
33471965
29872375
28972960
23356521
30185134
21485496
31295540
26590375
25800044
27459405
28785215
31365320
27003214
30294687
29127006
7715705
32890775
32479996
19084047
28112873
30087595
11137576
29731895
18499757
22633273
11071637
23756182
17517969
21422521
29740932
28970251
28127589
32019561
32111146
28969867
28445506
22398979
25526861
32612165
34348774
12928365
29950983
23197723
32643143
24398425
15755671
22698588
18053646
20153405
15044060
20455866
20455866
24911171
17470534
33535376",Functional Mechanism of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Animal Models with Alzheimer's Disease: Inhibition of Neuroinflammation.,"The transplantation of bone marrow-derived mesenchymal stem cells (BMMSCs) alleviates neuropathology and improves cognitive deficits in animal models with Alzheimer's disease. However, the underlying mechanisms remain to be determined. Available data demonstrate transplanted BMMSCs can inhibit neuroinflammation, which may be related to microglial M1/M2 polarization and is regulated by the secretion of autocrine and paracrine cytokines. BMMSCs also mitigate Aβ plaques and Tau tangles in the brain, which may be associated with the recruitment of peripheral blood monocytes and the subsequent comprehensive effects. The therapeutic effects of stem cells involve potential mechanisms such as immunomodulation, apoptosis, and proliferation. BMMSC-mediated functional reconstruction through dynamic remodeling develops a novel balance. Herein, present review recapitulates the molecular basis of BMMSC-assisted biological processes and summarizes the possible mechanisms related to the interaction between BMMSCs and microglia. The transplanted BMMSCs can suppress neuroinflammation that plays a key role in the pathogenesis of Alzheimer's disease.","['Alzheimer’s disease', 'apoptosis', 'bone marrow-derived mesenchymal stem cells', 'immunomodulation', 'microglia']",Journal of inflammation research,2021-09-28,"[{'lastname': 'Qin', 'firstname': 'Chuan', 'initials': 'C', 'affiliation': ""Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing, 100021, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Yongning', 'initials': 'Y', 'affiliation': ""Department of International Medical Service & Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.""}, {'lastname': 'Wang', 'firstname': 'Kewei', 'initials': 'K', 'affiliation': ""Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing, 100021, People's Republic of China.""}]",,,,© 2021 Qin et al.,"10.2147/JIR.S327538
10.1056/NEJMra0909142
10.1016/S1474-4422(16)30229-0
10.1016/j.ajpath.2019.03.006
10.15252/emmm.201303671
10.1007/s10571-019-00656-w
10.3233/JAD-2010-100666
10.5213/inj.2040432.216
10.1373/jalm.2018.027623
10.5213/inj.2142164.082
10.1111/jphp.12919
10.1186/s12883-019-1316-4
10.3233/JAD-170490
10.1016/j.bbr.2019.112303
10.1007/s00213-018-5108-0
10.1016/j.brainres.2018.03.034
10.3727/096368915X689604
10.1586/14737175.2015.1021787
10.5966/sctm.2016-0081
10.1016/j.expneurol.2015.07.008
10.1002/jnr.24066
10.1111/nan.12319
10.2174/15672050113109990027
10.3892/etm.2017.5059
10.1016/j.immuni.2018.11.004
10.1016/j.ejcb.2019.04.002
10.1186/s40035-020-00199-x
10.3727/096368914X684970
10.1016/j.bbr.2017.10.032
10.1159/000430356
10.1007/s11011-019-00421-4
10.1016/j.brainres.2015.02.011
10.1016/j.neurobiolaging.2016.11.009
10.3346/jkms.2009.24.4.547
10.1371/journal.pone.0215678
10.3390/ijms140917986
10.1172/JCI22326
10.1007/s11010-019-03671-z
10.1016/j.bbrep.2018.10.001
10.1089/scd.2009.0453
10.3892/ijmm.2014.1890
10.1089/ten.TEA.2008.0681
10.1186/s13287-018-0972-4
10.1016/j.jss.2013.04.054
10.1089/scd.2014.0337
10.1016/j.arcmed.2020.08.006
10.1210/jcem.83.6.4848
10.3892/etm.2018.6857
10.1158/0008-5472.CAN-10-4002
10.1002/stem.1125
10.1038/leu.2014.212
10.1089/ten.TEA.2010.0124
10.3760/cma.j.issn.2095-4352.2017.04.002
10.12659/MSM.912697
10.15283/ijsc.2009.2.1.59
10.1016/j.cyto.2009.08.013
10.1182/blood-2009-03-211342
10.1002/stem.277
10.1111/j.1474-9726.2012.00863.x
10.1210/jcem.87.6.8577
10.1016/j.neuroscience.2019.10.048
10.1002/sctm.19-0327
10.1016/j.physbeh.2018.11.034
10.1111/jcmm.13492
10.1002/biot.202000389
10.3389/fnins.2018.00333
10.1038/pr.2017.249
10.1186/scrt160
10.2217/imt-2018-0010
10.1016/j.neulet.2019.134372
10.12659/msm.894567
10.1111/bph.13139
10.1038/nn.4338
10.3389/fnagi.2017.00227
10.1152/jn.00395.2019
10.3233/JAD-151090
10.1016/j.heliyon.2018.e00837
10.1016/j.bbrc.2017.11.035
10.1038/374647a0
10.1016/j.nbd.2020.105072
10.1016/j.nbd.2020.104956
10.1016/j.neulet.2008.11.059
10.1002/term.2425
10.3389/fncel.2018.00215
10.1016/s0165-5728(00)00404-5
10.3892/ol.2017.7543
10.1210/en.2007-1795
10.1016/j.jneuroim.2012.04.018
10.1182/blood.V96.10.3422
10.1016/j.pbb.2013.05.015
10.1084/jem.20062481
10.3233/JAD-2011-110110
10.1111/acel.12774
10.1096/fj.201700600R
10.1186/s12974-020-1726-7
10.1089/scd.2019.0235
10.1016/j.neurobiolaging.2017.08.022
10.1371/journal.pone.0176460
10.1002/brb3.11
10.1007/s12035-014-9051-8
10.1038/s41598-020-67460-1
10.1186/s13287-021-02518-z
10.4049/jimmunol.171.5.2216
10.3389/fnsyn.2018.00014
10.1523/JNEUROSCI.1569-12.2012
10.1111/nan.12642
10.1016/j.bcp.2013.12.024
10.1016/j.nbd.2004.12.004
10.1016/j.neulet.2012.06.002
10.1016/j.neulet.2007.10.046
10.1016/j.neuroscience.2010.01.057
10.1016/j.brainres.2003.11.080
10.2174/156720510792231739
10.1002/jcp.24688
10.1634/stemcells.2006-0561
10.3390/ijms22031433",<Element 'PubmedArticle' at 0x7f05decc16d0>
51,"34446931
31748742
28886007
10806312
21777559
30227881
1759558
9330961
22487856
23332364
12084879
30052812
23775979
31164641
22008728
32398677
33098803
30064520
32671408
20160456
30572908
27318133
31698286
22996553
28197095
26754641
26754172
26364736
25472798
23967336
28810892
29516540
29673549
31958084
27316687
33669121
25050378
17981764
22002422
21527731
28123067
27351289
22057275
25130657
26988744
33472953
23824488
27371494
31768052
28205565
18786637
28930663
29196460
25766898
30171911
19457380
32737243
29396637
23227001
29723639
30980923
32333900
27378902",Microglial activation and tau propagate jointly across Braak stages.,Compelling experimental evidence suggests that microglial activation is involved in the spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the hypothesis that the spatial propagation of microglial activation and tau accumulation colocalize in a Braak-like pattern in the living human brain. We studied 130 individuals across the aging and AD clinical spectrum with positron emission tomography brain imaging for microglial activation ([,[],Nature medicine,2021-08-28,"[{'lastname': 'Pascoal', 'firstname': 'Tharick A', 'initials': 'TA', 'affiliation': ""Departments of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. PASCOAL@pitt.edu.\nDepartments of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. PASCOAL@pitt.edu.\nTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada. PASCOAL@pitt.edu.\nMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. PASCOAL@pitt.edu.""}, {'lastname': 'Benedet', 'firstname': 'Andrea L', 'initials': 'AL', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Ashton', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': ""Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.\nInstitute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London, London, UK.\nNIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation, London, UK.""}, {'lastname': 'Kang', 'firstname': 'Min Su', 'initials': 'MS', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.\nMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Therriault', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Chamoun', 'firstname': 'Mira', 'initials': 'M', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Savard', 'firstname': 'Melissa', 'initials': 'M', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Lussier', 'firstname': 'Firoza Z', 'initials': 'FZ', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Tissot', 'firstname': 'Cécile', 'initials': 'C', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Karikari', 'firstname': 'Thomas K', 'initials': 'TK', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'lastname': 'Ottoy', 'firstname': 'Julie', 'initials': 'J', 'affiliation': 'Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.\nLC Campbell Cognitive Neurology Unit, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Mathotaarachchi', 'firstname': 'Sulantha', 'initials': 'S', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Stevenson', 'firstname': 'Jenna', 'initials': 'J', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Massarweh', 'firstname': 'Gassan', 'initials': 'G', 'affiliation': 'Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Schöll', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.\nWallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.\nDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.'}, {'lastname': 'de Leon', 'firstname': 'Mony J', 'initials': 'MJ', 'affiliation': 'Department of Radiology Weill Medical Center Brain Health Imaging Institute, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Soucy', 'firstname': 'Jean-Paul', 'initials': 'JP', 'affiliation': 'Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Edison', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Department of Brain Sciences, Imperial College London, Hammersmith Hospital Campus, London, UK.'}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.\nDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.\nUK Dementia Research Institute at UCL, London, UK.'}, {'lastname': 'Gauthier', 'firstname': 'Serge', 'initials': 'S', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.""}, {'lastname': 'Rosa-Neto', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': ""Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada. pedro.rosa@mcgill.ca.\nMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. pedro.rosa@mcgill.ca.""}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.","10.1038/s41591-021-01456-w
10.1038/s41586-019-1769-z
10.1038/nm.4397
10.1016/S0304-3940(00)01037-5
10.1016/j.ajpath.2011.05.047
10.1186/s12974-018-1309-z
10.1007/BF00308809
10.1016/S0197-4580(97)00056-0
10.1097/NEN.0b013e31825018f7
10.1016/S1474-4422(12)70291-0
10.1212/WNL.58.12.1791
10.1093/brain/awt145
10.1038/s41467-019-10217-w
10.1038/jcbfm.2011.147
10.1038/s41467-020-15930-5
10.1016/S1474-4422(20)30346-X
10.1186/s13195-018-0402-y
10.1093/brain/awaa180
10.1159/000283480
10.1186/s13024-018-0298-9
10.1016/j.neurobiolaging.2016.04.011
10.1016/j.neurobiolaging.2019.09.019
10.1038/nature11405
10.3389/fnagi.2017.00008
10.1007/s00401-016-1533-5
10.1186/s13024-016-0071-x
10.1016/j.neurobiolaging.2015.08.019
10.1093/brain/awu318
10.1371/journal.pone.0072744
10.1186/s13024-017-0200-1
10.1002/gps.4871
10.1016/j.bj.2018.01.003
10.3233/JAD-190753
10.4049/jimmunol.1600502
10.3390/biom11030353
10.1007/s11357-013-9518-y
10.2741/2896
10.1097/NEN.0b013e318232a379
10.1152/physrev.00011.2010
10.1126/scitranslmed.aag0481
10.1002/ana.24716
10.1074/jbc.M111.277061
10.1016/j.jalz.2014.06.008
10.1038/nrn.2016.13
10.1126/scitranslmed.abc0655
10.1093/brain/awt171
10.1212/WNL.0000000000002923
10.1038/s41593-019-0539-4
10.1038/srep42370
10.1016/j.nbd.2008.08.001
10.1016/j.immuni.2017.08.008
10.1083/jcb.201709069
10.2967/jnumed.114.146027
10.1016/j.neulet.2018.08.038
10.1016/j.neuroimage.2009.01.045
10.2967/jnumed.120.245209
10.1007/s00259-018-3933-3
10.3389/fnins.2012.00171
10.1016/j.neuroimage.2018.04.068
10.1016/j.exger.2019.04.003
10.1016/S1474-4422(20)30071-5
10.3389/fninf.2016.00020",<Element 'PubmedArticle' at 0x7f05dec8b180>
52,"34371878
31753135
30954437
25621019
29299792
31313216
26227906
31820699
29273951
23063604
12379913
22715882
28862638
11906569
31357672
19923397
27782068
29232896
32942624
21906407
25568378
32076042
31562503
22288401
27094468
9088911
15374284
32690994
18546601
33571701
28466678
27188934
27662285
28836062
29454265
29948950
31296588
21677377
26088971
28712664
22776969
31865964
30630955
14586007
33132897
28009077
15350655
32488482
25227314
23943781
27716675
32908486
30532704
24368090
26538310
30949950
33805697
24973733
22986642
27776263
31921396
26306709
28109835
32257964
12772849
24333791",Dietary Spray-Dried Porcine Plasma Reduces Neuropathological Alzheimer's Disease Hallmarks in SAMP8 Mice.,"Alzheimer's disease (AD) is characterized by the aberrant processing of amyloid precursor protein (APP) and the accumulation of hyperphosphorylated tau, both of which are accompanied by neuroinflammation. Dietary supplementation with spray-dried porcine plasma (SDP) has anti-inflammatory effects in inflammation models. We investigated whether dietary supplementation with SDP prevents the neuropathological features of AD. The experiments were performed in 2- and 6-month-old SAMP8 mice fed a control diet, or a diet supplemented with 8% SDP, for 4 months. AD brain molecular markers were determined by Western blot and real-time PCR. Senescent mice showed reduced levels of p-GSK3β (Ser9) and an increase in p-CDK5, p-tau (Ser396), sAPPβ, and the concentration of Aβ","['Alzheimer’s disease', 'SAMP8', 'aging', 'dietary supplementation', 'neuroinflammation', 'plasma proteins']",Nutrients,2021-08-11,"[{'lastname': 'Rosell-Cardona', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Institute for Nutrition and Food Safety, Universitat de Barcelona (UB), 08028 Barcelona, Spain.'}, {'lastname': 'Griñan-Ferré', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Department of Pharmacology, Toxicology, and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neurosciences, CIBERNED, Universitat de Barcelona (UB), 08028 Barcelona, Spain.'}, {'lastname': 'Pérez-Bosque', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Institute for Nutrition and Food Safety, Universitat de Barcelona (UB), 08028 Barcelona, Spain.'}, {'lastname': 'Polo', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'APC Europe S.L.U., 08403 Granollers, Spain.'}, {'lastname': 'Pallàs', 'firstname': 'Mercè', 'initials': 'M', 'affiliation': 'Department of Pharmacology, Toxicology, and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neurosciences, CIBERNED, Universitat de Barcelona (UB), 08028 Barcelona, Spain.'}, {'lastname': 'Amat', 'firstname': 'Concepció', 'initials': 'C', 'affiliation': 'Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Institute for Nutrition and Food Safety, Universitat de Barcelona (UB), 08028 Barcelona, Spain.'}, {'lastname': 'Moretó', 'firstname': 'Miquel', 'initials': 'M', 'affiliation': 'Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Institute for Nutrition and Food Safety, Universitat de Barcelona (UB), 08028 Barcelona, Spain.'}, {'lastname': 'Miró', 'firstname': 'Lluïsa', 'initials': 'L', 'affiliation': 'Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Institute for Nutrition and Food Safety, Universitat de Barcelona (UB), 08028 Barcelona, Spain.\nAPC Europe S.L.U., 08403 Granollers, Spain.'}]",,,,,"10.3390/nu13072369
10.1016/B978-0-12-804766-8.00013-3
10.1016/j.clinbiochem.2019.04.001
10.1186/s13195-014-0089-7
10.1007/s10571-017-0574-1
10.1007/s11357-019-00085-z
10.1007/s12035-015-9369-x
10.2174/1567205016666191210094435
10.1007/s00702-017-1831-7
10.1016/j.expneurol.2012.10.007
10.1002/glia.10153
10.1146/annurev-neuro-061010-113810
10.1172/JCI90606
10.5713/ajas.2010.70630
10.1046/j.1439-0396.2002.00352.x
10.3390/microorganisms7080219
10.3945/jn.109.112466
10.3390/nu8100657
10.3390/nu9121346
10.3390/ijms21186760
10.1017/S0007114511003655
10.2527/jas.2014-7259
10.1038/s41598-020-59756-z
10.1093/jn/nxz239
10.2174/138161212799315795
10.1016/j.exger.2016.03.014
10.5402/2012/917167
10.1016/S0531-5565(96)00061-7
10.1016/0167-4943(94)90039-6
10.1186/s40813-020-00155-1
10.1038/nprot.2008.73
10.1038/s43587-021-00092-w
10.1016/j.arr.2021.101271
10.1080/1028415X.2017.1321813
10.1038/nrdp.2015.56
10.3233/JAD-160051
10.1007/s11064-017-2391-9
10.1016/j.jnutbio.2018.01.009
10.1007/s12035-018-1157-y
10.1136/jnnp-2018-320199
10.3233/JAD-2011-102016
10.1093/cercor/bhv032
10.1016/j.jbior.2017.06.003
10.3233/JAD-2012-120718
10.1007/s11055-016-0231-z
10.5483/BMBRep.2020.53.1.309
10.1136/jnnp-2018-319148
10.1523/JNEUROSCI.23-30-09796.2003
10.3389/fnagi.2020.566922
10.1111/bpa.12478
10.1016/j.neuroscience.2004.07.020
10.1007/s13311-020-00854-1
10.3233/JAD-141506
10.1093/brain/awt210
10.3233/JAD-160912
10.1155/2020/8836173
10.3389/fnagi.2018.00395
10.1016/j.neurobiolaging.2013.11.026
10.1186/s12974-015-0411-8
10.1007/s12640-019-00030-0
10.3390/ani11030807
10.1016/j.semcdb.2014.06.004
10.1159/000341630
10.1016/j.neurobiolaging.2016.08.019
10.1016/j.csbj.2019.09.008
10.1021/acs.jafc.5b02404
10.1016/j.arr.2017.01.001
10.3390/IECN2020-06995
10.3389/fcimb.2020.00104
10.2527/2003.8151220x
10.1016/j.mad.2013.11.011",<Element 'PubmedArticle' at 0x7f05dec42a40>
53,34323745,Chronic MC-LR exposure promoted Aβ and p-tau accumulation via regulating Akt/GSK-3β signal pathway.,"It has been reported that microcystin-leucine-arginine (MC-LR) can enter into the brain and demonstrate neurotoxicity resulting in learning and memory deficits. While, there is still a lack of clear understanding of the related molecular mechanisms. In this study, we observed β-amyloid (Aβ) accumulation and tau hyperphosphorylation (p-tau) at sites of Ser396 and Thr205 in mouse hippocampus and cortex, Alzheimer's disease (AD) like changes, after chronic exposure to MC-LR at different concentrations (1, 7.5, 15 and 30 μg/L) for 180 days. The hallmarks of AD are characterized by senile plaques and neurofibrillary tangles (NFT), with associated loss of neurons, resulting in cognitive impairment and dementia. Similarly, the production of Aβ and tau hyperphosphorylation was also detected in HT-22 cells treated with MC-LR. In addition, MC-LR promoted increased expressions of BACE1 and PS1, but reduced mRNA expressions of ADAM family members both in vivo and in vitro, promoting the Aβ production. Moreover, we identified Akt/GSK-3β signal pathway mediated the Aβ and p-tau accumulation, bringing about Alzheimer's disease-like changes. Furthermore, microglial cells were activated in those mice exposed to MC-LR. Inflammatory cytokines were also found being activated to release in vitro. In conclusion, this study could provide a clue for MC-LR-induced neurotoxicity, which gave insights into the environmental risks of Alzheimer's disease.","['Akt/GSK-3β signaling pathway', ""Alzheimer's disease"", 'Microcystin-LRs', 'Microglia', 'Neurotoxicity']",The Science of the total environment,2021-07-30,"[{'lastname': 'Ma', 'firstname': 'Yuhan', 'initials': 'Y', 'affiliation': 'Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China.'}, {'lastname': 'Wang', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China.'}, {'lastname': 'Xu', 'firstname': 'Dihui', 'initials': 'D', 'affiliation': 'Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China.'}, {'lastname': 'Chen', 'firstname': 'Yabing', 'initials': 'Y', 'affiliation': 'Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China. Electronic address: ybchen916218@126.com.'}, {'lastname': 'Han', 'firstname': 'Xiaodong', 'initials': 'X', 'affiliation': 'Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China. Electronic address: hanxd@nju.edu.cn.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.scitotenv.2021.148732,<Element 'PubmedArticle' at 0x7f05debfd8b0>
54,"34239348
11274343
24470773
30046078
18631749
32778792
30610216
19038212
24450891
2424016
21193853
20466736
12401334
3088567
23594602
9735171
2501795
1899184
7822317
7531159
26635213
21677377
20678074
19158430
9062903
1530909
18258852
12062036
20826658
12895417
11520987
20698823
19583853
17541419
29141245
1376245
15147305
15632108
11810403
28420982
23632019
25676491
12888622
24493463
25887395
27021818
27716675
20655099
28526038
29036830
17478722
19628305
9892651
21228179
20950339
17308309
16682536
25707991
28709498
28860088
9210467
10413115
27856911
30559471
21244356
11703942
19605646
19050078
22122400
19497367
16477035
20538375
15087549
21459773
19389700
11162250
17360912
18725189
20571215
17708691
22110363
23824488
31585077
22301467
17270732
25833819
26436904
17684513
7747799
26638867
30227881
20920788
31601677
22057275
22920859
31235932
29351512
16371949
22213821
32003282
12706236
25792098
18171944
22383525
25031402
23038755
23773064
12612547
22365544
28340083
30108137
30618641
28074262
24671193
26104290
22115520
22002422
19508444
1759558
12084879
30374196
28945221
10886685
16055747
21062360
19556894
22820466
27193083
22833681
23175838
25981034
26578881
23805846
29782321
10072051
22160320
21421841
31414210
22660329
23477989
25745095
29538647
30597624
28482211
29523644
28253546
28314821
29365053
26195256
28734653
30668647
29458036
27450471
27724156
25222039
30549303
22487856
23332364
15312913
12566928
24481039
23969120
28103749
27251914
33352989",Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.,"Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of Alzheimer's disease (AD), and the separate neurotoxicity of these proteins in AD has been extensively studied. However, interventions that target Aβ or tau individually have not yielded substantial breakthroughs. The interest in the interactions between Aβ and tau in AD is increasing, but related drug investigations are in their infancy. This review discusses how Aβ accelerates tau phosphorylation and the possible mechanisms and pathways by which tau mediates Aβ toxicity. This review also describes the possible synergistic effects between Aβ and tau on microglial cells and astrocytes. Studies suggest that the coexistence of Aβ plaques and phosphorylated tau is related to the mechanism by which Aβ facilitates the propagation of tau aggregation in neuritic plaques. The interactions between Aβ and tau mediate cognitive dysfunction in patients with AD. In summary, this review summarizes recent data on the interplay between Aβ and tau to promote a better understanding of the roles of these proteins in the pathological process of AD and provide new insights into interventions against AD.","[""Alzheimer's disease"", 'amyloid-β', 'interaction', 'phosphorylation', 'tau']",International journal of biological sciences,2021-07-10,"[{'lastname': 'Zhang', 'firstname': 'Huiqin', 'initials': 'H', 'affiliation': 'Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'lastname': 'Wei', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'lastname': 'Zhao', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'lastname': 'Ma', 'firstname': 'Lina', 'initials': 'L', 'affiliation': 'Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'lastname': 'Jiang', 'firstname': 'Xuefan', 'initials': 'X', 'affiliation': 'Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'lastname': 'Pei', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'lastname': 'Cao', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': 'Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}, {'lastname': 'Li', 'firstname': 'Hao', 'initials': 'H', 'affiliation': 'Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.'}]",,,,© The author(s).,10.7150/ijbs.57078,<Element 'PubmedArticle' at 0x7f05dec0a310>
55,34230948,[Chronic sleep deprivation exacerbates cognitive and pathological impairments in APP/PS1/tau triple transgenic Alzheimer's disease model mice].,"Sleep exerts important functions in the regulation of cognition and emotion. Recent studies have found that sleep disorder is one of the important risk factors for Alzheimer's disease (AD), but the effects of chronic sleep deprivation on the cognitive functions of AD model mice and its possible mechanism are still unclear. In the present study, 8-month-old male APP/PS1/tau triple transgenic AD model (3xTg-AD) mice and wild type (WT) mice (n = 8 for each group) were subjected to chronic sleep deprivation by using the modified multiple platform method, with 20 h of sleep deprivation each day for 21 days. Then, open field test, elevated plus maze test, sugar water preference test, object recognition test, Y maze test and conditioned fear memory test were performed to evaluate anxiety- and depression-like behaviors, and multiple cognitive functions. In addition, the immunohistochemistry technique was used to observe pathological characteristics in the hippocampus of mice. The results showed that: (1) Chronic sleep deprivation did not affect anxiety- (P = 0.539) and depression-like behaviors (P = 0.874) in 3xTg-AD mice; (2) Chronic sleep deprivation exacerbated the impairments of object recognition memory (P < 0.001), working memory (P = 0.002) and the conditioned fear memory (P = 0.039) in 3xTg-AD mice; (3) Chronic sleep deprivation increased amyloid β (Aβ) deposition (P < 0.001) and microglial activation (P < 0.001) in the hippocampus of 3xTg-AD mice, without inducing abnormal tau phosphorylation and neurofibrillary tangles. These results indicate that chronic sleep deprivation exacerbates the impairments of recognition memory, working memory and conditioned fear memory in 3xTg-AD mice by aggravating Aβ deposition and the excessive activation of microglia in the hippocampus.",[],Sheng li xue bao : [Acta physiologica Sinica],2021-07-08,"[{'lastname': 'Wang', 'firstname': 'Chun', 'initials': 'C', 'affiliation': 'Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.'}, {'lastname': 'Cao', 'firstname': 'Xu', 'initials': 'X', 'affiliation': 'The School of Imaging Medicine, Shanxi Medical University, Taiyuan 030001, China.'}, {'lastname': 'Yin', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.'}, {'lastname': 'Gao', 'firstname': 'Wen-Rui', 'initials': 'WR', 'affiliation': 'Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.'}, {'lastname': 'Li', 'firstname': 'Wei-Ran', 'initials': 'WR', 'affiliation': 'Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.'}, {'lastname': 'Qi', 'firstname': 'Jin-Shun', 'initials': 'JS', 'affiliation': 'Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.'}, {'lastname': 'Wu', 'firstname': 'Mei-Na', 'initials': 'MN', 'affiliation': 'Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China. wmna@163.com.'}]",,,,,,<Element 'PubmedArticle' at 0x7f05debd9b30>
56,"34209408
30497964
22265587
1549228
29077261
28386764
21215781
25775228
29311706
28678775
31439664
26891276
24007550
22674585
25792098
23254930
27291964
26549800
12191486
31277708
19776284
18604209
15525768
16148231
26436904
30227881
19289607
30721409
20225336
30617086
24012002
31121890
25628964
15751225
31503421
29024336
25766616
31748742
30200996
29893907
23792783
22743772
27792788
19897823
30071272
16125973
17406547
26038575
31841678
32019610
26868913
22019906
32239449
29772377
24889886
27459405
25598354
28282924
22286270
25650776
21228274
16286508
18083104
31300716",Aggregated Tau-PHF6 (VQIVYK) Potentiates NLRP3 Inflammasome Expression and Autophagy in Human Microglial Cells.,"Intra-neuronal misfolding of monomeric tau protein to toxic β-sheet rich neurofibrillary tangles is a hallmark of Alzheimer's disease (AD). Tau pathology correlates not only with progressive dementia but also with microglia-mediated inflammation in AD. Amyloid-beta (Aβ), another pathogenic peptide involved in AD, has been shown to activate NLRP3 inflammasome (NOD-like receptor family, pyrin domain containing 3), triggering the secretion of proinflammatory interleukin-1β (IL1β) and interleukin-18 (","['Alzheimer’s disease', 'HMC3', 'NLRP3', 'PHF6', 'autophagy', 'microglia', 'tau']",Cells,2021-07-03,"[{'lastname': 'Panda', 'firstname': 'Chinmaya', 'initials': 'C', 'affiliation': 'Biological Engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar 382355, India.\nInstitute of Neuroanatomy, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.'}, {'lastname': 'Voelz', 'firstname': 'Clara', 'initials': 'C', 'affiliation': 'Institute of Neuroanatomy, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.'}, {'lastname': 'Habib', 'firstname': 'Pardes', 'initials': 'P', 'affiliation': 'Department of Neurology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.'}, {'lastname': 'Mevissen', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Institut für Organische Chemie, RWTH Aachen University, 52074 Aachen, Germany.'}, {'lastname': 'Pufe', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Anatomy and Cell Biology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.'}, {'lastname': 'Beyer', 'firstname': 'Cordian', 'initials': 'C', 'affiliation': 'Institute of Neuroanatomy, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.'}, {'lastname': 'Gupta', 'firstname': 'Sharad', 'initials': 'S', 'affiliation': 'Biological Engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar 382355, India.'}, {'lastname': 'Slowik', 'firstname': 'Alexander', 'initials': 'A', 'affiliation': 'Institute of Neuroanatomy, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.\nDepartment of Anatomy and Cell Biology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.'}]",,,,,"10.3390/cells10071652
10.1016/S1474-4422(18)30403-4
10.1016/j.jalz.2011.10.007
10.1212/WNL.42.3.631
10.1111/tra.12537
10.1007/s00401-017-1707-9
10.1016/j.neuint.2010.12.023
10.1021/acs.jpcb.5b00175
10.1038/s41598-017-18443-2
10.1038/nature23002
10.1074/jbc.RA119.010003
10.1002/chem.201504950
10.1021/cn400151a
10.1002/glia.22350
10.1016/S1474-4422(15)70016-5
10.1038/nature11729
10.1038/nri.2016.58
10.1038/cmi.2015.95
10.1016/S1097-2765(02)00599-3
10.1186/s40478-019-0754-y
10.1523/JNEUROSCI.3158-09.2009
10.1038/ni.1636
10.1523/JNEUROSCI.2557-04.2004
10.1523/JNEUROSCI.1808-05.2005
10.1038/nn.4132
10.1186/s12974-018-1309-z
10.1096/fj.08-123877
10.1007/s00401-018-01957-y
10.1002/path.2697
10.15252/embj.201899430
10.1016/j.neuron.2013.06.046
10.3390/cells8050488
10.1093/jnen/64.2.113
10.1111/cns.13216
10.1111/acel.12692
10.1038/emm.2014.117
10.1038/s41586-019-1769-z
10.1186/s12974-018-1288-0
10.1093/nar/gky497
10.1016/j.jsbmb.2013.06.003
10.1038/nmeth.2019
10.1371/journal.pone.0165492
10.3758/BRM.41.4.1149
10.1016/j.bbagen.2018.07.030
10.1016/j.jsb.2005.06.006
10.1038/nprot.2006.202
10.1073/pnas.1500851112
10.1016/j.nbd.2019.104707
10.1186/s40478-020-0884-2
10.1038/cdd.2015.176
10.1016/j.cytogfr.2011.10.001
10.1007/s12035-020-01909-2
10.1016/j.jsbmb.2018.05.003
10.1186/1742-2094-11-98
10.1038/nn.4338
10.1007/s12035-014-9070-5
10.3390/ijms18030598
10.1038/ni.2215
10.1080/15548627.2015.1009787
10.1074/jbc.M110.202911
10.1083/jcb.200507002
10.1016/j.cell.2007.10.035
10.1038/s41598-019-46657-z",<Element 'PubmedArticle' at 0x7f05debe5040>
57,"34187889
11520930
22762014
19284597
21172610
22867711
26799652
26968346
26646497
19339967
26266977
21884931
16625205
16625204
27096368
33067381
26338325
25069841
31775806
19282288
21372138
19503072
22365544
23325240
24857020
1759558
26057852
30283031
26436904
31748742
30415998
28473584
25906181
24360280
29997299
29293211
30679807
31959936
27294511
29301957
16567856
16024916
22095718
30290707
21071715
28748360
15051507
20920788
31257024
26098576
22002674
32170061
32366951
30108137
23604321
19701197
27112488
30610193",Autophagy deficiency modulates microglial lipid homeostasis and aggravates tau pathology and spreading.,"The autophagy-lysosomal pathway plays a critical role in intracellular clearance and metabolic homeostasis. While neuronal autophagy is known to participate in the degradation of neurofibrillary tangles composed of hyperphosphorylated and misfolded tau protein in Alzheimer's disease and other tauopathies, how microglial-specific autophagy regulates microglial intrinsic properties and neuronal tau pathology is not well understood. We report here that Atg7, a key mediator of autophagosome biogenesis, plays an essential role in the regulation of microglial lipid metabolism and neuroinflammation. Microglia-specific deletion of ","[""Alzheimer's disease"", 'autophagy', 'lipid metabolism', 'microglia', 'tau']",Proceedings of the National Academy of Sciences of the United States of America,2021-07-01,"[{'lastname': 'Xu', 'firstname': 'Yin', 'initials': 'Y', 'affiliation': 'Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030; Yin.Xu@bcm.edu huiz@bcm.edu.'}, {'lastname': 'Propson', 'firstname': 'Nicholas E', 'initials': 'NE', 'affiliation': 'Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030.'}, {'lastname': 'Du', 'firstname': 'Shuqi', 'initials': 'S', 'affiliation': 'Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030.\nDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.'}, {'lastname': 'Xiong', 'firstname': 'Wen', 'initials': 'W', 'affiliation': 'Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030.'}, {'lastname': 'Zheng', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030; Yin.Xu@bcm.edu huiz@bcm.edu.\nDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.\nDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030.'}]",,,,,"10.1073/pnas.2023418118
10.1038/s41380-020-0738-0",<Element 'PubmedArticle' at 0x7f05deb9e540>
58,"34148071
29242522
23028132
21970975
29358399
29061693
30643288
21909359
8103579
14745459
22048062
26143259
19779720
23365075
16407166
18262660
19104500
20962261
21245195
12165536
17317721
12475898
23277546
10882119
27590054
17021169
15509565
12417659
29085990
7622868
14586007
27614112
27627784
26526972
23074027
26404120
22896675
27459939
26774030
26884167
27633771
31801888
32612231
18305170
22248728
22301467
22116809
25784952
24604078
11827998
31611708
27893874
22365952
28039950
18649401
19625660
22164217
31389028
31389038
25620241
28116038
10593871
11932745
23792494
30972066
31114582
19833956
20951217
18268341
17360529
21337419
30789943
29973407
15334582
23063647",Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-β and tau pathology.,"Alzheimer's disease, characterized by brain deposits of amyloid-β plaques and neurofibrillary tangles, is also linked to neurovascular dysfunction and blood-brain barrier breakdown, affecting the passage of substances into and out of the brain. We hypothesized that treatment of neurovascular alterations could be beneficial in Alzheimer's disease. Annexin A1 (ANXA1) is a mediator of glucocorticoid anti-inflammatory action that can suppress microglial activation and reduce blood-brain barrier leakage. We have reported recently that treatment with recombinant human ANXA1 (hrANXA1) reduced amyloid-β levels by increased degradation in neuroblastoma cells and phagocytosis by microglia. Here, we show the beneficial effects of hrANXA1 in vivo by restoring efficient blood-brain barrier function and decreasing amyloid-β and tau pathology in 5xFAD mice and Tau-P301L mice. We demonstrate that young 5xFAD mice already suffer cerebrovascular damage, while acute pre-administration of hrANXA1 rescued the vascular defects. Interestingly, the ameliorated blood-brain barrier permeability in young 5xFAD mice by hrANXA1 correlated with reduced brain amyloid-β load, due to increased clearance and degradation of amyloid-β by insulin degrading enzyme (IDE). The systemic anti-inflammatory properties of hrANXA1 were also observed in 5xFAD mice, increasing IL-10 and reducing TNF-α expression. Additionally, the prolonged treatment with hrANXA1 reduced the memory deficits and increased synaptic density in young 5xFAD mice. Similarly, in Tau-P301L mice, acute hrANXA1 administration restored vascular architecture integrity, affecting the distribution of tight junctions, and reduced tau phosphorylation. The combined data support the hypothesis that blood-brain barrier breakdown early in Alzheimer's disease can be restored by hrANXA1 as a potential therapeutic approach.","['ANXA1', 'Aβ', 'BBB', 'IDE', 'tau']",Brain : a journal of neurology,2021-06-21,"[{'lastname': 'Ries', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Watts', 'firstname': 'Helena', 'initials': 'H', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Mota', 'firstname': 'Bibiana C', 'initials': 'BC', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Lopez', 'firstname': 'Maria Yanez', 'initials': 'MY', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Donat', 'firstname': 'Cornelius K', 'initials': 'CK', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Baxan', 'firstname': 'Nicoleta', 'initials': 'N', 'affiliation': 'Biological Imaging Centre, Imperial College London, London, UK.'}, {'lastname': 'Pickering', 'firstname': 'James A', 'initials': 'JA', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Chau', 'firstname': 'Tsz Wing', 'initials': 'TW', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Semmler', 'firstname': 'Annika', 'initials': 'A', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Gurung', 'firstname': 'Brinda', 'initials': 'B', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Aleksynas', 'firstname': 'Robertas', 'initials': 'R', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Abelleira-Hervas', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Iqbal', 'firstname': 'Soha Jamshed', 'initials': 'SJ', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Romero-Molina', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Hernandez-Mir', 'firstname': 'Gerard', 'initials': 'G', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': ""d'Amati"", 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'William Harvey Research Institute, Queen Mary University London SMD, London, UK.'}, {'lastname': 'Reutelingsperger', 'firstname': 'Chris', 'initials': 'C', 'affiliation': 'Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.'}, {'lastname': 'Goldfinger', 'firstname': 'Marc H', 'initials': 'MH', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Gentleman', 'firstname': 'Steve M', 'initials': 'SM', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Van Leuven', 'firstname': 'Fred', 'initials': 'F', 'affiliation': 'Experimental Genetics Group-LEGTEGG, Department of Human Genetics, KU Leuven, Leuven, Belgium.'}, {'lastname': 'Solito', 'firstname': 'Egle', 'initials': 'E', 'affiliation': 'William Harvey Research Institute, Queen Mary University London SMD, London, UK.\nDipartimento di Medicina Molecolare e Biotecnologie Mediche, Universitá degli Studi di Napoli ""Federico II"", Naples, Italy.'}, {'lastname': 'Sastre', 'firstname': 'Magdalena', 'initials': 'M', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}]",,,,© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.,10.1093/brain/awab050,<Element 'PubmedArticle' at 0x7f05deb440e0>
59,"34116706
30046078
31564456
30046085
7566345
1549228
31748742
26631930
29895964
30392797
30001506
28420982
28983098
33058407
24512768
28971760
28284752
22194158
32278002
30820451
26270904
22445961
17176091
25264773
27475227
24653673
16262633
32973448
31368873
25533482
19387114
27025652
32778792
3088567
26242245
28772101
30193298
26635213
28386764
31277708
28668610
27264648
32333900",Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease.,"Tau pathology is a hallmark of Alzheimer's disease (AD) and other tauopathies. During disease progression, abnormally phosphorylated forms of tau aggregate and accumulate into neurofibrillary tangles, leading to synapse loss, neuroinflammation, and neurodegeneration. Thus, targeting of tau pathology is expected to be a promising strategy for AD treatment.
The effect of rutin on tau aggregation was detected by thioflavin T fluorescence and transmission electron microscope imaging. The effect of rutin on tau oligomer-induced cytotoxicity was assessed by MTT assay. The effect of rutin on tau oligomer-mediated the production of IL-1β and TNF-α in vitro was measured by ELISA. The uptake of extracellular tau by microglia was determined by immunocytochemistry. Six-month-old male Tau-P301S mice were treated with rutin or vehicle by oral administration daily for 30 days. The cognitive performance was determined using the Morris water maze test, Y-maze test, and novel object recognition test. The levels of pathological tau, gliosis, NF-kB activation, proinflammatory cytokines such as IL-1β and TNF-α, and synaptic proteins including synaptophysin and PSD95 in the brains of the mice were evaluated by immunolabeling, immunoblotting, or ELISA.
We showed that rutin, a natural flavonoid glycoside, inhibited tau aggregation and tau oligomer-induced cytotoxicity, lowered the production of proinflammatory cytokines, protected neuronal morphology from toxic tau oligomers, and promoted microglial uptake of extracellular tau oligomers in vitro. When applied to Tau-P301S mouse model of tauopathy, rutin reduced pathological tau levels, regulated tau hyperphosphorylation by increasing PP2A level, suppressed gliosis and neuroinflammation by downregulating NF-kB pathway, prevented microglial synapse engulfment, and rescued synapse loss in mouse brains, resulting in a significant improvement of cognition.
In combination with the previously reported therapeutic effects of rutin on Aβ pathology, rutin is a promising drug candidate for AD treatment based its combinatorial targeting of tau and Aβ.","['Alzheimer’s disease', 'Neurofibrillary tangles', 'Neuroinflammation', 'Rutin', 'Synapse loss', 'Tau pathology']",Journal of neuroinflammation,2021-06-13,"[{'lastname': 'Sun', 'firstname': 'Xiao-Ying', 'initials': 'XY', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.\nSchool of Chemistry and Chemical Engineering, University of Chinese Academy of Science, Beijing, 100049, China.'}, {'lastname': 'Li', 'firstname': 'Ling-Jie', 'initials': 'LJ', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.\nSchool of Chemistry and Chemical Engineering, University of Chinese Academy of Science, Beijing, 100049, China.'}, {'lastname': 'Dong', 'firstname': 'Quan-Xiu', 'initials': 'QX', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.\nSchool of Chemistry and Chemical Engineering, University of Chinese Academy of Science, Beijing, 100049, China.'}, {'lastname': 'Zhu', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.\nInnovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing, 100190, China.'}, {'lastname': 'Huang', 'firstname': 'Ya-Ru', 'initials': 'YR', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.\nSchool of Chemistry and Chemical Engineering, University of Chinese Academy of Science, Beijing, 100049, China.'}, {'lastname': 'Hou', 'firstname': 'Sheng-Jie', 'initials': 'SJ', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.\nSchool of Chemistry and Chemical Engineering, University of Chinese Academy of Science, Beijing, 100049, China.'}, {'lastname': 'Yu', 'firstname': 'Xiao-Lin', 'initials': 'XL', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. yuxiaolin@ipe.ac.cn.\nInnovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing, 100190, China. yuxiaolin@ipe.ac.cn.'}, {'lastname': 'Liu', 'firstname': 'Rui-Tian', 'initials': 'RT', 'affiliation': 'State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. rtliu@ipe.ac.cn.\nInnovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing, 100190, China. rtliu@ipe.ac.cn.'}]",,"In combination with the previously reported therapeutic effects of rutin on Aβ pathology, rutin is a promising drug candidate for AD treatment based its combinatorial targeting of tau and Aβ.","We showed that rutin, a natural flavonoid glycoside, inhibited tau aggregation and tau oligomer-induced cytotoxicity, lowered the production of proinflammatory cytokines, protected neuronal morphology from toxic tau oligomers, and promoted microglial uptake of extracellular tau oligomers in vitro. When applied to Tau-P301S mouse model of tauopathy, rutin reduced pathological tau levels, regulated tau hyperphosphorylation by increasing PP2A level, suppressed gliosis and neuroinflammation by downregulating NF-kB pathway, prevented microglial synapse engulfment, and rescued synapse loss in mouse brains, resulting in a significant improvement of cognition.",,"10.1186/s12974-021-02182-3
10.1038/d41586-018-05717-6
10.1016/j.cell.2019.09.001
10.1038/d41586-018-05718-5
10.1016/0197-4580(95)00025-A
10.1212/WNL.42.3.631
10.1038/s41586-019-1769-z
10.1038/nrn.2015.1
10.1038/s41582-018-0013-z
10.1016/j.neuron.2018.10.014
10.1016/j.neuron.2018.06.003
10.3389/fnagi.2017.00083
10.1038/nrd.2017.155
10.1016/j.bbr.2014.02.002
10.2174/0929867324666171003114154
10.1016/j.ejphar.2017.03.002
10.1007/s12640-011-9295-2
10.1016/j.fct.2020.111323
10.1126/sciadv.aau6328
10.1002/adma.201502227
10.1016/j.neuro.2012.03.003
10.1021/bi061422+
10.1038/nmeth.3125
10.1016/j.celrep.2016.06.099
10.3389/fnmol.2014.00016
10.1111/j.1460-9568.2005.04391.x
10.3389/fnmol.2020.00155
10.2174/1567205016666190801153751
10.1016/j.neuron.2014.11.018
10.3233/JAD-2009-0976
10.15252/emmm.201606210
10.1038/s41593-020-0687-6
10.1073/pnas.83.13.4913
10.1039/C5FO00500K
10.1146/annurev-neuro-072116-031153
10.1001/jamaneurol.2018.2505
10.1038/nrneurol.2015.225
10.1007/s00401-017-1707-9
10.1186/s40478-019-0754-y
10.1016/j.ijbiomac.2017.06.112
10.1016/j.ijbiomac.2016.06.001
10.1016/S1474-4422(20)30071-5",<Element 'PubmedArticle' at 0x7f05deb6c4f0>
60,"34103079
31686034
26436904
21212632
28500862
32179883
18055549
1759558
32479996
30052812
24742461
26481403
33609158
30125425
31414210
11520988
32544086
32792173
31768052
31157827
12130773
29200205
25792098
20802182
22265587
31748742
32375809
29653606
27371494
28602351
28930663
30820047
16541076
11520987
31235932
29073081
27373369
27909575
31504240
25833819
31042697
23447589
17021169
33257666
25220759
25853174
32015339
22229116
30140051
31601677
28959956
31951107
32112059
29490706
31434879
26921617
30721409
24604080
25862635
25407337
31178118
32161362
32997994
15184600
30241479
31061494
30599077
31164314
32579671
25728668
27091843
29024657
17270732
27196974
31932797","CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia.","Alzheimer's disease (AD) is characterized by a sequential progression of amyloid plaques (A), neurofibrillary tangles (T) and neurodegeneration (N), constituting ATN pathology. While microglia are considered key contributors to AD pathogenesis, their contribution in the combined presence of ATN pathologies remains incompletely understood. As sensors of the brain microenvironment, microglial phenotypes and contributions are importantly defined by the pathologies in the brain, indicating the need for their analysis in preclinical models that recapitulate combined ATN pathologies, besides their role in A and T models only. Here, we report a new tau-seed model in which amyloid pathology facilitates bilateral tau propagation associated with brain atrophy, thereby recapitulating robust ATN pathology. Single-cell RNA sequencing revealed that ATN pathology exacerbated microglial activation towards disease-associated microglia states, with a significant upregulation of Apoe as compared to amyloid-only models (A). Importantly, Colony-Stimulating Factor 1 Receptor inhibition preferentially eliminated non-plaque-associated versus plaque associated microglia. The preferential depletion of non-plaque-associated microglia significantly attenuated tau pathology and neuronal atrophy, indicating their detrimental role during ATN progression. Together, our data reveal the intricacies of microglial activation and their contributions to pathology in a model that recapitulates the combined ATN pathologies of AD. Our data may provide a basis for microglia-targeting therapies selectively targeting detrimental microglial populations, while conserving protective populations.","['ATN-continuum', 'Alzheimer’s disease', 'Amyloid pathology', 'CSF1R inhibition', 'Microglial profiling', 'Microgliosis', 'Neurodegeneration', 'Tau pathology']",Acta neuropathologica communications,2021-06-10,"[{'lastname': 'Lodder', 'firstname': 'Chritica', 'initials': 'C', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Scheyltjens', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.\nLab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.\nLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Beerse, Belgium.'}, {'lastname': 'Stancu', 'firstname': 'Ilie Cosmin', 'initials': 'IC', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Botella Lucena', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Gutiérrez de Ravé', 'firstname': 'Manuel', 'initials': 'M', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Vanherle', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Vanmierlo', 'firstname': 'Tim', 'initials': 'T', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Cremers', 'firstname': 'Niels', 'initials': 'N', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Vanrusselt', 'firstname': 'Hannah', 'initials': 'H', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Brône', 'firstname': 'Bert', 'initials': 'B', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.'}, {'lastname': 'Hanseeuw', 'firstname': 'Bernard', 'initials': 'B', 'affiliation': 'Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.\nDepartment of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.\nGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Octave', 'firstname': 'Jean-Noël', 'initials': 'JN', 'affiliation': 'Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.'}, {'lastname': 'Bottelbergs', 'firstname': 'Astrid', 'initials': 'A', 'affiliation': 'Neuroscience Department, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'lastname': 'Movahedi', 'firstname': 'Kiavash', 'initials': 'K', 'affiliation': 'Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium. kiavash.movahedi@vub.be.\nLab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium. kiavash.movahedi@vub.be.\nLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Beerse, Belgium. kiavash.movahedi@vub.be.'}, {'lastname': 'Dewachter', 'firstname': 'Ilse', 'initials': 'I', 'affiliation': 'Department of Neurosciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium. ilse.dewachter@uhasselt.be.'}]",,,,,"10.1186/s40478-021-01204-8
10.1038/s41591-019-0611-3
10.1038/nn.4132
10.1159/000322228
10.1016/j.ajpath.2017.03.011
10.1093/brain/awaa033
10.2353/ajpath.2007.070403
10.1007/BF00308809
10.1016/j.nbd.2020.104956
10.1093/brain/awy188
10.1016/j.neuron.2014.02.040
10.1016/j.neurobiolaging.2015.09.011
10.1007/s00401-021-02263-w
10.1002/pro.3499
10.1007/s00401-019-02053-5
10.1126/science.1062097
10.1172/JCI138179
10.1016/j.it.2020.07.001
10.1038/s41593-019-0539-4
10.1001/jamaneurol.2019.1424
10.1126/science.1072994
10.1038/nm.4443
10.1016/S1474-4422(15)70016-5
10.2353/ajpath.2010.100346
10.1016/j.jalz.2011.10.007
10.1038/s41586-019-1769-z
10.1186/s12974-020-01820-6
10.1016/j.jalz.2018.02.018
10.1212/WNL.0000000000002923
10.1016/j.cell.2017.05.018
10.1016/j.immuni.2017.08.008
10.1038/s41588-019-0358-2
10.1038/nature04533
10.1126/science.1058189
10.1038/s41593-019-0433-0
10.1073/pnas.1710311114
10.1038/ncomms12082
10.12688/f1000research.9501.2
10.1093/brain/awz241
10.1093/brain/awv081
10.1038/s41586-019-1195-2
10.1523/jneurosci.4251-12.2013
10.1523/JNEUROSCI.1202-06.2006
10.1038/s41467-020-19737-2
10.1016/j.nbd.2014.08.032
10.1186/s40478-015-0199-x
10.1038/s41467-019-14279-8
10.1101/cshperspect.a006189
10.1038/s41577-018-0051-1
10.1084/jem.20190980
10.1038/nature24016
10.15252/emmm.201910606
10.1038/s41593-020-0599-5
10.1186/s13024-018-0244-x
10.1038/s41467-019-11674-z
10.1093/brain/aww016
10.1007/s00401-018-01957-y
10.1096/fj.13-246702
10.1007/s00401-015-1413-4
10.1186/1750-1326-9-51
10.1016/j.cell.2019.05.031
10.1038/s41380-020-0688-6
10.1016/j.celrep.2020.108189
10.1212/01.wnl.0000128091.92139.0f
10.1186/s12974-018-1304-4
10.1038/s41593-019-0393-4
10.1007/s00401-018-1953-5
10.1016/j.jalz.2019.04.001
10.1084/jem.20200785
10.1016/j.cell.2015.01.049
10.1084/jem.20151948
10.1016/j.neuron.2017.09.026
10.1016/j.neuron.2007.01.010
10.1016/j.neuron.2016.05.003
10.1038/s41591-019-0695-9",<Element 'PubmedArticle' at 0x7f05deb14400>
61,"37117831
26007213
26871627
31564456
21193853
23798682
10460255
27165780
29844158
25673868
29403035
28912154
24725413
11875433
15951569
31926610
33289969
25231903
25332170
30557660
32284590
29533394
30962425
21515431
26444780
31042697
30820047
23332364
23398367
16932754
10896159
30266825
22184064
26885753
10604467
16766195
10217284
26603284
26793112
10715136
28007785
19590856
26414765
9452388
15489910
21442427
27001024
22220831
15735019
24509848
28863860
30919310
26929352
25514926
11574070
10820214
9412496
28802038
29906661
18287537
32770063
26687838
25186741
26745839
26814963
20703815
27083469
20461251
17016520
22677333
22964225
25670172
27302888
16030008
30172842
30563849",Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer's disease.,"Alzheimer's disease (AD) is a form of dementia characterized by amyloid-β plaques and tau neurofibrillary tangles that progressively disrupt neural circuits in the brain. The signaling networks underlying AD pathological changes are poorly characterized at the phosphoproteome level. Using mass spectrometry, we analyzed the proteome and tyrosine, serine and threonine phosphoproteomes of temporal cortex tissue from patients with AD and aged-matched controls. We identified cocorrelated peptide clusters that were linked to varying levels of phospho-tau, oligodendrocyte, astrocyte, microglia and neuron pathologies. We found that neuronal synaptic protein abundances were strongly anti-correlated with markers of microglial reactivity. We also observed that phosphorylation sites on kinases targeting tau and other new signaling factors were correlated with these peptide modules. Finally, we used data-driven statistical modeling to identify individual peptides and peptide clusters that were predictive of AD histopathologies. Together, these results build a map of pathology-associated phosphorylation signaling events occurring in AD.",[],Nature aging,2021-06-01,"[{'lastname': 'Morshed', 'firstname': 'Nader', 'initials': 'N', 'affiliation': 'Department of Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA.\nKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Lee', 'firstname': 'Meelim J', 'initials': 'MJ', 'affiliation': 'Department of Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Rodriguez', 'firstname': 'Felicia H', 'initials': 'FH', 'affiliation': 'Department of Chemical and Materials Engineering, New Mexico State University, Las Cruces, NM, USA.'}, {'lastname': 'Lauffenburger', 'firstname': 'Douglas A', 'initials': 'DA', 'affiliation': 'Department of Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Mastroeni', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'Arizona State University-Banner Neurodegenerative Disease Research Center, Tempe, AZ, USA.'}, {'lastname': 'White', 'firstname': 'Forest M', 'initials': 'FM', 'affiliation': 'Department of Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA. fwhite@mit.edu.\nKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. fwhite@mit.edu.\nCenter for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA. fwhite@mit.edu.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.","10.1038/s43587-021-00071-1
10.1038/nn.4018
10.1016/j.cell.2015.12.056
10.1016/j.cell.2019.09.001
10.1038/nrn2967
10.1074/jbc.M113.463984
10.1523/JNEUROSCI.19-17-07486.1999
10.1126/scisignal.aaf6209
10.1073/pnas.1805046115
10.1523/JNEUROSCI.3516-14.2015
10.1038/s41593-018-0080-x
10.1523/JNEUROSCI.0621-17.2017
10.1016/j.cell.2014.01.065
10.1038/nbt0302-301
10.1074/mcp.M500089-MCP200
10.1016/j.neuron.2019.12.015
10.15252/msb.20209819
10.1093/hmg/ddu475
10.1002/pmic.201400189
10.1016/j.nbd.2018.12.009
10.1038/s41591-020-0815-6
10.1038/sdata.2018.36
10.1038/s41467-019-09613-z
10.1016/j.jprot.2011.03.033
10.3233/JAD-150417
10.1038/s41586-019-1195-2
10.1038/s41588-019-0358-2
10.1016/S1474-4422(12)70291-0
10.1111/jnc.12195
10.1038/sj.cdd.4402033
10.1016/S0896-6273(00)81200-3
10.15252/embj.201899559
10.1128/MCB.06261-11
10.18632/oncotarget.7380
10.1038/45159
10.1016/j.nbd.2006.04.004
10.1046/j.1471-4159.1999.0722053.x
10.1186/s13041-015-0166-2
10.1021/bi992410+
10.1101/gad.290346.116
10.1007/s00216-009-2932-4
10.1038/ni.3268
10.1126/science.279.5352.870
10.1038/sj.onc.1208081
10.1007/s00018-011-0638-1
10.1002/1873-3468.12144
10.1111/j.1471-4159.2012.07650.x
10.1158/0008-5472.CAN-04-1949
10.1074/jbc.M113.541102
10.1016/j.jneuroim.2017.07.009
10.1007/s40268-019-0266-z
10.1073/pnas.1521288113
10.1093/nar/gku1267
10.1093/oxfordjournals.jbchem.a003013
10.1046/j.1471-4159.2000.0742520.x
10.1523/JNEUROSCI.18-01-00156.1998
10.1016/j.cell.2017.07.023
10.1016/j.neurobiolaging.2018.04.019
10.1091/mbc.e07-08-0802
10.1038/s41467-020-17405-z
10.1016/j.neuron.2015.11.013
10.1523/JNEUROSCI.1860-14.2014
10.1016/j.conb.2015.12.004
10.1038/nature16549
10.1007/s10561-010-9210-8
10.1007/s10561-016-9555-8
10.1039/c001196g
10.1039/c3ib40013a
10.1038/msb4100094
10.1016/j.semcdb.2012.05.008
10.1074/mcp.M112.019984
10.1158/0008-5472.CAN-14-2309
10.1074/mcp.M115.056911
10.1109/MCSE.2011.37
10.1109/MCSE.2007.55
10.1074/mcp.M500158-MCP200
10.1016/j.cels.2018.07.001
10.1074/mcp.TIR118.000943",<Element 'PubmedArticle' at 0x7f05deacde50>
62,34019997,THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency.,"The role played by microglia has taken the center of the stage in the etiology of Alzheimer's disease (AD). Several genome-wide association studies carried out on large cohorts of patients have indeed revealed a large number of genetic susceptibility factors corresponding to genes involved in neuroinflammation and expressed specifically by microglia in the brain. Among these genes TREM2, a cell surface receptor expressed by microglia, arouses strong interest because its R47H variant confers a risk of developing AD comparable to the ε4 allele of the APOE gene. Since this discovery, a growing number of studies have therefore examined the role played by TREM2 in the evolution of amyloid plaques and neurofibrillary tangles, the two brain lesions characteristic of AD. Many studies report conflicting results, reflecting the complex nature of microglial activation in AD. Here, we investigated the impact of TREM2 deficiency in the THY-Tau22 transgenic line, a well-characterized model of tauopathy. Our study reports an increase in the severity of tauopathy lesions in mice deficient in TREM2 occurring at an advanced stage of the pathology. This exacerbation of pathology was associated with a reduction in microglial activation indicated by typical morphological features and altered expression of specific markers. However, it was not accompanied by any further changes in memory performance. Our longitudinal study confirms that a defect in microglial TREM2 signaling leads to an increase in neuronal tauopathy occurring only at late stages of the disease.","['Animal model', 'Microglia', 'Tauopathy', 'Trem2']",Neurobiology of disease,2021-05-22,"[{'lastname': 'Vautheny', 'firstname': 'Audrey', 'initials': 'A', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Duwat', 'firstname': 'Charlotte', 'initials': 'C', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Aurégan', 'firstname': 'Gwennaëlle', 'initials': 'G', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Joséphine', 'firstname': 'Charlène', 'initials': 'C', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Hérard', 'firstname': 'Anne-Sophie', 'initials': 'AS', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Jan', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Mitja', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Gipchtein', 'firstname': 'Pauline', 'initials': 'P', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Gaillard', 'firstname': 'Marie-Claude', 'initials': 'MC', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Buée', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'University of Lille, Inserm, CHU Lille, U1172 LilNCog - Lille Neuroscience & Cognition, Lille, France; Alzheimer and Tauopathies, LabEx DISTALZ, France.'}, {'lastname': 'Blum', 'firstname': 'David', 'initials': 'D', 'affiliation': 'University of Lille, Inserm, CHU Lille, U1172 LilNCog - Lille Neuroscience & Cognition, Lille, France; Alzheimer and Tauopathies, LabEx DISTALZ, France.'}, {'lastname': 'Hantraye', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Bonvento', 'firstname': 'Gilles', 'initials': 'G', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Brouillet', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Cambon', 'firstname': 'Karine', 'initials': 'K', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.'}, {'lastname': 'Bemelmans', 'firstname': 'Alexis-Pierre', 'initials': 'AP', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France. Electronic address: alexis.bemelmans@cea.fr.'}]",,,,Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.nbd.2021.105398,<Element 'PubmedArticle' at 0x7f05dea8a310>
63,"33906678
30191777
26209472
25689443
23930978
18549522
32303136
31638084
29207027
23305876
32581723
23823143
31006066
32455781
29373564
15213811
27590897
11160123
29344292
29137980
16478649
32833280
27226561
28390192
29959397
24657939
6173426
8418845
1629216
8027086
6084591
2022338
10580137
12752430
8319774
32103922
11390481
12070075
19616076
9264263
21974805
27089335
29133191
19190323
30310317
32980351
32003113
24373698
14961764
15150087
16540661
32398681
31813797
3048398
12615069
7862663
11522829
12439750
14758076
8692888
30372548
28255782
25151395
29151590
26659872
25598354
29867350
30798442
20980634
25753426
28128358
30016630
22418727
19124760
29920290
18684969
22836271
28500071
19253007
18615637
31781126
29946038
20858960
30116300
33004513
27258416
25792098
30954437
22673112
30008660
31127200
32852752
30795916
32304438
25387690
28902142
28288987
23807898
30778105
31035637
27004748
31812510
32149158
32172066
31683865
32982368
20053377
32733573
28527044
31522366
32196999
27900991
20698585
30404656
24269728
23139902
30980848
25122523
31471077
31147178
17240289
31375685",Galectin-3: a key player in microglia-mediated neuroinflammation and Alzheimer's disease.,"Alzheimer's disease (AD) is the most common cause of dementia and is characterized by the deposition of extracellular aggregates of amyloid-β (Aβ), the formation of intraneuronal tau neurofibrillary tangles and microglial activation-mediated neuroinflammation. One of the key molecules involved in microglial activation is galectin-3 (Gal-3). In recent years, extensive studies have dissected the mechanisms by which Gal-3 modulates microglial activation, impacting Aβ deposition, in both animal models and human studies. In this review article, we focus on the emerging role of Gal-3 in biology and pathobiology, including its origin, its functions in regulating microglial activation and neuroinflammation, and its emergence as a biomarker in AD and other neurodegenerative diseases. These aspects are important to elucidate the involvement of Gal-3 in AD pathogenesis and may provide novel insights into the use of Gal-3 for AD diagnosis and therapy.","['Alzheimer’s disease', 'Amyloid-β', 'Galectin-3', 'Microglia', 'Neuroinflammation']",Cell & bioscience,2021-04-29,"[{'lastname': 'Tan', 'firstname': 'Yinyin', 'initials': 'Y', 'affiliation': 'Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.'}, {'lastname': 'Zheng', 'firstname': 'Yanqun', 'initials': 'Y', 'affiliation': 'Department of Neurology, The Dongshan Hospital of Linyi, Linyi, 276017, Shandong, China.'}, {'lastname': 'Xu', 'firstname': 'Daiwen', 'initials': 'D', 'affiliation': 'Department of Neurology, The People Hospital of Huaiyin Jinan, Jinan, 250021, Shandong, China.'}, {'lastname': 'Sun', 'firstname': 'Zhanfang', 'initials': 'Z', 'affiliation': 'Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.'}, {'lastname': 'Yang', 'firstname': 'Huan', 'initials': 'H', 'affiliation': 'Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.'}, {'lastname': 'Yin', 'firstname': 'Qingqing', 'initials': 'Q', 'affiliation': 'Department of Geriatric Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. yinyunqing11@126.com.'}]",,,,,"10.1186/s13578-021-00592-7
10.2174/0929867323666161213101126
10.1016/j.pneurobio.2015.07.003
10.1038/ni.3102
10.3109/00207454.2013.833510
10.1017/S1462399408000719
10.1080/14737175.2020.1750955
10.4103/1673-5374.266910
10.1016/j.acthis.2012.11.010
10.3389/fncel.2020.00162
10.1177/1533317513495107
10.1007/s00401-019-02013-z
10.3390/biom10050798
10.3390/ijms19020379
10.1007/s12565-016-0366-6
10.1074/jbc.M002523200
10.7150/thno.22196
10.1016/j.bbrc.2017.11.078
10.1016/j.bbagen.2005.12.020
10.1096/fj.202000970RR
10.1074/jbc.M116.715748
10.1002/jcb.26043
10.1038/s41598-018-28235-x
10.1016/j.semcancer.2014.03.004
10.1021/bi00052a033
10.1016/S0021-9258(19)49693-2
10.1016/S0021-9258(17)32441-9
10.1002/j.1460-2075.1984.tb02244.x
10.1016/0378-1119(91)90139-3
10.1016/S0304-4165(99)00177-4
10.1046/j.1432-1033.2003.03577.x
10.1006/excr.1993.1157
10.2147/CIA.S240400
10.4049/jimmunol.166.12.7309
10.1093/glycob/12.5.329
10.1016/j.bbagen.2009.07.005
10.1002/(SICI)1097-0177(199708)209:4<399::AID-AJA7>3.0.CO;2-D
10.1016/j.canlet.2011.09.003
10.3390/ijms17040565
10.1016/j.drudis.2017.11.004
10.1158/0008-5472.CAN-08-4153
10.2147/CMAR.S171146
10.1016/j.abb.2020.108602
10.1002/jbt.22463
10.1016/j.biopha.2013.10.011
10.1042/bj20031300
10.1158/0008-5472.CAN-04-0336
10.1158/0008-5472.CAN-05-3750
10.1038/s41419-020-2556-3
10.1016/j.devcel.2019.10.025
10.1021/bi00414a057
10.1016/S0006-291X(03)00151-7
10.1073/pnas.92.4.1213
10.1093/nar/29.17.3595
10.1038/sj.onc.1205820
10.1023/B:GLYC.0000014082.99675.2f
10.1073/pnas.93.13.6737
10.1111/1440-1681.13048
10.1007/s10735-017-9712-9
10.1007/978-1-4939-1154-7_24
10.1038/nri.2017.125
10.1007/s12035-015-9593-4
10.1007/s12035-014-9070-5
10.3389/fnmol.2018.00158
10.1007/s12035-019-1527-0
10.4049/jimmunol.1000154
10.1016/j.celrep.2015.02.012
10.1038/srep41689
10.1016/j.brainres.2018.07.018
10.1007/s12026-012-8286-6
10.4049/jimmunol.182.2.1167
10.1016/j.neuint.2018.06.007
10.4049/jimmunol.181.4.2781
10.1523/JNEUROSCI.1498-12.2012
10.4049/jimmunol.1502532
10.1007/s12031-009-9186-7
10.1002/glia.20713
10.3389/fimmu.2019.02647
10.1523/JNEUROSCI.3575-17.2018
10.3233/JAD-2010-100975
10.1177/1756286418791107
10.1126/science.abb8587
10.3233/JAD-160083
10.1016/S1474-4422(15)70016-5
10.1016/j.clinbiochem.2019.04.001
10.1016/j.neurobiolaging.2012.05.001
10.3389/fnins.2018.00430
10.1038/s41418-019-0348-z
10.1016/j.npep.2019.02.001
10.1097/WCO.0000000000000812
10.3390/ijms18091965
10.1161/CIRCHEARTFAILURE.116.003804
10.1007/s12975-012-0216-3
10.1038/s41598-019-38497-8
10.3390/antiox8050112
10.1111/odi.12479
10.1053/j.gastro.2019.11.296
10.1155/2020/5284728
10.1016/j.biopha.2020.110071
10.3390/nu11112619
10.2147/JIR.S273858
10.1016/j.nbd.2009.12.024
10.1155/2020/8878412
10.1007/s00401-017-1722-x
10.1007/s42000-019-00128-2
10.1111/jdi.13256
10.4103/0366-6999.194656
10.1021/pr100409r
10.1186/s13024-018-0292-2
10.1016/j.nbd.2013.11.009
10.1002/brb3.75
10.1016/j.lfs.2019.03.057
10.1038/nprot.2014.143
10.1016/j.jocn.2019.08.032
10.1016/j.clineuro.2019.105373
10.1016/S0140-6736(07)60111-1
10.1038/s41467-019-11441-0",<Element 'PubmedArticle' at 0x7f05dea9b770>
64,33895629,Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat model.,"Alzheimer's disease (AD) is a neurodegenerative condition affecting memory performance. This pathology is characterized by intracerebral amyloid plaques and tau tangles coupled with neuroinflammation. During the last century, numerous therapeutic trials unfortunately failed highlighting the need to find new therapeutic approaches. Low-dose brain radiotherapy (LD-RT) showed efficacy to reduce amyloid load and inflammation in patients with peripheral diseases. In this study, the therapeutic potential of 2 LD-RT schedules was tested on the TgF344-AD rat model of AD. Fifteen-month-old rats were irradiated with 5 fractions of 2 Gy delivered either daily or weekly. The daily treatment induced an improvement of memory performance in the Y-maze. In contrast, the weekly treatment increased the microglial reactivity in the hippocampus. A lack of effect of both regimens on amyloid pathology was unexpectedly observed. The positive effect on cognition encourages to further evaluate the LD-RT therapeutic potential and highlights the impact of the design choice of the LD-RT regimen.","[""Alzheimer's disease"", 'Amyloid', 'Low-dose', 'Neuroinflammation', 'Radiotherapy']",Neurobiology of aging,2021-04-26,"[{'lastname': 'Ceyzériat', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': 'Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland; Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospitals, and NimtLab, Faculty of Medicine, Geneva University, Geneva, Switzerland; Division of Radiation Oncology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland.'}, {'lastname': 'Zilli', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Division of Radiation Oncology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland.'}, {'lastname': 'Fall', 'firstname': 'Aïda B', 'initials': 'AB', 'affiliation': 'Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.'}, {'lastname': 'Millet', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland.'}, {'lastname': 'Koutsouvelis', 'firstname': 'Nikolaos', 'initials': 'N', 'affiliation': 'Division of Radiation Oncology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.'}, {'lastname': 'Dipasquale', 'firstname': 'Giovanna', 'initials': 'G', 'affiliation': 'Division of Radiation Oncology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni B', 'initials': 'GB', 'affiliation': 'Memory Center, Geneva University Hospitals, and LANVIE, Faculty of Medicine, Geneva University, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Tournier', 'firstname': 'Benjamin B', 'initials': 'BB', 'affiliation': 'Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland.'}, {'lastname': 'Garibotto', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospitals, and NimtLab, Faculty of Medicine, Geneva University, Geneva, Switzerland. Electronic address: valentina.garibotto@hcuge.ch.'}]",,,,Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2021.03.008,<Element 'PubmedArticle' at 0x7f05dea62130>
65,"33563332
27025652
29200205
30599077
31273083
26007212
24217510
7566337
27916654
22365536
24574966
24825318
22476197
30072954
21297276
24899525
28954880
26890736
22458300
28190681
27174003
22425595
22925597
30219731
21098287
26858121
24531916
24918340
27457264
31235932
31975051
32535554
20376313
24493463
17478722
24440055
21421841
20802182
25853174
28500862
23747045
22365544
22312444
15058484
16125396
23026200
21813771
29253574
15831717
22418067
17965659
25630253
30227881
26638867
25598354
32473247
30578282
28282924
25025689
21623793
20012266
20178983
19237574
26967226",Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.,"The neuropathological hallmarks of Alzheimer's disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). The amyloid cascade theory is the leading hypothesis of AD pathology. Aβ deposition precedes the aggregation of tau pathology and Aβ pathology precipitates tau pathology. Evidence also indicates the reciprocal interactions between amyloid and tau pathology. However, the detailed relationship between amyloid and tau pathology in AD remains elusive. Metformin might have a positive effect on cognitive impairments. However, whether metformin can reduce AD-related pathologies is still unconclusive.
Brain extracts containing tau aggregates were unilaterally injected into the hippocampus and the overlying cerebral cortex of 9-month-old APPswe/PS1DE9 (APP/PS1) mice and age-matched wild-type (WT) mice. Metformin was administrated in the drinking water for 2 months. Aβ pathology, tau pathology, plaque-associated microgliosis, and autophagy marker were analyzed by immunohistochemical staining and immunofluorescence analysis 2 months after injection of proteopathic tau seeds. The effects of metformin on both pathologies were explored.
We observed tau aggregates in dystrophic neurites surrounding Aβ plaques (NP tau) in the bilateral hippocampi and cortices of tau-injected APP/PS1 mice but not WT mice. Aβ plaques promoted the aggregation of NP tau pathology. Injection of proteopathic tau seeds exacerbated Aβ deposits and decreased the number of microglia around Aβ plaques in the hippocampus and cortex of APP/PS1 mice. Metformin ameliorated the microglial autophagy impairment, increased the number of microglia around Aβ plaques, promoted the phagocytosis of NP tau, and reduced Aβ load and NP tau pathology in APP/PS1 mice.
These findings indicate the existence of the crosstalk between amyloid and NP tau pathology. Metformin promoted the phagocytosis of pathological Aβ and tau proteins by enhancing microglial autophagy capability. It reduced Aβ deposits and limited the spreading of NP tau pathology in APP/PS1 mice, which exerts a beneficial effect on both pathologies.","['Alzheimer’ disease', 'Aβ pathology', 'Metformin', 'Microglia', 'Spread', 'Tau pathology']",Alzheimer's research & therapy,2021-02-11,"[{'lastname': 'Chen', 'firstname': 'Yanxing', 'initials': 'Y', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Zhao', 'firstname': 'Shuai', 'initials': 'S', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Fan', 'firstname': 'Ziqi', 'initials': 'Z', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Zheyu', 'initials': 'Z', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Zhu', 'firstname': 'Yueli', 'initials': 'Y', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.\nDepartment of Geriatrics, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Shen', 'firstname': 'Ting', 'initials': 'T', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Kaicheng', 'initials': 'K', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Yan', 'firstname': 'Yaping', 'initials': 'Y', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Tian', 'firstname': 'Jun', 'initials': 'J', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Liu', 'firstname': 'Zhirong', 'initials': 'Z', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Baorong', 'initials': 'B', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China. brzhang@zju.edu.cn.""}]",,"These findings indicate the existence of the crosstalk between amyloid and NP tau pathology. Metformin promoted the phagocytosis of pathological Aβ and tau proteins by enhancing microglial autophagy capability. It reduced Aβ deposits and limited the spreading of NP tau pathology in APP/PS1 mice, which exerts a beneficial effect on both pathologies.","We observed tau aggregates in dystrophic neurites surrounding Aβ plaques (NP tau) in the bilateral hippocampi and cortices of tau-injected APP/PS1 mice but not WT mice. Aβ plaques promoted the aggregation of NP tau pathology. Injection of proteopathic tau seeds exacerbated Aβ deposits and decreased the number of microglia around Aβ plaques in the hippocampus and cortex of APP/PS1 mice. Metformin ameliorated the microglial autophagy impairment, increased the number of microglia around Aβ plaques, promoted the phagocytosis of NP tau, and reduced Aβ load and NP tau pathology in APP/PS1 mice.",,"10.1186/s13195-020-00761-9
10.15252/emmm.201606210
10.1038/nm.4443
10.1007/s00401-018-1953-5
10.1074/jbc.RA119.009487
10.1038/nn.4017
10.1038/nrneurol.2013.223
10.1016/0197-4580(95)00021-6
10.1016/j.pharmthera.2016.11.010
10.1016/j.neuron.2012.02.006
10.3389/fncel.2014.00022
10.1016/j.nbd.2014.05.001
10.1172/JCI59903
10.3389/fendo.2018.00400
10.3233/JAD-2011-101524
10.1093/gerona/glu073
10.1212/WNL.0000000000004586
10.3233/JAD-150493
10.1111/j.1532-5415.2012.03916.x
10.1016/j.jdiacomp.2017.01.013
10.1016/j.brainres.2016.05.013
10.1016/j.pbb.2012.03.002
10.1016/j.lfs.2012.08.017
10.1016/j.expneurol.2018.09.008
10.1073/pnas.0912793107
10.1186/s13024-016-0082-7
10.1007/s00401-014-1254-6
10.1016/j.expneurol.2014.06.004
10.1111/acel.12498
10.1038/s41593-019-0433-0
10.1007/s11357-020-00161-9
10.18632/aging.103305
10.1371/journal.pone.0009979
10.1001/jamaneurol.2013.5847
10.1126/science.1141736
10.1016/j.nbd.2014.01.007
10.1073/pnas.1017033108
10.2353/ajpath.2010.100346
10.1186/s40478-015-0199-x
10.1016/j.ajpath.2017.03.011
10.1016/j.neurobiolaging.2013.05.003
10.1016/j.neuron.2011.11.033
10.1371/journal.pone.0031302
10.1002/hipo.10167
10.1016/j.nbd.2005.05.027
10.1016/j.ajpath.2012.08.012
10.4049/jimmunol.1100216
10.1016/j.bbi.2017.12.009
10.1126/science.1110647
10.1017/S1740925X12000038
10.1038/nn1997
10.1038/ncomms7176
10.1186/s12974-018-1309-z
10.3233/JAD-150704
10.1007/s12035-014-9070-5
10.1016/j.lfs.2020.117861
10.1083/jcb.201810099
10.3390/ijms18030598
10.1371/journal.pone.0102420
10.1111/j.1471-4159.2011.07331.x
10.1007/s00210-009-0477-x
10.1074/jbc.M110.100420
10.1073/pnas.0807991106
10.3233/JAD-151200",<Element 'PubmedArticle' at 0x7f05dea6bc70>
66,"33536876
32092298
28765513
23788612
22850316
28564651
7644037
22531427
29053874
29671419
21402058
29358399
21532579
29298435
30833695
31507408
23446889
21909359
17168643
18953056
10526957
21170538
31495298
22086139
24796856
18774188
20946471
28391400
28836062
19297138
30033062
18045930
25307057
22323736
30742116
11705631
31203725
7984357
8103579
29213627
12175481
19275634
22571615
23217740
19370387
26888634
12871590
24625061
23065792
27683451
22920254
32029735
16696577
20885394
11311463
29985474
23946647
18325636
15758166
19478233
32125005
23332358
10323857
28062555
15883316
30629191
23478306
31083442
31827267
23623698
26136682
29131981
28757617
24670647
29196460
1566067
30597624
19164591
29574591
18048770
31543810
20541661
15817521
22710914
21159946
31787864
21460840
18640458
17916337
23827227
28668375
22615835
10195200
22896675
24227727
27327500
23332364
24351529
22044867
28401931
29440986
28741167
27729011
26068894
22449478
28135240
9861040
32062666
24659966
10220456
19228947
20472896
21784149
32865691
24218661
23163235
25204284
22747753
15265268
18667150
30820047
26448331
31894103
24424381
25688079
28350801
30127389
24656052
30647119
11520987
31305237
28876960
28753206
31190145
29416015
27425620
10908610
17485668
31637009
25537011
31920472
19836631
30634016
10867223
30046080
32818618
20205644
21148344
18305170
28151041
9329678
32376954
29400711
30540774
19829367
23041958
21460841
30643288
28343848
11129782
11848685
31221773
26558786
23084084
25956993
27227831
15265595
14746921
15302999
29950669
28515043
25351853
16936277
32493753
27234656
24326519
2140065
12662319
29107626
26236233
24622517
31959516
23792494
26385017
9884387
30890171
23028132
28768718
30842086
2669844
32147113
10408445
30298180
28196095
16821113
21900936
31395769
27025652
19523516
27582220
31637161
31072403
20838242
10534240
27940601
32130931
29019677
31425794
29053753
29388925
27974666
25368028
30280653
24071439
27613724
26195256
18359131
11895043
18369648
31888974
19945109
16195368
29542681
32468646
14745459
12598159
18957478
27176461
15937198
29293211
15362715
31303538
32197217
27421879
26207229
15509618
19234858
18363936
15588287
26526066
12930788
11001067
24623839
32251378
30900389
30541012
15808355
31395777",Microvascular Alterations in Alzheimer's Disease.,"Alzheimer's disease (AD) is a neurodegenerative disorder associated with continual decline in cognition and ability to perform routine functions such as remembering familiar places or understanding speech. For decades, amyloid beta (Aβ) was viewed as the driver of AD, triggering neurodegenerative processes such as inflammation and formation of neurofibrillary tangles (NFTs). This approach has not yielded therapeutics that cure the disease or significant improvements in long-term cognition through removal of plaques and Aβ oligomers. Some researchers propose alternate mechanisms that drive AD or act in conjunction with amyloid to promote neurodegeneration. This review summarizes the status of AD research and examines research directions including and beyond Aβ, such as tau, inflammation, and protein clearance mechanisms. The effect of aging on microvasculature is highlighted, including its contribution to reduced blood flow that impairs cognition. Microvascular alterations observed in AD are outlined, emphasizing imaging studies of capillary malfunction. The review concludes with a discussion of two therapies to protect tissue without directly targeting Aβ for removal: (1) administration of growth factors to promote vascular recovery in AD; (2) inhibiting activity of a calcium-permeable ion channels to reduce microglial activation and restore cerebral vascular function.","[""Alzheimer's disease"", 'TRPM2', 'amyloid hypotheses', 'angiogeneis', 'growth factors', 'imaging', 'microvasculature', 'vasculature']",Frontiers in cellular neuroscience,2021-02-05,"[{'lastname': 'Steinman', 'firstname': 'Joe', 'initials': 'J', 'affiliation': 'Department of Physiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Sun', 'firstname': 'Hong-Shuo', 'initials': 'HS', 'affiliation': 'Department of Physiology, University of Toronto, Toronto, ON, Canada.\nDepartment of Surgery, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Feng', 'firstname': 'Zhong-Ping', 'initials': 'ZP', 'affiliation': 'Department of Physiology, University of Toronto, Toronto, ON, Canada.'}]",,,,"Copyright © 2021 Steinman, Sun and Feng.","10.3389/fncel.2020.618986
10.1016/j.expneurol.2020.113257
10.1126/scisignal.aal4161
10.1152/ajpgi.00127.2013
10.3233/JAD-2012-120067
10.1159/000477402
10.1212/WNL.45.8.1441
10.3233/JAD-2012-120292
10.1093/brain/awx243
10.1038/aps.2018.31
10.1016/j.brainres.2011.03.016
10.1073/pnas.1710329115
10.1038/nn.2801
10.1016/j.celrep.2017.12.016
10.1038/s41582-019-0158-4
10.3389/fphar.2019.00840
10.1038/srep01354
10.1371/journal.pone.0023789
10.2174/156720506779025242
10.1093/brain/awn261
10.1007/s00401-010-0789-4
10.1177/0271678X19873658
10.1007/s00702-011-0731-5
10.1089/brain.2014.0236
10.1016/j.tins.2008.07.003
10.1111/j.1365-2990.2010.01139.x
10.1007/s00429-017-1409-z
10.1007/s11064-017-2391-9
10.1016/j.etp.2009.02.117
10.1016/S1474-4422(18)30232-1
10.1523/JNEUROSCI.2718-07.2007
10.1038/nature13800
10.1126/science.1217697
10.1038/s41593-018-0329-4
10.1016/S0197-4580(01)00245-7
10.1161/HYPERTENSIONAHA.119.12892
10.1016/0149-7634(94)90052-3
10.1080/01616412.1993.11740127
10.1590/S1980-57642009DN30300003
10.1016/S0531-5565(02)00018-9
10.2174/187152709787601867
10.4155/fmc.12.51
10.1016/j.neuron.2012.10.029
10.1007/s00702-009-0226-9
10.1038/srep20833
10.1046/j.1471-4159.2003.01885.x
10.1186/1742-2094-11-48
10.1093/brain/aws243
10.1177/0271678X16669514
10.1016/j.neuron.2012.06.026
10.1038/s41419-020-2288-4
10.2165/00023210-200620050-00002
10.1038/nrd3288
10.1016/S0301-0082(00)00068-X
10.1038/s41582-018-0032-9
10.2147/CIA.S39959
10.1016/j.neurobiolaging.2008.01.012
10.1523/JNEUROSCI.4998-04.2005
10.1161/STROKEAHA.108.528091
10.1002/ddr.21652
10.1016/S1474-4422(12)70305-8
10.1101/gad.13.9.1055
10.1101/cshperspect.a024331
10.1212/01.WNL.0000159740.16984.3C
10.1093/jnen/nly125
10.3233/JAD-122011
10.3390/jcm8050651
10.1038/s41582-019-0281-2
10.1016/j.neuron.2013.04.014
10.3389/fnagi.2015.00115
10.1016/j.neurobiolaging.2017.10.006
10.1038/leu.2017.245
10.1038/nature13165
10.1083/jcb.201709069
10.1126/science.1566067
10.1002/ana.25406
10.1073/pnas.0805453106
10.1007/s00401-018-1834-y
10.1161/CIRCRESAHA.107.160176
10.3389/fnagi.2019.00233
10.1016/S0079-6123(10)82003-5
10.1093/brain/awh452
10.3233/JAD-2012-129025
10.1523/JNEUROSCI.4521-10.2010
10.3389/fnins.2019.01154
10.1038/ng.803
10.1016/S0140-6736(08)61075-2
10.1016/j.brainres.2007.08.063
10.1016/j.neulet.2013.06.031
10.1016/j.expneurol.2017.06.023
10.1371/journal.pone.0036893
10.1038/5715
10.1126/scitranslmed.3003748
10.1523/JNEUROSCI.1592-13.2013
10.1038/ncomms11934
10.1016/S1474-4422(12)70291-0
10.1186/alzrt230
10.1038/jcbfm.2011.153
10.1038/srep46427
10.3389/fnins.2018.00025
10.1007/s10456-017-9568-3
10.1186/s12877-016-0342-y
10.1038/nprot.2015.065
10.1016/j.pnpbp.2012.02.010
10.1038/nn.4489
10.1073/pnas.95.26.15741
10.1159/000505625
10.3389/fnagi.2014.00032
10.1073/pnas.96.9.5274
10.1073/pnas.0811698106
10.2353/ajpath.2010.090750
10.1016/j.bbadis.2011.07.004
10.4247/AM.2010.ABA005
10.1007/s00401-020-02215-w
10.1038/503031a
10.1111/nan.12003
10.1002/ana.24271
10.1186/1742-2094-9-151
10.1179/016164104225016281
10.1016/j.neuron.2008.06.008
10.1038/s41588-019-0358-2
10.1371/journal.pone.0139574
10.1126/scitranslmed.aau5732
10.1038/jcbfm.2013.241
10.1093/brain/awv023
10.1371/journal.pmed.1002270
10.1038/s41577-018-0056-9
10.1186/1471-2318-14-36
10.1084/jem.20181035
10.1126/science.1058189
10.7554/eLife.42299
10.1080/19336950.2017.1376982
10.1038/cdd.2017.118
10.1007/s12035-019-01656-z
10.1038/s41419-018-0270-1
10.1016/j.celrep.2016.06.060
10.1523/JNEUROSCI.20-15-05709.2000
10.1073/pnas.0701250104
10.1038/s41392-019-0063-8
10.3233/JAD-141959
10.3389/fnins.2019.01261
10.1016/j.archger.2009.09.027
10.1016/j.brainresbull.2019.01.004
10.1016/S0197-4580(00)00123-8
10.1038/d41586-018-05719-4
10.1016/j.neuroimage.2020.117269
10.2174/187152710791012071
10.1126/science.1197623
10.1073/pnas.0709788105
10.1177/0271678X17690761
10.1111/j.1749-6632.1997.tb48458.x
10.1038/s41586-020-2247-3
10.1038/nm.4482
10.1371/journal.pone.0207885
10.1038/461895a
10.1097/WCO.0b013e32835a30f4
10.1038/ng.801
10.1038/s41591-018-0297-y
10.1016/j.jalz.2017.02.007
10.1097/00004647-200012000-00005
10.1006/nbdi.2001.0460
10.1126/science.aav9518
10.1523/JNEUROSCI.4081-14.2015
10.1016/j.neurobiolaging.2012.09.011
10.1007/s11910-015-0557-x
10.1371/journal.pone.0155733
10.1016/j.neulet.2004.05.017
10.1016/j.brainres.2003.11.061
10.1023/B:AGEN.0000037335.17717.bf
10.1038/s41593-018-0175-4
10.1161/CIRCRESAHA.117.311054
10.1038/ncomms6318
10.2353/ajpath.2006.060269
10.1073/pnas.2008940117
10.1016/j.nbd.2016.05.015
10.3233/JAD-131544
10.1016/0006-8993(90)91111-S
10.1046/j.1365-2990.2003.00424.x
10.1016/j.neuropharm.2017.10.034
10.3389/fnagi.2015.00136
10.1371/journal.pone.0089095
10.1016/j.molmed.2019.11.008
10.1038/srep02053
10.1016/j.nrleng.2015.07.008
10.1161/01.CIR.99.1.111
10.1186/s12916-019-1299-4
10.1101/cshperspect.a011452
10.15252/embj.201797397
10.1136/bmj.l665
10.3109/07853898909149194
10.1016/j.it.2020.02.002
10.1038/22124
10.14283/jpad.2018.34
10.1371/journal.pcbi.1005392
10.1007/s10456-006-9030-4
10.1038/nm.2460
10.1126/science.aay5188
10.15252/emmm.201606210
10.1016/j.nbd.2009.05.025
10.1038/nature19323
10.1002/advs.201900962
10.1186/s12929-019-0524-y
10.1097/NEN.0b013e3181f46e25
10.1212/WNL.53.7.1391
10.1101/cshperspect.a024075
10.1016/j.jacc.2019.12.033
10.1021/acs.jnatprod.7b00515
10.1016/j.neuroimage.2019.116101
10.1371/journal.pone.0186676
10.1172/JCI97509
10.1126/scitranslmed.aag1767
10.1161/HYPERTENSIONAHA.114.03617
10.1152/physrev.00050.2017
10.1016/j.bbadis.2013.09.010
10.1007/s11357-016-9931-0
10.1038/nrneurol.2015.119
10.1016/j.neurobiolaging.2008.01.017
10.1093/jnen/61.3.282
10.1007/s00401-008-0366-2
10.1212/WNL.0000000000008838
10.1016/j.atherosclerosis.2009.10.040
10.1096/fj.04-3620rev
10.1038/aps.2017.194
10.1002/ana.25775
10.1080/mic.10.6.463.470
10.1016/S0140-6736(03)12521-4
10.1177/0269881108097630
10.1186/s13195-016-0189-7
10.1136/pgmj.2004.028290
10.1038/nature25158
10.1097/01.WCB.0000126564.89011.11
10.1016/j.tics.2019.06.004
10.1016/j.conb.2020.02.003
10.1016/j.expneurol.2016.07.006
10.3978/j.issn.2305-5839.2015.03.49
10.1093/brain/awh325
10.1007/s00401-009-0498-z
10.1111/j.1750-3639.2008.00133.x
10.1186/1742-2094-1-24
10.1186/s13024-015-0056-1
10.1523/JNEUROSCI.23-20-07504.2003
10.1038/35025215
10.1212/WNL.0000000000000285
10.1038/s41380-020-0721-9
10.1002/brb3.1268
10.1159/000492596
10.1016/j.tins.2005.02.001
10.1126/science.aay0198",<Element 'PubmedArticle' at 0x7f05dea1d400>
67,"33505871
30738892
31062335
31009755
32016606
31518519
24162652
24860431
25100587
17870248
25991443
26821015
24904276
25598354
26129625
23562658
24900687
23889535
27824163
30260294
28493698
19571253
19840952
32323731
26656484
24706865
31924119
19214751
22025910
22072675
16732273
20864679
28810892
25596843
25596843
30245615
21951685
9177350
9024663
12125082
25161610
10805752
18095157
21771791
19443728
9724801
22536384
10415068
10674423
28701948
17548644
11495925
21946268
17467666
12476352
23077045
17467666
20920788
21527754
23855980
20305648
9435482
20143170
31031598
17086106
19321774
14715932
30209761
30463629
30406177
19299738
31031598
12551918",Modulation of microglia activation and Alzheimer's disease: CX3 chemokine ligand 1/CX3CR and P2X,"Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive deficits. Two hallmarks of AD that cause chronic inflammation and lead to neuronal dysfunction and damage are tau tangles and amyloid plaques. Microglial cells, the primary immune cells of the central nervous system, maintain a homeostatic active/inactive state via a bidirectional, dynamic communication with neurons. Several studies have revealed that dysregulated microglial activation leads to AD pathology. Therefore, we reviewed the relationship between AD and two important signaling complexes, CX3 chemokine ligand 1 (CX3CL1)/CX3CR1 and ATP/P2X","[""Alzheimer's disease"", 'CX3 chemokine ligand 1/CX3CR1', 'Microglia', 'P2X7R']",Tzu chi medical journal,2021-01-29,"[{'lastname': 'Suresh', 'firstname': 'Pavithra', 'initials': 'P', 'affiliation': 'Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.'}, {'lastname': 'Phasuk', 'firstname': 'Sarayut', 'initials': 'S', 'affiliation': 'Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.'}, {'lastname': 'Liu', 'firstname': 'Ingrid Y', 'initials': 'IY', 'affiliation': 'Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.'}]",,,,Copyright: © 2021 Tzu Chi Medical Journal.,10.4103/tcmj.tcmj_144_20,<Element 'PubmedArticle' at 0x7f05dda1ad10>
68,"33461764
24663666
32903682
29499358
24567336
25891762
25891762
29253717
27570871
16135089
29685286
28197095
29482610
28912710
20831921
32466767
16472763
12847223
30200996
9846975
15637304
32096039
23314916
32172302
23150934
29196460
32009907
19302484
25146963
7478261
30980923
25047746
23150908
25716838
24990881
23577177
22737039
20375612
29663649
31134514
20880500
20205644
26129625
31902528
21718498
8922409
31273114
31958095
28855300
22229116
22388478
23301011
26941262
17425404
15728241
10648802
24892271
28802038
28426958
31028072
30725482
33081801
31959733
12843410
23197723
31649511
21422525
18097445
29518356
29518356
26261518
32401783","TREM2 alters the phagocytic, apoptotic and inflammatory response to Aβ","Alzheimer's disease (AD) is characterized by the accumulation in the brain of extracellular amyloid β (Aβ) plaques as well as intraneuronal inclusions (neurofibrillary tangles) consisting of total tau and phosphorylated tau. Also present are dystrophic neurites, loss of synapses, neuronal death, and gliosis. AD genetic studies have highlighted the importance of inflammation in this disease by identifying several risk associated immune response genes, including TREM2. TREM2 has been strongly implicated in basic microglia function including, phagocytosis, apoptosis, and the inflammatory response to Aβ in mouse brain and primary cells. These studies show that microglia are key players in the response to Aβ and in the accumulation of AD pathology. However, details are still missing about which apoptotic or inflammatory factors rely on TREM2 in their response to Aβ, especially in human cell lines. Given these previous findings our hypothesis is that TREM2 influences the response to Aβ toxicity by enhancing phagocytosis and inhibiting both the BCL-2 family of apoptotic proteins and pro-inflammatory cytokines. Aβ","['Apoptosis', 'Aβ', 'Inflammatory factors', 'Microglia', 'Phagocytosis', 'TREM2']",Molecular immunology,2021-01-20,"[{'lastname': 'Akhter', 'firstname': 'Rumana', 'initials': 'R', 'affiliation': 'Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.'}, {'lastname': 'Shao', 'firstname': 'Yvonne', 'initials': 'Y', 'affiliation': 'Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.'}, {'lastname': 'Formica', 'firstname': 'Shane', 'initials': 'S', 'affiliation': 'Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.'}, {'lastname': 'Khrestian', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.'}, {'lastname': 'Bekris', 'firstname': 'Lynn M', 'initials': 'LM', 'affiliation': 'Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: bekrisl@ccf.org.'}]",,,,Copyright © 2021 Elsevier Ltd. All rights reserved.,10.1016/j.molimm.2020.12.035,<Element 'PubmedArticle' at 0x7f05dd9c0220>
69,33459716,Learning Deficits Accompanied by Microglial Proliferation After the Long-Term Post-Injection of Alzheimer's Disease Brain Extract in Mouse Brains.,"Human tauopathy brain injections into the mouse brain induce the development of tau aggregates, which spread to functionally connected brain regions; however, the features of this neurotoxicity remain unclear. One reason may be short observational periods because previous studies mostly used mutated-tau transgenic mice and needed to complete the study before these mice developed neurofibrillary tangles.
To examine whether long-term incubation of Alzheimer's disease (AD) brain in the mouse brain cause functional decline.
We herein used Tg601 mice, which overexpress wild-type human tau, and non-transgenic littermates (NTg) and injected an insoluble fraction of the AD brain into the unilateral hippocampus.
After a long-term (17-19 months) post-injection, mice exhibited learning deficits detected by the Barnes maze test. Aggregated tau pathology in the bilateral hippocampus was more prominent in Tg601 mice than in NTg mice. No significant changes were observed in the number of Neu-N positive cells or astrocytes in the hippocampus, whereas that of Iba-I-positive microglia increased after the AD brain injection.
These results potentially implicate tau propagation in functional decline and indicate that long-term changes in non-mutated tau mice may reflect human pathological conditions.","['Microglia', 'neurodegeneration', 'propagation', 'tau protein', 'tauopathies']",Journal of Alzheimer's disease : JAD,2021-01-19,"[{'lastname': 'Hayashi', 'firstname': 'Tetsuo', 'initials': 'T', 'affiliation': 'Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.'}, {'lastname': 'Shimonaka', 'firstname': 'Shotaro', 'initials': 'S', 'affiliation': 'Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University School of Medicine, Tokyo, Japan.\nResearch Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'lastname': 'Elahi', 'firstname': 'Montasir', 'initials': 'M', 'affiliation': 'Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.\nDepartment of Diagnosis, Prevention and Treatment of Dementia, Juntendo University School of Medicine, Tokyo, Japan.'}, {'lastname': 'Matsumoto', 'firstname': 'Shin-Ei', 'initials': 'SE', 'affiliation': 'Department of Immunology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.'}, {'lastname': 'Ishiguro', 'firstname': 'Koichi', 'initials': 'K', 'affiliation': 'Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.'}, {'lastname': 'Takanashi', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': 'Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.'}, {'lastname': 'Hattori', 'firstname': 'Nobutaka', 'initials': 'N', 'affiliation': 'Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.\nDepartment of Diagnosis, Prevention and Treatment of Dementia, Juntendo University School of Medicine, Tokyo, Japan.'}, {'lastname': 'Motoi', 'firstname': 'Yumiko', 'initials': 'Y', 'affiliation': 'Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.\nDepartment of Diagnosis, Prevention and Treatment of Dementia, Juntendo University School of Medicine, Tokyo, Japan.'}]",,These results potentially implicate tau propagation in functional decline and indicate that long-term changes in non-mutated tau mice may reflect human pathological conditions.,"After a long-term (17-19 months) post-injection, mice exhibited learning deficits detected by the Barnes maze test. Aggregated tau pathology in the bilateral hippocampus was more prominent in Tg601 mice than in NTg mice. No significant changes were observed in the number of Neu-N positive cells or astrocytes in the hippocampus, whereas that of Iba-I-positive microglia increased after the AD brain injection.",,10.3233/JAD-201002,<Element 'PubmedArticle' at 0x7f05dd972630>
70,"33446720
29027541
27025652
10932182
11520930
30204256
22464953
17021169
19781645
18055549
16125396
12895417
11520987
23747045
24604080
24076100
27748574
14643377
28025715
30483077
28111080
30296688
30733674
32679907
30406177
29895964
28768718
27373369
10912917
14507668
27239489
1566067
3670729
9100668
27404378
23316765
20619937
31426329",Spatial memory deficiency early in 6xTg Alzheimer's disease mouse model.,"Alzheimer's disease (AD) is mainly characterized by the deposition of extracellular amyloid plaques and intracellular accumulation of neurofibrillary tangles (NFTs). While the recent 5xFAD AD mouse model exhibits many AD-related phenotypes and a relatively early and aggressive amyloid β production, it does not show NFTs. Here, we developed and evaluated a novel AD mouse model (6xTg-AD, 6xTg) by crossbreeding 5xFAD mice with mice expressing mutant (P301L) tau protein (MAPT). Through behavioral and histopathological tests, we analyzed cognitive changes and neuropathology in 6xTg mice compared to their respective parental strains according to age. Spatial memory deficits occurred in 6xTg mice at 2 months of age, earlier than they occurred in 5xFAD mice. Histopathological data revealed aggressive Aβ42 and p-tau accumulation in 6xTg mice. Microglial activation occurred in the cortex and hippocampus of 6xTg mice beginning at 2 months. In 6xTg model mice, the synaptic loss was observed in the cortex from 4 months of age and in the hippocampus from 6 months of age, and neuronal loss appeared in the cortex from 4 months of age and in the hippocampus 6 months of age, earlier than it is observed in the 5xFAD and JNPL3 models. These results showed that each pathological symptom appeared much faster than in their parental animal models. In conclusion, these novel 6xTg-AD mice might be an advanced animal model for studying AD, representing a promising approach to developing effective therapy.",[],Scientific reports,2021-01-16,"[{'lastname': 'Kang', 'firstname': 'Shinwoo', 'initials': 'S', 'affiliation': 'Department of Pharmacology, College of Medicine, Gachon University, Incheon, 21999, Republic of Korea.\nNeuroscience Research Institute, Gachon University, Incheon, 21565, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Jinho', 'initials': 'J', 'affiliation': 'Neuroscience Research Institute, Gachon University, Incheon, 21565, Republic of Korea.\nDepartment of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, Republic of Korea.'}, {'lastname': 'Chang', 'firstname': 'Keun-A', 'initials': 'KA', 'affiliation': 'Department of Pharmacology, College of Medicine, Gachon University, Incheon, 21999, Republic of Korea. keuna705@gachon.ac.kr.\nNeuroscience Research Institute, Gachon University, Incheon, 21565, Republic of Korea. keuna705@gachon.ac.kr.\nDepartment of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, Republic of Korea. keuna705@gachon.ac.kr.'}]",,,,,"10.1038/s41598-020-79344-5
10.1038/nrneurol.2017.147
10.15252/emmm.201606210
10.1038/78078
10.1146/annurev.neuro.24.1.1121
10.1002/jnr.24328
10.1016/j.neurobiolaging.2012.02.027
10.1523/JNEUROSCI.1202-06.2006
10.1016/j.nbd.2009.09.004
10.2353/ajpath.2007.070403
10.1016/j.nbd.2005.05.027
10.1016/S0896-6273(03)00434-3
10.1126/science.1058189
10.1016/j.neurobiolaging.2013.05.003
10.1096/fj.13-246702
10.1016/j.nbd.2013.09.010
10.1111/ejn.13442
10.1016/j.neurobiolaging.2003.08.012
10.1007/s00401-016-1662-x
10.3389/fnbeh.2018.00273
10.1016/j.neuron.2016.12.023
10.1016/j.ejmech.2018.09.069
10.3389/fphar.2019.00002
10.3390/ijms21145007
10.1016/j.trci.2018.06.014
10.1038/s41582-018-0013-z
10.15252/embj.201797397
10.1038/ncomms12082
10.1007/s004010051189
10.1016/S0002-9440(10)63518-3
10.1016/j.dadm.2014.12.001
10.1126/science.1566067
10.1016/0304-3940(87)90696-3
10.1097/00005072-199704000-00006
10.1002/glia.23024
10.1186/1750-1326-8-2
10.1016/j.neurobiolaging.2010.05.027
10.3390/ijms20163992",<Element 'PubmedArticle' at 0x7f05dd97f090>
71,"33417222
22137045
1961359
20431570
31824296
32471464
29036828
30742114
28190529
32462551
26971934
28111074
21193853
15734686
1566067
16541076
23663320
17234594
24179789
26721364
30970186
24450891
24450890
32040044
31168802
21868666
15924570
28409745
27767992
27662318
20937894
30191401
19667196
22492996
15193340
10939564
22526016
22229260
24885175
19914335
21461357
31256128
21459773
19342591
18648507
11387250
19081372
25176146
16943564
20829454
18202255
17051205
26883165
22771760
20144757
22331844
21613495
17204855
21092184
18992957
21884931
30661803
20660724
23921753
11978769
18191218
16625204
16625205
28647367
26611876
20404107
26266977
27291334
26738589
26549682
25678552
27813694
15751225
26903809
21296668
20541250
24418614
16298992
29077793
20376313
30135585
25611507
19653858
21258367
25796566
31585361
21772323
20178983
25645581
26240184
30679718
25069841
25031402
26338325
31858697
25665440
25720963
30458799
30116051
16497721
18596167
20463407
26125932
22218207
30256725
30154567
22934639
27091447
30894073
31339428
19605646
29710722
26729583
25064321
28118288
22367970
29986938
28973308
19050078
28432138
12415294
18675468
12909083
8561910
11950589
7615058
7588778
23919677
25641096
8464868
11231011
25416777
30767411
21952260
19840553
12165466
19014446
27789101
24445162
17658666
11923192
22342844
30046112
23254930
19193605
24962261
26919428
21151103
17180163
27940349
25056458
28404595
26942670
18604209
31702392
29293211
31748742
21124315
25313054
31257024
30074231
22229116
17196061
7598831
15033800
11741396
11048732
7696596
8939196
16408008
30467385
27034377
25867066
28176780
27640145
28758999
28904096
27493188
24508385
29466734
25801023
27861127
29089374
25083992
27219062",Aging-Dependent Mitophagy Dysfunction in Alzheimer's Disease.,"Alzheimer's disease (AD) is the most common late-onset dementia characterized by the deposition of extracellular amyloid plaques and formation of intracellular neurofibrillary tangles, which eventually lead to neuronal loss and cognitive deficits. Multiple lines of evidence indicate that mitochondrial dysfunction is involved in the initiation and progression of AD. As essential machinery for mitochondrial quality control, mitophagy plays a housekeeping role in neuronal cells by eliminating dysfunctional or excessive mitochondria. At present, mounting evidence support that the activity of mitophagy markedly declines in human brains during aging. Impaired mitophagy and mitochondrial dysfunction were causally linked to bioenergetic deficiency, oxidative stress, microglial activation, and chronic inflammation, thereby aggravating the Aβ and tau pathologies and leading to neuron loss in AD. This review summarizes recent evidence for age-associated mitophagy decline during human aging and provides an overview of mitochondrial dysfunction involved in the process of AD. It also discusses the underlying mechanisms through which defective mitophagy leads to neuronal cell death in AD. Therapeutic interventions aiming to restore mitophagy functions can be used as a strategy for ameliorating AD pathogenesis.","['Alzheimer’s disease', 'mitochondrial dysfunction', 'mitophagy', 'neuroinflammation']",Molecular neurobiology,2021-01-09,"[{'lastname': 'Song', 'firstname': 'Mingxue', 'initials': 'M', 'affiliation': ""Department of Toxicology and Nutrition, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan, 250012, Shandong, People's Republic of China.""}, {'lastname': 'Zhao', 'firstname': 'Xiulan', 'initials': 'X', 'affiliation': ""Department of Toxicology and Nutrition, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan, 250012, Shandong, People's Republic of China.""}, {'lastname': 'Song', 'firstname': 'Fuyong', 'initials': 'F', 'affiliation': ""Department of Toxicology and Nutrition, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan, 250012, Shandong, People's Republic of China. fysong3707@sdu.edu.cn.""}]",,,,,10.1007/s12035-020-02248-y,<Element 'PubmedArticle' at 0x7f05dd99fa40>
72,"33413691
17925367
759733
12058090
26721908
21801803
28483344
26869150
12130773
18038275
7937774
9258890
23881733
28888720
18481275
29241829
27842611
21557687
9083560
7483216
8744405
26651821
31273784
23056312
21712514
24779910
18568014
22028219
1656157
15864339
18836460
7857653
12084879
20101720
27090093
30807796
17306303
20940625
2484340
10320789
26576562
16906426
25242217
31417394
17239007","Amyloid β and tau pathology in brains of aged pinniped species (sea lion, seal, and walrus).","Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) as senile plaques and cerebral amyloid angiopathy, and hyperphosphorylated tau (hp-tau) as neurofibrillary tangles in the brain. The AD-related pathology has been reported in several non-human animals, and most animals develop only the Aβ or tau pathology. We herein describe the Aβ and hp-tau pathology in the brains of aged pinniped species (seal, sea lion, and walrus). Molecular analyses revealed that the sequence of pinniped Aβ was identical to that of human Aβ. Histopathological examinations detected argyrophilic plaques composed of Aβ associated with dystrophic neurites in the cerebral cortex of aged pinnipeds. Astrogliosis and microglial infiltration were identified around Aβ plaques. Aβ deposits were observed in the blood vessel walls of the meninges and cerebrum. Pinniped tau protein was physiologically subjected to alternative splicing at exons 2, 3, and 10, and presented as five isoforms: two 3-repeat tau isoforms (1N3R, 2N3R) and three 4-repeat tau isoforms (0N4R, 1N4R, 2N4R); 0N3R tau isoform was absent. Histopathological examinations revealed argyrophilic fibrillar aggregates composed of hp-tau in the neuronal somata and neurites of aged pinniped brains. Few hp-tau aggregates were found in oligodendrocytes and microglia. Biochemically, hp-tau of the 3-repeat and 4-repeat isoforms was detected in brain sarkosyl-insoluble fractions. Aβ and hp-tau both predominantly accumulated in the neocortex, particularly the frontal cortex. Furthermore, the activation of GSK-3β was detected within cells containing hp-tau aggregates, and activated GSK-3β was strongly expressed in cases with severe hp-tau pathologies. The present results suggest that, in association with Aβ deposition, the activation of GSK-3β contributes to hp-tau accumulation in pinniped brains. Here, we report that pinniped species naturally accumulate Aβ and tau with aging, similar to the human AD pathology.","['Alzheimer’s disease', 'Amyloid β', 'GSK-3β', 'Neurodegeneration', 'Pinniped', 'Tau']",Acta neuropathologica communications,2021-01-09,"[{'lastname': 'Takaichi', 'firstname': 'Yuta', 'initials': 'Y', 'affiliation': 'Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}, {'lastname': 'Chambers', 'firstname': 'James K', 'initials': 'JK', 'affiliation': 'Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan. achamber@mail.ecc.u-tokyo.ac.jp.'}, {'lastname': 'Takahashi', 'firstname': 'Kei', 'initials': 'K', 'affiliation': 'Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}, {'lastname': 'Soeda', 'firstname': 'Yoshiyuki', 'initials': 'Y', 'affiliation': 'Department of Life Science, Faculty of Science, Gakushuin University, Tokyo, Japan.'}, {'lastname': 'Koike', 'firstname': 'Riki', 'initials': 'R', 'affiliation': 'Department of Life Science, Faculty of Science, Gakushuin University, Tokyo, Japan.'}, {'lastname': 'Katsumata', 'firstname': 'Etsuko', 'initials': 'E', 'affiliation': 'Kamogawa Seaworld, Chiba, Japan.'}, {'lastname': 'Kita', 'firstname': 'Chiaki', 'initials': 'C', 'affiliation': 'Shikoku Cytopathological Laboratory, Kagawa, Japan.'}, {'lastname': 'Matsuda', 'firstname': 'Fuko', 'initials': 'F', 'affiliation': 'Laboratory of Theriogenology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.'}, {'lastname': 'Haritani', 'firstname': 'Makoto', 'initials': 'M', 'affiliation': 'Environmental Science for Sustainable Development, The University of Tokyo, Tokyo, Japan.'}, {'lastname': 'Takashima', 'firstname': 'Akihiko', 'initials': 'A', 'affiliation': 'Department of Life Science, Faculty of Science, Gakushuin University, Tokyo, Japan.'}, {'lastname': 'Nakayama', 'firstname': 'Hiroyuki', 'initials': 'H', 'affiliation': 'Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}, {'lastname': 'Uchida', 'firstname': 'Kazuyuki', 'initials': 'K', 'affiliation': 'Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}]",,,,,"10.1186/s40478-020-01104-3
10.3174/ajnr.A0781
10.1212/WNL.58.11.1629
10.1177/0300985815612154
10.1016/j.pneurobio.2011.07.006
10.1016/j.molmed.2017.04.001
10.1177/0300985815623997
10.1126/science.1072994
10.1007/s00401-007-0312-8
10.1016/S0197-4580(97)00012-2
10.1002/cne.23428
10.1016/j.neurobiolaging.2017.07.006
10.1002/cne.21744
10.1016/j.jalz.2017.11.005
10.1186/s40478-016-0385-5
10.3109/13506129.2011.570385
10.1007/s004010050615
10.1177/030098589503200410
10.1016/0197-4580(95)02069-1
10.1186/s40478-015-0258-3
10.1002/cne.24741
10.1371/journal.pone.0046452
10.1177/0300985811410719
10.3109/13506129.2014.908840
10.1038/nrn2420
10.1002/ana.22615
10.1016/0169-328X(91)90088-F
10.1038/nm.1872
10.1016/0896-6273(95)90301-1
10.1212/WNL.58.12.1791
10.1002/msj.20157
10.1038/srep24544
10.1016/j.neulet.2019.02.033
10.1016/j.jns.2007.01.013
10.1097/NEN.0b013e3181fab558
10.1016/0896-6273(89)90210-9
10.1016/S0169-328X(99)00079-0
10.1007/s00401-015-1507-z
10.1007/s00401-006-0127-z
10.1016/j.neuron.2014.08.048
10.3389/fnagi.2019.00184
10.1111/j.1365-2990.2006.00795.x",<Element 'PubmedArticle' at 0x7f05dd8fbb30>
73,"33404280
15295589
11891821
20107219
12130773
21148344
26195256
20178983
21980451
1740188
10966461
22078875
22187000
32560738
18059160
20711477
16203860
18032783
18497889
29408999
31874705
28089566
25636868
22128217
28770439
21352900
30971876
27865556
30450117
28471166
9639028
23294027
27902765
24095740
29416016
28205624
20833817
24711225
29441009
20551691
18596167
30894052
21258367
20852062
21778691
27494711
27133377
16823475
24611741
21947382
28984607
28801921
32580974
17116223
31444241
32123170
29988365
31927167
17021169
27833158
18987198",Crocetin promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway.,"Alzheimer disease (AD) is usually accompanied by two prominent pathological features, cerebral accumulation of amyloid-β (Aβ) plaques and presence of MAPT/tau neurofibrillary tangles. Dysregulated clearance of Aβ largely contributes to its accumulation and plaque formation in the brain. Macroautophagy/autophagy is a lysosomal degradative process, which plays an important role in the clearance of Aβ. Failure of autophagic clearance of Aβ is currently acknowledged as a contributing factor to increased accumulation of Aβ in AD brains. In this study, we have identified crocetin, a pharmacologically active constituent from the flower stigmas of ","['AMPK pathway', 'Alzheimer disease', 'LKB1', 'amyloid-β', 'autophagy']",Autophagy,2021-01-07,"[{'lastname': 'Wani', 'firstname': 'Abubakar', 'initials': 'A', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nAcademy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.\nDepartment of Neurology, Washington University, St. Louis, Missouri, USA.'}, {'lastname': 'Al Rihani', 'firstname': 'Sweilem B', 'initials': 'SB', 'affiliation': 'Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA.'}, {'lastname': 'Sharma', 'firstname': 'Ankita', 'initials': 'A', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nAcademy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.'}, {'lastname': 'Weadick', 'firstname': 'Brenna', 'initials': 'B', 'affiliation': 'Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio, USA.'}, {'lastname': 'Govindarajan', 'firstname': 'Rajgopal', 'initials': 'R', 'affiliation': 'Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio, USA.'}, {'lastname': 'Khan', 'firstname': 'Sameer U', 'initials': 'SU', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nDivision of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Jammu, India.'}, {'lastname': 'Sharma', 'firstname': 'Parduman R', 'initials': 'PR', 'affiliation': 'Academy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.\nDivision of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Jammu, India.'}, {'lastname': 'Dogra', 'firstname': 'Ashish', 'initials': 'A', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nAcademy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.'}, {'lastname': 'Nandi', 'firstname': 'Utpal', 'initials': 'U', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nAcademy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.'}, {'lastname': 'Reddy', 'firstname': 'Chilakala N', 'initials': 'CN', 'affiliation': 'Preformulation Laboratory, PK-PD Toxicology and Formulation Division, CSIR- Indian Institute of Integrative Medicine, Jammu, India.'}, {'lastname': 'Bharate', 'firstname': 'Sonali S', 'initials': 'SS', 'affiliation': ""Preformulation Laboratory, PK-PD Toxicology and Formulation Division, CSIR- Indian Institute of Integrative Medicine, Jammu, India.\nShobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India.""}, {'lastname': 'Singh', 'firstname': 'Gurdarshan', 'initials': 'G', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nAcademy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.'}, {'lastname': 'Bharate', 'firstname': 'Sandip B', 'initials': 'SB', 'affiliation': 'Academy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.\nDivision of Medicinal Chemistry, CSIR-Indian Institute of Integrative Medicine, Jammu, India.'}, {'lastname': 'Vishwakarma', 'firstname': 'Ram A', 'initials': 'RA', 'affiliation': 'Academy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.\nDivision of Medicinal Chemistry, CSIR-Indian Institute of Integrative Medicine, Jammu, India.'}, {'lastname': 'Kaddoumi', 'firstname': 'Amal', 'initials': 'A', 'affiliation': 'Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA.'}, {'lastname': 'Kumar', 'firstname': 'Ajay', 'initials': 'A', 'affiliation': 'Division of PK-PD-Toxicology and Formulation, CSIR-Indian Institute of Integrative Medicine, Jammu, India.\nAcademy of Scientiﬁc and Innovative Research (Acsir), Ghaziabad, India.'}]",,,,,10.1080/15548627.2021.1872187,<Element 'PubmedArticle' at 0x7f05dd920450>
74,33301880,Leptin enhances adult neurogenesis and reduces pathological features in a transgenic mouse model of Alzheimer's disease.,"Alzheimer's disease (AD) is the most common dementia worldwide and is characterized by the presence of senile plaques by amyloid-beta (Aβ) and neurofibrillary tangles of hyperphosphorylated Tau protein. These changes lead to progressive neuronal degeneration and dysfunction, resulting in severe brain atrophy and cognitive deficits. With the discovery that neurogenesis persists in the adult mammalian brain, including brain regions affected by AD, studies of the use of neural stem cells (NSCs) for the treatment of neurodegenerative diseases to repair or prevent neuronal cell loss have increased. Here we demonstrate that leptin administration increases the neurogenic process in the dentate gyrus of the hippocampus as well as in the subventricular zone of lateral ventricles of adult and aged mice. Chronic treatment with leptin increased NSCs proliferation with significant effects on proliferation and differentiation of newborn cells. The expression of the long form of the leptin receptor, LepRb, was detected in the neurogenic niches by reverse qPCR and immunohistochemistry. Moreover, leptin modulated astrogliosis, microglial cell number and the formation of senile plaques. Additionally, leptin led to attenuation of Aβ-induced neurodegeneration and superoxide anion production as revealed by Fluoro-Jade B and dihydroethidium staining. Our study contributes to the understanding of the effects of leptin in the brain that may lead to the development of new therapies to treat Alzheimer's disease.","['Alzheimer’s disease', 'amyloid-beta', 'hippocampus', 'leptin', 'neural stem cells', 'neurogenesis']",Neurobiology of disease,2020-12-11,"[{'lastname': 'Calió', 'firstname': 'Michele Longoni', 'initials': 'ML', 'affiliation': 'Department of Biochemistry, Laboratory of Neurobiology, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil; Department of Physiology, Laboratory of Neurobiology, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil. Electronic address: michele.longoni@unifesp.br.'}, {'lastname': 'Mosini', 'firstname': 'Amanda Cristina', 'initials': 'AC', 'affiliation': 'Department of Physiology, Laboratory of Neurobiology, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil.'}, {'lastname': 'Marinho', 'firstname': 'Darci Souza', 'initials': 'DS', 'affiliation': 'Department of Ginecology, Laboratory of Genetic Control, Universidade Federal de São Paulo, São Paulo, SP 04023-062, Brazil.'}, {'lastname': 'Salles', 'firstname': 'Geisa Nogueira', 'initials': 'GN', 'affiliation': 'Institute of Research and Development, Laboratory of Biomedical Nanotechnology, Universidade do Vale do Paraíba, São José dos Campos, SP, 12244-000, Brazil.'}, {'lastname': 'Massinhani', 'firstname': 'Fernando Henrique', 'initials': 'FH', 'affiliation': 'Department of Biochemistry, Laboratory of Neurobiology, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil.'}, {'lastname': 'Ko', 'firstname': 'Gui Mi', 'initials': 'GM', 'affiliation': 'Institute of Pharmacology and Molecular Biology INFAR, Universidade Federal de São Paulo, São Paulo, SP, 04044-020, Brazil.'}, {'lastname': 'Porcionatto', 'firstname': 'Marimélia Aparecida', 'initials': 'MA', 'affiliation': 'Department of Biochemistry, Laboratory of Neurobiology, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil. Electronic address: marimelia.pocionatto@unifesp.br.'}]",,,,Copyright © 2020. Published by Elsevier Inc.,10.1016/j.nbd.2020.105219,<Element 'PubmedArticle' at 0x7f05dd8ceb30>
75,"33289969
28426964
14559209
27165780
24841380
11579105
15331780
30643263
31926610
8407912
18832152
31815204
20703815
2110186
23708142
24316888
31602409
32049030
23798682
26414614
15240681
27362227
25307057
30872531
26911435
27938491
17035538
14642273
23500044
25332170
29961576
31464373
31986070
29191879
11875433
16337919
21105711
25670172
20087405
26603284
25693568
31100266
31301936
23623698
31740823
19565166
25673868
27466139
25514926
30617256
22964225
22677333
19081932
24951455
28602351
25497369
22749793
30022098
30563849
30820047
24162737
10830966
29861287
25907764
27302888
30557660
19808651
29020624
30577865
21307310
25128699
21460841
24097270
28734845
17021169
32008854
10604467
28263959
30944478
28360834
26929352
22677334
26539879
28009266
31232447
31740814
24725413
28747436
7874496
23806637
25431548
26871627
16274240
25231903
15972893
17562860
32015543
27083469
17947393
27049636
9452427
18266992
17016520
26564777
17270732
31401630
17272508
25186741
26687838
15951569
27054030
31932797
18699932",Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration.,"Alzheimer's disease (AD) is characterized by the appearance of amyloid-β plaques, neurofibrillary tangles, and inflammation in brain regions involved in memory. Using mass spectrometry, we have quantified the phosphoproteome of the CK-p25, 5XFAD, and Tau P301S mouse models of neurodegeneration. We identified a shared response involving Siglec-F which was upregulated on a subset of reactive microglia. The human paralog Siglec-8 was also upregulated on microglia in AD. Siglec-F and Siglec-8 were upregulated following microglial activation with interferon gamma (IFNγ) in BV-2 cell line and human stem cell-derived microglia models. Siglec-F overexpression activates an endocytic and pyroptotic inflammatory response in BV-2 cells, dependent on its sialic acid substrates and immunoreceptor tyrosine-based inhibition motif (ITIM) phosphorylation sites. Related human Siglecs induced a similar response in BV-2 cells. Collectively, our results point to an important role for mouse Siglec-F and human Siglec-8 in regulating microglial activation during neurodegeneration.","[""Alzheimer's disease"", 'Siglec-8', 'Siglec-F', 'microglia', 'phosphoproteomics']",Molecular systems biology,2020-12-09,"[{'lastname': 'Morshed', 'firstname': 'Nader', 'initials': 'N', 'affiliation': 'Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.\nKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Ralvenius', 'firstname': 'William T', 'initials': 'WT', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Nott', 'firstname': 'Alexi', 'initials': 'A', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain Sciences, Imperial College, London, UK.\nUK Dementia Research Institute at Imperial College London, London, UK.'}, {'lastname': 'Watson', 'firstname': 'L Ashley', 'initials': 'LA', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Rodriguez', 'firstname': 'Felicia H', 'initials': 'FH', 'affiliation': 'Department of Chemical and Materials Engineering, New Mexico State University, Las Cruces, NM, USA.'}, {'lastname': 'Akay', 'firstname': 'Leyla A', 'initials': 'LA', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Joughin', 'firstname': 'Brian A', 'initials': 'BA', 'affiliation': 'Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.\nKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Pao', 'firstname': 'Ping-Chieh', 'initials': 'PC', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Penney', 'firstname': 'Jay', 'initials': 'J', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'LaRocque', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': 'Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'lastname': 'Mastroeni', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'ASU-Banner Neurodegenerative Disease Research Center, Tempe, AZ, USA.'}, {'lastname': 'Tsai', 'firstname': 'Li-Huei', 'initials': 'LH', 'affiliation': 'Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.\nDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.\nBroad Institute of MIT and Harvard, Cambridge, MA, USA.'}, {'lastname': 'White', 'firstname': 'Forest M', 'initials': 'FM', 'affiliation': 'Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.\nKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.\nCenter for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA.'}]",,,,© 2020 The Authors. Published under the terms of the CC BY 4.0 license.,10.15252/msb.20209819,<Element 'PubmedArticle' at 0x7f05dd8dd180>
76,33213314,Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease.,"Alzheimer's disease (AD) is an irrevocable chronic brain disorder featured by neuronal loss, microglial accumulation, and progressive cognitive impairment. The proper pathophysiology of this life-threatening disorder is not completely understood and no exact remedies have been found yet. Over the last few decades, research on AD has mainly highlighted pathomechanisms linked to a couple of the major pathological hallmarks, including extracellular senile plaques made of amyloid-β (Aβ) peptides, and intracellular neurofibrillary tangles (NFTs) made of tau proteins. Aβ can induce apoptosis, trigger an inflammatory response, and inhibit the synaptic plasticity of the hippocampus, which ultimately contributes to reducing cognitive functions and memory impairment. Recently, a third disease hallmark, the neuroinflammatory reaction that is mediated by cerebral innate immune cells, has become a spotlight in the current research area, assured by pre-clinical, clinical, and genetic investigations. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a cytokine producer, is significantly associated with physiological inflammatory proceedings and thus shows a promising candidate for inflammation- based AD therapy. Recent data reveal that phytochemicals, mainly polyphenol compounds, exhibit potential neuroprotective functions and these may be considered as a vital resource for discovering several drug candidates against AD. Interestingly, phytochemicals can easily interfere with the signaling pathway of NF-κB. This review represents the anti-neuroinflammatory potential of polyphenols as inhibitors of NF-κB to combat AD pathogenesis.","[""Alzheimer's disease"", 'NF-κB', 'Polyphenols', 'anti-neuroinflammatory', 'neuroinflammation', 'pathomechanisms']",Current pharmaceutical design,2020-11-21,"[{'lastname': 'Uddin', 'firstname': 'Md Sahab', 'initials': 'MS', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh.'}, {'lastname': 'Hasana', 'firstname': 'Sharifa', 'initials': 'S', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh.'}, {'lastname': 'Ahmad', 'firstname': 'Jamil', 'initials': 'J', 'affiliation': 'Department of Human Nutrition, The University of Agriculture Peshawar, Khyber Pakhtunkhwa, Pakistan.'}, {'lastname': 'Hossain', 'firstname': 'Md Farhad', 'initials': 'MF', 'affiliation': 'Pharmakon Neuroscience Research Network, Dhaka, Bangladesh.'}, {'lastname': 'Rahman', 'firstname': 'Md Mosiqur', 'initials': 'MM', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh.'}, {'lastname': 'Behl', 'firstname': 'Tapan', 'initials': 'T', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab, India.'}, {'lastname': 'Rauf', 'firstname': 'Abdur', 'initials': 'A', 'affiliation': 'Department of Chemistry, University of Swabi, Swabi, Anbar, Khyber Pakhtunkhwa, Pakistan.'}, {'lastname': 'Ahmad', 'firstname': 'Ausaf', 'initials': 'A', 'affiliation': 'Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus, Uttar Pradesh, India.'}, {'lastname': 'Hafeez', 'firstname': 'Abdul', 'initials': 'A', 'affiliation': 'Glocal School of Pharmacy, Glocal University, Saharanpur, India.'}, {'lastname': 'Perveen', 'firstname': 'Asma', 'initials': 'A', 'affiliation': 'Glocal School of Life Sciences, Glocal University, Saharanpur, India.'}, {'lastname': 'Ashraf', 'firstname': 'Ghulam Md', 'initials': 'GM', 'affiliation': 'King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1381612826666201118092422,<Element 'PubmedArticle' at 0x7f05dd829220>
77,"33192310
27499754
19745156
8713166
27686658
11598490
6814231
26045020
29037207
19899077
28115589
16361024
20715114
25191325
22476196
24069439
23746840
30497964
25630253
22936011
29914035
24380887
28836226
11390952
23303049
25076901
31027873
1414275
9422548
25595674
8557327
26004161
24510633
26134003
31122931
27769915
23150934
19664276
23254930
21471435
15094078
25086775
29058362
29247992
5166216
31748742
26556658
30044944
32284590
23150908
27687525
23276384
28602351
31349033
28559417
29599194
21130529
10634967
28662669
29073081
29205357
20195797
7926364
31042697
29700251
30154787
26119735
23948931
24471431
31757576
3800971
27396447
13940299
30367958
27497943
21741992
9830016
9045694
24845831
27459405
15123336
20450347
30170611
32154671
22229116
29768217
27520774
27395435
15750215
22476197
29955649
21293295
30266932
28802038
24893973
26854967
28426958
16229744
29293211
26719249
23395614
25728668
30634998
26207229
27091843
26431938
31914599
31367008
26923399
25686106
27196974
25186741
25790769
28957663
32121028
31932797",Microglial Immunometabolism in Alzheimer's Disease.,"Alzheimer's disease (AD) is a neurodegenerative disorder characterized by amyloid-β (Aβ) plaques and the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. In response to Aβ and tau aggregates, microglia, the primary innate immune cells of the central nervous system (CNS), facilitate Aβ and tau clearance and contribute to neuroinflammation that damages neurons. Microglia also perform a wide range of other functions, e.g., synaptic pruning, within the CNS that require a large amount of energy. Glucose appears to be the primary energy source, but microglia can utilize several other substrates for energy production including other sugars and ketone bodies. Recent studies have demonstrated that changes in the metabolic profiles of immune cells, including macrophages, are important in controlling their activation and effector functions. Additional studies have focused on the role of metabolism in neuron and astrocyte function while until recently microglia metabolism has been considerably less well understood. Considering many neurological disorders, such as neurodegeneration associated with AD, are associated with chronic inflammation and alterations in brain energy metabolism, it is hypothesized that microglial metabolism plays a significant role in the inflammatory responses of microglia during neurodegeneration. Here, we review the role of microglial immunometabolism in AD.","['Alzheimer’s disease', 'glucose', 'immunometabolism', 'ketone bodies', 'microglia', 'neurodegeneration', 'neuroinflammation']",Frontiers in cellular neuroscience,2020-11-17,"[{'lastname': 'Shippy', 'firstname': 'Daniel C', 'initials': 'DC', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, United States.'}, {'lastname': 'Ulland', 'firstname': 'Tyler K', 'initials': 'TK', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, United States.'}]",,,,Copyright © 2020 Shippy and Ulland.,"10.3389/fncel.2020.563446
10.3389/fimmu.2016.00278
10.1126/science.1174331
10.1002/ca.980080612
10.1007/s11064-016-2070-2
10.1097/00004647-200110000-00001
10.1093/ajcn/36.5.950
10.1016/j.jalz.2015.05.016
10.1186/s13024-017-0216-6
10.1002/pmic.200900195
10.4049/jimmunol.1601318
10.1016/S1474-4422(05)70284-2
10.1002/ijc.25599
10.3389/fimmu.2014.00402
10.1172/jci57256
10.1371/journal.pone.0075713
10.1016/j.cell.2013.05.016
10.1016/S1474-4422(18)30403-4
10.1038/ncomms7176
10.3233/JAD-2012-129042
10.3233/jad-180202
10.1016/j.bcp.2013.12.012
10.1007/s11481-017-9754-5
10.1152/physiologyonline.2001.16.2.71
10.1038/npp.2012.255
10.3389/fnagi.2014.00133
10.1016/j.jalz.2018.12.017
10.1007/bf00227813
10.1186/s12974-014-0230-3
10.1128/iai.64.1.108-112.1996
10.1016/j.jneuroim.2015.04.006
10.1002/jnr.23356
10.1101/cshperspect.a020537
10.15252/emmm.201809711
10.1016/j.bbi.2016.10.018
10.1056/NEJMoa1211851
10.1186/1743-7075-6-31
10.1038/nature11729
10.1126/scitranslmed.3002369
10.1016/j.ejphar.2004.02.049
10.1038/ni.2956
10.1002/glia.23241
10.1111/imr.12608
10.1212/wnl.21.11.1097
10.1038/s41586-019-1769-z
10.1016/j.bcp.2015.11.003
10.1016/j.expneurol.2018.07.009
10.1038/s41591-020-0815-6
10.1056/NEJMoa1211103
10.1016/j.mce.2016.09.028
10.1016/j.neurobiolaging.2012.11.023
10.1016/j.cell.2017.05.018
10.1016/j.nbd.2019.104541
10.15252/embj.201796516
10.1126/science.aan4665
10.1016/j.neurobiolaging.2010.10.006
10.1002/(sici)1520-7560(199911/12)15:6<412::aid-dmrr72>3.0.co;2-8
10.1186/s13024-017-0192-x
10.1073/pnas.1710311114
10.1111/jnc.14267
10.1007/s12035-010-8106-8
10.1096/fasebj.8.13.7926364
10.1038/s41586-019-1195-2
10.1126/science.aat4984
10.3389/fimmu.2018.01832
10.1016/j.celrep.2015.05.046
10.3233/jad-131843
10.1146/annurev-immunol-032713-120240
10.1016/j.neurobiolaging.2019.09.015
10.1042/bj2390121
10.1038/nri.2016.70
10.1083/jcb.17.3.487
10.1016/j.neulet.2018.10.048
10.1007/s00401-016-1605-6
10.1016/j.plipres.2011.06.002
10.1074/jbc.273.49.32730
10.1074/jbc.272.10.6641
10.1038/ncomms4944
10.1038/nn.4338
10.1016/S0197-4580(03)00087-3
10.3109/01612841003768231
10.1186/s12974-018-1281-7
10.15252/emmm.201911227
10.1101/cshperspect.a006189
10.1016/j.celrep.2018.04.052
10.1016/j.jalz.2016.07.004
10.1016/j.bbi.2016.07.003
10.3233/jad-2005-7107
10.1172/jci59903
10.1016/j.trci.2017.11.002
10.1097/nen.0b013e31820e1152
10.1038/s41582-018-0072-1
10.1016/j.cell.2017.07.023
10.1186/1750-1326-9-20
10.1021/acschemneuro.5b00313
10.1016/j.neuron.2017.02.042
10.1186/1743-7075-2-28
10.1038/nature25158
10.1128/jvi.02613-15
10.1016/j.febslet.2013.01.067
10.1016/j.cell.2015.01.049
10.1186/s13024-019-0305-9
10.3978/j.issn.2305-5839.2015.03.49
10.1084/jem.20151948
10.1016/j.it.2015.08.008
10.1096/fj.201901984R
10.1038/s41582-019-0228-7
10.1016/j.neurobiolaging.2015.11.018
10.1038/nm.3804
10.1016/j.neuron.2016.05.003
10.1523/JNEUROSCI.1860-14.2014
10.1159/000373972
10.1016/j.neuron.2017.09.003
10.3390/cells9030562
10.1038/s41591-019-0695-9",<Element 'PubmedArticle' at 0x7f05dd832f40>
78,"33066368
1259639
27583652
30497964
3159021
8239273
1608956
14032480
2419127
10805776
22229116
1566067
28003277
1549228
7826280
12743238
31894103
11959919
17478722
16894106
19001171
29660934
30630532
1057175
7479786
25186741
26687838
3103857
15615629
9641683
25402454
21807765
22710833
3930508
20655099
1700432
7566354
8522593
29162800
24386422
1465130
7964749
2516729
9763511
30605723
29157277
1560225
3088567
8393323
21172610
17304350
16115884
18467332
19491104
1336152
11943212
16262633
19246243
11520930
21720721
11381127
15009652
32571418
10090741
20658984
3129414
9836646
8849730
8985176
23964266
29988016
7929085
1639844
17561815
17338548
28678775
30158706
30894745
32050258
32032505
30008334
18202255
2105469
24298146
24913895
27198172
21131359
24672431
8202139
27736877
22286308
25124182
19282288
19503072
22365544
29740275
31249873
30724769
8748926
16914144
23412472
25393609
22138183
22057275
24971751
22668776
29768203
30463001
23188818
18272392
31555098
32296178
23898162
27760323
27809932
31667556
28527044
26057852
26638867
28519902
31118883
25833819
30227881
30108137
31826239
31229689
20753232
25926775
31635851
10567732
20966214
18026097
28076784
28746864
2089275
26780511
30760929
30559476
28602351
31844328
30471926
29924994
31873194
18510934
20887954
31896673
18083105
27558646
32615087
31831638
28963396
20404134
15895084
15831717
24162652
17115040
29290552
10627602
1782548
8751442
17270732
25261551
32008854
31748742
18604209
23254930
21775213
20334662
17203473
8423063
14730714
30378163
26436904
31504240
30232451
29490706
31434879
30820047
8446617
24655576
3283935
9354781
18549781
21715678
29483128
7972031
28959956
31601677
22622580
32376954
30737131
26374899
26374897
28930663
23150908
30266932
25728668
27091843
32579671
29037207
29073081
31235932
32544086
12080485
31630996
31462511
32790063
18976728
21460840
21460841
7718872
22224769
23623698
31301936
11852060
26685795
22633458
12125082
9724801
9024663
9893054
12729461
24860431
10652441
16732273
24277722
28810892
27832289
20864679
20920788
12629164
30769286
31792059
31849963
23332170
30253780
31822518
32410624
2628782
10029101
24368848
15930395
16020737
21325519
22532069
30559471
31825838
32572268
32778792
20634292
22024719
32020597
24625061
26269332
29382714
32296183
21388709
10685603
32341125
32858428
30138606
25693568
29643512
31915375
32479993
26030851
27443609
28874832
31097468
30276955
30944478",Microglia in Alzheimer's Disease in the Context of Tau Pathology.,"Microglia are the cells that comprise the innate immune system in the brain. First described more than a century ago, these cells were initially assigned a secondary role in the central nervous system (CNS) with respect to the protagonists, neurons. However, the latest advances have revealed the complexity and importance of microglia in neurodegenerative conditions such as Alzheimer's disease (AD), the most common form of dementia associated with aging. This pathology is characterized by the accumulation of amyloid-β peptide (Aβ), which forms senile plaques in the neocortex, as well as by the aggregation of hyperphosphorylated tau protein, a process that leads to the development of neurofibrillary tangles (NFTs). Over the past few years, efforts have been focused on studying the interaction between Aβ and microglia, together with the ability of the latter to decrease the levels of this peptide. Given that most clinical trials following this strategy have failed, current endeavors focus on deciphering the molecular mechanisms that trigger the tau-induced inflammatory response of microglia. In this review, we summarize the most recent studies on the physiological and pathological functions of tau protein and microglia. In addition, we analyze the impact of microglial AD-risk genes (","['Alzheimer’s disease', 'ApoE', 'Aβ', 'CD33', 'CX3CR1', 'TREM2', 'microglia', 'neuroinflammation', 'tau', 'tauopathies']",Biomolecules,2020-10-18,"[{'lastname': 'Perea', 'firstname': 'Juan Ramón', 'initials': 'JR', 'affiliation': 'Department of Molecular Neuropathology, Centro de Biología Molecular ""Severo Ochoa"" (CSIC-UAM), 1 Nicolás Cabrera, 28049 Madrid, Spain.\nNetwork Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED), 5 Valderrebollo, 28031 Madrid, Spain.'}, {'lastname': 'Bolós', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Department of Molecular Neuropathology, Centro de Biología Molecular ""Severo Ochoa"" (CSIC-UAM), 1 Nicolás Cabrera, 28049 Madrid, Spain.\nNetwork Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED), 5 Valderrebollo, 28031 Madrid, Spain.'}, {'lastname': 'Avila', 'firstname': 'Jesús', 'initials': 'J', 'affiliation': 'Department of Molecular Neuropathology, Centro de Biología Molecular ""Severo Ochoa"" (CSIC-UAM), 1 Nicolás Cabrera, 28049 Madrid, Spain.\nNetwork Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED), 5 Valderrebollo, 28031 Madrid, Spain.'}]",,,,,"10.3390/biom10101439
10.1001/archneur.1976.00500040001001
10.1016/j.jalz.2016.07.150
10.1016/S1474-4422(18)30403-4
10.1073/pnas.82.12.4245
10.1111/j.1749-6632.1993.tb23043.x
10.1073/pnas.89.12.5462
10.1038/197192b0
10.1002/j.1460-2075.1985.tb04132.x
10.1073/pnas.97.10.5129
10.1101/cshperspect.a006189
10.1126/science.1566067
10.1101/cshperspect.a024539
10.1212/WNL.42.3.631
10.1001/archneur.1995.00540250089017
10.1212/01.WNL.0000063311.58879.01
10.1126/scitranslmed.aau5732
10.1073/pnas.092136199
10.1126/science.1141736
10.1212/01.wnl.0000228230.26044.a4
10.1001/archneur.65.11.1509
10.3233/JAD-170887
10.1186/s13024-018-0301-5
10.1073/pnas.72.5.1858
10.1073/pnas.92.22.10369
10.1523/JNEUROSCI.1860-14.2014
10.1016/j.neuron.2015.11.013
10.1016/0169-328X(86)90033-1
10.1016/j.bbadis.2004.08.010
10.1038/31508
10.1371/journal.pone.0113070
10.1093/hmg/ddr330
10.1038/embor.2012.90
10.1083/jcb.101.4.1371
10.1016/j.cell.2010.06.036
10.1073/pnas.87.21.8422
10.1016/0197-4580(95)00023-8
10.1083/jcb.131.5.1327
10.1038/s41467-017-01575-4
10.1371/journal.pone.0084849
10.1038/360674a0
10.1046/j.1471-4159.1994.63062288.x
10.1016/0896-6273(89)90050-0
10.1016/j.pneurobio.2018.12.005
10.1186/s13024-017-0229-1
10.1111/j.1471-4159.1992.tb10039.x
10.1073/pnas.83.13.4913
10.1016/0896-6273(93)90279-Z
10.1016/j.neuron.2010.11.030
10.1172/JCI29715
10.1074/jbc.M505895200
10.1074/jbc.M709715200
10.1074/jbc.M109.014472
10.1016/0304-3940(92)90774-2
10.1016/S0014-5793(02)02460-2
10.1111/j.1460-9568.2005.04391.x
10.1016/j.molmed.2009.01.003
10.1146/annurev.neuro.24.1.1121
10.1007/s12031-011-9589-0
10.1073/pnas.121119298
10.1046/j.1471-4159.2003.02287.x
10.1186/s40478-020-00967-w
10.1021/bi981874p
10.1042/BST0380955
10.1093/oxfordjournals.jbchem.a122187
10.1126/science.282.5395.1914
10.1038/383550a0
10.1016/S0014-5793(96)01386-5
10.3389/fneur.2013.00114
10.7554/eLife.36584
10.1083/jcb.118.3.573
10.1111/j.1460-9568.2007.05555.x
10.1021/bi061359o
10.1038/nature23002
10.1038/s41586-018-0454-y
10.1038/s41586-019-1026-5
10.1038/s41586-020-2043-0
10.1016/j.cell.2020.01.027
10.1016/j.cub.2018.05.045
10.1126/science.1152993
10.1038/343461a0
10.1098/rstb.2013.0144
10.1016/j.neurobiolaging.2014.05.005
10.15252/embj.201593518
10.1074/jbc.M110.199976
10.3389/fncel.2014.00084
10.1038/369488a0
10.1371/journal.pone.0163236
10.1038/nm.2613
10.1186/1750-1326-9-29
10.1074/jbc.M808759200
10.1038/ncb1901
10.1016/j.neuron.2011.11.033
10.3389/fnins.2018.00267
10.1126/sciadv.aaw6404
10.1097/WCO.0000000000000672
10.1007/BF02815140
10.1016/j.febslet.2006.07.078
10.1038/embor.2013.15
10.1111/jnc.12991
10.1016/j.febslet.2011.11.022
10.1074/jbc.M111.277061
10.1371/journal.pone.0100760
10.1016/j.nbd.2012.05.021
10.1016/j.celrep.2018.04.056
10.1016/j.celrep.2018.10.078
10.1074/jbc.M112.394528
10.1016/j.mcn.2007.12.010
10.3389/fncel.2019.00403
10.1038/s41586-020-2156-5
10.1073/pnas.1301440110
10.1016/j.celrep.2016.09.063
10.1186/s40478-016-0386-4
10.1007/s00018-019-03349-1
10.1007/s00401-017-1722-x
10.1038/srep11161
10.3233/JAD-150704
10.1002/glia.23163
10.3389/fnins.2019.00442
10.1093/brain/awv081
10.1186/s12974-018-1309-z
10.1084/jem.20172158
10.1084/jem.20190783
10.1016/j.nbd.2019.104518
10.1136/bmj.1.1570.213
10.3389/fnana.2015.00045
10.1016/j.tins.2019.09.004
10.1016/S0165-3806(99)00113-3
10.1126/science.1194637
10.1038/nn2014
10.1016/j.celrep.2016.12.041
10.1016/j.celrep.2017.07.004
10.1016/0306-4522(90)90229-W
10.1038/nn.4222
10.1038/s41586-019-0924-x
10.1038/s41593-018-0290-2
10.1016/j.cell.2017.05.018
10.1038/s41577-019-0262-0
10.1016/j.immuni.2018.11.004
10.1016/j.celrep.2018.05.048
10.20517/2347-8659.2019.31
10.1038/s41593-019-0560-7
10.1016/j.cell.2008.04.037
10.1016/j.stem.2010.08.014
10.1523/JNEUROSCI.0993-19.2019
10.1016/j.cell.2007.10.036
10.1038/ncomms12540
10.1016/j.cell.2020.05.050
10.1126/science.aax6752
10.15252/embj.201696056
10.1182/blood-2009-12-257832
10.1038/nn1472
10.1126/science.1110647
10.1038/nn.3554
10.1038/nn1805
10.1016/j.neuron.2017.12.002
10.1523/JNEUROSCI.20-01-00251.2000
10.1016/0006-8993(91)90783-R
10.1038/382716a0
10.1016/j.neuron.2007.01.010
10.1073/pnas.1411649111
10.1016/j.neurobiolaging.2020.01.003
10.1038/s41586-019-1769-z
10.1038/ni.1636
10.1038/nature11729
10.1016/S1474-4422(11)70072-2
10.1186/1750-1326-5-12
10.1002/glia.20468
10.1002/glia.440070111
10.1002/glia.10319
10.1002/glia.23529
10.1038/nn.4132
10.1093/brain/awz241
10.1038/s41586-018-0543-y
10.1186/s13024-018-0244-x
10.1038/s41467-019-11674-z
10.1038/s41588-019-0358-2
10.1073/pnas.90.5.1977
10.1016/j.jaci.2014.01.032
10.1126/science.3283935
10.1038/ng1197-263
10.1016/j.neuron.2008.04.010
10.1126/scitranslmed.3002156
10.1084/jem.20171265
10.1073/pnas.91.23.11183
10.1038/nature24016
10.1084/jem.20190980
10.1038/nature11087
10.1038/s41586-020-2247-3
10.1016/j.neuron.2019.01.014
10.1074/jbc.M115.679043
10.1074/jbc.M115.677286
10.1016/j.immuni.2017.08.008
10.1056/NEJMoa1211103
10.1038/s41582-018-0072-1
10.1016/j.cell.2015.01.049
10.1084/jem.20151948
10.1084/jem.20200785
10.1186/s13024-017-0216-6
10.1073/pnas.1710311114
10.1038/s41593-019-0433-0
10.1172/JCI138179
10.1086/342259
10.1016/j.jalz.2019.07.018
10.1126/scitranslmed.aav6221
10.15252/emmm.202012308
10.1016/j.ajhg.2008.10.008
10.1038/ng.803
10.1038/ng.801
10.1182/blood.V85.8.2005.bloodjournal8582005
10.1146/annurev-immunol-020711-075018
10.1016/j.neuron.2013.04.014
10.1016/j.neuron.2019.06.010
10.1016/S0014-5793(02)02228-7
10.1111/neup.12277
10.1016/j.immuni.2012.05.008
10.1002/jnr.10304
10.1073/pnas.95.18.10896
10.1038/385640a0
10.1046/j.1365-2567.1998.00603.x
10.1042/bj20030207
10.3389/fncel.2014.00129
10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V
10.1038/nn1715
10.1093/brain/awt323
10.1186/s13024-017-0200-1
10.1007/s00018-016-2408-6
10.2353/ajpath.2010.100265
10.1016/j.neuron.2010.08.023
10.1523/JNEUROSCI.23-05-01605.2003
10.1016/j.redox.2019.101118
10.26508/lsa.201900453
10.3389/fimmu.2019.02780
10.1016/j.neurobiolaging.2012.12.011
10.1186/s12974-018-1310-6
10.1523/JNEUROSCI.1333-19.2019
10.1186/s12974-020-01828-y
10.1016/0197-4580(89)90007-9
10.1097/00005072-199902000-00008
10.1073/pnas.1318807111
10.1523/JNEUROSCI.4637-04.2005
10.1126/science.1113694
10.1523/JNEUROSCI.5245-10.2011
10.1007/s00401-012-0987-3
10.1038/s41593-018-0289-8
10.1016/j.celrep.2019.11.044
10.1038/s41591-020-0938-9
10.1038/s41593-020-0687-6
10.1074/jbc.M110.145003
10.1159/000329722
10.1111/ahg.12375
10.1186/1742-2094-11-48
10.1074/mcp.M115.050724
10.1074/jbc.RA118.001784
10.1038/s41586-020-2188-x
10.1101/2020.05.07.083295
10.1016/j.neurobiolaging.2011.01.005
10.1023/A:1007583214722
10.1074/jbc.RA119.012517
10.1016/j.jneuroim.2020.577362
10.1016/j.expneurol.2018.08.007
10.1038/nature14252
10.1101/810291
10.1038/s41586-018-0023-4
10.1038/s41586-019-1895-7
10.1016/j.bbi.2020.05.070
10.1038/nn.4030
10.1038/srep30028
10.1038/s41598-017-11047-w
10.1084/jem.20182386
10.1111/acel.12832
10.1038/s41586-019-1088-4",<Element 'PubmedArticle' at 0x7f05dd7faa40>
79,"32975239
26264566
30587772
30804776
31727856
31632307
8090931
12011758
29705945
26091541
10739087
1852778
29756604
11113503
24357508
8090788
8648133
9195191
14737036
8996828
9329682
31809494
32722745
30631032",Dysregulation of Nitric Oxide Signaling in Microglia: Multiple Points of Functional Convergence in the Complex Pathophysiology of Alzheimer Disease.,"Current critical thinking has displaced the elaborated beta amyloid theory as the underlying unitary mechanism of Alzheimer disease (AD) in favor of concerted, long-term disruption or dysregulation of broad-based physiological processes. We present a critical discussion in which a chronic state of systemic proinflammation sustained over the course of several decades and engendered by ongoing metabolic or autoimmune disease is predicted to promote severe disruptions of central neurological processes. Specifically, long-term functional rundown of microglial-mediated phagocytic activity in concert with aberrant expression and cellular deposition of beta amyloid and tau protein facilitates formation of senile plaques and neurofibrillary tangles. Within this functional context, we hypothesize that early initiation events in the pathophysiology of AD may operationally involve a convergence of dysregulated peripheral and central constitutive nitric oxide signaling pathways resulting from a chronic state of systemic proinflammation and leading to severely dysfunctional ""hyperactivated"" microglia.",[],Medical science monitor : international medical journal of experimental and clinical research,2020-09-26,"[{'lastname': 'Stefano', 'firstname': 'George B', 'initials': 'GB', 'affiliation': 'Department of Psychiatry, First Faculty of Medicine Charles University in Prague and General University Hospital in Prague, Center for Cognitive and Molecular Neuroscience, Prague, Czech Republic.'}, {'lastname': 'Esch', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'Faculty of Health, School of Medicine, University Clinic for Integrative Health Care, Institute for Integrative Health Care and Health Promotion, Witten/Herdecke University, Witten, Germany.'}, {'lastname': 'Ptacek', 'firstname': 'Radek', 'initials': 'R', 'affiliation': 'Department of Psychiatry, First Faculty of Medicine Charles University in Prague and General University Hospital in Prague, Center for Cognitive and Molecular Neuroscience, Prague, Czech Republic.'}, {'lastname': 'Kream', 'firstname': 'Richard M', 'initials': 'RM', 'affiliation': 'Department of Psychiatry, First Faculty of Medicine Charles University in Prague and General University Hospital in Prague, Center for Cognitive and Molecular Neuroscience, Prague, Czech Republic.'}]",,,,,10.12659/MSM.927739,<Element 'PubmedArticle' at 0x7f05dd72b040>
80,"32973488
25523424
29037207
29198280
30033062
31507410
22514691
19808793
31019207
27422544
19895660
26871627
24625061
32588460
30742114
24395130
26251237
30572908
29196460
23254930
21292280
28473584
15615638
20678074
28768545
24899047
12972166
12395106
30406177
28930663
28872215
31100304
29636771
31235932
29073081
22399427
31274278
28458631
22460333
24445162
30820451
26754641
25221640
20107219
28588356
19299738
26921134
19637926
22072659
20037584
18425443
28802038
26257642
28960209
7876258
24189435
30135715
28491064
24144623
28939404
27477018
26104799
30532704",Mitochondrial Dysfunction and Alzheimer's Disease: Role of Microglia.,"In 1907, Alois Alzheimer observed, as he quoted, development of ""numerous fibers"" and ""adipose saccules"" in the brain of his diseased patient Auguste Deter. The neurodegenerative disease became known as Alzheimer's disease (AD) and is the most common cause of dementia worldwide. AD normally develops with aging and is mostly initiated because of the imbalance between the formation and clearance of amyloid-β (Aβ). Formation of neurofibrillary tangles (NFTs) of hyperphosphorylated tau is another hallmark of AD. Neuroinflammation plays a significant role in the development and pathology of AD. This chapter explores the role of mitochondrial dysfunction in microglia in case of AD. Mitochondrial oxidative stress in microglia has been linked to the development of AD. Elevated generation of reactive oxygen species (ROS) and loss of mitochondrial membrane potential through various mechanisms have been observed in AD. Aβ interacts with microglial receptors, such as triggering receptor expressed in myeloid cells 2 (TREM2), activating downstream pathways causing mitochondrial damage and aggravating inflammation and cytotoxicity. Fibrillar Aβ activates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in microglia leading to elevated induction of mitochondrial ROS which further causes neurotoxicity. Elevated ROS in microglia causes activation of inflammatory and cell death pathways. Production of ATP, regulation of mitochondrial health, autophagy, and mitophagy in microglia play significant roles in the AD pathology. Understanding microglial physiology and mitochondrial dysfunction will enable better therapeutic interventions.","['ROS', 'amyloid-β', 'microglia', 'mitochondria', 'neurodegeneration']",Frontiers in aging neuroscience,2020-09-26,"[{'lastname': 'Agrawal', 'firstname': 'Ishan', 'initials': 'I', 'affiliation': 'Inflammation, Immunity and Tumour Biology Laboratory, Department of Bioscience and Bioengineering, Indian Institute of Technology (IIT) Jodhpur, Jodhpur, India.'}, {'lastname': 'Jha', 'firstname': 'Sushmita', 'initials': 'S', 'affiliation': 'Inflammation, Immunity and Tumour Biology Laboratory, Department of Bioscience and Bioengineering, Indian Institute of Technology (IIT) Jodhpur, Jodhpur, India.'}]",,,,Copyright © 2020 Agrawal and Jha.,"10.3389/fnagi.2020.00252
10.1016/j.jalz.2018.02.001
10.2174/1567205012666141218140953
10.1186/s13024-017-0216-6
10.1017/S135561771700100X
10.1016/S1474-4422(18)30232-1
10.3389/fphar.2019.00902
10.1371/journal.pone.0034929
10.1093/hmg/ddp326
10.1038/s41598-019-42931-2
10.1007/s10863-016-9669-5
10.1111/j.1471-4159.2009.06485.x
10.1016/j.cell.2015.12.056
10.1186/1742-2094-11-48
10.1111/imr.12896
10.1038/s41593-018-0332-9
10.1007/s40473-019-00179-0
10.1007/s12035-013-8620-6
10.1007/s00281-015-0518-0
10.1186/s13024-018-0298-9
10.1083/jcb.201709069
10.1038/nature11729
10.1016/j.jns.2011.01.003
10.1126/science.aal3535
10.1016/j.bbadis.2004.09.008
10.2174/156720510793611592
10.1186/s13024-017-0197-5
10.1093/hmg/ddu277
10.1016/s0304-3940(03)00898-x
10.1097/00001756-200210280-00032
10.1016/j.trci.2018.06.014
10.1016/j.immuni.2017.08.008
10.1111/ene.13439
10.1016/j.neuint.2019.104469
10.1186/s11658-018-0081-5
10.1038/s41593-019-0433-0
10.1073/pnas.1710311114
10.1007/978-94-007-2869-1_12
10.1021/acs.accounts.9b00248
10.3389/fnmol.2017.00108
10.3233/jad-2012-120145
10.1016/j.bcp.2014.01.008
10.1126/sciadv.aau6328
10.1007/s00401-016-1533-5
10.1155/2014/780179
10.1056/NEJMra0909142
10.1159/000464422
10.4049/jimmunol.0803612
10.1016/S0140-6736(15)01124-1
10.1021/cr9000176
10.1523/jneurosci.3454-11.2011
10.1038/ni.1836
10.1007/978-1-59745-157-4_4
10.1016/j.cell.2017.07.023
10.3389/fnagi.2015.00124
10.1038/nrneurol.2017.111
10.1074/jbc.270.9.4854
10.1016/j.bbadis.2013.10.015
10.12688/f1000research.14506.1
10.3389/fimmu.2017.00508
10.1016/j.neuroscience.2013.10.011
10.1016/j.brainres.2017.08.035
10.1016/j.neuron.2016.06.015
10.1186/s12974-015-0343-3
10.3389/fnagi.2018.00395",<Element 'PubmedArticle' at 0x7f05dd7390e0>
81,32941933,Actin-mediated Microglial Chemotaxis via G-Protein Coupled Purinergic Receptor in Alzheimer's Disease.,"Alzheimer's disease (AD) is a neurodegenerative disease mainly associated with aging, oxidative stress and genetic mutations. There are two pathological proteins involved in AD; Amyloid-β peptide and microtubule-associated protein Tau (MAPT). The β- and γ-secretase enzyme cleaves the Amyloid precursor protein, which results in the formation of extracellular plaques in brain. While, Tau undergoes hyperphosphorylation and other post-translational modifications (PTMs), which eventually generates Tau oligomers, and intracellular neurofibrillary tangles (NFTs) in neurons. Moreover, the brain-resident glia and infiltrated macrophages elevate the level of CNS inflammation, which trigger the oxidative damage of neuronal circuits by reactive oxygen species (ROS) and Nitric oxide (NO). Microglia is the primary immune cell in the CNS, which is continuously surveilling the neuronal synapses and pathogen invasion. Microglia in the resting state is called 'Ramified', which possess long surveilling extensions with a small cell body. But, upon activation, microglia retracts the cellular extensions and transform into round migratory cells, called as 'Amoeboid' state. Activated microglia undergoes actin remodeling by forming lamellipodia and filopodia, which directs the migratory axis while podosomes formed are involved in extracellular matrix degradation for invasion. Protein-aggregates in malfunctioning synapses and in CNS milieu can be detected by microglia, which results in its activation and migration. Subsequently, the phagocytosis of synapses leads to the inflammatory burst and memory loss. The extracellular nucleotides released from damaged neurons and the cytokine-chemokine gradients allow the neighboring microglia and macrophages to migrate-infiltrate at the site of neuronal-damage. The ionotropic (P2XR) and metabotropic (P2YR) purinergic receptor recognize extracellular ATP/ADP, which propagates through the intracellular calcium signaling, chemotaxis, phagocytosis and inflammation. The P2Y receptors give 'find me' or 'eat me' signals to microglia to either migrate or phagocytose cellular debris. Further, the actin cytoskeleton helps microglia to mediate directed chemotaxis and neuronal repair during neurodegeneration. Hence, we aim to emphasize the connection between purinergic signaling and actin-driven mechanical movements of microglia for migration and inflammation in AD.","['Alzheimer’s disease', 'P2Y signaling', 'Tauopathy', 'actin remodeling', 'microglia', 'purinergic GPCRs']",Neuroscience,2020-09-18,"[{'lastname': 'Das', 'firstname': 'Rashmi', 'initials': 'R', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, 411008 Pune, India; Academy of Scientific and Innovative Research (AcSIR), 411008 Pune, India.'}, {'lastname': 'Chinnathambi', 'firstname': 'Subashchandrabose', 'initials': 'S', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, 411008 Pune, India; Academy of Scientific and Innovative Research (AcSIR), 411008 Pune, India. Electronic address: s.chinnathambi@ncl.res.in.'}]",,,,Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2020.09.024,<Element 'PubmedArticle' at 0x7f05dd6e5540>
82,"32660586
22229116
27979768
23684085
28662669
30052812
31748742
30131755
26912432
12417659
29059326
24865638
15509534
26057852
30134156
26912428
28705919
26609163
30617257
31302633
28988133
30262517
18930824
30400912
31772305
21430171
17270732
29865053
29653606
30339715
30262517
29332041
30232451
28122877",Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning.,"P301S tau transgenic mice show age-dependent accumulation of neurofibrillary tangles in the brainstem, hippocampus, and neocortex, leading to neuronal loss and cognitive deterioration. However, there is hitherto only sparse documentation of the role of neuroinflammation in tau mouse models. Thus, we analyzed longitudinal microglial activation by small animal 18 kDa translocator protein positron-emission-tomography (TSPO μPET) imaging in vivo, in conjunction with terminal assessment of tau pathology, spatial learning, and cerebral glucose metabolism.
Transgenic P301S (n = 33) and wild-type (n = 18) female mice were imaged by 
TSPO expression in all target regions of P301S mice increased exponentially from 1.9 to 6.4 months, leading to significant differences in the contrasts with wild-type mice at 6.4 months (+ 11-23%, all p < 0.001), but the apparent microgliosis proceeded more slowly than in our experience in amyloid-β mouse models. Spatial learning and glucose metabolism of AT8-positive P301S mice were significantly impaired at 6.3-6.5 months compared to the wild-type group. Longitudinal increases in TSPO expression predicted greater tau accumulation and lesser spatial learning performance at 6.3-6.7 months.
Monitoring of TSPO expression as a surrogate of microglial activation in P301S tau transgenic mice by μPET indicates a delayed time course when compared to amyloid-β mouse models. Detrimental associations of microglial activation with outcome parameters are opposite to earlier data in amyloid-β mouse models. The contribution of microglial response to pathology accompanying amyloid-β and tau over-expression merits further investigation.","['Glucose metabolism', 'Microglia', 'P301S', 'PET', 'Spatial learning', 'TSPO', 'Tau']",Journal of neuroinflammation,2020-07-15,"[{'lastname': 'Eckenweber', 'firstname': 'Florian', 'initials': 'F', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Medina-Luque', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Center of Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Blume', 'firstname': 'Tanja', 'initials': 'T', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nCenter of Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.'}, {'lastname': 'Sacher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Biechele', 'firstname': 'Gloria', 'initials': 'G', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Wind', 'firstname': 'Karin', 'initials': 'K', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Deussing', 'firstname': 'Maximilian', 'initials': 'M', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Briel', 'firstname': 'Nils', 'initials': 'N', 'affiliation': 'Center of Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Lindner', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Boening', 'firstname': 'Guido', 'initials': 'G', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'von Ungern-Sternberg', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Unterrainer', 'firstname': 'Marcus', 'initials': 'M', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Albert', 'firstname': 'Nathalie L', 'initials': 'NL', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Zwergal', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'German Center for Vertigo and Balance Disorders, DSGZ, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nDepartment of Neurology, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.\nDepartment of Neurology, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany.'}, {'lastname': 'Bartenstein', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany.'}, {'lastname': 'Cumming', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Department of Nuclear Medicine, Inselspital Bern, Bern, Switzerland.\nSchool of Psychology and Counselling and IHBI, Queensland University of Technology, Brisbane, Australia.'}, {'lastname': 'Rominger', 'firstname': 'Axel', 'initials': 'A', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany.\nDepartment of Nuclear Medicine, Inselspital Bern, Bern, Switzerland.'}, {'lastname': 'Höglinger', 'firstname': 'Günter U', 'initials': 'GU', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.\nDepartment of Neurology, Hannover Medical School, Hannover, Germany.\nDepartment of Neurology, Technical University of Munich, Munich, Germany.'}, {'lastname': 'Herms', 'firstname': 'Jochen', 'initials': 'J', 'affiliation': 'Center of Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, 81377, Munich, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany.'}, {'lastname': 'Brendel', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377, Munich, Germany. matthias.brendel@med.uni-muenchen.de.\nMunich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany. matthias.brendel@med.uni-muenchen.de.'}]",,,"TSPO expression in all target regions of P301S mice increased exponentially from 1.9 to 6.4 months, leading to significant differences in the contrasts with wild-type mice at 6.4 months (+ 11-23%, all p < 0.001), but the apparent microgliosis proceeded more slowly than in our experience in amyloid-β mouse models. Spatial learning and glucose metabolism of AT8-positive P301S mice were significantly impaired at 6.3-6.5 months compared to the wild-type group. Longitudinal increases in TSPO expression predicted greater tau accumulation and lesser spatial learning performance at 6.3-6.7 months.",,"10.1186/s12974-020-01883-5
10.1101/cshperspect.a006189
10.1016/j.exger.2016.12.006
10.1016/S1474-4422(13)70090-5
10.1186/s13024-017-0192-x
10.1038/s41586-019-1769-z
10.3389/fneur.2018.00625
10.2967/jnumed.115.163493
10.1523/JNEUROSCI.22-21-09340.2002
10.1001/jamaneurol.2017.2822
10.1111/nan.12160
10.1016/S0002-9440(10)63421-9
10.1038/srep11161
10.1016/j.celrep.2018.07.072
10.2967/jnumed.115.167858
10.2967/jnumed.117.195107
10.1523/JNEUROSCI.0996-15.2015
10.1038/s41593-018-0296-9
10.1016/j.neuroimage.2017.10.006
10.2967/jnumed.118.217703
10.1016/j.nbd.2008.09.016
10.1186/s12974-018-1347-6
10.1038/s41380-019-0609-8
10.1523/JNEUROSCI.3076-10.2011
10.1016/j.neuron.2007.01.010
10.3233/JAD-179929
10.1016/j.jalz.2018.02.018
10.1111/jnc.14615
10.3233/JAD-170509
10.1038/s41586-018-0543-y",<Element 'PubmedArticle' at 0x7f05dd6ed540>
83,32643143,Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials.,"Alzheimer's disease (AD) pathology is multi-faceted, including extracellular accumulation of amyloid-β (Aβ), accumulation of tau within neurons, glial activation and loss of neurons and synapses. From a neuropathological perspective, usually at a single time-point and often at the end-stage of the disease, it is challenging to understand the cause and effect relationships between these components. There are at least four ways of trying to unravel these relationships. First, genetic studies demonstrate mutations that influence Aβ production, but not tau, can initiate AD; whereas genetic variants influencing AD risk are related to innate immunity and lipid metabolism. Second, studies at early time points show that pathology begins decades before the onset of dementia and indicate different anatomical locations for initiation of Aβ and tau accumulation. Third, cause and effect can be studied in experimental models, but most animal models do not fully replicate AD pathology. However, induced pluripotent stem cells (iPSCs) to study live human neurons has introduced a new perspective. Fourth, clinical trials may alter AD pathology giving insights into cause and effect relationships. Therefore, a sequence of (i) neocortical Aβ accumulation followed by (ii) a microglial inflammatory reaction to Aβ, causing neuritic dystrophy which promotes (iii) spread of tau from the limbic system to the neocortex with (iv) progressive tau accumulation and spread resulting in (v) neurodegeneration, explains the evidence. It is proposed that different therapeutic targets are required for different stages of the disease process: Aβ for primary prevention, microglia for secondary prevention, and tau for established disease.","['Alzheimer’s disease', 'Aβ', 'immunotherapy', 'microglia', 'pathophysiology', 'tau', 'treatment']",Neuropathology and applied neurobiology,2020-07-10,"[{'lastname': 'Boche', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'lastname': 'Nicoll', 'firstname': 'J A R', 'initials': 'JAR', 'affiliation': 'Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.\nDepartment of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}]",,,,© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.,10.1111/nan.12642,<Element 'PubmedArticle' at 0x7f05dd7122c0>
84,"32544086
27570871
21471435
20831921
22229116
28662669
28602351
28930663
26232392
23150934
23150908
12472885
11602640
30572908
25728668
29321225
24893973
25732305
29859094
31564456
26754641
26941262
25936935
23562540
17012293
29073081
30232263
29037207
31601677
17270732
31504240
31413141
28099414
28959956
30392797
25855189
32392471
15728241
19302484
29752066
24899047
28714976
31235932
31932797
26436904
25833819
32008854
24344647
23047530
22047170
24385951
18021299
22095718
28077724
25716838
26374899
31219699
27520774
24899047
27033548
12080485
15049507
25160042
22423084
24075978
18773952
20689505
26847266
22223464
30992040
1136711
31392680
26362250",Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration.,"Alzheimer's disease (AD) is characterized by plaques containing amyloid-β (Aβ) and neurofibrillary tangles composed of aggregated, hyperphosphorylated tau. Beyond tau and Aβ, evidence suggests that microglia play an important role in AD pathogenesis. Rare variants in the microglia-expressed triggering receptor expressed on myeloid cells 2 (TREM2) gene increase AD risk 2- to 4-fold. It is likely that these TREM2 variants increase AD risk by decreasing the response of microglia to Aβ and its local toxicity. However, neocortical Aβ pathology occurs many years before neocortical tau pathology in AD. Thus, it will be important to understand the role of TREM2 in the context of tauopathy. We investigated the impact of the AD-associated TREM2 variant (R47H) on tau-mediated neuropathology in the PS19 mouse model of tauopathy. We assessed PS19 mice expressing human TREM2CV (common variant) or human TREM2R47H. PS19-TREM2R47H mice had significantly attenuated brain atrophy and synapse loss versus PS19-TREM2CV mice. Gene expression analyses and CD68 immunostaining revealed attenuated microglial reactivity in PS19-TREM2R47H versus PS19-TREM2CV mice. There was also a decrease in phagocytosis of postsynaptic elements by microglia expressing TREM2R47H in the PS19 mice and in human AD brains. These findings suggest that impaired TREM2 signaling reduces microglia-mediated neurodegeneration in the setting of tauopathy.","['Alzheimer’s disease', 'Inflammation', 'Innate immunity', 'Neurodegeneration', 'Neuroscience']",The Journal of clinical investigation,2020-06-17,"[{'lastname': 'Gratuze', 'firstname': 'Maud', 'initials': 'M', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Leyns', 'firstname': 'Cheryl Eg', 'initials': 'CE', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Sauerbeck', 'firstname': 'Andrew D', 'initials': 'AD', 'affiliation': 'Department of Neurology.'}, {'lastname': 'St-Pierre', 'firstname': 'Marie-Kim', 'initials': 'MK', 'affiliation': 'Axe Neurosciences, Centre de Recherche, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, Québec, Canada.\nDivision of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.'}, {'lastname': 'Xiong', 'firstname': 'Monica', 'initials': 'M', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Kim', 'firstname': 'Nayeon', 'initials': 'N', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Serrano', 'firstname': 'Javier Remolina', 'initials': 'JR', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Tremblay', 'firstname': 'Marie-Ève', 'initials': 'MÈ', 'affiliation': 'Axe Neurosciences, Centre de Recherche, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, Québec, Canada.\nDivision of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.'}, {'lastname': 'Kummer', 'firstname': 'Terrance T', 'initials': 'TT', 'affiliation': 'Department of Neurology.'}, {'lastname': 'Colonna', 'firstname': 'Marco', 'initials': 'M', 'affiliation': ""Hope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.\nDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Ulrich', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}, {'lastname': 'Holtzman', 'firstname': 'David M', 'initials': 'DM', 'affiliation': ""Department of Neurology.\nHope Center for Neurological Disorders, and.\nKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.""}]",,,,,"10.1172/JCI138179
10.1016/j.jalz.2016.03.001
10.1016/j.disamonth.2010.06.001
10.1186/s13024-017-0192-x
10.1016/j.cell.2017.05.018
10.1016/j.immuni.2017.08.008
10.1007/s00005-015-0351-0
10.1056/NEJMoa1211851
10.1056/NEJMoa1211103
10.1046/j.1471-4159.2002.01243.x
10.1084/jem.194.8.1111
10.1186/s13024-018-0298-9
10.1016/j.cell.2015.01.049
10.1084/jem.20171529
10.1084/jem.20142322
10.1186/s13024-018-0262-8
10.1016/j.cell.2019.09.001
10.1007/s00401-016-1533-5
10.15252/emmm.201506123
10.1016/j.jalz.2014.12.009
10.1016/j.neuron.2013.02.026
10.1073/pnas.1710311114
10.1073/pnas.1811411115
10.1186/s13024-017-0216-6
10.1084/jem.20190980
10.1016/j.neuron.2007.01.010
10.1093/brain/awz241
10.1126/scitranslmed.aau2291
10.1038/nature21029
10.1038/nature24016
10.1016/j.neuron.2018.10.014
10.1523/JNEUROSCI.4274-14.2015
10.1016/j.neuron.2020.04.012
10.1084/jem.20041611
10.1111/j.1471-4159.2009.06042.x
10.1016/j.immuni.2018.04.016
10.1093/hmg/ddu277
10.1038/ng.3916
10.1038/s41593-019-0433-0
10.1038/s41591-019-0695-9
10.1038/nn.4132
10.1016/j.neurobiolaging.2020.01.003
10.1002/cne.23234
10.1111/j.1471-4159.2007.05127.x
10.4049/jimmunol.1100620
10.1523/JNEUROSCI.2459-16.2017
10.1523/JNEUROSCI.2620-14.2015
10.1074/jbc.M115.679043
10.1096/fj.201900527R
10.1016/j.jalz.2016.07.004
10.1093/hmg/ddu277
10.1126/science.aad8373
10.1086/342259
10.1023/B:CEMN.0000012721.08168.ee
10.1016/j.jalz.2014.05.1751
10.1523/JNEUROSCI.4922-11.2012
10.1016/j.neuron.2013.07.046
10.1016/j.jchemneu.2008.08.003
10.3791/2021
10.1002/glia.22966
10.1002/glia.22287
10.1186/s12974-019-1473-9
10.1007/BF00688146
10.1007/978-1-4939-9658-2_8
10.1093/hmg/ddv377",<Element 'PubmedArticle' at 0x7f05dd6af2c0>
85,"32477095
30472949
30696811
25425146
26436904
30038282
2199458
30929793
16862116
11158256
30705270
19345183
28884281
30652266
30559476
26891626
19078960
29296000
28405851
27339073
18070361
30937446
25126727
18760694
15535133
16407953
30326945
31263146
29548672
27862631
30392797
26511503
22231629
9144231
31006494
30232325
30949760
19332546
29752066
30637614
24141946
28404595
29488822
27091974
28846081
30528430
29809138
26780511
23773994
22983114
31209379
18604209
20967887
23266471
31286366
19458225
30643230
29556031
23173708
31331998
30451830
31451800
22643886
26001208
27670763
25485684
29202785
30940800
24951455
21070854
23164821
12923068
27869648
22095718
31026414
15834427
28930663
29508987
20676056
29662056
30143647
23201120
21907199
25242217
31930681
15857927
25136317
31134514
24012002
23260141
27114033
30566373
18234671
28456633
27723233
22771380
22742992
30879788
29948952
31980586
28855509
29426702
28948967
21903584
30850344
26747862
29875132
28669544
30617257
28011153
23265086
30766992
30944478
25902418
2880184
25012223
27021820
29643768
15608632
31471472
29473513
31256143
30232263
27458802
22632727
26766444
29055813
30718903
18568035
28790030
28959956
20887954
28167393
31810470
30721409
19621015
28168961
25735590
23525041
28802038
31665242
29293211
30472088
8705855
23535903
29643512
29376888
16123145
26322584
28963396
28187755
27166859
21029241
31026457
30692699
17270732
31323530
30143969
9790190
30382187
25326800
28077724
30756214",Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer's Disease.,"Alzheimer's disease (AD) has been a major health issue for more than one century since it was first reported in 1906. As one of the most common neurodegenerative diseases, AD is characterized by the presence of senile plaques and neurofibrillary tangles (NFTs) in the affected brain area. Microglia are the major regulators of neuroinflammation in the brain, and neuroinflammation has become recognized as the core pathophysiological process of various neurodegenerative diseases. In the central nervous system (CNS), microglia play a dual role in AD development. For one thing, they degrade amyloid β (Aβ) to resist its deposition; for another, microglia release pro-inflammatory and inflammatory factors, contributing to neuroinflammation as well as the spreading of Aβ and tau pathology. Wnt pathways are important regulators of cell fate and cell activities. The dysregulation of Wnt pathways is responsible for both abnormal tau phosphorylation and synaptic loss in AD. Recent studies have also confirmed the regulatory effect of Wnt signaling on microglial inflammation. Thus, the study of microglia, Wnt pathways, and their possible interactions may open up a new direction for understanding the mechanisms of neuroinflammation in AD. In this review, we summarize the functions of microglia and Wnt pathways and their roles in AD in order to provide new ideas for understanding the pathogenesis of AD.","['AD pathology', 'Alzheimer’s disease', 'Wnt pathway', 'microglia', 'neuroinflammation']",Frontiers in aging neuroscience,2020-06-02,"[{'lastname': 'Yang', 'firstname': 'Yunying', 'initials': 'Y', 'affiliation': 'Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'lastname': 'Zhang', 'firstname': 'Zhentao', 'initials': 'Z', 'affiliation': 'Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.'}]",,,,Copyright © 2020 Yang and Zhang.,"10.3389/fnagi.2020.00110
10.1134/S0006297918090122
10.1038/s41398-019-0388-7
10.1038/ncomms6611
10.1038/nn.4132
10.1038/s41593-018-0192-3
10.1083/jcb.111.2.495
10.1016/j.tcb.2019.02.007
10.1038/nature05016
10.1046/j.1471-4159.2001.00075.x
10.1038/s41467-019-08446-0
10.1016/j.cell.2009.03.024
10.1007/s12035-017-0754-5
10.1007/s12035-019-1467-8
10.1038/s41593-018-0290-2
10.1038/nrn.2015.29
10.1038/nature07441
10.1038/s41467-017-02440-0
10.1007/s10753-017-0556-y
10.1186/s40478-016-0336-1
10.1186/1742-2094-4-29
10.1093/nar/gkz199
10.4161/auto.29647
10.1016/j.neuron.2008.07.033
10.1093/jnen/63.10.1058
10.1038/nature04375
10.1186/s13024-018-0289-x
10.1038/s41598-019-45676-0
10.1016/j.immuni.2018.02.016
10.1111/bpa.12456
10.1016/j.neuron.2018.10.014
10.1016/j.yexcr.2015.10.022
10.1038/cr.2012.10
10.1073/pnas.94.10.5296
10.1016/j.tins.2019.03.003
10.1038/s41398-018-0231-6
10.1007/s00401-019-02000-4
10.1074/jbc.M808986200
10.1016/j.immuni.2018.04.016
10.1007/s10571-019-00649-9
10.1038/nature12631
10.1084/jem.20150237
10.1152/physrev.00011.2017
10.1073/pnas.1604032113
10.1038/nn.4631
10.1016/j.cell.2018.10.049
10.7554/eLife.33385
10.1038/nn.4222
10.1093/hmg/ddt277
10.1038/ncb2574
10.1038/s41593-019-0419-y
10.1038/ni.1636
10.1002/glia.21081
10.1016/j.cellsig.2012.12.006
10.1007/s11626-019-00375-y
10.1523/JNEUROSCI.0421-09.2009
10.1038/s41583-018-0113-1
10.1038/s41593-018-0120-6
10.1186/1471-2202-13-144
10.1523/JNEUROSCI.2994-18.2019
10.1038/s41467-018-07302-x
10.1038/s41551-019-0448-6
10.1038/ncomms1861
10.3109/00207454.2015.1008696
10.1007/s00401-016-1622-5
10.1172/JCI77487
10.1186/s13024-017-0230-8
10.1038/s41467-019-09298-4
10.1016/j.biopsych.2014.05.006
10.1016/j.cellsig.2010.11.004
10.1038/mp.2012.163
10.1096/fj.03-0106fje
10.1172/JCI88486
10.4049/jimmunol.1100620
10.1146/annurev-immunol-042718-041417
10.1038/nm1234
10.1016/j.immuni.2017.08.008
10.1021/acs.accounts.7b00554
10.1038/emboj.2010.167
10.1038/s41467-018-03674-2
10.1038/s41467-018-05858-2
10.1016/j.devcel.2012.10.027
10.1016/j.febslet.2011.08.046
10.1016/j.neuron.2014.08.048
10.15252/embr.201948328
10.1093/brain/awh531
10.3389/fnagi.2014.00198
10.1007/s11064-019-02817-1
10.1016/j.neuron.2013.06.046
10.1016/j.cell.2012.11.024
10.1016/j.cell.2016.04.001
10.1146/annurev-biochem-013118-111829
10.1074/jbc.M707108200
10.1016/j.pneurobio.2017.04.005
10.1111/acel.12522
10.1016/j.arr.2012.06.008
10.1016/j.arr.2012.06.003
10.1016/j.cell.2019.02.014
10.1007/s12035-018-1150-5
10.1523/JNEUROSCI.1871-19.2019
10.1038/s41467-017-00926-5
10.1016/j.immuni.2018.02.014
10.1038/mp.2017.180
10.1074/jbc.M111.267583
10.1016/j.immuni.2019.02.007
10.1093/brain/awv379
10.15252/embj.201798697
10.1016/j.neuron.2017.05.037
10.1038/s41593-018-0296-9
10.1016/j.neuroscience.2016.12.020
10.1021/ja3112093
10.1093/cercor/bhz016
10.1038/s41586-019-1088-4
10.1038/ncomms7906
10.1016/s0140-6736(87)91754-5
10.1093/brain/awu190
10.1038/mp.2016.35
10.3389/fncel.2018.00087
10.1038/nn1374
10.1523/JNEUROSCI.2851-18.2019
10.2174/1570159X16666180222165418
10.3233/JAD-190451
10.1073/pnas.1811411115
10.7554/eLife.15224
10.1016/j.neuron.2012.03.026
10.1016/j.devcel.2015.12.015
10.1016/j.jalz.2017.09.008
10.1038/s41593-018-0334-7
10.1038/nm1782
10.1158/2159-8290.CD-17-0037
10.1038/nature24016
10.1016/j.stem.2010.08.014
10.1016/j.biomaterials.2017.01.024
10.1186/s12974-019-1660-8
10.1007/s00401-018-01957-y
10.1038/mp.2009.72
10.1016/j.biopsych.2016.12.015
10.1016/j.neurobiolaging.2014.12.033
10.1038/nn.3358
10.1016/j.cell.2017.07.023
10.1093/brain/awz319
10.1038/nature25158
10.1016/j.ebiom.2018.11.026
10.1038/nm0896-871
10.1158/2159-8290.CD-13-0081
10.1038/s41586-018-0023-4
10.1172/JCI97229
10.1093/brain/awh609
10.1038/nature14864
10.15252/embj.201696056
10.1186/s12883-017-0813-6
10.1016/j.pneurobio.2016.05.001
10.1111/j.1750-3639.2010.00445.x
10.1016/j.brainres.2019.04.025
10.1038/s41591-018-0336-8
10.1016/j.neuron.2007.01.010
10.1016/j.intimp.2019.105760
10.1007/s12035-018-1299-y
10.1038/27208
10.1038/s41380-018-0286-z
10.1038/nm.3700
10.1523/JNEUROSCI.2459-16.2017
10.1007/s11064-019-02748-x",<Element 'PubmedArticle' at 0x7f05dd669220>
86,"32468440
11034902
20079340
16174740
15615629
27615390
15181244
27877124
17684513
22706086
19258656
15931380
20920788
16866910
14764421
20802793
26638867
28810892
29217824
25517094
23708142
30134156
27169802
20133765
19339974
30559471
27760323
22986780
29906661
20554627
23399914
21771791
24145152
28226226
15229308
15294142
21448224
19166320
15254070
15589694
23494712
22749401
11208902
19156851
22279231
24300092
26150787
11969204
21412171
25101701
21785996
18996096
23623698
23150934
23150934
29196460
10890900
25689443
23254930
15033922
25024306
21460840
22393530
18088381
27133892
15473963
23709744
22896675
15615638
15615638
19184068
28768545
18627032
23150908
21586568
9756854
24904407
24305823
21289173
22766509
24991952
24951455
16352604
19936237
21951685
17973979
22095718
16192374
25945723
18402986
19780903
15181251
24162737
1603325
25596342
23132858
11279214
20103534
18616804
18052981
21159977
17920016
26057852
19945749
20682182
19402773
16567625
26438529
23946390
25721445
20966918
20197276
25833819
20739649
17609668
28483841
27468758
20553310
24795568
16866907
19326444
26192747
21460841
5001846
16452683
12937126
20484116
31815669
26217196
21741992
16939415
22472873
12658281
21281610
17428920
16288750
24381305
26236233
18241055
17598919
14703504
25218443
26296892
11742412
27025652
9735171
11120756
24067533
16476660
23785352
10748223
15130918
29982964
24114864
22934024
25812851
28753424
23871436
26195256
17916878
11581286
21562267
24067654
28426958
30686764
25425283
20406638
18676367
20566652
18363936
23849219
12598530
17868647
14643126
12851640
24860500
15813750
27477018
20478062
24487234
25682154
28077724
25051234",Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer's Disease.,"Cholesterol, a principal constituent of the cell membrane, plays a crucial role in the brain by regulating the synaptic transmission, neuronal signaling, as well as neurodegenerative diseases. Defects in the cholesterol trafficking are associated with enhanced generation of hyperphosphorylated Tau and Amyloid-β protein. Tau, a major microtubule-associated protein in the brain, is the key regulator of the mature neuron. Abnormally hyperphosphorylated Tau hampers the major functions related to microtubule assembly by promoting neurofibrillary tangles of paired helical filaments, twisted ribbons, and straight filaments. The observed pathological changes due to impaired cholesterol and Tau protein accumulation cause Alzheimer's disease. Thus, in order to regulate the pathogenesis of Alzheimer's disease, regulation of cholesterol metabolism, as well as Tau phosphorylation, is essential. The current review provides an overview of (1) cholesterol synthesis in the brain, neurons, astrocytes, and microglia; (2) the mechanism involved in modulating cholesterol concentration between the astrocytes and brain; (3) major mechanisms involved in the hyperphosphorylation of Tau and amyloid-β protein; and (4) microglial involvement in its regulation. Thus, the answering key questions will provide an in-depth information on microglia involvement in managing the pathogenesis of cholesterol-modulated hyperphosphorylated Tau protein.","['Alzheimer’s disease', 'Amyloid-β protein', 'Cholesterol', 'Microglia', 'Tau hyperphosphorylation']",Cellular and molecular neurobiology,2020-05-30,"[{'lastname': 'Nanjundaiah', 'firstname': 'Shwetha', 'initials': 'S', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory (CSIR-NCL), Dr. Homi Bhabha Road, Pune, 411008, India.'}, {'lastname': 'Chidambaram', 'firstname': 'Hariharakrishnan', 'initials': 'H', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory (CSIR-NCL), Dr. Homi Bhabha Road, Pune, 411008, India.\nAcademy of Scientific and Innovative Research (AcSIR), New Delhi, 110025, India.'}, {'lastname': 'Chandrashekar', 'firstname': 'Madhura', 'initials': 'M', 'affiliation': 'School of Biomedical Engineering and Sciences, MIT University, Loni Kalbhor, Pune, 412201, India.'}, {'lastname': 'Chinnathambi', 'firstname': 'Subashchandrabose', 'initials': 'S', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory (CSIR-NCL), Dr. Homi Bhabha Road, Pune, 411008, India. s.chinnathambi@ncl.res.in.\nAcademy of Scientific and Innovative Research (AcSIR), New Delhi, 110025, India. s.chinnathambi@ncl.res.in.'}]",,,,,"10.1007/s10571-020-00883-6
10.1016/j.brainres.2010.01.006
10.1074/jbc.M405131200
10.1073/pnas.91.12.5562
10.1073/pnas.0503689102
10.1016/0014-5793(90)81107-Y
10.1016/j.bbadis.2004.08.010
10.1016/j.brainresbull.2016.08.018
10.1385/JMN:23:3:157
10.3389/fnagi.2016.00262
10.1074/jbc.274.21.14624
10.1038/nrn2194
10.4049/jimmunol.1200887
10.1172/JCI24761
10.1016/j.neuron.2010.08.023
10.1111/j.1600-0404.2006.00684.x
10.1161/01.ATV.0000120374.59826.1b
10.1016/j.jacl.2009.11.003
10.3233/JAD-150704
10.1186/s13024-017-0200-1
10.1038/s41398-017-0013-6
10.1038/nature14067
10.1038/nn.3435
10.1016/j.celrep.2018.07.072
10.1126/scitranslmed.aaf2362
10.1073/pnas.0913828107
10.1038/nrn2620
10.1038/s41593-018-0289-8
10.1016/j.celrep.2016.09.063
10.3233/JAD-2012-121399
10.1016/j.neurobiolaging.2018.04.019
10.1001/archneurol.2010.147
10.1126/science.277.5323.228
10.1038/mp.2013.1
10.1074/jbc.M111.254268
10.1016/j.matbio.2013.10.004
10.1146/annurev-immunol-051116-052358
10.1126/science.8346443
10.1056/NEJMra040223
10.1186/s12974-019-1694-y
10.1074/jbc.272.49.30766
10.1016/j.neuron.2004.07.017
10.4161/cam.2.2.6374
10.1016/S0021-9258(19)45374-X
10.1038/nrn3012
10.1515/BC.2009.035
10.1097/00041433-200104000-00003
10.1194/jlr.R400004-JLR200
10.1016/j.biochi.2004.09.018
10.3389/fphys.2013.00045
10.1016/j.molcel.2012.05.037
10.1046/j.1471-4159.2001.00063.x
10.1002/hipo.20548
10.1523/JNEUROSCI.2272-11.2012
10.1016/j.bbrc.2013.11.077
10.3389/fnagi.2015.00119
10.1006/bbrc.2001.2008
10.1097/NEN.0b013e318212f185
10.1097/NEN.0000000000000103
10.1007/s12031-011-9593-4
10.2174/092986708785909111
10.3233/JAD-2006-9101
10.1016/j.brainres.2008.10.036
10.1016/j.neuron.2013.04.014
10.1056/NEJMoa1211851
10.1056/NEJMoa1211851
10.1046/j.1471-4159.2003.02287.x
10.3389/fphar.2012.00014
10.1073/pnas.140218797
10.1038/ni.3102
10.1038/nature11729
10.1096/fj.03-0978fje
10.3233/JAD-132450
10.1038/ng.803
10.1101/cshperspect.a006312
10.1111/j.1471-4159.2007.05194.x
10.1186/s12974-018-1309-z
10.1007/978-1-4419-8969-7_8
10.1016/j.jalz.2016.01.014
10.1016/j.neuron.2004.08.043
10.1161/STROKEAHA.112.678698
10.1126/scitranslmed.3003748
10.1016/j.bbadis.2004.09.008
10.1016/j.bbadis.2004.09.008
10.1007/s00401-009-0486-3
10.1186/s13024-017-0197-5
10.3233/JAD-1999-14-512
10.1002/jnr.21787
10.1056/NEJMoa1211103
10.1074/jbc.M110.172445
10.1074/jbc.273.41.26285
10.3389/fnagi.2014.00093
10.1523/JNEUROSCI.3487-13.2013
10.1523/JNEUROSCI.5491-10.2011
10.1210/er.2011-1049
10.1083/jcb.101.2.446
10.1016/j.neuron.2014.05.041
10.1016/j.biopsych.2014.05.006
10.1074/jbc.M508915200
10.1371/journal.pone.0007917
10.1111/j.1471-4159.1992.tb09432.x
10.1182/blood-2011-04-348946
10.1111/j.1471-4159.2007.05099.x
10.4049/jimmunol.1100620
10.1523/JNEUROSCI.2868-05.2005
10.1016/S0021-9258(20)80536-5
10.1515/bmc-2015-0007
10.1016/j.neuropharm.2008.02.019
10.1111/j.1471-4159.2009.06402.x
10.1385/JMN:23:3:225
10.1038/ng.2802
10.1016/0306-4522(92)90500-2
10.1016/j.bbalip.2014.12.018
10.1186/s12974-018-1148-y
10.1074/jbc.M112.420224
10.1074/jbc.M101589200
10.1016/S0021-9258(17)42989-9
10.1242/jcs.060681
10.1155/2018/3965054
10.1186/1750-1326-3-8
10.1111/j.1460-9568.2007.05955.x
10.1523/JNEUROSCI.4067-10.2010
10.1016/j.neuron.2007.08.008
10.1016/S0960-9822(02)00777-7
10.1038/srep11161
10.1016/j.molimm.2009.11.004
10.1016/j.arcmed.2010.03.007
10.1586/ern.09.18
10.1007/s00109-016-1427-y
10.1073/pnas.0600549103
10.1186/s13024-015-0048-1
10.1523/JNEUROSCI.1224-13.2013
10.1159/000373949
10.1038/mp.2010.17
10.1074/jbc.M109.085126
10.1093/brain/awv081
10.1212/WNL.0b013e3181eee25f
10.1038/nrm2216
10.15252/embr.201743922
10.1096/fj.201600275R
10.1111/j.1755-5949.2010.00177.x
10.3389/fncel.2014.00113
10.1111/j.1600-0404.2006.00681.x
10.1002/jnr.22073
10.1007/BF02527711
10.1038/nn.4067
10.1038/ng.801
10.1146/annurev-immunol-032713-120240
10.1523/JNEUROSCI.4946-05.2006
10.1155/2012/292598
10.1161/01.ATV.19.5.1306
10.1126/science.1202529
10.1016/S0002-9440(10)63445-1
10.1126/scisignal.2000500
10.3389/fncel.2018.00172
10.7554/eLife.50830
10.3389/fnana.2015.00092
10.1016/j.plipres.2011.06.002
10.1038/nature01640
10.1042/BJ20060463
10.1038/mp.2012.15
10.1007/s00109-014-1138-1
10.1038/nn0403-345
10.14336/AD.2018.1025
10.1016/j.brainres.2011.01.084
10.1073/pnas.0700899104
10.1016/j.febslet.2005.10.024
10.1093/hmg/ddt666
10.3389/fnagi.2015.00136
10.1002/cne.21605
10.1046/j.1471-4159.1998.70062369.x
10.1186/1750-1326-2-12
10.1016/0896-6273(93)90070-8
10.1194/jlr.D300032-JLR200
10.3233/JAD-2010-100432
10.1016/j.jsbmb.2014.09.008
10.1074/jbc.M115.637207
10.1038/414799a
10.3389/fendo.2014.00143
10.15252/emmm.201606210
10.1006/abbi.1998.0813
10.1172/JCI10498
10.1093/hmg/ddt478
10.1016/j.neuron.2006.01.022
10.3389/fneur.2013.00074
10.1007/BF00925955
10.1074/jbc.M910430199
10.1161/01.ATV.0000131264.66417.d5
10.1007/s12031-018-1111-5
10.1002/ana.24029
10.3389/fphys.2012.00269
10.3233/JAD-150072
10.1016/j.cell.2017.07.004
10.1083/jcb.150.5.989
10.1016/j.molmed.2013.06.004
10.1038/nrneurol.2015.119
10.1194/jlr.M700364-JLR200
10.1083/jcb.200106025
10.1523/JNEUROSCI.6546-10.2011
10.1073/pnas.1315110110
10.1016/j.neuron.2017.02.042
10.1016/j.stem.2018.12.013
10.1007/s10545-014-9794-4
10.1016/0169-328X(95)00316-K
10.1016/j.expneurol.2010.04.006
10.1038/nrn.2015.1
10.1074/jbc.M804808200
10.1074/jbc.M110.145318
10.1111/j.1750-3639.2008.00133.x
10.1186/alzrt187
10.1074/jbc.M208786200
10.1016/j.bbrc.2007.08.109
10.1016/S0140-6736(03)14856-8
10.3390/ijms20010081
10.1038/sj.mp.4001296
10.3389/fnagi.2014.00091
10.1111/j.1600-0854.2005.00285.x
10.1016/j.bbadis.2017.07.019
10.1016/j.neuron.2016.06.015
10.1186/1750-1326-5-19
10.1038/nn.3641
10.1007/s13238-014-0131-3
10.1523/JNEUROSCI.2459-16.2017
10.1371/journal.pone.0103187",<Element 'PubmedArticle' at 0x7f05dd64adb0>
87,"32391019
10858586
23046210
24638131
22921944
25120476
19014446
30250480
24162737
19812666
28714976
23390181
24833586
30287177
25504093
23266538
25331895
25364500
25417146
23589904
17908844
19767111
16567719
30087609
25309543
20303872
31708347
21616434
18803306
19089397
19052556
18620057
20346772
18297073
12855817
14699082
16697053
25017883
23463005
25969543
14570867
16908670
16179587
20218969
21772670
24145446
30692699
25059667
27379212
28325905
12200037
31312202
26572245
24794147
9324355
16801213
30186497
15701712
20385881
20484116
12782711
10531067
14722108
31413141
22474023
16887962
21956652
29887864
24945405
30548312
28768545
19459036
16157451
31175027
21236243
22272615
23272070
15857927
19776284
20037584
19834064
16984903
16219804
16339765
19559490
11755009
15473997
15649704
23322736
19211891
25178404
28123027
11553297
13678674
19320056
21827663
18510752
18509040
21084593
22051943
21115468
17167474
22395709
20231468
18926603
21593864
23774505
14633589
15031312
15907742
18316138
17536046
24991031
30630955
21238472
26431348
15249654
20814545
25182736
24910016
23993702
18759972
22249135
22747753
16192374
31803043
26838764
21722209
29134111
28610747
28406691
28088641
30833177
31075861
15716415
29643512
24766892
26121197
31036962
26482651
29457783
24093676
17203473
30261683
23831373
18604209
29293211
23254930
18302763
21763676
31748742
30206330
27923741
29789522
31053149
31082627
31359456
27669650
24043892
19570822
28109721
31702392
24357806
30459926
29880500
16760575
24499275
28600003
21546088
22715882
23946404
31906973
26400934
2360787
1789684
19734903
6382906
1438191
9330973
10666378
30415998
11027207
27567854
26887322
30243924
31032394
31047856
15269255
27033548
30392797
8431789
28566429
31433986
31774586
19561098
23150673
18562603
12119423
24948809
28099414
17363730
20800895
10996210
23613465
24043889
27211870
26657954
29777220
31391546",TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease.,"Amyloid plaques, mainly composed of abnormally aggregated amyloid β-protein (Aβ) in the brain parenchyma, and neurofibrillary tangles (NFTs), consisting of hyperphosphorylated tau protein aggregates in neurons, are two pathological hallmarks of Alzheimer's disease (AD). Aβ fibrils and tau aggregates in the brain are closely associated with neuroinflammation and synapse loss, characterized by activated microglia and dystrophic neurites. Genome-wide genetic association studies revealed important roles of innate immune cells in the pathogenesis of late-onset AD by recognizing a dozen genetic risk loci that modulate innate immune activities. Furthermore, microglia, brain resident innate immune cells, have been increasingly recognized to play key, opposing roles in AD pathogenesis by either eliminating toxic Aβ aggregates and enhancing neuronal plasticity or producing proinflammatory cytokines, reactive oxygen species, and synaptotoxicity. Aggregated Aβ binds to toll-like receptor 4 (TLR4) and activates microglia, resulting in increased phagocytosis and cytokine production. Complement components are associated with amyloid plaques and NFTs. Aggregated Aβ can activate complement, leading to synapse pruning and loss by microglial phagocytosis. Systemic inflammation can activate microglial TLR4, NLRP3 inflammasome, and complement in the brain, leading to neuroinflammation, Aβ accumulation, synapse loss and neurodegeneration. The host immune response has been shown to function through complex crosstalk between the TLR, complement and inflammasome signaling pathways. Accordingly, targeting the molecular mechanisms underlying the TLR-complement-NLRP3 inflammasome signaling pathways can be a preventive and therapeutic approach for AD.","[""Alzheimer's disease"", 'TLR4', 'amyloid', 'complement', 'inflammasome', 'synapse']",Frontiers in immunology,2020-05-12,"[{'lastname': 'Yang', 'firstname': 'Junling', 'initials': 'J', 'affiliation': 'Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, United States.'}, {'lastname': 'Wise', 'firstname': 'Leslie', 'initials': 'L', 'affiliation': 'Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, United States.'}, {'lastname': 'Fukuchi', 'firstname': 'Ken-Ichiro', 'initials': 'KI', 'affiliation': 'Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, United States.'}]",,,,"Copyright © 2020 Yang, Wise and Fukuchi.","10.3389/fimmu.2020.00724
10.1016/S0197-4580(00)00124-X
10.1111/j.1365-2990.2012.01307.x
10.1038/nrneurol.2014.38
10.1016/j.brainresbull.2012.08.003
10.3389/fnagi.2014.00171
10.1186/1742-2094-5-51
10.3389/fgene.2018.00362
10.1038/ng.2802
10.1038/nature08494
10.1038/ng.3916
10.1212/WNL.0b013e31828726f5
10.1093/gerona/glu057
10.1016/j.smim.2018.09.003
10.1002/gps.4245
10.1001/2013.jamapsychiatry.102
10.1073/pnas.1415191111
10.1186/2045-5380-4-10
10.1016/j.cell.2014.10.039
10.2174/1381612811319090015
10.14219/jada.archive.2007.0046
10.1016/j.jneuroim.2009.08.013
10.1212/01.wnl.0000203644.68059.5f
10.3389/fnagi.2018.00224
10.3389/fimmu.2014.00461
10.1016/j.cell.2010.01.022
10.1016/j.smim.2019.101340
10.1016/j.immuni.2011.05.006
10.1002/glia.20763
10.1007/s00109-008-0426-z
10.1038/nrc2541
10.1016/j.phrs.2008.06.007
10.1016/j.immuni.2010.03.012
10.1038/ni1569
10.1126/science.1087262
10.1084/jem.20031237
10.1016/j.jneuroim.2006.03.012
10.1016/j.expneurol.2014.01.001
10.1038/ncomms2534
10.1126/scisignal.2005965
10.1074/jbc.M309888200
10.1083/jcb.200601030
10.1161/01.RES.0000187467.67684.43
10.1042/BJ20100016
10.1155/2011/949072
10.1073/pnas.1314145110
10.1038/s41591-018-0336-8
10.1074/jbc.M113.523480
10.3389/fonc.2016.00151
10.1038/s41598-017-00290-w
10.1016/S1357-2725(02)00041-9
10.3389/fimmu.2019.01493
10.1111/imm.12556
10.1007/s12035-014-8723-8
10.1016/S1074-7613(00)80356-8
10.1080/15216540600756004
10.3892/etm.2018.6460
10.1182/blood-2005-01-0191
10.4049/jimmunol.0901423
10.1126/scisignal.2000500
10.1084/jem.20021842
10.1126/science.286.5440.790
10.1074/jbc.C300487200
10.1126/scitranslmed.aau2291
10.4049/jimmunol.1200202
10.4049/jimmunol.177.4.2051
10.1002/eji.201141679
10.3389/fimmu.2018.01121
10.1371/journal.ppat.1004167
10.1002/glia.23563
10.1186/s13024-017-0197-5
10.1007/s10875-009-9297-5
10.1016/j.neulet.2005.08.047
10.1016/j.jalz.2019.03.012
10.1016/j.brainres.2011.01.007
10.2174/156720512800492495
10.1371/journal.pone.0050771
10.1093/brain/awh531
10.1523/JNEUROSCI.3158-09.2009
10.1038/ni.1836
10.2353/ajpath.2009.090418
10.1093/brain/awl249
10.1096/fj.05-4578fje
10.1074/jbc.M508125200
10.1016/j.jneuroim.2009.05.018
10.1016/S0197-4580(01)00292-5
10.1016/j.expneurol.2004.07.007
10.1016/j.nbd.2004.09.009
10.1073/pnas.1215165110
10.1523/JNEUROSCI.5715-08.2009
10.1186/PREACCEPT-2151623761356337
10.1523/JNEUROSCI.1967-16.2016
10.1046/j.0953-816x.2001.01666.x
10.1016/S0969-9961(03)00069-X
10.1016/j.nbd.2009.01.006
10.1186/1742-2094-8-92
10.1186/1742-2094-5-23
10.1523/JNEUROSCI.1146-08.2008
10.1523/JNEUROSCI.2637-10.2010
10.1016/j.bbr.2011.10.027
10.1093/brain/awq325
10.1038/nature05485
10.1038/nm.2627
10.1073/pnas.1000645107
10.1016/j.neurobiolaging.2008.08.022
10.1038/nature10146
10.1093/cvr/cvt161
10.1016/S0002-9440(10)63572-9
10.1093/gerona/59.3.M268
10.1016/S1474-4422(05)70099-5
10.1016/j.neurobiolaging.2008.01.008
10.1212/01.wnl.0000263217.36439.da
10.1212/WNL.0000000000000665
10.1136/jnnp-2018-319148
10.1016/j.mad.2010.12.005
10.1159/000430248
10.1073/pnas.0403249101
10.1155/2010/212563
10.3233/JAD-140621
10.1111/ene.12477
10.1016/j.neurobiolaging.2013.07.025
10.1186/1742-2094-5-37
10.1016/j.bbr.2012.01.010
10.1186/1742-2094-9-151
10.1523/JNEUROSCI.2868-05.2005
10.3389/fnagi.2019.00279
10.1186/s12974-016-0493-y
10.1111/j.1460-9568.2011.07764.x
10.1038/s41514-017-0015-x
10.1016/j.bbi.2017.06.002
10.33549/physiolres.933480
10.1016/j.bbi.2017.01.010
10.1016/j.it.2019.02.001
10.3390/ijms20092293
10.1523/JNEUROSCI.4268-04.2005
10.1038/s41586-018-0023-4
10.1016/j.molcel.2014.03.030
10.1038/nm.3893
10.1038/s41577-019-0165-0
10.1186/s13073-015-0232-5
10.1172/JCI95145
10.1016/j.cmet.2013.09.010
10.1002/glia.20468
10.3390/ijms19102937
10.1016/j.neurobiolaging.2013.05.018
10.1038/ni.1636
10.1038/nature25158
10.1038/nature11729
10.1186/1742-2094-5-7
10.1016/j.ajpath.2011.05.045
10.1038/s41586-019-1769-z
10.1038/s41583-018-0055-7
10.1016/j.neuroscience.2016.11.037
10.1038/s41467-018-04376-5
10.1186/s13041-019-0463-2
10.1016/j.jad.2019.05.009
10.15252/embj.2018101064
10.1016/j.tibs.2016.09.002
10.4049/jimmunol.1301681
10.4049/jimmunol.0901363
10.1016/j.molmed.2016.12.007
10.1096/fj.201900439
10.1038/cddis.2013.503
10.1186/s41232-018-0085-6
10.1161/CIRCRESAHA.118.311362
10.1385/IR:34:2:157
10.1146/annurev-immunol-032713-120154
10.1016/j.molimm.2017.05.019
10.1016/j.molimm.2011.04.003
10.1146/annurev-neuro-061010-113810
10.1523/JNEUROSCI.1333-13.2013
10.1186/s12974-019-1683-1
10.1523/JNEUROSCI.1698-15.2015
10.1002/ana.410270502
10.1002/ana.410300410
10.1038/ng.439
10.1007/BF00687336
10.1073/pnas.89.21.10016
10.1016/S0197-4580(97)00042-0
10.1016/S0002-9440(10)64753-0
10.1016/j.neuron.2018.10.031
10.1523/JNEUROSCI.20-20-07505.2000
10.3233/JAD-160420
10.1186/s40478-016-0277-8
10.1016/j.jalz.2018.07.223
10.1016/j.dadm.2018.11.002
10.1016/j.jalz.2019.03.007
10.1523/JNEUROSCI.0901-04.2004
10.1126/science.aad8373
10.1016/j.neuron.2018.10.014
10.1016/0006-8993(93)91698-R
10.1126/scitranslmed.aaf6295
10.1016/j.celrep.2019.07.060
10.1002/glia.23757
10.4049/jimmunol.0901005
10.1074/jbc.M112.400168
10.1523/JNEUROSCI.0829-08.2008
10.1073/pnas.162350199
10.1523/JNEUROSCI.5002-13.2014
10.1038/nature21029
10.1182/blood-2006-12-063636
10.1016/j.molimm.2010.07.004
10.1016/S0165-5728(00)00291-5
10.1242/jcs.124388
10.4049/jimmunol.1301355
10.1038/nrneph.2016.70
10.1038/npp.2015.262
10.1038/s41590-018-0110-6
10.1038/s41380-019-0468-3",<Element 'PubmedArticle' at 0x7f05dd5c72c0>
88,"32375809
15172746
21777559
27179961
24144733
23477989
23446680
12743238
12130773
28077397
25792098
17270732
25833819
28122877
26687817
28575151
29902557
10190820
27563289
8126267
12874777
9345505
17204713
17354849
23719155
18051085
20656036
24412399
31074062
26984188
26141264
25953778
31276244
8843599
27190023","The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.","The aim of this longitudinal study was to assess with positron emission tomography (PET) the relationship between levels of inflammation and the loads of aggregated β-amyloid and tau at baseline and again after 2 years in prodromal Alzheimer's disease.
Forty-three subjects with mild cognitive impairment (MCI) had serial 
Those MCI subjects with high 
Our baseline and 2-year imaging findings are compatible with a biphasic trajectory of inflammation in Alzheimer's disease: MCI cases with low baseline but subsequently rising β-amyloid load show correlated levels of microglial activation which then later decline when the β-amyloid load approaches AD levels. Later, as tau tangles form in β-amyloid positive MCI cases with prodromal AD, the rising tau load is associated with higher levels of inflammation.","['Alzheimer', 'Flortaucipir', 'MCI', 'Microglia', 'Neuroinflammation', 'PET', 'PK11195', 'PiB', 'Tau', 'β-amyloid']",Journal of neuroinflammation,2020-05-08,"[{'lastname': 'Ismail', 'firstname': 'Rola', 'initials': 'R', 'affiliation': 'Department of Clinical Medicine, PET-Centre, Aarhus University, Aarhus, Denmark. rola.ismail@clin.au.dk.'}, {'lastname': 'Parbo', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.'}, {'lastname': 'Madsen', 'firstname': 'Lasse Stensvig', 'initials': 'LS', 'affiliation': 'Department of Clinical Medicine, PET-Centre, Aarhus University, Aarhus, Denmark.'}, {'lastname': 'Hansen', 'firstname': 'Allan K', 'initials': 'AK', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.'}, {'lastname': 'Hansen', 'firstname': 'Kim V', 'initials': 'KV', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.'}, {'lastname': 'Schaldemose', 'firstname': 'Jeppe L', 'initials': 'JL', 'affiliation': 'Department of Clinical Medicine, PET-Centre, Aarhus University, Aarhus, Denmark.'}, {'lastname': 'Kjeldsen', 'firstname': 'Pernille L', 'initials': 'PL', 'affiliation': 'Department of Clinical Medicine, PET-Centre, Aarhus University, Aarhus, Denmark.'}, {'lastname': 'Stokholm', 'firstname': 'Morten G', 'initials': 'MG', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.'}, {'lastname': 'Gottrup', 'firstname': 'Hanne', 'initials': 'H', 'affiliation': 'Dept. of Neurology, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Eskildsen', 'firstname': 'Simon F', 'initials': 'SF', 'affiliation': 'Centre of Functionally Integrative Neuroscience (CFIN), Aarhus University, Aarhus, Denmark.'}, {'lastname': 'Brooks', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Clinical Medicine, PET-Centre, Aarhus University, Aarhus, Denmark.\nInstitute of Neuroscience, University of Newcastle upon Tyne, Tyne, UK.\nDepartment of Medicine, Imperial College London, London, UK.'}]",,,Those MCI subjects with high ,,"10.1186/s12974-020-01820-6
10.1016/j.neurobiolaging.2004.01.007
10.1212/WNL.0b013e3182840bbe
10.1016/j.neuron.2007.01.010
10.1093/brain/awx120
10.1007/BFb0056229
10.1002/hbm.10123
10.1007/11866763_101
10.1007/978-3-540-75757-3_50
10.1111/jon.12629
10.1093/brain/aww017
10.1111/bpa.12763
10.1093/brain/aww098",<Element 'PubmedArticle' at 0x7f05dd544d60>
89,"32144141
7539162
6812382
2974227
3670729
24052108
25022541
22336816
28867259
29494807
21784351
12429373
11207825
10623648
9218507
30362029
21683475
29843241
27770234
10487842
10589538
12414533
23575824
12895417
25540024
15748844
15541880
21143159
25278855
24903713
20164597
30210330
22472085
24831823
25808554
16212664
16232318
21414686
30182855
19629762
12440481
12214085
30833695
24951455
28099414
23981039
30134156
26487484
21821124
20655510
26772638
18572275
9144231
10980129
18637012
9665462
22543850
9225377
26747862
26547034
16307829
16606766
31047856
23380586
29352259
22303443
27453930
30814948
31353852
23628985
11959396
16843497
16688597
29367720
15895084
15831717
21527731
19339593
20678811
26511387
26759481
28763060
31297718
19277012
30173917
31831638
1549228
4919693
2360787
8042925
1789684
7175555",Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain.,"Chronic inflammation during Alzheimer's disease (AD) is most often attributed to sustained microglial activation in response to amyloid-β (Aβ) plaque deposits and cell death. However, cytokine release and microgliosis are consistently observed in AD transgenic animal models devoid of such pathologies, bringing into question the underlying processes that may be at play during the earliest AD-related immune response. We propose that this plaque-independent inflammatory reaction originates from neurons burdened with increasing levels of soluble and oligomeric Aβ, which are known to be the most toxic amyloid species within the brain. Laser microdissected neurons extracted from preplaque amyloid precursor protein (APP) transgenic rats were found to produce a variety of potent immune factors, both at the transcript and protein levels. Neuron-derived cytokines correlated with the extent of microglial activation and mobilization, even in the absence of extracellular plaques and cell death. Importantly, we identified an inflammatory profile unique to Aβ-burdened neurons, since neighboring glial cells did not express similar molecules. Moreover, we demonstrate within disease-vulnerable regions of the human brain that a neuron-specific inflammatory response may precede insoluble Aβ plaque and tau tangle formation. Thus, we reveal the Aβ-burdened neuron as a primary proinflammatory agent, implicating the intraneuronal accumulation of Aβ as a significant immunological component in the AD pathogenesis.","['Alzheimer’s disease', 'intraneuronal Aβ', 'neuronal inflammation', 'preplaque pathology']",Proceedings of the National Academy of Sciences of the United States of America,2020-03-08,"[{'lastname': 'Welikovitch', 'firstname': 'Lindsay A', 'initials': 'LA', 'affiliation': 'Department of Neurology and Neurosurgery, McGill University, Montreal, QC H3G 1Y6, Canada.'}, {'lastname': 'Do Carmo', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada.'}, {'lastname': 'Maglóczky', 'firstname': 'Zsófia', 'initials': 'Z', 'affiliation': 'Human Brain Research Laboratory, Institute of Experimental Medicine of the Hungarian Academy of Sciences, 1051 Budapest, Hungary.'}, {'lastname': 'Malcolm', 'firstname': 'Janice C', 'initials': 'JC', 'affiliation': 'Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3G 1Y6, Canada.'}, {'lastname': 'Lőke', 'firstname': 'János', 'initials': 'J', 'affiliation': 'Department of Psychiatry, Szent Borbála Hospital, 2800 Tatabánya, Hungary.'}, {'lastname': 'Klein', 'firstname': 'William L', 'initials': 'WL', 'affiliation': 'Department of Neurobiology, Northwestern University, Evanston, IL 60208.'}, {'lastname': 'Freund', 'firstname': 'Tamás', 'initials': 'T', 'affiliation': 'Laboratory of Cerebral Cortex Research, Institute of Experimental Medicine of the Hungarian Academy of Sciences, 1051 Budapest, Hungary.'}, {'lastname': 'Cuello', 'firstname': 'A Claudio', 'initials': 'AC', 'affiliation': 'Department of Neurology and Neurosurgery, McGill University, Montreal, QC H3G 1Y6, Canada; claudio.cuello@mcgill.ca.\nDepartment of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada.\nDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC H3G 1Y6, Canada.\nDepartment of Pharmacology, University of Oxford, OX1 2JD Oxford, Oxford, United Kingdom.'}]",,,,Copyright © 2020 the Author(s). Published by PNAS.,10.1073/pnas.1914593117,<Element 'PubmedArticle' at 0x7f05dd4e48b0>
90,32067292,Progression of Alzheimer's disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy.,"Alzheimer's disease (AD) is an incurable disease that affects most of the 47 million people estimated as living with dementia worldwide. The main histopathological hallmarks of AD are extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. In recent years, Aβ-immunotherapy has been revealed as a potential tool in AD treatment. One strategy consists of using single-chain variable fragments (scFvs), which avoids the fragment crystallizable (Fc) effects that are supposed to trigger a microglial response, leading to microhemorrhages and vasogenic edemas, as evidenced in clinical trials with bapineuzumab. The scFv-h3D6 generated by our research group derives from this monoclonal antibody, which targets the N-terminal of the Aβ peptide and recognizes monomers, oligomers and fibrils. In this study, 3xTg-AD mice were intraperitoneally and monthly treated with 100 μg of scFv-h3D6 (a dose of ~3.3 mg/kg) or PBS, from 5 to 12 months of age (-mo), the age at which the mice were sacrificed and samples collected for histological and biochemical analyses. During treatments, four monitoring sessions using magnetic resonance imaging and spectroscopy (MRI/MRS) were performed at 5, 7, 9, and 12 months of age. MRI/MRS techniques are widely used in both human and mouse research, allowing to draw an in vivo picture of concrete aspects of the pathology in a non-invasive manner and allowing to monitor its development across time. Compared with the genetic background, 3xTg-AD mice presented a smaller volume in almost all cerebral regions and ages examined, an increase in both the intra and extracellular Aβ","['3xTg-AD', ""Alzheimer's disease"", 'MRI', 'MRS', 'immunotherapy', 'scFv-h3D6']",NMR in biomedicine,2020-02-19,"[{'lastname': 'Güell-Bosch', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.'}, {'lastname': 'Lope-Piedrafita', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Servei de Ressonància Magnètica Nuclear, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.\nCentro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.'}, {'lastname': 'Esquerda-Canals', 'firstname': 'G', 'initials': 'G', 'affiliation': 'Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.'}, {'lastname': 'Montoliu-Gaya', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.'}, {'lastname': 'Villegas', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.'}]",,,,"© 2020 John Wiley & Sons, Ltd.",10.1002/nbm.4263,<Element 'PubmedArticle' at 0x7f05dd51a220>
91,"32046119
30643396
29673549
9562472
23276979
20955934
22035455
23085451
29067297
20123072
29530410
31229535
29447008
26715031
25346011
19414536
18431461
17032697
30572254
12565837
8751438
29782315
26175217
17982277
30406177
25991443
30339715
20632195
9518610
30116300
25716012
30953557
26224068
22580958
22293756
24531836
27797173
27557632
15499593
22645697
11520119
16984903
23905994
31130513
30911133
26639620
16432899
15340159
31271749
23554486
21884699
30902646
20014975
26253613
15915542
17241110
14623906
29106804
26226128
19387116
12808450
19464758
15882940
27323891
18657529
15457210
19906677
29329433
21548780
22330073
11062499
25071777
29275160
19776284
17986235
18510752
31134514
21956652
30756214
21827663
27641666
27605009
24355566
18596701
8532113
13678674
24223593
31047856
29432519
23524657
28328043
30728536
27553758
11150482
15212827
18855584
16865397
16286548
22166855
30071285
19006850
24220159
31105025
31972087
24859607
30417405
31229637
26921471
24352029
31073286
29034441
26605648
29391235
26295040
26899576
22406537
29115637
26391026
30610591
23322736
26643273
30676698
30756299
31260721
22118570
30031930
20107219
31104627
11754986
12476347
29850777
26886723
29127006
28205565
21192237
24696507","Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting.","Alzheimer's disease (AD) is a devastating neurodegenerative disorder and a leading cause of dementia, with accumulation of amyloid-beta (Aβ) and neurofibrillary tangles (NFTs) as defining pathological features. AD presents a serious global health concern with no cure to date, reflecting the complexity of its pathogenesis. Recent evidence indicates that neuroinflammation serves as the link between amyloid deposition, Tau pathology, and neurodegeneration. The high mobility group box 1 (HMGB1) protein, an initiator and activator of neuroinflammatory responses, has been involved in the pathogenesis of neurodegenerative diseases, including AD. HMGB1 is a typical damage-associated molecular pattern (DAMP) protein that exerts its biological activity mainly through binding to the receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4). RAGE and TLR4 are key components of the innate immune system that both bind to HMGB1. Targeting of HMGB1, RAGE, and TLR4 in experimental AD models has demonstrated beneficial effects in halting AD progression by suppressing neuroinflammation, reducing Aβ load and production, improving spatial learning, and inhibiting microglial stimulation. Herein, we discuss the contribution of HMGB1 and its receptor signaling in neuroinflammation and AD pathogenesis, providing evidence of its beneficial effects upon therapeutic targeting.","['Alzheimer’s disease', 'HMGB1', 'Neuroinflammation', 'RAGE', 'TLR4']",Cells,2020-02-13,"[{'lastname': 'Paudel', 'firstname': 'Yam Nath', 'initials': 'YN', 'affiliation': 'Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor 46150, Malaysia.'}, {'lastname': 'Angelopoulou', 'firstname': 'Efthalia', 'initials': 'E', 'affiliation': 'Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.'}, {'lastname': 'Piperi', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.'}, {'lastname': 'Othman', 'firstname': 'Iekhsan', 'initials': 'I', 'affiliation': 'Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor 46150, Malaysia.'}, {'lastname': 'Aamir', 'firstname': 'Khurram', 'initials': 'K', 'affiliation': ""School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya 47500, Malaysia.""}, {'lastname': 'Shaikh', 'firstname': 'Mohd Farooq', 'initials': 'MF', 'affiliation': 'Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor 46150, Malaysia.'}]",,,,,"10.3390/cells9020383
10.2147/CIA.S159148
10.1016/j.bj.2018.01.003
10.1016/S0197-4580(98)00033-5
10.2741/E605
10.1016/j.neuron.2010.10.013
10.1111/j.1365-2125.2011.04134.x
10.1016/j.arcmed.2012.09.009
10.1016/j.trci.2016.05.001
10.1016/j.bbagrm.2009.09.008
10.1016/j.ejphar.2019.172487
10.1080/14728222.2018.1439924
10.1089/ars.2015.6409
10.1111/joim.12309
10.1189/jlb.1008585
10.2119/2008-00034.Klune
10.1189/jlb.0306164
10.1016/j.intimp.2018.12.027
10.1016/S0006-291X(03)00024-X
10.1038/382685a0
10.3233/JAD-171160
10.1007/s10571-015-0233-3
10.1159/000110455
10.1016/j.trci.2018.06.014
10.1038/nrn3880
10.1111/jnc.14615
10.1007/s00702-010-0438-z
10.1016/S0006-8993(97)01318-8
10.1177/1756286418791107
10.1007/s11910-015-0531-7
10.1186/s12974-019-1453-0
10.1186/s12974-015-0360-2
10.1007/s12035-012-8264-y
10.1038/nrrheum.2011.222
10.2119/molmed.2013.00164
10.1021/acschemneuro.6b00250
10.1038/srep31895
10.1002/jnr.20340
10.1155/2012/685739
10.1006/exnr.2001.7732
10.1093/brain/awl249
10.2174/15672050113109990135
10.1016/j.stem.2019.05.003
10.1038/s41591-019-0375-9
10.1016/j.neuroscience.2015.11.054
10.1002/cne.20840
10.1073/pnas.0403678101
10.1016/j.stem.2019.06.001
10.1523/JNEUROSCI.2052-12.2013
10.1016/j.expneurol.2011.08.012
10.1016/j.neuint.2019.03.012
10.3109/08916930903384591
10.2337/db15-0575
10.1002/eji.200526066
10.1111/j.1600-6143.2006.01617.x
10.1084/jem.20030800
10.1146/annurev-med-041316-085215
10.1515/revneuro-2015-0003
10.3233/JAD-2009-1030
10.1038/nm890
10.1016/j.neurobiolaging.2009.04.016
10.1016/j.bbadis.2005.03.014
10.1080/00207454.2016.1193861
10.1016/j.brainres.2008.06.124
10.1038/sj.emboj.7600415
10.1096/fj.09-139634
10.1093/hmg/ddy017
10.1146/annurev-biochem-052909-141507
10.1016/j.cellsig.2012.01.018
10.1038/80833
10.3389/fimmu.2014.00316
10.1016/j.exger.2017.12.019
10.1523/JNEUROSCI.3158-09.2009
10.1186/1742-2094-5-23
10.1007/s11064-019-02817-1
10.1002/eji.201141679
10.1007/s11064-019-02748-x
10.1186/1742-2094-8-92
10.1016/j.bbrc.2016.09.073
10.4049/jimmunol.1600873
10.1016/j.bcp.2013.11.021
10.1038/cr.2008.78
10.1016/0197-4580(95)00092-S
10.1016/S0969-9961(03)00069-X
10.1155/2013/576383
10.1016/j.jalz.2019.03.007
10.1093/ageing/afy004
10.3233/JAD-130203
10.1002/14651858.CD010803.pub2
10.1038/s41591-019-0348-z
10.1186/s12974-016-0670-z
10.1016/S0006-8993(00)03075-4
10.1016/j.neurobiolaging.2003.11.001
10.2174/156720508785908937
10.1007/s00401-006-0115-3
10.1001/archneur.62.11.1734
10.1016/j.jns.2011.11.032
10.1016/j.exger.2018.07.018
10.2174/138161208786264089
10.1016/j.pharmthera.2013.11.001
10.1016/j.jphs.2019.04.006
10.1021/acschemneuro.9b00640
10.1016/j.neuropharm.2014.05.007
10.1111/jphp.13040
10.1016/j.expneurol.2019.112979
10.1016/j.nbd.2016.02.018
10.3390/molecules181215788
10.29219/fnr.v63.1516
10.2119/molmed.2015.00087
10.1016/j.phrs.2018.01.017
10.1155/2015/508342
10.1007/s12035-016-9783-8
10.1172/JCI58642
10.1016/j.jalz.2014.05.1119
10.3892/mmr.2017.7983
10.1007/s12272-015-0662-z
10.1007/s12031-018-1249-1
10.1073/pnas.1215165110
10.1002/eji.201545855
10.1111/cns.13086
10.1007/s12035-019-1512-7
10.1016/j.pnpbp.2019.109684
10.1111/j.1471-4159.2011.07594.x
10.1016/j.neurobiolaging.2018.06.020
10.1056/NEJMra0909142
10.2174/156720501604190424114752
10.1016/S0197-4580(01)00289-5
10.1080/13550280290100969
10.1093/brain/awy132
10.1089/ars.2015.6494
10.1016/j.bbrc.2017.11.035
10.1038/srep42370
10.1097/WAD.0b013e318204b550
10.1212/WNL.0000000000000364",<Element 'PubmedArticle' at 0x7f05dd4ae8b0>
92,"32038221
28426964
26374899
26374897
14742539
29037207
18417708
31006066
30206328
25631124
30541602
29859094
28226226
25630253
25717186
23467340
15895084
31413141
28549481
31462511
28923481
29752066
27423963
25693568
30572908
23150934
30471926
30089221
29196460
30610221
25689443
26754172
30258234
21460840
21471435
2808689
25732305
28768545
23150908
24951455
28602351
28559417
24990881
24162737
29518357
30341064
31235932
29073081
30171911
26438529
30577865
16759751
28212663
21460841
15831717
26754805
21778362
30617257
18790823
26754641
29784049
30232263
22632727
28855300
12472885
30140051
29321225
27974666
26941262
28855301
28802038
24893973
18685038
25728668
25897174
24078628
27477018
27196974
28606182
29518356
28077724
28209725
25957402
29587871
30911003",The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease.,"Alzheimer's disease (AD) is the most common form of dementia characterized by the deposition of extracellular amyloid-β (Aβ)-containing plaques, the formation of intraneuronal neurofibrillary tangles as well as neuroinflammatory changes. As the key player in the brain innate immune system, microglia has now taken a center stage in AD research. A large number of AD risk loci identified by genome-wide association studies are located in or near the genes highly expressed in microglia. Among them, the triggering receptor expressed on myeloid cells 2 (TREM2) has drawn much attention. A rare variant in TREM2 increases AD risk with an odds ratio comparable to the strongest genetic risk factor apolipoprotein ε4 allele. In the past 6 years, extensive studies have dissected the mechanisms by which TREM2 and its variants modulate microglial functions impacting amyloid and tau pathologies in both animal models and human studies. In addition to the full-length TREM2, research on the soluble form of TREM2 (sTREM2) has facilitated the translation of preclinical findings on TREM2. In this review, we summarize our current understanding of the biology and pathobiology of sTREM2 including its origin, its emergence as a disease biomarker, and its potential neuroprotective functions. These aspects are important for understanding the involvement of sTREM2 in AD pathogenesis and may provide novel insights into applying sTREM2 for AD diagnosis and therapy.","['Alzheimer’s disease', 'biomarker', 'microglia', 'neuroinflammation', 'soluble TREM2']",Frontiers in aging neuroscience,2020-02-11,"[{'lastname': 'Zhong', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.'}, {'lastname': 'Chen', 'firstname': 'Xiao-Fen', 'initials': 'XF', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.\nShenzhen Research Institute of Xiamen University, Shenzhen, China.'}]",,,,Copyright © 2019 Zhong and Chen.,"10.3389/fnagi.2019.00328
10.1016/j.neuron.2017.03.042
10.1074/jbc.M115.679043
10.1074/jbc.m115.677286
10.1128/iai.72.2.937-948.2004
10.1186/s13024-017-0216-6
10.1523/jneurosci.4814-07.2008
10.1007/s00401-019-02013-z
10.1038/s41583-018-0057-5
10.1007/s00401-015-1388-1
10.1186/s13024-018-0299-8
10.1186/s13024-018-0262-8
10.1146/annurev-immunol-051116-052358
10.1038/ncomms7176
10.1091/mbc.e14-07-1221
10.1523/JNEUROSCI.3441-12.2013
10.1038/nn1472
10.1126/scitranslmed.aau2291
10.1186/s13024-017-0184-x
10.1126/scitranslmed.aav6221
10.1016/j.neulet.2017.09.034
10.1016/j.immuni.2018.04.016
10.1016/j.jalz.2016.06.005
10.1038/nature14252
10.1186/s13024-018-0298-9
10.1056/NEJMoa1211851
10.1016/j.immuni.2018.11.004
10.1146/annurev-cellbio-100616-060509
10.1083/jcb.201709069
10.1038/s41577-018-0112-5
10.1038/ni.3102
10.1186/s13024-016-0071-x
10.1038/s41593-018-0242-x
10.1038/ng.803
10.1126/scitranslmed.3002369
10.1016/0165-5728(89)90115-x
10.1084/jem.20142322
10.1186/s13024-017-0197-5
10.1056/NEJMoa1211103
10.1016/j.biopsych.2014.05.006
10.1016/j.cell.2017.05.018
10.15252/embj.201796516
10.1126/scitranslmed.3009093
10.1038/ng.2802
10.1016/j.neuron.2018.02.002
10.15252/emmm.201809027
10.1038/s41593-019-0433-0
10.1073/pnas.1710311114
10.1016/j.neulet.2018.08.038
10.1186/s13024-015-0048-1
10.1186/s13024-018-0297-x
10.1016/j.neuint.2006.04.002
10.1186/s40478-017-0418-8
10.1038/ng.801
10.1126/science.1110647
10.1177/1352458515624558
10.1126/science.1202529
10.1038/s41593-018-0296-9
10.1093/brain/awn217
10.1007/s00401-016-1533-5
10.1186/s13024-018-0254-8
10.1073/pnas.1811411115
10.1016/j.neuron.2012.03.026
10.15252/emmm.201707672
10.1046/j.1471-4159.2002.01243.x
10.1038/s41577-018-0051-1
10.1084/jem.20171529
10.1126/scitranslmed.aag1767
10.15252/emmm.201506123
10.15252/emmm.201707673
10.1016/j.cell.2017.07.023
10.1186/1750-1326-9-20
10.1523/JNEUROSCI.1006-08.2008
10.1016/j.cell.2015.01.049
10.1084/jem.20141732
10.1074/jbc.M113.517540
10.1016/j.neuron.2016.06.015
10.1016/j.neuron.2016.05.003
10.1186/s13024-017-0188-6
10.1016/j.neuron.2018.01.031
10.1523/JNEUROSCI.2459-16.2017
10.1084/jem.20160844
10.1084/jem.20160844
10.1186/s13024-018-0247-7
10.1038/s41467-019-09118-9",<Element 'PubmedArticle' at 0x7f05dd4848b0>
93,"32012676
16713924
27630867
23733125
12808492
25792098
25873768
22251135
21718498
22655214
26106485
31506524
26557684
21734608
26088679
27645291
28729832
30377086
20691201
28814675
11433431
18728752
10880403
12895417
17021169
20136653
20550967
29880901
18566467
20205644
26341532
22666623
18791173
19834067
26517861
15831717
17950926
19028958
22824429
29316776
28862638
24398104
20581818
24412599
22363486
31415594
29526796
28438892
31318452
27154981
30878483
25786173
20168318
7941395
19249294
8580206
31443568
25064005",Microglial Activation in the Retina of a Triple-Transgenic Alzheimer's Disease Mouse Model (3xTg-AD).,"Alzheimer's disease (AD) is the most common type of dementia in the world. The main biomarkers associated with AD are protein amyloid-β (Aβ) plaques and protein tau neurofibrillary tangles, which are responsible for brain neuroinflammation mediated by microglial cells. Increasing evidence has shown that the retina can also be affected in AD, presenting some molecular and cellular changes in the brain, such as microglia activation. However, there are only a few studies assessing such changes in the retinal microglia in animal models of AD. These studies use retinal sections, which have some limitations. In this study, we performed, for the first time in a triple-transgenic AD mouse model (3xTg-AD), a quantitative morphometric analysis of microglia activation (using the anti-Iba-1 antibody) in retinal whole-mounts, allowing visualization of the entire microglial cell, as well as its localization along the extension of the retina in different layers. Compared to age-matched animals, the retina of 3xTg-AD mice presents a higher number of microglial cells and a thicker microglial cell body area. Moreover, the microglia migrate, reorient, and retract their processes, changing their localization from a parallel to a perpendicular position relative to the retinal surface. These findings demonstrate clear microglia remodeling in the retina of 3xTg-AD mice.","['3xTg-AD', 'Alzheimer’s disease', 'microglia', 'morphometric analysis', 'neuroinflammation', 'retina', 'triple transgenic Alzheimer’s disease mouse model']",International journal of molecular sciences,2020-02-06,"[{'lastname': 'Salobrar-García', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.'}, {'lastname': 'Rodrigues-Neves', 'firstname': 'Ana C', 'initials': 'AC', 'affiliation': 'Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.\nCenter for innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-517 Coimbra, Portugal.'}, {'lastname': 'Ramírez', 'firstname': 'Ana I', 'initials': 'AI', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.\nFac. Óptica y Optometría, Universidad Complutense de Madrid, 28037 Madrid, Spain.'}, {'lastname': 'de Hoz', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.\nFac. Óptica y Optometría, Universidad Complutense de Madrid, 28037 Madrid, Spain.'}, {'lastname': 'Fernández-Albarral', 'firstname': 'José A', 'initials': 'JA', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.'}, {'lastname': 'López-Cuenca', 'firstname': 'Inés', 'initials': 'I', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.'}, {'lastname': 'Ramírez', 'firstname': 'José M', 'initials': 'JM', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.\nFac. Medicina, Departamento de Oftalmología. Universidad Complutense de Madrid, 20040 Madrid, Spain.'}, {'lastname': 'Ambrósio', 'firstname': 'António F', 'initials': 'AF', 'affiliation': 'Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.\nCenter for innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-517 Coimbra, Portugal.\nAIBILI-Association for Innovation and Biomedical Research on Light and Image, 3000-548 Coimbra, Portugal.'}, {'lastname': 'Salazar', 'firstname': 'Juan J', 'initials': 'JJ', 'affiliation': 'Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense de Madrid, 28040 Madrid, Spain.\nFac. Óptica y Optometría, Universidad Complutense de Madrid, 28037 Madrid, Spain.'}]",,,,,"10.3390/ijms21030816
10.1016/S1474-4422(06)70471-9
10.7860/JCDR/2016/18828.8166
10.1097/IJG.0b013e3182934af6
10.1016/S1474-4422(15)70016-5
10.1155/2015/673090
10.1111/j.1471-4159.2012.07664.x
10.1186/1750-1326-6-45
10.1155/2012/737846
10.1155/2015/736949
10.1038/s41598-019-49353-0
10.1155/2015/636548
10.1097/WNR.0b013e3283497334
10.1038/eye.2015.100
10.1007/s00401-016-1613-6
10.3389/fnagi.2017.00214
10.1016/j.optom.2018.07.001
10.1016/j.visres.2010.07.023
10.1172/jci.insight.93621
10.1002/jnr.1129
10.1016/S0002-9440(10)64544-0
10.1016/S0896-6273(03)00434-3
10.1523/JNEUROSCI.1202-06.2006
10.1111/j.1742-4658.2010.07564.x
10.1038/s41419-018-0740-5
10.1167/iovs.08-1849
10.2174/187152710791012071
10.1016/j.brainres.2015.08.031
10.1155/2012/786494
10.1167/iovs.08-2384
10.2353/ajpath.2009.090159
10.1159/000440887
10.1126/science.1110647
10.1016/j.tins.2007.08.007
10.1189/jlb.0608385
10.1016/j.neuroscience.2012.07.029
10.4062/biomolther.2017.133
10.1172/JCI90606
10.1167/iovs.13-12888
10.1038/nn.2583
10.1016/j.bbi.2013.12.010
10.1371/journal.pone.0030763
10.1371/journal.pone.0220535
10.1016/j.exer.2018.03.006
10.15252/embj.201695810
10.1111/jnc.14829
10.1016/j.freeradbiomed.2016.04.200
10.1016/j.jmb.2019.03.006
10.1016/j.immuni.2015.02.002
10.1038/nri2725
10.1016/0042-6989(94)90024-8
10.1016/j.brainres.2009.02.031
10.3109/10520299509108199
10.3390/ijms20174110
10.1186/1742-2094-11-133",<Element 'PubmedArticle' at 0x7f05dd43bd10>
94,32008854,Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.,"Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia are characterized by neuronal expression of aberrant tau protein, tau hyperphosphorylation (pTAU), tau aggregation and neurofibrillary tangle formation sequentially culminating into neuronal cell death, a process termed tauopathy. Our aim was to address at which tauopathy stage neuroinflammation starts and to study the related microglial phenotype. We used Thy1-hTau.P301S (PS) mice expressing human tau with a P301S mutation specifically in neurons. Significant levels of cortical pTAU were present from 2 months onwards. Dystrophic morphological complexity of cortical microglia arose after pTAU accumulation concomitant with increased microglial lysosomal volumes and a significant loss of homeostatic marker Tmem119. Interestingly, we detected increases in neuronal pTAU and postsynaptic structures in the lysosomes of PS microglia. Moreover, the overall cortical postsynaptic density was decreased in 6-month-old PS mice. Together, our results indicate that microglia adopt a pTAU-associated phenotype, and are morphologically and functionally distinct from wild-type microglia after neuronal pTAU accumulation has initiated.","[""Alzheimer's disease"", 'FTD', 'Hyperphosphorylated tau', 'Microglia', 'P301S', 'Synapses']",Neurobiology of aging,2020-02-06,"[{'lastname': 'van Olst', 'firstname': 'Lynn', 'initials': 'L', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands. Electronic address: l.vanolst@amsterdamumc.nl.'}, {'lastname': 'Verhaege', 'firstname': 'Daan', 'initials': 'D', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands; VIB Center for Inflammation Research, Gent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.'}, {'lastname': 'Franssen', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'lastname': 'Kamermans', 'firstname': 'Alwin', 'initials': 'A', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'lastname': 'Roucourt', 'firstname': 'Bart', 'initials': 'B', 'affiliation': 'reMYND NV, Leuven, Belgium.'}, {'lastname': 'Carmans', 'firstname': 'Sofie', 'initials': 'S', 'affiliation': 'reMYND NV, Leuven, Belgium.'}, {'lastname': 'Ytebrouck', 'firstname': 'Ellen', 'initials': 'E', 'affiliation': 'reMYND NV, Leuven, Belgium.'}, {'lastname': 'van der Pol', 'firstname': 'Susanne M A', 'initials': 'SMA', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'lastname': 'Wever', 'firstname': 'Dennis', 'initials': 'D', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'lastname': 'Popovic', 'firstname': 'Marko', 'initials': 'M', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'lastname': 'Vandenbroucke', 'firstname': 'Roosmarijn E', 'initials': 'RE', 'affiliation': 'VIB Center for Inflammation Research, Gent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.'}, {'lastname': 'Sobrino', 'firstname': 'Tomás', 'initials': 'T', 'affiliation': 'Clinical Neurosciences Research Laboratory, Department of Neurology, Clinical University Hospital, Health Research Institute of Santiago de Compostela, Spain.'}, {'lastname': 'Schouten', 'firstname': 'Marijn', 'initials': 'M', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.'}, {'lastname': 'de Vries', 'firstname': 'Helga E', 'initials': 'HE', 'affiliation': 'Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands; Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, the Netherlands.'}]",,,,Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2020.01.003,<Element 'PubmedArticle' at 0x7f05dd3f18b0>
95,"31968618
3670729
1693471
28862638
25991443
8423066
10858586
11794217
25644018
28602351
26884166
28671693
29020624
29346778
29775591
24316888
1977769
7514086
30076830
2082650
24528486
28541408
28601280
25186950
25448602
17115040
22528678
14603465
31242692
27862351
28073370
19783848
31829283
25732305
27862631
23252647
19557827
31864418
27256292
27459405
18938162
25821842
22509390
25430817
19525944
31549730
24643079
23940669
28258398
29344869
18347928
25619230
10560657
16237129
22112552
19246619","Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer's Disease Brains.","Neuroinflammation is considered a key pathological process in neurodegenerative diseases of aging, including Alzheimer's disease (AD). Many studies have defined phenotypes of reactive microglia, the brain-resident macrophages, with different antigenic markers to identify those potentially causing inflammatory damage. We took an alternative approach with the goal of characterizing the distribution of purinergic receptor P2RY12-positive microglia, a marker previously defined as identifying homeostatic or non-activated microglia. We examined the expression of P2RY12 by dual-color light and fluorescence immunohistochemistry using sections of middle temporal gyrus from AD, high plaque and low plaque non-demented cases in relation to amyloid beta (Aβ) plaques and phosphorylated tau, markers of pathology, and HLA-DR, IBA-1, CD68, and progranulin, microglial phenotype markers. In low plaque cases, P2RY12-positive microglia mostly had non-activated morphologies, while the morphologies of P2RY12-positive microglia in AD brains were highly variable, suggesting its expression could encompass a wider range of phenotypes than originally hypothesized. P2RY12 expression by microglia differed depending on the types of plaques or tangles they were associated with. Areas of inflammation characterized by lack of P2RY12-positive microglia around mature plaques could be observed, but many diffuse plaques showed colocalization with P2RY12-positive microglia. Based on these results, P2RY12 expression by microglia should not be considered solely a marker of resting microglia as P2RY12 immunoreactivity was identifying microglia positive for CD68, progranulin and to a limited extent HLA-DR, markers of activation.","['Alzheimer’s disease', 'activation phenotypes', 'amyloid', 'immunohistochemistry', 'microglia', 'neuroinflammation', 'temporal cortex']",International journal of molecular sciences,2020-01-24,"[{'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu 520-0072, Japan.\nNeurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287, USA.'}, {'lastname': 'Tang', 'firstname': 'Tiffany M', 'initials': 'TM', 'affiliation': 'Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287, USA.'}, {'lastname': 'Mendsaikhan', 'firstname': 'Anarmaa', 'initials': 'A', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu 520-0072, Japan.'}, {'lastname': 'Tooyama', 'firstname': 'Ikuo', 'initials': 'I', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu 520-0072, Japan.'}, {'lastname': 'Serrano', 'firstname': 'Geidy E', 'initials': 'GE', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.'}, {'lastname': 'Sue', 'firstname': 'Lucia I', 'initials': 'LI', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.'}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.'}, {'lastname': 'Lue', 'firstname': 'Lih-Fen', 'initials': 'LF', 'affiliation': 'Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287, USA.\nCivin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.'}]",,,,,"10.3390/ijms21020678
10.1016/0304-3940(87)90696-3
10.1172/JCI90606
10.1038/nrn3880
10.1002/glia.440070114
10.1016/S0197-4580(00)00124-X
10.1056/NEJMoa010178
10.1007/s40266-015-0239-z
10.1016/j.cell.2017.05.018
10.1073/pnas.1525528113
10.1038/nn.4597
10.1016/j.celrep.2017.09.039
10.1016/j.celrep.2017.12.066
10.1016/j.cell.2018.05.003
10.1038/nn.3599
10.1016/0165-5728(90)90055-R
10.1016/0006-8993(94)91779-5
10.1016/j.expneurol.2018.07.016
10.1007/BF00334497
10.1186/2051-5960-2-21
10.1093/brain/awx113
10.1016/j.jneuroim.2017.04.007
10.1111/bpa.12190
10.1016/j.neurobiolaging.2014.09.023
10.1038/nn1805
10.1007/s11302-012-9303-x
10.1002/glia.10293
10.3390/cells8060639
10.1002/glia.23097
10.1186/s40478-016-0405-5
10.1093/cercor/bhp193
10.1186/s40478-019-0850-z
10.1084/jem.20142322
10.1111/bpa.12456
10.1111/nan.12011
10.1002/path.2580
10.1186/s40478-019-0862-8
10.1186/s12974-016-0601-z
10.1038/nn.4338
10.1016/j.expneurol.2008.09.003
10.1212/NXI.0000000000000080
10.1371/journal.pone.0035115
10.1002/path.4491
10.1038/nn.2341
10.1002/eji.201848013
10.1038/jcbfm.2014.45
10.1371/journal.pone.0070927
10.1007/s00401-017-1691-0
10.1007/978-1-4939-7558-7_18
10.1007/s10561-008-9067-2
10.1111/neup.12189
10.1097/00005072-199911000-00004
10.1212/01.wnl.0000187889.17253.b1
10.3233/JAD-2011-111340
10.1373/clinchem.2008.112797",<Element 'PubmedArticle' at 0x7f05dd4004a0>
96,"31947996
20012068
27442752
16938356
19279265
31583592
8957017
10322493
11331400
26316984
18586353
20880504
11936845
24816982
17998568
15207261
28670853
20886841
27154863
12845671
21247902
29476556
31250377
21422529
26341979
31341912
11756501
24390566
31778735
24697507
25663025
27256292
18520995
21672576
23451161
31004356
11837743
19422529
9572090
9330994
1759558
26455863",NDRG2 Expression Correlates with Neurofibrillary Tangles and Microglial Pathology in the Ageing Brain.,"Astrocytes play a major role in the pathogenesis of a range of neurodegenerative diseases, including Alzheimer's disease (AD), undergoing dramatic morphological and molecular changes that can cause potentially both beneficial and detrimental effects. They comprise a heterogeneous population, requiring a panel of specific phenotype markers to identify astrocyte subtypes, changes in function and their relation to pathology. This study aimed to characterise expression of the astrocyte marker N-myc downstream regulated gene 2 (NDRG2) in the ageing brain, investigate the relationship between NDRG2 and a panel of astrocyte markers, and relate NDRG2 expression to pathology. NDRG2 specifically immunolabelled the cell body and radiating processes of astrocytes in the temporal cortex of the Cognitive Function and Ageing Study (CFAS) neuropathology cohort. Expression of NDRG2 did not correlate with other astrocyte markers, including glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 2 (EAAT2) and glutamine synthetase (GS). NDRG2 showed a relationship to AT8","['N-myc downstream regulated gene 2 (NDRG2)', 'ageing brain', 'astrocyte', 'neurofibrillary tangles']",International journal of molecular sciences,2020-01-18,"[{'lastname': 'Fadul', 'firstname': 'Motaz M', 'initials': 'MM', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}, {'lastname': 'Garwood', 'firstname': 'Claire J', 'initials': 'CJ', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}, {'lastname': 'Waller', 'firstname': 'Rachel', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}, {'lastname': 'Garrett', 'firstname': 'Navonna', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}, {'lastname': 'Heath', 'firstname': 'Paul R', 'initials': 'PR', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}, {'lastname': 'Matthews', 'firstname': 'Fiona E', 'initials': 'FE', 'affiliation': 'Population Health Sciences Institute, University of Newcastle, Newcastle NE4 5PL, UK.'}, {'lastname': 'Brayne', 'firstname': 'Carol', 'initials': 'C', 'affiliation': 'Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 0SR, UK.'}, {'lastname': 'Wharton', 'firstname': 'Stephen B', 'initials': 'SB', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}, {'lastname': 'Simpson', 'firstname': 'Julie E', 'initials': 'JE', 'affiliation': 'Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.'}]",,,,,"10.3390/ijms21010340
10.1007/s00401-009-0619-8
10.1111/nan.12338
10.1016/j.tins.2006.08.004
10.1523/JNEUROSCI.4707-08.2009
10.1007/978-981-13-9913-8_11
10.1002/ana.410400512
10.1016/S0166-2236(98)01349-6
10.1046/j.1471-4159.2001.00322.x
10.1155/2013/234572
10.1016/j.neurobiolaging.2008.05.015
10.1016/j.nurt.2010.05.017
10.1023/A:1017934810825
10.1007/s00441-014-1837-5
10.1369/jhc.7A7323.2007
10.1016/j.nbd.2004.01.003
10.1111/cns.12716
10.1021/pr100666c
10.1007/s12035-016-9814-5
10.1002/ijc.11228
10.1074/jbc.M110.170803
10.1002/glia.23315
10.1007/s12975-019-00708-9
10.3233/JAD-2011-091402
10.1093/abbs/gmv082
10.1155/2019/9605265
10.1523/JNEUROSCI.22-01-00183.2002
10.1007/s12035-013-8609-1
10.1016/j.bbr.2019.112384
10.1111/jnc.12729
10.3233/JAD-143156
10.1186/s12974-016-0601-z
10.1097/WNR.0b013e32830163d0
10.1016/j.neuint.2011.03.019
10.1371/journal.pone.0057130
10.1002/jcp.28689
10.1007/s004010100418
10.1111/j.1365-2990.2009.01030.x
10.1016/S0197-4580(97)00058-4
10.1007/BF00308809
10.1016/j.neulet.2015.10.001",<Element 'PubmedArticle' at 0x7f05dd3a94f0>
97,"31915009
17604998
28455089
22762014
21427723
31036717
20357768
20658996
23043292
16406150
22253473
30787269
24504409
23050084
31554666
19269040
30465259
29988016
25887395
26458742
29982964
28408124
26861995
26283915
31293377
24860099
31093687
28662669
10542270
26057852
30392797
25217135
26126828
21125659
21527731
23526370
17909522
6256755
8608589
20971854
15467307
30058022
11340235
23786632
22651808
31460408
31646215
25339173
17338548
17270732
24647946
28528849
16914838
28280572
23129775
30315761
21889505
27731899
29028540
29590627
29686391
20205642
30849448
24146816
19380717
25989853
30276955
28846081
25104923
23121979
30267382
26834532
27975241
22655214
30680593
29348668
30134156
30227881
31277708
23590220
30485549
31242692
26441534
23139861
17623670
23158496
14756805",Phagocytosis of full-length Tau oligomers by Actin-remodeling of activated microglia.,"Alzheimer's disease is associated with the accumulation of intracellular Tau tangles within neurons and extracellular amyloid-β plaques in the brain parenchyma, which altogether results in synaptic loss and neurodegeneration. Extracellular concentrations of oligomers and aggregated proteins initiate microglial activation and convert their state of synaptic surveillance into a destructive inflammatory state. Although Tau oligomers have fleeting nature, they were shown to mediate neurotoxicity and microglial pro-inflammation. Due to the instability of oligomers, in vitro experiments become challenging, and hence, the stability of the full-length Tau oligomers is a major concern.
In this study, we have prepared and stabilized hTau40
Full-length Tau oligomers were detected in heterogeneous globular structures ranging from 5 to 50 nm as observed by high-resolution transmission electron microscopy, which was further characterized by oligomer-specific A11 antibody. Immunocytochemistry studies for oligomer treatment were evidenced with A11
The peri-membrane polymerization of actin filament and co-localization of Iba1 relate to the microglial movements for phagocytosis. Here, these findings suggest that microglia modified actin cytoskeleton for phagocytosis and rapid clearance of Tau oligomers in Alzheimer's disease condition.","['Actin', 'Activation', 'Alzheimer’s disease', 'Microglia', 'Migration', 'Neurodegeneration', 'Tau oligomers', 'Tauopathy']",Journal of neuroinflammation,2020-01-10,"[{'lastname': 'Das', 'firstname': 'Rashmi', 'initials': 'R', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory (CSIR-NCL), Pune, 411008, India.\nAcademy of Scientific and Innovative Research (AcSIR), Pune, 411008, India.'}, {'lastname': 'Balmik', 'firstname': 'Abhishek Ankur', 'initials': 'AA', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory (CSIR-NCL), Pune, 411008, India.\nAcademy of Scientific and Innovative Research (AcSIR), Pune, 411008, India.'}, {'lastname': 'Chinnathambi', 'firstname': 'Subashchandrabose', 'initials': 'S', 'affiliation': 'Neurobiology Group, Division of Biochemical Sciences, CSIR-National Chemical Laboratory (CSIR-NCL), Pune, 411008, India. s.chinnathambi@ncl.res.in.\nAcademy of Scientific and Innovative Research (AcSIR), Pune, 411008, India. s.chinnathambi@ncl.res.in.'}]",,"The peri-membrane polymerization of actin filament and co-localization of Iba1 relate to the microglial movements for phagocytosis. Here, these findings suggest that microglia modified actin cytoskeleton for phagocytosis and rapid clearance of Tau oligomers in Alzheimer's disease condition.","Full-length Tau oligomers were detected in heterogeneous globular structures ranging from 5 to 50 nm as observed by high-resolution transmission electron microscopy, which was further characterized by oligomer-specific A11 antibody. Immunocytochemistry studies for oligomer treatment were evidenced with A11",,"10.1186/s12974-019-1694-y
10.1007/s00018-007-7220-x
10.1016/j.tips.2017.03.011
10.1101/cshperspect.a006247
10.1038/ncomms1255
10.1042/BCJ20190042
10.1038/nature08890
10.1042/BST0381016
10.1021/bi3010818
10.1016/j.neures.2005.11.009
10.1096/fj.11-199851
10.1038/s41419-019-1404-9
10.1038/nm.3457
10.1038/srep00700
10.1523/ENEURO.0166-19.2019
10.1016/j.jneuroim.2009.02.003
10.1007/s00401-018-1937-5
10.7554/eLife.36584
10.1074/jbc.M115.652693
10.1038/ncomms9490
10.1007/s12031-018-1111-5
10.1016/j.ajpath.2017.01.022
10.1093/jb/mvw009
10.3389/fncel.2015.00278
10.1074/jbc.R114.549295
10.1186/s13024-017-0192-x
10.1074/jbc.274.45.32301
10.1038/srep11161
10.1016/j.neuron.2018.10.014
10.1186/s12974-014-0161-z
10.1074/jbc.M115.657924
10.1002/glia.21104
10.1152/physrev.00011.2010
10.1007/s12031-013-0002-z
10.1038/ncb1007-1110
10.1073/pnas.77.11.6687
10.1016/S0092-8674(00)81280-5
10.1074/jbc.M110.135244
10.1159/000080469
10.1007/s12035-018-1275-6
10.1161/01.STR.32.5.1208
10.1186/1742-2094-10-75
10.1186/1742-2094-9-115
10.1021/acsomega.9b01411
10.1021/acsomega.9b00692
10.1074/jbc.M114.611368
10.1021/bi061359o
10.1016/j.neuron.2007.01.010
10.1523/JNEUROSCI.3192-13.2014
10.1016/j.jalz.2017.04.002
10.3233/JAD-2006-9307
10.1098/rsos.160696
10.1074/jbc.M112.396176
10.1016/j.ab.2018.10.013
10.1016/j.febslet.2011.08.033
10.1111/jnc.13866
10.1016/j.conb.2017.09.005
10.1016/j.celrep.2018.03.021
10.1038/s41598-018-24904-z
10.1016/j.neuroscience.2019.02.029
10.1371/journal.pone.0076057
10.1073/pnas.0810420106
10.1007/s00429-015-1067-y
10.1111/acel.12832
10.1038/nn.4631
10.3389/fncel.2014.00202
10.1016/j.cellimm.2012.06.001
10.1007/s12031-018-1174-3
10.3389/fnins.2016.00003
10.1155/2012/737846
10.1007/s12031-019-1258-8
10.1038/nrn.2018.3
10.1016/j.celrep.2018.07.072
10.1186/s12974-018-1309-z
10.1186/s40478-019-0754-y
10.1111/ejn.12213
10.1002/glia.23536
10.3390/cells8060639
10.3389/fncel.2015.00363
10.1038/srep00809
10.1074/jbc.M702887200
10.1186/1742-2094-9-250
10.1046/j.1471-4159.2003.02213.x",<Element 'PubmedArticle' at 0x7f05dd3d2680>
98,31872431,Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia.,"Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder causing memory loss, language problems and behavioural disturbances. AD is associated with the accumulation of fibrillar amyloid-β (Aβ) and the formation of neurofibrillary tau tangles. Fibrillar Aβ itself represents a danger-associated molecular pattern, which is recognized by specific microglial receptors. One of the key players is formation of the NOD-, LRR- and pyrin domain-containing 3 (NLRP3) inflammasome, whose activation has been demonstrated in AD patient brains and transgenic animal models of AD. Here, we investigated whether Aβ oligomers or protofibrils that represent lower molecular aggregates prior to Aβ deposition are able to activate the NLRP3 inflammasome and subsequent interleukin-1 beta (IL-1β) release by microglia. In our study, we used Aβ preparations of different sizes: small oligomers and protofibrils of which the structure was confirmed by atomic force microscopy. Primary microglial cells from C57BL/6 mice were treated with the respective Aβ preparations and NLRP3 inflammasome activation, represented by caspase-1 cleavage, IL-1β production, and apoptosis-associated speck-like protein containing a CARD speck formation was analysed. Both protofibrils and low molecular weight Aβ aggregates induced a significant increase in IL-1β release. Inflammasome activation was confirmed by apoptosis-associated speck-like protein containing a CARD speck formation and detection of active caspase-1. The NLRP3 inflammasome inhibitor MCC950 completely inhibited the Aβ-induced immune response. Our results show that the NLRP3 inflammasome is activated not only by fibrillar Aβ aggregates as reported before, but also by lower molecular weight Aβ oligomers and protofibrils, highlighting the possibility that microglial activation by these Aβ species may initiate innate immune responses in the central nervous system prior to the onset of Aβ deposition. Cover Image for this issue: https://doi.org/10.1111/jnc.14773.","['ASC speck', 'Alzheimer', 'IL-1β', 'NLRP3 inflammasome', 'microglia', 's disease', 'soluble Aβ']",Journal of neurochemistry,2019-12-25,"[{'lastname': 'Lučiūnaitė', 'firstname': 'Asta', 'initials': 'A', 'affiliation': 'Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.\nDepartment of Neurodegenerative Disease and Geriatric Psychiatry, Bonn, Germany.\nGerman Center for Neurodegenerative Disease (DZNE), Bonn, Germany.'}, {'lastname': 'McManus', 'firstname': 'Róisín M', 'initials': 'RM', 'affiliation': 'Department of Neurodegenerative Disease and Geriatric Psychiatry, Bonn, Germany.\nGerman Center for Neurodegenerative Disease (DZNE), Bonn, Germany.'}, {'lastname': 'Jankunec', 'firstname': 'Marija', 'initials': 'M', 'affiliation': 'Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.'}, {'lastname': 'Rácz', 'firstname': 'Ildikó', 'initials': 'I', 'affiliation': 'Department of Neurodegenerative Disease and Geriatric Psychiatry, Bonn, Germany.'}, {'lastname': 'Dansokho', 'firstname': 'Cira', 'initials': 'C', 'affiliation': 'Department of Neurodegenerative Disease and Geriatric Psychiatry, Bonn, Germany.\nGerman Center for Neurodegenerative Disease (DZNE), Bonn, Germany.'}, {'lastname': 'Dalgėdienė', 'firstname': 'Indrė', 'initials': 'I', 'affiliation': 'Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.'}, {'lastname': 'Schwartz', 'firstname': 'Stephanie', 'initials': 'S', 'affiliation': 'Department of Neurodegenerative Disease and Geriatric Psychiatry, Bonn, Germany.'}, {'lastname': 'Brosseron', 'firstname': 'Frederic', 'initials': 'F', 'affiliation': 'German Center for Neurodegenerative Disease (DZNE), Bonn, Germany.'}, {'lastname': 'Heneka', 'firstname': 'Michael T', 'initials': 'MT', 'affiliation': 'Department of Neurodegenerative Disease and Geriatric Psychiatry, Bonn, Germany.'}]",,,,© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.,10.1111/jnc.14945,<Element 'PubmedArticle' at 0x7f05dd38ad60>
99,"31780819
1763432
1673054
26888304
30753379
29435558
29050382
27025652
26871627
24450891
29221491
29365294
30970197
30970186
30610216
26007213
16120771
29046362
12084879
22002422
1759558
26505746
25988462
22229116
25988462
24360540
26419799
26962052
29228201
30326496
26936940
30626656
30068637
29053874
28253546
28545932
28456479
31501889
25348064
25628035
30926651
10072051
30926651
30597624
29538647
31009046
25600871
29403032
19038212
21448224
23296339
30617256
30820047
15473963
22134919
15473963
11584272
9600988
22654059
19225406
25710536
1631093
21825135
22539346
24577224
27895104
27179792
24747528
28537274
24747528
16452683
18480253
30487734
23399914
24205320
30692199
30992433
25241929
25594180
11701931
29601787
8346443
24690272
19106071
29743204
5641217
29632371
5641217
29311783
29946028
9669695
18155324
30040735
30465754
30128317
28549481
31131421
5803269
29196460
26436904
26057852
25833819
20920788
28662669
7715705
26802771
26364736
29037207
29073081
22344463
24524897
22344463
22278060
28768718
12890772
26194181
27732852
31416668
27255958
17086100
31157360
28743782
17615094
30508025
29191858
29284675
24648338
29895964
27328687
21422459
22323736
24849361
23704555
23704554
23704553
26822146
16344478
21454574
24411104
16315276
30710128
29151590
20864679
21159979
30185230
29181493
29687023
21733175
28714976
20472556
21112317
27942728
21987540
22084122
17901546
20473136
28821686
17183151
24352658
28655608
28642370
27056331
18322393
16020737
30559471
28123067
29733334
11520987
12895417
27138984
30429473
29867356
23663320
11520988
18055549
15294141
17056594
21852788
29858247
30157425
25772071
29166618
23434393
28504679
23764284
25307057
19625658",Amyloid-β-independent regulators of tau pathology in Alzheimer disease.,"The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment can revert or arrest progression of this disease. AD pathology is characterized by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain. Genetic data, as well as autopsy and neuroimaging studies in patients with AD, indicate that Aβ plaque deposition precedes cortical tau pathology. Because Aβ accumulation has been considered the initial insult that drives both the accumulation of tau pathology and tau-mediated neurodegeneration in AD, the development of AD therapeutics has focused mostly on removing Aβ from the brain. However, striking preclinical evidence from AD mouse models and patient-derived human induced pluripotent stem cell models indicates that tau pathology can progress independently of Aβ accumulation and arises downstream of genetic risk factors for AD and aberrant metabolic pathways. This Review outlines novel insights from preclinical research that implicate apolipoprotein E, the endocytic system, cholesterol metabolism and microglial activation as Aβ-independent regulators of tau pathology. These factors are discussed in the context of emerging findings from clinical pathology, functional neuroimaging and other approaches in humans. Finally, we discuss the implications of these new insights for current Aβ-targeted strategies and highlight the emergence of novel therapeutic strategies that target processes upstream of both Aβ and tau.",[],Nature reviews. Neuroscience,2019-11-30,"[{'lastname': 'van der Kant', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands. r.h.n.vander.kant@vu.nl.\nAlzheimer Center Amsterdam Department of Neurology, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands. r.h.n.vander.kant@vu.nl.'}, {'lastname': 'Goldstein', 'firstname': 'Lawrence S B', 'initials': 'LSB', 'affiliation': 'Department of Cellular and Molecular Medicine, University of California, San\xa0Diego, La Jolla, CA, USA.\nSanford Consortium for Regenerative Medicine, La\xa0Jolla, CA, USA.\nDepartment of Neurosciences, University of\xa0California, San Diego, La\xa0Jolla, CA, USA.'}, {'lastname': 'Ossenkoppele', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Alzheimer Center Amsterdam Department of Neurology, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands.\nClinical Memory Research Unit, Lund University, Lund, Sweden.'}]",,,,,10.1038/s41583-019-0240-3,<Element 'PubmedArticle' at 0x7f05dd39fe50>
100,"31748742
29371603
30206330
29293211
18604209
23254930
26576562
16877359
24093676
24262201
25879763
15615638
18596935
27818384
21951326
29559111
20920788
30721409
26436904
11520988
18055549
28420982
26490863
23105105
24534188
16407888
21047142
28416651
27924014",NLRP3 inflammasome activation drives tau pathology.,"Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline",[],Nature,2019-11-22,"[{'lastname': 'Ising', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Venegas', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.'}, {'lastname': 'Zhang', 'firstname': 'Shuangshuang', 'initials': 'S', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Scheiblich', 'firstname': 'Hannah', 'initials': 'H', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Schmidt', 'firstname': 'Susanne V', 'initials': 'SV', 'affiliation': 'Institute of Innate Immunity, University Hospital Bonn, Bonn, Germany.'}, {'lastname': 'Vieira-Saecker', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Schwartz', 'firstname': 'Stephanie', 'initials': 'S', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Albasset', 'firstname': 'Shadi', 'initials': 'S', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'McManus', 'firstname': 'Róisín M', 'initials': 'RM', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Tejera', 'firstname': 'Dario', 'initials': 'D', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Griep', 'firstname': 'Angelika', 'initials': 'A', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Santarelli', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Brosseron', 'firstname': 'Frederic', 'initials': 'F', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Opitz', 'firstname': 'Sabine', 'initials': 'S', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.'}, {'lastname': 'Stunden', 'firstname': 'James', 'initials': 'J', 'affiliation': 'IFM Therapeutics GmbH, Bonn, Germany.'}, {'lastname': 'Merten', 'firstname': 'Maximilian', 'initials': 'M', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany.'}, {'lastname': 'Kayed', 'firstname': 'Rakez', 'initials': 'R', 'affiliation': 'Mitchell Center for Neurodegenerative Diseases and Departments of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA.'}, {'lastname': 'Golenbock', 'firstname': 'Douglas T', 'initials': 'DT', 'affiliation': 'Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.'}, {'lastname': 'Blum', 'firstname': 'David', 'initials': 'D', 'affiliation': 'University of Lille, Inserm, CHU-Lille, UMR-S 1172, ""Alzheimer & Tauopathies"", Labex DISTALZ, Lille, France.'}, {'lastname': 'Latz', 'firstname': 'Eicke', 'initials': 'E', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.\nInstitute of Innate Immunity, University Hospital Bonn, Bonn, Germany.\nDivison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.'}, {'lastname': 'Buée', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'University of Lille, Inserm, CHU-Lille, UMR-S 1172, ""Alzheimer & Tauopathies"", Labex DISTALZ, Lille, France.'}, {'lastname': 'Heneka', 'firstname': 'Michael T', 'initials': 'MT', 'affiliation': 'Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany. michael.heneka@ukbonn.de.\nGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. michael.heneka@ukbonn.de.\nDivison of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA. michael.heneka@ukbonn.de.'}]",,,,,"10.1038/s41586-019-1769-z
10.1007/s00401-018-01957-y",<Element 'PubmedArticle' at 0x7f05dd305d10>
101,31699331,Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease.,"The pathogenesis of Alzheimer's disease (AD) is only partly understood. This is the probable reason why significant efforts to treat or prevent AD have been unsuccessful. In fact, as of April 2019, there have been 2094 studies registered for AD on the clinicaltrials.gov U.S. National Library of Science web page, of which only a few are still ongoing. In AD, abnormal accumulation of amyloid and tau proteins in the brain are thought to begin 10-20 years before the onset of overt symptoms, suggesting that interventions designed to prevent pathological amyloid and tau accumulation may be more effective than attempting to reverse a pathology once it is established. However, to be successful, such early interventions need to be selectively administered to individuals who will likely develop the disease long before the symptoms occur. Therefore, it is critical to identify early biomarkers that are strongly predictive of AD. Currently, patients are diagnosed on the basis of a variety of clinical scales, neuropsychological tests, imaging and laboratory modalities, but definitive diagnosis can be made only by postmortem assessment of underlying neuropathology. People suffering from AD thus may be misdiagnosed clinically with other primary causes of dementia, and vice versa, thereby also reducing the power of clinical trials. The amyloid cascade hypothesis fits well for the familial cases of AD with known mutations, but is not sufficient to explain sporadic, late-onset AD (LOAD) that accounts for over 95% of all cases. Since the earliest descriptions of AD there have been neuropathological features described other than amyloid plaques (AP) and neurofibrillary tangles (NFT), most notably gliosis and neuroinflammation. However, it is only recently that genetic and experimental studies have implicated microglial dysfunction as a causal factor for AD, as opposed to a merely biological response of its accumulation around AP. Additionally, many studies have suggested the importance of changes in blood-brain barrier (BBB) permeability in the pathogenesis of AD. Here we suggest how these less investigated aspects of the disease that have gained increased attention in recent years may contribute mechanistically to the development of lesions and symptoms of AD.","[""Alzheimer's disease"", 'Amyloid β', 'Astrocytes', 'Blood-brain barrier', 'Cerebrospinal fluid', 'Innate immunity', 'Microglia', 'Monocytes', 'Neuroinflammation', 'Tau proteins']",Progress in molecular biology and translational science,2019-11-09,"[{'lastname': 'Šimić', 'firstname': 'Goran', 'initials': 'G', 'affiliation': 'Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia. Electronic address: gsimic@hiim.hr.'}, {'lastname': 'Španić', 'firstname': 'Ena', 'initials': 'E', 'affiliation': 'Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia.'}, {'lastname': 'Langer Horvat', 'firstname': 'Lea', 'initials': 'L', 'affiliation': 'Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia.'}, {'lastname': 'Hof', 'firstname': 'Patrick R', 'initials': 'PR', 'affiliation': ""Nash Family Department of Neuroscience, Friedman Brain Institute, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, United States.""}]",,,,© 2019 Elsevier Inc. All rights reserved.,10.1016/bs.pmbts.2019.06.003,<Element 'PubmedArticle' at 0x7f05dd2a69a0>
102,31481170,Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease.,"Neuroinflammation is thought to play a key role in the development and progression of neurodegenerative diseases such as Alzheimer's disease. Positron emission tomography (PET) is an in vivo imaging technique capable of studying the biochemical processes which provide the molecular basis of disease. PET imaging of neuroinflammation, which is characterized by the activation of glial cells in the central nervous system (CNS), has been traditionally studied using radiotracers targeting the translocator protein 18kDa (TSPO). However, limitations in the properties of PET radiotracers for imaging the TSPO has led to the search for alternative strategies for imaging neuroinflammation. The current review presents the current status of PET radiotracers for imaging the TSPO, and describes alternative biological targets that have gained interest for imaging of microglial activation over recent years. These include cannabinoid receptor type-2, cyclooxygenase-2, the P2X","['Cannabinoid receptor type 2', 'Colony stimulating factor 1 receptor', 'Cyclooxygenase-2', 'Microglia', 'Microglial activation', 'Neuroinflammation', 'P2X(7) receptor', 'Positron emission tomography', 'Reactive oxygen species', 'Translocator protein 18kDa']",Progress in molecular biology and translational science,2019-09-05,"[{'lastname': 'Janssen', 'firstname': 'Bieneke', 'initials': 'B', 'affiliation': 'Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.'}, {'lastname': 'Mach', 'firstname': 'Robert H', 'initials': 'RH', 'affiliation': 'Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: rmach@pennmedicine.upenn.edu.'}]",,,,© 2019 Elsevier Inc. All rights reserved.,10.1016/bs.pmbts.2019.04.005,<Element 'PubmedArticle' at 0x7f05dd2b0900>
103,31481003,"Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles.","Alzheimer's Disease (AD) is age-related neurodegenerative disorder recognized by a steadily gradual cognitive decline that has devastating personal and socioeconomic implications. Recently, some genetic factors for AD have been identified which attracted wide attention of researchers in different areas of AD biology and possible new therapeutic targets. Alternative forms of triggering receptor expressed on myeloid cells 2 (TREM2) genes are examples of such risk factors, which contribute higher risk for developing AD. Comprehending TREM2 function pledge to provide salient insight into how neuroinflammation contributes to AD pathology. The dearth of microglial TREM2 shepherd to augmented tau pathology is couple with frequent enhancement of activated neuronal stress kinases. The involvement of TREM2 in the regulation of tau-associated innate immune response of the CNS has clearly demonstrated through these findings. However, whether decrease level of TREM2 assists pathology of tau through changed clearance and pathological escalation of tau or through direct contact between microglia and neuron and any alternative possible mechanisms need to examine. This review briefly summarizes distinct functional roles of TREM2 in AD pathology and highlights the TREM2 gene regulation. We have also addressed the impact of TREM2 on β-amyloid plaques and tau pathology in Alzheimer's disease.","['Alzheimer’s disease', 'TREM2', 'microglia', 'neuronal degeneration', 'tau pathology', 'β-amyloid plaques.']",Current Alzheimer research,2019-09-05,"[{'lastname': 'Singh', 'firstname': 'Anurag K', 'initials': 'AK', 'affiliation': 'Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India.'}, {'lastname': 'Mishra', 'firstname': 'Gaurav', 'initials': 'G', 'affiliation': 'Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Kishangarh, Ajmer-305817, Rajasthan, India.'}, {'lastname': 'Maurya', 'firstname': 'Anand', 'initials': 'A', 'affiliation': 'Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Kishangarh, Ajmer-305817, Rajasthan, India.'}, {'lastname': 'Awasthi', 'firstname': 'Rajendra', 'initials': 'R', 'affiliation': 'Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector 125, Noida - 201303, India.'}, {'lastname': 'Kumari', 'firstname': 'Komal', 'initials': 'K', 'affiliation': 'Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Kishangarh, Ajmer-305817, Rajasthan, India.'}, {'lastname': 'Thakur', 'firstname': 'Abhimanyu', 'initials': 'A', 'affiliation': 'Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Rai', 'firstname': 'Arati', 'initials': 'A', 'affiliation': 'Hygia Institute of Pharmaceutical Education & Research, Lucknow-226020, Uttar Pradesh, India.'}, {'lastname': 'Rai', 'firstname': 'Gopal Kumar', 'initials': 'GK', 'affiliation': 'Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi- 221005, Uttar Pradesh, India.'}, {'lastname': 'Sharma', 'firstname': 'Bhupesh', 'initials': 'B', 'affiliation': 'Department of Pharmacology, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector 125, Noida - 201303, India.'}, {'lastname': 'Kulkarni', 'firstname': 'Giriraj T', 'initials': 'GT', 'affiliation': 'Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector 125, Noida - 201303, India.'}, {'lastname': 'Singh', 'firstname': 'Santosh Kumar', 'initials': 'SK', 'affiliation': 'Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1567205016666190903102822,<Element 'PubmedArticle' at 0x7f05dd2b9860>
104,"31448566
22732773
25549971
25853864
16862115
16862116
21944778
21944779
24800652
16950801
22890575
23596077
22366793
17579875
21644037
26374446
24366528
23746459
26989253
28828399
9855500
21325651
23359374
24011653
25805643
19383787
19816201
23053135
30029693
23147507
19513731
28916533
22366790
22366791
22300876
27435172
18245784
18234697
18192287
25186741
27114033
25261995
24117616
15266782
26001591
30112957
7583681",Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations.,"To identify clinicopathological differences between frontotemporal lobar degeneration (FTLD) due to mutations in progranulin (FTLD-GRN) and chromosome 9 open reading frame 72 (FTLD-C9ORF72).
We performed quantitative neuropathologic comparison of 17 FTLD-C9ORF72 and 15 FTLD-GRN with a focus on microglia. For clinical comparisons, only cases with high quality medical documentation and concurring diagnoses by at least two neurologists were included (14 FTLD-GRN and 13 FTLD-C9ORF72). Neuropathological analyses were limited to TDP-43 Type A to assure consistent assessment between the groups, acknowledging that Type A is a minority of C9ORF72 patients. Furthermore, only cases with sufficient tissue from all regions were studied (11 FTLD-GRN and 11 FTLD-C9ORF72). FTLD cases were also compared to age- and sex-matched normal controls. Immunohistochemistry was performed for pTDP-43, IBA-1, CD68, and GFAP. Morphological characterization of microglia was performed in sections of cortex blinded to clinical and genetic information.
FTLD-GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD-C9ORF72 had greater hippocampal tau pathology and more TDP-43 neuronal cytoplasmic inclusions. FTLD-GRN had more neocortical microvacuolation, as well as more IBA-1-positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD-GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD-GRN and FTLD-C9ORF72 differed from controls.
Our findings underscore differences in microglial response in FTLD-C9ORF72 and FTLD-GRN as shown by significant differences in ameboid microglia in gray and white matter. These results suggest the differential contribution of microglial dysfunction in FTLD-GRN and FTLD-C9ORF72 and suggest that clinical, neuroimaging and pathologic differences could in part be related to differences in microglia response.",[],Annals of clinical and translational neurology,2019-08-27,"[{'lastname': 'Sakae', 'firstname': 'Nobutaka', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Roemer', 'firstname': 'Shanu F', 'initials': 'SF', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Bieniek', 'firstname': 'Kevin F', 'initials': 'KF', 'affiliation': 'Department of Pathology & Laboratory Medicine, University of Texas Health Science Center, San Antonio, Texas.'}, {'lastname': 'Murray', 'firstname': 'Melissa E', 'initials': 'ME', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Baker', 'firstname': 'Matthew C', 'initials': 'MC', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Kasanuki', 'firstname': 'Koji', 'initials': 'K', 'affiliation': 'Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.'}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Petrucelli', 'firstname': 'Leonard', 'initials': 'L', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Van Blitterswijk', 'firstname': 'Marka', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}]",,,"FTLD-GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD-C9ORF72 had greater hippocampal tau pathology and more TDP-43 neuronal cytoplasmic inclusions. FTLD-GRN had more neocortical microvacuolation, as well as more IBA-1-positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD-GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD-GRN and FTLD-C9ORF72 differed from controls.","© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.","10.1002/acn3.50875
10.1523/ENEURO.0100-17.2017",<Element 'PubmedArticle' at 0x7f05dd2c4bd0>
105,"31410002
27809929
18691147
25908410
12417558
15516999
5662937
21456963
20107219
25984581
26250687
20463403
20413653
18304698
18650430
18160654
9770546
7888181
27511009
1439760
11544248
20129170
25394486
30189209
22627093
22091726
11520930
12761533
12761548
18955053
15494420
27794478
15272266
22496686
18393798
12679784
17197420
22186258
26072273
24183015
17453016
20975755
25774124
25290336
32669903
21216877
21482442
19625751
28670349
23393609
25792098
12684452
15857927
18470479
18701698
23151315
25728668
19302484
15075502
15075493
9667557
15750394
19288202
29902695
29067343
12876705
19559008
18980178
16386399
18463738
12459582
15695586
11433435
18829296
30356847
28181394
25692749
28164767
29906562
22829203
26582895
28696296
28762183
26944096
27621624
23591874
18778113
19453284
28906159
18191511
27540518
27143580
20551152
24860796
29023366
22728642
21070825
18654511
24818261
26851586
24395761","Alzheimer's disease: pathogenesis, diagnostics, and therapeutics.","Currently, 47 million people live with dementia globally, and it is estimated to increase more than threefold (~131 million) by 2050. Alzheimer's disease (AD) is one of the major causative factors to induce progressive dementia. AD is a neurodegenerative disease, and its pathogenesis has been attributed to extracellular aggregates of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles made of hyperphosphorylated τ-protein in cortical and limbic areas of the human brain. It is characterized by memory loss and progressive neurocognitive dysfunction. The anomalous processing of APP by β-secretases and γ-secretases leads to production of Aβ","['amyloid beta', 'amyloid precursor proteins', 'amyloidogenesis', 'tau phosphorylation', 'β-secretases', 'γ-secretases']",International journal of nanomedicine,2019-08-15,"[{'lastname': 'Tiwari', 'firstname': 'Sneham', 'initials': 'S', 'affiliation': 'Department of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.'}, {'lastname': 'Atluri', 'firstname': 'Venkata', 'initials': 'V', 'affiliation': 'Department of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.'}, {'lastname': 'Kaushik', 'firstname': 'Ajeet', 'initials': 'A', 'affiliation': 'Department of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.'}, {'lastname': 'Yndart', 'firstname': 'Adriana', 'initials': 'A', 'affiliation': 'Department of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.'}, {'lastname': 'Nair', 'firstname': 'Madhavan', 'initials': 'M', 'affiliation': 'Department of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.'}]",,,,,"10.2147/IJN.S200490
10.1186/s13041-016-0272-9
10.1016/j.peptides.2015.04.009
10.1172/JCI16781
10.1038/ncb1104-1054
10.1146/annurev-neuro-061010-113613
10.1056/NEJMra0909142
10.1016/j.jalz.2015.02.003
10.1126/science.1255555
10.3233/JAD-2010-100357
10.1093/hmg/ddq160
10.1016/j.neurobiolaging.2007.12.024
10.1074/jbc.R800019200
10.1523/JNEUROSCI.4701-07.2007
10.1073/pnas.95.21.12683
10.1146/annurev.cb.10.110194.002105
10.1523/JNEUROSCI.4130-15.2016
10.1074/jbc.C100447200
10.1016/S1474-4422(09)70332-1
10.1186/1750-1326-9-48
10.1016/j.neuron.2018.07.039
10.1016/j.cellsig.2012.05.008
10.3109/01677063.2011.626471
10.1146/annurev.neuro.24.1.1121
10.1038/423392a
10.1038/nature01640
10.1016/j.febslet.2008.10.026
10.1074/jbc.M403364200
10.1016/j.drudis.2016.10.010
10.1038/nm1067
10.1038/ncb960
10.1073/pnas.0608332104
10.1093/ije/dyr184
10.1016/j.pneurobio.2015.05.002
10.1016/j.neuron.2013.10.023
10.1038/nrn2132
10.1038/nn.2511
10.1016/j.neuint.2014.09.012
10.2147/DNND.S37341
10.1093/hmg/ddq561
10.1016/j.neurobiolaging.2010.08.017
10.3233/JAD-2009-1134
10.1186/s13148-017-0365-z
10.1371/journal.pone.0056293
10.1016/S1474-4422(15)70016-5
10.1093/brain/awh531
10.1007/s00018-008-8112-4
10.1523/JNEUROSCI.0616-08.2008
10.1056/NEJMe1213157
10.1016/j.cell.2015.01.049
10.1111/j.1471-4159.2009.06042.x
10.1097/00002030-200401001-00012
10.1097/00002030-200401001-00003
10.1136/jnnp.65.1.29
10.1007/s11481-009-9151-9
10.1016/j.cbpa.2018.05.018
10.1002/mrm.10529
10.1016/j.bbrc.2009.06.110
10.1002/jbm.a.32232
10.1016/j.ijdevneu.2005.11.012
10.1039/b803294g
10.1126/science.1077194
10.1073/pnas.0409336102
10.1016/j.bios.2008.08.018
10.3389/fnagi.2018.00291
10.1002/tox.22397
10.1021/es504705p
10.2174/1567205014666170203125008
10.1016/j.ijpharm.2018.06.031
10.1158/1078-0432.CCR-12-1414
10.1126/scitranslmed.aad3106
10.1073/pnas.1701911114
10.1007/s13365-017-0538-8
10.2147/IJN.S109943
10.1038/ncomms2717
10.2165/00063030-200822050-00004
10.1517/14728210902907847
10.1080/1061186X.2017.1380655
10.1016/j.ijpharm.2007.11.030
10.1063/1.4978642
10.1038/srep25309
10.1056/NEJMp1006304
10.1007/s40336-014-0051-5
10.3390/jpm7040012
10.1016/j.addr.2012.06.006
10.1016/j.jconrel.2010.10.038
10.1038/nnano.2008.114
10.1016/j.jalz.2014.02.001
10.1016/j.bios.2016.01.065
10.1002/rmv.1778",<Element 'PubmedArticle' at 0x7f05dd2647c0>
106,"31340569
2974227
3670729
2808689
25644018
28671693
23943781
25904988
27256292
30076830
26994418
24528486
25186950
25448602
1537377
1692830
1395096
30761306
15923183
27010826
8453039
7595653
8891264
8632765
7543987
22985514
15240683
9335500
10623661
22511296
21085906
17168649
19925479
30995509
10560657
16237129
22112552
25619230
19399512
2341813
11814408
16365156
11520119
18938162
26834537
17639428
22347366
8955115
10576593
1961019
8370410
8655583
9590131
29286924
29334284
29734249
31015843
19957214
24316888
30283455
30630955
27756506",Microglial Phenotyping in Neurodegenerative Disease Brains: Identification of Reactive Microglia with an Antibody to Variant of CD105/Endoglin.,"Inflammation is considered a key pathological process in neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), but there are still mechanisms not understood. In the brain, most microglia are performing essential homeostatic functions, but can also respond to pathogenic stimuli by producing harmful pro-inflammatory cytokines or free radicals. Distinguishing between damaging and homeostatic microglia in human diseased brain tissues is a challenge. This report describes findings using a monoclonal antibody to CD105/Endoglin (R&D Systems MAB1097) that identifies subtypes of activated microglia. CD105/Endoglin is a co-receptor for transforming growth factor beta (TGFβ) receptor that antagonizes TGFβ signaling. CD105/Endoglin is a marker for vascular endothelial cells, but was originally identified as a marker for activated macrophages. This antibody did not identify endothelial cells in brain sections, only microglia-like cells. In this study, we examined with this antibody tissue section from middle temporal gyrus derived from human brains from normal control subjects with low-plaque pathology, high-plaque pathology, and AD cases, and also substantia nigra samples from control and PD cases, in conjunction with antibodies to markers of pathology and microglia. In low-plaque pathology cases, CD105-positive microglia were mostly absent, but noticeably increased with increasing pathology. CD105-positive cells strongly colocalized with amyloid-beta plaques, but not phosphorylated tau positive tangles. In substantia nigra, strong microglial CD105 staining was observed in microglia associated with degenerating dopaminergic neurons and neuromelanin. In PD cases with few surviving dopaminergic neurons, this staining had decreased. By Western blot, this antibody identified polypeptide bands of 70 kDa in brain samples, and samples from microglia, macrophages, and brain endothelial cells. In comparison with other tested CD105 antibodies, this antibody did not recognize the glycosylated forms of CD105 on Western blots. Overall, the data indicate that this antibody and this marker could have utility for subtyping of microglia in pathologically-involved tissue.","['activation', 'human', 'immunohistochemistry', 'microglia', 'neuroinflammation', 'neuropathology', 'transforming growth factor']",Cells,2019-07-26,"[{'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan. walkerdg@gmail.com.\nSchool of Life Sciences and Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287, USA. walkerdg@gmail.com.'}, {'lastname': 'Lue', 'firstname': 'Lih-Fen', 'initials': 'LF', 'affiliation': 'School of Life Sciences and Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ 85287, USA.\nCivin Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.'}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Civin Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.'}, {'lastname': 'Tooyama', 'firstname': 'Ikuo', 'initials': 'I', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan.'}]",,,,,"10.3390/cells8070766
10.1007/BF00689592
10.1016/0304-3940(87)90696-3
10.1016/0165-5728(89)90115-X
10.1007/s40266-015-0239-z
10.1038/nn.4597
10.1093/brain/awt210
10.1186/s13195-015-0126-1
10.1186/s12974-016-0601-z
10.1016/j.expneurol.2018.07.016
10.1186/2051-5960-2-21
10.1111/bpa.12190
10.1016/j.neurobiolaging.2014.09.023
10.1002/eji.1830220216
10.1111/j.1365-2249.1992.tb05848.x
10.3389/fmed.2019.00010
10.1074/jbc.M503471200
10.1371/journal.pgen.1005935
10.1097/00001756-199301000-00018
10.1097/00005072-199511000-00007
10.1016/0006-8993(96)00458-1
10.1212/WNL.45.8.1561
10.1016/j.neulet.2012.08.071
10.4049/jimmunol.173.2.962
10.1038/39321
10.1016/S0002-9440(10)64713-X
10.1002/glia.22343
10.1007/s12603-010-0325-1
10.2174/156720506779025297
10.1111/j.1755-5949.2009.00115.x
10.1016/j.immuni.2019.03.016
10.1097/00005072-199911000-00004
10.1212/01.wnl.0000187889.17253.b1
10.3233/JAD-2011-111340
10.1111/neup.12189
10.1007/s00401-009-0538-8
10.1016/S0006-8993(01)03298-X
10.1189/jlb.0705377
10.1006/exnr.2001.7732
10.1016/j.expneurol.2008.09.003
10.3389/fnins.2015.00507
10.1007/s00401-007-0250-5
10.1371/journal.pone.0029948
10.1074/jbc.271.51.32789
10.1016/S0024-3205(99)00486-5
10.1002/eji.1830230943
10.1083/jcb.133.5.1109
10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A
10.3233/CBM-170755
10.1080/10428194.2017.1416366
10.1097/PAI.0000000000000668
10.1155/2019/9060152
10.1007/s12640-009-9140-z
10.1038/nn.3599
10.3389/fimmu.2018.02122
10.1136/jnnp-2018-319148",<Element 'PubmedArticle' at 0x7f05dd224d10>
107,"31281511
23684085
27615390
26871627
27306859
10417659
27686274
28864542
28983098
22929442
29789530
30046032
28395123
26891768
26486334
26907805
16868082
18378064
20485502
23707300
25222068
25761889
28379300
30098799
18832465
22689910
19695986
20643941
29332046
26635213
27751442
29467614
23528736
21311563
23202584
28832529
28846632
19200883
27339763
30613294
25041093
22867711
15751225
16098202
23667480
22361619
26551002",Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions.,"Intracellular deposits of pathological tau are the hallmark of a broad spectrum of neurodegenerative disorders collectively known as tauopathies, with Alzheimer's disease, a secondary tauopathy, being further characterized by extracellular amyloid plaques. A major obstacle in developing effective treatments for tauopathies is the presence of the blood-brain barrier, which restricts the access of therapeutic agents to the brain. An emerging technology to overcome this limitation is the application of low-intensity ultrasound which, together with intravenously injected microbubbles, transiently opens the blood-brain barrier, thereby facilitating the delivery of therapeutic agents into the brain. Interestingly, even in the absence of therapeutic agents, ultrasound has previously been shown to reduce amyloid plaques and improve cognitive functions in amyloid-depositing mice through microglial clearance. Ultrasound has also been shown to facilitate the delivery of antibody fragments against pathological tau in P301L tau transgenic mice; however, the effect of ultrasound alone has not been thoroughly investigated in a tauopathy mouse model. ","['Autophagy', 'blood-brain barrier', 'protein aggregation disorders', 'tau', 'therapeutic ultrasound']",Theranostics,2019-07-10,"[{'lastname': 'Pandit', 'firstname': 'Rucha', 'initials': 'R', 'affiliation': 'Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.'}, {'lastname': 'Leinenga', 'firstname': 'Gerhard', 'initials': 'G', 'affiliation': 'Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.'}, {'lastname': 'Götz', 'firstname': 'Jürgen', 'initials': 'J', 'affiliation': 'Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.'}]",,,,,10.7150/thno.34388,<Element 'PubmedArticle' at 0x7f05dd24fea0>
108,"31006066
26601965
21627779
25746226
21371747
15297300
29053874
23237904
23857120
25753426
30206328
23926108
22028908
17339281
26911435
26793098
23150934
25619654
25792098
24962261
23254930
16381938
26001565
19302484
25732305
18510752
14681465
28602351
27023127
27995897
28930663
21903077
22227962
22836271
29518357
29073081
17998437
23403532
29020624
28483841
16990547
17476317
21516511
28500071
30617257
29284090
24224195
17701901
9830016
20807768
20873803
22020633
15701008
15464951
29490706
24927710
26905516
29293211
23713775
25728668
21379329
25950236
27402340
28434692
28128358
27196974
28209725
28197669","Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease.","Alzheimer's disease (AD) is a progressive neurodegenerative disease in which the formation of extracellular aggregates of amyloid beta (Aβ) peptide, fibrillary tangles of intraneuronal tau and microglial activation are major pathological hallmarks. One of the key molecules involved in microglial activation is galectin-3 (gal3), and we demonstrate here for the first time a key role of gal3 in AD pathology. Gal3 was highly upregulated in the brains of AD patients and 5xFAD (familial Alzheimer's disease) mice and found specifically expressed in microglia associated with Aβ plaques. Single-nucleotide polymorphisms in the LGALS3 gene, which encodes gal3, were associated with an increased risk of AD. Gal3 deletion in 5xFAD mice attenuated microglia-associated immune responses, particularly those associated with TLR and TREM2/DAP12 signaling. In vitro data revealed that gal3 was required to fully activate microglia in response to fibrillar Aβ. Gal3 deletion decreased the Aβ burden in 5xFAD mice and improved cognitive behavior. Interestingly, a single intrahippocampal injection of gal3 along with Aβ monomers in WT mice was sufficient to induce the formation of long-lasting (2 months) insoluble Aβ aggregates, which were absent when gal3 was lacking. High-resolution microscopy (stochastic optical reconstruction microscopy) demonstrated close colocalization of gal3 and TREM2 in microglial processes, and a direct interaction was shown by a fluorescence anisotropy assay involving the gal3 carbohydrate recognition domain. Furthermore, gal3 was shown to stimulate TREM2-DAP12 signaling in a reporter cell line. Overall, our data support the view that gal3 inhibition may be a potential pharmacological approach to counteract AD.","['Alzheimer’s disease (AD)', 'Amyloid aggregation', 'Galectin-3', 'Inflammation', 'Microglia', 'TREM2']",Acta neuropathologica,2019-04-22,"[{'lastname': 'Boza-Serrano', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, 221 84, Lund, Sweden. antonio.boza_serrano@med.lu.se.'}, {'lastname': 'Ruiz', 'firstname': 'Rocío', 'initials': 'R', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain.'}, {'lastname': 'Sanchez-Varo', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': 'Departamento de Biología Celular, Genética y Fisiología, Instituto de Investigación Biomédica de Málaga (IBIMA), Facultad de Ciencias, Universidad de Málaga, Málaga, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'García-Revilla', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain.'}, {'lastname': 'Yang', 'firstname': 'Yiyi', 'initials': 'Y', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, 221 84, Lund, Sweden.'}, {'lastname': 'Jimenez-Ferrer', 'firstname': 'Itzia', 'initials': 'I', 'affiliation': 'Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, 221 84, Lund, Sweden.'}, {'lastname': 'Paulus', 'firstname': 'Agnes', 'initials': 'A', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, 221 84, Lund, Sweden.'}, {'lastname': 'Wennström', 'firstname': 'Malin', 'initials': 'M', 'affiliation': 'Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.'}, {'lastname': 'Vilalta', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Department of Biochemistry, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Allendorf', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Biochemistry, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Davila', 'firstname': 'Jose Carlos', 'initials': 'JC', 'affiliation': 'Departamento de Biología Celular, Genética y Fisiología, Instituto de Investigación Biomédica de Málaga (IBIMA), Facultad de Ciencias, Universidad de Málaga, Málaga, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'Stegmayr', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology (MIG), Lund University, Lund, Sweden.'}, {'lastname': 'Jiménez', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'Roca-Ceballos', 'firstname': 'Maria A', 'initials': 'MA', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain.'}, {'lastname': 'Navarro-Garrido', 'firstname': 'Victoria', 'initials': 'V', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'Swanberg', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Translational Neurogenetics Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, 221 84, Lund, Sweden.'}, {'lastname': 'Hsieh', 'firstname': 'Christine L', 'initials': 'CL', 'affiliation': 'Immunology Section, Department of Medicine, San Francisco VA Medical Center, UCSF School of Medicine, 4150 Clement St. 111R, San Francisco, CA, 94121, USA.'}, {'lastname': 'Real', 'firstname': 'Luis M', 'initials': 'LM', 'affiliation': 'Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Seville, Spain.'}, {'lastname': 'Englund', 'firstname': 'Elisabet', 'initials': 'E', 'affiliation': 'Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.'}, {'lastname': 'Linse', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden.'}, {'lastname': 'Leffler', 'firstname': 'Hakon', 'initials': 'H', 'affiliation': 'Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology (MIG), Lund University, Lund, Sweden.'}, {'lastname': 'Nilsson', 'firstname': 'Ulf J', 'initials': 'UJ', 'affiliation': 'Department of Chemistry, Centre for Analysis and Synthesis, Lund University, Lund, Sweden.'}, {'lastname': 'Brown', 'firstname': 'Guy C', 'initials': 'GC', 'affiliation': 'Department of Biochemistry, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Gutierrez', 'firstname': 'Antonia', 'initials': 'A', 'affiliation': 'Departamento de Biología Celular, Genética y Fisiología, Instituto de Investigación Biomédica de Málaga (IBIMA), Facultad de Ciencias, Universidad de Málaga, Málaga, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'Vitorica', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'Venero', 'firstname': 'Jose Luis', 'initials': 'JL', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Instituto de Biomedicina de Sevilla (IBiS, HUVR/CSIC/Universidad de Sevilla), Universidad de Sevilla, Seville, Spain. jlvenero@us.es.'}, {'lastname': 'Deierborg', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': 'Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, Lund University, 221 84, Lund, Sweden. tomas.deierborg@med.lu.se.'}]",,,,,"10.1007/s00401-019-02013-z
10.2174/1381612822666151125000300
10.1186/gm249
10.1007/s00018-015-1878-2
10.1016/s0140-6736(10)61349-9
10.1093/bioinformatics/bth457
10.1093/brain/awx243
10.1016/S1474-4422(12)70259-4
10.1038/mp.2013.86
10.1016/j.celrep.2015.02.012
10.1038/s41583-018-0057-5
10.1074/jbc.M113.487793
10.1371/journal.pone.0026560
10.1093/glycob/cwm026
10.1038/nrn.2016.7
10.3389/fnagi.2015.00245
10.1056/NEJMoa1211851
10.1016/j.neuron.2014.12.068
10.1016/s1474-4422(15)70016-5
10.1038/nri3705
10.1038/nature11729
10.1093/nar/gkj144
10.1186/s40478-015-0203-5
10.1111/j.1471-4159.2009.06042.x
10.1084/jem.20142322
10.1186/1742-2094-5-23
10.1093/nar/gkh103
10.1016/j.cell.2017.05.018
10.3791/53308
10.7554/elife.20391
10.1016/j.immuni.2017.08.008
10.1016/j.neuron.2011.07.001
10.1007/s11481-011-9339-7
10.1523/JNEUROSCI.1498-12.2012
10.1016/j.neuron.2018.02.002
10.1073/pnas.1710311114
10.1001/archneurol.2007.3
10.3233/JAD-122257
10.1016/j.celrep.2017.09.039
10.15252/embr.201743922
10.1126/science.1131864
10.1016/j.jalz.2005.06.003
10.1007/s00401-011-0826-y
10.4049/jimmunol.1502532
10.1038/s41593-018-0296-9
10.1021/acs.jmedchem.7b01626
10.1007/s00401-013-1182-x
10.1086/519795
10.1074/jbc.273.49.32730
10.1074/jbc.M109.098160
10.1021/bi1009584
10.1007/s00401-011-0896-x
10.1021/ja043475p
10.1016/j.ab.2004.06.042
10.1186/s13024-018-0244-x
10.3233/JAD-140495
10.1021/acsami.6b00811
10.1038/nature25158
10.2174/13816128113199990068
10.1016/j.cell.2015.01.049
10.1371/journal.pgen.1001308
10.1038/nprot.2015.052
10.15252/emmm.201606370
10.1016/j.neurobiolaging.2017.03.021
10.1038/srep41689
10.1016/j.neuron.2016.05.003
10.1084/jem.20160844
10.1007/s00018-017-2463-7",<Element 'PubmedArticle' at 0x7f05dd1eacc0>
109,"30953557
3263583
2559373
11578769
12383924
10674423
10817926
11245811
15051507
12629164
17549256
23486975
16481342
9458167
10858586
22315714
25792098
25991443
27843334
17658666
22824372
22024597
27054030
18302763
17255335
19825975
20846376
15895461
26268530
27014584
27669650
18604209
23254930
15148142
27509875
28003153
28255908
24561250
28019679
30206330
7543987
8556481
17080199
11329064
22342341
26538310
26538654
29371994
29151590
9225377
9422548
22286176
25045405
18339452
19123954
12796468
18417708
25630253
28924036
10588577
20368278
12119423
18562603
27033548
28566429
30392797
30415998
28483841
23150908
24119542
29859094
27402340
27196974
24355566
26364736
24966389
25062954
24021538
27338705
29346778
27459405
24669294
30606613
30760929
24316888
28521131
28602351
28930663
17950926
16551245
25732305
19513731
12027877
16247185
29402847
15649704
24874542
16476660
17351623
22160221
25878730
20014009
24070198
19164591
2972943
11958825
9209275
10894180
15001224
17353159
18462836
20520819
29422891
15141078
26884167
26558367
21867926
27818384
2419430
12847155
20060887
19808651
23365075
16549802
12417433
17264212
19167499
23597431
17279093
12640446
19923550
20375655
28967385
24217510
25179671
19874269
20546729
24075978
29181488
16864778
26284939
26049087
11548979
12020957
12707324
17531858
14568126
27587303
25300334
20440079
26779813
12754353
15536110
19738171
22647384
21899735
23993702
13678674
12667645
17203472
18759972
19486646
25687824
29643512
22747709
21704698
19320056
28237313
28579870
22632257
22642825
26436670
25596877
18184433
25934853
23178247
26084021
19204726
27091974
18827826
28675392
19211891
25178404
28123027
16973389
29955663
8544901
11794217
12869452
16195368
20725517
18474729
23562431
12783912
17068392
11755002
11700559
15817521",Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease.,"Neuroinflammation is considered one of the cardinal features of Alzheimer's disease (AD). Neuritic plaques composed of amyloid β and neurofibrillary tangle-laden neurons are surrounded by reactive astrocytes and microglia. Exposure of microglia, the resident myeloid cell of the CNS, to amyloid β causes these cells to acquire an inflammatory phenotype. While these reactive microglia are important to contain and phagocytose amyloid plaques, their activated phenotype impacts CNS homeostasis. In rodent models, increased neuroinflammation promoted by overexpression of proinflammatory cytokines can cause an increase in hyperphosphorylated tau and a decrease in hippocampal function. The peripheral immune system can also play a detrimental or beneficial role in CNS inflammation. Systemic inflammation can increase the risk of developing AD dementia, and chemokines released directly by microglia or indirectly by endothelial cells can attract monocytes and T lymphocytes to the CNS. These peripheral immune cells can aid in amyloid β clearance or modulate microglia responses, depending on the cell type. As such, several groups have targeted the peripheral immune system to modulate chronic neuroinflammation. In this review, we focus on the interplay of immunomodulating factors and cell types that are being investigated as possible therapeutic targets for the treatment or prevention of AD.","['Adaptive immunity', 'Alzheimer’s disease', 'Cytokines', 'Innate immunity', 'Microglia', 'Therapeutics']",Journal of neuroinflammation,2019-04-07,"[{'lastname': 'Dionisio-Santos', 'firstname': 'Dawling A', 'initials': 'DA', 'affiliation': 'Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 603, Rochester, NY, 14642, USA.'}, {'lastname': 'Olschowka', 'firstname': 'John A', 'initials': 'JA', 'affiliation': 'Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 603, Rochester, NY, 14642, USA.'}, {'lastname': ""O'Banion"", 'firstname': 'M Kerry', 'initials': 'MK', 'affiliation': 'Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 603, Rochester, NY, 14642, USA. Kerry_obanion@urmc.rochester.edu.'}]",,,,,"10.1186/s12974-019-1453-0
10.1016/S0197-4580(88)80079-4
10.1016/0304-3940(89)90843-4
10.1016/S0197-0186(01)00041-9
10.1016/S0304-3940(02)00888-1
10.1016/S0197-4580(99)00065-2
10.1016/S0006-8993(00)03176-0
10.1016/j.yexcr.2004.01.002
10.1523/JNEUROSCI.23-05-01605.2003
10.1523/JNEUROSCI.4361-12.2013
10.1093/intimm/dxh394
10.1111/j.1750-3639.1998.tb00136.x
10.1101/cshperspect.a006346
10.1016/S1474-4422(15)70016-5
10.1038/nrn3880
10.2147/JIR.S86958
10.1016/j.neurobiolaging.2007.06.006
10.1186/1742-2094-9-179
10.1016/j.brainresbull.2011.10.004
10.1186/s40035-016-0054-4
10.1186/1742-2094-5-7
10.2353/ajpath.2007.060378
10.1096/fj.09-141754
10.1186/1742-2094-7-56
10.1002/humu.20180
10.1093/brain/awv231
10.1016/j.tibs.2016.09.002
10.1038/ni.1636
10.1038/nature11729
10.1001/archneur.61.5.668
10.1038/ncomms12504
10.1016/j.bbi.2016.12.014
10.1007/s12035-017-0467-9
10.1016/j.arr.2013.12.007
10.1111/bpa.12483
10.1038/s41583-018-0055-7
10.1172/JCI27341
10.1038/87945
10.1016/j.neuroscience.2012.01.049
10.1186/s12974-015-0411-8
10.1523/JNEUROSCI.3959-14.2015
10.18632/oncotarget.23106
10.1038/nri.2017.125
10.1111/j.1440-1819.1997.tb02375.x
10.1038/nn.3028
10.1186/alzrt272
10.1016/j.neurobiolaging.2008.01.011
10.1186/1742-2094-6-1
10.1084/jem.20021546
10.1523/JNEUROSCI.4814-07.2008
10.1038/ncomms7176
10.1074/jbc.M117.801514
10.1016/S0197-4580(99)00020-2
10.4049/jimmunol.0903382
10.1073/pnas.162350199
10.1523/JNEUROSCI.0829-08.2008
10.1126/science.aad8373
10.1126/scitranslmed.aaf6295
10.1016/j.neuron.2018.10.014
10.1016/j.neuron.2018.10.031
10.15252/embr.201743922
10.1056/NEJMoa1211103
10.1016/j.neurobiolaging.2013.09.009
10.1186/s13024-018-0262-8
10.15252/emmm.201606370
10.1016/j.neuron.2016.05.003
10.1016/j.bcp.2013.11.021
10.1016/j.neurobiolaging.2015.08.019
10.1523/JNEUROSCI.1146-14.2014
10.1186/1742-2094-11-127
10.1159/000354228
10.1126/science.aad8670
10.1016/j.celrep.2017.12.066
10.1038/nn.4338
10.12703/P6-13
10.1016/j.neuron.2018.12.006
10.1038/s41586-019-0924-x
10.1038/nn.3599
10.1016/j.neuron.2017.04.043
10.1016/j.cell.2017.05.018
10.1016/j.immuni.2017.08.008
10.1016/j.tins.2007.08.007
10.1146/annurev.immunol.24.021605.090737
10.1084/jem.20142322
10.1007/s00401-009-0556-6
10.1046/j.1365-2362.2002.00994.x
10.1385/NMM:7:3:255
10.1159/000486200
10.1016/j.nbd.2004.09.009
10.1016/j.nbd.2014.05.018
10.1016/j.neuron.2006.01.022
10.1038/nm1555
10.2119/molmed.2011.00306
10.1186/s13195-015-0125-2
10.3727/096368913X672181
10.1073/pnas.0805453106
10.1016/0304-3940(88)90690-8
10.1016/S0165-5728(01)00496-9
10.1016/S0165-5728(97)00067-2
10.1097/00004647-200006000-00009
10.1016/j.micpath.2003.11.004
10.1016/j.neurobiolaging.2008.03.024
10.1371/journal.pone.0010830
10.3389/fimmu.2017.01905
10.1073/pnas.0402268101
10.1073/pnas.1525466113
10.1016/j.immuni.2011.07.010
10.1093/brain/aww270
10.1212/01.WNL.0000073623.84147.A8
10.1016/j.bbi.2010.01.003
10.2353/ajpath.2009.090059
10.4049/jimmunol.1200947
10.1073/pnas.0506209103
10.1016/S0165-5728(02)00307-7
10.1073/pnas.0609377104
10.1016/j.nbd.2008.12.015
10.1016/j.bbi.2013.04.002
10.1038/sj.mp.4001947
10.1038/nm840
10.1212/WNL.0b013e3181c67808
10.1016/j.biopsych.2017.08.010
10.1038/nrneurol.2013.223
10.1186/s12883-014-0169-0
10.2174/156720509789207930
10.1016/j.expneurol.2010.05.010
10.1016/j.neuron.2013.07.046
10.1073/pnas.0604681103
10.1038/ncomms8967
10.1093/brain/awv150
10.1177/135245850100700401
10.1016/S0165-5728(02)00053-X
10.4049/jimmunol.170.9.4483
10.1016/S0074-7742(07)79024-4
10.1016/S0022-510X(03)00177-1
10.1016/j.expneurol.2016.08.012
10.1172/JCI41911
10.1038/nm.4022
10.1136/jnnp.74.6.788
10.1001/jama.292.18.2237
10.1212/WNL.0b013e3181b6bb95
10.1186/alzrt118
10.1186/1742-2094-8-112
10.1016/j.neurobiolaging.2013.07.025
10.1016/S0969-9961(03)00069-X
10.1016/S0165-5728(03)00037-7
10.1002/glia.20467
10.1186/1742-2094-5-37
10.1016/j.bbi.2009.01.017
10.1038/srep08489
10.1038/s41586-018-0023-4
10.1186/1742-2094-9-150
10.1016/j.bbi.2011.06.006
10.1016/j.nbd.2009.01.006
10.1016/j.nbd.2017.02.010
10.1177/1179573517709278
10.1186/1742-2094-9-99
10.1371/journal.pone.0137305
10.1016/j.acthis.2014.12.002
10.1186/1742-2094-5-2
10.1212/WNL.0000000000001617
10.1038/nm.2965
10.1016/j.immuni.2015.06.006
10.1038/mp.2009.10
10.1073/pnas.1604032113
10.1038/nrd2660
10.1038/tp.2017.142
10.1523/JNEUROSCI.5715-08.2009
10.1523/JNEUROSCI.1967-16.2016
10.1016/j.immuni.2006.07.013
10.1016/0197-4580(95)00049-K
10.1056/NEJMoa010178
10.1136/bmj.327.7407.128
10.1096/fj.04-3620rev
10.1001/archneur.2008.65.7.nct70006
10.1016/j.jalz.2012.11.012
10.1001/jama.289.21.2819
10.1159/000096588
10.1016/S0197-4580(01)00296-2
10.1038/35102591
10.1093/brain/awh452
10.1016/j.jalz.2014.05.1588",<Element 'PubmedArticle' at 0x7f05dd1ac1d0>
110,30878533,Regional hypometabolism in the 3xTg mouse model of Alzheimer's disease.,"Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. Although neurofibrillary tangles and amyloid beta are classic hallmarks of AD, the earliest deficits in AD progression may be caused by unknown factors. One suspected factor has to do with brain energy metabolism. To investigate this factor, brain metabolic activity in 3xTg-AD mice and age-matched controls were measured with FDG-PET. Significant hypometabolic changes (p < .01) in brain metabolism were detected in the cortical piriform and insular regions of AD brains relative to controls. These regions are associated with olfaction, which is a potential clinical marker for AD progression as well as neurogenesis. The activity of the terminal component of the mitochondrial respiratory chain (complex IV) and the expression of complex I-V were significantly decreased (p < .05), suggesting that impaired metabolic activity coupled with impaired oxidative phosphorylation leads to decreased mitochondrial bioenergetics and subsequent Neurodegeneration. Although there is an association between neuroinflammatory pathological markers (microglial) and hypometabolism in AD, there was no association found between neuropathological (Aβ, tau, and astrocytes) and functional changes in AD sensitive brain regions, also suggesting that brain hypometabolism occurs prior to AD pathology. Therefore, targeting metabolic mechanisms in cortical piriform and insular regions at early stages may be a promising approach for preventing, slowing, and/or blocking the onset of AD and preserving neurogenesis.","[""Alzheimer's disease, 3xTg-AD, neurofibrillary tangles"", 'Amyloid beta', 'FDG-PET', 'Insular', 'Pirifom']",Neurobiology of disease,2019-03-18,"[{'lastname': 'Adlimoghaddam', 'firstname': 'Aida', 'initials': 'A', 'affiliation': 'St. Boniface Hospital Research, Canada; Dept. of Pharmacology & Therapeutics, University of Manitoba, Canada. Electronic address: aadlimoghaddam@sbrc.ca.'}, {'lastname': 'Snow', 'firstname': 'Wanda M', 'initials': 'WM', 'affiliation': 'St. Boniface Hospital Research, Canada.'}, {'lastname': 'Stortz', 'firstname': 'Greg', 'initials': 'G', 'affiliation': 'University of British Columbia, Canada.'}, {'lastname': 'Perez', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'St. Boniface Hospital Research, Canada; Dept. of Pharmacology & Therapeutics, University of Manitoba, Canada.'}, {'lastname': 'Djordjevic', 'firstname': 'Jelena', 'initials': 'J', 'affiliation': 'St. Boniface Hospital Research, Canada; Dept. of Pharmacology & Therapeutics, University of Manitoba, Canada.'}, {'lastname': 'Goertzen', 'firstname': 'Andrew L', 'initials': 'AL', 'affiliation': 'Dept. of Radiology, University of Manitoba, Canada.'}, {'lastname': 'Ko', 'firstname': 'Ji Hyun', 'initials': 'JH', 'affiliation': 'Dept. of Human Anatomy and Cell Science, University of Manitoba, Canada; Health Sciences Centre, Canada.'}, {'lastname': 'Albensi', 'firstname': 'Benedict C', 'initials': 'BC', 'affiliation': 'St. Boniface Hospital Research, Canada; Dept. of Pharmacology & Therapeutics, University of Manitoba, Canada. Electronic address: balbensi@sbrc.ca.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2019.03.008,<Element 'PubmedArticle' at 0x7f05dd12a220>
111,"30821420
17997332
21481640
10848580
21029237
25687824
12437593
12499843
23202496
23320095
19381658
9108217
12667446
28982375
21738672
20619937
20164343
23092889
24522206
28549133
22306812
22281122
25590804
17021169
16581193
21790829
9687506
16611824
30315100
26921134
26210990
27025652
17652745
12975376
15659232
24211709
8557029
22153080",PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions.,"Brain lesions in Alzheimer's disease (AD) include amyloid plaques made of Aβ peptides and neurofibrillary tangles composed of hyperphosphorylated tau protein with synaptic and neuronal loss and neuroinflammation. Aβ oligomers can trigger tau phosphorylation and neuronal alterations through activation of neuronal kinases leading to progressive cognitive decline. PKR is a ubiquitous pro-apoptotic serine/threonine kinase, and levels of activated PKR are increased in AD brains and AD CSF. In addition, PKR regulates negatively memory formation in mice. To assess the role of PKR in an AD in vivo model, we crossed 5xFAD transgenic mice with PKR knockout (PKRKO) mice and we explored the contribution of PKR on cognition and brain lesions in the 5xFAD mouse model of AD as well as in neuron-microglia co-cultures exposed to the innate immunity activator lipopolysaccharide (LPS). Nine-month-old double-mutant mice revealed significantly improved memory consolidation with the new object location test, starmaze test, and elevated plus maze test as compared to 5xFAD mice. Brain amyloid accumulation and BACE1 levels were statistically decreased in double-mutant mice. Apoptosis, neurodegeneration markers, and synaptic alterations were significantly reduced in double-mutant mice as well as neuroinflammation markers such as microglial load and brain cytokine levels. Using cocultures, we found that PKR in neurons was essential for LPS microglia-induced neuronal death. Our results demonstrate the clear involvement of PKR in abnormal spatial memory and brain lesions in the 5xFAD model and underline its interest as a target for neuroprotection in AD.","['Alzheimer', 'PKR', 'amyloid', 'memory', 'neurodegeneration', 'neuroinflammation']",Aging cell,2019-03-02,"[{'lastname': 'Tible', 'firstname': 'Marion', 'initials': 'M', 'affiliation': 'Inserm U1144, Paris, France.'}, {'lastname': 'Mouton Liger', 'firstname': 'François', 'initials': 'F', 'affiliation': 'Inserm U1144, Paris, France.\nInserm U1127, Paris, France.'}, {'lastname': 'Schmitt', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'Institut de Biologie Paris Seine, CNRS, UMR 8246, Paris, France.\nInserm U1130, Paris, France.\nSorbonne Université, Paris, France.'}, {'lastname': 'Giralt', 'firstname': 'Albert', 'initials': 'A', 'affiliation': 'Sorbonne Université, Paris, France.\nInserm U839, Paris, France.\nInstitut du Fer à Moulin, Paris, France.'}, {'lastname': 'Farid', 'firstname': 'Karim', 'initials': 'K', 'affiliation': 'Department of Nuclear Medicine, CHU Fort de France, Martinique, France.\nCenter of Cognitive Neurology, Lariboisière Fernand Widal Hospital, APHP, Paris, France.'}, {'lastname': 'Thomasseau', 'firstname': 'Sylvie', 'initials': 'S', 'affiliation': 'Inserm U1144, Paris, France.'}, {'lastname': 'Gourmaud', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Inserm U1144, Paris, France.\nPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'lastname': 'Paquet', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'Inserm U1144, Paris, France.\nCenter of Cognitive Neurology, Lariboisière Fernand Widal Hospital, APHP, Paris, France.\nParis Diderot University, Paris, France.'}, {'lastname': 'Rondi Reig', 'firstname': 'Laure', 'initials': 'L', 'affiliation': 'Institut de Biologie Paris Seine, CNRS, UMR 8246, Paris, France.\nInserm U1130, Paris, France.\nSorbonne Université, Paris, France.'}, {'lastname': 'Meurs', 'firstname': 'Eliane', 'initials': 'E', 'affiliation': 'Hepacivirus and Innate Immunity Unit, Institut Pasteur, Paris, France.\nCNRS, UMR 3569, Paris, France.'}, {'lastname': 'Girault', 'firstname': 'Jean-Antoine', 'initials': 'JA', 'affiliation': 'Sorbonne Université, Paris, France.\nInserm U839, Paris, France.\nInstitut du Fer à Moulin, Paris, France.'}, {'lastname': 'Hugon', 'firstname': 'Jacques', 'initials': 'J', 'affiliation': 'Inserm U1144, Paris, France.\nCenter of Cognitive Neurology, Lariboisière Fernand Widal Hospital, APHP, Paris, France.\nParis Diderot University, Paris, France.'}]",,,,© 2019 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.,"10.1111/acel.12887
10.1016/j.nlm.2007.10.001
10.1016/S1474-4422(11)70077-1
10.1128/MCB.20.13.4532-4542.2000
10.1111/j.1750-3639.2010.00437.x
10.1038/srep08489
10.1097/01.wnr.0000048020.74602.bb
10.3390/v4112598
10.1371/journal.pone.0053587
10.1007/s00401-009-0532-1
10.1007/PL00005603
10.1016/S1097-2765(03)00105-9
10.1186/s13195-017-0308-0
10.1371/journal.pone.0021456
10.1016/j.neurobiolaging.2010.05.027
10.1523/JNEUROSCI.3971-09.2010
10.1126/scisignal.2003511
10.1096/fj.13-248294
10.1093/brain/awx107
10.1016/j.bbadis.2012.01.009
10.1016/j.biopsych.2011.11.031
10.1038/cddis.2014.552
10.1523/JNEUROSCI.1202-06.2006
10.1016/j.neuroscience.2006.01.047
10.1111/j.1750-3639.2011.00520.x
10.1093/emboj/17.15.4379
10.1523/JNEUROSCI.3408-05.2006
10.1074/jbc.RA118.005769
10.1016/S0140-6736(15)01124-1
10.1007/s00401-015-1462-8
10.15252/emmm.201606210
10.1167/iovs.06-1122
10.1074/jbc.M306503200
10.1111/j.1471-4159.2004.02895.x
10.1016/j.neuint.2013.10.012
10.1002/j.1460-2075.1995.tb00300.x
10.1016/j.cell.2011.11.029",<Element 'PubmedArticle' at 0x7f05dd133ef0>
112,"30803086
20232465
1549228
26001591
23109154
23252647
1759558
7566337
23100432
27862631
24346482
30108586
20010301
9403139
9005861
25494366
18604209
12927762
27033548
29230021
9600222
22265587
18520776
9630473
11916959
28602351
21527731
9219961
18270320
28099414
8858005
26438529
24996286
2011243
19473297
22101365
9447441
19010392
15831717
7886226
24360280
2097581
25024349
28746864
19388207
27743026
9341931
22632727
23602650
21777559
27989508
21689123
9224523
21514248
19513731
2976393
14730714
25257319
21175619
12084879
27404378
28350400
12498966
1285496
27918243",The relationship between the morphological subtypes of microglia and Alzheimer's disease neuropathology.,"Microglial associations with both the major Alzheimer's disease (AD) pathognomonic entities, β-amyloid-positive plaques and tau-positive neurofibrillary tangles, have been noted in previous investigations of both human tissue and mouse models. However, the precise nature of their role in the pathogenesis of AD is debated; the major working hypothesis is that pro-inflammatory activities of activated microglia contribute to disease progression. In contrast, others have proposed that microglial dystrophy with a loss of physiological and neuroprotective activities promotes neurodegeneration. This immunohistochemical study sought to gain clarity in this area by quantifying the morphological subtypes of microglia in the mildly-affected primary visual cortex (PVC), the moderately affected superior frontal cortex (SFC) and the severely affected inferior temporal cortex (ITC) of 8 AD cases and 15 age and gender-matched, non-demented controls with ranging AD-type pathology. AD cases had increased β-amyloid and tau levels compared to controls in all regions. Neuronal loss was observed in the SFC and ITC, and was associated with atrophy in the latter. A major feature of the ITC in AD was a decrease in ramified (healthy) microglia with image analysis confirming reductions in arborized area and skeletal complexity. Activated microglia were not associated with AD but were increased in non-demented controls with greater AD-type pathology. Microglial clusters were occasionally associated with β-amyloid- and tau-positive plaques but represented less than 2% of the total microglial population. Dystrophic microglia were not associated with AD, but were inversely correlated with brain pH suggesting that agonal events were responsible for this morphological subtype. Overall these novel findings suggest that there is an early microglial reaction to AD-type pathology but a loss of healthy microglia is the prominent feature in severely affected regions of the AD brain.","['Alzheimer’s disease', 'brain pH', 'microglia', 'post-mortem human brain', 'quantitative neuropathology']","Brain pathology (Zurich, Switzerland)",2019-02-26,"[{'lastname': 'Paasila', 'firstname': 'Patrick Jarmo', 'initials': 'PJ', 'affiliation': 'Discipline of Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'lastname': 'Davies', 'firstname': 'Danielle Suzanne', 'initials': 'DS', 'affiliation': 'The University of Sydney Brain & Mind Centre, Sydney, Australia.'}, {'lastname': 'Kril', 'firstname': 'Jillian June', 'initials': 'JJ', 'affiliation': 'Discipline of Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'lastname': 'Goldsbury', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'The University of Sydney Brain & Mind Centre, Sydney, Australia.'}, {'lastname': 'Sutherland', 'firstname': 'Greg Trevor', 'initials': 'GT', 'affiliation': 'Discipline of Pathology, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}]",,,,© 2019 International Society of Neuropathology.,10.1111/bpa.12717,<Element 'PubmedArticle' at 0x7f05dd159d60>
113,"30721409
29691517
26436904
27497324
24952504
21212632
15509534
20920788
26638867
1759558
25045869
19794442
24603946
11823641
25589773
23383169
25686105
26818951
30052812
28003153
23712122
18403674
22424229
24952505
20029438
19282288
27878366
16108021
15390000
23486975
28986461
30193298
26250687
28772101
20133726
26121197
21372138
27810929
18604209
12130773
25792098
24962261
23254930
30206330
24860099
25261551
11398841
23332364
20083042
22028219
24005412
16407888
29752551
28587664
17897471
12702875
22461630
27751442
16192374
28858314
22974247
29061692
23050084
20846376
28662669
12629164
25274309
21430171
25833819
15190255
16407890
12191486
16407889
20835230
24052108
29258615
18288107
29054878
27716675
25220759
27540165
25050810
28845751
28855077
24857020
22229116
21777559
25862635
25407337
28238712
19513731
22541070
12084879
25043000
26739002
29293211
25840008
27270558
28083634
12165466
21847625
17270732",Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo.,"Brains of Alzheimer's disease patients are characterized by the presence of amyloid plaques and neurofibrillary tangles, both invariably associated with neuroinflammation. A crucial role for NLRP3-ASC inflammasome [NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-Apoptosis-associated speck-like protein containing a CARD (ASC)] in amyloid-beta (Aβ)-induced microgliosis and Aβ pathology has been unequivocally identified. Aβ aggregates activate NLRP3-ASC inflammasome (Halle et al. in Nat Immunol 9:857-865, 2008) and conversely NLRP3-ASC inflammasome activation exacerbates amyloid pathology in vivo (Heneka et al. in Nature 493:674-678, 2013), including by prion-like ASC-speck cross-seeding (Venegas et al. in Nature 552:355-361, 2017). However, the link between inflammasome activation, as crucial sensor of innate immunity, and Tau remains unexplored. Here, we analyzed whether Tau aggregates acting as prion-like Tau seeds can activate NLRP3-ASC inflammasome. We demonstrate that Tau seeds activate NLRP3-ASC-dependent inflammasome in primary microglia, following microglial uptake and lysosomal sorting of Tau seeds. Next, we analyzed the role of inflammasome activation in prion-like or templated seeding of Tau pathology and found significant inhibition of exogenously seeded Tau pathology by ASC deficiency in Tau transgenic mice. We furthermore demonstrate that chronic intracerebral administration of the NLRP3 inhibitor, MCC950, inhibits exogenously seeded Tau pathology. Finally, ASC deficiency also decreased non-exogenously seeded Tau pathology in Tau transgenic mice. Overall our findings demonstrate that Tau-seeding competent, aggregated Tau activates the ASC inflammasome through the NLRP3-ASC axis, and we demonstrate an exacerbating role of the NLRP3-ASC axis on exogenously and non-exogenously seeded Tau pathology in Tau mice in vivo. The NLRP3-ASC inflammasome, which is an important sensor of innate immunity and intensively explored for its role in health and disease, hence presents as an interesting therapeutic approach to target three crucial pathogenetic processes in AD, including prion-like seeding of Tau pathology, Aβ pathology and neuroinflammation.","['AD and Tauopathies', 'In vivo models', 'Inflammation', 'Propagation of Tau pathology', 'Tau', 'Tau pathology']",Acta neuropathologica,2019-02-06,"[{'lastname': 'Stancu', 'firstname': 'Ilie-Cosmin', 'initials': 'IC', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.\nAlzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.'}, {'lastname': 'Cremers', 'firstname': 'Niels', 'initials': 'N', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.'}, {'lastname': 'Vanrusselt', 'firstname': 'Hannah', 'initials': 'H', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.'}, {'lastname': 'Couturier', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'Alzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.'}, {'lastname': 'Vanoosthuyse', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Alzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.'}, {'lastname': 'Kessels', 'firstname': 'Sofie', 'initials': 'S', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.'}, {'lastname': 'Lodder', 'firstname': 'Chritica', 'initials': 'C', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.'}, {'lastname': 'Brône', 'firstname': 'Bert', 'initials': 'B', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.'}, {'lastname': 'Huaux', 'firstname': 'François', 'initials': 'F', 'affiliation': 'Louvain Center for Toxicology and Applied Pharmacology, Catholic University of Louvain, 1200, Brussels, Belgium.'}, {'lastname': 'Octave', 'firstname': 'Jean-Noël', 'initials': 'JN', 'affiliation': 'Alzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.'}, {'lastname': 'Terwel', 'firstname': 'Dick', 'initials': 'D', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.'}, {'lastname': 'Dewachter', 'firstname': 'Ilse', 'initials': 'I', 'affiliation': 'Biomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium. ilse.dewachter@uhasselt.be.\nAlzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium. ilse.dewachter@uhasselt.be.'}]",,,,,10.1007/s00401-018-01957-y,<Element 'PubmedArticle' at 0x7f05dd1048b0>
114,30691318,The P2X7 receptor: a new therapeutic target in Alzheimer's disease.,"Alzheimer's disease (AD) is a neurodegenerative illness with genetic risk as an etiological factor in a subset of cases. In AD with autosomal dominant inheritance, the extracellular β-amyloid (Aβ) aggregates and intracellular neurofibrillary tangles which consist of hyperphosphorylated tau, appear to be involved in the neuronal damage; however, other forms of AD may have a polygenetic causality. Microglial cells orchestrate pathophysiological events responsible for neuronal damage in AD. They surround Aβ aggregates and the stimulation of microglial P2X7 receptors (P2X7Rs) by high local concentrations of ATP which originates from damaged CNS cells, results in degeneration of nearby neurons. Areas covered: We discuss the pathogenesis of Alzheimer's disease, the role of P2X7 receptors and their potential as therapeutic targets. We also address the fundamental hurdles in the development of new therapeutic strategies for Alzheimer's disease. Expert opinion: There are many difficulties associated with the development of efficient pharmacological strategies for AD; the lack of good animal and cellular models for this illness is a key obstacle. None of the pharmacological strategies developed so far have led to an improvement of the treatment of AD. Hence, the consideration of blood-brain barrier-permeable P2X7R antagonists as possible therapeutic agents in AD is a must.","['Alzheimer’s disease', 'P2X7 receptor', 'activated microglia', 'hyperphosphorylated tau', 'β-amyloid']",Expert opinion on therapeutic targets,2019-01-30,"[{'lastname': 'Illes', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'a Rudolf-Boehm-Institut für Pharmakologie und Toxikologie , Universität Leipzig , Leipzig , Germany.\nb Acupuncture and Tuina School , Chengdu University of TCM , Chengdu , China.'}, {'lastname': 'Rubini', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': 'b Acupuncture and Tuina School , Chengdu University of TCM , Chengdu , China.'}, {'lastname': 'Huang', 'firstname': 'Lumei', 'initials': 'L', 'affiliation': 'b Acupuncture and Tuina School , Chengdu University of TCM , Chengdu , China.'}, {'lastname': 'Tang', 'firstname': 'Yong', 'initials': 'Y', 'affiliation': 'b Acupuncture and Tuina School , Chengdu University of TCM , Chengdu , China.'}]",,,,,10.1080/14728222.2019.1575811,<Element 'PubmedArticle' at 0x7f05dd0bb9f0>
115,"30532704
27570871
28327181
26374899
26374897
29037207
24131187
16505336
24493463
24139279
23708142
28818091
19794442
24535663
29768169
21800138
18391000
29859094
28774322
29843241
26911435
8346443
20534741
12847223
20604710
29282133
30282364
28477215
19381658
28549481
19325568
28173832
23855984
18551625
24211851
29219210
20966214
27423963
24143816
23150934
19853650
26754172
30258234
28978423
26851150
29273078
28100745
28768545
25732305
28320424
24323045
27067662
24899047
23150908
25716838
18329368
26758977
15681802
28559417
15883308
27995897
28432014
30127720
28930663
23702978
29518357
11520930
30341064
28662669
28983098
25936935
28478762
24012002
28095923
26438529
29734735
29686264
18305538
28122627
18393795
19171755
27314526
22312126
19503107
26337043
11402114
10888890
12080485
28143566
25114293
18790823
28282924
25893602
29887864
19079182
22197934
23800361
23827971
28886007
26939933
28862638
27859676
30232263
26187728
11274343
27325789
27459603
30140051
28714976
27520774
29321225
9786340
25807283
25144717
28866979
28003277
25394486
29518360
30266932
28802038
27033414
24893973
26854967
28426958
29483128
25604547
28086931
25728668
27091843
25897174
29237931
24078628
30185230
28442216
27477018
28434692
27196974
23622250
25565961
28606182
29611543
29518356
28077724
27143430
28209725
28680398
25957402
29587871
30038567
27358059",TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism.,"Alzheimer's disease (AD) is the leading cause of age-related dementia among the elderly population. Recent genetic studies have identified rare variants of the gene encoding the triggering receptor expressed on myeloid cells-2 (TREM2) as significant genetic risk factors in late-onset AD (LOAD). TREM2 is specifically expressed in brain microglia and modulates microglial functions in response to key AD pathologies such as amyloid-β (Aβ) plaques and tau tangles. In this review article, we discuss recent research progress in our understanding on the role of TREM2 in microglia and its relevance to AD pathologies. In addition, we discuss evidence describing new TREM2 ligands and the role of TREM2 signaling in microglial survival and energy metabolism. A comprehensive understanding of TREM2 function in the pathogenesis of AD offers a unique opportunity to explore the potential of this microglial receptor as an alternative target in AD therapy.","['Alzheimer’s disease', 'TREM2', 'metabolism', 'microglia', 'survival']",Frontiers in aging neuroscience,2018-12-12,"[{'lastname': 'Zheng', 'firstname': 'Honghua', 'initials': 'H', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.\nShenzhen Research Institute, Xiamen University, Shenzhen, China.'}, {'lastname': 'Cheng', 'firstname': 'Baoying', 'initials': 'B', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.'}, {'lastname': 'Li', 'firstname': 'Yanfang', 'initials': 'Y', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.\nShenzhen Research Institute, Xiamen University, Shenzhen, China.'}, {'lastname': 'Li', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.'}, {'lastname': 'Chen', 'firstname': 'Xiaofen', 'initials': 'X', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.\nShenzhen Research Institute, Xiamen University, Shenzhen, China.'}, {'lastname': 'Zhang', 'firstname': 'Yun-Wu', 'initials': 'YW', 'affiliation': 'Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen, China.'}]",,,,,"10.3389/fnagi.2018.00395
10.1016/j.jalz.2016.03.001
10.1186/s13024-017-0169-9
10.1074/jbc.M115.679043
10.1074/jbc.M115.677286
10.1186/s13024-017-0216-6
10.1056/NEJMc1306509
10.1212/01.wnl.0000216105.11788.0f
10.1001/jamaneurol.2013.5847
10.1016/j.neurobiolaging.2013.09.017
10.1038/nn.3435
10.1186/s13195-017-0293-3
10.1038/nrd2959
10.1001/jamaneurol.2013.6237
10.1016/j.immuni.2018.04.034
10.1007/s00251-011-0562-4
10.1128/iai.00115-08
10.1186/s13024-018-0262-8
10.1186/s13024-017-0199-3
10.3233/jad-179941
10.1038/nrn.2016.7
10.1126/science.8346443
10.1093/hmg/ddq221
10.4049/jimmunol.171.2.594
10.1146/annurev-cellbio-100109-104117
10.1186/s13024-017-0232-6
10.3233/jad-180583
10.1007/s12031-017-0928-7
10.1007/s00401-009-0532-1
10.1186/s13024-017-0184-x
10.1038/cdd.2009.33
10.1186/s13024-017-0155-2
10.1016/j.neurobiolaging.2013.05.001
10.1002/glia.20710
10.1016/j.pneurobio.2013.10.004
10.1002/glia.23271
10.1126/science.1194637
10.1016/j.jalz.2016.06.005
10.1056/NEJMc1306509
10.1056/NEJMoa1211851
10.1016/j.exger.2009.10.010
10.1186/s13024-016-0071-x
10.1038/s41593-018-0242-x
10.1016/j.cmet.2017.09.010
10.1016/j.proghi.2016.01.001
10.1186/s13024-017-0231-7
10.1523/JNEUROSCI.2110-16.2016
10.1186/s13024-017-0197-5
10.1084/jem.20142322
10.1186/s12974-017-0835-4
10.1038/cr.2013.161
10.1016/j.neurobiolaging.2016.02.023
10.1093/hmg/ddu277
10.1056/NEJMoa1211103
10.1523/JNEUROSCI.2620-14.2015
10.1016/j.cell.2007.12.040
10.1186/s13024-016-0068-5
10.1196/annals.1332.006
10.15252/embj.201796516
10.1212/01.wnl.0000160304.00003.ca
10.7554/eLife.20391
10.1016/j.jmb.2017.04.004
10.3389/fncel.2018.00206
10.1016/j.immuni.2017.08.008
10.1038/nri3452
10.1016/j.neuron.2018.02.002
10.1146/annurev.neuro.24.1.1121
10.15252/emmm.201809027
10.1186/s13024-017-0192-x
10.1038/nrd.2017.155
10.1016/j.jalz.2014.12.009
10.1186/s13024-017-0161-4
10.1016/j.neuron.2013.06.046
10.1186/s13024-017-0150-7
10.1186/s13024-015-0048-1
10.3390/cells7050037
10.1038/s41556-018-0092-5
10.1038/nature06639
10.1186/s13024-017-0154-3
10.2174/156720508783954721
10.1083/jcb.200808080
10.3233/jad-160197
10.4049/jimmunol.1102836
10.1038/ni.1744
10.1186/s13024-015-0040-9
10.1212/wnl.56.11.1552
10.1038/77153
10.1086/342259
10.1186/s13024-017-0156-1
10.2337/db13-1869
10.1093/brain/awn217
10.3390/ijms18030598
10.1172/jci77983
10.3389/fimmu.2018.01121
10.1038/mi.2008.1
10.1038/ng.1027
10.1186/1750-1326-8-19
10.1016/j.pneurobio.2013.06.002
10.1038/nm.4397
10.1186/s13024-016-0088-1
10.1172/JCI90606
10.1111/neup.12354
10.1073/pnas.1811411115
10.1101/cshperspect.a020545
10.1152/physrev.2001.81.2.741
10.1083/jcb.201602089
10.1371/journal.pone.0159099
10.1038/s41577-018-0051-1
10.1038/ng.3916
10.1016/j.jalz.2016.07.004
10.1084/jem.20171529
10.1016/s0166-2236(98)01337-x
10.1038/ng.3246
10.1038/cddis.2014.348
10.1186/s13024-017-0206-8
10.1101/cshperspect.a024539
10.1186/1750-1326-9-48
10.1016/j.neuron.2018.02.018
10.1038/s41582-018-0072-1
10.1016/j.cell.2017.07.023
10.1016/j.smim.2016.03.011
10.1186/1750-1326-9-20
10.1021/acschemneuro.5b00313
10.1016/j.neuron.2017.02.042
10.1084/jem.20171265
10.1007/s00401-015-1386-3
10.1186/s13024-016-0143-y
10.1016/j.cell.2015.01.049
10.1084/jem.20151948
10.1084/jem.20141732
10.4103/0366-6999.220313
10.1074/jbc.m113.517540
10.1186/s13024-018-0280-6
10.1016/j.molmed.2017.03.008
10.1016/j.neuron.2016.06.015
10.1016/j.neurobiolaging.2017.03.021
10.1016/j.neuron.2016.05.003
10.1016/j.cell.2013.03.030
10.3389/fncel.2014.00427
10.1186/s13024-017-0188-6
10.1038/emm.2017.200
10.1016/j.neuron.2018.01.031
10.1523/JNEUROSCI.2459-16.2017
10.1016/j.neurobiolaging.2016.03.004
10.1084/jem.20160844
10.3389/fnagi.2017.00204
10.1074/jbc.m115.645986
10.1186/s13024-018-0247-7
10.3389/fnagi.2018.00202
10.2174/1389450117666160625072521",<Element 'PubmedArticle' at 0x7f05dd0c5b30>
116,30417428,Microglial activation occurs late during preclinical Alzheimer's disease.,"Sporadic Alzheimer's disease (AD) is marked by a lengthy preclinical phase during which patients are nonsymptomatic but show pathology in variable manifestations. Whether or not neuroinflammation occurs in such nondemented individuals is unknown. We evaluated the medial temporal lobe of 66 nondemented subjects, aged 42-93, in terms of tau pathology, Aβ deposition, and microglial activation. We show that 100% of subjects had neurofibrillary degeneration (NFD), 35% had Aβ deposits, and 8% revealed microglial activation in individuals where early amyloid formation was apparent by Congo Red staining. Amyloid-induced neuroinflammatory clusters of Iba1, CD68, and ferritin-positive microglia were evident in the immediate vicinity of aggregated Aβ. Microglia in the adjacent neuropil were nonactivated. Thus, neuroinflammation in AD represents a highly localized phagocyte reaction, essentially a foreign body response, geared toward removal of insoluble Aβ. Because clustered microglia in some amyloid plaques were dystrophic and ferritin-positive, we hypothesize that these cells were exhausted by their attempts to remove the aggregated, insoluble Aβ. Our findings show that the sequence of pathologic events in AD begins with tau pathology, followed by Aβ deposition, and then by microglial activation. Because only 8% of our subjects revealed all three hallmark pathologic features, we propose that these nondemented individuals were near the threshold of transitioning from nonsymptomatic to symptomatic disease. The onset of neuroinflammation in AD may thus represent a tipping point in AD pathogenesis. Our study suggests that the role of microglia in AD pathogenesis entails primarily the attempted removal of potentially toxic, extracellular material.","[""Alzheimer's disease (AD)"", 'human subjects', 'microglial activation', 'neuroinflammation', 'pathogenesis']",Glia,2018-11-13,"[{'lastname': 'Streit', 'firstname': 'Wolfgang J', 'initials': 'WJ', 'affiliation': 'Department of Neuroscience, University of Florida College of Medicine, Gainesville, Florida.'}, {'lastname': 'Braak', 'firstname': 'Heiko', 'initials': 'H', 'affiliation': 'Clinical Neuroanatomy (Department of Neurology), Center for Biomedical Research, University of Ulm, Ulm, Germany.'}, {'lastname': 'Del Tredici', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': 'Clinical Neuroanatomy (Department of Neurology), Center for Biomedical Research, University of Ulm, Ulm, Germany.'}, {'lastname': 'Leyh', 'firstname': 'Judith', 'initials': 'J', 'affiliation': 'Institute of Anatomy, Leipzig University, Leipzig, Germany.'}, {'lastname': 'Lier', 'firstname': 'Julia', 'initials': 'J', 'affiliation': 'Institute of Anatomy, Leipzig University, Leipzig, Germany.'}, {'lastname': 'Khoshbouei', 'firstname': 'Habibeh', 'initials': 'H', 'affiliation': 'Department of Neuroscience, University of Florida College of Medicine, Gainesville, Florida.'}, {'lastname': 'Eisenlöffel', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Department of Neuropathology, Leipzig University, Leipzig, Germany.'}, {'lastname': 'Müller', 'firstname': 'Wolf', 'initials': 'W', 'affiliation': 'Department of Neuropathology, Leipzig University, Leipzig, Germany.'}, {'lastname': 'Bechmann', 'firstname': 'Ingo', 'initials': 'I', 'affiliation': 'Institute of Anatomy, Leipzig University, Leipzig, Germany.'}]",,,,"© 2018 Wiley Periodicals, Inc.",10.1002/glia.23510,<Element 'PubmedArticle' at 0x7f05dd0238b0>
117,"30322903
29273772
26436904
7346592
8027789
22872230
22002422
12196665
29133432
21618234
21825035
26786552
6308694
20980612
25241606
20495529
15883264
28601280
27033548
23325240
26150341
20655099
19779148
29752551
28109312
25687142
26470054
25178396
19152834
28099414
21098982
25833819
27589517
29540553
25573097
21411645
23589584
27521751
17478722
12472903
16020737
19190638
26165593
10591214
15269349
21698260
9915705
7582091
28086931
11016541
2358525
27322420
24136970
24865638
24534188
17270732
21219931
24647961
26074865
27306266",Chronic Sleep Disruption Advances the Temporal Progression of Tauopathy in P301S Mutant Mice.,"Brainstem locus ceruleus neurons (LCn) are among the first neurons across the lifespan to evidence tau pathology, and LCn are implicated in tau propagation throughout the cortices. Yet, events influencing LCn tau are poorly understood. Activated persistently across wakefulness, LCn experience significant metabolic stress in response to chronic short sleep (CSS). Here we explored whether CSS influences LCn tau and the biochemical, neuroanatomical, and/or behavioral progression of tauopathy in male and female P301S mice. CSS in early adult life advanced the temporal progression of neurobehavioral impairments and resulted in a lasting increase in soluble tau oligomers. Intriguingly, CSS resulted in an early increase in AT8 and MC1 tau pathology in the LC. Over time tau pathology, including tangles, was evident in forebrain tau-vulnerable regions. Sustained microglial and astrocytic activation was observed as well. Remarkably, CSS resulted in significant loss of neurons in the two regions examined: the basolateral amygdala and LC. A second, distinct form of chronic sleep disruption, fragmentation of sleep, during early adult life also increased tau deposition and imparted early neurobehavioral impairment. Collectively, the findings demonstrate that early life sleep disruption has important lasting effects on the temporal progression in P301S mice, influencing tau pathology and hastening neurodegeneration, neuroinflammation, and neurobehavioral impairments.","['Gallayas', 'locus ceruleus', 'sleep deprivation', 'tauopathy']",The Journal of neuroscience : the official journal of the Society for Neuroscience,2018-10-17,"[{'lastname': 'Zhu', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Zhan', 'firstname': 'Guanxia', 'initials': 'G', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Fenik', 'firstname': 'Polina', 'initials': 'P', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Brandes', 'firstname': 'Madison', 'initials': 'M', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Bell', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Francois', 'firstname': 'Noelle', 'initials': 'N', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Shulman', 'firstname': 'Katherine', 'initials': 'K', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.'}, {'lastname': 'Veasey', 'firstname': 'Sigrid', 'initials': 'S', 'affiliation': 'Center for Sleep and Circadian Neurobiology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 veasey@mail.med.upenn.edu.'}]",,,,Copyright © 2018 Zhu et al.,"10.1523/JNEUROSCI.0275-18.2018
10.1038/s41593-017-0022-z
10.1038/nn.4132
10.1523/JNEUROSCI.01-08-00876.1981
10.1523/JNEUROSCI.14-07-04467.1994
10.1038/jcbfm.2012.115
10.1097/NEN.0b013e318232a379
10.1212/WNL.59.4.627
10.1002/cne.22677
10.1096/fj.11-186650
10.1038/srep19393
10.1152/physrev.1983.63.3.844
10.1523/JNEUROSCI.3037-10.2010
10.4274/Jcrpe.1471
10.3791/1787
10.1001/archneur.62.5.770
10.1016/j.jneuroim.2017.04.007
10.1126/science.aad8373
10.1523/JNEUROSCI.2642-12.2013
10.1007/s00401-015-1458-4
10.1016/j.cell.2010.06.036
10.1126/science.1180962
10.1007/s00401-018-1855-6
10.1186/s40478-017-0411-2
10.1542/peds.2014-2707
10.1038/srep15231
10.1111/neup.12144
10.1016/j.jchemneu.2008.12.008
10.1038/nature21029
10.3233/JAD-2010-101218
10.1093/brain/awv081
10.3233/JAD-150960
10.1523/JNEUROSCI.2369-17.2018
10.1016/j.neurobiolaging.2014.12.001
10.1523/JNEUROSCI.5166-10.2011
10.1093/aje/kws342
10.1016/j.neulet.2016.08.007
10.1126/science.1141736
10.1046/j.1471-4159.2002.01241.x
10.1126/science.1113694
10.1038/nrn2573
10.1016/j.str.2015.06.002
10.1038/990114
10.1073/pnas.0404282101
10.1371/journal.pone.0021050
10.1126/science.283.5401.549
10.1111/j.1460-9568.1995.tb01108.x
10.1186/s13024-016-0143-y
10.1016/S0197-4580(00)00157-3
10.1002/cne.902960102
10.1038/nn.4328
10.1126/science.1241224
10.1111/nan.12160
10.1084/jem.20131685
10.1016/j.neuron.2007.01.010
10.1016/j.jneumeth.2010.12.025
10.1523/JNEUROSCI.5025-12.2014
10.3389/fneur.2015.00109
10.5665/sleep.6030",<Element 'PubmedArticle' at 0x7f05dd034b30>
118,"30319529
24450890
28202490
20083042
21368376
21152343
20205647
11513911
17052803
19782411
28099414
21051630
21527731
23307732
29151590
24889886
27459405
10674423
11141480
16212664
19883753
15509534
17270732
24973918
12020956
15762998
23178247
16267225
17724122
9291938
9278541
12895417
20871861
23316765
22213821
15464759
12692086
12391607
16371322
14751283
23152597
25186741
25533482
26758846
28614301
25100586
15895084
21778362
22632727
26948129
12052537
28642233
2169597
9107270
30001512
7531760
29379210
26487282
20418874
28680301
23038755
25731615
15163694
18541537
19828810
23372043
28377875
28467927
26526066
29765306
28505967
23301011
12472885
24744699
22491322
22637583
22805771
20221562
16094385
20957276
23665843
11958825
20847401
24210819
24485508
26214837
28591653
28426964
29950669
25307057
25047746",Elucidating the Interactive Roles of Glia in Alzheimer's Disease Using Established and Newly Developed Experimental Models.,"Alzheimer's disease (AD) is an irreversible neurodegenerative illness and the exact etiology of the disease remains unknown. It is characterized by long preclinical and prodromal phases with pathological features including an accumulation of amyloid-beta (Aβ) peptides into extracellular Aβ plaques in the brain parenchyma and the formation of intracellular neurofibrillary tangles (NFTs) within neurons as a result of abnormal phosphorylation of microtubule-associated tau proteins. In addition, prominent activation of innate immune cells is also observed and/or followed by marked neuroinflammation. While such neuroinflammatory responses may function in a neuroprotective manner by clearing neurotoxic factors, they can also be neurotoxic by contributing to neurodegeneration ","[""Alzheimer's disease"", 'animal models', 'astrogliosis', 'astrogliosis-microgliosis axis', 'brain-on-a-chip', 'microgliosis', 'neuroinflammation']",Frontiers in neurology,2018-10-16,"[{'lastname': 'Chun', 'firstname': 'Heejung', 'initials': 'H', 'affiliation': 'Center for Glia-Neuron Interaction, Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea.'}, {'lastname': 'Marriott', 'firstname': 'Ian', 'initials': 'I', 'affiliation': 'Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.'}, {'lastname': 'Lee', 'firstname': 'C Justin', 'initials': 'CJ', 'affiliation': 'Center for Glia-Neuron Interaction, Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea.\nBio-Med, University of Science and Technology, Daejeon, South Korea.'}, {'lastname': 'Cho', 'firstname': 'Hansang', 'initials': 'H', 'affiliation': 'Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.\nDepartment of Mechanical Engineering and Engineering Science, University of North Carolina at Charlotte, Charlotte, NC, United States.\nCenter for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, United States.\nThe Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, United States.'}]",,,,,"10.3389/fneur.2018.00797
10.1056/NEJMoa1312889
10.1136/bmj.j845
10.1016/S1474-4422(09)70299-6
10.3233/JAD-2011-101815
10.3389/fnagi.2010.00142
10.2174/187152710791012026
10.1016/S0140-6736(01)05625-2
10.1016/j.neurobiolaging.2006.08.014
10.1016/j.tins.2009.08.002
10.1038/nature21029
10.1126/science.1190929
10.1152/physrev.00011.2010
10.1126/science.1227901
10.1038/nri.2017.125
10.1186/1742-2094-11-98
10.1038/nn.4338
10.1016/S0197-4580(99)00065-2
10.1016/S0002-9440(10)63945-4
10.1186/1742-2094-2-22
10.1016/j.bbadis.2009.10.013
10.1016/S0002-9440(10)63421-9
10.1016/j.neuron.2007.01.010
10.1038/nm.3639
10.1016/S0165-5728(02)00050-4
10.1186/1742-2094-2-9
10.1038/nm.2965
10.1523/JNEUROSCI.3591-05.2005
10.1083/jcb.200705042
10.1016/S0896-6273(03)00434-3
10.4061/2010/723782
10.1186/1750-1326-8-2
10.2967/jnumed.110.087031
10.1016/j.brainres.2004.07.084
10.1096/fj.02-0825fje
10.1002/jnr.10351
10.1007/BF03033981
10.1016/j.neuroscience.2003.10.037
10.1523/JNEUROSCI.2323-12.2012
10.1523/JNEUROSCI.1860-14.2014
10.1016/j.neuron.2014.11.018
10.1523/JNEUROSCI.2117-15.2016
10.1038/nature22821
10.1523/JNEUROSCI.0405-14.2014
10.1038/nn1472
10.1126/science.1202529
10.1016/j.neuron.2012.03.026
10.1038/ncomms10905
10.1016/S0304-3940(02)00307-5
10.1124/jpet.117.241653
10.1111/j.1365-2990.1990.tb01158.x
10.1016/S0140-6736(05)62325-2
10.1016/j.neuron.2018.06.030
10.1016/0022-510X(94)90271-2
10.1038/s41564-017-0092-4
10.1038/srep15444
10.1038/nn.2535
10.5607/en.2017.26.3.158
10.1096/fj.12-208660
10.1002/glia.22800
10.1523/JNEUROSCI.0820-04.2004
10.1074/jbc.M800148200
10.1523/JNEUROSCI.1064-09.2009
10.1093/hmg/ddt036
10.1016/j.molmet.2017.01.010
10.1016/j.cmet.2017.04.002
10.1186/s13024-015-0056-1
10.3389/fncel.2018.00116
10.3233/JAD-151203
10.1371/journal.pone.0052982
10.1046/j.1471-4159.2002.01243.x
10.3389/fncel.2014.00094
10.1038/ncomms1783
10.1093/brain/aws127
10.1097/NEN.0b013e31825e77de
10.1039/b918640a
10.1038/nmeth777
10.1039/c0ib00055h
10.1038/srep01823
10.1016/S0165-5728(01)00496-9
10.3233/JAD-2010-100852
10.1016/j.celrep.2013.10.010
10.1016/j.neurobiolaging.2014.01.003
10.1038/nm.3913
10.1016/j.stemcr.2017.05.017
10.1016/j.neuron.2017.03.042
10.1038/s41593-018-0175-4
10.1038/nature13800
10.1038/npp.2014.164",<Element 'PubmedArticle' at 0x7f05dd05fa40>
119,30218757,"Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease.","Parkinson's disease (PD) is a neurodegenerative disorder characterized by accumulation of misfolded α-synuclein within the central nervous system (CNS). Visual problems in PD patients are common, although retinal pathology associated with PD is not well understood. The purpose of this study was to investigate retinal pathology in a transgenic mouse model (TgM83) expressing the human A53T α-synuclein mutation and assess the effect of α-synuclein ""seeding"" on the development of retinal pathology. Two-month-old TgM83 mice were intracerebrally inoculated with brain homogenate from old (12-18 months) TgM83 mice. Retinas were then analyzed at 5 months of age. We analyzed retinas from 5-month-old and 8-month-old uninoculated healthy TgM83 mice, and old (12-18 months) mice that were euthanized following the development of clinical signs. Retinas of B6C3H mice (genetic background of the TgM83 mouse) served as control. We used immunohistochemistry and western blot analysis to detect accumulation of α-synuclein, pTau","['Autophagy in PD retina', 'Human A53T mutated α-synuclein', 'Microglial activation in retina', 'Misfolded α-synuclein', 'Müller glial activation', 'Photoreceptor cell loss', 'Raman Spectroscopy', ""Retina in Parkinson's Disease"", 'Tau in retina']",Neurobiology of disease,2018-09-16,"[{'lastname': 'Mammadova', 'firstname': 'Najiba', 'initials': 'N', 'affiliation': 'Department of Genetics, Development, and Cell Biology, Iowa State University, Ames, IA, United States; Immunobiology Graduate Program, Iowa State University, United States; Neuroscience Graduate Program, Iowa State University, United States. Electronic address: najibam@iastate.edu.'}, {'lastname': 'Summers', 'firstname': 'Corey M', 'initials': 'CM', 'affiliation': 'Immunobiology Graduate Program, Iowa State University, United States; Department of Kinesiology, Iowa State University, United States. Electronic address: summers@iastate.edu.'}, {'lastname': 'Kokemuller', 'firstname': 'Robyn D', 'initials': 'RD', 'affiliation': 'Neuroscience Graduate Program, Iowa State University, United States; Virus and Prion Research Unit, National Animal Disease Center, USDA, Agricultural Research Service, Ames, IA, United States; Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States. Electronic address: robynk13@iastate.edu.'}, {'lastname': 'He', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': 'Department of Agriculture and Biosystems Engineering, Iowa State University, Ames, IA, United States. Electronic address: qinghe@iastate.edu.'}, {'lastname': 'Ding', 'firstname': 'Shaowei', 'initials': 'S', 'affiliation': 'Department of Mechanical Engineering, Iowa State University, Ames, IA, United States. Electronic address: swding@iastate.edu.'}, {'lastname': 'Baron', 'firstname': 'Thierry', 'initials': 'T', 'affiliation': 'Anses, Laboratoire de Lyon, Unité Maladies Neurodégénératives, Lyon, France. Electronic address: thierry.baron@anses.fr.'}, {'lastname': 'Yu', 'firstname': 'Chenxu', 'initials': 'C', 'affiliation': 'Department of Agriculture and Biosystems Engineering, Iowa State University, Ames, IA, United States. Electronic address: chenxuyu@iastate.edu.'}, {'lastname': 'Valentine', 'firstname': 'Rudy J', 'initials': 'RJ', 'affiliation': 'Immunobiology Graduate Program, Iowa State University, United States; Department of Kinesiology, Iowa State University, United States. Electronic address: rvalenti@iastate.edu.'}, {'lastname': 'Sakaguchi', 'firstname': 'Donald S', 'initials': 'DS', 'affiliation': 'Department of Genetics, Development, and Cell Biology, Iowa State University, Ames, IA, United States; Neuroscience Graduate Program, Iowa State University, United States. Electronic address: dssakagu@iastate.edu.'}, {'lastname': 'Kanthasamy', 'firstname': 'Anumantha G', 'initials': 'AG', 'affiliation': 'Immunobiology Graduate Program, Iowa State University, United States; Neuroscience Graduate Program, Iowa State University, United States; Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States. Electronic address: akanthas@iastate.edu.'}, {'lastname': 'Greenlee', 'firstname': 'Justin J', 'initials': 'JJ', 'affiliation': 'Virus and Prion Research Unit, National Animal Disease Center, USDA, Agricultural Research Service, Ames, IA, United States. Electronic address: Justin.Greenlee@ars.usda.gov.'}, {'lastname': 'Heather West Greenlee', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Immunobiology Graduate Program, Iowa State University, United States; Neuroscience Graduate Program, Iowa State University, United States; Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States. Electronic address: mheather@iastate.edu.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2018.09.013,<Element 'PubmedArticle' at 0x7f05dd017f90>
120,"30136084
25428369
27115769
27727239
25324900
29107053
26436904
10802651
22419166
17309878
9371909
27939925
19136949
21254760
27037234
14642273
27571263
17493041
28504111
18467348
24464041
23613214
24334724
26300125
7969952
26138499
21685912
23197718
28351896
26328540
27543120
26077951
29421605
23050260
19114008
29518357
26576562
21130836
25833819
24382028
10604467
30772379
16987883
17701901
26098518
16776819
19915575
27097852
25930971
22751100
12883005
27030133
21789182
11829342
12200627
20616382
26335643
29518356
22685416",Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.,"Progressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder characterized by tau pathology in neurons and glial cells. Transcriptional regulation has been implicated as a potential mechanism in conferring disease risk and neuropathology for some PSP genetic risk variants. However, the role of transcriptional changes as potential drivers of distinct cell-specific tau lesions has not been explored. In this study, we integrated brain gene expression measurements, quantitative neuropathology traits and genome-wide genotypes from 268 autopsy-confirmed PSP patients to identify transcriptional associations with unique cell-specific tau pathologies. We provide individual transcript and transcriptional network associations for quantitative oligodendroglial (coiled bodies = CB), neuronal (neurofibrillary tangles = NFT), astrocytic (tufted astrocytes = TA) tau pathology, and tau threads and genomic annotations of these findings. We identified divergent patterns of transcriptional associations for the distinct tau lesions, with the neuronal and astrocytic neuropathologies being the most different. We determined that NFT are positively associated with a brain co-expression network enriched for synaptic and PSP candidate risk genes, whereas TA are positively associated with a microglial gene-enriched immune network. In contrast, TA is negatively associated with synaptic and NFT with immune system transcripts. Our findings have implications for the diverse molecular mechanisms that underlie cell-specific vulnerability and disease risk in PSP.",[],Acta neuropathologica,2018-08-24,"[{'lastname': 'Allen', 'firstname': 'Mariet', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Wang', 'firstname': 'Xue', 'initials': 'X', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Serie', 'firstname': 'Daniel J', 'initials': 'DJ', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Strickland', 'firstname': 'Samantha L', 'initials': 'SL', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Burgess', 'firstname': 'Jeremy D', 'initials': 'JD', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Koga', 'firstname': 'Shunsuke', 'initials': 'S', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Younkin', 'firstname': 'Curtis S', 'initials': 'CS', 'affiliation': 'Division of Information Technology, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Nguyen', 'firstname': 'Thuy T', 'initials': 'TT', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Malphrus', 'firstname': 'Kimberly G', 'initials': 'KG', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Lincoln', 'firstname': 'Sarah J', 'initials': 'SJ', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Alamprese', 'firstname': 'Melissa', 'initials': 'M', 'affiliation': 'Banner Behavior Health, Phoenix, AZ, 85016, USA.'}, {'lastname': 'Zhu', 'firstname': 'Kuixi', 'initials': 'K', 'affiliation': 'The Center for Innovation in Brain Sciences, University of Arizona, Tucson, AZ, 85721, USA.'}, {'lastname': 'Chang', 'firstname': 'Rui', 'initials': 'R', 'affiliation': 'The Center for Innovation in Brain Sciences, University of Arizona, Tucson, AZ, 85721, USA.\nDepartment of Neurology, University of Arizona, Tucson, AZ, 85721, USA.'}, {'lastname': 'Carrasquillo', 'firstname': 'Minerva M', 'initials': 'MM', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Kouri', 'firstname': 'Naomi', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Murray', 'firstname': 'Melissa E', 'initials': 'ME', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Reddy', 'firstname': 'Joseph S', 'initials': 'JS', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Funk', 'firstname': 'Cory', 'initials': 'C', 'affiliation': 'Institute for Systems Biology, 401 Terry Avenue N, Seattle, WA, 98109, USA.'}, {'lastname': 'Price', 'firstname': 'Nathan D', 'initials': 'ND', 'affiliation': 'Institute for Systems Biology, 401 Terry Avenue N, Seattle, WA, 98109, USA.'}, {'lastname': 'Golde', 'firstname': 'Todd E', 'initials': 'TE', 'affiliation': 'Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA.'}, {'lastname': 'Younkin', 'firstname': 'Steven G', 'initials': 'SG', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Asmann', 'firstname': 'Yan W', 'initials': 'YW', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Crook', 'firstname': 'Julia E', 'initials': 'JE', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.'}, {'lastname': 'Ertekin-Taner', 'firstname': 'Nilüfer', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA. taner.nilufer@mayo.edu.\nDepartment of Neurology, Mayo Clinic, 4500 San Pablo Road, Birdsall 3, Jacksonville, FL, 32224, USA. taner.nilufer@mayo.edu.'}]",,,,,"10.1007/s00401-018-1900-5
10.1093/nar/gku1179
10.1007/s00401-016-1576-7
10.1038/sdata.2016.89
10.1186/alzrt268
10.1016/j.jalz.2017.09.012
10.1038/nn.4132
10.1038/75556
10.1101/gr.134098.111
10.1093/hmg/ddm011
10.1212/WNL.49.5.1284
10.1016/j.jalz.2016.10.005
10.1038/ng.305
10.1021/pr101065j
10.1212/WNL.0000000000002638
10.1016/S0896-6273(03)00627-5
10.1038/ng.3656
10.1111/j.1750-3639.2007.00054.x
10.1016/S1474-4422(17)30123-0
10.1093/bioinformatics/btn224
10.1038/nn.3639
10.1007/s12035-013-8460-4
10.3233/JAD-131280
10.1016/j.cell.2015.07.048
10.1212/WNL.44.11.2015
10.1111/cge.12637
10.1038/ng.859
10.1523/JNEUROSCI.3300-12.2012
10.1042/BSR20160183
10.1007/s12035-015-9405-x
10.1093/jnen/nlw073
10.1038/ncomms8247
10.1016/j.exger.2018.02.005
10.18637/jss.v046.i11
10.1186/1471-2105-9-559
10.1016/j.neuron.2018.02.002
10.1007/s00401-015-1507-z
10.1016/j.biopsycho.2010.11.008
10.1093/brain/awv081
10.1186/alzrt231
10.1038/45159
10.1101/190959
10.1093/hmg/ddl190
10.1086/519795
10.1146/annurev-biophys-060414-034057
10.18637/jss.v017.i05
10.1186/1471-2105-7-302
10.1038/ng.487
10.1038/ncomms11295
10.1111/cge.12605
10.1038/ng.2335
10.1073/pnas.1530509100
10.1186/s12864-016-2590-9
10.1371/journal.pone.0021800
10.1093/jnen/61.1.33
10.1007/s00401-002-0569-x
10.1093/bioinformatics/btq340
10.1016/j.neuron.2015.08.020
10.1016/j.neuron.2018.01.031
10.1371/journal.pgen.1002707",<Element 'PubmedArticle' at 0x7f05dcfa9e50>
121,"30069256
11578751
21605046
28293421
23028126
20682182
10526177
12401334
25407337
27429978
29226873
18599959
19236346
20134203
11262183
21785188
26935478
28662669
19282288
28566949
10858586
24795567
23948931
18597739
21252989
19052878
9817438
10567732
23616747
18508444
11754995
20205642
21527731
26556658
10936187
15489356
18401707
19359988",Alzheimer´s Disease in the Perspective of Neuroimmunology.,"Alzheimer's Disease (AD) is a severe neurodegenerative disorder that includes the occurrence of behavioral disorders as well as memory and cognitive impairment as major symptoms. AD affects around 12% of the aged population in the world. Considerable research efforts have pointed to the role of innate immunity as the main culprit in the pathogenesis of AD. In this context, and according to with our neuroimmunomodulation theory, microglial activation modifies the cross-talks between microglia and neurons. We postulated that glial activation triggered by ""damage signals"" activates a pathological molecular cascade that finally leads to hyperphosphorylation and oligomerization of the tau protein. Interestingly, these modifications correlate with the gradual cognitive impairment of patients with the AD. Microglial activation is determined by the nature and strength of the stimulus. In the AD, a continuous activation state of microglia appears to generate neuronal injury and neurodegeneration, producing the outflow of pathological tau from the inner of neurons to the extraneuronal space. Released tau, together with the contribution of ApoE4 protein, would then produce reactivation of microglia, thus inducing a positive feedback that stimulates the vicious cycle in neurodegeneration.
Nevertheless, from the pathophysiological perspective AD is significantly more than a loss of memory. In the initial stages of AD pathogenesis, variations in the dopaminergic pathway along with serotonin diminution play an important role. This may explain why depression is associated with the onset of AD. All these pathophysiological events take place together with immunomodulatory changes that trigger tau oligomerization in the course of neurofibrillary tangles formation. Interestingly, mood disorders appear to be followed by neuroinflammatory processes and structural/functional alterations that lead to cognitive impairment in the context of AD.","['Alzheimer´s disease', 'Microglial cells', 'Neuroimmunology', 'Proinflammatory cytokines', 'Tau protein', 'The neuroimmunomodulation theory']",The open neurology journal,2018-08-03,"[{'lastname': 'Maccioni', 'firstname': 'Ricardo B', 'initials': 'RB', 'affiliation': 'Laboratory of Neuroscience, Faculty of Science, University of Chile & International Center for Biomedicine (ICC), Santiago, Chile.'}, {'lastname': 'González', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Laboratory of Neuroscience, Faculty of Science, University of Chile & International Center for Biomedicine (ICC), Santiago, Chile.'}, {'lastname': 'Andrade', 'firstname': 'Víctor', 'initials': 'V', 'affiliation': 'Laboratory of Neuroscience, Faculty of Science, University of Chile & International Center for Biomedicine (ICC), Santiago, Chile.'}, {'lastname': 'Cortés', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': 'Laboratory of Neuroscience, Faculty of Science, University of Chile & International Center for Biomedicine (ICC), Santiago, Chile.'}, {'lastname': 'Tapia', 'firstname': 'José Pablo', 'initials': 'JP', 'affiliation': 'Laboratory of Neuroscience, Faculty of Science, University of Chile & International Center for Biomedicine (ICC), Santiago, Chile.'}, {'lastname': 'Guzmán-Martínez', 'firstname': 'Leonardo', 'initials': 'L', 'affiliation': 'Laboratory of Neuroscience, Faculty of Science, University of Chile & International Center for Biomedicine (ICC), Santiago, Chile.'}]",,"Nevertheless, from the pathophysiological perspective AD is significantly more than a loss of memory. In the initial stages of AD pathogenesis, variations in the dopaminergic pathway along with serotonin diminution play an important role. This may explain why depression is associated with the onset of AD. All these pathophysiological events take place together with immunomodulatory changes that trigger tau oligomerization in the course of neurofibrillary tangles formation. Interestingly, mood disorders appear to be followed by neuroinflammatory processes and structural/functional alterations that lead to cognitive impairment in the context of AD.",,,"10.2174/1874205X01812010050
10.1016/S0188-4409(01)00316-2
10.2174/156720511796717258
10.1186/s40035-017-0077-5
10.1101/cshperspect.a006296
10.1016/j.arcmed.2010.03.007
10.1016/S0014-5793(99)01279-X
10.1016/S0306-4522(02)00404-9
10.1186/1750-1326-9-51
10.1155/2016/3245935
10.3233/JAD-2008-14307
10.1111/j.1749-6632.2008.03972.x
10.1159/000258724
10.1006/excr.2001.5152
10.3233/JAD-2011-110623
10.3892/mmr.2016.4948
10.1186/s13024-017-0192-x
10.1074/jbc.M808759200
10.1016/S0197-4580(00)00124-X
10.3389/fncel.2014.00112
10.3233/JAD-131843
10.1016/j.biopsych.2008.05.019
10.1038/nri2921
10.1007/s11481-008-9142-2
10.1016/S0165-5728(98)00145-3
10.1016/S0165-3806(99)00113-3
10.3389/fncel.2013.00045
10.2741/2937
10.1016/S0197-4580(01)00307-4
10.2174/187152710791012053
10.1152/physrev.00011.2010
10.1016/j.bcp.2015.11.003
10.1046/j.1471-4159.2000.0751060.x
10.1128/CMR.17.4.942-964.2004
10.1007/s11064-008-9682-0
10.1097/WCO.0b013e32832a3225",<Element 'PubmedArticle' at 0x7f05dcfde900>
122,30052812,Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.,"Alzheimer's disease is characterized by the histopathological presence of amyloid-β plaques and tau-containing neurofibrillary tangles. Microglial activation is also a recognized pathological component. The relationship between microglial activation and protein aggregation is still debated. We investigated the relationship between amyloid plaques, tau tangles and activated microglia using PET imaging. Fifty-one subjects (19 healthy controls, 16 mild cognitive impairment and 16 Alzheimer's disease subjects) participated in the study. All subjects had neuropsychometric testing, MRI, amyloid (18F-flutemetamol), and microglial (11C-PBR28) PET. All subjects with mild cognitive impairment and Alzheimer's disease and eight of the controls had tau (18F-AV1451) PET. 11C-PBR28 PET was analysed using Logan graphical analysis with an arterial plasma input function, while 18F-flutemetamol and 18F-AV1451 PET were analysed as target:cerebellar ratios to create parametric standardized uptake value ratio maps. Biological parametric mapping in the Statistical Parametric Mapping platform was used to examine correlations between uptake of tracers at a voxel-level. There were significant widespread clusters of positive correlation between levels of microglial activation and tau aggregation in both the mild cognitive impairment (amyloid-positive and amyloid-negative) and Alzheimer's disease subjects. The correlations were stronger in Alzheimer's disease than in mild cognitive impairment, suggesting that these pathologies increase together as disease progresses. Levels of microglial activation and amyloid deposition were also correlated, although in a different spatial distribution; correlations were stronger in mild cognitive impairment than Alzheimer's subjects, in line with a plateauing of amyloid load with disease progression. Clusters of positive correlations between microglial activation and protein aggregation often targeted similar areas of association cortex, indicating that all three processes are present in specific vulnerable brain areas. For the first time using PET imaging, we show that microglial activation can correlate with both tau aggregation and amyloid deposition. This confirms the complex relationship between these processes. These results suggest that preventative treatment for Alzheimer's disease should target all three processes.",[],Brain : a journal of neurology,2018-07-28,"[{'lastname': 'Dani', 'firstname': 'Melanie', 'initials': 'M', 'affiliation': 'Neurology Imaging Unit, Department of Medicine, Imperial College London, Hammersmith Hospital, UK.'}, {'lastname': 'Wood', 'firstname': 'Melanie', 'initials': 'M', 'affiliation': 'Neurology Imaging Unit, Department of Medicine, Imperial College London, Hammersmith Hospital, UK.'}, {'lastname': 'Mizoguchi', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Neurology Imaging Unit, Department of Medicine, Imperial College London, Hammersmith Hospital, UK.'}, {'lastname': 'Fan', 'firstname': 'Zhen', 'initials': 'Z', 'affiliation': 'Neurology Imaging Unit, Department of Medicine, Imperial College London, Hammersmith Hospital, UK.'}, {'lastname': 'Walker', 'firstname': 'Zuzana', 'initials': 'Z', 'affiliation': 'Division of Psychiatry, University College London, UK.\nEssex Partnership University NHS Foundation Trust, UK.'}, {'lastname': 'Morgan', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'Chelsea and Westminster Hospital, London, UK.'}, {'lastname': 'Hinz', 'firstname': 'Rainer', 'initials': 'R', 'affiliation': 'Wolfson Molecular Imaging Centre, University of Manchester, UK.'}, {'lastname': 'Biju', 'firstname': 'Maya', 'initials': 'M', 'affiliation': 'Gether NHS Foundation Trust, Gloucester, UK.'}, {'lastname': 'Kuruvilla', 'firstname': 'Tarun', 'initials': 'T', 'affiliation': 'Gether NHS Foundation Trust, Gloucester, UK.'}, {'lastname': 'Brooks', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Neurology Imaging Unit, Department of Medicine, Imperial College London, Hammersmith Hospital, UK.\nDepartment of Nuclear Medicine, Aarhus University, Denmark.\nInstitute of Neuroscience, University of Newcastle upon Tyne, UK.'}, {'lastname': 'Edison', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Neurology Imaging Unit, Department of Medicine, Imperial College London, Hammersmith Hospital, UK.'}]",,,,,10.1093/brain/awy188,<Element 'PubmedArticle' at 0x7f05dcf7be00>
123,"30029687
23307732
2183538
27474742
20577631
2870372
27445641
7550600
23252647
1759558
7843307
22505025
19729484
1701963
26853809
16355225
15895084
24065890
28549481
11867565
16027166
9171327
12453671
16612984
25693568
3288247
27389701
15474363
15311281
11168370
11159188
11895040
2808689
8952519
8490014
8513491
26315807
2765920
21527731
20818335
18282158
21752791
20552234
9173910
27131040
1575018
15983050
18753367
28628896
23000062
23428224
22101365
15644323
20354142
1716046
25591542
1727015
19302036
27590054
24519982
8229002
21131363
15968464
12354296
24157239
17956719
15286082
29490706
19513731
28547526
26481686
15734686
26195256
12084879
10952063
18650430
16091362
23525041
19300446
10391242
10781099
28083634
28978359
9690671
22267726
24756575
16314258",The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease.,"In the majority of affected brain regions the pathological hallmarks of Alzheimer's disease (AD) are β-amyloid (Aβ) deposits in the form of diffuse and neuritic plaques, tau pathology in the form of neurofibrillary tangles, neuropil threads and plaque-associated abnormal neurites in combination with an inflammatory response. However, the anatomical area of the presubiculum, is characterised by the presence of a single large evenly distributed 'lake-like' Aβ deposit with minimal tau deposition or accumulation of inflammatory markers. Post-mortem brain samples from sporadic AD (SAD) and familial AD (FAD) and two hereditary cerebral amyloid diseases, familial British dementia (FBD) and familial Danish dementia (FDD) were used to compare the morphology of the extracellular proteins deposited in the presubiculum compared to the entorhinal cortex. The level of tau pathology and the extent of microglial activation were quantitated in the two brain regions in SAD and FAD. Frozen tissue was used to investigate the Aβ species and proteomic differences between the two regions. Consistent with our previous investigations of FBD and FDD cases we were able to establish that the 'lake-like' pre-amyloid deposits of the presubiculum were not a unique feature of AD but they also found two non-Aβ amyloidosis. Comparing the presubiculum to the entorhinal cortex the number of neurofibrillary tangles and tau load were significantly reduced; there was a reduction in microglial activation; there were differences in the Aβ profiles and the investigation of the whole proteome showed significant changes in different protein pathways. In summary, understanding why the presubiculum has a different morphological appearance, biochemical and proteomic makeup compared to surrounding brain regions severely affected by neurodegeneration could lead us to understanding protective mechanisms in neurodegenerative diseases.","['Alzheimer’s disease', 'Amyloid', 'Neuroinflammation', 'Presubiculum', 'Tau']",Acta neuropathologica communications,2018-07-22,"[{'lastname': 'Murray', 'firstname': 'Christina E', 'initials': 'CE', 'affiliation': 'The Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK.\nDementia Research Institute, UCL , London, UK.'}, {'lastname': 'Gami-Patel', 'firstname': 'Priya', 'initials': 'P', 'affiliation': 'The Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK.'}, {'lastname': 'Gkanatsiou', 'firstname': 'Eleni', 'initials': 'E', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Brinkmalm', 'firstname': 'Gunnar', 'initials': 'G', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Portelius', 'firstname': 'Erik', 'initials': 'E', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'lastname': 'Wirths', 'firstname': 'Oliver', 'initials': 'O', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August-University, Goettingen, Germany.'}, {'lastname': 'Heywood', 'firstname': 'Wendy', 'initials': 'W', 'affiliation': 'Centre for Translational Omics, Great Ormond Street Institute of Child health, UCL, London, UK.'}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'lastname': 'Ghiso', 'firstname': 'Jorge', 'initials': 'J', 'affiliation': 'New York University, New York, NY, USA.'}, {'lastname': 'Holton', 'firstname': 'Janice L', 'initials': 'JL', 'affiliation': 'The Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK.'}, {'lastname': 'Mills', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Centre for Translational Omics, Great Ormond Street Institute of Child health, UCL, London, UK.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.\nDementia Research Institute, UCL , London, UK.'}, {'lastname': 'Revesz', 'firstname': 'Tamas', 'initials': 'T', 'affiliation': 'The Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK.'}, {'lastname': 'Lashley', 'firstname': 'Tammaryn', 'initials': 'T', 'affiliation': 'The Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK. T.Lashley@ucl.ac.uk.'}]",,,,,"10.1186/s40478-018-0563-8
10.1111/j.1750-3639.1997.tb01009.x",<Element 'PubmedArticle' at 0x7f05dcf8d0e0>
124,30010136,Ginkgo biloba Extract EGb 761 and Its Specific Components Elicit Protective Protein Clearance Through the Autophagy-Lysosomal Pathway in Tau-Transgenic Mice and Cultured Neurons.,"Alzheimer's disease (AD) is a neurodegenerative disease pathologically characterized by extracellular amyloid-β (Aβ) deposits and intracellular neurofibrillary tangles (NFT) in many brain regions. NFT are primarily composed of hyperphosphorylated tau protein (p-Tau). Aβ and p-Tau are two major pathogenic molecules with tau acting downstream to Aβ to induce neuronal degeneration. In this study, we investigated whether Ginkgo biloba extract EGb 761 reduces cerebral p-Tau level and prevents AD pathogenesis. Human P301S tau mutant-transgenic mice were fed with EGb 761, added to the regular diet for 2 or 5 months. We observed that treatment with EGb 761 for 5 months significantly improved the cognitive function of mice, attenuated the loss of synaptophysin and recovered the phosphorylation of CREB in the mouse brain. Treatment with EGb 761 for 5 but not 2 months also decreased p-Tau protein amount and shifted microglial pro-inflammatory to anti-inflammatory activation in the brain. As potential therapeutic mechanisms, we demonstrated that treatment with EGb 761, especially the components of ginkgolide A, bilobalide, and flavonoids, but not with purified ginkgolide B or C, increased autophagic activity and degradation of p-Tau in lysosomes of neurons. Inhibiting ATG5 function or treating cells with Bafilomycin B1 abolished EGb 761-enhanced degradation of p-Tau in cultured neurons. Additionally, we observed that 5- instead of 2-month-treatment with EGb 761 inhibited the activity of p38-MAPK and GSK-3β. Therefore, long-term treatment with Ginkgo biloba extract EGb 761, a clinically available and well-tolerated herbal medication, ameliorates AD pathology through mechanisms against multiple AD pathogenic processes.","['Alzheimer’s disease', 'Ginkgo biloba extract', 'autophagy', 'inflammation', 'tauopathies']",Journal of Alzheimer's disease : JAD,2018-07-17,"[{'lastname': 'Qin', 'firstname': 'Yiren', 'initials': 'Y', 'affiliation': 'Department of Neurology, Saarland University, Homburg, Germany.\nDepartment of Neurology, First Affiliated Hospital, Soochow University, Suzhou, China.\nDepartment of Neurology, Second Affiliated Hospital, Soochow University, Suzhou, China.'}, {'lastname': 'Zhang', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': 'Department of Neurology, Saarland University, Homburg, Germany.\nDepartment of Clinical Laboratory, Tongji Hospital, Tongji University Medical School, Shanghai, China.'}, {'lastname': 'Tomic', 'firstname': 'Inge', 'initials': 'I', 'affiliation': 'Department of Neurology, Saarland University, Homburg, Germany.'}, {'lastname': 'Hao', 'firstname': 'Wenlin', 'initials': 'W', 'affiliation': 'Department of Neurology, Saarland University, Homburg, Germany.'}, {'lastname': 'Menger', 'firstname': 'Michael D', 'initials': 'MD', 'affiliation': 'Institute for Clinical and Experimental Surgery, Saarland University, Homburg, Germany.'}, {'lastname': 'Liu', 'firstname': 'Chunfeng', 'initials': 'C', 'affiliation': 'Department of Neurology, Second Affiliated Hospital, Soochow University, Suzhou, China.'}, {'lastname': 'Fassbender', 'firstname': 'Klaus', 'initials': 'K', 'affiliation': 'Department of Neurology, Saarland University, Homburg, Germany.'}, {'lastname': 'Liu', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'Department of Neurology, Saarland University, Homburg, Germany.\nDepartment of Clinical Laboratory, Tongji Hospital, Tongji University Medical School, Shanghai, China.'}]",,,,,10.3233/JAD-180426,<Element 'PubmedArticle' at 0x7f05dcf3e9f0>
125,"29992181
14570867
22201866
8820967
23490070
26374899
21098983
26374897
12794041
17524488
15134560
10576429
10336441
26847266
17956294
7638161
19840552
21170538
10586975
26847047
25125464
25631124
24013726
21976528
25107477
12787059
23190711
22664354
26505565
26911435
29169609
25630253
9387865
26141617
10760063
23747799
25056803
21059265
19584430
15283960
29325447
28477215
18786637
28549481
26254232
24280315
19269917
28264694
15269255
1659618
20305648
2891875
23719156
15132438
12605412
25061569
6236805
19838177
16943563
23623698
21736918
3088567
23150934
14612429
1566067
25495202
26576722
23254930
25991443
21878486
21471435
27033548
21114967
16908670
16467370
24368090
24471710
20488887
22286853
23150908
26034266
15860348
28127589
28602351
23467355
24990881
28930663
21422524
28350801
20552234
27581371
21170282
26517904
22615186
28676747
17052351
28928988
21441306
26438529
23946390
16156895
25833819
27723233
11440793
9065490
16151535
10649824
10681886
28373688
3986610
20640189
12654514
26231972
25245500
23850597
24361584
22248368
21398043
25227402
21834902
10066249
26555430
27837698
16651510
26337043
24360280
15935057
1484388
24638131
1742020
28185874
25893602
26458768
15172743
26354893
3702410
2998738
27890560
25828532
26431692
21306736
21855175
1455057
25471398
26612494
3998818
28862638
24485715
29259854
9109537
22632727
20064826
9636227
17716101
24198349
25408333
24400870
18571629
22229116
21777559
15548205
28566429
12842310
18286612
28714976
26948129
7891134
17290797
22363284
24853936
23946404
18083105
17433555
21115202
22967840
7894471
9464214
15728241
9145302
27104646
28095309
17920693
20865724
16501568
16291918
18606570
16014749
29293211
27034847
28092020
22404853
15857398
22209424
23849219
17094809
28736330
25653581
28697890
19763906
1705153
27196974
15942322
23983897
28077724
28680398
12859672
11279122
8810256
11337275
15601849
10818140
17021169
12895417
16906128
14523101
17270732","Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress.","Microglia are the predominant immune cells of the central nervous system (CNS) that exert key physiological roles required for maintaining CNS homeostasis, notably in response to chronic stress, as well as mediating synaptic plasticity, learning and memory. The repeated exposure to stress confers a higher risk of developing neurodegenerative diseases including sporadic Alzheimer's disease (AD). While microglia have been causally linked to amyloid beta (Aβ) accumulation, tau pathology, neurodegeneration, and synaptic loss in AD, they were also attributed beneficial roles, notably in the phagocytic elimination of Aβ. In this review, we discuss the interactions between chronic stress and AD pathology, overview the roles played by microglia in AD, especially focusing on chronic stress as an environmental risk factor modulating their function, and present recently-described microglial phenotypes associated with neuroprotection in AD. These microglial phenotypes observed under both chronic stress and AD pathology may provide novel opportunities for the development of better-targeted therapeutic interventions.","['ABCA7, ATP-binding cassette transporter A7', ""AD, Alzheimer's disease"", 'APOE, Apolipoprotein E', 'APP, amyloid precursor protein', ""Alzheimer's disease"", 'Aβ, Amyloid beta', 'BDNF, brain derived neurotrophic factor', 'CD11b, cluster of differentiation molecule 11B', 'CD33, cluster of differentiation 33', 'CNS, central nervous system', 'CR, complement receptor', 'CRF, corticotropin releasing factor', 'DAM, disease associated microglia', 'DAP12, DNAX-activation protein 12', 'Dark microglia', ""FAD, Familial Alzheimer's disease"", 'FCRLS, Fc receptor-like S scavenger receptor', 'GR, glucocorticoid receptor', 'HPA axis, hypothalamic pituitary adrenocortical axis', 'IBA1, ionized calcium-binding adapter molecule 1', 'IL, interleukin', 'LTP, long-term potentiation', 'MGnD, microglia with a neurodegenerative phenotype', 'MR, mineralocorticoid receptor', 'Microglia', 'Microglial phenotypes', 'NADPH, nicotinamide adenine dinucleotide phosphate', 'NFT, neurofibrillary tangles', 'Neurodegeneration', 'Neuroinflammation', 'PS, presenilin', 'ROS, reactive oxygen species', 'Stress', 'Synaptic remodeling', 'TGFβ, transforming growth factor β', 'TLR, Toll-like receptors', 'TMEM119, transmembrane protein 119', 'TNFα, tumor necrosis factor-α', 'TREM2, triggering receptor expressed in myeloid cells 2', 'TYROBP, TYRO protein tyrosine kinase binding protein', 'mPFC, medial prefrontal cortex']",Neurobiology of stress,2018-07-12,"[{'lastname': 'Bisht', 'firstname': 'Kanchan', 'initials': 'K', 'affiliation': 'Axe Neurosciences, CRCHU de Québec-Université Laval, Québec, QC, Canada.'}, {'lastname': 'Sharma', 'firstname': 'Kaushik', 'initials': 'K', 'affiliation': 'Axe Neurosciences, CRCHU de Québec-Université Laval, Québec, QC, Canada.'}, {'lastname': 'Tremblay', 'firstname': 'Marie-Ève', 'initials': 'MÈ', 'affiliation': 'Axe Neurosciences, CRCHU de Québec-Université Laval, Québec, QC, Canada.\nDépartement de médecine moléculaire, Université Laval, Québec, QC, Canada.'}]",,,,,"10.1016/j.ynstr.2018.05.003
10.1016/B978-0-12-802175-0.00019-X",<Element 'PubmedArticle' at 0x7f05dcf4e3b0>
126,29902557,Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.,"Our aim was to assess with positron emission tomography (PET) the temporal and spatial inter-relationships between levels of cortical microglial activation and the aggregated amyloid-β and tau load in mild cognitive impairment (MCI) and early Alzheimer's disease (AD).
Six clinically probable AD and 20 MCI subjects had inflammation (
55% of MCI and 83% of AD subjects had a high amyloid-β load. We have previously reported that clusters of correlated amyloid and inflammation levels are present in cortex. Here we found no correlation between levels of inflammation (
While correlated levels of amyloid-β and inflammation can be seen in MCI, we did not detect an association between levels of cortical tau tangles and inflammation in our series of high amyloid-β cases. High levels of inflammation could be seen in amyloid-β positive MCI cases where ","[""Alzheimer's disease"", 'Amyloid PET', 'Microglial activation', 'Positron emission tomography', 'Tau PET']",Neurobiology of disease,2018-06-15,"[{'lastname': 'Parbo', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark. Electronic address: peter.parbo@clin.au.dk.'}, {'lastname': 'Ismail', 'firstname': 'Rola', 'initials': 'R', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Sommerauer', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark; Department of Neurology, University Hospital Cologne, Cologne, Germany.'}, {'lastname': 'Stokholm', 'firstname': 'Morten G', 'initials': 'MG', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Hansen', 'firstname': 'Allan K', 'initials': 'AK', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Hansen', 'firstname': 'Kim V', 'initials': 'KV', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Amidi', 'firstname': 'Ali', 'initials': 'A', 'affiliation': 'Department of Psychology and Behavioural Sciences, Department of Oncology, Aarhus University & Aarhus University Hospital, Denmark.'}, {'lastname': 'Schaldemose', 'firstname': 'Jeppe L', 'initials': 'JL', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Gottrup', 'firstname': 'Hanne', 'initials': 'H', 'affiliation': 'Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Brændgaard', 'firstname': 'Hans', 'initials': 'H', 'affiliation': 'Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Eskildsen', 'firstname': 'Simon F', 'initials': 'SF', 'affiliation': 'Center of Functionally Integrative Neuroscience (CFIN), Aarhus University, Aarhus, Denmark.'}, {'lastname': 'Borghammer', 'firstname': 'Per', 'initials': 'P', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Hinz', 'firstname': 'Rainer', 'initials': 'R', 'affiliation': 'Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.'}, {'lastname': 'Aanerud', 'firstname': 'Joel', 'initials': 'J', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'lastname': 'Brooks', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark; Division of Neuroscience, Newcastle University, Newcastle, UK.'}]",,,55% of MCI and 83% of AD subjects had a high amyloid-β load. We have previously reported that clusters of correlated amyloid and inflammation levels are present in cortex. Here we found no correlation between levels of inflammation (,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2018.06.004,<Element 'PubmedArticle' at 0x7f05dceafb30>
127,29710717,Behavioral and Neuropsychiatric Disorders in Alzheimer's Disease.,"Alzheimer's disease (AD) is the most frequent type of dementia in the elderly, severely affecting functional and executive skills of subjects suffering from this disease. Moreover, the distress of caregivers as well as the social implications constitute a critical issue for families. Furthermore, cognitive impairment, along with behavioral disorders and neuropsychiatric symptoms are characteristics of AD. Although these are present with variations in prevalence, intensity, and progression, an important core of them is visible before cognitive impairment, especially depression and apathy, which affect at least 50% of patients. The most updated literature shows that depression and/or behavioral and neuropsychiatric symptoms (BNS) are part of the initial phase of the disease rather than just a risk factor. Thus, mood disorders are associated with anomalies in specific brain regions that disturb the normal balance of neurotransmission. This in turn is linked with an inflammatory pathway that leads to microglial activation and aggregated neurofibrillary tangle formation, finally triggering neuronal loss, according to our neuroimmunomodulation theory. Altogether, inflammation and tau aggregation are observed in preclinical stages, preceding the BNS of patients, which in turn are exhibited earlier than cognitive and functional impairment detected in AD. This review is focused on the latest insights of cellular and molecular processes associated with BNS in asymptomatic early-onset stages of AD. An important medical research focus is to improve quality of life of patients, through prevention and treatments of AD, and the study of behavioral disorders and early event in AD pathogenesis has a major impact.","['Alzheimer’s disease', 'apathy', 'asymptomatic stages', 'behavioral disorders', 'neuroimmunomodulation', 'neuroinflammation', 'neuropsychiatric symptoms']",Journal of Alzheimer's disease : JAD,2018-05-02,"[{'lastname': 'Cortés', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': 'International Center for Biomedicine (ICC), Santiago, Chile.\nLaboratory of Cellular and Molecular Neurosciences, Faculty of Sciences, University of Chile, Santiago, Chile.'}, {'lastname': 'Andrade', 'firstname': 'Víctor', 'initials': 'V', 'affiliation': 'International Center for Biomedicine (ICC), Santiago, Chile.\nLaboratory of Cellular and Molecular Neurosciences, Faculty of Sciences, University of Chile, Santiago, Chile.'}, {'lastname': 'Maccioni', 'firstname': 'Ricardo B', 'initials': 'RB', 'affiliation': 'International Center for Biomedicine (ICC), Santiago, Chile.\nLaboratory of Cellular and Molecular Neurosciences, Faculty of Sciences, University of Chile, Santiago, Chile.\nDepartment of Neurological Sciences, Faculty of Medicine, East Campus, University of Chile, Santiago, Chile.'}]",,,,,10.3233/JAD-180005,<Element 'PubmedArticle' at 0x7f05dcebfea0>
128,"29705945
18218341
17551515
15295589
21456963
21214928
24103387
21605035
25231068
24179789
22982299
22748834
21802369
26892287
23983897
24247053
20442494
19853658
28122877
26510952
29067297
27260250
25870960
24512022
26858599
25645581
24669288
17562162
24860501
21197404
26545340
19494434
28736551
29078813
20692646
29051531
28928740
23850509
24529521
23307037
25385852
19076441
19389821
25193936
26651341
22363258
25916586
27998621
27255824
28407483
25224899
23049498
15717023
22393530
18525129
25071582
24143816
28209725
28700589
26734709
24244562
27522519
25129077
25129075
23892237
26402071
27051467
28794151
22884900
19738171
24492001
20110595
21753171
25148802
21971479
16247185
22153977
21167930
25277040
27328788
26567747
26872418
28582858
26516722
23874844
26401929
18534566
20454852
18486927
14732472
27634186
27349436
20880743
18355243
18819072
22826216
24659688
19380779
19405031
28424490
23372571
10861046
11911998
22889057
17416347
20183830
22730380
27558816
18835196
23084918
25516615
28341870
27383250
25983691
26943045
24293102
27212168
27307950
27882346
24597547
26954942
29021573
25324823
21956652
28928485
26374897
28412600
26332043
28453482
26131975
26317424
25856766
29052145
25257319
28575151
22363284
24224195
24625061
17220915
25445485
27555812
24223593
23150934
25186950
24355566
25281879
28768545
28930663
25593125
25957402
26001891
28680398
27798193
24078628
27573688
27054339
23593217
28965852
27320175
26238736
27698829
28924214
19576187
28115590
25275372
25619654
28802038
26202100
23622250
28197669
22198949
19513731
20880504
19057621
15778078
22622580
16567625
21872592
22047170
25342943
19367002
25801843
20730621
16344479
17620484
17316168
18680556
19560504
18005001
18436531
15059975
17586478
12514700
15689551
26576216
26171115
25061569
11087369
11079778
10525118
10671320
12374623
26962052
16873957
16210396
24189435
16873962
27114851
21545753
20687493
17245412
24747741
22466004
22821186
27339878
24669210
24557875
28789902
9869323
23151073
28984592
27328316
25745640
25511446
28059794
20847408
24702820
27662318
25897356
26650926
20837822
21423525
21942330
27767992
24669210
26310971
21321399
17087050
20552050
26813123
25937383
22058656
25774178
24771316
26971324
16330153
25889215
14688411
29159058
28890300
28507319
28097205
21629716
22272620
28093238
22363262
18088381
14769913
17239007
8990130
10499443
8870824
15555766
16428884
17229088
14690523
11872257
12761548
23062700
12146803
22122372
27435766
14622095
23594965
28933638
18266959
29033830
24171818
20660724
20847427
16298241
14722078
20157541
19812304
22500797
25105207
23979023
23470275
24525424
29259984
24252508
23278352
20178983
23585566
20178983
18046414
21368289
18410586
25460724
21543789
11295490
11375979
28821611
18172548
24879151
11716763
18764739
11162237
24278382
19709998
21823025
20061651
22306005
24319154
22932892
15124018
17241879
16946298
16835372
23506423
24009582
22298416
24659348
25843914
16850017
25738751
12730455
11264285
7796817
12820873
12044177
12547230
16911529
10875438
19387120
17325276
19166904
20558735
19021541
7798927
18466351
16942750
25231526
24671940
24559299
24671940
28890316
22245578
11182300
17455909
23703910
15578276
21147772
23874300
22717236
15665406
16917148
16629179
17886035
23262393
16399210
25114080
24501157
12045736
23502468
11803037
24954589
25278564
19038359
24395787
27425887
29061693
26913031
26551716
26995317
25757748
25136294
27668667
26464797
17332139
28289797",Could Alzheimer's Disease Originate in the Periphery and If So How So?,"The classical amyloid cascade model for Alzheimer's disease (AD) has been challenged by several findings. Here, an alternative molecular neurobiological model is proposed. It is shown that the presence of the APOE ε4 allele, altered miRNA expression and epigenetic dysregulation in the promoter region and exon 1 of TREM2, as well as ANK1 hypermethylation and altered levels of histone post-translational methylation leading to increased transcription of TNFA, could variously explain increased levels of peripheral and central inflammation found in AD. In particular, as a result of increased activity of triggering receptor expressed on myeloid cells 2 (TREM-2), the presence of the apolipoprotein E4 (ApoE4) isoform, and changes in ANK1 expression, with subsequent changes in miR-486 leading to altered levels of protein kinase B (Akt), mechanistic (previously mammalian) target of rapamycin (mTOR) and signal transducer and activator of transcription 3 (STAT3), all of which play major roles in microglial activation, proliferation and survival, there is activation of microglia, leading to the subsequent (further) production of cytokines, chemokines, nitric oxide, prostaglandins, reactive oxygen species, inducible nitric oxide synthase and cyclooxygenase-2, and other mediators of inflammation and neurotoxicity. These changes are associated with the development of amyloid and tau pathology, mitochondrial dysfunction (including impaired activity of the electron transport chain, depleted basal mitochondrial potential and oxidative damage to key tricarboxylic acid enzymes), synaptic dysfunction, altered glycogen synthase kinase-3 (GSK-3) activity, mTOR activation, impairment of autophagy, compromised ubiquitin-proteasome system, iron dyshomeostasis, changes in APP translation, amyloid plaque formation, tau hyperphosphorylation and neurofibrillary tangle formation.","['Alzheimer’s disease', 'Gene expression', 'Inflammation', 'Microglia', 'Mitochondria', 'Molecular neurobiology']",Molecular neurobiology,2018-05-01,"[{'lastname': 'Morris', 'firstname': 'Gerwyn', 'initials': 'G', 'affiliation': 'IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, P.O. Box 291, Geelong, Victoria, Australia.'}, {'lastname': 'Berk', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, P.O. Box 291, Geelong, Victoria, Australia.\nDepartment of Psychiatry, Level 1 North, Main Block, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.\nFlorey Institute for Neuroscience and Mental Health, Kenneth Myer Building, University of Melbourne, 30 Royal Parade, Parkville, Victoria, Australia.\nOrygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, Victoria, Australia.'}, {'lastname': 'Maes', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, P.O. Box 291, Geelong, Victoria, Australia.\nDepartment of Psychiatry, Chulalongkorn University, Bangkok, Thailand.'}, {'lastname': 'Puri', 'firstname': 'Basant K', 'initials': 'BK', 'affiliation': 'Department of Medicine, Hammersmith Hospital, Imperial College London, London, UK. basant.puri@imperial.ac.uk.'}]",,,,,"10.1007/s12035-018-1092-y
10.1016/j.molmed.2007.12.002
10.1038/nrn2168
10.1038/nature02621
10.1146/annurev-neuro-061010-113613
10.1186/1756-6606-4-3
10.1186/alzrt211
10.2174/156720512799361673
10.1186/s40478-014-0135-5
10.1016/j.nicl.2013.02.006
10.1016/j.neuint.2012.08.014
10.1016/s1474-4422(11)70156-9
10.2174/1567205013666160219113112
10.1155/2013/316523
10.3233/jad-2010-100339
10.1016/j.bbadis.2009.10.006
10.1093/brain/aww349
10.1093/brain/awv288
10.1016/j.trci.2016.05.001
10.1007/s10571-016-0386-8
10.1515/revneuro-2014-0076
10.1179/1743132813y.0000000288
10.1111/jnc.13037
10.1155/2014/427318
10.1007/s11064-007-9394-x
10.3389/fnagi.2014.00092
10.4061/2011/971021
10.1111/jnc.13425
10.3233/jad-2009-1015
10.3389/fimmu.2017.00783
10.1186/s13024-017-0222-8
10.1016/j.biopsych.2010.06.012
10.1038/s41598-017-13601-y
10.1016/j.pneurobio.2013.06.004
10.1016/j.jalz.2013.12.004
10.1007/s00005-012-0210-1
10.1530/EC-14-0092
10.1196/annals.1427.007
10.2337/dc09-0259
10.4049/jimmunol.1401174
10.2174/1567205012666151020114607
10.1007/978-1-4939-2404-2_3
10.1016/j.neurobiolaging.2016.11.011
10.1016/j.neurobiolaging.2016.04.002
10.1016/j.chom.2017.03.002
10.1159/000346362
10.3389/fncel.2012.00038
10.1602/neurorx.1.2.226
10.1101/cshperspect.a006312
10.3233/JAD-2008-14107
10.3389/fphar.2014.00165
10.1371/journal.pone.0177814
10.3389/fnbeh.2015.00347
10.1371/journal.pone.0079771
10.1016/j.neurobiolaging.2016.07.008
10.1038/nn.3782
10.1038/nn.3786
10.1093/hmg/ddt354
10.3233/jad-143060
10.1186/s13148-016-0202-9
10.1016/j.bbi.2012.07.012
10.1212/wnl.0b013e3181b6bb95
10.3233/jad-2010-1252
10.1212/wnl.0b013e318225ae07
10.1016/j.jalz.2010.05.178
10.3233/jad-2011-0044
10.1385/nmm:7:3:255
10.1038/ni.3427
10.1016/j.jneuroim.2011.11.005
10.1016/j.neurobiolaging.2014.08.008
10.1016/j.neubiorev.2016.06.014
10.2174/1567205013666151116124912
10.1016/j.bbi.2016.02.009
10.3233/jad-161304
10.1016/j.coph.2015.10.003
10.1371/journal.pone.0068996
10.3233/jad-150236
10.1016/j.brainres.2008.02.060
10.1007/s10875-010-9414-5
10.1016/j.autrev.2008.03.004
10.1016/j.neulet.2003.10.071
10.2174/1381612822666160914182822
10.1016/j.it.2010.08.005
10.1111/j.1365-2567.2008.02832.x
10.1002/eji.200738094
10.1073/pnas.1120585109
10.4049/jimmunol.1302569
10.4049/jimmunol.0803616
10.1002/eji.200838866
10.1038/s41598-017-01033-7
10.3389/fimmu.2013.00011
10.4049/jimmunol.165.1.139
10.1016/S0306-4530(01)00062-2
10.1111/j.1365-3083.2012.02769.x
10.1016/j.bbrc.2007.03.150
10.1002/mnfr.200900398
10.1074/jbc.M112.377549
10.1007/978-3-319-39406-0_2
10.1016/j.immuni.2008.08.009
10.1016/j.chom.2012.09.009
10.1007/s10620-017-4538-6
10.1038/srep29353
10.18632/oncotarget.7862
10.1007/s12035-013-8595-3
10.4172/1948-5948.1000276
10.1172/jci.insight.87748
10.1016/j.atherosclerosis.2015.04.295
10.1210/me.2013-1293
10.1097/shk.0000000000000604
10.1038/s41467-017-00972-z
10.3389/fneur.2014.00181
10.1002/eji.201141679
10.1038/s41598-017-12330-6
10.1074/jbc.M115.677286
10.1016/j.jpsychires.2017.04.003
10.1371/journal.pone.0136835
10.3233/jad-161277
10.3390/biom5031284
10.1371/journal.pone.0137177
10.1186/s12916-014-0259-2
10.1186/s40478-014-0142-6
10.1093/brain/awx120
10.1007/s00401-013-1182-x
10.1186/1742-2094-11-48
10.1038/nri2015
10.1016/j.neuropharm.2014.10.028
10.3389/fnhum.2016.00398
10.1155/2013/576383
10.1056/nejmoa1211851
10.1111/bpa.12190
10.1016/j.bcp.2013.11.021
10.1016/j.neuroscience.2014.09.050
10.1186/s13024-017-0197-5
10.1016/j.immuni.2017.08.008
10.1096/fj.14-262683
10.1074/jbc.M115.645986
10.1007/s10048-015-0451-3
10.3389/fnagi.2017.00204
10.1523/jneurosci.1238-16.2016
10.1074/jbc.M113.517540
10.1007/s00401-016-1612-7
10.1038/cddis.2016.91
10.1371/journal.pone.0060436
10.1016/j.canlet.2017.09.038
10.1038/srep28006
10.3892/or.2015.4141
10.3892/ol.2016.4914
10.1038/s41598-017-10407-w
10.1016/j.bcp.2009.06.097
10.4049/jimmunol.1601515
10.1371/journal.pone.0108318
10.1016/j.neuron.2014.12.068
10.1038/srep12393
10.1016/j.cell.2013.03.030
10.1007/s00018-017-2463-7
10.4049/jimmunol.1101121
10.1007/s00401-009-0556-6
10.1016/j.nurt.2010.05.017
10.1038/cdd.2008.172
10.1016/j.biocel.2004.10.004
10.1073/pnas.0600549103
10.1016/j.febslet.2011.08.027
10.1186/1742-2094-8-150
10.2174/1570159X12666140828214701
10.2174/1871527314666150317224645
10.1007/s11010-010-0563-x
10.1073/pnas.0508254102
10.1001/archneur.64.7.954
10.2174/156720507779939788
10.1111/j.1471-4159.2008.05603.x
10.1016/j.neuint.2009.06.012
10.1074/jbc.M800013200
10.1016/j.brainres.2007.05.050
10.1038/nm0103-3
10.1523/jneurosci.4736-04.2005
10.1155/2015/151979
10.1155/2015/352723
10.1016/j.redox.2014.03.002
10.1021/bi001876l
10.1016/s0197-4580(00)83154-1
10.1016/s0021-9150(99)00257-9
10.1006/nbdi.1999.0273
10.1016/s0891-5849(02)01001-8
10.1016/j.jalz.2014.05.1213
10.1093/brain/aww027
10.3233/jad-2006-9202
10.1016/j.bbadis.2013.10.015
10.3233/jad-2006-9207
10.1186/alzrt74
10.1038/nrm2101
10.1016/j.bbadis.2014.04.012
10.3233/jad-2012-111592
10.1007/s12035-012-8300-y
10.2174/1570159x11666131120224653
10.1007/s11011-013-9435-x
10.1007/s007020050099
10.2174/1567202611310010010
10.3233/jad-170361
10.1016/j.neulet.2016.05.050
10.13188/2376-922X.1000003
10.1007/s12035-014-9053-6
10.3233/JAD-161088
10.3233/jad-2010-100129
10.1016/j.neurobiolaging.2014.03.006
10.3233/JAD-160702
10.4239/wjd.v6.i3.456
10.1371/journal.pone.0144116
10.1001/archneurol.2010.225
10.3389/fnsyn.2010.00139
10.1089/ars.2011.4277
10.3233/JAD-160726
10.2174/1570159X11666131120224653
10.1007/s12035-015-9392-y
10.3233/jad-2011-101785
10.3177/jnsv.52.248
10.2174/1570159X13666150716165726
10.1016/j.cbpc.2015.04.003
10.2478/v10102-011-0023-9
10.3969/j.issn.1673-5374.2012.05.009
10.1007/s11064-014-1313-3
10.1007/s10072-016-2546-5
10.1016/j.neuroscience.2005.10.014
10.1186/s12916-015-0310-y
10.1073/pnas.2635903100
10.1016/j.nicl.2017.09.016
10.1016/j.neurobiolaging.2017.08.008
10.1002/acn3.339
10.4061/2011/985085
10.2174/156720512802455386
10.1016/j.neubiorev.2017.01.014
10.1111/j.1471-4159.2007.05194.x
10.1073/pnas.0308512100
10.1097/00005072-199701000-00007
10.1097/00005072-199909000-00011
10.1007/s004010050513
10.1016/j.neulet.2004.10.031
10.1159/000091044
10.1111/j.1460-9568.2006.05243.x
10.1111/j.1471-4159.2004.02155.x
10.1016/s0304-3940(01)02583-6
10.1038/nature01640
10.1016/j.neurobiolaging.2012.09.012
10.1111/j.1750-3639.2002.tb00449.x
10.1111/j.1471-4159.2011.07519.x
10.1046/j.1471-4159.2003.02088.x
10.1159/000348599
10.1111/j.1582-4934.2008.00276.x
10.3389/fnagi.2017.00320
10.1186/alzrt217
10.1073/pnas.1009485107
10.3233/jad-2010-101080
10.1016/j.neurobiolaging.2004.12.004
10.1074/jbc.M314124200
10.18632/aging.100070
10.1242/jcs.051011
10.1016/j.cell.2012.03.017
10.3109/07853890.2014.941921
10.3233/jad-131124
10.1016/j.exger.2013.02.025
10.1016/j.bbr.2014.02.005
10.1155/2017/7082696
10.1186/2051-5960-1-3
10.1111/jnc.12098
10.1074/jbc.m110.100420
10.1074/jbc.m112.435123
10.1016/j.jalz.2013.04.139
10.1016/j.jalz.2010.05.519
10.1038/nature06322
10.1182/blood-2010-09-310888
10.1111/j.1600-079x.2007.00539.x
10.1016/j.redox.2013.12.008
10.1016/s0300-9084(01)01250-0
10.1074/jbc.m100142200
10.1074/jbc.M117.803619
10.4161/auto.28477
10.1042/0264-6021:3600355
10.1089/ars.2008.2263
10.1006/nbdi.2000.0364
10.1371/journal.pone.0081093
10.1148/radiol.2532082324
10.1007/s11596-011-0493-1
10.3233/jad-2010-1239
10.1016/j.bbamcr.2012.01.014
10.1182/asheducation-2013.1.1
10.1074/jbc.M112.358911
10.1172/jci20945
10.1053/j.gastro.2006.10.018
10.1182/blood-2006-07-033969
10.1182/blood-2006-06-027631
10.1111/jnc.12244
10.3389/fneng.2013.00007
10.1002/glia.22303
10.1007/s12035-014-8671-3
10.1016/j.bbadis.2015.03.011
10.1038/nchembio807
10.1371/journal.pone.0118830
10.1093/jn/133.5.1510S
10.1074/jbc.M100245200
10.1002/j.1460-2075.1995.tb07291.x
10.1021/bi030041i
10.1021/bi025756k
10.1006/bcmd.2002.0579
10.1111/j.1742-4658.2006.05390.x
10.3233/jad-2009-1010
10.1212/01.wnl.0000255938.33739.46
10.1016/j.bbagen.2008.12.001
10.1074/jbc.M110.149161
10.1042/bst0361282
10.1046/j.1471-4159.1995.64010307.x
10.1111/j.1582-4934.2008.00356.x
10.1016/j.bbrc.2006.08.077
10.1098/rsif.2014.0165
10.1021/ic402406g
10.1098/rsif.2014.0165
10.1016/j.chembiol.2017.07.014
10.1016/j.jmb.2011.12.057
10.1016/s0891-5849(00)00494-9
10.1021/bi7000032
10.1073/pnas.1218402110
10.1007/s00775-004-0602-8
10.1074/jbc.M110.158980
10.1016/j.neurobiolaging.2012.05.009
10.3233/JAD-2004-6610
10.3233/JAD-2006-9405
10.4067/S0716-97602006000100021
10.1080/10715760701609061
10.1016/j.neuint.2012.12.005
10.1016/j.neurobiolaging.2005.01.016
10.3233/jad-140567
10.1515/revneuro-2013-0046
10.1097/00019052-200206000-00020
10.3390/ijms14036044
10.1016/S0162-0134(01)00376-2
10.1134/s0006297914050022
10.1182/blood-2014-08-594093
10.1016/j.biocel.2008.10.029
10.1073/pnas.1322614111
10.1084/jem.20171406
10.3389/fimmu.2016.00033
10.1042/bst20140319
10.1016/j.bbi.2016.03.010
10.1038/jcbfm.2015.32
10.3389/fncel.2014.00211
10.1001/jamaneurol.2016.2742
10.1186/s40035-015-0042-0
10.1136/oem.2006.027003
10.1007/s00115-017-0288-0",<Element 'PubmedArticle' at 0x7f05dcec9a40>
129,"29636460
17493041
25495175
28653647
26595641
17616482
22265587
19915575
23900411
21292315
19714246
27172939
25352339
15956162
25324900
12056929
10072441
17514749
21685912
27899424
25862742
27088644
23375658
23637625
7969952
24943344
24162737
11315092
25687773
25174004
25954001
24013639
20576703
18613948
18223198
17571925
25620700
25425146
9847323
9634238
11983855
28271184
24154522
20682445
21745188
18227351
16049180
19339947
11278753
21220432
11426226
26884166
23226438
10932182
16964252
15145320
9118323
18583990
12775414
27905517
19255243
23404337",CXCR4 involvement in neurodegenerative diseases.,"Neurodegenerative diseases likely share common underlying pathobiology. Although prior work has identified susceptibility loci associated with various dementias, few, if any, studies have systematically evaluated shared genetic risk across several neurodegenerative diseases. Using genome-wide association data from large studies (total n = 82,337 cases and controls), we utilized a previously validated approach to identify genetic overlap and reveal common pathways between progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), Parkinson's disease (PD) and Alzheimer's disease (AD). In addition to the MAPT H1 haplotype, we identified a variant near the chemokine receptor CXCR4 that was jointly associated with increased risk for PSP and PD. Using bioinformatics tools, we found strong physical interactions between CXCR4 and four microglia related genes, namely CXCL12, TLR2, RALB, and CCR5. Evaluating gene expression from post-mortem brain tissue, we found that expression of CXCR4 and microglial genes functionally related to CXCR4 was dysregulated across a number of neurodegenerative diseases. Furthermore, in a mouse model of tauopathy, expression of CXCR4 and functionally associated genes was significantly altered in regions of the mouse brain that accumulate neurofibrillary tangles most robustly. Beyond MAPT, we show dysregulation of CXCR4 expression in PSP, PD, and FTD brains, and mouse models of tau pathology. Our multi-modal findings suggest that abnormal signaling across a 'network' of microglial genes may contribute to neurodegeneration and may have potential implications for clinical trials targeting immune dysfunction in patients with neurodegenerative diseases.",[],Translational psychiatry,2018-04-11,"[{'lastname': 'Bonham', 'firstname': 'Luke W', 'initials': 'LW', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Karch', 'firstname': 'Celeste M', 'initials': 'CM', 'affiliation': 'Department of Psychiatry, Washington University, St. Louis, MO, USA.'}, {'lastname': 'Fan', 'firstname': 'Chun C', 'initials': 'CC', 'affiliation': 'Department of Cognitive Sciences, University of California, San Diego, La Jolla, CA, USA.'}, {'lastname': 'Tan', 'firstname': 'Chin', 'initials': 'C', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Geier', 'firstname': 'Ethan G', 'initials': 'EG', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Wang', 'firstname': 'Yunpeng', 'initials': 'Y', 'affiliation': 'NORMENT; Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.'}, {'lastname': 'Wen', 'firstname': 'Natalie', 'initials': 'N', 'affiliation': 'Department of Psychiatry, Washington University, St. Louis, MO, USA.'}, {'lastname': 'Broce', 'firstname': 'Iris J', 'initials': 'IJ', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Li', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Barkovich', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Ferrari', 'firstname': 'Raffaele', 'initials': 'R', 'affiliation': 'Department of Molecular Neuroscience, Institute of Neurology, UCL, London, UK.'}, {'lastname': 'Hardy', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Molecular Neuroscience, Institute of Neurology, UCL, London, UK.'}, {'lastname': 'Momeni', 'firstname': 'Parastoo', 'initials': 'P', 'affiliation': 'Department of Internal Medicine, Laboratory of Neurogenetics, Texas Tech University Health Science Center, Lubbock, TX, USA.'}, {'lastname': 'Höglinger', 'firstname': 'Günter', 'initials': 'G', 'affiliation': 'Department of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.\nDepartment of Neurology, Technical University of Munich; Munich Cluster for Systems Neurology SyNergy, Munich, Germany.'}, {'lastname': 'Müller', 'firstname': 'Ulrich', 'initials': 'U', 'affiliation': 'Institut for Humangenetik, Justus-Liebig-Universität, Giessen, Germany.'}, {'lastname': 'Hess', 'firstname': 'Christopher P', 'initials': 'CP', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Sugrue', 'firstname': 'Leo P', 'initials': 'LP', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Dillon', 'firstname': 'William P', 'initials': 'WP', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Schellenberg', 'firstname': 'Gerard D', 'initials': 'GD', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Andreassen', 'firstname': 'Ole A', 'initials': 'OA', 'affiliation': 'NORMENT; Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.'}, {'lastname': 'Dale', 'firstname': 'Anders M', 'initials': 'AM', 'affiliation': 'Department of Cognitive Sciences, University of California, San Diego, La Jolla, CA, USA.\nDepartment of Neurosciences and Radiology, University of California, San Diego, La Jolla, CA, USA.'}, {'lastname': 'Barkovich', 'firstname': 'A James', 'initials': 'AJ', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Yokoyama', 'firstname': 'Jennifer S', 'initials': 'JS', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Desikan', 'firstname': 'Rahul S', 'initials': 'RS', 'affiliation': 'Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, San Francisco, San Francisco, CA, USA. rahul.desikan@ucsf.edu.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,"10.1038/s41398-017-0049-7
10.1111/j.1750-3639.2007.00054.x
10.1111/nan.12208
10.1016/S1474-4422(17)30157-6
10.1016/S0140-6736(15)00461-4
10.1016/S1474-4422(07)70178-3
10.1016/j.jalz.2011.10.007
10.1038/ng.487
10.1038/nrn3549
10.1016/S0140-6736(10)62345-8
10.1136/jnnp-2014-308350
10.1186/1750-1326-9-43
10.1001/archneur.62.6.917
10.1186/alzrt268
10.1001/archneur.59.6.935
10.1093/hmg/8.4.711
10.1002/ana.21157
10.1038/ng.859
10.1136/jnnp-2016-314411
10.1161/CIRCULATIONAHA.115.015489
10.1016/j.ajhg.2013.01.001
10.1371/journal.pgen.1003455
10.1212/WNL.44.11.2015
10.1016/S1474-4422(14)70065-1
10.1038/ng.2802
10.1111/j.0006-341X.1999.00997.x
10.1038/nn.3801
10.1126/science.1262110
10.1038/ng.2756
10.1186/gb-2008-9-s1-s4
10.1093/hmg/ddn023
10.1371/journal.pgen.0030098
10.1016/j.celrep.2014.12.041
10.1038/ncomms6611
10.1038/31269
10.1073/pnas.092013799
10.1242/dev.098145
10.1016/j.stem.2010.05.019
10.1042/CS20110164
10.1182/blood-2007-08-106583
10.1523/JNEUROSCI.5171-04.2005
10.1097/COH.0b013e328324bbec
10.1074/jbc.M010809200
10.1074/jbc.M110.193276
10.1038/89490
10.1073/pnas.1525528113
10.1038/78078
10.1038/nn1764
10.1016/j.it.2004.04.002
10.1038/cdd.2008.95
10.1080/13550280390201010
10.1038/srep38144
10.1124/mol.108.053389
10.1093/brain/aws360",<Element 'PubmedArticle' at 0x7f05dcda6f40>
130,"29570615
20388643
23149157
11578751
21605046
24191153
19752451
599557
10605456
18599959
19236346
20134203
24795567
18067990
23948931
22742992
26227906
26819770
21776376
27678414
25309941
14872255
29029390
28492240
28482642
28500878
23579330
15509534
21212632
15258209
17270732
25153994
15562429
19052878
26022249
9855500
28410663
26001387
21584654
27037234
12913196
23611343
12058088
21810890
26631930
25549971
19924424
22890575
25556536
28097206
27797445
28087578
28621768
25633670
21520350
21878805
15178953
27429978
27293957
8786384
17623039
22889670
17911161
16237129
19822029
19768526
20070435
19924423
20198481
11150486
12557014
16374822
2963585
20599975
21453448
17000465
17077307
20965169
15985574
8105420
9710002
12714745
15036877
10464279
18343584
15755545
16691114
19266322
19369384
23393603
21985244
21445308
21812967
23560093
22824345
8849730",Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.,"Progressive neurodegenerative pathologies in aged populations are an issue of major concern worldwide. The microtubule-associated protein tau is able to self-aggregate to form abnormal supramolecular structures that include small oligomers up to complex polymers. Tauopathies correspond to a group of diseases that share tau pathology as a common etiological agent. Since microglial cells play a preponderant role in innate immunity and are the main source of proinflammatory factors in the central nervous system (CNS), the alterations in the cross-talks between microglia and neuronal cells are the main focus of studies concerning the origins of tauopathies. According to evidence from a series of studies, these changes generate a feedback mechanism reactivating microglia and provoking constant cellular damage. Thus, the previously summarized mechanisms could explain the onset and progression of different tauopathies and their functional/behavioral effects, opening the window towards an understanding of the molecular basis of anomalous tau interactions. Despite clinical and pathological differences, increasing experimental evidence indicates an overlap between tauopathies and synucleinopathies, considering that neuroinflammatory events are involved and the existence of protein misfolding. Neurofibrillary tangles of pathological tau (NFT) and Lewy bodies appear to coexist in certain brain areas. Thus, the co-occurrence of synucleinopathies with tauopathies is evidenced by several investigations, in which NFT were found in the substantia nigra of patients with Parkinson's disease, suggesting that the pathologies share some common features at the level of neuroinflammatory events.","['Alzheimer’s disease', 'inflammation', 'molecular functions', 'molecular networks', 'neuroimmunomodulation', 'tau protein', 'tauopathies']",International journal of molecular sciences,2018-03-24,"[{'lastname': 'Cortés', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': 'Laboratory of Neurosciences, International Center for Biomedicine (ICC), Santiago 7630457, Chile. nicole.somnus@gmail.com.'}, {'lastname': 'Andrade', 'firstname': 'Víctor', 'initials': 'V', 'affiliation': 'Laboratory of Neurosciences, International Center for Biomedicine (ICC), Santiago 7630457, Chile. victor.andrademf@gmail.com.'}, {'lastname': 'Guzmán-Martínez', 'firstname': 'Leonardo', 'initials': 'L', 'affiliation': 'Laboratory of Neurosciences, International Center for Biomedicine (ICC), Santiago 7630457, Chile. lguzmar@gmail.com.'}, {'lastname': 'Estrella', 'firstname': 'Matías', 'initials': 'M', 'affiliation': 'Laboratory of Neurosciences, International Center for Biomedicine (ICC), Santiago 7630457, Chile. matiasestrella9@gmail.com.'}, {'lastname': 'Maccioni', 'firstname': 'Ricardo B', 'initials': 'RB', 'affiliation': 'Laboratory of Neurosciences, International Center for Biomedicine (ICC), Santiago 7630457, Chile. rmaccion@manquehue.net.\nFaculty of Science, University of Chile, Santiago 7800020, Chile. rmaccion@manquehue.net.'}]",,,,,"10.3390/ijms19040956
10.1093/hmg/ddq142
10.1016/j.arcmed.2012.11.001
10.1016/S0188-4409(01)00316-2
10.2174/156720511796717258
10.3389/fneur.2013.00167
10.1212/WNL.0b013e3181b78448
10.1016/0022-2836(77)90213-3
10.1083/jcb.76.2.547
10.3233/JAD-2008-14307
10.1111/j.1749-6632.2008.03972.x
10.1159/000258724
10.3389/fncel.2014.00112
10.1016/j.arcmed.2007.10.001
10.3233/JAD-131843
10.1016/j.arr.2012.06.003
10.1007/s12035-015-9369-x
10.1155/2016/6790743
10.4061/2011/352805
10.1016/j.neuropharm.2016.09.025
10.13188/2327-204X.1000001
10.1007/s00401-004-0820-8
10.18632/oncotarget.17371
10.1038/ncomms15295
10.3233/JAD-170168
10.1016/j.neurobiolaging.2017.04.007
10.3233/JAD-130032
10.1016/S0002-9440(10)63421-9
10.1159/000322228
10.1136/jnnp.2003.019422
10.1016/j.neuron.2007.01.010
10.1371/journal.pone.0106050
10.1002/ana.20332
10.1007/s11481-008-9142-2
10.1186/s12974-015-0236-5
10.1212/WNL.51.6.1546
10.1016/j.ncl.2017.01.008
10.1093/brain/awv133
10.1007/s12031-011-9538-y
10.1212/WNL.0000000000002638
10.1212/01.WNL.0000078928.20107.52
10.3109/09540261.2013.776523
10.1212/WNL.58.11.1615
10.1093/brain/awr179
10.1038/nrn.2015.1
10.1007/s00401-014-1380-1
10.1007/s00401-009-0612-2
10.1007/s00401-012-1029-x
10.1111/nan.12213
10.1002/acn3.366
10.1111/ene.13164
10.1093/brain/aww339
10.1038/nrneurol.2017.75
10.3233/JAD-141986
10.1002/hbm.21282
10.1097/JGP.0b013e31823033f3
10.1159/000077171
10.1155/2016/3245935
10.1155/2016/7049108
10.1097/00005072-199603000-00001
10.1111/j.1471-4159.2007.04764.x
10.1179/1743132812Y.0000000063
10.1093/hmg/ddm159
10.1212/01.wnl.0000187889.17253.b1
10.1186/alzrt5
10.1007/s10930-009-9201-4
10.1111/j.1582-4934.2010.01010.x
10.1007/s00401-009-0613-1
10.1007/s00401-010-0658-1
10.1016/S0006-8993(00)03082-1
10.1007/s00401-002-0644-3
10.1002/ana.20723
10.1002/ana.410220411
10.1016/j.expneurol.2010.06.017
10.1111/j.1460-9568.2011.07660.x
10.1007/BF03033329
10.1096/fj.06-6092com
10.1016/j.expneurol.2010.10.006
10.1212/01.WNL.0000165987.89198.65
10.1212/WNL.43.10.1927
10.1212/WNL.51.2.351
10.1126/science.1082324
10.1016/j.tins.2004.01.007
10.1074/jbc.274.36.25481
10.1016/j.neuroscience.2008.01.030
10.1016/j.expneurol.2004.07.016
10.1097/01.jnen.0000218441.00040.82
10.1007/s12031-009-9190-y
10.1096/fj.08-120410
10.1371/journal.pone.0055848
10.1111/j.1742-4658.2011.08389.x
10.1371/journal.pone.0017953
10.1186/1471-2202-12-79
10.1371/journal.pone.0060378
10.1186/1750-1326-7-35
10.1038/383550a0",<Element 'PubmedArticle' at 0x7f05dcd7be00>
131,29562520,Toward a New Concept of Alzheimer's Disease Models: A Perspective from Neuroinflammation.,"The continuing failure to develop an effective treatment for Alzheimer's disease urges a better understanding of the pathogenic mechanisms and the improvement of current animal models to facilitate success for clinical interventions. The transgenic models have been so far designed to recapitulate one, or both, protein lesions found in the brain of patients, the extracellular amyloid plaques and the intraneuronal neurofibrillary tangles. However, in recent years, a third pathogenic component is gaining strength in the onset and progression of this disease, the neuroinflammatory response mediated primarily by the brain's resident immune cells, microglia. This has been highlighted by the identification of genes involved in innate immunity as risk factors to develop this neurodegenerative disease. Our current concept, mostly derived from amyloid-β producing models which show a robust microglial activation, supports an initial beneficial role of these glial cells followed by a pro-inflammatory cytotoxic function later on. This view is now challenged by emerging data in human postmortem samples. We have recently demonstrated that in the hippocampus of Braak V-VI individuals there is a prominent degenerative process of the microglial population, driven by phospho-tau, that might compromise neuronal homeostasis. This scenario of microglial dysfunction/degeneration should be taken into account for developing more reliable animal models of this disease and improve their predictive value for human drug efficacy testing. Finally, correcting dysregulated brain inflammatory responses might be a promising avenue to restore cognitive function.","['Alzheimer’s disease', 'degeneration', 'inflammatory', 'innate immunity', 'microglia', 'transgenic models']",Journal of Alzheimer's disease : JAD,2018-03-23,"[{'lastname': 'Gutierrez', 'firstname': 'Antonia', 'initials': 'A', 'affiliation': 'Departamento Biologia Celular, Genetica y Fisiologia, Facultad de Ciencias, Instituto de Biomedicina de Malaga (IBIMA), Universidad de Malaga, Spain.\nCentro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}, {'lastname': 'Vitorica', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Departamento Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad de Sevilla, Spain.\nInstituto de Biomedicina de Sevilla (IBiS)-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain.\nCentro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.'}]",,,,,10.3233/JAD-179914,<Element 'PubmedArticle' at 0x7f05dcd39810>
132,"29552443
15883308
15049507
21118401
25728668
27477018
26478868
28768545
22229116
23150934
27196974
27091843
6681564
2011243
16906426
24990881
12484568
28100745
23332364
29142083
28612290
26364736",Alzheimer's disease pathology in Nasu-Hakola disease brains.,"Nasu-Hakola disease (NHD) is a rare autosomal recessive disorder, characterized by progressive presenile dementia and formation of multifocal bone cysts, caused by genetic mutations of either triggering receptor expressed on myeloid cells 2 (","[""Alzheimer's disease"", 'Nasu-Hakola disease', 'amyloid-β', 'phosphorylated tau']",Intractable & rare diseases research,2018-03-20,"[{'lastname': 'Satoh', 'firstname': 'Jun-Ichi', 'initials': 'JI', 'affiliation': 'Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Tokyo, Japan.'}, {'lastname': 'Kino', 'firstname': 'Yoshihiro', 'initials': 'Y', 'affiliation': 'Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Tokyo, Japan.'}, {'lastname': 'Yanaizu', 'firstname': 'Motoaki', 'initials': 'M', 'affiliation': 'Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Tokyo, Japan.'}, {'lastname': 'Saito', 'firstname': 'Yuko', 'initials': 'Y', 'affiliation': 'Department of Laboratory Medicine, National Center Hospital, NCNP, Tokyo, Japan.'}]",,,,,10.5582/irdr.2017.01088,<Element 'PubmedArticle' at 0x7f05dcd3ef40>
133,29512077,Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.,"The recent progress in the development of in vivo biomarkers is rapidly changing how neurodegenerative diseases are conceptualized and diagnosed, and how clinical trials are designed today. Alzheimer's disease (AD)-the most common neurodegenerative disorder-is characterized by a complex neuropathology involving the deposition of extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFT) of hyperphosphorylated tau proteins, accompanied by the activation of glial cells-astrocytes and microglia-and neuroinflammatory responses, leading to neurodegeneration and cognitive dysfunction. An increasing diversity of positron emission tomography (PET) imaging radiotracers are available to selectively target the different pathophysiological processes of AD. Along with the success of Aβ PET and the more recent tau PET imaging, there is also a great interest to develop PET tracers to image glial activation and neuroinflammation. While most research to date has focused on imaging microgliosis, recent studies using ","['11C-Pittsburgh compound B (11C-PiB)', '11C-deuterium-L-deprenyl (11C-DED)', '18F-fluorodeoxyglucose (18F-FDG)', 'Alzheimer’s disease', 'Amyloid', 'Astrocytosis', 'Multitracer PET Imaging', 'Neuroinflammation', 'Positron emission tomography']","Methods in molecular biology (Clifton, N.J.)",2018-03-08,"[{'lastname': 'Rodriguez-Vieitez', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. Elena.Rodriguez-Vieitez@ki.se.'}, {'lastname': 'Nordberg', 'firstname': 'Agneta', 'initials': 'A', 'affiliation': 'Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.\nDepartment of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.'}]",,,,,10.1007/978-1-4939-7704-8_16,<Element 'PubmedArticle' at 0x7f05dcd4f1d0>
134,29432723,"Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.","Tau-immumotherapy has shown promising results in tangle/tauopathy-tg animal models. Here we immunized amyloid-mice (APPSwe/PSEN1dE9-tg, presenting amyloid-plaques, not neurofibrillary-tangles) with phos-tau peptides, previously shown by us to have high efficacy in mutant-tau tauopathy-mice. These amyloid-mice allowed us to test the effect of the vaccine in a model of familial AD patients with mutant amyloid plaque pathology, where tau pathology - once develops - is of non-mutant tau. Fourteen-month-old amyloid-mice were immunized with phos-tau peptides or vehicle. Eight weeks later, amelioration of cognitive impairment was noticed. Histological analysis revealed that the phos (non-mutant)-tau pathology (detected by us in these aged amyloid-mice while not in non-tg-mice), was lower in the phos-tau immunized amyloid-mice than in the non-immunized mice. Interestingly, we detected a decrease in amyloid plaque pathology, probably associated with the increased microglial burden, which surrounded both tau and amyloid pathology. These results point to the added value of immunizing AD-mice with the phos-tau-vaccine, targeting both tau and amyloid pathology, which may have clinical relevance. It also points to the multifaceted interplay between tau/amyloid pathologies.","[""Alzheimer's disease"", 'Amyloid', 'Immunotherapy', 'Phosphorylated tau', 'Tau', 'Tauopathy']",Experimental neurology,2018-02-13,"[{'lastname': 'Benhamron', 'firstname': 'Sandrine', 'initials': 'S', 'affiliation': 'The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.'}, {'lastname': 'Rozenstein-Tsalkovich', 'firstname': 'Lea', 'initials': 'L', 'affiliation': 'The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.'}, {'lastname': 'Nitzan', 'firstname': 'Keren', 'initials': 'K', 'affiliation': 'The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.'}, {'lastname': 'Abramsky', 'firstname': 'Oded', 'initials': 'O', 'affiliation': 'The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.'}, {'lastname': 'Rosenmann', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': 'The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel. Electronic address: rosenman@hadassah.org.il.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.expneurol.2018.02.004,<Element 'PubmedArticle' at 0x7f05dcd58450>
135,29274876,Roles of tau pathology in the locus coeruleus (LC) in age-associated pathophysiology and Alzheimer's disease pathogenesis: Potential strategies to protect the LC against aging.,"The locus coeruleus (LC) is the noradrenaline (norepinephrine, NE)-containing nucleus in the brainstem and innervates into widespread brain regions. This LC-NE system plays a critical role in a variety of brain functions, including attention, arousal, emotion, cognition, and the sleep-wake cycle. The LC is one of the brain regions vulnerable to the occurrence of neurofibrillary tangles (NFTs), which is associated with ""primary age-related tauopathy (PART)"" that describes the pathology commonly observed in the brains of aged individuals. In Alzheimer's disease (AD), the LC is one of the first places to develop NFTs, which may act as a seed for subsequent spreading of the pathology throughout the brain upon amyloid-β (Aβ) accumulation. As AD progresses, significant neuron loss occurs in the LC. Moreover, LC neurodegeneration is not only a consequence of AD, but also drives clinical and pathological manifestations of AD, such as microglial dysregulation, sleep disturbance, cognitive decline, and neurovascular dysfunction. Therefore, prevention of NFT pathology and neuron loss in the LC-NE system is critical for suppressing the progression of AD. We propose that targeting aging itself may be a proactive intervention against age-associated changes in the LC. Such an approach could open the way for novel interventions against age-associated neurodegenerative disorders, in particular, AD.","['Aging', 'Alzheimer’s disease', 'Hypothalamus', 'Locus coeruleus', 'Neurofibrillary tangles', 'Sirtuins', 'Sleep', 'mTOR signaling']",Brain research,2017-12-25,"[{'lastname': 'Satoh', 'firstname': 'Akiko', 'initials': 'A', 'affiliation': 'Sleep and Aging Regulation Research Project Team, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan. Electronic address: asatoh@ncgg.go.jp.'}, {'lastname': 'Iijima', 'firstname': 'Koichi M', 'initials': 'KM', 'affiliation': ""Department of Alzheimer's Disease Research, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan; Department of Experimental Gerontology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan. Electronic address: iijimakm@ncgg.go.jp.""}]",,,,Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2017.12.027,<Element 'PubmedArticle' at 0x7f05dcce71d0>
136,"29273951
21460841
19834064
17982277
25792098
25278875
26436904
25620700
18981147
18510752
22654722
26091541
11958825
19776284
22258606
3061340
25744023
11708985
25239737
27751869
23150908
24531916
25728668
19211891
23150934
21946017
23964266
25686105
22095718
11424194
3401721
22057275
16157451
27658901
12085093
28019679
27509875
28049142
26939933
12869452
27716675
12791976
27605009
10932230
20037584
25227314
20393137
26268530
23852599
19122031
24399084
19734902
15932500
15096476
19688332
23948931
20846376
11561079
24197756
17667932
21460840
24962261
20532897
19734903
22198949
23686772
16906128
15857927
28940479
15688088
15295589
23943781
24162737
21785996
25686106
19386997
10408445
16984903
22538615
25178404
22850787
26422006
17549252
25144717
26984188
21827663
3670729
21084593
24052108
28123027
22365544
21148344
23254930
26121197
12640446
12839942
12796468
18604209
17905482
23322736
19339974
23812099
14597556
11140685
18509040
24161618
26526648
25974006
23622250
18363936
26134003
11027491",Neuroinflammatory responses in Alzheimer's disease.,"Neuroinflammatory responses in Alzheimer's disease (AD) are complex and not fully understood. They involve various cellular and molecular players and associate interaction between the central nervous system (CNS) and the periphery. Amyloid peptides within the senile plaques and abnormally phosphorylated tau in neurofibrillary tangles are able to initiate inflammatory responses, in brain of AD patients and in mouse models of this disease. The outcome of these responses on the pathophysiology of AD depends on several factors and can be either beneficial or detrimental. Thus, understanding the role of neuroinflammation in AD could help to develop safer and more efficient therapeutic strategies. This review discusses recent knowledge on microglia responses toward amyloid and tau pathology in AD, focusing on the role of Toll-like receptors and NOD-like receptor protein 3 (NLRP3) inflammasome activation in microglial cells.","['Alzheimer’s disease', 'Innate immunity', 'Microglia', 'NLRP3 inflammasome', 'Neurodegenerative diseases', 'Neuroinflammation', 'TLRs']","Journal of neural transmission (Vienna, Austria : 1996)",2017-12-24,"[{'lastname': 'Dansokho', 'firstname': 'Cira', 'initials': 'C', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany.'}, {'lastname': 'Heneka', 'firstname': 'Michael Thomas', 'initials': 'MT', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Sigmund Freud Str. 27, 53127, Bonn, Germany. michael.heneka@ukbonn.de.\nDepartment of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany. michael.heneka@ukbonn.de.'}]",,,,,10.1007/s00702-017-1831-7,<Element 'PubmedArticle' at 0x7f05dccf3770>
137,"29021554
26635213
15615638
9641683
9636220
9629852
7946342
10932182
10783293
18568014
12417659
12859672
11741399
15509565
12895417
19781645
11520987
22096518
27748574
25492702
21193853
24493463
11520988
20802182
17478722
22660329
11959919
20829454
23783030
21482827
25543463
27856911
27505014
26417601
12444595
26852117
17897967
19363289
28334843
27760324
28656156
11071755
18510934
26537835
23168169
21595047
25732305
22007133
22824261
23138980
22016188
22105794
22028327
25977550
25307057
23002015
16914859
23486975
20209626
25991443
16960575
10858586
23280835
20173336
25842390
21858823
19729894
26932669
19439592
15157802
23594743
23798682
21138979
27037086
22397366
15681802
16954650
25739812
24029244
21044883
28238547
26931567
23680655
12210822
21117149
19247481
8530974
3537114
25894337
23728426
22076157
23028067
25183871",Human TAU,"Microtubule-associated TAU protein is a pathological hallmark in Alzheimer's disease (AD), where hyperphosphorylation of TAU generates neurofibrillary tangles. To investigate the effects of TAU in a regenerative adult vertebrate brain system, we generated a cre/lox-based transgenic model of zebrafish that chronically expresses human TAU",[],Scientific reports,2017-10-13,"[{'lastname': 'Cosacak', 'firstname': 'Mehmet I', 'initials': 'MI', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Bhattarai', 'firstname': 'Prabesh', 'initials': 'P', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Bocova', 'firstname': 'Ledio', 'initials': 'L', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Dzewas', 'firstname': 'Tim', 'initials': 'T', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Mashkaryan', 'firstname': 'Violeta', 'initials': 'V', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.\nCenter for Regenerative Therapies Dresden (CRTD), TU Dresden, Fetscherstrasse 105, 01307, Dresden, Germany.'}, {'lastname': 'Papadimitriou', 'firstname': 'Christos', 'initials': 'C', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Brandt', 'firstname': 'Kerstin', 'initials': 'K', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Hollak', 'firstname': 'Heike', 'initials': 'H', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany.'}, {'lastname': 'Antos', 'firstname': 'Christopher L', 'initials': 'CL', 'affiliation': 'School of Life Sciences and Technology, ShanghaiTech University, 100 Haike Road, Shanghai, China.'}, {'lastname': 'Kizil', 'firstname': 'Caghan', 'initials': 'C', 'affiliation': 'German Center for Neurodegenerative Diseases (DZNE), Arnoldstrasse 18, 01307, Dresden, Germany. caghan.kizil@dzne.de.\nCenter for Regenerative Therapies Dresden (CRTD), TU Dresden, Fetscherstrasse 105, 01307, Dresden, Germany. caghan.kizil@dzne.de.'}]",,,,,"10.1038/s41598-017-13311-5
10.1038/nrneurol.2015.225
10.1016/j.bbadis.2004.09.008
10.1038/31508
10.1073/pnas.95.13.7737
10.1002/ana.410430617
10.1016/0896-6273(94)90264-X
10.1038/78078
10.1006/nbdi.1999.0279
10.1038/nrn2420
10.1046/j.1471-4159.2003.01879.x
10.1006/nbdi.2001.0439
10.1074/jbc.M409876200
10.1016/S0896-6273(03)00434-3
10.1016/j.nbd.2009.09.004
10.1126/science.1058189
10.1371/journal.pone.0027068
10.1111/ejn.13442
10.1007/s00401-014-1371-2
10.1038/nrn2967
10.1001/jamaneurol.2013.5847
10.1126/science.1062097
10.2353/ajpath.2010.100346
10.1126/science.1141736
10.1038/nature11060
10.1073/pnas.092136199
10.1126/science.1194653
10.1091/mbc.E12-12-0858
10.1074/jbc.M111.234674
10.1016/j.neurobiolaging.2014.11.018
10.1126/science.aah6205
10.1155/2015/769763
10.1002/jnr.10451
10.1186/s12929-016-0237-4
10.1093/nar/gkm608
10.1172/JCI37537
10.1093/brain/awx005
10.1016/j.celrep.2016.09.075
10.1006/dbio.2000.9898
10.1016/j.cell.2008.04.037
10.1038/srep16273
10.1016/j.devcel.2012.10.014
10.1002/dneu.20918
10.1084/jem.20142322
10.1242/dev.072587
10.1186/1749-8104-7-27
10.1126/science.1228773
10.1002/dvdy.22710
10.1002/glia.22269
10.1242/dmm.007336
10.1126/science.aaa2729
10.1038/nature13800
10.3233/JAD-2006-9S323
10.1523/JNEUROSCI.4361-12.2013
10.1002/jnr.22387
10.1038/nrn3880
10.1016/S0197-4580(00)00124-X
10.1002/ana.23722
10.1159/000285515
10.1093/brain/awv056
10.1002/cne.22757
10.1159/000229011
10.1242/dev.122796
10.1523/JNEUROSCI.0072-09.2009
10.1016/j.brainres.2004.02.073
10.1038/nature12111
10.1074/jbc.M113.463984
10.1242/dev.059345
10.1186/s40478-016-0300-0
10.1186/1742-2094-9-47
10.1196/annals.1332.006
10.1159/000095638
10.15252/embr.201439702
10.1016/j.tcb.2013.08.004
10.1016/j.bbadis.2010.10.012
10.15252/embr.201541438
10.1016/j.ajpath.2013.03.015
10.1002/jnr.10328
10.1002/dvdy.22497
10.1371/journal.pone.0004640
10.1007/BF00867417
10.1177/34.12.3537114
10.1371/journal.pone.0124073
10.1371/journal.pone.0027395
10.1242/dev.108415",<Element 'PubmedArticle' at 0x7f05dcd17310>
138,"28356893
9600986
7964904
7980587
15537891
15071107
10818140
16282321
20371804
21414686
25312309
17116235
18300294
22528081
23173076
16412101
12925731
16541076
19625522
8191290
26051935
26697885
25604547
17403556
24065130
24100688
25853174
25297091
21143159
23542865
27218118
23672786
25281869
27582220
24553930
23540266
25802556
25531084
20650286
21914486
26719327
25810517
27751442
7533843
8817572
22987042
24012003
24495408
17308309
20547131
17720802
15014916
12424218
17251419
25928376
26224839
12176077
19759000
19836392
23404286
22695678
25381029
14993422
16267270
19242475
26323479
21272290
27175374
24315369
22217416
14596589
20083042
15695586
25928376
19605645
20826658
11932745
11750898
16469784
18359102
18568035
20097446
18155846
18585407
16415866
17360908
20056779
15722360
20061018
11032887
12435748
16141213
18335524
19164507
16025111
16319306
16945109
22505713
19406747
19188609
19321417
19540623
20950339
9518610
18987201
18945886
19291319
19926863",Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station.,"Toxic amyloid beta oligomers (AβOs) are known to accumulate in Alzheimer's disease (AD) and in animal models of AD. Their structure is heterogeneous, and they are found in both intracellular and extracellular milieu. When given to CNS cultures or injected ICV into non-human primates and other non-transgenic animals, AβOs have been found to cause impaired synaptic plasticity, loss of memory function, tau hyperphosphorylation and tangle formation, synapse elimination, oxidative and ER stress, inflammatory microglial activation, and selective nerve cell death. Memory loss and pathology in transgenic models are prevented by AβO antibodies, while Aducanumab, an antibody that targets AβOs as well as fibrillar Aβ, has provided cognitive benefit to humans in early clinical trials. AβOs have now been investigated in more than 3000 studies and are widely thought to be the major toxic form of Aβ. Although much has been learned about the downstream mechanisms of AβO action, a major gap concerns the earliest steps: How do AβOs initially interact with surface membranes to generate neuron-damaging transmembrane events? Findings from Ohnishi et al (PNAS 2005) combined with new results presented here are consistent with the hypothesis that ","['Abeta oligomers', 'Alzheimer’s', 'NaK ATPase', 'receptor', 'sodium-potassium ATPase', 'spine loss', 'synapse', 'toxicity']",The Yale journal of biology and medicine,2017-03-31,"[{'lastname': 'DiChiara', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'DiNunno', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Clark', 'firstname': 'Jeffrey', 'initials': 'J', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Bu', 'firstname': 'Riana Lo', 'initials': 'RL', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Cline', 'firstname': 'Erika N', 'initials': 'EN', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Rollins', 'firstname': 'Madeline G', 'initials': 'MG', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Gong', 'firstname': 'Yuesong', 'initials': 'Y', 'affiliation': 'Department of Neurology, Drexel Medical School.'}, {'lastname': 'Brody', 'firstname': 'David L', 'initials': 'DL', 'affiliation': 'Department of Neurology, Washington University Medical School.'}, {'lastname': 'Sligar', 'firstname': 'Stephen G', 'initials': 'SG', 'affiliation': 'School of Molecular and Cell Biology, University of Illinois, Urbana-Champagne.'}, {'lastname': 'Velasco', 'firstname': 'Pauline T', 'initials': 'PT', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Viola', 'firstname': 'Kirsten L', 'initials': 'KL', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University.'}, {'lastname': 'Klein', 'firstname': 'William L', 'initials': 'WL', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts & Sciences, Northwestern University; Department of Neurology, Feinberg School of Medicine, Northwestern University.'}]",,,,,,<Element 'PubmedArticle' at 0x7f05dccd8360>
139,"28122877
20561356
17398120
23930978
17070709
21035623
22674585
24625061
23303049
18786637
25239737
26510952
19919576
24143816
21787322
26984188
25792098
26754172
20957767
21460840
20083042
22336816
23407992
24176981
24144733
23876085
20205644
19587325
21718498
26754641
24224195
12379913
23506036
16472958
22840559
18852055
26941262
17204713
11304087
25449529
22710659
23477989
26257642
22892349
23943781",An early and late peak in microglial activation in Alzheimer's disease trajectory.,"Amyloid-β deposition, neuroinflammation and tau tangle formation all play a significant role in Alzheimer's disease. We hypothesized that there is microglial activation early on in Alzheimer's disease trajectory, where in the initial phase, microglia may be trying to repair the damage, while later on in the disease these microglia could be ineffective and produce proinflammatory cytokines leading to progressive neuronal damage. In this longitudinal study, we have evaluated the temporal profile of microglial activation and its relationship between fibrillar amyloid load at baseline and follow-up in subjects with mild cognitive impairment, and this was compared with subjects with Alzheimer's disease. Thirty subjects (eight mild cognitive impairment, eight Alzheimer's disease and 14 controls) aged between 54 and 77 years underwent 11C-(R)PK11195, 11C-PIB positron emission tomography and magnetic resonance imaging scans. Patients were followed-up after 14 ± 4 months. Region of interest and Statistical Parametric Mapping analysis were used to determine longitudinal alterations. Single subject analysis was performed to evaluate the individualized pathological changes over time. Correlations between levels of microglial activation and amyloid deposition at a voxel level were assessed using Biological Parametric Mapping. We demonstrated that both baseline and follow-up microglial activation in the mild cognitive impairment cohort compared to controls were increased by 41% and 21%, respectively. There was a longitudinal reduction of 18% in microglial activation in mild cognitive impairment cohort over 14 months, which was associated with a mild elevation in fibrillar amyloid load. Cortical clusters of microglial activation and amyloid deposition spatially overlapped in the subjects with mild cognitive impairment. Baseline microglial activation was increased by 36% in Alzheimer's disease subjects compared with controls. Longitudinally, Alzheimer's disease subjects showed an increase in microglial activation. In conclusion, this is one of the first longitudinal positron emission tomography studies evaluating longitudinal changes in microglial activation in mild cognitive impairment and Alzheimer's disease subjects. We found there is an initial longitudinal reduction in microglial activation in subjects with mild cognitive impairment, while subjects with Alzheimer's disease showed an increase in microglial activation. This could reflect that activated microglia in mild cognitive impairment initially may adopt a protective activation phenotype, which later change to a cidal pro-inflammatory phenotype as disease progresses and amyloid clearance fails. Thus, we speculate that there might be two peaks of microglial activation in the Alzheimer's disease trajectory; an early protective peak and a later pro-inflammatory peak. If so, anti-microglial agents targeting the pro-inflammatory phenotype would be most beneficial in the later stages of the disease.","['Alzheimer’s disease', 'amyloid imaging', 'microglial activation', 'mild cognitive impairment', 'neuropathology']",Brain : a journal of neurology,2017-01-27,"[{'lastname': 'Fan', 'firstname': 'Zhen', 'initials': 'Z', 'affiliation': 'Neurology Imaging Unit, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.'}, {'lastname': 'Brooks', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Neurology Imaging Unit, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.\nDepartment of Nuclear Medicine, Institute of Medicine, Aarhus University, Denmark.'}, {'lastname': 'Okello', 'firstname': 'Aren', 'initials': 'A', 'affiliation': 'Neurology Imaging Unit, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.'}, {'lastname': 'Edison', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Neurology Imaging Unit, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.'}]",,,,"© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.",10.1093/brain/aww349,<Element 'PubmedArticle' at 0x7f05dcc8ea40>
140,"28004107
21504121
25673992
24490742
17430245
16402761
17605000
17222916
18835047
22836247
19001528
20589102
16534778
22642825
9714315
18562609
20386657
15590663
24260980
14645205
11337275
25164669
22490364
22160349
24096193
19915563
24480473
22738723
21224067
9830016
16472958
8866675
22566778
16259628
12845153
10696521
24973918
10858586
25662507
12679784
10531052
10655101
14687544
10684867
17021402
12507914
20388078",Humulus japonicus inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse model.,"Humulus japonicus Siebold & Zucc. (HJ) has traditionally been administered to patients with pulmonary disease, skin disease and hypertension in Korea, and it is considered to exert anti-inflammatory, antioxidant, antimicrobial and antimycobacterial effects. However, its effects against Alzheimer's disease (AD) have yet to be explored. Thus, this study was carried out to investigate whether HJ has a beneficial effect on the progression of AD in an animal model. A methanolic extract of HJ (500 mg/kg/day) was intragastrically administered to 5-month-old APP/PS1 transgenic (Tg-APP/PS1) mice for 2.5 months. Novel object recognition and Y-maze alteration tests were used to assess cognitive function, and an immunohistochemical assay was performed to assess amyloid β (Aβ)deposition, tau phosphorylation and gliosis. An in vitro assay using a microglial cell line was also performed to investigate the anti-inflammatory effects of HJ. Our results revealed that HJ significantly decreased the mRNA and protein expression levels of tumor necrosis factor-α (TNF‑α), interleukin (IL)-1β, IL-6 and inducible nitric oxide synthase (iNOS) induced by lipopolysaccharide in the microglial cell line. The administration of HJ for 2 months improved the cognitive function of Tg-APP/PS1 mice. HJ notably reduced the area occupied by Aβ and neurofibrillary tangles, and the number of activated astrocytes and microglia in the cortex of Tg-APP/PS1 mice. The findings of our study suggest that HJ has the therapeutic potential to inhibit the progression of AD and to improve cognitive deterioration in Tg-APP/PS1 mice.",[],International journal of molecular medicine,2016-12-23,"[{'lastname': 'Park', 'firstname': 'Tae-Shin', 'initials': 'TS', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Ryu', 'firstname': 'Young-Kyoung', 'initials': 'YK', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Park', 'firstname': 'Hye-Yeon', 'initials': 'HY', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Jae Yun', 'initials': 'JY', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Go', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Noh', 'firstname': 'Jung-Ran', 'initials': 'JR', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Yong-Hoon', 'initials': 'YH', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Hwang', 'firstname': 'Jung Hwan', 'initials': 'JH', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Choi', 'firstname': 'Dong-Hee', 'initials': 'DH', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Oh', 'firstname': 'Won-Keun', 'initials': 'WK', 'affiliation': 'Korea Bioactive Natural Material Bank, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea.'}, {'lastname': 'Lee', 'firstname': 'Chul-Ho', 'initials': 'CH', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Kyoung-Shim', 'initials': 'KS', 'affiliation': 'Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Republic of Korea.'}]",,,,,"10.3892/ijmm.2016.2804
10.1071/CH04026
10.2147/NDT.S75546
10.1186/1742-2094-11-25
10.2174/156720507780362254
10.1080/10401230500296428
10.1007/s00018-007-7218-4
10.1016/j.jneuroim.2006.11.017
10.1016/j.tips.2008.08.004
10.1523/JNEUROSCI.5268-11.2012
10.1096/fj.08-113795
10.1002/glia.20338
10.1186/1742-2094-9-106
10.1016/S0006-2952(98)00114-2
10.1523/JNEUROSCI.0364-08.2008
10.3390/ijms11020622
10.1074/jbc.M404751200
10.9799/ksfan.2012.25.2.357
10.1093/hmg/ddh019
10.1016/S1389-0344(01)00067-3
10.1523/JNEUROSCI.0864-14.2014
10.1016/j.bbr.2012.03.022
10.1007/s10339-011-0430-z
10.1016/j.physbeh.2013.09.012
10.1038/nn.2447
10.1016/j.brainres.2014.01.023
10.1016/j.neurobiolaging.2012.05.012
10.1016/j.ajpath.2010.11.012
10.1074/jbc.273.49.32730
10.1016/j.ijdevneu.2005.11.014
10.1016/0165-0173(95)00011-9
10.1186/1742-2094-2-24
10.1385/MN:27:3:325
10.1046/j.1440-1681.2000.03200.x
10.1038/nm.3639
10.1016/S0197-4580(00)00124-X
10.1016/j.neuroscience.2015.01.058
10.1038/ncb960
10.1126/science.286.5440.735
10.1038/77399
10.1016/S0896-6273(03)00787-6
10.1097/01.jnen.0000235853.70092.ba
10.1016/S0002-9440(10)63822-9
10.9721/KJFST.2014.46.1.94
10.2174/138161210790883769",<Element 'PubmedArticle' at 0x7f05dcc2d7c0>
141,"27979768
12859672
11837744
15044677
19735725
23740819
20920788
26638867
23562431
7708769
24161403
17656824
26696824
27248001
19560105
18974297
22336816
16192374
24162737
20846376
12629164
25217135
19808651
18374906
26891690
26711676
20471138
19001528
12895417
26662122
16715377
21722209
16020737
26938442
21777559
21531375
25161013
18458226
25227314
22397366",A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease.,"Alzheimer's disease (AD), the predominant form of dementia, is highly correlated with the abnormal hyperphosphorylation and aggregation of tau. Immune responses are key drivers of AD and how they contribute to tau pathology in human disease remains largely unknown. This review summarises current knowledge on the association between inflammatory processes and tau pathology. While, preclinical evidence suggests that inflammation can indeed induce tau hyperphosphorylation at both pre- and post-tangles epitopes, a better understanding of whether this develops into advanced pathological features such as neurofibrillary tangles is needed. Microglial cells, the immune phagocytes in the central nervous system, appear to play a key role in regulating tau pathology, but the underlying mechanisms are not fully understood. Their activation can be detrimental via the secretion of pro-inflammatory mediators, particularly interleukin-1β, but also potentially beneficial through phagocytosis of extracellular toxic tau oligomers. Nevertheless, anti-inflammatory treatments in animal models were found protective, but whether or not they affect microglial phagocytosis of tau species is unknown. However, one major challenge to our understanding of the role of inflammation in the progression of tau pathology is the preclinical models used to address this question. They mostly rely on the use of septic doses of lipopolysaccharide that do not reflect the inflammatory conditions experienced AD patients, questioning whether the impact of inflammation on tau pathology in these models is dose-dependent and relevant to the human disease. The use of more translational models of inflammation corroborated with verification in clinical investigations are necessary to progress our understanding of the interplay between inflammation and tau pathology.","[""Alzheimer's disease"", 'Inflammation', 'Lipopolysaccharide', 'Phosphorylation', 'Preclinical models', 'Tau']",Experimental gerontology,2016-12-17,"[{'lastname': 'Barron', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'School of Life sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, UK.'}, {'lastname': 'Gartlon', 'firstname': 'Jane', 'initials': 'J', 'affiliation': 'Eisai Inc., 4 Corporate Drive, Andover, MA 01810, USA.'}, {'lastname': 'Dawson', 'firstname': 'Lee A', 'initials': 'LA', 'affiliation': 'Astex Pharmaceuticals, 436 Cambridge Science Park Rd, Cambridge CB4 0QA, UK.'}, {'lastname': 'Atkinson', 'firstname': 'Peter J', 'initials': 'PJ', 'affiliation': 'Eisai Ltd., EMEA Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.'}, {'lastname': 'Pardon', 'firstname': 'Marie-Christine', 'initials': 'MC', 'affiliation': 'School of Life sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, UK. Electronic address: marie.pardon@nottingham.ac.uk.'}]",,,,Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.exger.2016.12.006,<Element 'PubmedArticle' at 0x7f05dcc5a4a0>
142,27692981,The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease.,"While a number of endogenous risk factors including age and genetics are established for Alzheimer's disease (AD), identification of acquired, potentially preventable or treatable causes, remains limited. In this paper, we review three epidemiologic case studies and present extensive biologic, immunologic and anatomic evidence to support a novel hypothesis that Bordetella pertussis (BP), the bacterium better known to cause whooping cough, is an important potential cause of AD. Cross-cultural documentation of nasopharyngeal subclinical BP colonization reflecting BP-specific mucosal immunodeficiency, proximate anatomy of intranasal mucosal surfaces to central nervous system (CNS) olfactory pathways, and mechanisms by which BP and BP toxin account for all hallmark pathology of AD are reviewed, substantiating biologic plausibility. Notably, respiratory BP infection and BP toxin secreted from subclinical BP colonization can account for the initiation and accumulation of amyloid β plaques and tau tangles. Additional mechanisms consistent with the immunobiologic effects of subclinical BP colonization include microglial activation and inflammation, atrophy and neurodegeneration, excitotoxicity, distinctive anatomic distribution and sequential spread of disease, impaired glucose utilization, and other characteristic CNS pathology of AD. We conclude by assessing the evidence for causation against the Bradford Hill criteria, and advocate for further investigation into the potential role of BP in the etiology of AD.","['Alzheimer’s disease', 'Asymptomatic infections', 'Bordetella pertussis', 'Etiology', 'Pertussis toxin']",Immunobiology,2016-10-04,"[{'lastname': 'Rubin', 'firstname': 'Keith', 'initials': 'K', 'affiliation': 'ILiAD Biotechnologies, 230 East 15th Street, Suite 1-A, New York, NY 10003, United States. Electronic address: keith@iliadbio.com.'}, {'lastname': 'Glazer', 'firstname': 'Steven', 'initials': 'S', 'affiliation': 'ILiAD Biotechnologies, 230 East 15th Street, Suite 1-A, New York, NY 10003, United States. Electronic address: glazer@iliadbio.com.'}]",,,,Copyright © 2016 The Author(s). Published by Elsevier GmbH.. All rights reserved.,10.1016/j.imbio.2016.09.017,<Element 'PubmedArticle' at 0x7f05dcbf6ae0>
143,"27566602
16481071
22531422
25307057
20630619
21881209
25446622
24398425
21460840
22618995
22086139
23524002
15748782
19910078
22869717
25351914
23547147
23710760
23948903
25084549
25337333
25602247
26897365
16906128
9254694
16218944
23814667
22545122
26319560
26657517
11395399
3084478
21738590
20413866
23618870
18376983
19685013
22545812
10413512
15160315
10841784
16595673
15668252
24273049
25576082
24360504
10619481
12675155
25202238
23995563
25817252
19409206
23174209
25659859
23405115
12558980
21234330
25505567
25500888
11524148",Revisiting rodent models: Octodon degus as Alzheimer's disease model?,"Alzheimer's disease primarily occurs as sporadic disease and is accompanied with vast socio-economic problems. The mandatory basic research relies on robust and reliable disease models to overcome increasing incidence and emerging social challenges. Rodent models are most efficient, versatile, and predominantly used in research. However, only highly artificial and mostly genetically modified models are available. As these 'engineered' models reproduce only isolated features, researchers demand more suitable models of sporadic neurodegenerative diseases. One very promising animal model was the South American rodent Octodon degus, which was repeatedly described as natural 'sporadic Alzheimer's disease model' with 'Alzheimer's disease-like neuropathology'. To unveil advantages over the 'artificial' mouse models, we re-evaluated the age-dependent, neurohistological changes in young and aged Octodon degus (1 to 5-years-old) bred in a wild-type colony in Germany. In our hands, extensive neuropathological analyses of young and aged animals revealed normal age-related cortical changes without obvious signs for extensive degeneration as seen in patients with dementia. Neither significant neuronal loss nor enhanced microglial activation were observed in aged animals. Silver impregnation methods, conventional, and immunohistological stains as well as biochemical fractionations revealed neither amyloid accumulation nor tangle formation. Phosphoepitope-specific antibodies against tau species displayed similar intraneuronal reactivity in both, young and aged Octodon degus.In contrast to previous results, our study suggests that Octodon degus born and bred in captivity do not inevitably develop cortical amyloidosis, tangle formation or neuronal loss as seen in Alzheimer's disease patients or transgenic disease models.","['Alzheimer’s disease', 'Amyloid beta-Peptides', 'Animal models', 'Neurodegenerative diseases', 'Neuropathology', 'Octodon degus', 'Rodentia', 'Tau proteins']",Acta neuropathologica communications,2016-08-28,"[{'lastname': 'Steffen', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'University of Lübeck (UzL), LIED, Lübeck, Germany.'}, {'lastname': 'Krohn', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neuro-/Pathology, University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo, Norway.'}, {'lastname': 'Paarmann', 'firstname': 'Kristin', 'initials': 'K', 'affiliation': 'University of Lübeck (UzL), LIED, Lübeck, Germany.\nDepartment of Neuro-/Pathology, University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo, Norway.\nLeibniz Institute for Plant Biochemistry (IPB), Halle, Germany.'}, {'lastname': 'Schwitlick', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'University of Lübeck (UzL), LIED, Lübeck, Germany.\nDepartment of Neuro-/Pathology, University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo, Norway.'}, {'lastname': 'Brüning', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Neuro-/Pathology, University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo, Norway.'}, {'lastname': 'Marreiros', 'firstname': 'Rita', 'initials': 'R', 'affiliation': 'Department of Neuropathology, Heinrich Heine University Düsseldorf (HHU), Düsseldorf, Germany.'}, {'lastname': 'Müller-Schiffmann', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Department of Neuropathology, Heinrich Heine University Düsseldorf (HHU), Düsseldorf, Germany.'}, {'lastname': 'Korth', 'firstname': 'Carsten', 'initials': 'C', 'affiliation': 'Department of Neuropathology, Heinrich Heine University Düsseldorf (HHU), Düsseldorf, Germany.'}, {'lastname': 'Braun', 'firstname': 'Katharina', 'initials': 'K', 'affiliation': 'Department of Zoology/Developmental Neurobiology, Otto von Guericke University Magdeburg (OvGU), Magdeburg, Germany.'}, {'lastname': 'Pahnke', 'firstname': 'Jens', 'initials': 'J', 'affiliation': 'University of Lübeck (UzL), LIED, Lübeck, Germany. jens.pahnke@medisin.uio.no.\nDepartment of Neuro-/Pathology, University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo, Norway. jens.pahnke@medisin.uio.no.\nLeibniz Institute for Plant Biochemistry (IPB), Halle, Germany. jens.pahnke@medisin.uio.no.\nDepartment of Pathology (PAT), Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo, Postboks 4950, Nydalen, 0424, Oslo, Norway. jens.pahnke@medisin.uio.no.'}]",,,,,"10.1186/s40478-016-0363-y
10.1016/j.neurobiolaging.2005.04.017
10.1038/nature13800
10.1016/j.neurobiolaging.2010.05.025
10.1172/JCI57867
10.1016/j.arcmed.2014.10.010
10.1016/j.bcp.2013.12.024
10.1038/ng.803
10.1007/s00401-012-0996-2
10.1007/s00702-011-0731-5
10.1016/j.ygcen.2013.02.044
10.1016/j.neurobiolaging.2004.09.016
10.1016/j.neurobiolaging.2009.10.008
10.1073/pnas.1201209109
10.1111/bpa.12226
10.1101/pdb.emo071357
10.1111/cns.12125
10.1016/j.pneurobio.2014.07.004
10.1186/s40659-016-0074-7
10.1038/sj.embor.7400784
10.1093/nar/25.17.3389
10.1111/j.1742-4658.2005.04945.x
10.1556/EuJMI.3.2013.1.3
10.1371/journal.pone.0035613
10.1007/s12035-015-9399-4
10.1093/brain/awv355
10.1016/S0002-9440(10)64693-7
10.1371/journal.pone.0020878
10.1016/j.neurobiolaging.2013.03.032
10.1063/1.2890033
10.1007/s12031-009-9282-8
10.1021/bi300275g
10.1021/bi990205o
10.1007/s00775-004-0556-x
10.1021/bi0002479
10.1074/jbc.M600417200
10.1074/jbc.M414178200
10.1002/jnr.23320
10.1016/j.neurobiolaging.2014.12.004
10.1016/j.neurobiolaging.2013.11.020
10.1016/S0306-4522(99)00390-5
10.1023/A:1022850113083
10.1007/s00221-013-3667-1
10.2174/1567205012666150324181652
10.1016/j.neuroscience.2009.02.008
10.1016/j.bbr.2012.10.060
10.1016/j.neurobiolaging.2015.01.004
10.1371/journal.pone.0055091
10.1046/j.1471-4159.2003.01556.x
10.1155/2011/617974
10.1002/prp2.12
10.1172/JCI66771
10.1016/S0304-3940(01)02076-6",<Element 'PubmedArticle' at 0x7f05dcc04450>
144,"27339073
10858586
19628305
11245811
26436904
24818261
2229411
21569847
22286176
24439484
20920788
26847266
17180163
17168643
11786218
23708142
1735956
23197725
24440055
25619653
11160388
15895084
23316765
17656824
11520988
23623698
9458167
23150934
25619654
12130773
1566067
19734902
9507169
20632195
24076100
9518610
12379903
9130141
16192374
16148231
15833363
24162737
25213090
24780254
7890333
15266782
11520987
21143158
12629164
12490568
24012002
25217135
2969441
26884167
7715705
23948931
11481032
12186424
12553488
11826115
17021169
12895417
20096353
20234358
19321417
25853174
16125396
11578768
12379913
9341931
23747045
16877359
2104886
17549256
24604080
22715882
10600748
16377636
2949367
24830807
24893973
12572918
15485483
17270732
20542579
23622250
23111107
19232747
10652441",Increased tauopathy drives microglia-mediated clearance of beta-amyloid.,"Alzheimer disease is characterized by the accumulation of β-amyloid (Aβ) plaques and tau-laden neurofibrillary tangles. Emerging studies suggest that in neurodegenerative diseases, aggregation of one protein species can promote other proteinopathies and that inflammation plays an important role in this process. To study the interplay between Aβ deposition, tau pathology, and microgliosis, we established a new AD transgenic mouse model by crossing 5xfAD mice with Thy-Tau22 transgenic mice. The resulting 'T5x' mice exhibit a greater than three-fold increase in misfolded and hyperphosphorylated tau and further substantiates the hypothesis that Aβ accelerates tau pathology. Surprisingly, T5x mice exhibit a 40-50 % reduction in Aβ plaque load and insoluble Aβ species when compared with aged-matched 5xfAD littermates. T5x mice exhibit significant changes in cytokine production, an almost doubling of microglial number, and a dramatic shift in microglia activation state. Furthermore, T5x microglia exhibit increased phagocytic capacity that enhances the clearance of insoluble Aβ and decreasing plaque load. Therefore, our results suggest that strategies to increase the phagocytic ability of microglia can be employed to reduce Aβ and that tau-induced changes in microglial activation state can promote the clearance of Aβ.","['Amyloid', 'Aβ', 'Cytokines', 'Mice', 'Microglia', 'Pathology', 'Phagocytosis', 'Tau']",Acta neuropathologica communications,2016-06-25,"[{'lastname': 'Chen', 'firstname': 'Wesley', 'initials': 'W', 'affiliation': 'Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA, 92697, USA.\nSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, 92697, USA.'}, {'lastname': 'Abud', 'firstname': 'Edsel A', 'initials': 'EA', 'affiliation': 'Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA, 92697, USA.\nSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, 92697, USA.'}, {'lastname': 'Yeung', 'firstname': 'Stephen T', 'initials': 'ST', 'affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California Irvine, 845 Health Science Rd, 3200 Gross Hall, Irvine, CA, 92697, USA.\nPresent Address: Department of Immunology, University of Connecticut School of Medicine, Farmington, CT, 06030, USA.'}, {'lastname': 'Lakatos', 'firstname': 'Anita', 'initials': 'A', 'affiliation': 'Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA, 92697, USA.\nInstitute for Memory Impairments and Neurological Disorders, University of California Irvine, 845 Health Science Rd, 3200 Gross Hall, Irvine, CA, 92697, USA.'}, {'lastname': 'Nassi', 'firstname': 'Trevor', 'initials': 'T', 'affiliation': 'Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA, 92697, USA.'}, {'lastname': 'Wang', 'firstname': 'Jane', 'initials': 'J', 'affiliation': 'Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA, 92697, USA.'}, {'lastname': 'Blum', 'firstname': 'David', 'initials': 'D', 'affiliation': 'University Lille, Inserm, CHU-Lille, UMR-S 1172, Alzheimer & Tauopathies, Lille, France.'}, {'lastname': 'Buée', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'University Lille, Inserm, CHU-Lille, UMR-S 1172, Alzheimer & Tauopathies, Lille, France.'}, {'lastname': 'Poon', 'firstname': 'Wayne W', 'initials': 'WW', 'affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California Irvine, 845 Health Science Rd, 3200 Gross Hall, Irvine, CA, 92697, USA.'}, {'lastname': 'Blurton-Jones', 'firstname': 'Mathew', 'initials': 'M', 'affiliation': 'Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA, 92697, USA. mblurton@uci.edu.\nSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, 92697, USA. mblurton@uci.edu.\nInstitute for Memory Impairments and Neurological Disorders, University of California Irvine, 845 Health Science Rd, 3200 Gross Hall, Irvine, CA, 92697, USA. mblurton@uci.edu.'}]",,,,,"10.1186/s40478-016-0336-1
10.1016/S0197-4580(00)00124-X
10.1016/j.neurobiolaging.2009.06.005
10.1016/S0006-8993(00)03176-0
10.1016/j.jalz.2014.02.001
10.1016/0165-5728(90)90108-Y
10.1016/j.nbd.2011.04.022
10.1038/nn.3028
10.1016/j.neurobiolaging.2013.12.010
10.1016/j.neuron.2010.08.023
10.1038/nrn2038
10.2174/156720506779025242
10.1016/S0304-3940(01)02461-2
10.1523/JNEUROSCI.0172-12.2012
10.1016/j.nbd.2014.01.007
10.1016/j.neuron.2014.11.020
10.1038/nn1472
10.1186/1750-1326-8-2
10.1126/science.1062097
10.1016/j.neuron.2013.04.014
10.1111/j.1750-3639.1998.tb00136.x
10.1056/NEJMoa1211851
10.1016/j.neuron.2014.12.068
10.1126/science.1072994
10.1126/science.1566067
10.1038/ng.440
10.1016/S0006-8993(97)01215-8
10.1007/s00702-010-0438-z
10.1016/j.nbd.2013.09.010
10.1016/S0006-8993(97)01318-8
10.1002/glia.10150
10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E
10.1523/JNEUROSCI.2868-05.2005
10.1523/JNEUROSCI.1808-05.2005
10.1016/j.jneuroim.2005.01.015
10.1038/ng.2802
10.1186/1750-1326-9-33
10.1016/j.neurobiolaging.2014.03.027
10.1002/glia.440120407
10.1126/science.1058189
10.2174/156720511794604543
10.1124/jpet.102.035048
10.1016/j.neuron.2013.06.046
10.1186/s12974-014-0161-z
10.1016/0047-6374(88)90041-3
10.1073/pnas.1525466113
10.1038/374647a0
10.1093/oxfordjournals.jbchem.a002969
10.1248/bpb.25.945
10.1080/078538902321117698
10.1523/JNEUROSCI.1202-06.2006
10.1016/S0896-6273(03)00434-3
10.1016/j.cellsig.2010.01.010
10.1038/nrneurol.2010.17
10.1073/pnas.0901229106
10.1186/s40478-015-0199-x
10.1016/j.nbd.2005.05.027
10.1016/S0197-0186(01)00040-7
10.1002/glia.10153
10.1007/s004010050713
10.1016/j.neurobiolaging.2013.05.003
10.2353/ajpath.2006.060002
10.1172/JCI31450
10.1096/fj.13-246702
10.1146/annurev-neuro-061010-113810
10.1126/science.286.5448.2352
10.1074/jbc.M509145200
10.1126/science.2949367
10.1371/journal.pone.0097096
10.1186/1750-1326-9-20
10.1111/j.1471-4159.2004.02737.x
10.1016/j.neuron.2007.01.010
10.1016/j.tins.2010.05.004
10.1016/j.cell.2013.03.030
10.1186/1742-2094-9-247
10.1016/j.jneuroim.2009.01.013
10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V",<Element 'PubmedArticle' at 0x7f05dcbb13b0>
145,"27144524
24462903
26582973
26412218
27084356
1759558
24368087
9255065
25151388
25688919
23054683
25711455
25774009
15755686
23312015
1693468
19359244
9512407
11771751
17389683
17935993
11783716
26611261
12850546
26772638
20395292
19110058
19096009
22188425
24887203
18987198
25407337
20561519
23962087
21876254
26517091
24554308
12110446
11090612
20332016
15013227
11404397
10196463
23297063
10341237
14552880
24141019
25061569
19193879
23497056
24529528
12815703
25756590
23028621
20934487
17314675
19406203
22209051
15212842
18039691
21955146
17623646
15858219
25820729
18212344
25515237
24727771
25807253
22649059
25178396
4107507
4064076
17046655",An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model.,"The aim of this study was to elucidate the molecular signature of Alzheimer's disease-associated amyloid pathology.We used the double APPswe/PS1ΔE9 mouse, a widely used model of cerebral amyloidosis, to compare changes in proteome, including global phosphorylation and sialylated N-linked glycosylation patterns, pathway-focused transcriptome and neurological disease-associated miRNAome with age-matched controls in neocortex, hippocampus, olfactory bulb and brainstem. We report that signalling pathways related to synaptic functions associated with dendritic spine morphology, neurite outgrowth, long-term potentiation, CREB signalling and cytoskeletal dynamics were altered in 12 month old APPswe/PS1ΔE9 mice, particularly in the neocortex and olfactory bulb. This was associated with cerebral amyloidosis as well as formation of argyrophilic tangle-like structures and microglial clustering in all brain regions, except for brainstem. These responses may be epigenetically modulated by the interaction with a number of miRNAs regulating spine restructuring, Aβ expression and neuroinflammation.We suggest that these changes could be associated with development of cognitive dysfunction in early disease states in patients with Alzheimer's disease.","['Pathology Section', 'miRNA', 'neuroinflammation', 'proteomics', 'synapse', 'tau protein']",Oncotarget,2016-05-05,"[{'lastname': 'Kempf', 'firstname': 'Stefan J', 'initials': 'SJ', 'affiliation': 'Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark.'}, {'lastname': 'Metaxas', 'firstname': 'Athanasios', 'initials': 'A', 'affiliation': 'Institute of Molecular Medicine, University of Southern Denmark, Odense C, Denmark.'}, {'lastname': 'Ibáñez-Vea', 'firstname': 'María', 'initials': 'M', 'affiliation': 'Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark.'}, {'lastname': 'Darvesh', 'firstname': 'Sultan', 'initials': 'S', 'affiliation': 'Department of Medical Neuroscience, Dalhousie University, Halifax, NS, Canada.\nDepartment of Medicine (Neurology and Geriatric Medicine), Dalhousie University, Halifax, NS, Canada.'}, {'lastname': 'Finsen', 'firstname': 'Bente', 'initials': 'B', 'affiliation': 'Institute of Molecular Medicine, University of Southern Denmark, Odense C, Denmark.'}, {'lastname': 'Larsen', 'firstname': 'Martin R', 'initials': 'MR', 'affiliation': 'Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark.'}]",,,,,"10.18632/oncotarget.9092
10.18632/oncotarget.6254",<Element 'PubmedArticle' at 0x7f05dcb72270>
146,"26939023
25024750
24353405
25702360
25621019
25734590
24962891
23390181
21959585
20610346
15096334
20431570
14709552
20697724
19633196
22083255
20519526
22042871
19198615
24533803
23795307
26176331
25727952
24934355
23674053
25047000
11005546
24068826
21358740
3588941
15974914
8965648
18289037
23348013
24440408
24172866
20479525
25496439
25492116
23791683
22301160
21763720
21356235
20157238
24861941
24681396
24245248
22978318
24735640
19889988
3294053
24057103
15115815
10899941
8381903
7519761
11422214
16280414
1697263
15863029
10799753
11102578
2403357
9125385
10521575
22193058
20528078
23026373
19100261
25205959
25457554
11304894
8918827
10704499
12791257
15863038
20175207
15337521
15662836
15525346
22363206
16784819
17223274
16197499
15189333
17375985
18573344
15766712
9390770
11528012
21871956
20413847
20673847
17302992
11335065
15569259
12421370
24609976
17545746
11752056
22532442
25914873
11381127
14643377
16282321
24150104
23036017
15748844
20934413
17659878
18486110
23523959
25154625
24636461
24024604
23575981
24525328
25575647
21948060
21476939
20017031
21943025
16125823
20361010
12409305
19278841
17989287
11035810
20308788
16519508
11086171","BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR.","An enormous amount of efforts have been poured to find an effective therapeutic agent for the treatment of neurodegenerative diseases including Alzheimer's disease (AD). Among those, neurotrophic peptides that regenerate neuronal structures and increase neuron survival show a promise in slowing neurodegeneration. However, the short plasma half-life and poor blood-brain-barrier (BBB)-permeability of neurotrophic peptides limit their in vivo efficacy. Thus, an alternative neurotrophic agent that has longer plasma half-life and better BBB-permeability has been sought for. Based on the recent findings of neuroprotective polysaccharides, we searched for a BBB-permeable neuroprotective polysaccharide among natural polysaccharides that are approved for human use. Then, we discovered midi-GAGR, a BBB-permeable, long plasma half-life, strong neuroprotective and neurotrophic polysaccharide. Midi-GAGR is a 4.7kD cleavage product of low acyl gellan gum that is approved by FDA for human use. Midi-GAGR protected rodent cortical neurons not only from the pathological concentrations of co-/post-treated free reactive radicals and Aβ42 peptide but also from activated microglial cells. Moreover, midi-GAGR showed a good neurotrophic effect; it enhanced neurite outgrowth and increased phosphorylated cAMP-responsive element binding protein (pCREB) in the nuclei of primary cortical neurons. Furthermore, intra-nasally administered midi-GAGR penetrated the BBB and exerted its neurotrophic effect inside the brain for 24 h after one-time administration. Midi-GAGR appears to activate fibroblast growth factor receptor 1 (FGFR1) and its downstream neurotrophic signaling pathway for neuroprotection and CREB activation. Additionally, 14-day intranasal administration of midi-GAGR not only increased neuronal activity markers but also decreased hyperphosphorylated tau, a precursor of neurofibrillary tangle, in the brains of the AD mouse model, 3xTg-AD. Taken together, midi-GAGR with good BBB-permeability, long plasma half-life, and strong neuroprotective and neurotrophic effects has a great therapeutic potential for the treatment of neurodegenerative diseases, especially AD.",[],PloS one,2016-03-05,"[{'lastname': 'Makani', 'firstname': 'Vishruti', 'initials': 'V', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Jang', 'firstname': 'Yong-Gil', 'initials': 'YG', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Christopher', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Judy', 'firstname': 'Wesley', 'initials': 'W', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Eckstein', 'firstname': 'Jacob', 'initials': 'J', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Hensley', 'firstname': 'Kenneth', 'initials': 'K', 'affiliation': 'Department of Pathology, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Chiaia', 'firstname': 'Nicolas', 'initials': 'N', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Kim', 'firstname': 'Dong-Shik', 'initials': 'DS', 'affiliation': 'Department of Chemical Engineering, College of Engineering, University of Toledo, Toledo, Ohio, United States of America.'}, {'lastname': 'Park', 'firstname': 'Joshua', 'initials': 'J', 'affiliation': 'Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America.'}]",,,,,"10.1371/journal.pone.0149715
10.1186/alzrt269
10.2147/DDDT.S41431
10.1186/s13195-014-0089-7
10.1002/14651858.CD009444.pub3
10.1517/14740338.2014.931369
10.1212/WNL.0b013e31828726f5
10.1007/s00401-011-0878-z
10.1016/S1474-4422(10)70119-8
10.1038/nrd2896
10.1074/jbc.M311652200
10.1007/s00401-010-0734-6
10.1073/pnas.0901402106
10.1007/s00401-011-0908-x
10.1523/JNEUROSCI.4182-09.2010
10.1073/pnas.1102349108
10.1038/nm.1912
10.1089/hum.2015.065
10.1016/j.jphs.2014.12.015
10.1038/nrn3505
10.1186/1471-2202-15-90
10.1523/JNEUROSCI.5195-12.2013
10.1038/nrd3366
10.1016/j.pharmthera.2013.01.004
10.1016/j.nbd.2014.01.009
10.1038/mt.2013.260
10.3233/RNN-2010-0528
10.3109/03639045.2014.991400
10.1038/jcbfm.2014.220
10.1016/j.ejpb.2013.06.005
10.1016/j.ijbiomac.2011.06.031
10.1016/j.ijbiomac.2011.02.011
10.3233/JAD-2010-1280
10.1016/j.ijpharm.2014.05.038
10.1016/j.ejpb.2014.03.010
10.1111/j.1365-2125.2012.04460.x
10.1016/j.jconrel.2014.04.010
10.1523/JNEUROSCI.4246-09.2009
10.1080/02652038809373701
10.1007/s11481-013-9501-5
10.1523/JNEUROSCI.0436-04.2004
10.1016/j.cytogfr.2005.01.008
10.1016/j.ijpharm.2011.12.008
10.1016/j.ejphar.2012.09.020
10.1016/j.expneurol.2008.11.011
10.1016/j.neurobiolaging.2014.10.004
10.1006/mcne.1996.0049
10.1016/j.cytogfr.2005.01.007
10.1002/jnr.22374
10.1016/j.cellsig.2004.05.001
10.1111/j.1471-4159.2004.02779.x
10.1371/journal.pbio.1001262
10.1016/j.neuroscience.2006.04.059
10.1111/j.1460-9568.2005.04345.x
10.1111/j.1471-4159.2004.02422.x
10.1016/j.mcn.2008.05.016
10.1016/j.ab.2004.12.001
10.1016/j.bbadis.2011.08.005
10.3233/JAD-2010-100504
10.1016/j.freeradbiomed.2010.07.015
10.1111/j.1745-7254.2007.00512.x
10.1111/j.1471-4159.2004.02805.x
10.1007/s11481-014-9533-5
10.1096/fj.11-203042
10.1073/pnas.121119298
10.1074/jbc.M507892200
10.3233/JAD-130680
10.1016/j.neuron.2005.01.040
10.1016/j.nbd.2007.06.013
10.1016/j.brainres.2008.03.079
10.1016/j.bbr.2013.03.021
10.1111/epi.12755
10.1016/j.euroneuro.2014.02.001
10.1111/head.12181
10.1007/s40272-013-0019-3
10.1016/j.jneumeth.2014.02.001
10.1007/s13311-014-0327-5
10.1007/s12035-011-8209-x
10.1515/RNS.2011.018
10.1007/978-1-4419-1170-4_20
10.1186/alzrt90
10.1016/j.neurobiolaging.2005.07.003
10.2217/BMM.09.83
10.1074/jbc.M206236200
10.1016/j.pathophys.2009.02.008
10.1523/JNEUROSCI.3321-07.2007
10.1073/pnas.220413597
10.3233/JAD-2010-1317
10.1021/bi051635j",<Element 'PubmedArticle' at 0x7f05dcb94db0>
147,26923011,"Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.","Recent epidemiological evidence suggests that diabetes mellitus (DM) is a risk factor for Alzheimer's disease (AD). One of the pathological hallmarks of AD is hyperphosphorylated tau protein, which forms neurofibrillary tangles. Oxidative stress and the activation of inflammatory pathways are features that are associated with both DM and AD. However, the brain region specificity of AD-related neurodegeneration, which mainly occurs in the hippocampus while the cerebellum is relatively unaffected, has not yet been clarified. Therefore, we used experimental DM mice (caused by an intraperitoneal injection of streptozotocin [STZ]) to determine whether these neurodegeneration-associated mechanisms were associated with region-specific selective vulnerability or tau phosphorylation. The hippocampus, midbrain, and cerebellum of aged (14 to 18 months old) non-transgenic (NTg) and transgenic mice overexpressing wild-type human tau (Tg601 mice) were evaluated after a treatment with STZ. The STZ injection increased reactive oxygen species, lipid peroxidation markers such as 4-hydroxynonenal and malondialdehyde in the hippocampus, but not in the midbrain or cerebellum. The STZ treatment also increased the number of Iba-1-positive and CD68-positive microglial cells, astrocytes, and IL-1β, IL-6, IL-10, and IL-18 levels in the hippocampus, but not in the midbrain or cerebellum. Tau hyperphosphorylation was also enhanced in the hippocampus, but not in the midbrain or cerebellum. When the effects of STZ were compared between Tg601 and NTg mice, microglial proliferation and elevations in IL-6 and phosphorylated tau were higher in Tg601 mice. These results suggest that neuroinflammation and oxidative stress in STZ-treated mice are associated with tau hyperphosphorylation, which may contribute to selective neurodegeneration in human AD.","['Alzheimer’s disease', 'cytokines', 'diabetes mellitus', 'microglia', 'neuroinflammation', 'oxidative stress', 'tauopathy']",Journal of Alzheimer's disease : JAD,2016-03-01,"[{'lastname': 'Elahi', 'firstname': 'Montasir', 'initials': 'M', 'affiliation': 'Sportology Center, Juntendo University Graduate of Medicine, Tokyo, Japan.\nDepartment of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate of Medicine, Tokyo, Japan.'}, {'lastname': 'Hasan', 'firstname': 'Zafrul', 'initials': 'Z', 'affiliation': 'Sportology Center, Juntendo University Graduate of Medicine, Tokyo, Japan.'}, {'lastname': 'Motoi', 'firstname': 'Yumiko', 'initials': 'Y', 'affiliation': 'Sportology Center, Juntendo University Graduate of Medicine, Tokyo, Japan.\nDepartment of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate of Medicine, Tokyo, Japan.\nDepartment of Neurology, Juntendo University Graduate of Medicine, Tokyo, Japan.'}, {'lastname': 'Matsumoto', 'firstname': 'Shin-Ei', 'initials': 'SE', 'affiliation': 'Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate of Medicine, Tokyo, Japan.\nDepartment of Neurology, Juntendo University Graduate of Medicine, Tokyo, Japan.'}, {'lastname': 'Ishiguro', 'firstname': 'Koichi', 'initials': 'K', 'affiliation': 'Department of Neurology, Juntendo University Graduate of Medicine, Tokyo, Japan.'}, {'lastname': 'Hattori', 'firstname': 'Nobutaka', 'initials': 'N', 'affiliation': 'Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate of Medicine, Tokyo, Japan.\nDepartment of Neurology, Juntendo University Graduate of Medicine, Tokyo, Japan.'}]",,,,,10.3233/JAD-150820,<Element 'PubmedArticle' at 0x7f05dcb5f860>
148,"26921617
10713108
10850730
23589030
26436904
5706753
19151372
23708142
24055684
24316888
15270199
11513911
19295150
25619653
23399914
22923495
25630253
22294205
25620736
23454195
23417057
26232154
11440311
11755009
2456021
17111375
23316765
25849463
24742461
1745413
20305648
22632257
23392676
19838177
21357119
23150934
25619654
12359175
9225377
16279840
20619937
25732305
25485684
25878270
24583793
23467355
22095718
16192374
20371618
26297559
16148231
19734903
25761889
10987824
2251906
10526088
7715705
24443964
24247719
25184527
21460841
21414900
17021169
21718498
20555131
4985058
24056773
24268883
26156998
25012223
23747512
2874657
16289476
26299968
20460622
17549256
17717139
24218450
26222558
25497089
19339593
25728668
10683279
10918055
23197723
20157291",Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology.,"In addition to amyloid-β plaque and tau neurofibrillary tangle deposition, neuroinflammation is considered a key feature of Alzheimer's disease pathology. Inflammation in Alzheimer's disease is characterized by the presence of reactive astrocytes and activated microglia surrounding amyloid plaques, implicating their role in disease pathogenesis. Microglia in the healthy adult mouse depend on colony-stimulating factor 1 receptor (CSF1R) signalling for survival, and pharmacological inhibition of this receptor results in rapid elimination of nearly all of the microglia in the central nervous system. In this study, we set out to determine if chronically activated microglia in the Alzheimer's disease brain are also dependent on CSF1R signalling, and if so, how these cells contribute to disease pathogenesis. Ten-month-old 5xfAD mice were treated with a selective CSF1R inhibitor for 1 month, resulting in the elimination of ∼80% of microglia. Chronic microglial elimination does not alter amyloid-β levels or plaque load; however, it does rescue dendritic spine loss and prevent neuronal loss in 5xfAD mice, as well as reduce overall neuroinflammation. Importantly, behavioural testing revealed improvements in contextual memory. Collectively, these results demonstrate that microglia contribute to neuronal loss, as well as memory impairments in 5xfAD mice, but do not mediate or protect from amyloid pathology.","['Alzheimer’s disease', 'amyloid', 'cognition', 'inflammation', 'microglia']",Brain : a journal of neurology,2016-02-28,"[{'lastname': 'Spangenberg', 'firstname': 'Elizabeth E', 'initials': 'EE', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA.'}, {'lastname': 'Lee', 'firstname': 'Rafael J', 'initials': 'RJ', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA.'}, {'lastname': 'Najafi', 'firstname': 'Allison R', 'initials': 'AR', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA.'}, {'lastname': 'Rice', 'firstname': 'Rachel A', 'initials': 'RA', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA.'}, {'lastname': 'Elmore', 'firstname': 'Monica R P', 'initials': 'MR', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA.'}, {'lastname': 'Blurton-Jones', 'firstname': 'Mathew', 'initials': 'M', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA.'}, {'lastname': 'West', 'firstname': 'Brian L', 'initials': 'BL', 'affiliation': 'Plexxikon Inc., Berkeley, California, 94710, USA.'}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': 'Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697-4545, USA kngreen@uci.edu.'}]",,,,"© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.",10.1093/brain/aww016,<Element 'PubmedArticle' at 0x7f05dcaee770>
149,26854967,TREM2 Function in Alzheimer's Disease and Neurodegeneration.,"Alzheimer's disease (AD), the most common cause of dementia in the elderly, is a complex neurodegenerative disease marked by the appearance of amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles. Alzheimer's disease has a strong genetic component, and recent advances in genome technology have unearthed novel variants in several genes, which could provide insight into the pathogenic mechanisms that contribute to AD. Particularly interesting are variants in the microglial-expressed receptor TREM2 which are associated with a 2-4-fold increased risk of developing AD. Since the discovery of a link between TREM2 and AD, multiple studies have emerged testing whether partial or complete loss of TREM2 function contributed to Aβ deposition or Aβ-associated microgliosis. Although some confounding conflicting data have emerged from these studies regarding the role of TREM2 in regulating Aβ deposition within the hippocampus, the most consistent and striking observation is a strong decrease in microgliosis surrounding Aβ plaques in TREM2 haploinsufficient and TREM2 deficient mice. Interestingly, a similar impairment in microgliosis has been reported in mouse models of prion disease, stroke, and multiple sclerosis, suggesting a critical role for TREM2 in supporting microgliosis in response to pathology in the central nervous system. In this Review, we summarize recent reports on the role of TREM2 in AD pathology and hypothesized mechanisms by which TREM2 function could influence AD-induced microgliosis.","['Alzheimer’s disease', 'TREM2', 'amyloid-β', 'apolipoprotein E', 'microglia', 'neurodegeneration']",ACS chemical neuroscience,2016-02-09,"[{'lastname': 'Ulrich', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': ""Department of Neurology, Knight Alzheimer's Disease Research Center, and Hope Center for Neurological Disorders, Washington University School of Medicine , St. Louis, Missouri 63110, United States.""}, {'lastname': 'Holtzman', 'firstname': 'David M', 'initials': 'DM', 'affiliation': ""Department of Neurology, Knight Alzheimer's Disease Research Center, and Hope Center for Neurological Disorders, Washington University School of Medicine , St. Louis, Missouri 63110, United States.""}]",,,,,10.1021/acschemneuro.5b00313,<Element 'PubmedArticle' at 0x7f05dcb20950>
150,"26687817
22229116
1673054
12130773
15037694
21777559
22805771
20083042
23332364
22784036
18256671
21514250
6610841
22265587
9330978
22101365
23656989
23602650
20360050
10220456
11487049
12578223
16079410
9005861
22393530
20164348
17086105
7876895
10666378
9829809
2360787
1789684
7826280
8699259
12743238
17470753
24226270
15872113
23665843
21460840
21460841
23150934
23150908
19734903
23708142
23623698
24893973
25728668
23454195
20418874
24923909
24973918
9630473
9469259
8398148
8415756
7566000
8572669
15184600
25623662
21385991
22228589
24948358
25092803
23038755
19838177
15883316
24450891
24450890
15668737
19465012
20532897
21166690
23943781",Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease.,"Amyloid (senile) plaques, one of the two pathologic hallmarks of Alzheimer disease (AD), are associated with dystrophic neurites and glial responses, both astrocytic and microglial. Although plaque burden remains relatively stable through the clinical course of AD, whether these features of local plaque toxicity continue to worsen over the course of the disease is unclear. We performed an unbiased plaque-centered quantification of SMI312(+) dystrophic neurites, GFAP(+) reactive astrocytes, and IBA1(+) and CD68(+) activated microglia in randomly selected dense-core (Thioflavin-S(+)) plaques from the temporal neocortex of 40 AD subjects with a symptom duration ranging from 4 to 20 years, and nine nondemented control subjects with dense-core plaques. Dystrophic neurites (Kendall τ = 0.34, P = 0.001), reactive astrocytes (Kendall τ = 0.30, P = 0.003), and CD68(+) (Kendall τ = 0.48, P < 0.0001), but not IBA1 microglia (Kendall τ = 0.045, P = 0.655), exhibited a significant positive correlation with symptom duration. When excluding control subjects, only the positive association between CD68(+) microglia and symptom duration remained significant (Kendall τ = 0.39, P = 0.0003). The presence of the APOEε4 allele did not affect these results. We conclude that plaques exert an increasing toxicity in the surrounding neuropil over the clinical course of AD, thereby potentially contributing to cognitive decline.",[],The American journal of pathology,2015-12-22,"[{'lastname': 'Serrano-Pozo', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Massachusetts Alzheimer Disease Research Center, Massachusetts General Hospital, Charlestown, Massachusetts; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology, University of Iowa Hospitals & Clinics, Iowa City, Iowa.'}, {'lastname': 'Betensky', 'firstname': 'Rebecca A', 'initials': 'RA', 'affiliation': 'Massachusetts Alzheimer Disease Research Center, Massachusetts General Hospital, Charlestown, Massachusetts; Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.'}, {'lastname': 'Frosch', 'firstname': 'Matthew P', 'initials': 'MP', 'affiliation': 'Massachusetts Alzheimer Disease Research Center, Massachusetts General Hospital, Charlestown, Massachusetts; C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'lastname': 'Hyman', 'firstname': 'Bradley T', 'initials': 'BT', 'affiliation': 'Massachusetts Alzheimer Disease Research Center, Massachusetts General Hospital, Charlestown, Massachusetts; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: bhyman@mgh.harvard.edu.'}]",,,,Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.,10.1016/j.ajpath.2015.10.010,<Element 'PubmedArticle' at 0x7f05dcaabbd0>
151,26592481,Short-term treadmill exercise increased tau insolubility and neuroinflammation in tauopathy model mice.,"Physical exercise has been identified as a preventive measure for Alzheimer's disease (AD), one of the neuropathological hallmarks of which, neurofibrillary tangles, consist of hyperphosphorylated insoluble tau. Previous studies demonstrated that long-term treadmill exercise reduced tau hyperphosphorylation and insolubility; however, whether short-term treadmill exercise (STE) alters tau modifications currently remains unknown. In the present study, we attempted to characterize the effects of STE on tau solubility and determine its relationship with neuroinflammation using tauopathy model mice (Tg601), which express wild-type human tau. The results obtained showed that 3 weeks of non-shock treadmill exercise in Tg601 and non-transgenic female mice markedly increased insoluble tau. An analysis of phosphorylation patterns indicated that changes in tau solubility were related to an increase in phosphorylation at the tau C-terminal end. The results of immunohistochemical analyses revealed that STE increased the number of Iba-1-positive microglial cells in the hippocampus. Elevations in the levels of the lipid peroxidation markers, 4-hydroxy-trans-2-noneal and malondialdehyde, indicated the presence of oxidative stress. Moreover, higher levels of cytokines, IL-1β and IL-18, and chemokines, CXCL-1 and CXCL-12, supported neuroinflammation.","['Alzheimer’s disease', 'Chemokines', 'Cytokines', 'Immunohistochemistry', 'Microglia']",Neuroscience letters,2015-11-26,"[{'lastname': 'Elahi', 'firstname': 'Montasir', 'initials': 'M', 'affiliation': 'Sportology Center, Juntendo University Graduate of Medicine, Japan; Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate School of Medicine, Japan.'}, {'lastname': 'Motoi', 'firstname': 'Yumiko', 'initials': 'Y', 'affiliation': 'Sportology Center, Juntendo University Graduate of Medicine, Japan; Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate School of Medicine, Japan; Department of Neurology, Juntendo University Graduate School of Medicine, Japan. Electronic address: motoi@juntendo.ac.jp.'}, {'lastname': 'Matsumoto', 'firstname': 'Shin-Ei', 'initials': 'SE', 'affiliation': 'Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate School of Medicine, Japan; Department of Neurology, Juntendo University Graduate School of Medicine, Japan.'}, {'lastname': 'Hasan', 'firstname': 'Zafrul', 'initials': 'Z', 'affiliation': 'Sportology Center, Juntendo University Graduate of Medicine, Japan.'}, {'lastname': 'Ishiguro', 'firstname': 'Koichi', 'initials': 'K', 'affiliation': 'Department of Neurology, Juntendo University Graduate School of Medicine, Japan.'}, {'lastname': 'Hattori', 'firstname': 'Nobutaka', 'initials': 'N', 'affiliation': 'Department of Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate School of Medicine, Japan; Department of Neurology, Juntendo University Graduate School of Medicine, Japan.'}]",,,,Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.neulet.2015.11.010,<Element 'PubmedArticle' at 0x7f05dcad5db0>
152,"26538351
21414557
26192465
17715348
15642910
22174735
11739546
20546729
21644996
21147995
8307060
24925454
20943926
20951738
24603946
24647946
26235058
21841002
20431570
25085375
23638068
17590238
17986870
18525123
25864199
16368167
22044248
24406245
26002154
22790092
21172610
22461630
21605039
21645391
23050084
22253473
26041104
11520930
24148220
22762014
8624133
20553310
20553310
21158978
21555069
21040568
18657136
12847155
20450868
17030663
23876516
16020737
22796753
25183004
18953105
19874269
22305802
25590418
22272619
16176937
24887583
25131590
22817709
19096156
17137722
15240806
20012091
24278740
21917794
24075978
22393063",Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.,"Immunotherapy directed against tau is a promising treatment strategy for Alzheimer's Disease (AD) and tauopathies. We review initial studies on tau-directed immunotherapy, and present data from our laboratory testing antibodies using the rTg4510 mouse model, which deposits tau in forebrain neurons. Numerous antibodies have been tested for their efficacy in treating both pathology and cognitive function, in different mouse models, by different routes of administration, and at different ages or durations. We report, here, that the conformation-specific antibody MC-1 produces some degree of improvement to both cognition and pathology in rTg4510. Pathological improvements as measured by Gallyas staining for fully formed tangles and phosphorylated tau appeared 4 days after intracranial injection into the hippocampus. We also examined markers for microglial activation, which did not appear impacted from treatment. Behavioral effects were noted after continuous infusion of antibodies into the lateral ventricle for approximately 2 weeks. We examined basic motor skills, which were not impacted by treatment, but did note cognitive improvements with both novel object and radial arm water maze testing. Our results support earlier reports in the initial review presented here, and collectively show promise for this strategy of treatment. The general absence of extracellular tau deposits may avoid the opsonization and phagocytosis mechanisms activated by antibodies against amyloid, and make anti tau approaches a safer method of immunotherapy for Alzheimer's disease.","['Active immunization', 'Dementia', 'Gallyas', 'Passive immunization', 'Tau', 'Transgenic mice', 'Vaccination', 'rTg4510']",Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,2015-11-06,"[{'lastname': 'Schroeder', 'firstname': 'Sulana K', 'initials': 'SK', 'affiliation': ""Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Byrd Alzheimer's Institute, 4001 E. Fletcher Avenue, Tampa, FL, 33613, USA.""}, {'lastname': 'Joly-Amado', 'firstname': 'Aurelie', 'initials': 'A', 'affiliation': ""Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Byrd Alzheimer's Institute, 4001 E. Fletcher Avenue, Tampa, FL, 33613, USA.""}, {'lastname': 'Gordon', 'firstname': 'Marcia N', 'initials': 'MN', 'affiliation': ""Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Byrd Alzheimer's Institute, 4001 E. Fletcher Avenue, Tampa, FL, 33613, USA.""}, {'lastname': 'Morgan', 'firstname': 'Dave', 'initials': 'D', 'affiliation': ""Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Byrd Alzheimer's Institute, 4001 E. Fletcher Avenue, Tampa, FL, 33613, USA. scientist.dave@gmail.com.""}]",,,,,10.1007/s11481-015-9637-6,<Element 'PubmedArticle' at 0x7f05dca62b30>
153,26510980,Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice.,"Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the fourth leading cause of death in the United States and most common cause of adult-onset dementia. The major hallmarks of AD are the formation of senile amyloid plaques made of beta amyloid and neurofibrillary tangles (NFT) which are primarily composed of phosphorylated tau protein. Although numerous agents have been considered as providing protection against AD, identification of potential agents with neuroprotective ability is limited. Thioflavin T has been used in the past to stain amyloid beta plaques in brain. In this study, Thioflavin T (ThT) and vehicle (infant formula) were administered orally by gavage to transgenic (B6C3 APP PS1; AD-Tg) mice beginning at 4 months age and continuing until sacrifice at 9 months of age at 40 mg/kg dose. The number of amyloid plaques was reduced dramatically by ThT treatment in both male and female transgenic mice compared to those in control mice. Additionally, GFAP and Amylo-Glo labeling suggest that astrocytic hypertrophy is minimized in ThT-treated animals. Similarly, CD68 labeling, which detects activated microglia, along with Amylo-Glo labeling, suggests that microglial activation is significantly less in ThT-treated mice. Both Aβ-40 and Aβ-42 concentrations in blood rose significantly in the ThT-treated animals suggesting that ThT may inhibit the deposition, degradation, and/or clearance of Aβ plaques in brain.",[],Current Alzheimer research,2015-10-30,"[{'lastname': 'Sarkar', 'firstname': 'Sumit', 'initials': 'S', 'affiliation': 'National Center for Toxicological Research/FDA, 3900 NCTR Road, HFT-132, Jefferson, AR-72079, USA. sumit.sarkar@fda.hhs.gov.'}, {'lastname': 'Raymick', 'firstname': 'James', 'initials': 'J', 'affiliation': None}, {'lastname': 'Ray', 'firstname': 'Balmiki', 'initials': 'B', 'affiliation': None}, {'lastname': 'Lahiri', 'firstname': 'Debomoy K', 'initials': 'DK', 'affiliation': None}, {'lastname': 'Paule', 'firstname': 'Merle G', 'initials': 'MG', 'affiliation': None}, {'lastname': 'Schmued', 'firstname': 'Larry', 'initials': 'L', 'affiliation': None}]",,,,,10.2174/156720501209151019105647,<Element 'PubmedArticle' at 0x7f05dca8e6d0>
154,26239295,Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment.,"Canine cognitive impairment syndrome (CDS) represents a group of symptoms related to the aging of the canine brain. These changes ultimately lead to a decline of memory function and learning abilities, alteration of social interaction, impairment of normal housetraining, and changes in sleep-wake cycle and general activity. We have clinically examined 215 dogs, 28 of which underwent autopsy. With canine brains, we performed extensive analysis of pathological abnormalities characteristic of human Alzheimer's disease and frontotemporal lobar degeneration, including β-amyloid senile plaques, tau neurofibrillary tangles, and fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP43) inclusions. Most demented dogs displayed senile plaques, mainly in the frontal and temporal cortex. Tau neurofibrillary inclusions were found in only one dog. They were identified with antibodies used to detect tau neurofibrillary lesions in the human brain. The inclusions were also positive for Gallyas silver staining. As in humans, they were distributed mainly in the entorhinal cortex, hippocampus, and temporal cortex. On the other hand, FUS and TDP43 aggregates were not present in any of the examined brain samples. We also found that CDS was characterized by the presence of reactive and senescent microglial cells in the frontal cortex. Our transcriptomic study revealed a significant dysregulation of genes involved in neuroinflammation. Finally, we analyzed tau phosphoproteome in the synaptosomes. Proteomic studies revealed a significant increase of hyperphosphorylated tau in synaptosomes of demented dogs compared with nondemented dogs. This study suggests that cognitive decline in dogs is related to the tau synaptic impairment and neuroinflammation. J. Comp. Neurol. 524:874-895, 2016. © 2015 Wiley Periodicals, Inc.","['canine cognitive impairment', 'dementia', 'microglia', 'neurofibrillary tangles', 'synapse', 'tau protein']",The Journal of comparative neurology,2015-08-05,"[{'lastname': 'Smolek', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10, Bratislava, Slovak Republic.'}, {'lastname': 'Madari', 'firstname': 'Aladar', 'initials': 'A', 'affiliation': 'University of Veterinary Medicine and Pharmacy, 040 01, Kosice, Slovak Republic.'}, {'lastname': 'Farbakova', 'firstname': 'Jana', 'initials': 'J', 'affiliation': 'University of Veterinary Medicine and Pharmacy, 040 01, Kosice, Slovak Republic.'}, {'lastname': 'Kandrac', 'firstname': 'Ondrej', 'initials': 'O', 'affiliation': 'University of Veterinary Medicine and Pharmacy, 040 01, Kosice, Slovak Republic.'}, {'lastname': 'Jadhav', 'firstname': 'Santosh', 'initials': 'S', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10, Bratislava, Slovak Republic.'}, {'lastname': 'Cente', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10, Bratislava, Slovak Republic.\nAxon Neuroscience SE, 811 02, Bratislava, Slovak Republic.'}, {'lastname': 'Brezovakova', 'firstname': 'Veronika', 'initials': 'V', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10, Bratislava, Slovak Republic.'}, {'lastname': 'Novak', 'firstname': 'Michal', 'initials': 'M', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10, Bratislava, Slovak Republic.\nAxon Neuroscience SE, 811 02, Bratislava, Slovak Republic.'}, {'lastname': 'Zilka', 'firstname': 'Norbert', 'initials': 'N', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10, Bratislava, Slovak Republic.\nAxon Neuroscience SE, 811 02, Bratislava, Slovak Republic.\nInstitute of Neuroimmunology, n.o., 811 02, Bratislava, Slovak Republic.'}]",,,,"© 2015 Wiley Periodicals, Inc.",10.1002/cne.23877,<Element 'PubmedArticle' at 0x7f05dca9b810>
155,26147615,Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.,"To give perspectives on current limitations and recent developments in the field of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD).
Three CSF biomarkers for the neuropathological hallmarks of Alzheimer's disease, namely total tau (T-tau), phospho-tau (P-tau) and the 42 amino acid form of amyloid β (Aβ42), reflecting neurodegeneration, neurofibrillary tangles and amyloid/senile plaques, respectively, have been developed, validated and incorporated into new diagnostic criteria for the disease. Thanks to global collaborative research efforts, these have been to a large extent a success story but there are a number of limitations that warrant further research and discussion. First, bias and random variation in biomarker measurements both within and between laboratories remain an issue. Second, current markers only reflect part of the pathology underlying Alzheimer's disease; new markers of synaptic dysfunction, microglial activation and protein aggregates that are frequently seen alongside plaque and tangle pathology are needed. Third, fluid markers do not represent the anatomic location of any pathological change; CSF markers may be complemented with high resolution molecular imaging techniques.
There has been considerable progress in the validation and standardization of assays for CSF T-tau, P-tau and Aβ42. Novel biomarkers for synaptic function, microglial activation and protein accumulations other than tau and Aβ are in development. Future fluid biomarker research should be conducted in close collaboration with molecular imaging specialists.",[],Current opinion in psychiatry,2015-07-07,"[{'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'aClinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden bDepartment of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.'}]",,,,,10.1097/YCO.0000000000000179,<Element 'PubmedArticle' at 0x7f05dca29270>
156,"26057852
23954969
23719156
23623698
19295164
18701698
20552234
22666621
7545739
24534188
9056542
9034367
21777559
23656989
19282288
19503072
22312444
23050084
22365544
23325240
23690619
24857020
24075978
20029438
22174735
20546729
17715348
21644996
22272619
21841002
23638068
2116006
12417659
9130141
20234358
23318515
23150934
24139279
24990881
10806312
1782548
23171029
19513731
24445162
22002425
15240806
21158978
3018187",Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody.,"Microglia have been shown to contribute to the clearance of brain amyloid β peptides (Aβ), the major component of amyloid plaques, in Alzheimer's disease (AD). However, it is not known whether microglia play a similar role in the clearance of tau, the major component of neurofibrillary tangles (NFTs). We now report that murine microglia rapidly internalize and degrade hyperphosphorylated pathological tau isolated from AD brain tissue in a time-dependent manner in vitro. We further demonstrate that microglia readily degrade human tau species released from AD brain sections and eliminate NFTs from brain sections of P301S tauopathy mice. The anti-tau monoclonal antibody MC1 enhances microglia-mediated tau degradation in an Fc-dependent manner. Our data identify a potential role for microglia in the degradation and clearance of pathological tau species in brain and provide a mechanism explaining the potential therapeutic actions of passively administered anti-tau monoclonal antibodies.",[],Scientific reports,2015-06-10,"[{'lastname': 'Luo', 'firstname': 'Wenjie', 'initials': 'W', 'affiliation': ""Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.""}, {'lastname': 'Liu', 'firstname': 'Wencheng', 'initials': 'W', 'affiliation': ""Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.""}, {'lastname': 'Hu', 'firstname': 'Xiaoyan', 'initials': 'X', 'affiliation': ""Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.""}, {'lastname': 'Hanna', 'firstname': 'Mary', 'initials': 'M', 'affiliation': ""Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.""}, {'lastname': 'Caravaca', 'firstname': 'April', 'initials': 'A', 'affiliation': ""Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.""}, {'lastname': 'Paul', 'firstname': 'Steven M', 'initials': 'SM', 'affiliation': ""Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.""}]",,,,,10.1038/srep11161,<Element 'PubmedArticle' at 0x7f05dca30db0>
157,"25830951
20107219
15608634
22286176
23007711
20155817
24210819
20660248
16476660
17351623
23892208
21813677
19151372
19164591
19669892
18516051
19840549
20517700
24713688
25217135
16006665
20565954
23758797
22708967
25105870
22357203
24793238
14985348
2740429
12600702
20696249
21044172
20560880
23973449
19495971
16920499
17135573
21820744
20531383
23682015
19273628
21292246
17475785
24157572
24813244
23966702
24012002
23125823
23577177
20303880
22315714
10858586
19825975
19593388
19838177",Intravenous infusion of monocytes isolated from 2-week-old mice enhances clearance of Beta-amyloid plaques in an Alzheimer mouse model.,"Alzheimer's disease (AD) is characterized by the deposition of β-amyloid (Aβ) senile plaques and tau-associated neurofibrillary tangles. Other disease features include neuroinflammation and cholinergic neurodegeneration, indicating their possible importance in disease propagation. Recent studies have shown that monocytic cells can migrate into the AD brain toward Aβ plaques and reduce plaque burden. The purpose of this study was to evaluate whether the administration of intravenous infusions of 'young' CD11b-positive (+) monocytes into an AD mouse model can enhance Aβ plaque clearance and attenuate cognitive deficits. Peripheral monocytes were isolated from two-week-old wildtype mice using the Pluriselect CD11b+ isolation method and characterized by FACS analysis for surface marker expression and effective phagocytosis of 1 μm fluorescent microspheres, FITC-Dextran or FITC-Aβ1-42. The isolated monocytes were infused via the tail vein into a transgenic AD mouse model, which expresses the Swedish, Dutch/Iowa APP mutations (APPSwDI). The infusions began when animals reached 5 months of age, when little plaque deposition is apparent and were repeated again at 6 and 7 months of age. At 8 months of age, brains were analyzed for Aβ+ plaques, inflammatory processes and microglial (Iba1) activation. Our data show that infusions of two-week-old CD11b+ monocytes into adult APPSwDI mice results in a transient improvement of memory function, a reduction (30%) in Aβ plaque load and significantly in small (<20 μm) and large (>40 μm) plaques. In addition, we observe a reduction in Iba1+ cells, as well as no marked elevations in cytokine levels or other indicators of inflammation. Taken together, our findings indicate that young CD11b+ monocytes may serve as therapeutic candidates for improved Aβ clearance in AD.",[],PloS one,2015-04-02,"[{'lastname': 'Hohsfield', 'firstname': 'Lindsay A', 'initials': 'LA', 'affiliation': ""Laboratory of Psychiatry and Experimental Alzheimer's Research, Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.""}, {'lastname': 'Humpel', 'firstname': 'Christian', 'initials': 'C', 'affiliation': ""Laboratory of Psychiatry and Experimental Alzheimer's Research, Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.""}]",,,,,"10.1371/journal.pone.0121930
10.1056/NEJMra0909142
10.1038/nn.3028
10.1002/path.4106
10.1002/glia.20973
10.1016/j.celrep.2013.10.010
10.1523/JNEUROSCI.0329-10.2010
10.1093/jmcb/mjt028
10.1523/JNEUROSCI.6209-10.2011
10.1093/brain/awn331
10.1073/pnas.0805453106
10.1007/s11481-009-9166-2
10.1038/nm1781
10.1016/j.neuron.2009.09.035
10.1007/s00702-010-0422-7
10.1038/nrn3722
10.1186/s12974-014-0161-z
10.1186/1471-2172-11-30
10.1186/1742-4933-10-22
10.1111/j.1474-9726.2012.00851.x
10.1371/journal.pone.0104522
10.1038/nm.3569
10.1016/j.mcn.2010.08.001
10.1111/j.1460-9568.2010.07434.x
10.1007/s11064-009-0014-9
10.1016/j.jneuroim.2011.07.002
10.1038/nrneurol.2010.71
10.1002/cne.23363
10.1084/jem.20081385
10.1016/j.cellimm.2010.12.004
10.1038/nri3547
10.1111/acel.12223
10.1523/JNEUROSCI.1671-13.2013
10.1016/j.neuron.2013.06.046
10.3389/fncel.2012.00051
10.1371/journal.pone.0060921
10.1016/j.cell.2010.02.016
10.1101/cshperspect.a006346
10.1096/fj.09-141754
10.1371/journal.pone.0006197
10.1038/nn.2432",<Element 'PubmedArticle' at 0x7f05dca4dbd0>
158,25430817,Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.,"Amyloid β peptide (Aβ) immunization of Alzheimer's disease (AD) patients has been reported to induce amyloid plaque removal, but with little impact on cognitive decline. We have explored the consequences of Aβ immunotherapy on neurons in post mortem brain tissue. Eleven immunized (AN1792, Elan Pharmaceuticals) AD patients were compared to 28 non-immunized AD cases. Immunohistochemistry on sections of neocortex was performed for neuron-specific nuclear antigen (NeuN), neurofilament protein (NFP) and phosphorylated-(p)PKR (pro-apoptotic kinase detected in degenerating neurons). Quantification was performed for pPKR and status spongiosis (neuropil degeneration), NeuN-positive neurons/field, curvature of the neuronal processes and interneuronal distance. Data were corrected for age, gender, duration of dementia and APOE genotype and also assessed in relation to Aβ42 and tau pathology and key features of AD. In non-immunized patients, the degree of neuritic curvature correlated with spongiosis and pPKR, and overall the neurodegenerative markers correlated better with tau pathology than Aβ42 load. Following immunization, spongiosis increased, interneuronal distance increased, while the number of NeuN-positive neurons decreased, consistent with enhanced neuronal loss. However, neuritic curvature was reduced and pPKR was associated with Aβ removal in immunized patients. In AD, associations of spongiosis status, curvature ratio and pPKR load with microglial markers Iba1, CD68 and CD32 suggest a role for microglia in neurodegeneration. After immunization, correlations were detected between the number of NeuN-positive neurons and pPKR with Iba1, CD68 and CD64, suggesting that microglia are involved in the neuronal loss. Our findings suggest that in established AD this form of active Aβ immunization may predominantly accelerate loss of damaged degenerating neurons. This interpretation is consistent with in vivo imaging indicating an increased rate of cerebral atrophy in immunized AD patients.","['Aβ immunotherapy', 'PKR', 'amyloid', 'neurodegeneration', 'neuron', 'tau']",The Journal of pathology,2014-11-29,"[{'lastname': 'Paquet', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'Alzheimer Clinical Centre, Lariboisiere FW Saint-Louis Hospital, AP-HP University of Paris Diderot, France; Department of Histology and Biology of Ageing, Lariboisiere FW Saint-Louis Hospital, AP-HP University of Paris Diderot, France; INSERM U942, Paris, France.'}, {'lastname': 'Amin', 'firstname': 'Jay', 'initials': 'J', 'affiliation': None}, {'lastname': 'Mouton-Liger', 'firstname': 'François', 'initials': 'F', 'affiliation': None}, {'lastname': 'Nasser', 'firstname': 'Mariam', 'initials': 'M', 'affiliation': None}, {'lastname': 'Love', 'firstname': 'Seth', 'initials': 'S', 'affiliation': None}, {'lastname': 'Gray', 'firstname': 'Françoise', 'initials': 'F', 'affiliation': None}, {'lastname': 'Pickering', 'firstname': 'Ruth M', 'initials': 'RM', 'affiliation': None}, {'lastname': 'Nicoll', 'firstname': 'James A R', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Holmes', 'firstname': 'Clive', 'initials': 'C', 'affiliation': None}, {'lastname': 'Hugon', 'firstname': 'Jacques', 'initials': 'J', 'affiliation': None}, {'lastname': 'Boche', 'firstname': 'Delphine', 'initials': 'D', 'affiliation': None}]",,,,"Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.",10.1002/path.4491,<Element 'PubmedArticle' at 0x7f05dc9f2ea0>
159,"25297091
22476196
1759558
22002422
8318230
23197725
15707899
14596589
23575824
22388811
3146006
21487307
17308309
17403556
22772545
18525123
21914486
23739959
21196063
22218781
19372439
9662375
17082447
12925731
18568014
10623648
2116006
19508444
12130773
22288403
9130141
21421841
22865408
17251419
23002015
15823755
17551515
9600986
17116235
22253473
23183490
19349094
24315369
9345504
20042680
11148253
15295589
16567017
8621419
22762015
21802369
21222592
19156775
7817900
7679073
14643377
12895417
17472708
20004650
15242691
21550980
23824488
19074479
1905108
20107219
16291936
15232619
17470753
11124441
22235132
21900936
15831394
21777559
17360908
9636220
22867711
18624777
11118482
21871692
24183027
10731219
3132715
3083509
17270732
16753151",Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates.,"Alzheimer's disease (AD) is a devastating neurodegenerative disorder and a major medical problem. Here, we have investigated the impact of amyloid-β (Aβ) oligomers, AD-related neurotoxins, in the brains of rats and adult nonhuman primates (cynomolgus macaques). Soluble Aβ oligomers are known to accumulate in the brains of AD patients and correlate with disease-associated cognitive dysfunction. When injected into the lateral ventricle of rats and macaques, Aβ oligomers diffused into the brain and accumulated in several regions associated with memory and cognitive functions. Cardinal features of AD pathology, including synapse loss, tau hyperphosphorylation, astrocyte and microglial activation, were observed in regions of the macaque brain where Aβ oligomers were abundantly detected. Most importantly, oligomer injections induced AD-type neurofibrillary tangle formation in the macaque brain. These outcomes were specifically associated with Aβ oligomers, as fibrillar amyloid deposits were not detected in oligomer-injected brains. Human and macaque brains share significant similarities in terms of overall architecture and functional networks. Thus, generation of a macaque model of AD that links Aβ oligomers to tau and synaptic pathology has the potential to greatly advance our understanding of mechanisms centrally implicated in AD pathogenesis. Furthermore, development of disease-modifying therapeutics for AD has been hampered by the difficulty in translating therapies that work in rodents to humans. This new approach may be a highly relevant nonhuman primate model for testing therapeutic interventions for AD.","[""Alzheimer's disease"", 'amyloid-β oligomers', 'nonhuman primate', 'synapse loss', 'tau pathology']",The Journal of neuroscience : the official journal of the Society for Neuroscience,2014-10-10,"[{'lastname': 'Forny-Germano', 'firstname': 'Leticia', 'initials': 'L', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil.'}, {'lastname': 'Lyra e Silva', 'firstname': 'Natalia M', 'initials': 'NM', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and.'}, {'lastname': 'Batista', 'firstname': 'André F', 'initials': 'AF', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and.'}, {'lastname': 'Brito-Moreira', 'firstname': 'Jordano', 'initials': 'J', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and.'}, {'lastname': 'Gralle', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and.'}, {'lastname': 'Boehnke', 'firstname': 'Susan E', 'initials': 'SE', 'affiliation': ""Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.""}, {'lastname': 'Coe', 'firstname': 'Brian C', 'initials': 'BC', 'affiliation': ""Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.""}, {'lastname': 'Lablans', 'firstname': 'Ann', 'initials': 'A', 'affiliation': ""Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.""}, {'lastname': 'Marques', 'firstname': 'Suelen A', 'initials': 'SA', 'affiliation': 'Departament of Neurobiology, Institute of Biology, Fluminense Federal University, Niterói, RJ, 24020-140 Brazil, and.'}, {'lastname': 'Martinez', 'firstname': 'Ana Maria B', 'initials': 'AM', 'affiliation': 'Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil.'}, {'lastname': 'Klein', 'firstname': 'William L', 'initials': 'WL', 'affiliation': 'Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208.'}, {'lastname': 'Houzel', 'firstname': 'Jean-Christophe', 'initials': 'JC', 'affiliation': 'Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil.'}, {'lastname': 'Ferreira', 'firstname': 'Sergio T', 'initials': 'ST', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and.'}, {'lastname': 'Munoz', 'firstname': 'Douglas P', 'initials': 'DP', 'affiliation': ""Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada, felice@bioqmed.ufrj.br doug.munoz@queensu.ca.""}, {'lastname': 'De Felice', 'firstname': 'Fernanda G', 'initials': 'FG', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis and felice@bioqmed.ufrj.br doug.munoz@queensu.ca.'}]",,,,Copyright © 2014 the authors 0270-6474/14/3413629-15$15.00/0.,"10.1523/JNEUROSCI.1353-14.2014
10.1172/JCI57256
10.1007/BF00308809
10.1097/NEN.0b013e318232a379
10.1016/0896-6273(93)90057-X
10.1523/JNEUROSCI.0172-12.2012
10.1016/j.cell.2004.12.020
10.1021/bi030029q
10.1523/JNEUROSCI.3672-12.2013
10.1038/nature10841
10.1016/0165-0270(88)90160-4
10.1097/NEN.0b013e318217a118
10.1074/jbc.M607483200
10.1016/j.neurobiolaging.2007.02.029
10.1038/nm0712-1003
10.1016/j.nlm.2011.08.003
10.1523/JNEUROSCI.0482-13.2013
10.1016/j.neurobiolaging.2010.10.015
10.1007/s11357-011-9355-9
10.1161/STROKEAHA.109.548131
10.1038/nm0798-827
10.1126/science.1132814
10.1073/pnas.1834302100
10.1038/nrn2420
10.1016/S0002-9440(10)64700-1
10.1073/pnas.87.15.5827
10.1111/j.1365-2990.2008.00997.x
10.1126/science.1072994
10.2174/138161212799315885
10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E
10.1073/pnas.1017033108
10.1002/ajp.22065
10.1523/JNEUROSCI.3501-06.2007
10.1101/cshperspect.a006320
10.1016/j.molmed.2005.02.009
10.1038/nrn2168
10.1073/pnas.95.11.6448
10.1111/j.1471-4159.2006.04157.x
10.1096/fj.11-199851
10.1038/mp.2012.168
10.1016/j.neurobiolaging.2009.02.025
10.1016/j.cmet.2013.11.002
10.1006/nimg.1996.0036
10.2353/ajpath.2010.090452
10.1212/WNL.56.1.127
10.1038/nature02621
10.1016/j.tig.2006.03.007
10.1074/jbc.271.10.5589
10.1101/cshperspect.a006338
10.1016/S1474-4422(11)70156-9
10.2174/156720511795745302
10.1002/path.2504
10.1016/j.neurobiolaging.2003.08.012
10.1016/S0896-6273(03)00434-3
10.1111/j.1471-4159.2007.04607.x
10.1016/j.brainres.2009.12.005
10.1016/j.tics.2004.05.009
10.1074/jbc.M111.237974
10.1093/brain/awt171
10.1161/STROKEAHA.108.524330
10.1056/NEJMra0909142
10.1523/JNEUROSCI.3279-05.2005
10.1172/JCI20640
10.1212/01.wnl.0000260698.46517.8f
10.1016/S0197-4580(00)00176-7
10.1074/jbc.M111.298471
10.1038/nm.2460
10.1016/j.conb.2005.03.014
10.1016/j.ajpath.2011.05.047
10.1523/JNEUROSCI.4970-06.2007
10.1073/pnas.95.13.7737
10.1016/j.ajpath.2012.06.033
10.1111/j.1582-4934.2008.00411.x
10.1177/002215540104900110
10.1016/j.nrl.2011.05.004
10.1016/j.neuron.2013.10.027
10.1093/cercor/10.3.243
10.1073/pnas.85.12.4506
10.1126/science.3083509
10.1016/j.neuron.2007.01.010
10.1016/j.febslet.2006.05.029",<Element 'PubmedArticle' at 0x7f05dca0b090>
160,"25217135
10858586
15853506
17036175
7715705
10600748
2553231
1414275
10542270
20155817
16476660
16006665
1782548
9034367
9056542
10208278
10806312
8255555
8919296
11398841
15390000
15254941
15509534
15681835
17270732
18457819
19232747
20937161
21813771
22397366
24418258
16406150
17338548
23050084
1712107
7679073
12544837
16753151
18702695
15135415
12787065
9665729
19565166
23028862
22396532
18373181
6375662
3159021
3132715
1759558
7817900
20678074
11578768
11231639
15459709
12612547
16960575
17117171
7635444
7494597
18701698
17203473
10028915
9361021
17222479
9329688
11164276
12624793
1578513
9798938
14502239
15525768
6736651
11755009
15197750
2972943
11958825
12027877
17934472
15649704
17722035
11726978
9713826",Microglia display modest phagocytic capacity for extracellular tau oligomers.,"Abnormal misfolded tau protein is a driving force of neurofibrillary degeneration in Alzheimer's disease. It has been shown that tau oligomers play a crucial role in the formation of intracellular neurofibrillary tangles. They are intermediates between soluble tau monomers and insoluble tau filaments and are suspected contributors to disease pathogenesis. Oligomeric tau can be released into the extracellular space and spread throughout the brain. This finding opens the question of whether brain macrophages or blood monocytes have the potential to phagocytose extracellular oligomeric tau.
We have used stable rat primary microglial cells, rat peripheral monocytes-derived macrophages, BV2 microglial and TIB67 macrophage immortalized cell lines that were challenged by tau oligomers prepared by an in vitro aggregation reaction. The efficiency of cells to phagocytose oligomeric protein was evaluated with confocal microscopy. The ability to degrade tau protein was analyzed by immunoblotting.
Confocal microscopy analyses showed that macrophages were significantly more efficient in phagocytosing oligomerized tau proteins than microglial cells. In contrast to macrophages, microglia are able to degrade the internalized oligomeric tau only after stimulation with lipopolysaccharide (LPS).
Our data suggests that microglia may not be the principal phagocytic cells able to target extracellular oligomeric tau. We found that peripheral macrophages display a high potency for elimination of oligomeric tau and therefore could play an important role in the modulation of neurofibrillary pathology in Alzheimer's disease.",[],Journal of neuroinflammation,2014-09-14,"[{'lastname': 'Majerova', 'firstname': 'Petra', 'initials': 'P', 'affiliation': None}, {'lastname': 'Zilkova', 'firstname': 'Monika', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kazmerova', 'firstname': 'Zuzana', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Kovac', 'firstname': 'Andrej', 'initials': 'A', 'affiliation': None}, {'lastname': 'Paholikova', 'firstname': 'Kristina', 'initials': 'K', 'affiliation': None}, {'lastname': 'Kovacech', 'firstname': 'Branislav', 'initials': 'B', 'affiliation': None}, {'lastname': 'Zilka', 'firstname': 'Norbert', 'initials': 'N', 'affiliation': None}, {'lastname': 'Novak', 'firstname': 'Michal', 'initials': 'M', 'affiliation': None}]",,,"Confocal microscopy analyses showed that macrophages were significantly more efficient in phagocytosing oligomerized tau proteins than microglial cells. In contrast to macrophages, microglia are able to degrade the internalized oligomeric tau only after stimulation with lipopolysaccharide (LPS).",,"10.1186/s12974-014-0161-z
10.1016/S0197-4580(00)00124-X
10.1586/14737175.4.5.793
10.1007/s00702-006-0575-6
10.1038/374647a0
10.1126/science.286.5448.2352
10.1074/jbc.274.45.32301
10.1016/j.neuron.2006.01.022
10.1016/0006-8993(91)90783-R
10.1097/00005072-199702000-00004
10.1097/00005072-199703000-00007
10.1007/s004010051002
10.1016/S0304-3940(00)01037-5
10.1016/0304-3940(93)90147-D
10.1016/0006-8993(95)01257-5
10.1002/mds.20162
10.1002/mds.20040
10.1016/S0002-9440(10)63421-9
10.1016/S0002-9440(10)62274-2
10.1016/j.neuron.2007.01.010
10.1016/j.brainres.2008.02.084
10.1016/j.jneuroim.2009.01.013
10.1186/1742-2094-7-64
10.4049/jimmunol.1100216
10.1186/1742-2094-9-47
10.1016/j.ajpath.2013.11.026
10.1016/j.neures.2005.11.009
10.1021/bi061359o
10.1038/srep00700
10.1073/pnas.88.13.5837
10.1097/00001756-200301200-00017
10.1016/j.febslet.2006.05.029
10.1111/j.1460-9568.2008.06329.x
10.1016/j.pep.2004.01.012
10.1046/j.1471-4159.2003.01788.x
10.1021/bi980537d
10.1371/journal.pone.0045227
10.1074/jbc.M111.329003
10.1007/s11095-008-9562-y
10.1016/S0006-291X(84)80190-4
10.1073/pnas.82.12.4245
10.1073/pnas.85.12.4506
10.1007/BF00308809
10.2174/156720510793611592
10.1016/S0197-0186(01)00040-7
10.1038/85525
10.1038/nm838
10.1038/ncpneuro0355
10.1016/0046-8177(95)90001-2
10.1111/j.1365-2990.1995.tb01063.x
10.1523/JNEUROSCI.0616-08.2008
10.1002/glia.20468
10.1002/(SICI)1098-1136(19990215)25:4<324::AID-GLIA2>3.0.CO;2-5
10.1074/jbc.272.46.29390
10.1016/j.neurobiolaging.2006.12.001
10.1111/j.1749-6632.1997.tb48468.x
10.1016/S0197-4580(00)00181-0
10.1002/jnr.490310405
10.1046/j.1471-4159.1998.71052123.x
10.1038/sj.cdd.4401286
10.1523/JNEUROSCI.2557-04.2004
10.1016/S0197-4580(01)00292-5
10.1002/jnr.20093
10.1016/0304-3940(88)90690-8
10.1016/S0165-5728(01)00496-9
10.1046/j.1365-2362.2002.00994.x
10.1038/nm1653
10.1016/j.nbd.2004.09.009
10.1002/cne.21469
10.1038/nm1201-1356",<Element 'PubmedArticle' at 0x7f05dc9c8040>
161,"25178404
24412277
1414275
23574177
22416831
24223593
17667932
19211030
19211891
23171029
18040847
24040235
21159979
20864679
20920788
12895417
24117759
24330773
17100841
18374906
17715348
16141783
22369693
22960311
12511873
22919031
19513731
23943781
21239853
18615702
17116874
17056594
23383382
20967130
24050316
23576130
22489141
20846376
22095718
11754997
23322736
19486646
24450891
24450890
23085937
23582316
23277060
23946308
23252647
22737039
23682015
18614025
23126372
14612429
21441973
22290798
23948931
18457819
23208281
24655894
12434053
17137722
15588287
19923550
23622060
24198349
18509040
19834064
23486975
15855647
18040846
19277012
16006665
17314396
24908174
16219804
16984903",Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.,"Alzheimer's disease (AD) is the most common cause of dementia, and currently, there is no effective treatment. The major neuropathological lesions in AD are accumulation of amyloid β (Aβ) as amyloid plaques and congophilic amyloid angiopathy, as well as aggregated tau in the form of neurofibrillary tangles (NFTs). In addition, inflammation and microglia/macrophage function play an important role in AD pathogenesis. We have hypothesized that stimulation of the innate immune system via Toll-like receptor 9 (TLR9) agonists, such as type B CpG oligodeoxynucleotides (ODNs), might be an effective way to ameliorate AD related pathology. We have previously shown in the Tg2576 AD model that CpG ODN can reduce amyloid deposition and prevent cognitive deficits. In the present study, we used the 3xTg-AD mice with both Aβ and tau related pathology. The mice were divided into 2 groups treated from 7 to 20 months of age, prior to onset of pathology and from 11 to 18 months of age, when pathology is already present. We demonstrated that immunomodulatory treatment with CpG ODN reduces both Aβ and tau pathologies, as well as levels of toxic oligomers, in the absence of any apparent inflammatory toxicity, in both animal groups. This pathology reduction is associated with a cognitive rescue in the 3xTg-AD mice. Our data indicate that modulation of microglial function via TLR9 stimulation is effective at ameliorating all the cardinal AD related pathologies in an AD mouse model suggesting such an approach would have a greater chance of achieving clinical efficacy.",[],Acta neuropathologica communications,2014-09-03,"[{'lastname': 'Scholtzova', 'firstname': 'Henrieta', 'initials': 'H', 'affiliation': None}, {'lastname': 'Chianchiano', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Pan', 'firstname': 'Jason', 'initials': 'J', 'affiliation': None}, {'lastname': 'Sun', 'firstname': 'Yanjie', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Goñi', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': None}, {'lastname': 'Mehta', 'firstname': 'Pankaj D', 'initials': 'PD', 'affiliation': None}, {'lastname': 'Wisniewski', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Departments of Neurology, Pathology and Psychiatry, New York University School of Medicine, Rm 802, Alexandria ERSP, 450 East 29th Street, New York 10016, NY, USA. thomas.wisniewski@nyumc.org.'}]",,,,,"10.1186/s40478-014-0101-2
10.1016/j.bcp.2013.12.020
10.1007/BF00227813
10.2174/1871527311312050008
10.1111/j.1479-8301.2011.00378.x
10.1155/2013/576383
10.1038/sj.icb.7100103
10.1016/j.addr.2008.12.008
10.1523/JNEUROSCI.5715-08.2009
10.1111/nan.12002
10.1007/s11481-007-9069-z
10.1371/journal.pone.0074377
10.1523/JNEUROSCI.4403-10.2010
10.2353/ajpath.2010.100265
10.1016/j.neuron.2010.08.023
10.1016/S0896-6273(03)00434-3
10.1186/1742-2094-10-150
10.1111/j.1460-9568.2006.05149.x
10.1016/j.brainres.2008.01.095
10.1523/JNEUROSCI.2361-07.2007
10.1097/01.jnen.0000178444.33972.e0
10.1186/1742-2094-9-40
10.1016/j.neuroscience.2012.08.058
10.1038/nri978
10.1182/blood-2012-04-422758
10.1007/s00401-009-0556-6
10.1093/brain/awt210
10.1002/jnr.21713
10.1073/pnas.0604011103
10.1074/jbc.M608485200
10.1371/journal.pone.0013391
10.1089/neu.2013.3017
10.1093/brain/awt062
10.3390/ijms13033038
10.1186/1742-2094-7-56
10.4049/jimmunol.1100620
10.1016/S0197-4580(01)00287-1
10.1073/pnas.1215165110
10.1016/j.bbi.2009.01.017
10.1056/NEJMoa1304839
10.1056/NEJMoa1312889
10.1136/jnnp-2012-303144
10.1016/j.tips.2013.03.002
10.2741/S381
10.1212/WNL.0b013e3182a4a577
10.1111/nan.12011
10.2217/fnl.12.6
10.1002/cne.23463
10.1016/j.neuron.2008.06.014
10.1111/bpa.12004
10.1189/jlb.0303114
10.1007/s12264-011-1205-3
10.1002/glia.22298
10.1016/j.brainres.2008.02.084
10.4161/pri.23061
10.1186/1742-2094-11-54
10.1126/science.1078259
10.1016/j.neuroscience.2006.10.020
10.1186/1742-2094-1-24
10.1212/WNL.0b013e3181c67808
10.1016/j.neuron.2013.04.005
10.1523/JNEUROSCI.3241-13.2013
10.1523/JNEUROSCI.1146-08.2008
10.2353/ajpath.2009.090418
10.1523/JNEUROSCI.4361-12.2013
10.1016/S0002-9440(10)62364-4
10.1007/s11481-006-9049-8
10.1038/mt.2009.44
10.1091/mbc.E06-10-0975
10.1016/j.coi.2014.05.005
10.1093/brain/awl249",<Element 'PubmedArticle' at 0x7f05dc978cc0>
162,25169677,Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis.,"Neuroinflammation is hypothesized to be a major driving force behind Alzheimer's disease (AD) pathogenesis. This hypothesis predicts that activated microglial cells can stimulate neurons to produce excessive amounts of β-amyloid protein (Aβ₁₋₄₂) and tau. The excess Aβ₁₋₄₂ forms extracellular deposits which stimulate further microglial activation. The excess tau is partially released but also becomes phosphorylated forming intracellular neurofibrillary deposits. The end result is a positive feedback mechanism which drives the disease development. To test the viability of this hypothesis, we exposed differentiated SH-SY5Y and N-tera2/D1 (N-tera2) cells to conditioned medium (CM) from LPS/IFNγ-stimulated human microglia. We found that the CM caused a large increase in the production and release of Aβ and tau. The CM also caused SH-SY5Y cells to increase their expression of amyloid precursor protein and release of its β-secretase cleaved products (sAPPβs) as well as Aβ oligomers, but the CM reduced release of its α-secretase cleaved products (sAPPαs). Direct treatment of SH-SY5Y and N-tera2 cells with the inflammatory cytokines IL-6 and IL-1β as well as with Aβ₁₋₄₂, resulted in an increase in tau messenger RNA and protein expression. Pretreatment of LPS/IFNγ-stimulated human microglia cells with the nonsteroidal anti-inflammatory drugs ibuprofen and aspirin, the antioxidant GSH, the H₂S donor NaSH, and the anti-inflammatory cytokine IL-10, resulted in a CM with diminished ability to stimulate tau expression. There was no effect on the morphology of SH-SY5Y cells, or on their viability, following exposure to micromolar levels of Aβ₁₋₄₂. Our data indicate that reactive microglia play an important role in governing the expression of Aβ and tau, and therefore the progression of AD. They provide further evidence that appropriate anti-inflammatory treatment should be beneficial in AD.","['Amyloid precursor protein', 'Aspirin', 'Glutathione', 'IL-10', 'Ibuprofen', 'Neurofibrillary tangles', 'Tauopathy']",Neurobiology of aging,2014-08-30,"[{'lastname': 'Lee', 'firstname': 'Moonhee', 'initials': 'M', 'affiliation': 'Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'McGeer', 'firstname': 'Edith', 'initials': 'E', 'affiliation': 'Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'McGeer', 'firstname': 'Patrick L', 'initials': 'PL', 'affiliation': 'Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: mcgeerpl@mail.ubc.ca.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2014.07.024,<Element 'PubmedArticle' at 0x7f05dc935310>
163,25115544,Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults.,"Alzheimer's disease (AD) is characterized by deleterious accumulation of amyloid-β (Aβ) peptide into senile plaque, neurofibrillary tangles formed from hyperphosphorylated tau protein, and loss of cholinergic synapses in the cerebral cortex. The deposition of Aβ-loaded plaques results in microglial activation and subsequent production of reactive oxygen species (ROS), including free radicals. Neurons in aging and AD brains are particularly vulnerable to ROS and other toxic stimuli. Therefore, agents that decrease the vulnerability of neurons against ROS may provide therapeutic values for the treatment or prevention of AD. In the present study, our goal was to test whether intravenous immunoglobulin (IVIG) treatment could preserve as well as protect neurons from oxidative damage. We report that treatment with IVIG protects neuronal viability and synaptic proteins in primary rat hippocampal neurons. Further, we demonstrate the tolerability of IVIG treatment in the primary human fetal mixed brain cultures. Indeed, a high dose (20 mg/ml) of IVIG treatment was well-tolerated by primary human brain cultures that exhibit a normal neuronal phenotype. We also observed a potent neuropreservatory effect of IVIG against ROS-mediated oxidative insults in these human fetal brain cultures. These results indicate that IVIG treatment has great potential to preserve and protect primary human neuronal-enriched cultures and to potentially rescue dying neurons from oxidative insults. Therefore, our findings suggest that IVIG treatment may represent an important therapeutic agent for clinical trials designed to prevent and delay the onset of neurodegeneration as well as AD pathology.",[],Current Alzheimer research,2014-08-15,"[{'lastname': 'Lahiri', 'firstname': 'Debomoy K', 'initials': 'DK', 'affiliation': None}, {'lastname': 'Ray', 'firstname': 'Balmiki', 'initials': 'B', 'affiliation': 'Indiana University School of Medicine, Department of Psychiatry, Department of Psychiatry, Neuroscience Research Center, 320 West 15th Street, NB 200C, Indianapolis IN 46202, USA. dlahiri@iupui.edu.'}]",,,,,10.2174/1567205011666140812113851,<Element 'PubmedArticle' at 0x7f05dc945c70>
164,24292188,[Molecular targeting and translational research for new therapeutic strategies on Alzheimer's disease].,"Alzheimer's disease (AD) is the most common cause of dementia. AD treatments currently approved are commonly regarded as purely symptomatic. Therefore, development of effective disease modifying treatments is eagerly required. Pathological hallmarks of AD brain include amyloid-β (Aβ) accumulation, neurofibrillary tangle (NFT), synaptic loss, and neurodegeneration. Understanding of AD pathogenesis provides deep insight into the therapeutic approach for AD. In this review, we introduce our current translational researches for new therapeutic strategies against AD. We recently revealed that a key molecule for actin assembly, Wiscott-Aldrich syndrome protein family verprolin-homologous protein (WAVE), is accumulated into NFT in an Aβ pathology-dependent manner. Because synaptic function is maintained by precise regulation of actin assembly, abnormal accumulation of WAVE induced by Aβ pathology may expand the NFT pathology to synaptic dysfunction. These results imply that lowering of brain Aβ at the early stage of AD pathogenesis is a promising therapeutic approach. As the approach for the elimination of brain Aβ, we have studied microglial Aβ phagocytosis and proposed its therapeutic application for AD treatment. We demonstrated that anti-Aβ antibody and galantamine promote microglial Aβ phagocytosis by binding to Fc receptors and nicotinic acetylcholine receptors on microglia, respectively. On the other hand, we demonstrated that the transplantation with microglia effectively eliminate brain Aβ and microglia-like Aβ phagocytic cells were successfully prepared from bone marrow derived cells by the stimulation with macrophage colony-stimulating factor. Thus, we have studied cell therapeutic strategy aim at its clinical application for AD treatment by the activation of endogenous microglia and transplantation of exogenous microglia-like Aβ phagocytic cells.",[],Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,2013-12-03,"[{'lastname': 'Takata', 'firstname': 'Kazuyuki', 'initials': 'K', 'affiliation': 'Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University.'}]",,,,,10.1248/yakushi.13-00219,<Element 'PubmedArticle' at 0x7f05dc950ae0>
165,24272705,Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain.,"This study investigated the allegedly causal relationship between microglial activation and neurofibrillary degeneration (NFD) typical of Alzheimer's disease (AD) by determining if presence of extreme microglial activation coincides with intensified NFD. We performed comparative histopathological analyses of NFD and microglial reactivity in 18 primary subjects ranging from 4 to 51 years of age. Ten of these subjects (median age 34) died from infectious disease (HIV, sepsis) and CNS trauma, while eight subjects (median age 32.5) died from non-infectious conditions (controls). Second, we also examined two 52-year-old subjects with Down syndrome where one had comorbid sepsis and the other one did not. We found that all 10 subjects with infectious/traumatic diagnoses showed severe neuroinflammation, while the 8 control subjects completely lacked neuroinflammatory changes. However, all 18 primary subjects were found to show the same early-stage, pretangle neuropathology of Braak stage 1a and 1b, that is, they exhibited primarily subcortical NFD in the locus coeruleus and sporadic lesions in the transentorhinal cortex. Similarly, the two subjects with Down syndrome showed the same high levels of NFD (Braak stage VI) irrespective of the comorbid sepsis-related neuroinflammation present in one of these individuals. Collectively, our findings show that despite rampant microglial activation in all subjects with neuroinflammatory conditions the extent of NFD is at the same level as seen in non-inflamed controls. These findings demonstrate that microglial activation does not initiate or exacerbate NFD, and we conclude that CNS inflammation is unlikely to be causally involved in the development of NFD characteristic of AD dementia.","['Alzheimer', 'Down syndrome', 'infection', 'microglial activation', 'sepsis']",Glia,2013-11-26,"[{'lastname': 'Streit', 'firstname': 'Wolfgang J', 'initials': 'WJ', 'affiliation': 'Department of Neuroscience, University of Florida College of Medicine and McKnight Brain Institute, Gainesville, Florida.'}, {'lastname': 'Xue', 'firstname': 'Qing-Shan', 'initials': 'QS', 'affiliation': None}, {'lastname': 'Braak', 'firstname': 'Heiko', 'initials': 'H', 'affiliation': None}, {'lastname': 'del Tredici', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': None}]",,,,"Copyright © 2013 Wiley Periodicals, Inc.",10.1002/glia.22589,<Element 'PubmedArticle' at 0x7f05dc958180>
166,"24059692
9786340
1057175
2873777
3103857
2484340
2497170
10685603
9736660
10526177
16253246
15823754
16651626
8843599
10202538
1638276
11596125
12379902
17509690
17136771
18567623
19513731
17572395
11494368
17270732
19289607
16192374
9712878
17339406
21902630
16258544
11857068
10872770
18316474
22029397
21904449
19850336
15899247
19107792
15850662
12629164
12379913
20134203
15051507
16556968
15044677
17822910
19109498
942051
16020737
15140924",Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles.,"Tau dysfunction is believed to be the primary cause of neurodegenerative disorders referred to as tauopathies, including Alzheimer's disease, Pick's disease, frontotemporal dementia and Parkinsonism. The role of microglial cells in the pathogenesis of tauopathies is still unclear. The activation of microglial cells has been correlated with neuroprotective effects through the release of neurotrophic factors and through clearance of cell debris and phagocytosis of cells with intracellular inclusions. In contrast, microglial activation has also been linked with chronic neuroinflammation contributing to the development of neurodegenerative diseases such as tauopathies. Microglial activation has been recently reported to precede tangle formation and the attenuation of tau pathology occurs after immunosuppression of transgenic mice.
Here we report the specific inhibition of microglial cells in rTg4510 tau-mutant mice by using fibrin γ377-395 peptide conjugated to iron oxide (γ-Fe2O3) nanoparticles of 21 ± 3.5 nm diameter.
Stabilization of the peptide by its covalent conjugation to the γ-Fe2O3 nanoparticles significantly decreased the number of the microglial cells compared to the same concentration of the free peptide. The specific microglial inhibition induces different effects on tau pathology in an age dependent manner. The reduction of activation of microglial cells at an early age increases the number of neurons with hyperphosphorylated tau in transgenic mice. In contrast, reduction of activation of microglial cells reduced the severity of the tau pathology in older mice. The number of neurons with hyperphosphorylated tau and the number of neurons with tangles are reduced than those in animals not receiving the fibrin γ377-395 peptide-nanoparticle conjugate.
These results demonstrate a differential effect of microglial activity on tau pathology using the fibrin γ377-395 peptide-nanoparticle conjugate, depending on age and/or stage of the neuropathological accumulation and aggregation.",[],Journal of nanobiotechnology,2013-09-26,"[{'lastname': 'Glat', 'firstname': 'Micaela', 'initials': 'M', 'affiliation': 'Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan 52900, Israel. sterned@mail.biu.ac.il.'}, {'lastname': 'Skaat', 'firstname': 'Hadas', 'initials': 'H', 'affiliation': None}, {'lastname': 'Menkes-Caspi', 'firstname': 'Noa', 'initials': 'N', 'affiliation': None}, {'lastname': 'Margel', 'firstname': 'Shlomo', 'initials': 'S', 'affiliation': None}, {'lastname': 'Stern', 'firstname': 'Edward A', 'initials': 'EA', 'affiliation': None}]",,,"Stabilization of the peptide by its covalent conjugation to the γ-Fe2O3 nanoparticles significantly decreased the number of the microglial cells compared to the same concentration of the free peptide. The specific microglial inhibition induces different effects on tau pathology in an age dependent manner. The reduction of activation of microglial cells at an early age increases the number of neurons with hyperphosphorylated tau in transgenic mice. In contrast, reduction of activation of microglial cells reduced the severity of the tau pathology in older mice. The number of neurons with hyperphosphorylated tau and the number of neurons with tangles are reduced than those in animals not receiving the fibrin γ377-395 peptide-nanoparticle conjugate.",,"10.1186/1477-3155-11-32
10.1016/S0166-2236(98)01337-X
10.1073/pnas.72.5.1858
10.1111/j.1749-6632.1986.tb38398.x
10.1016/0896-6273(89)90210-9
10.1093/geronj/44.6.55
10.1023/A:1007583214722
10.1016/S0014-5793(99)01279-X
10.1016/j.febslet.2005.09.095
10.1016/j.molmed.2005.02.008
10.2353/ajpath.2006.050840
10.1016/0166-2236(96)10049-7
10.1146/annurev.neuro.22.1.219
10.1016/0165-0173(92)90007-9
10.1002/glia.1106
10.1002/glia.10161
10.1016/j.brainresrev.2007.03.012
10.1002/glia.20462
10.1007/s00401-009-0556-6
10.1002/jnr.1157
10.1016/j.neuron.2007.01.010
10.1096/fj.08-123877
10.1523/JNEUROSCI.2868-05.2005
10.1074/jbc.273.35.22519
10.1084/jem.20061931
10.2174/138920111798377003
10.1038/nbt1154
10.1016/j.jmmm.2003.09.001
10.1038/sj.gt.3301624
10.1016/S0142-9612(00)00006-5
10.1215/15228517-2008-002
10.1021/bc200454k
10.1016/j.biomaterials.2009.09.093
10.1016/j.expneurol.2005.01.020
10.1016/j.brainresrev.2004.12.013
10.1002/glia.10153
10.1159/000258724
10.1016/j.yexcr.2004.01.002
10.1152/physrev.00024.2003
10.1016/j.nbd.2007.07.019
10.1016/0003-2697(76)90527-3
10.1126/science.1113694
10.1523/JNEUROSCI.0462-04.2004",<Element 'PubmedArticle' at 0x7f05dc8e39f0>
167,"24029727
23299379
21739165
17715348
21147995
21644996
22025915
23587140
23599928
23384597
20546729
21841002
22174735
22272619
22461630
23638068
17030663
21971458
21436112
22683529
23234879
9339438
22406355
12418000
15761950
22960250",Tau immunotherapy and imaging.,"Disappointing findings from recent phase III trials on amyloid-β (Aβ) immunotherapy for Alzheimer's disease (AD) have shifted the focus of such treatments to the tau protein. As tau pathology correlates better with the degree of dementia than Aβ plaque burden, it is a more attractive target once cognitive impairments are evident, while Aβ therapies may be better suited for the presymptomatic phase of the disease. Over 12 years ago, we initiated a tau immunotherapy program, seeking to alleviate the functional impairments associated with tau lesions in tauopathies. We have reported that various active and passive tau immunizations diminish tau pathology and improve function, including cognition, in different mouse models. Both extra- and intracellular pathways are likely involved. The antibodies may block the spread of tau pathology via microglial phagocytosis of the antibody-tau complex and facilitate lysosomal tau clearance in neurons after endosomal uptake. We have observed such antibody internalization following intracarotid injection in mice and in various culture models. These include brain slices and primary neurons from tangle mice as well as human neuroblastoma cell lines. Antibody targeting of different intracellular protein aggregates, including α-synuclein, Aβ and superoxide dismutase has been reported by others. Now, several laboratories have confirmed and extended our findings using various active and passive tau immunizations in different models, thereby clearly establishing the feasibility of this approach for clinical trials. We are also working on imaging approaches to monitor tau pathology, its consequences and the efficacy of treatments. Dire need exists for such diagnostic methods for tauopathies. Overall, therapies and diagnostic tools targeting tau pathology have a great potential for AD and other tauopathies.",[],Neuro-degenerative diseases,2013-09-14,"[{'lastname': 'Sigurdsson', 'firstname': 'Einar M', 'initials': 'EM', 'affiliation': 'Department of Neuroscience and Physiology, New York University School of Medicine, New York, N.Y., USA.'}]",,,,,10.1159/000354491,<Element 'PubmedArticle' at 0x7f05dc909400>
168,23954730,Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3β signaling pathway.,"Alzheimer's disease (AD), a neurodegenerative disorder exhibiting progressive loss of memory and cognitive functions, is characterized by the presence of neuritic plaques composed of neurofibrillary tangles and β-amyloid (Aβ) peptide. Drug delivery to the brain still remains highly challenging for the treatment of AD. Several studies have been shown that curcumin is associated with anti-amyloidogenic properties, but therapeutic application of its beneficial effects is limited. Here we investigated possible mechanisms involved in curcumin protection against Aβ(1-42)-induced cognitive impairment and, due to its poor bioavailability, we developed curcumin-loaded lipid-core nanocapsules in an attempt to improve the neuroprotective effect of this polyphenol. Animals received a single intracerebroventricular injection of Aβ(1-42) and they were administered either free curcumin or curcumin-loaded lipid-core nanocapsules (Cur-LNC) intraperitoneally for 10days. Aβ(1-42)-infused animals showed a significant impairment on learning-memory ability, which was paralleled by a significant decrease in hippocampal synaptophysin levels. Furthermore, animals exhibited activated astrocytes and microglial cells, as well as disturbance in BDNF expression and Akt/GSK-3β signaling pathway, beyond tau hyperphosphorylation. Our findings demonstrate that administration of curcumin was effective in preventing behavioral impairments, neuroinflammation, tau hyperphosphorylation as well as cell signaling disturbances triggered by Aβ in vivo. Of high interest, Cur-LNC in a dose 20-fold lower presented similar neuroprotective results compared to the effective dose of free curcumin. Considered overall, the data suggest that curcumin is a potential therapeutic agent for neurocognition and nanoencapsulation of curcumin in LNC might constitute a promising therapeutic alternative in the treatment of neurodegenerative diseases such as AD.","['Akt/GSK-3β pathway', 'Alzheimer’s disease', 'BDNF', 'Curcumin', 'Hippocampus', 'Lipid-core nanocapsules', 'β-Amyloid']",Neurobiology of learning and memory,2013-08-21,"[{'lastname': 'Hoppe', 'firstname': 'Juliana B', 'initials': 'JB', 'affiliation': 'Programa de Pós-Graduação em Bioquímica, Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul - UFRGS, Rua Ramiro Barcelos, 2600, Porto Alegre, Rio Grande do Sul 90035-003, Brazil. Electronic address: juhoppe@hotmail.com.'}, {'lastname': 'Coradini', 'firstname': 'Karine', 'initials': 'K', 'affiliation': None}, {'lastname': 'Frozza', 'firstname': 'Rudimar L', 'initials': 'RL', 'affiliation': None}, {'lastname': 'Oliveira', 'firstname': 'Claudia M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Meneghetti', 'firstname': 'André B', 'initials': 'AB', 'affiliation': None}, {'lastname': 'Bernardi', 'firstname': 'Andressa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Pires', 'firstname': 'Elisa Simões', 'initials': 'ES', 'affiliation': None}, {'lastname': 'Beck', 'firstname': 'Ruy C R', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Salbego', 'firstname': 'Christianne G', 'initials': 'CG', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.nlm.2013.08.001,<Element 'PubmedArticle' at 0x7f05dc91d770>
169,"23567638
8034754
17949824
17052803
19828948
7715705
1745413
9100663
11772511
11121190
14643377
12895417
16232318
18974297
12655295
17724122
20110607
7507336
7568127
8673925
10378869
19320056
16926764
21835156
12427305
20551911
18700006
15493873
19070941
17168643
11520987
11520988
2808689
21777559
11099416
10981966
10978311
15095367
18418902
11943805
20038584
17483297
12962917
14973251
20971085
22642825
11283158
21771791
11495925
15772355
18701698",Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and Tau-related pathologies.,"Neuroinflammation, through production of proinflammatory molecules and activated glial cells, is implicated in Alzheimer's disease (AD) pathogenesis. One such proinflammatory mediator is tumor necrosis factor α (TNF-α), a multifunctional cytokine produced in excess and associated with amyloid β-driven inflammation and cognitive decline. Long-term global inhibition of TNF receptor type I (TNF-RI) and TNF-RII signaling without cell or stage specificity in triple-transgenic AD mice exacerbates hallmark amyloid and neurofibrillary tangle pathology. These observations revealed that long-term pan anti-TNF-α inhibition accelerates disease, cautions against long-term use of anti-TNF-α therapeutics for AD, and urges more selective regulation of TNF signaling. We used adeno-associated virus vector-delivered siRNAs to selectively knock down neuronal TNF-R signaling. We demonstrate divergent roles for neuronal TNF-RI and TNF-RII where loss of opposing TNF-RII leads to TNF-RI-mediated exacerbation of amyloid β and Tau pathology in aged triple-transgenic AD mice. Dampening of TNF-RII or TNF-RI+RII leads to a stage-independent increase in Iba-1-positive microglial staining, implying that neuronal TNF-RII may act nonautonomously on the microglial cell population. These results reveal that TNF-R signaling is complex, and it is unlikely that all cells and both receptors will respond positively to broad anti-TNF-α treatments at various stages of disease. In aggregate, these data further support the development of cell-, stage-, and/or receptor-specific anti-TNF-α therapeutics for AD.",[],The American journal of pathology,2013-04-10,"[{'lastname': 'Montgomery', 'firstname': 'Sara L', 'initials': 'SL', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA.'}, {'lastname': 'Narrow', 'firstname': 'Wade C', 'initials': 'WC', 'affiliation': None}, {'lastname': 'Mastrangelo', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Olschowka', 'firstname': 'John A', 'initials': 'JA', 'affiliation': None}, {'lastname': ""O'Banion"", 'firstname': 'M Kerry', 'initials': 'MK', 'affiliation': None}, {'lastname': 'Bowers', 'firstname': 'William J', 'initials': 'WJ', 'affiliation': None}]",,,,Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.,10.1016/j.ajpath.2013.02.030,<Element 'PubmedArticle' at 0x7f05dc8ad6d0>
170,23493130,Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease.,"To review the rationale behind and the use of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD). Established as well as new candidate biomarkers will be covered.
AD is a complex disorder and the AD brain is characterized by multiple pathological processes, in addition to well-described plaque and tangle diseases. Recent studies have tried to address this by evaluating biomarkers related to features such as neuroinflammation, oxidative stress, microglial activation and synaptic degeneration, with some positive results.
The CSF biomarkers total tau, phosphorylated-tau and the 42 amino acid isoform of amyloid beta reflect core elements of AD, that is, axonal degeneration, tangle disease and senile plaques, have been thoroughly tested and provide high diagnostic accuracy in the discrimination of patients with AD as compared with cognitively normal controls. They are also highly predictive of AD with dementia in patients with mild cognitive impairment, and have been included in new diagnostic criteria. New biomarkers may add to their diagnostic performance. Other potential fields of use include the monitoring of disease progression or pharmacodynamic drug effects. A common denominator for the candidate biomarkers is the need for validation in further studies to clarify their potential.",[],Current opinion in psychiatry,2013-03-16,"[{'lastname': 'Rosén', 'firstname': 'Christoffer', 'initials': 'C', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg Mölndal, Sweden. christoffer.rosen@neuro.gu.se'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': None}]",,,,,10.1097/YCO.0b013e32835f6747,<Element 'PubmedArticle' at 0x7f05dc8d1180>
171,"23486975
10858586
16034365
9918122
9278049
10674423
20920788
7708769
12409305
17127334
19655259
15967035
11440715
16477040
11755009
16687499
17059563
22438044
2508093
8412571
2529544
9458167
12130773
17222916
15473997
18040847
18701698
18640458
12937146
16192374
22095718
16572453
22121920
20846376
20864679
15347683
12629164
22198949
11226152
22131415
15649704
18700006
22173340
3670729
10378868
12895417
17329210
10037734
21900936
17728444
17549256
18302763
9373175
8892349
9224523
9056542
10833312
11578769
16476660",Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model.,"Neuroinflammation is an important component of Alzheimer's disease (AD) pathogenesis and has been implicated in neurodegeneration. Interleukin-1 (IL-1), a potent inflammatory cytokine in the CNS, is chronically upregulated in human AD and believed to serve as part of a vicious inflammatory cycle that drives AD pathology. To further understand the role of IL-1β in AD pathogenesis, we used an inducible model of sustained IL-1β overexpression (IL-1β(XAT)) developed in our laboratory. The triple transgenic mouse model of AD, which develops plaques and tangles later in its life cycle, was bred with IL-1β(XAT) mice, and effects of IL-1β overexpression on AD pathology were assessed in F1 progeny. After 1 and 3 months of transgene expression, we found robust increases in tau phosphorylation despite an ∼70-80% reduction in amyloid load and fourfold to sixfold increase in plaque-associated microglia, as well as evidence of greater microglial activation at the site of inflammation. We also found evidence of increased p38 mitogen-activated protein kinase and glycogen synthase kinase-3β activity, which are believed to contribute to tau phosphorylation. Thus, neuroinflammation regulates amyloid and tau pathology in opposing ways, suggesting that it provides a link between amyloid accumulation and changes in tau and raising concerns about the use of immunomodulatory therapies in AD.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2013-03-15,"[{'lastname': 'Ghosh', 'firstname': 'Simantini', 'initials': 'S', 'affiliation': 'Department of Neurobiology and Anatomy, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.'}, {'lastname': 'Wu', 'firstname': 'Michael D', 'initials': 'MD', 'affiliation': None}, {'lastname': 'Shaftel', 'firstname': 'Solomon S', 'initials': 'SS', 'affiliation': None}, {'lastname': 'Kyrkanides', 'firstname': 'Stephanos', 'initials': 'S', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}, {'lastname': 'Olschowka', 'firstname': 'John A', 'initials': 'JA', 'affiliation': None}, {'lastname': ""O'Banion"", 'firstname': 'M Kerry', 'initials': 'MK', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.4361-12.2013,<Element 'PubmedArticle' at 0x7f05dc8d7900>
172,"23486963
15661919
10932230
18953056
15608634
12663680
19865176
21806809
22301697
17403556
21883222
11438712
14997933
19355933
14635031
16368167
15883316
18723507
17168641
17245412
16472206
1566067
1763432
12130773
9190286
12765607
18640458
21471435
8810256
17906339
11140685
17897471
21144050
15172732
9600986
19660650
20140000
11193172
16541076
17545160
15642916
11140686
18838175
18461171
12640446
17086100
19225519
12847155
16936277
12565127
18003852
1786545
8198393
19228370
1673054
8083687
18568035
15254082
9268388
17287052
21697382
17137722
11788051
22677258
11756677","Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.","The Alzheimer's disease (AD) process is understood to involve the accumulation of amyloid plaques and tau tangles in the brain. However, attempts at targeting the main culprits, neurotoxic Aβ peptides, have thus far proven unsuccessful for improving cognitive function. Recent clinical trials with passively administrated anti-Aβ antibodies failed to slow cognitive decline in mild to moderate AD patients, but suggest that an immunotherapeutic approach could be effective in patients with mild AD. Using an AD mouse model (Tg2576), we tested the immunogenicity (cellular and humoral immune responses) and efficacy (AD-like pathology) of clinical grade Lu AF20513 vaccine. We found that Lu AF20513 induces robust ""non-self"" T-cell responses and the production of anti-Aβ antibodies that reduce AD-like pathology in the brains of Tg2576 mice without inducing microglial activation and enhancing astrocytosis or cerebral amyloid angiopathy. A single immunization with Lu AF20513 induced strong humoral immunity in mice with preexisting memory T-helper cells. In addition, Lu AF20513 induced strong humoral responses in guinea pigs and monkeys. These data support the translation of Lu AF20513 to the clinical setting with the aims of: (1) inducing therapeutically potent anti-Aβ antibody responses in patients with mild AD, particularly if they have memory T-helper cells generated after immunizations with conventional tetanus toxoid vaccine, and (2) preventing pathological autoreactive T-cell responses.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2013-03-15,"[{'lastname': 'Davtyan', 'firstname': 'Hayk', 'initials': 'H', 'affiliation': 'Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, California 92647, USA.'}, {'lastname': 'Ghochikyan', 'firstname': 'Anahit', 'initials': 'A', 'affiliation': None}, {'lastname': 'Petrushina', 'firstname': 'Irina', 'initials': 'I', 'affiliation': None}, {'lastname': 'Hovakimyan', 'firstname': 'Armine', 'initials': 'A', 'affiliation': None}, {'lastname': 'Davtyan', 'firstname': 'Arpine', 'initials': 'A', 'affiliation': None}, {'lastname': 'Poghosyan', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Marleau', 'firstname': 'Annette M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Movsesyan', 'firstname': 'Nina', 'initials': 'N', 'affiliation': None}, {'lastname': 'Kiyatkin', 'firstname': 'Anatoly', 'initials': 'A', 'affiliation': None}, {'lastname': 'Rasool', 'firstname': 'Suhail', 'initials': 'S', 'affiliation': None}, {'lastname': 'Larsen', 'firstname': 'Anna Kirstine', 'initials': 'AK', 'affiliation': None}, {'lastname': 'Madsen', 'firstname': 'Peter Juul', 'initials': 'PJ', 'affiliation': None}, {'lastname': 'Wegener', 'firstname': 'Karen Malene', 'initials': 'KM', 'affiliation': None}, {'lastname': 'Ditlevsen', 'firstname': 'Dorte Kornerup', 'initials': 'DK', 'affiliation': None}, {'lastname': 'Cribbs', 'firstname': 'David H', 'initials': 'DH', 'affiliation': None}, {'lastname': 'Pedersen', 'firstname': 'Lars Ostergaard', 'initials': 'LO', 'affiliation': None}, {'lastname': 'Agadjanyan', 'firstname': 'Michael G', 'initials': 'MG', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.4672-12.2013,<Element 'PubmedArticle' at 0x7f05dc881cc0>
173,"23332170
10680787
12783912
10858586
17487150
11164808
20920788
15294177
16732273
21976528
20951738
10899174
19074615
12519085
20305648
11495925
11822882
17460158
9724801
18040847
9427614
12714508
9390561
21951685
17955025
20846376
20864679
17479179
19627440
15530839
16914866
20134203
16141783
23077045
21266082
16020737
17549256
19368990
15197750
16859761
15742005
15554430
16960575
12594832
12413414
10652441",Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.,"Alzheimer's disease is characterized by amyloid plaques, neurofibrillary tangles, glial activation, and neurodegeneration. In mouse models, inflammatory activation of microglia accelerates tau pathology. The chemokine fractalkine serves as an endogenous neuronal modulator to quell microglial activation. Experiments with fractalkine receptor null mice suggest that fractalkine signaling diminishes tau pathology, but exacerbates amyloid pathology. Consistent with this outcome, we report here that soluble fractalkine overexpression using adeno-associated viral vectors significantly reduced tau pathology in the rTg4510 mouse model of tau deposition. Furthermore, this treatment reduced microglial activation and appeared to prevent neurodegeneration normally found in this model. However, in contrast to studies with fractalkine receptor null mice, parallel studies in an APP/PS1 model found no effect of increased fractalkine signaling on amyloid deposition. These data argue that agonism at fractalkine receptors might be an excellent target for therapeutic intervention in tauopathies, including those associated with amyloid deposition.",[],Neurobiology of aging,2013-01-22,"[{'lastname': 'Nash', 'firstname': 'Kevin R', 'initials': 'KR', 'affiliation': 'Molecular Pharmacology and Physiology Department, Byrd Alzheimer Institute, University of South Florida, Tampa, FL, USA. knash@health.usf.edu'}, {'lastname': 'Lee', 'firstname': 'Daniel C', 'initials': 'DC', 'affiliation': None}, {'lastname': 'Hunt', 'firstname': 'Jerry B', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Morganti', 'firstname': 'Josh M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Selenica', 'firstname': 'Maj-Linda', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Moran', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Reid', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': None}, {'lastname': 'Brownlow', 'firstname': 'Milene', 'initials': 'M', 'affiliation': None}, {'lastname': 'Guang-Yu Yang', 'firstname': 'Clement', 'initials': 'C', 'affiliation': None}, {'lastname': 'Savalia', 'firstname': 'Miloni', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gemma', 'firstname': 'Carmelina', 'initials': 'C', 'affiliation': None}, {'lastname': 'Bickford', 'firstname': 'Paula C', 'initials': 'PC', 'affiliation': None}, {'lastname': 'Gordon', 'firstname': 'Marcia N', 'initials': 'MN', 'affiliation': None}, {'lastname': 'Morgan', 'firstname': 'David', 'initials': 'D', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2012.12.011,<Element 'PubmedArticle' at 0x7f05dc834540>
174,"23301030
15295589
11274343
17245412
16354549
9427614
15608634
15834427
9600986
17505973
17286590
6375662
10850703
12214065
17477976
11457586
12391608
8463843
7798921
2218531
21703413
11150591
11403592
18585459
18621989
9030890
8822355
8883881
17057756
12478619
19052542
11166290
17223274
19889791
12832007
15205309
15519243
7557541
12736326
15231696
16457953
16328175
14984798
16246051
15979880
3670729
3263583
2549464
16042131
17036175
15172746
18673008
18067990
16876668
19330877
10844576
17541643
15829187
8103203
7901339
18282566
17912249
8780008
3953862
2560104
14634622
12097332
11919205
19473994
9024796
17254009
17086548
18846424
18420184
1759558
22752387
22278629
12084879
16456666
9705127
1653521
19263040
9461057
16877359
20394726
10516307
20201807","Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats.","Alzheimer's disease (AD) is a neurodegenerative pathology associated with aging characterized by the presence of senile plaques and neurofibrillary tangles that finally result in synaptic and neuronal loss. The major component of senile plaques is an amyloid-β protein (Aβ). Recently, we characterized the effects of a single intracerebroventricular (icv) injection of Aβ fragment (25-35) oligomers (oAβ(25-35)) for up to 3 weeks in rats and established a clear parallel with numerous relevant signs of AD. To clarify the long-term effects of oAβ(25-35) and its potential role in the pathogenesis of AD, we determined its physiological, behavioral, biochemical and morphological impacts 6 weeks after injection in rats. oAβ(25-35) was still present in the brain after 6 weeks. oAβ(25-35) injection did not affect general activity and temperature rhythms after 6 weeks, but decreased body weight, induced short- and long-term memory impairments, increased corticosterone plasma levels, brain oxidative (lipid peroxidation), mitochondrial (caspase-9 levels) and reticulum stress (caspase-12 levels), astroglial and microglial activation. It provoked cholinergic neuron loss and decreased brain-derived neurotrophic factor levels. It induced cell loss in the hippocampic CA subdivisions and decreased hippocampic neurogenesis. Moreover, oAβ(25-35) injection resulted in increased APP expression, Aβ(1-42) generation, and increased Tau phosphorylation. In conclusion, this in vivo study evidenced that the soluble oligomeric forms of short fragments of Aβ, endogenously identified in AD patient brains, not only provoked long-lasting pathological alterations comparable to the human disease, but may also directly contribute to the progressive increase in amyloid load and Tau pathology, involved in the AD physiopathology.",[],PloS one,2013-01-10,"[{'lastname': 'Zussy', 'firstname': 'Charleine', 'initials': 'C', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U710, Montpellier, France.'}, {'lastname': 'Brureau', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': None}, {'lastname': 'Keller', 'firstname': 'Emeline', 'initials': 'E', 'affiliation': None}, {'lastname': 'Marchal', 'firstname': 'Stéphane', 'initials': 'S', 'affiliation': None}, {'lastname': 'Blayo', 'firstname': 'Claire', 'initials': 'C', 'affiliation': None}, {'lastname': 'Delair', 'firstname': 'Brice', 'initials': 'B', 'affiliation': None}, {'lastname': 'Ixart', 'firstname': 'Guy', 'initials': 'G', 'affiliation': None}, {'lastname': 'Maurice', 'firstname': 'Tangui', 'initials': 'T', 'affiliation': None}, {'lastname': 'Givalois', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': None}]",,,,,10.1371/journal.pone.0053117,<Element 'PubmedArticle' at 0x7f05dc851db0>
175,"22869464
21112383
20623294
14980533
21135839
12130773
20718101
15837518
96891
19723026
8489110
17916180
16269641
22205954
20547128
12027877
20704556
17132984
17664291
18657226
21970975
14745459
16782234
11438712
17694066
14617754
19896503
18391792
12624314
17849175
19507189
15172734
18369648
3551211
20946241
18359131
19443808
19137294
15734937
22302811
21098282
22120142
22238323
20505729
15115813
20600909
5082125
8854311
701697
15550013
21576658
19249797
22193532
22234334
17503514
21951407
19551707
18753650
8815562
15707465
10420068
21839029
20032290
18282807
16627934
20150433
11263499
19222708
14523088
9561982
16442186
16194197
17380246
18774538
16256140
20561356
15184294
14993335
14568360
1438191
11403931
10079271
9330973
20870944
21918806
9157602
15692257
16982920
22363284
15173886
22037947
19630788
21526197
22045497
17565664",Fibrinogen and altered hemostasis in Alzheimer's disease.,"Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques, tau tangles, brain atrophy, and vascular pathology. Vascular defects include cerebrovascular dysfunction, decreased cerebral blood flow, and blood brain barrier (BBB) disruption, among others. Here, we review the evidence that links Aβ with the vascular pathology present in AD, with a specific focus on the hemostatic system and the clotting protein fibrinogen. Fibrinogen is normally found circulating in blood, but in AD it deposits with Aβ in the brain parenchyma and cerebral blood vessels. We found that Aβ and fibrin(ogen) interact, and their binding leads to increased fibrinogen aggregation, Aβ fibrillization, and the formation of degradation-resistant fibrin clots. Decreasing fibrinogen levels not only lessens cerebral amyloid angiopathy and BBB permeability, but it also reduces microglial activation and improves cognitive performance in AD mouse models. Moreover, a prothrombotic state in AD is evidenced by increased clot formation, decreased fibrinolysis, and elevated levels of coagulation factors and activated platelets. Abnormal deposition and persistence of fibrin(ogen) in AD may result from Aβ-fibrin(ogen) binding and altered hemostasis and could thus contribute to Aβ deposition, decreased cerebral blood flow, exacerbated neuroinflammation, and eventual neurodegeneration. Blocking the interaction between fibrin(ogen) and Aβ may be a promising therapeutic target for AD.",[],Journal of Alzheimer's disease : JAD,2012-08-08,"[{'lastname': 'Cortes-Canteli', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY 10065, USA.'}, {'lastname': 'Zamolodchikov', 'firstname': 'Daria', 'initials': 'D', 'affiliation': None}, {'lastname': 'Ahn', 'firstname': 'Hyung Jin', 'initials': 'HJ', 'affiliation': None}, {'lastname': 'Strickland', 'firstname': 'Sidney', 'initials': 'S', 'affiliation': None}, {'lastname': 'Norris', 'firstname': 'Erin H', 'initials': 'EH', 'affiliation': None}]",,,,,10.3233/JAD-2012-120820,<Element 'PubmedArticle' at 0x7f05dc801810>
176,22688056,Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice.,"Calpains are cysteine proteinases that selectively cleave proteins in response to calcium signals. Exacerbated activation of calpain has been implicated as a major component in the signaling cascade that leads to β-amyloid (Aβ) production and tau hyperphosphorylation in Alzheimer's disease (AD). In this study, we analyzed the potential therapeutic efficacy of inhibiting the activation of calpain by a novel calpain inhibitor in aged 3xTgAD mice with well-established cognitive impairment, plaques, and tangles. The administration of a novel inhibitor of calpain, A-705253, attenuated cognitive impairment and synaptic dysfunction in a dose-dependent manner in 3xTgAD mice. Inhibition of calpain lowered Aβ(40) and Aβ(42) levels in both detergent-soluble and detergent-insoluble fractions and also reduced the total number and size of thioflavin S-positive fibrillar Aβ deposits. Mechanistically, these effects were, in part, explained by a down-regulation of β-secretase 1 (BACE1) and an up-regulation of ATP-binding cassette transporter A1 (ABCA1) expression, which, in turn, contributed to reduced production and increased clearance of Aβ, respectively. Moreover, A-705253 decreased the activation of cyclin-dependent kinase 5 (CDK5) and thereby diminished the hyperphosphorylation of tau. Finally, blockage of calpain activation reduced the astrocytic and microglial responses associated with AD-like pathological characteristics in aged 3xTgAD mice. Our data provide relevant functional and molecular insights into the beneficial therapeutic effects of inhibiting calpain activation for the management of AD.",[],The American journal of pathology,2012-06-13,"[{'lastname': 'Medeiros', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California 92697-4545, USA.'}, {'lastname': 'Kitazawa', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': None}, {'lastname': 'Chabrier', 'firstname': 'Meredith A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Cheng', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Baglietto-Vargas', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Kling', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': None}, {'lastname': 'Moeller', 'firstname': 'Achim', 'initials': 'A', 'affiliation': None}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}]",,,,Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.,10.1016/j.ajpath.2012.04.020,<Element 'PubmedArticle' at 0x7f05dc7b0b80>
177,22652882,Manipulation of microglial activity as a therapy for Alzheimer's disease.,"The review aims to elucidate the potential of microglia as a therapeutic target in alleviating Alzheimer's Disease (AD). Microglia are the resident immune cells in the brain which respond to the presence of the hallmarks of AD, amyloid-beta (A beta) plaques and neurofibrillary tangles (NFT). Activated microglia are able to phagocytose and secrete pro-inflammatory and anti-inflammatory cytokines. However, the eventual accumulation of excess A beta peptides and NFT in AD means that microglial clearance of pathogens has been impaired. Pro-inflammatory cytokines may also contribute to the neurodegeneration. Based on the amyloid cascade hypothesis, A beta-activated microglia can produce pro-inflammatory cytokines which may exacerbate the hyperphosporylation of tau proteins that forms NFT in AD pathology. Microglial activation can thus be manipulated to prevent neurodegeneration and promote neuroprotection through several therapeutic agents and methods. Further studies regarding comprehensive microglial response towards A beta and NFT are required to develop an effective treatment of AD involving microglia.",[],Frontiers in bioscience (Scholar edition),2012-06-02,"[{'lastname': 'Tan', 'firstname': 'Bobby', 'initials': 'B', 'affiliation': 'Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.'}, {'lastname': 'Choi', 'firstname': 'Rachel Huiyi', 'initials': 'RH', 'affiliation': None}, {'lastname': 'Chin', 'firstname': 'Tammy Jing Yee', 'initials': 'TJ', 'affiliation': None}, {'lastname': 'Kaur', 'firstname': 'Charanjit', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ling', 'firstname': 'Eng-Ang', 'initials': 'EA', 'affiliation': None}]",,,,,10.2741/s342,<Element 'PubmedArticle' at 0x7f05dc7bfe00>
178,"22485096
10850730
15930395
10322493
14556712
14517353
11231639
21184278
19575680
21103384
17451936
18417708
15668737
21136067
18802001
10570203
16732273
21483675
21222549
11238054
11157072
21113149
20119496
12578223
20357768
19535996
9117556
2321027
15232608
16042310
11086982
12944519
20305648
17406260
19124175
17086105
17029828
19419556
12743238
19182459
6375662
15465275
19838177
19854041
10674422
17413007
12756137
14749724
17245412
9242912
21228171
19005470
19617885
15664179
2808689
21514247
21787318
10378882
21951279
21527731
12230326
18438727
19109498
19228947
11818564
15195085
2424016
18667150
19251629
21422524
17251419
20864679
21413990
21159979
16540580
7970158
1899001
3159021
18256671
16141783
15172746
15831717
15782150
2423512
15294141
12895417
21346746
19584439
18004725
17314293
18270700
16291936
16407531
19665462
19057621
17341135
16020737
17006900
16289476
18596154
18407457
21075920
16476660
22133718
16079410
16651626
18216194
21163350
17717139
19028582
19162340
11378249
10362792
15975065
12777621
16251544
1789684
12490942
15475950
7219539
15474976
11021833
20144673
20880504
20694024
21312224
11222652
20164348
12612547
19710322
17046788",A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging.,"Alzheimer's disease (AD) is a protein conformational disorder characterized by two major neuropathological features: extracellular accumulations of amyloid-β peptides in the form of plaques and intracellular tangles, consisting of hyperphosphorylated tau proteins. Several morphological and functional changes are associated with these lesions in the diseased brain, such as dendritic and synaptic alterations, as well as microglial and astroglial recruitment and their activation. The availability of transgenic mouse models that mimic key aspects of the disease in conjunction with recent advances in two-photon imaging facilitate the study of fundamental aspects of AD pathogenesis and allow for longitudinally monitoring the efficacy of therapeutic interventions. Here, we review the ambitious efforts to understand the relationship between the main neuropathological hallmarks of AD and their associated structural and functional abnormalities by means of in vivo two-photon imaging.","['CAA', 'amyloid plaques', 'calcium imaging', 'dendritic spines', 'glial cells', 'microglia', 'multiphoton imaging', 'neurofibrillary tangles']",Frontiers in psychiatry,2012-04-10,"[{'lastname': 'Liebscher', 'firstname': 'Sabine', 'initials': 'S', 'affiliation': 'Department of Cellular and Systems Neurobiology, Max Planck Institute of Neurobiology Martinsried, Germany.'}, {'lastname': 'Meyer-Luehmann', 'firstname': 'Melanie', 'initials': 'M', 'affiliation': None}]",,,,,"10.3389/fpsyt.2012.00026
10.1097/00002093-200000001-00008
10.1523/JNEUROSCI.4637-04.2005
10.1016/S0166-2236(98)01349-6
10.1016/S0896-6273(03)00639-1
10.1073/pnas.2034101100
10.1038/85525
10.1007/s11064-010-0371-4
10.1146/annurev.physiol.010908.163140
10.1371/journal.pone.0015477
10.1016/j.conb.2007.04.003
10.1523/JNEUROSCI.4814-07.2008
10.1172/JCI200523269
10.1007/s00401-010-0787-6
10.1126/science.1162844
10.1073/pnas.96.24.14088
10.1038/nn1715
10.1371/journal.pone.0018296
10.1517/14656566.2011.520702
10.1016/S0002-9440(10)64053-9
10.1038/nature09635
10.2174/157018009789057526
10.1038/nature08890
10.1097/NEN.0b013e3181a9fc66
10.1006/neur.1996.0056
10.1126/science.2321027
10.1172/JCI22317
10.1016/S0896-6273(00)00084-2
10.1038/nn.2511
10.1038/nprot.2006.58
10.1016/j.neurobiolaging.2008.11.006
10.1097/01.jnen.0000240469.20167.89
10.1016/j.nbd.2006.08.017
10.1186/1750-1326-4-19
10.1159/000197881
10.1016/S0006-291X(84)80190-4
10.1016/j.ijdevneu.2004.07.013
10.1038/nn.2432
10.1016/j.conb.2009.09.003
10.1016/S0197-4580(99)00063-9
10.1196/annals.1379.003
10.1001/archneur.60.5.729
10.1038/sj.emboj.7600061
10.1038/nrm2101
10.1146/annurev.biochem.66.1.385
10.1523/JNEUROSCI.5147-10.2011
10.1038/nature07487
10.1038/nprot.2009.89
10.1016/j.neuron.2005.01.003
10.1016/0165-5728(89)90115-X
10.1016/j.jalz.2011.05.731
10.1042/BST0390886
10.1016/S0165-5728(98)00226-4
10.1111/j.1471-4159.2011.07503.x
10.1152/physrev.00011.2010
10.1007/s12035-008-8018-z
10.1523/JNEUROSCI.4147-08.2008
10.1073/pnas.0811698106
10.1073/pnas.032670899
10.1038/nm1058
10.1073/pnas.83.11.4044
10.1016/j.neuron.2008.06.008
10.1126/science.1169096
10.1523/JNEUROSCI.3501-06.2007
10.2353/ajpath.2010.100265
10.1111/j.1471-4159.2011.07248.x
10.1523/JNEUROSCI.3941-09.2010
10.1523/JNEUROSCI.4454-05.2006
10.1016/0304-3940(94)90121-X
10.1073/pnas.82.12.4245
10.1038/nature06616
10.1097/01.jnen.0000178444.33972.e0
10.1016/j.neurobiolaging.2004.01.007
10.1126/science.1110647
10.1038/nmeth706
10.1016/j.neuron.2004.07.003
10.1016/S0896-6273(03)00434-3
10.1038/nn.2741
10.1002/glia.20599
10.1523/JNEUROSCI.5426-06.2007
10.1007/s00259-007-0704-y
10.1523/JNEUROSCI.3279-05.2005
10.1523/JNEUROSCI.2138-06.2006
10.1016/j.expneurol.2009.07.029
10.1038/cdd.2008.172
10.1371/journal.pbio.0050066
10.1126/science.1113694
10.1002/glia.20374
10.1016/j.neurobiolaging.2005.09.012
10.1523/JNEUROSCI.2377-07.2008
10.1016/j.biopha.2008.02.005
10.1177/0192623310385254
10.1016/j.neuron.2006.01.022
10.1126/scitranslmed.3002609
10.1523/JNEUROSCI.1879-05.2005
10.2353/ajpath.2006.050840
10.1111/j.1460-9568.2008.06367.x
10.1016/j.ymeth.2010.12.009
10.2353/ajpath.2007.070055
10.1016/j.nbd.2008.10.011
10.1016/j.tins.2008.11.007
10.1016/S0197-4580(01)00209-3
10.1016/S0002-9440(10)65423-5
10.2174/1567205043332081
10.1073/pnas.1232232100
10.1056/NEJMcibr055003
10.1002/ana.410300410
10.1038/nature01273
10.1038/nn1335
10.1038/290527a0
10.1016/j.biocel.2004.07.009
10.1016/S0002-9440(10)64644-5
10.1016/j.neuint.2010.02.002
10.1016/j.nurt.2010.05.017
10.1038/aps.2010.189
10.1002/jnr.22572
10.1523/JNEUROSCI.1602-10.2010
10.1038/nm838
10.1523/JNEUROSCI.2637-09.2009
10.1016/j.jmb.2006.09.046",<Element 'PubmedArticle' at 0x7f05dc7c7270>
179,"22017610
16300758
8593893
20064386
2407121
20846907
17952290
20012109
11124442
11837744
16310834
18004574
18769444
15562429
17579875
17591968
19503072
2493277
4729191
7991117
20357768
17420316
20879875
14751769
17936612
21173899
20029438
19282288
12888622
21074091
10442557
18288693
20493564
7830934
16832629
19395353
1285493
21187847
9562475
15542981
8176223
9130141
10946737
7574475
9214529
20102526
18391962
21600984
17493044
17492294
6716598
21994365
18391963
16402109
16083355
10485683
11910543
1736183
19535999
8910904
11708987
16990547
10663461
9855500
17023659
15986225
11994753
19642506
7534834
18003852
15232619
2904573
19317178
11484824
12615642
10210712
13990135
18216194
7533559
16195918
1759560
10794842
11784789
12794047
21982369
9202333
21326809
16238489
17032883
12533327",Frontal cortex neuropathology in dementia pugilistica.,"Dementia pugilistica (DP) is associated with chronic traumatic brain injury (CTBI), and leads to a ""punch drunk"" syndrome characterized by impairments in memory and executive function, behavioral changes, and motor signs. Microscopic features include the accumulation of neurofibrillary tangles (NFTs), beta-amyloid (Aβ), and TAR DNA binding protein 43 (TDP-43) pathology. Here we describe detailed clinical and neuropathological data about a 55-year-old retired boxer (ApoE3/4), who presented with executive dysfunction and behavioral impairments. At autopsy, significant Aβ pathology was seen, primarily in the form of diffuse plaques. Tau pathology was extensive and was determined to be of Braak and Braak stage VI. Frontal white matter showed evidence of glial tau inclusions (astrocytes and oligodendroglia). Cerebrovascular pathology was minimal with patchy amyloid angiopathy. Inflammation was another key feature, including microglial activation and significant C1q labeling of neurons, along with NFTs. TDP-43-positive pathology was also observed. Inflammation may be a key inciting as well as propagating feature of DP neuropathology.",[],Journal of neurotrauma,2011-10-25,"[{'lastname': 'Saing', 'firstname': 'Tommy', 'initials': 'T', 'affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California-Irvine, Irvine, California, USA.'}, {'lastname': 'Dick', 'firstname': 'Malcolm', 'initials': 'M', 'affiliation': None}, {'lastname': 'Nelson', 'firstname': 'Peter T', 'initials': 'PT', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Ronald C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Cribbs', 'firstname': 'David H', 'initials': 'DH', 'affiliation': None}, {'lastname': 'Head', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': None}]",,,,,10.1089/neu.2011.1957,<Element 'PubmedArticle' at 0x7f05dc792770>
180,21847625,Microglial pathology in Down syndrome.,"Subjects with Down syndrome (DS) inevitably develop histopathological features pathognomonic of Alzheimer's disease (AD), and DS can therefore be considered a human model of AD. Similar to AD, microglial activation has been reported in DS and the idea that detrimental neuroinflammation plays a key role in the pathogenesis of neurodegeneration is firmly embedded. However, recent work from this laboratory has offered evidence for an alternative view regarding the role of microglial cells in AD pathogenesis by showing presence of dystrophic (senescent) rather than activated microglia in both the AD and DS brain. In this report, we build on previously published observations in human brain and offer a detailed analysis of microglial senescent pathology in the temporal cortices of 6 DS cases in their 40s, a critical age bracket where virtually all DS subjects acquire neurofibrillary degeneration characteristic of AD. Our findings using both Iba1 and anti-ferritin immunostaining of microglial cells show that coincident with the appearance of tau pathology in DS subjects there is consistent presence of dystrophic microglial cells and conspicuous absence of activated microglia using both markers. The extent of microglial pathology varied among the individual DS cases, but they all revealed decreased numbers of normal microglia ranging from 19 to 85% of the controls. Nearly all of the ferritin-positive microglia, which constitute a subset of the total Iba1-reactive microglial population, exhibited dystrophic morphology. In its most severe form dystrophy was evident as total fragmentation of the cells' cytoplasm (cytorrhexis), which likely reflects terminal degeneration of microglia. Severely dystrophic, ferritin-positive cells were often found to be colocalized with tau-positive senile plaques. Our findings help to consolidate the idea that microglial degeneration and neurofibrillary degeneration are closely linked events in a human model of AD. They suggest that microglial degeneration follows a gradually progressive course that increases in its severity in parallel with the progression of AD neurodegenerative changes.",[],Acta neuropathologica,2011-08-19,"[{'lastname': 'Xue', 'firstname': 'Qing-Shan', 'initials': 'QS', 'affiliation': 'Department of Neuroscience, McKnight Brain Institute, University of Florida College of Medicine, PO Box 100244, Gainesville, FL, 32610-0244, USA.'}, {'lastname': 'Streit', 'firstname': 'Wolfgang J', 'initials': 'WJ', 'affiliation': None}]",,,,,10.1007/s00401-011-0864-5,<Element 'PubmedArticle' at 0x7f05dc740db0>
181,"21825035
11520930
11898551
17596718
15615642
12470988
15615643
20522014
17270732
17051205
15831501
17579710
19914323
8439309
13862582
20700717
2164576
21529244
12101069
18088381
19782073
8552282
20004218
15721985
11119717
12605413
19076429
18709343
16930434
17173140
21237293
18486110
20416276
20167003
19931595
19559056
20937894
21172610","Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice.","Abnormal tau accumulation can lead to the development of neurodegenerative diseases. P301S mice overexpress the human tau mutated gene, resulting in tau hyperphosphorylation and tangle formation. Mice also develop synaptic deficits and microglial activation prior to any neurodegeneration and tangles. Oxidative stress can also affect tauopathy. We studied the role of oxidative stress in relationship to behavioral abnormalities and disease progression in P301S mice at 2, 7, and 10 mo of age. At 7 mo of age, P301S mice had behavioral abnormalities, such as hyperactivity and disinhibition. At the same age, we observed increased carbonyls in P301S mitochondria (∼215 and 55% increase, males/females), and deregulation in the activity and content of mitochondrial enzymes involved in reactive oxygen species formation and energy metabolism, such as citrate synthase (∼19 and ∼5% decrease, males/females), MnSOD (∼16% decrease, males only), cytochrome C (∼19% decrease, females only), and cytochrome C oxidase (∼20% increase, females only). These changes in mitochondria proteome appeared before tau hyperphosphorylation and tangle formation, which were observed at 10 mo and were associated with GSK3β activation. At that age, mitochondria proteome deregulation became more apparent in male P301S mitochondria. The data strongly suggest that oxidative stress and mitochondrial abnormalities appear prior to tau pathology.",[],FASEB journal : official publication of the Federation of American Societies for Experimental Biology,2011-08-10,"[{'lastname': 'Dumont', 'firstname': 'Magali', 'initials': 'M', 'affiliation': 'Weill Cornell Medical College, Department of Neurology and Neuroscience, 525 East 68th St., Rm. A569A, New York, NY 10065, USA. mad2138@med.cornell.edu'}, {'lastname': 'Stack', 'firstname': 'Cliona', 'initials': 'C', 'affiliation': None}, {'lastname': 'Elipenahli', 'firstname': 'Ceyhan', 'initials': 'C', 'affiliation': None}, {'lastname': 'Jainuddin', 'firstname': 'Shari', 'initials': 'S', 'affiliation': None}, {'lastname': 'Gerges', 'firstname': 'Meri', 'initials': 'M', 'affiliation': None}, {'lastname': 'Starkova', 'firstname': 'Natalia N', 'initials': 'NN', 'affiliation': None}, {'lastname': 'Yang', 'firstname': 'Lichuan', 'initials': 'L', 'affiliation': None}, {'lastname': 'Starkov', 'firstname': 'Anatoly A', 'initials': 'AA', 'affiliation': None}, {'lastname': 'Beal', 'firstname': 'Flint', 'initials': 'F', 'affiliation': None}]",,,,,"10.1096/fj.11-186650
10.1089/ars.2010.3849",<Element 'PubmedArticle' at 0x7f05dc74ca40>
182,"21704011
20107219
20610346
18322400
17762886
1941081
3992249
16129514
10188787
11718746
1467980
1411529
8592166
9798935
18842902
11423097
16504943
10518584
11876777
20335454
12483218
14985348
12895417
11438599
21145362
21156158
17507561
19729478
20025958
17218018
7519660
11752469
20080609
9371842
11278934
8942969
10357228
10357227
10357226
12669026
10357230
19355845
16540327
11409420
11761474
11683988
9736023
17456772
8552282
14642273
16828202
2772638
7750571
11884598
11970863
15585346",Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.,"Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and β-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M(1) receptors (M(1)Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M(1)Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M(1)R(-/-) mice. Our data show that M(1)R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M(1)R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Aβ in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M(1)R were attributed to changes in the glycogen synthase kinase 3β and protein kinase C activities. Finally, deleting the M(1)R increased the astrocytic and microglial response associated with Aβ plaques. Our data highlight the significant role that disrupting the M(1)R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M(1)R agonists for treating AD.",[],The American journal of pathology,2011-06-28,"[{'lastname': 'Medeiros', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California 92697-4545, USA.'}, {'lastname': 'Kitazawa', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': None}, {'lastname': 'Caccamo', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': None}, {'lastname': 'Baglietto-Vargas', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Estrada-Hernandez', 'firstname': 'Tatiana', 'initials': 'T', 'affiliation': None}, {'lastname': 'Cribbs', 'firstname': 'David H', 'initials': 'DH', 'affiliation': None}, {'lastname': 'Fisher', 'firstname': 'Avraham', 'initials': 'A', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}]",,,,Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.,10.1016/j.ajpath.2011.04.041,<Element 'PubmedArticle' at 0x7f05dc6e3db0>
183,21458164,Dental X-ray exposure and Alzheimer's disease: a hypothetical etiological association.,"Despite the fact that Alzheimer's disease was identified more than 100 years ago, its cause remains elusive. Although the chance of developing Alzheimer's disease increases with age, it is not a natural consequence of aging. This article proposes that dental X-rays can damage microglia telomeres - the structures at the end of chromosomes that determine how many times cells divide before they die - causing them to age prematurely. Degenerated microglia lose their neuroprotective properties, resulting in the formation of neurofibrillary tau tangles and consequently, the neuronal death that causes Alzheimer's dementia. The hypothesis that Alzheimer's is caused specifically by microglia telomere damage would explain the delay of one decade or longer between the presence of Alzheimer's brain pathology and symptoms; telomere damage would not cause any change in microglial function, it would just reset the countdown clock so that senescence and apoptosis occurred earlier than they would have without the environmental insult. Once microglia telomere damage causes premature aging and death, the adjacent neurons are deprived of the physical support, maintenance and nourishment they require to survive. This sequence of events would explain why therapies and vaccines that eliminate amyloid plaques have been unsuccessful in stopping dementia. Regardless of whether clearing plaques is beneficial or harmful - which remains a subject of debate - it does not address the failing microglia population. If microglia telomere damage is causing Alzheimer's disease, self-donated bone marrow or dental pulp stem cell transplants could give rise to new microglia populations that would maintain neuronal health while the original resident microglia population died.",[],Medical hypotheses,2011-04-05,"[{'lastname': 'Rodgers', 'firstname': 'Caroline C', 'initials': 'CC', 'affiliation': 'caroline.rodgers@hotmail.com'}]",,,,Copyright © 2011 Elsevier Ltd. All rights reserved.,10.1016/j.mehy.2011.03.016,<Element 'PubmedArticle' at 0x7f05dc7073b0>
184,21212607,[Pathological changes induced by amyloid-β in Alzheimer's disease].,"The pathologic hallmarks of Alzheimer's disease (AD) include senile plaque, neurofibrillary tangles (NFTs), synaptic loss, and neurodegeneration. Senile plaque and NFTs are formed by accumulation of amyloid-β (Aβ) and hyperphosphorylated tau, respectively. Progressive synaptic dysfunction and loss closely correlate with cognitive deficits in AD. Based on studies of the genes responsible for familial AD and temporal patterns of pathologic changes in AD brains, the Aβ accumulation is thought to be a primary event that influences other AD pathologies in the developmental cascade of AD. However, the details of Aβ effects on the other AD pathologies remain poorly understood. In this review, we provide an overview of the effects of Aβ in AD brains, especially focusing on synaptic dysfunction and microglia. We have recently found abnormal accumulation of a key molecule for actin assembly in NFTs of AD brains, and it was revealed that the accumulation requires not only tau pathology but also an Aβ burden in a study using transgenic mouse models of AD. Synaptic integrity is morphologically maintained by the precise regulation of actin assembly. Therefore, the results suggest the possibility that Aβ may promote NFT maturation and induce synaptic dysfunction through the disturbance of actin assembly. Thus Aβ seems to be a promoting factor in brain aging. On the other hand, we have studied microglial phagocytic ability for a compensatory pathologic reaction to Aβ accumulation. Further studies on the Aβ-dependent AD pathologies may contribute to determining novel mechanisms of AD development and new therapeutic targets in AD.",[],Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,2011-01-08,"[{'lastname': 'Takata', 'firstname': 'Kazuyuki', 'initials': 'K', 'affiliation': 'Department of Neurobiology, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan. kaz@mb.kyoto-phu.ac.jp'}, {'lastname': 'Kitamura', 'firstname': 'Yoshihisa', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Taniguchi', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': None}]",,,,,10.1248/yakushi.131.3,<Element 'PubmedArticle' at 0x7f05dc70dc20>
185,"21152933
19717642
20547123
16051543
10219785
19535996
20357768
18661556
17353226
15163359
12888622
9824291
12165467
16221853
9836646
18400396
19184068
16859829
18184367
17690183
10932182
11520987
12507904
15044841
16902761
10218629
10360762
20101720
10805089
18368144
16291936
18261828
15232619
19665462
19317178
16020737
16877359
16651626
1057175",Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study.,"rTg4510 transgenic (TG) mice overexpress mutant (P301L) human tau protein. We have compared the dorsal premotor cortex of TG mice versus non-transgenic (NT) mice at 4, 9, and 13 months of age, using light (LM) and electron microscopy (EM). LM assessment shows that cortical thickness in TG mice is reduced by almost 50% from 4 to 13 months of age, while at the same time layer I thickness is reduced by 80%, with most of the cortical thinning occurring between 4 and 9 months. In TG mice, spherical, empty vacuoles, up to 60 μm in diameter, become increasingly abundant with age and by 9 months, pyramidal and non-pyramidal neurons with large intracellular tangles of tau protein are common throughout the cortex. These tangles occur in the perikarya; we have not observed them entering into cellular processes, nor have we observed ghost tangles in the intercellular matrix. In TG mice, nerve fiber pathology is widespread by 13 months, and split myelin sheaths, ballooned sheaths, and swollen axons containing mitochondrial aggregations are all common. Astrocytes become increasingly filled with glial filaments as TG mice age, and microglial cells almost always contain phagocytic inclusions. However, no glial cells are seen to contain tau in their cytoplasm. These observations add to the base of knowledge available on this commonly employed model of tauopathy.",[],Brain structure & function,2010-12-15,"[{'lastname': 'Ludvigson', 'firstname': 'Adam E', 'initials': 'AE', 'affiliation': 'Department of Anatomy and Neurobiology, M949, Boston University School of Medicine, 85 East Newton Street, Boston, MA 02118, USA.'}, {'lastname': 'Luebke', 'firstname': 'Jennifer I', 'initials': 'JI', 'affiliation': None}, {'lastname': 'Lewis', 'firstname': 'Jada', 'initials': 'J', 'affiliation': None}, {'lastname': 'Peters', 'firstname': 'Alan', 'initials': 'A', 'affiliation': None}]",,,,,10.1007/s00429-010-0295-4,<Element 'PubmedArticle' at 0x7f05dc7169f0>
186,21126996,Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.,"Cognitive impairment is a recognized effect of drug misuse, including the use of opiates. The pathological basis for this is unknown but the temporal and frontal cortices have been implicated. We have shown previously that deposits of hyperphosphorylated tau in drug user brains exceed those seen in age-matched controls. The present quantitative study of hyperphosphorylated tau and beta amyloid in drug user brains allows comparison with the related pathology in Alzheimer's disease. Brains were obtained from the Edinburgh Medical Research Council Brain Banks, comprising 39 human immunodeficiency virus negative drug users, five subjects with Alzheimer's disease and 37 age-matched, cognitively normal controls, all legally and ethically approved for research. Hyperphosphorylated tau positive (AT8, AT100) neuropil threads were significantly increased in the frontal and temporal cortex, and in the locus coeruleus, of drug users aged > 30 years (all P = 0.04). Under the age of 30 years, drug users showed a similar increase in neuropil threads compared with controls, but this reached significance only in the frontal cortex (P = 0.03). Immunopositivity for both three- and four-repeat tau was present in drug user brains. There was a direct relationship between the numbers of neuropil threads and of neurofibrillary tangles: neurofibrillary tangles were sparse in brains that had neuropil thread counts below 200 cm(2). Hyperphosphorylated tau positive neuropil threads increased at a faster rate in drug users than in controls and the levels of the phosphorylating enzyme, GSK-3, was raised in drug user brains. Beta amyloid (AB4, AB42 and 4G8) was raised in drug user brains (mainly as shadow plaques) but not significantly different from controls and there was no correlation between high beta amyloid and hyperphosphorylated tau in individual cases. Hyperphosphorylated tau levels correlated significantly (P = 0.038) with microglial activation in drug users but not in controls. The levels of hyperphosphorylated tau in drug users fell far short of those seen in Alzheimer's disease but overlapped with those in elderly controls. We conclude that drug users show early Alzheimer's disease-related brain pathology that may be the basis for cognitive impairment and that neuroinflammation is an early accompanying feature. This provides an opportunity to study the pathogenesis of tau pathology in the human brain.",[],Brain : a journal of neurology,2010-12-04,"[{'lastname': 'Anthony', 'firstname': 'Iain C', 'initials': 'IC', 'affiliation': 'Neuropathology and Forensic Medicine Units, Department of General Practice, University of Edinburgh, Edinburgh, EH8 9AG, UK.'}, {'lastname': 'Norrby', 'firstname': 'Katherine E', 'initials': 'KE', 'affiliation': None}, {'lastname': 'Dingwall', 'firstname': 'Tommy', 'initials': 'T', 'affiliation': None}, {'lastname': 'Carnie', 'firstname': 'Frances W', 'initials': 'FW', 'affiliation': None}, {'lastname': 'Millar', 'firstname': 'Tracey', 'initials': 'T', 'affiliation': None}, {'lastname': 'Arango', 'firstname': 'Juan Carlos', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Robertson', 'firstname': 'Roy', 'initials': 'R', 'affiliation': None}, {'lastname': 'Bell', 'firstname': 'Jeanne E', 'initials': 'JE', 'affiliation': None}]",,,,,10.1093/brain/awq263,<Element 'PubmedArticle' at 0x7f05dc6b49a0>
187,"20937161
17502288
19906263
15064035
11408299
18197729
9302276
15810905
18433892
14506131
17168645
15254013
17400334
16785251
15364459
12450704
11796140
14640889
15308481
16753151
19232747
17169350
18977247
5432063
4107507
16914861
7817900
8866675
7635444
9056542
1759558
17009920
20021370
16930778
20213229
19865478
18702695
15143297
19080338
16906331
7528999
7909612
14501946
9622153
17656824
19139910
10941152
8989657
15894332
16374800
11245811
10911965
16192374
12895417
17549256
1371849
7884819
7918676
11754999",Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.,"Numerous epidemiological studies demonstrate that genetic background modifies the onset and the progression of Alzheimer's disease and related neurodegenerative disorders. The efficacious influence of genetic background on the disease pathway of amyloid beta has been meticulously described in rodent models. Since the impact of genetic modifiers on the neurodegenerative and neuroinflammatory cascade induced by misfolded tau protein is yet to be elucidated, we have addressed the issue by using transgenic lines expressing the same human truncated tau protein in either spontaneously hypertensive rat (SHR) or Wistar-Kyoto (WKY) genetic background.
Brains of WKY and SHR transgenic rats in the terminal stage of phenotype and their age-matched non-transgenic littermates were examined by means of immunohistochemistry and unbiased stereology. Basic measures of tau-induced neurodegeneration (load of neurofibrillary tangles) and neuroinflammation (number of Iba1-positive microglia, their activated morphology, and numbers of microglia immunoreactive for MHCII and astrocytes immunoreactive for GFAP) were quantified with an optical fractionator in brain areas affected by neurofibrillary pathology (pons, medulla oblongata). The stereological data were evaluated using two-way ANOVA and Student's t-test.
Tau neurodegeneration (neurofibrillary tangles (NFTs), axonopathy) and neuroinflammation (microgliosis, astrocytosis) appeared in both WKY and SHR transgenic rats. Although identical levels of transgene expression in both lines were present, terminally-staged WKY transgenic rats displayed significantly lower final NFT loads than their SHR transgenic counterparts. Interestingly, microglial responses showed a striking difference between transgenic lines. Only 1.6% of microglia in SHR transgenic rats expressed MHCII in spite of having a robust phagocytic phenotype, whereas in WKY transgenic rats, 23.2% of microglia expressed MHCII despite displaying a considerably lower extent of transformation into phagocytic phenotype.
These results show that the immune response represents a pivotal and genetically variable modifying factor that is able to influence vulnerability to neurodegeneration. Therefore, targeted immunomodulation could represent a prospective therapeutic approach to Alzheimer's disease.",[],Journal of neuroinflammation,2010-10-13,"[{'lastname': 'Stozicka', 'firstname': 'Zuzana', 'initials': 'Z', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, AD Centre, Dubravska cesta 9, 845 10 Bratislava, Slovak Republic.'}, {'lastname': 'Zilka', 'firstname': 'Norbert', 'initials': 'N', 'affiliation': None}, {'lastname': 'Novak', 'firstname': 'Petr', 'initials': 'P', 'affiliation': None}, {'lastname': 'Kovacech', 'firstname': 'Branislav', 'initials': 'B', 'affiliation': None}, {'lastname': 'Bugos', 'firstname': 'Ondrej', 'initials': 'O', 'affiliation': None}, {'lastname': 'Novak', 'firstname': 'Michal', 'initials': 'M', 'affiliation': None}]",,,"Tau neurodegeneration (neurofibrillary tangles (NFTs), axonopathy) and neuroinflammation (microgliosis, astrocytosis) appeared in both WKY and SHR transgenic rats. Although identical levels of transgene expression in both lines were present, terminally-staged WKY transgenic rats displayed significantly lower final NFT loads than their SHR transgenic counterparts. Interestingly, microglial responses showed a striking difference between transgenic lines. Only 1.6% of microglia in SHR transgenic rats expressed MHCII in spite of having a robust phagocytic phenotype, whereas in WKY transgenic rats, 23.2% of microglia expressed MHCII despite displaying a considerably lower extent of transformation into phagocytic phenotype.",,"10.1186/1742-2094-7-64
10.1016/j.crvi.2007.02.018
10.1111/j.1749-6632.2009.04945.x
10.1016/S0140-6736(04)15900-X
10.1136/bmj.322.7300.1447
10.1093/hmg/6.11.1951
10.1111/j.1601-183X.2005.00124.x
10.1016/j.bbr.2008.03.017
10.1093/hmg/ddg322
10.2174/156720506779025198
10.1093/hmg/ddh210
10.1016/j.neurobiolaging.2007.02.017
10.1093/hmg/ddl157
10.1016/j.vaccine.2004.03.061
10.1016/S0264-410X(02)00464-4
10.1016/S0047-6374(01)00362-1
10.1152/ajpheart.01061.2003
10.1016/j.febslet.2006.05.029
10.1016/j.jneuroim.2009.01.013
10.1016/j.brainres.2006.10.085
10.1016/j.jneumeth.2008.09.027
10.1038/227680a0
10.1016/0165-0173(95)00011-9
10.1016/0046-8177(95)90001-2
10.1097/00005072-199703000-00007
10.1007/BF00308809
10.1586/14737175.6.9.1327
10.2174/1874609810801010030
10.1016/j.neurobiolaging.2006.07.007
10.1007/s10072-010-0221-9
10.1371/journal.pone.0007642
10.1111/j.1460-9568.2008.06329.x
10.1161/01.STR.0000129788.26346.18
10.1097/01.shk.0000084342.58020.1e
10.1007/s00401-008-0481-0
10.1002/1098-1136(200009)31:3<262::AID-GLIA70>3.0.CO;2-2
10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S
10.1016/j.jns.2005.03.020
10.1002/cne.20827
10.1016/S0006-8993(00)03176-0
10.1111/j.1749-6632.2000.tb06653.x
10.1523/JNEUROSCI.2868-05.2005
10.1016/S0896-6273(03)00434-3
10.1172/JCI31450
10.1016/0197-4580(92)90002-F
10.1002/jnr.490390406
10.1016/0167-4889(94)90101-5
10.1016/S0197-4580(01)00293-7",<Element 'PubmedArticle' at 0x7f05dc6c1770>
188,"20846376
17409229
10932182
16020737
16291936
15867159
11013232
12967765
19523516
19793966
17304350
16464956
15294141
19553436
19808651
19232747
16192374
12629164
19833208
17005052
18987201
12667645
15649704
18040847
15473997
11755009
17934472
16651626
11822882
9814991
19074615
15659610
12101265
19105661
11278670
8849730
18974297
18374906
17549256
19825975",LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice.,"Inflammation and microglial activation are associated with Alzheimer's disease (AD) pathology. Somewhat surprisingly, injection of a prototypical inflammatory agent, lipopolysaccharide (LPS) into brains of amyloid precursor protein (APP) transgenic mice clears some of the pre-existing amyloid deposits. It is less well understood how brain inflammation modulates tau pathology in the absence of Aβ. These studies examined the role of LPS-induced inflammation on tau pathology. We used transgenic rTg4510 mice, which express the P301L mutation (4R0N TauP301L) and initiate tau pathology between 3-5 months of age. First, we found an age-dependent increase in several markers of microglial activation as these rTg4510 mice aged and tau tangles accumulated. LPS injections into the frontal cortex and hippocampus induced significant activation of CD45 and arginase 1 in rTg4510 and non-transgenic mice. In addition, activation of YM1 by LPS was exaggerated in transgenic mice relative to non-transgenic animals. Expression of Ser199/202 and phospho-tau Ser396 was increased in rTg4510 mice that received LPS compared to vehicle injections. However, the numbers of silver-positive neurons, implying presence of more pre- and mature tangles, was not significantly affected by LPS administration. These data suggest that inflammatory stimuli can facilitate tau phosphorylation. Coupled with prior results demonstrating clearance of Aβ by similar LPS injections, these results suggest that brain inflammation may have opposing effects on amyloid and tau pathology, possibly explaining the failures (to date) of anti-inflammatory therapies in AD patients.",[],Journal of neuroinflammation,2010-09-18,"[{'lastname': 'Lee', 'firstname': 'Daniel C', 'initials': 'DC', 'affiliation': ""Byrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Fl 33612, USA. dlee1@health.usf.edu""}, {'lastname': 'Rizer', 'firstname': 'Justin', 'initials': 'J', 'affiliation': None}, {'lastname': 'Selenica', 'firstname': 'Maj-Linda B', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Reid', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': None}, {'lastname': 'Kraft', 'firstname': 'Clara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Johnson', 'firstname': 'Amelia', 'initials': 'A', 'affiliation': None}, {'lastname': 'Blair', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Gordon', 'firstname': 'Marcia N', 'initials': 'MN', 'affiliation': None}, {'lastname': 'Dickey', 'firstname': 'Chad A', 'initials': 'CA', 'affiliation': None}, {'lastname': 'Morgan', 'firstname': 'Dave', 'initials': 'D', 'affiliation': None}]",,,,,"10.1186/1742-2094-7-56
10.1523/JNEUROSCI.0587-07.2007
10.1038/78078
10.1126/science.1113694
10.1523/JNEUROSCI.3279-05.2005
10.1073/pnas.0500466102
10.1074/jbc.M002466200
10.1016/S0165-6147(03)00206-2
10.1016/j.nbd.2009.05.025
10.1523/JNEUROSCI.3345-09.2009
10.1172/JCI29715
10.1016/j.neuron.2004.07.003
10.1523/JNEUROSCI.1339-09.2009
10.2353/ajpath.2009.090059
10.1016/j.jneuroim.2009.01.013
10.1523/JNEUROSCI.2868-05.2005
10.1016/j.nbd.2009.10.006
10.1186/1742-2094-3-27
10.1523/JNEUROSCI.3024-08.2008
10.1016/S0165-5728(03)00037-7
10.1016/j.nbd.2004.09.009
10.1007/s11481-007-9069-z
10.1016/j.expneurol.2004.07.007
10.1016/S0197-4580(01)00292-5
10.1038/nm1653
10.2353/ajpath.2006.050840
10.1006/exnr.2001.7754
10.2353/ajpath.2009.080764
10.1523/JNEUROSCI.4469-04.2005
10.1146/annurev.immunol.021908.132532
10.1074/jbc.M010416200
10.1038/383550a0
10.2353/ajpath.2008.080528
10.1016/j.brainres.2008.01.095
10.1172/JCI31450
10.1096/fj.09-141754",<Element 'PubmedArticle' at 0x7f05dc665cc0>
189,20546729,Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.,"As an abnormally folded and aggregated protein, tau composed of neurofibrillary tangles (NFTs) in Alzheimer's disease and other tauopathies seems to be a candidate for immunotherapy. Yet, the encephalitogenicity of full-length tau protein, recently reported by us in immunized mice, demands to carefully and selectively target pathological tau and address both efficacy (anti-NFT effect) and safety (free of encephalitis). We immunized NFT mice with NFT-related phosphorylated (phos) tau peptides, using an immunization protocol aimed to predispose a proinflammatory milieu in CNS as a set up to detect biohazard, an approach we used when the neurotoxicity of full-length tau was detected [use of complete Freund adjuvant (CFA) with pertussis toxin (PT)]. A decrease of about 40% in NFT burden in CNS was demonstrated and was accompanied with an increase in microglial burden. Anti-phos-tau antibodies were detected in serum and blood vessels in the CNS, while no encephalitogenicity (free of clinical neurological deficits, of adverse effects on brain inflammatory cells and of axonal damage) was recorded. The level of the lysosomal proteases, cathepsins D and L, was affected in the immunized mice suggesting the possible involvement of the lysosomal system in the decrease of NFTs. The robust anti-NFT effect and the lack of encephalitogenicity in NFT mice immunized with phos-tau peptides, even though CFA with PT was included in vaccine, point to their anti-NFT therapeutic potential.",[],Experimental neurology,2010-06-16,"[{'lastname': 'Boimel', 'firstname': 'Moran', 'initials': 'M', 'affiliation': 'The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Hospital, Jerusalem, Israel.'}, {'lastname': 'Grigoriadis', 'firstname': 'Nikolaos', 'initials': 'N', 'affiliation': None}, {'lastname': 'Lourbopoulos', 'firstname': 'Athanasios', 'initials': 'A', 'affiliation': None}, {'lastname': 'Haber', 'firstname': 'Esther', 'initials': 'E', 'affiliation': None}, {'lastname': 'Abramsky', 'firstname': 'Oded', 'initials': 'O', 'affiliation': None}, {'lastname': 'Rosenmann', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': None}]",,,,(c) 2010 Elsevier Inc. All rights reserved.,10.1016/j.expneurol.2010.05.010,<Element 'PubmedArticle' at 0x7f05dc6876d0>
190,20136701,"Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation.","Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by accumulation of extracellular deposits of amyloid-beta (Abeta) peptide in brain regions that are important for memory and cognition. The buildup of Abeta aggregates in the AD is followed by the formation of intracellular neurofibrillary tangles and activation of neuroinflammatory reactions. The present study investigated whether melatonin possesses a neuroprotective effect against Abeta-induced toxicity. For this purpose, organotypic hippocampal slices were cultured and exposed to 25 microm of Abeta(25-35) in the absence or in the presence of melatonin (25, 50, or 100 microm). In addition, the authors have investigated the involvement of GSK-3beta, tau protein, astroglial, and microglial activation, and cytokine levels in the melatonin protection against Abeta-induced neurotoxicity. Melatonin prevented the cell damage in hippocampus induced by the exposure to Abeta(25-35). In addition, melatonin significantly reduced the activation of GSK-3beta, the phosphorylation of tau protein, the glial activation and the Abeta-induced increase of TNF-alpha and IL-6 levels. On the basis of these findings, we speculate that melatonin may provide an effective therapeutic strategy for AD, by attenuating Abeta-induced phosphorylation of tau protein, and preventing GSK-3beta activation and neuroinflammation.",[],Journal of pineal research,2010-02-09,"[{'lastname': 'Hoppe', 'firstname': 'Juliana Bender', 'initials': 'JB', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Frozza', 'firstname': 'Rudimar Luiz', 'initials': 'RL', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Horn', 'firstname': 'Ana Paula', 'initials': 'AP', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Comiran', 'firstname': 'Ricardo Argenta', 'initials': 'RA', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Bernardi', 'firstname': 'Andressa', 'initials': 'A', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Campos', 'firstname': 'Maria Martha', 'initials': 'MM', 'affiliation': 'Faculdade de Odontologia e Instituto de Toxicologia, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Battastini', 'firstname': 'Ana Maria Oliveira', 'initials': 'AMO', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Salbego', 'firstname': 'Christianne', 'initials': 'C', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}]",,,,,10.1111/j.1600-079X.2010.00747.x,<Element 'PubmedArticle' at 0x7f05dc695d60>
191,20014009,Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses.,"Alzheimer's disease (AD) is characterized by the deposition of amyloid-beta peptide (Abeta) and the formation of neurofibrillary tangles. Transplantation of bone marrow-derived mesenchymal stem cells (BM-MSCs) has been suggested as a potential therapeutic approach to prevent various neurodegenerative disorders, including AD. However, the actual therapeutic impact of BM-MSCs and their mechanism of action in AD have not yet been ascertained. The aim of this study was therefore to evaluate the therapeutic effect of BM-MSC transplantation on the neuropathology and memory deficits in amyloid precursor protein (APP) and presenilin one (PS1) double-transgenic mice. Here we show that intracerebral transplantation of BM-MSCs into APP/PS1 mice significantly reduced amyloid beta-peptide (Abeta) deposition. Interestingly, these effects were associated with restoration of defective microglial function, as evidenced by increased Abeta-degrading factors, decreased inflammatory responses, and elevation of alternatively activated microglial markers. Furthermore, APP/PS1 mice treated with BM-MSCs had decreased tau hyperphosphorylation and improved cognitive function. In conclusion, BM-MSCs can modulate immune/inflammatory responses in AD mice, ameliorate their pathophysiology, and improve the cognitive decline associated with Abeta deposits. These results demonstrate that BM-MSCs are a potential new therapeutic agent for AD.",[],"Stem cells (Dayton, Ohio)",2009-12-17,"[{'lastname': 'Lee', 'firstname': 'Jong Kil', 'initials': 'JK', 'affiliation': 'Stem Cell Neuroplasticity Research Group, Kyungpook National University, Daegu, Korea.'}, {'lastname': 'Jin', 'firstname': 'Hee Kyung', 'initials': 'HK', 'affiliation': None}, {'lastname': 'Endo', 'firstname': 'Shogo', 'initials': 'S', 'affiliation': None}, {'lastname': 'Schuchman', 'firstname': 'Edward H', 'initials': 'EH', 'affiliation': None}, {'lastname': 'Carter', 'firstname': 'Janet E', 'initials': 'JE', 'affiliation': None}, {'lastname': 'Bae', 'firstname': 'Jae-Sung', 'initials': 'JS', 'affiliation': None}]",,,,,10.1002/stem.277,<Element 'PubmedArticle' at 0x7f05dc630400>
192,"19834067
18039130
9748011
17222916
12130773
18957434
15295589
15021233
12851187
11561036
8714529
7609938
11988830
10102412
8659604
2678551
16518161
2819446
17543991
17130422
1993028
3736630
11923249
10406623
12466113
12699953
18791173
8810256
16332263
17897471
12702875
15883316
17046404
17912249
2893290
7896005
10588572
11735776
1708927
1723659
9630473
7624036
9341701
11852039
9291938
18566467
10028915
11377835
12446973
11523060
11305871
9329688
15172735
16612980
2314846
10343807
11595144
18823564
17137722
18208483
18953056
10932230
17822910
14593170
18184372
16187817
17351136
3618708
8725900
1753255
17460292",Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.,"Alzheimer's disease (AD) is pathologically characterized by accumulation of beta-amyloid (Abeta) protein deposits and/or neurofibrillary tangles in association with progressive cognitive deficits. Although numerous studies have demonstrated a relationship between brain pathology and AD progression, the Alzheimer's pathological hallmarks have not been found in the AD retina. A recent report showed Abeta plaques in the retinas of APPswe/PS1DeltaE9 transgenic mice. We now report the detection of Abeta plaques with increased retinal microvascular deposition of Abeta and neuroinflammation in Tg2576 mouse retinas. The majority of Abeta-immunoreactive plaques were detected from the ganglion cell layer to the inner plexiform layer, and some plaques were observed in the outer nuclear layer, photoreceptor outer segment, and optic nerve. Hyperphosphorylated tau was labeled in the corresponding areas of the Abeta plaques in adjacent sections. Although Abeta vaccinations reduced retinal Abeta deposits, there was a marked increase in retinal microvascular Abeta deposition as well as local neuroinflammation manifested by microglial infiltration and astrogliosis linked with disruption of the retinal organization. These results provide evidence to support further investigation of the use of retinal imaging to diagnose AD and to monitor disease activity.",[],The American journal of pathology,2009-10-17,"[{'lastname': 'Liu', 'firstname': 'Bingqian', 'initials': 'B', 'affiliation': 'Department of Neurology, University of California Irvine School of Medicine, USA.'}, {'lastname': 'Rasool', 'firstname': 'Suhail', 'initials': 'S', 'affiliation': None}, {'lastname': 'Yang', 'firstname': 'Zhikuan', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Glabe', 'firstname': 'Charles G', 'initials': 'CG', 'affiliation': None}, {'lastname': 'Schreiber', 'firstname': 'Steven S', 'initials': 'SS', 'affiliation': None}, {'lastname': 'Ge', 'firstname': 'Jian', 'initials': 'J', 'affiliation': None}, {'lastname': 'Tan', 'firstname': 'Zhiqun', 'initials': 'Z', 'affiliation': None}]",,,,,10.2353/ajpath.2009.090159,<Element 'PubmedArticle' at 0x7f05dc63a2c0>
193,"19513731
8871945
8871945
18519870
18519870
18363937
18363937
1759558
1759558
1669710
1669710
15935098
15935098
1311804
1311804
17328801
17328801
17378753
17378753
8227316
8227316
8815885
8815885
1669689
1669689
10674422
10674422
18795148
18795148
17965659
17965659
1763432
1763432
3302117
3302117
3276004
3276004
9630473
9630473
12505355
12505355
8252383
8252383
8843599
8843599
17224051
17224051
18442088
18442088
10487842
10487842
18474729
18474729
1693471
1693471
9065490
9065490
9762518
9762518
3670729
3670729
10589538
10589538
7715705
7715705
18567623
18567623
15831717
15831717
2058362
2058362
17220915
17220915
12112102
12112102
3263583
3263583
9341931
9341931
18457819
18457819
9224523
9224523
17551926
17551926
15197750
15197750
14730714
14730714
15850662
15850662
16859761
16859761
9600217
9600217
15535034
15535034",Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.,"The role of microglial cells in the pathogenesis of Alzheimer's disease (AD) neurodegeneration is unknown. Although several works suggest that chronic neuroinflammation caused by activated microglia contributes to neurofibrillary degeneration, anti-inflammatory drugs do not prevent or reverse neuronal tau pathology. This raises the question if indeed microglial activation occurs in the human brain at sites of neurofibrillary degeneration. In view of the recent work demonstrating presence of dystrophic (senescent) microglia in aged human brain, the purpose of this study was to investigate microglial cells in situ and at high resolution in the immediate vicinity of tau-positive structures in order to determine conclusively whether degenerating neuronal structures are associated with activated or with dystrophic microglia. We used a newly optimized immunohistochemical method for visualizing microglial cells in human archival brain together with Braak staging of neurofibrillary pathology to ascertain the morphology of microglia in the vicinity of tau-positive structures. We now report histopathological findings from 19 humans covering the spectrum from none to severe AD pathology, including patients with Down's syndrome, showing that degenerating neuronal structures positive for tau (neuropil threads, neurofibrillary tangles, neuritic plaques) are invariably colocalized with severely dystrophic (fragmented) rather than with activated microglial cells. Using Braak staging of Alzheimer neuropathology we demonstrate that microglial dystrophy precedes the spread of tau pathology. Deposits of amyloid-beta protein (Abeta) devoid of tau-positive structures were found to be colocalized with non-activated, ramified microglia, suggesting that Abeta does not trigger microglial activation. Our findings also indicate that when microglial activation does occur in the absence of an identifiable acute central nervous system insult, it is likely to be the result of systemic infectious disease. The findings reported here strongly argue against the hypothesis that neuroinflammatory changes contribute to AD dementia. Instead, they offer an alternative hypothesis of AD pathogenesis that takes into consideration: (1) the notion that microglia are neuron-supporting cells and neuroprotective; (2) the fact that development of non-familial, sporadic AD is inextricably linked to aging. They support the idea that progressive, aging-related microglial degeneration and loss of microglial neuroprotection rather than induction of microglial activation contributes to the onset of sporadic Alzheimer's disease. The results have far-reaching implications in terms of reevaluating current treatment approaches towards AD.",[],Acta neuropathologica,2009-06-11,"[{'lastname': 'Streit', 'firstname': 'Wolfgang J', 'initials': 'WJ', 'affiliation': 'Department of Neuroscience, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL 32610-0244, USA. streit@mbi.ufl.edu'}, {'lastname': 'Braak', 'firstname': 'Heiko', 'initials': 'H', 'affiliation': None}, {'lastname': 'Xue', 'firstname': 'Qing-Shan', 'initials': 'QS', 'affiliation': None}, {'lastname': 'Bechmann', 'firstname': 'Ingo', 'initials': 'I', 'affiliation': None}]",,,,,"10.1007/s00401-009-0556-6
10.1007/BF02815208
10.1212/01.wnl.0000313813.48505.86
10.1111/j.1750-3639.2008.00134.x
10.1007/BF00308809
10.1111/j.1750-3639.1991.tb00661.x
10.1186/1742-2094-2-14
10.1016/0197-4580(92)90027-U
10.1186/1742-2094-4-9
10.1089/rej.2006.9096
10.1016/0165-5728(93)90191-Z
10.1111/j.1750-3639.1990.tb00630.x
10.1016/S0197-4580(99)00063-9
10.1371/journal.pone.0001590
10.1038/nn1997
10.1016/0165-6147(91)90609-V
10.1016/0022-510X(87)90218-8
10.1126/science.3276004
10.1016/S0169-328X(98)00040-0
10.1016/S0300-483X(02)00457-2
10.1016/0006-8993(93)90068-X
10.1016/0166-2236(96)10049-7
10.1186/1742-2094-4-4
10.1002/glia.20678
10.1001/archneur.65.12.noc80051
10.1016/S0531-5565(98)00013-8
10.1016/0304-3940(87)90696-3
10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
10.1038/374647a0
10.1093/brain/awn109
10.1126/science.1110647
10.1007/BF00305864
10.1038/nri2015
10.1002/ana.10161
10.1016/S0197-4580(88)80079-4
10.1007/s004010050713
10.1016/j.brainres.2008.02.084
10.1007/s004010050664
10.1002/glia.20526
10.1002/jnr.20093
10.1002/glia.10319
10.1016/j.brainresrev.2004.12.013
10.1016/j.tins.2006.07.001
10.1097/00005072-199803000-00006",<Element 'PubmedArticle' at 0x7f05dc660360>
194,19289607,Accumulation of tau induced in neurites by microglial proinflammatory mediators.,"Aggregated fibrillary microtubule-associated protein tau is the major component of neurofibrillary tangles in Alzheimer's disease. The exact molecular mechanism of tau aggregation is unknown. Microglial cell activation and migration toward amyloid-beta plaques precede the appearance of dysmorphic neurites and formation of neurofibrillary tangles. Here, we analyzed the accumulation of tau at a distance range of expected spontaneous aggregation by fluorescence lifetime-based Förster resonance energy transfer in cultured primary murine neurons cotransfected with the human tau gene tagged to the green fluorescent protein variants Citrine (tau-Citrine) and Cerulean (tau-Cerulean). No spontaneous accumulation of cotransfected tau-Citrine and tau-Cerulean was detected in untreated neurons. Coculture of neurons with activated microglia induced aggregation of tau in neurites. Treatment of neurons with tumor necrosis factor-alpha (TNF-alpha) stimulated reactive oxygen species generation and resulted in the accumulation of tau-Citrine and tau-Cerulean in neurites, which was inhibited by neutralization of TNF and the free radical inhibitor 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox). These data demonstrate that activated microglia and the microglial-derived proinflammatory cytokine TNF can induce accumulation of the aggregation-prone tau molecules in neurites via reactive oxygen species.",[],FASEB journal : official publication of the Federation of American Societies for Experimental Biology,2009-03-18,"[{'lastname': 'Gorlovoy', 'firstname': 'Philipp', 'initials': 'P', 'affiliation': 'Neural Regeneration Unit, Institute of Reconstructive Neurobiology, University Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany.'}, {'lastname': 'Larionov', 'firstname': 'Sergey', 'initials': 'S', 'affiliation': None}, {'lastname': 'Pham', 'firstname': 'Thao Thi Hien', 'initials': 'TT', 'affiliation': None}, {'lastname': 'Neumann', 'firstname': 'Harald', 'initials': 'H', 'affiliation': None}]",,,,,10.1096/fj.08-123877,<Element 'PubmedArticle' at 0x7f05dc60cdb0>
195,19198115,[Neurodegeneration and inflammation: analysis of a FTDP-17 model mouse].,"Filamentous tau inclusions are hallmarks of Alzheimer's disease (AD) and related tauopathies, and the discovery of mutations in the tau gene in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) constitutes convincing evidence that tau proteins play a key role in the pathogenesis of neurodegenerative disorders. To investigate the pathomechanism of tauopathies, we generated and studied P301S mutant human tau transgenic mice (line PS19). Filamentous tau lesions developed in PS19 mice at 6-months of age, and progressively accumulated in association with striking neuron loss as well as hippocampal and entorhinal cortical atrophy by 9-12 months of age. Remarkably, hippocampal synapse loss and impaired synaptic function were detected in 3 month old PS19 mice before fibrillary tau tangles emerged. Prominent microglial activation and proinflammatory cytokine expressions in neurons also preceded tangle formation. Importantly, immunosuppression of young PS19 mice with FK506 attenuated tau pathology, thereby linking neuroinflammation to early progression of tauopathies. Recently, an anti-inflammatory function of acetylcholine (ACh) has been reported, suggesting that synaptic dysfunction might accelerate neuroinflammatory reaction by depletion of ACH. To investigate this, we administered donepezil (DZ), an ACh-esterase inhibitor, and trihexiphenidyl (TP), an anti-cholinergic agent to PS19 mice. Interestingly, DZ ameliorated but TP deteriorated microglial activation, tau pathology and neuronal loss, indicating the ACh level in the brain might play roles in not only neurotransmission, but also suppressing neuroinflammation in the brain.",[],Rinsho shinkeigaku = Clinical neurology,2009-02-10,"[{'lastname': 'Yoshiyama', 'firstname': 'Yasumasa', 'initials': 'Y', 'affiliation': 'Department of Neurology, Laboratory for Neurodegenerative Disorder Research, Clinical Research Center, Chiba-East National Hospital.'}]",,,,,10.5692/clinicalneurol.48.910,<Element 'PubmedArticle' at 0x7f05dc618900>
196,"19139300
2011243
12921904
7710373
16894106
17928318
15944649
16330558
14991808
3670729
14741426
17156911
18178291
15057304
17353386
11134385
6610841
9417971
17406654
17519979
16162478
19001171
12084879
1822725
2209775
1652108
7816197
17920902
8523106
11513911
12824711
9502214
17400599
12640446
14997933
12765607",Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.,"Alzheimer disease (AD) is defined neuropathologically by the presence of neurofibrillary tangles and plaques associated with tau and beta-amyloid protein deposition. The colocalization of microglia and beta-amyloid plaques has been widely reported in pathological examination of AD and suggests that neuroinflammation may play a role in pathogenesis and/or progression. Because postmortem histopathological analyses are limited to single end-stage assessment, the time course and nature of this relationship are not well understood.
To image microglial activation and beta-amyloid deposition in the brains of subjects with and without AD.
Using two carbon 11 ([11C])-labeled positron emission tomographic imaging agents, Pittsburgh Compound B (PiB) and (R)-PK11195, we examined the relationship between amyloid deposition and microglial activation in different stages of AD using 5 control subjects, 6 subjects diagnosed with mild cognitive impairment, and 6 patients with mild to moderate AD.
Consistent with prior reports, subjects with a clinical diagnosis of probable AD showed significantly greater levels of [11C]PiB retention than control subjects, whereas patients with mild cognitive impairment spanned a range from control-like to AD-like levels of [11C]PiB retention. Additionally, 2 asymptomatic control subjects also exhibited evidence of elevated PiB retention in regions associated with the early emergence of plaques in AD and may represent prodromal cases of AD. We observed no differences in brain [11C](R)-PK11195 retention when subjects were grouped by clinical diagnosis or the presence or absence of beta-amyloid pathological findings as indicated by analyses of [11C]PiB retention.
These findings suggest that either microglial activation is limited to later stages of severe AD or [11C](R)-PK11195 is too insensitive to detect the level of microglial activation associated with mild to moderate AD.",[],Archives of neurology,2009-01-14,"[{'lastname': 'Wiley', 'firstname': 'Clayton A', 'initials': 'CA', 'affiliation': 'Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA. wiley1@pitt.edu'}, {'lastname': 'Lopresti', 'firstname': 'Brian J', 'initials': 'BJ', 'affiliation': None}, {'lastname': 'Venneti', 'firstname': 'Sriram', 'initials': 'S', 'affiliation': None}, {'lastname': 'Price', 'firstname': 'Julie', 'initials': 'J', 'affiliation': None}, {'lastname': 'Klunk', 'firstname': 'William E', 'initials': 'WE', 'affiliation': None}, {'lastname': 'DeKosky', 'firstname': 'Steven T', 'initials': 'ST', 'affiliation': None}, {'lastname': 'Mathis', 'firstname': 'Chester A', 'initials': 'CA', 'affiliation': None}]",,,"Consistent with prior reports, subjects with a clinical diagnosis of probable AD showed significantly greater levels of [11C]PiB retention than control subjects, whereas patients with mild cognitive impairment spanned a range from control-like to AD-like levels of [11C]PiB retention. Additionally, 2 asymptomatic control subjects also exhibited evidence of elevated PiB retention in regions associated with the early emergence of plaques in AD and may represent prodromal cases of AD. We observed no differences in brain [11C](R)-PK11195 retention when subjects were grouped by clinical diagnosis or the presence or absence of beta-amyloid pathological findings as indicated by analyses of [11C]PiB retention.",,10.1001/archneurol.2008.511,<Element 'PubmedArticle' at 0x7f05dc5a6090>
197,"18700006
16360788
12128091
9330961
8810256
8824314
8744400
10037741
9371838
7845465
10860782
11786218
11013246
10595524
10805089
10595944
11741399
12895417
14643377
15748844
7489411
8878479
8938131
11033346
9125370
17551515
16400022
12727331
16860394
599557
8789453
12472903
8068626
7954847
3098742
1057175
3131773
7992852
2483104
2116006
2494388
10517511
3088567
2495152
7566350
7566345
8393323
11520930
15913839
17472708
11381127
7507514
16232318
15172747
17036175
10392655
11754075
11556547
7798922
9670219
12625464
11816787
15172746
1378573
9278541
17072762
11238065
17659878
18045930
11520988
12379846
15705720
11735776
1729400
17549256",Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice.,"Several transgenic animal models genetically predisposed to develop Alzheimer's disease (AD)-like pathology have been engineered to facilitate the study of disease pathophysiology and the vetting of potential disease-modifying therapeutics. The triple transgenic mouse model of AD (3xTg-AD) harbors three AD-related genetic loci: human PS1M146V, human APPswe, and human tauP301L. These mice develop both amyloid plaques and neurofibrillary tangle-like pathology in a progressive and age-dependent manner, while these pathological hallmarks are predominantly restricted to the hippocampus, amygdala, and the cerebral cortex the main foci of AD neuropathology in humans. This model represents, at present, one of the most advanced preclinical tools available and is being employed ever increasingly in the study of mechanisms underlying AD, yet a detailed regional and temporal assessment of the subtleties of disease-related pathologies has not been reported.
In this study, we immunohistochemically documented the evolution of AD-related transgene expression, amyloid deposition, tau phosphorylation, astrogliosis, and microglial activation throughout the hippocampus, entorhinal cortex, primary motor cortex, and amygdala over a 26-month period in male 3xTg-AD mice. Intracellular amyloid-beta accumulation is detectable the earliest of AD-related pathologies, followed temporally by phospho-tau, extracellular amyloid-beta, and finally paired helical filament pathology. Pathology appears to be most severe in medial and caudal hippocampus. While astrocytic staining remains relatively constant at all ages and regions assessed, microglial activation appears to progressively increase temporally, especially within the hippocampal formation.
These data fulfill an unmet need in the ever-widening community of investigators studying 3xTg-AD mice and provide a foundation upon which to design future experiments that seek to examine stage-specific disease mechanisms and/or novel therapeutic interventions for AD.",[],BMC neuroscience,2008-08-14,"[{'lastname': 'Mastrangelo', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': 'Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA. michael_mastrangelo@urmc.rochester.edu'}, {'lastname': 'Bowers', 'firstname': 'William J', 'initials': 'WJ', 'affiliation': None}]",,These data fulfill an unmet need in the ever-widening community of investigators studying 3xTg-AD mice and provide a foundation upon which to design future experiments that seek to examine stage-specific disease mechanisms and/or novel therapeutic interventions for AD.,,,"10.1186/1471-2202-9-81
10.1016/S0140-6736(05)67889-0
10.1016/S0196-9781(02)00070-0
10.1016/S0197-4580(97)00056-0
10.1126/science.274.5284.99
10.1016/0197-4580(95)02074-8
10.1074/jbc.274.10.6483
10.1073/pnas.94.24.13287
10.1038/373523a0
10.1006/nbdi.2000.0283
10.1016/S0304-3940(01)02461-2
10.1074/jbc.M006531200
10.1016/S0896-6273(00)81127-7
10.1007/s004010051148
10.1006/nbdi.2001.0439
10.1016/S0896-6273(03)00434-3
10.1016/j.neurobiolaging.2003.08.012
10.1016/j.neuron.2005.01.040
10.1038/nm1295-1291
10.1038/383710a0
10.1016/S0896-6273(00)80230-5
10.1016/S0014-5793(00)02076-7
10.1016/S0165-0270(96)00121-5
10.1038/nrn2168
10.2353/ajpath.2006.050593
10.1016/S0304-3940(03)00252-0
10.1016/j.jneumeth.2006.06.010
10.1016/0022-2836(77)90213-3
10.1093/hmg/5.1.151
10.1046/j.1471-4159.2002.01241.x
10.1021/bi00198a017
10.1002/cm.970280302
10.1083/jcb.103.6.2739
10.1073/pnas.72.5.1858
10.1073/pnas.85.11.4051
10.1016/0896-6273(88)90129-8
10.1073/pnas.87.15.5827
10.1073/pnas.83.13.4913
10.1016/0006-8993(89)91396-6
10.1016/0197-4580(95)97327-D
10.1016/0197-4580(95)00025-A
10.1016/0896-6273(93)90279-Z
10.1146/annurev.neuro.24.1.1121
10.1016/j.molbrainres.2005.04.015
10.1111/j.1471-4159.2007.04607.x
10.1073/pnas.121119298
10.1186/1742-2094-2-23
10.1016/j.neurobiolaging.2003.12.026
10.1007/s00702-006-0575-6
10.1016/S0149-7634(98)00058-X
10.1002/jnr.10121
10.1016/S0301-0082(98)00021-5
10.1002/hipo.10037
10.1385/JMN:17:2:137
10.1016/j.neurobiolaging.2004.01.007
10.1016/0306-4522(92)90265-4
10.1007/s10519-006-9118-z
10.1016/j.nbd.2007.06.013
10.1523/JNEUROSCI.2718-07.2007
10.1126/science.1062097
10.1038/nm783
10.1073/pnas.0408500102
10.1001/archneur.58.12.2025
10.1111/j.1471-4159.1992.tb09754.x
10.1172/JCI31450",<Element 'PubmedArticle' at 0x7f05dc5c8950>
198,17270732,Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.,"Filamentous tau inclusions are hallmarks of Alzheimer's disease (AD) and related tauopathies, but earlier pathologies may herald disease onset. To investigate this, we studied wild-type and P301S mutant human tau transgenic (Tg) mice. Filamentous tau lesions developed in P301S Tg mice at 6 months of age, and progressively accumulated in association with striking neuron loss as well as hippocampal and entorhinal cortical atrophy by 9-12 months of age. Remarkably, hippocampal synapse loss and impaired synaptic function were detected in 3 month old P301S Tg mice before fibrillary tau tangles emerged. Prominent microglial activation also preceded tangle formation. Importantly, immunosuppression of young P301S Tg mice with FK506 attenuated tau pathology and increased lifespan, thereby linking neuroinflammation to early progression of tauopathies. Thus, hippocampal synaptic pathology and microgliosis may be the earliest manifestations of neurodegenerative tauopathies, and abrogation of tau-induced microglial activation could retard progression of these disorders.",[],Neuron,2007-02-03,"[{'lastname': 'Yoshiyama', 'firstname': 'Yasumasa', 'initials': 'Y', 'affiliation': 'The Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.'}, {'lastname': 'Higuchi', 'firstname': 'Makoto', 'initials': 'M', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Bin', 'initials': 'B', 'affiliation': None}, {'lastname': 'Huang', 'firstname': 'Shu-Ming', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Iwata', 'firstname': 'Nobuhisa', 'initials': 'N', 'affiliation': None}, {'lastname': 'Saido', 'firstname': 'Takaomi C', 'initials': 'TC', 'affiliation': None}, {'lastname': 'Maeda', 'firstname': 'Jun', 'initials': 'J', 'affiliation': None}, {'lastname': 'Suhara', 'firstname': 'Tetsuya', 'initials': 'T', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Virginia M-Y', 'initials': 'VM', 'affiliation': None}]",,,,,10.1016/j.neuron.2007.01.010,<Element 'PubmedArticle' at 0x7f05dc577900>
199,16410745,Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain.,"Thrombin is a serine protease that is generated by proteolytic cleavage of its precursor, prothrombin. We previously showed that thrombin proteolyses the microtubule-associated protein tau and that phosphorylation of tau inhibits this process. To characterize further the role of thrombin in the brain, we investigated prothrombin and thrombin expression in cultured brain cells and in brains of control, Alzheimer disease (AD) and parkinsonism-dementia complex of Guam (PDCG). We show by reverse transcriptase-polymerase chain reaction that prothrombin mRNA is expressed in brain tissues, neuroblastoma cells, and cultured human astrocytes, oligodendrocytes, and microglial cells. We also show by immunohistochemistry that the proteins prothrombin and thrombin are present in brain using specific monoclonal and polyclonal antibodies for both proteins. All antibodies stained residual serum in blood vessels, as well as normal pyramidal neurons and their processes, and some astrocytes. Additionally, in AD and PDCG cases, all antibodies stained extra- and intracellular neurofibrillary tangles (NFTs), senile plaques, and reactive microglial cells. The ubiquitous expression of prothrombin and thrombin in brain cells suggests that thrombin plays an important physiological role in normal brain. The accumulation of thrombin and prothrombin in NFTs supports the hypothesis that thrombin may be involved in tau proteolysis and that failure to metabolize tau may lead to its aggregation in neurodegenerative diseases.",[],Journal of neuropathology and experimental neurology,2006-01-18,"[{'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': 'Department of Psychiatry, Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC, Canada.'}, {'lastname': 'Miklossy', 'firstname': 'Judith', 'initials': 'J', 'affiliation': None}, {'lastname': 'Klegeris', 'firstname': 'Andis', 'initials': 'A', 'affiliation': None}, {'lastname': 'Guo', 'firstname': 'Jian-Ping', 'initials': 'JP', 'affiliation': None}, {'lastname': 'McGeer', 'firstname': 'Patrick L', 'initials': 'PL', 'affiliation': None}]",,,,,10.1097/01.jnen.0000196133.74087.cb,<Element 'PubmedArticle' at 0x7f05dc584db0>
200,"16192374
10706614
10858586
10526177
10851364
11245811
11764091
12071639
10932230
12566568
8282104
15509534
11074790
11584304
14642273
2360787
8423065
11000423
10818091
1376558
9422548
9546359
12505419
11822882
12000710
2529544
7830934
7876895
3265161
12165795
7676810
10683146
1658692
12719630
10830966
12629164
10908610
14713290
11181841
14720213
11290552
2974227
11140686
11754997
12765608
12895417
9727024
10604467
9666145
2097581
12404061
11978814
10408445
11274343
15048935
11578769
13678674
10362792
9065537
11812770
9458784
1789684
8090221
11700559
9482801
15331409
14615541",Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.,"Inflammation is a critical component of the pathogenesis of Alzheimer's disease (AD). Although not an initiator of this disorder, inflammation nonetheless plays a pivotal role as a driving force that can modulate the neuropathology. Here, we characterized the time course of microglia activation in the brains of a transgenic model of AD (3xTg-AD) and discerned its relationship to the plaque and tangle pathology. We find that microglia became activated in a progressive and age-dependent manner, and this activation correlated with the onset of fibrillar amyloidbeta-peptide plaque accumulation and tau hyperphosphorylation. To determine whether microglial activation can exacerbate the pathology, we exposed young 3xTg-AD mice to lipopolysaccharide (LPS), a known inducer of CNS inflammation. Although amyloid precursor protein processing appeared unaffected, we find that LPS significantly induced tau hyperphosphorylation at specific sites that were mediated by the activation of cyclin-dependent kinase 5 (cdk5) through increased formation of the p25 fragment. We further show that administration of roscovitine, a selective and potent inhibitor of cdk5, markedly blocked the LPS-induced tau phosphorylation in the hippocampus. Therefore, this study clearly demonstrates that microglial activation exacerbates key neuropathological features such as tangle formation.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2005-09-30,"[{'lastname': 'Kitazawa', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': 'Department of Neurobiology and Behavior, University of California-Irvine, California 92697-4545, USA.'}, {'lastname': 'Oddo', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'Yamasaki', 'firstname': 'Tritia R', 'initials': 'TR', 'affiliation': None}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.2868-05.2005,<Element 'PubmedArticle' at 0x7f05dc590090>
201,16008828,Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers.,"Drug abuse is a major problem worldwide. The incidence of drug-related deaths attributed to opiate abuse is increasing annually. Apart from routine examination, little is known of the neuropathology of drug abuse. We, and others, have shown previously that drug abuse is associated with microglial activation. We hypothesised that neuroinflammation might lead to premature neurodegeneration in drug abusers. We investigated the brains of young opiate abusers (n=34, all<40 years) for the presence of proteins associated with neurodegenerative diseases and compared them with the brains of age-matched, non-drug users (n=16) all of whom died suddenly. Detailed immunohistochemical analysis of the hippocampus, brainstem and basal ganglia for hyperphosphorylated tau, beta-amyloid, beta-amyloid precursor protein (betaAPP) and ubiquitin demonstrated an excess of AT 8-positive neurofibrillary tangles (NFT) in the drug abusers. These were not only more prevalent in the drug abusers than in controls (44%vs. 19%) but also involved more brain areas. In controls NFT were confined to the entorhinal cortex whereas in drug users they were also found in the subiculum, temporal neocortex, nucleus basalis of Meynert and the locus coeruleus. Virtually no amyloid plaques were present but betaAPP positivity was again much more common in drug abusers than controls (73%vs. 20% in the brainstem and 59%vs. 23% in the temporal lobe). There is no suggestion that these drug abusers had displayed major cognitive impairment although detailed neuropsychological assessment is difficult in this subject group. Likely causes of hyperphosphorylated tau deposition in drug abuse include hypoxic-ischaemic injury, microglial-associated cytokine release and possibly drug-associated neurotoxicity or hepatitis. Head injury, which is another major risk factor, does not appear to have contributed to our findings. Genetic factors also merit consideration. It is unclear at present how much of the hyperphosphorylated tau detected in these young drug abusers represents a transitory phenomenon.",[],Neuropathology and applied neurobiology,2005-07-13,"[{'lastname': 'Ramage', 'firstname': 'S N', 'initials': 'SN', 'affiliation': 'Neuropathology Unit, University of Edinburgh, Alexander Donald Building, Western General Hospital, Edinburgh, UK.'}, {'lastname': 'Anthony', 'firstname': 'I C', 'initials': 'IC', 'affiliation': None}, {'lastname': 'Carnie', 'firstname': 'F W', 'initials': 'FW', 'affiliation': None}, {'lastname': 'Busuttil', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Robertson', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Bell', 'firstname': 'J E', 'initials': 'JE', 'affiliation': None}]",,,,,10.1111/j.1365-2990.2005.00670.x,<Element 'PubmedArticle' at 0x7f05dc536040>
202,"15960984
12070670
11487471
12783912
10405156
11262183
12556443
12736687
12099705
11463759
9106738
11193159
12689596
9721089
9369980
10934466
1833819
12136057
10674423
12846581
10995469
8834355
12297502
11124942
11141480
9348292
12692899
10102273
11735041
9525997
12392766
11513911
9736630
12460542
11149923
12897406
12907606
12633901
12460881
12011585
12769640
12621307
12684267
12507297
14514016
15149850
15025929
15241181
15578447
10671558
11162250
7991571
12888118
11160388
9382837
9346240
10867216
12594242
1933277
11073947
11815629
10756084
12934969
9114067
11717309
12626504
10872455
16181084
12504864
2111583
10986279
10899937
11054815
8302573
10873683
14729974
12888622
11029754
12397090
12953274
12913110
10383401
11590144
9701251
15155946
12829723
12125082
14996635
9175472
11706053
9312151
10393175
10386999
9482734
11487632
10674630
12556497
14522996
12003671
9593752
11192610
9084433
9740801
13130504
12920191
11290326
12194869
12923068
12629169
12504778
8574969
12425945
9045726
12809603
14501021
8624110
12177298
9390557
9727492
11312610
15353303
15627815
10994860
11585595
11295881
12648681
8689682
12490568
9252383
10071053
9930752
10742146
15190254
11226152
8725904
12707770
8977301
11332719
10679797
12767721
15272144
8632165
15491780
10677567
11444918
10537063
11559373
12890786
9176387
10817926
11571313
12654514
10427605
11893336
11413227
9045699
11438574
15152078
9271202
11589997
10638761
9367994
11840170
8593575
9356924
16181081
9020768
9647782
8922409
8774708
10604467
9666145
10499443
12633148
9566966
12603823
10460254
10878584
14599661
11817900
12672860
15053264
10358075
12242657
12598612
8938824
11578768
11141492
10487751
9712638
16181080
12578834
9606965
1549180
9464999
7678698
12880480
9210524
9224523
10402474
8781412
12452789
9389482
9572310
11266469
12615641
9814551
8195114
10769246
10366428
8356085
9809590
8207432
12054580
11231011
12657674
12960154
10201372
9987030
7499373
9352093
10943996
12125077
10662829
11279271
9103492
10069390
9729047
12028355
11672523
10219058
9925743
11031084
9404717
9918707
11726766
9271238
11516430
12704812
16185191
10985692
11029006
11006271
12151519
10936187
9764817
11054421
11793158
12684440
12200426
11980918
12702569
11815632
9546672",Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.,"More than a century has elapsed since the description of Alois Alzheimer's patient Auguste D. Yet, the well-documented generation of beta-amyloid aggregates and neurofibrillary tangles that define Alzheimer's disease is believed to represent only a portion of the cellular processes that can determine the course of Alzheimer's disease. Understanding of the complex nature of this disorder has evolved with an increased appreciation for pathways that involve the generation of reactive oxygen species and oxidative stress, apoptotic injury that leads to nuclear degradation in both neuronal and vascular populations, and the early loss of cellular membrane asymmetry that mitigates inflammation and vascular occlusion. Recent work has identified novel pathways, such as the Wnt pathway and the serine-threonine kinase Akt, as central modulators that oversee cellular apoptosis and the formation of neurofibrillary tangles through their downstream substrates that include glycogen synthase kinase-3beta, Bad, and Bcl-xL. Other closely integrated pathways control microglial activation, release of inflammatory cytokines, and caspase and calpain activation for the processing of amyloid precursor protein, tau protein cleavage, and presenilin disposal. New therapeutic avenues that are just open to exploration, such as with nicotinamide adenine dinucleotide modulation, cell cycle modulation, metabotropic glutamate system modulation, and erythropoietin targeted expression, may provide both attractive and viable alternatives to treat Alzheimer's disease.",[],Brain research. Brain research reviews,2005-06-18,"[{'lastname': 'Chong', 'firstname': 'Zhao Zhong', 'initials': 'ZZ', 'affiliation': 'Division of Cellular and Molecular Cerebral Ischemia, Wayne State University School of Medicine, Detroit, MI 48201, USA.'}, {'lastname': 'Li', 'firstname': 'Faqi', 'initials': 'F', 'affiliation': None}, {'lastname': 'Maiese', 'firstname': 'Kenneth', 'initials': 'K', 'affiliation': None}]",,,,,10.1016/j.brainresrev.2004.11.005,<Element 'PubmedArticle' at 0x7f05dc53f630>
203,15681802,Microglia as a potential bridge between the amyloid beta-peptide and tau.,"Inflammation is a critical component of the pathogenesis of Alzheimer's disease (AD), consisting of the activation of both microglia and astrocytes. Activated microglia and reactive astrocytes are found in and around extraneuronal amyloid-beta plaques and are thought to facilitate the clearance of these deposits from the brain parenchyma. However, mounting evidence indicates that chronic activation of microglia, presumably via the secretion of cytokines and reactive molecules, may exacerbate plaque pathology as well as enhance the hyperphosphorylation of tau and the subsequent development of neurofibrillary tangles. Thus, suppression of microglial activity in AD brain has been considered as a potential treatment of AD and may slow the disease progression. Along these lines, anti-inflammatory drugs, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), lessen the effects of AD pathology. In this review, we discuss the molecular mechanism of inflammatory responses in AD brain as well as animal models, and current therapies using NSAIDs, antioxidants, and immunotherapy as neuroprotective strategies for AD.",[],Annals of the New York Academy of Sciences,2005-02-01,"[{'lastname': 'Kitazawa', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': 'Laboratory of Molecular Neuropathogenesis, Department of Neurobiology and Behavior, University of California, Irvine, 92697-4545, USA.'}, {'lastname': 'Yamasaki', 'firstname': 'Tritia R', 'initials': 'TR', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}]",,,,,10.1196/annals.1332.006,<Element 'PubmedArticle' at 0x7f05dc4a5e50>
204,15575491,Mouse models of Alzheimer's disease: insight into treatment.,"Mice overexpressing mutant Alzheimer's disease (AD)-related proteins exhibit many of the neuropathological and behavioral features of the human disease. Transgenic animals have been created that express mutations in the amyloid precursor protein (APP), presenilin (PS)1, and PS2, and also animals expressing more than one of these mutations. For example, in APP mouse models, there are age-related accumulations of amyloid-beta (Abeta)-containing neuritic plaques in the hippocampus and cerebral cortex, activation of astrocytes and microglial cells in regions containing plaques, and degeneration of cholinergic nerve terminals in brain regions that eventually become plaque containing. Missing in the APP and PS mouse models are neurofibrillary tangles and robust neuronal loss in cerebral cortical and subcortical regions such as the basal forebrain cholinergic and locus coeruleus noradrenergic nuclei. Neurofibrillary tangles can be produced in mice expressing mutant tau protein, and the tangle formation is further enhanced in animals that also express mutant APP. Studies in APP mouse models indicate that, like AD, there are abnormalities in adult hippocampal neurogenesis. The animal models of AD have been used to develop and test treatments that reduce brain levels of the Abeta42 protein, neuritic plaque load and glial activation, and some have been found to restore learning and memory function. If such treatments can be shown to stop the neurodegenerative process and restore hippocampal neurogenesis, damaged brain circuits may be replaceable in patients with AD.",[],Reviews in the neurosciences,2004-12-04,"[{'lastname': 'German', 'firstname': 'Dwight C', 'initials': 'DC', 'affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical School, Dallas, TX 75390-9070, USA. dwight.german@utsouthwestern.edu'}, {'lastname': 'Eisch', 'firstname': 'Amelia J', 'initials': 'AJ', 'affiliation': None}]",,,,,10.1515/revneuro.2004.15.5.353,<Element 'PubmedArticle' at 0x7f05dc4adc20>
205,15191802,Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease.,"We compared lesions in elderly transgenic (tg) mice carrying the Swedish double mutation KM670/671NL with lesions in Alzheimer disease (AD) by histochemical and immunohistochemical techniques. Highly similar staining for beta-amyloid protein (Abeta) was observed in AD and the mouse models. The abundant amyloid deposits in tg mice were in a consolidated state as revealed by strong Congo red birefringence. In both tg mice and AD, amyloid deposits were ApoE-positive and were surrounded by activated astrocytes. However, Bielschowsky silver staining and immunostaining with tau antibodies revealed no neurofibrillary tangles (NFTs) in the mice as opposed to abundant NFTs in AD. The microglial pattern was also distinctly different. Tg mice had only weakly activated microglia, which expressed low levels of the complement receptor CD11b. They were gathered around the periphery of the deposits. In contrast, AD lesions had strongly activated microglia, which expressed high levels of CD11b. They were associated with the plaque core. Immunostaining for complement proteins was weak in tg mice but very strong in AD deposits. We conclude that the weak inflammatory response and absence of NFTs indicate that tg mice are only a limited model of AD. Therapeutic strategies for the treatment of AD based on tg mouse models that overexpress Abeta may be limited in their application.",[],Experimental neurology,2004-06-12,"[{'lastname': 'Schwab', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Kinsmen Laboratory of Neurological Research, Division of Neurology, University of British Columbia, Vancouver, BC, Canada V6T 1Z3.'}, {'lastname': 'Hosokawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': None}, {'lastname': 'McGeer', 'firstname': 'Patrick L', 'initials': 'PL', 'affiliation': None}]",,,,,10.1016/j.expneurol.2004.03.016,<Element 'PubmedArticle' at 0x7f05dc4b8450>
206,"14997933
11764091
10932230
10096843
12566926
11875473
10410804
1965862
11823817
9857172
11584304
12410379
11810404
11194941
9600213
7856748
9759494
7513982
11140685
12471455
12641733
8239314
11489136
11520987
11295500
9989456
9700653
11305871
11140686
12640446
1372157
10499443
12214011
12434053
10358773
12446974
11978814
10408445
11169410
11485902
9572310
10899439
9371838
9100978
11026440
12566928
11208906
11079778",Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.,"Immunizing transgenic PDAPP mice, which overexpress mutant APP and develop beta-amyloid deposition resembling plaques in Alzheimer's disease (AD), results in a decrease of amyloid burden when compared with non-treated transgenic animals. Immunization with amyloid-beta peptide has been initiated in a randomised pilot study in AD. Yet a minority of patients developed a neurological complication consistent with meningoencephalitis and one patient died; the trial has been stopped. Neuropathological examination in that patient showed meningoencephalitis, and focal atypically low numbers of diffuse and neuritic plaques but not of vascular amyloid, nor regression of tau pathology in neurofibrillary tangles and neuropil threads. The present neuropathological study reports the second case of meningoencephalitis following immunization with amyloid-beta peptide in AD, and has been directed toward exploring mechanisms underlying decreased tau pathology in relation with amyloid deposit regression, and possible molecular bases involved in the inflammatory response following immunization. Inflammatory infiltrates were composed of CD8+, CD4+, CD3+, CD5+ and, rarely, CD7+ lymphocytes, whereas B lymphocytes and T cytotoxic cells CD16, CD57, TIA and graenzyme were negative. Characteristic neuropathological findings were focal depletion of diffuse and neuritic plaques, but not of amyloid angiopathy, and the presence of small numbers of extremely dense (collapsed) plaques surrounded by active microglia, and multinucleated giant cells filled with dense Abeta42 and Abeta40, in addition to severe small cerebral blood vessel disease and multiple cortical hemorrhages. Reduced amyloid burden was accompanied by low amyloid-associated oxidative stress responses (reduced superoxide dismutase-1: SOD-1 expression) and by local inhibition of the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 kinase which are involved in tau phosphorylation. These results support the amyloid cascade of tau phosphorylation in AD regarding phosphorylation of tau dependent on beta-amyloid deposition in neuritic plaques, but not of tau in neurofibrillary tangles and threads. Furthermore, amyloid reduction was accompanied by increased expression of the PA28a/beta inductor, and of LMP7, LMP2 and MECL1 subunits of the immunoproteasome in microglial and inflammatory cells surrounding collapsed plaques, and in multinucleated giant cells. Immunoproteasome subunit expression was accompanied by local presentation of MHC class I molecules. Release of antigenic peptides derived from beta-amyloid processing may enhance T-cell inflammatory responses accounting for the meningoencephalitis following amyloid-beta peptide immunization.",[],"Brain pathology (Zurich, Switzerland)",2004-03-05,"[{'lastname': 'Ferrer', 'firstname': 'Isidre', 'initials': 'I', 'affiliation': 'Servei Anatomia Patològica, Institut de Neuropatologia, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. 8082ifa@comb.es'}, {'lastname': 'Boada Rovira', 'firstname': 'Mercé', 'initials': 'M', 'affiliation': None}, {'lastname': 'Sánchez Guerra', 'firstname': 'Maria Luisa', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Rey', 'firstname': 'Maria Jesús', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Costa-Jussá', 'firstname': 'Frederic', 'initials': 'F', 'affiliation': None}]",,,,,10.1111/j.1750-3639.2004.tb00493.x,<Element 'PubmedArticle' at 0x7f05dc4c52c0>
207,14730711,Microglial tau undergoes phosphorylation-independent modification after ischemia.,"Tau2 is a phosphorylation-independent antibody that immunolabels neurofibrillary tangles (NFTs) of Alzheimer type and microglia around ischemic foci on formalin-fixed, paraffin-embedded sections. We found that copresence of polyethyleneglycol-p-isooctylphenyl ether (Triton X-100; TX) with tau2 abolished its immunoreactivity (IR) in these microglia but not its IR on NFTs. Tau2-immunoreactive bands, exclusively retrieved in Tris-soluble fraction of brain homogenates from ischemic foci, normal human and bovine brains, were of similar electrophoretic mobility, indicating that tau2 IR in these microglia is unrelated to hyperphosphorylation of tau. These tau2-immunoreactive bands except those from bovine brain were abolished in the copresence of TX. This was not due to washing out of tau, because similar immunoreactive bands were detectable with another antitau antibody even under a higher concentration of TX and because washing after TX exposure restored similar tau2 IR both on immunohistochemistry and immunoblot. These findings are explained if tau, modified after ischemia, undergoes a reversible conformational change on TX exposure. Because conformation at Ser101 of bovine tau is crucial for its affinity to tau2, this Ser-like conformation mimicked by its human counterpart Pro may represent pathological modification of tau shared by microglia around ischemic foci and NFTs. Relative resistance of tau2 epitope in NFTs to TX exposure suggests that tau woven into NFTs confers additional stability to this pathological modification on tau2 epitope. Susceptibility of tau2 epitope to TX, seen in these microglia, is shared with glial cytoplasmic inclusions and will show its conformational state to be different from that in NFTs.",[],Glia,2004-01-20,"[{'lastname': 'Uchihara', 'firstname': 'Toshiki', 'initials': 'T', 'affiliation': 'Department of Neuropathology, Tokyo Metropolitan Institute for Neuroscience, 2-6 Musashi-dai, Fuchu, Tokyo 183-8526, Japan. uchihara@tmin.ac.jp'}, {'lastname': 'Nakamura', 'firstname': 'Ayako', 'initials': 'A', 'affiliation': None}, {'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': None}, {'lastname': 'Ikeda', 'firstname': 'Kenji', 'initials': 'K', 'affiliation': None}, {'lastname': 'Tsuchiya', 'firstname': 'Kuniaki', 'initials': 'K', 'affiliation': None}]",,,,"Copyright 2003 Wiley-Liss, Inc.",10.1002/glia.10318,<Element 'PubmedArticle' at 0x7f05dc462220>
208,12975286,Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.,"Most patients with dementia with Lewy bodies (DLB) exhibit diffuse plaque-only pathology with rare neocortical neurofibrillary tangles (NFTs), as opposed to the widespread cortical neurofibrillary-tau involvement in Alzheimer disease (AD). Another pathological difference is the astrocytic and microglial inflammatory responses, including release of interleukins (ILs), around the neuritic plaques and NFTs in AD brains that are absent or much lower in DLB. We analyzed cerebrospinal fluid (CSF) markers that reflect the pathological differences between AD and DLB.
To determine CSF concentrations of tau, beta-amyloid, IL-1beta, and IL-6 as potential diagnostic clues to distinguish between AD and DLB.
We measured total tau, beta-amyloid1-42, IL-1beta, and IL-6 levels in CSF samples of 33 patients with probable AD without parkinsonism, 25 patients with all the core features of DLB, and 46 age-matched controls.
Patients with AD had significantly higher levels of tau protein than patients with DLB and controls (P<.001). The most efficient cutoff value provided 76% specificity to distinguish AD and DLB cases. Patients with AD and DLB had lower, but not significantly so, beta-amyloid levels than controls. The combination of tau and beta-amyloid levels provided the best sensitivity (84%) and specificity (79%) to differentiate AD vs controls but was worse than tau values alone in discriminating between AD and DLB. Beta-amyloid levels had the best correlation with disease progression in both AD and DLB (P =.01). There were no significant differences in IL-1beta levels among patients with AD, patients with DLB, and controls. Patients with AD and DLB showed slightly, but not significantly, higher IL-6 levels than controls.
The tau levels in CSF may contribute to the clinical distinction between AD and DLB. Beta-amyloid CSF levels are similar in both dementia disorders and reflect disease progression better than tau levels. Interleukin CSF concentrations do not distinguish between AD and DLB.",[],Archives of neurology,2003-09-17,"[{'lastname': 'Gómez-Tortosa', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': 'Department of Neurology, Fundación Jiménez Díaz, the Brain Bank for Neurological Research, Complutense University, Madrid, Spain. egomez@fjd.es'}, {'lastname': 'Gonzalo', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Fanjul', 'firstname': 'Samira', 'initials': 'S', 'affiliation': None}, {'lastname': 'Sainz', 'firstname': 'Maria José', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Cantarero', 'firstname': 'Susana', 'initials': 'S', 'affiliation': None}, {'lastname': 'Cemillán', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': None}, {'lastname': 'Yébenes', 'firstname': 'Justo García', 'initials': 'JG', 'affiliation': None}, {'lastname': 'del Ser', 'firstname': 'Teodoro', 'initials': 'T', 'affiliation': None}]",,,"Patients with AD had significantly higher levels of tau protein than patients with DLB and controls (P<.001). The most efficient cutoff value provided 76% specificity to distinguish AD and DLB cases. Patients with AD and DLB had lower, but not significantly so, beta-amyloid levels than controls. The combination of tau and beta-amyloid levels provided the best sensitivity (84%) and specificity (79%) to differentiate AD vs controls but was worse than tau values alone in discriminating between AD and DLB. Beta-amyloid levels had the best correlation with disease progression in both AD and DLB (P =.01). There were no significant differences in IL-1beta levels among patients with AD, patients with DLB, and controls. Patients with AD and DLB showed slightly, but not significantly, higher IL-6 levels than controls.",,10.1001/archneur.60.9.1218,<Element 'PubmedArticle' at 0x7f05dc46c9f0>
209,"12629164
1549228
11158256
9278049
7521944
1359534
7566340
7681038
2360787
9034367
7655344
12149413
2529544
9458167
10959036
9626992
9228012
1899488
9751173
10627591
10617115
11592111
8858005
11148253
9354812
7715705
10934165
10737616
8835888
9056542
11578769
7538561
1789684
8855335
7481820",Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.,"The presence of tangles of abnormally phosphorylated tau is a characteristic of Alzheimer's disease (AD), and the loss of synapses correlates with the degree of dementia. In addition, the overexpression of interleukin-1 (IL-1) has been implicated in tangle formation in AD. As a direct test of the requirement for IL-1 in tau phosphorylation and synaptophysin expression, IL-1 actions in neuron-microglia cocultures were manipulated. Activation of microglia with secreted beta-amyloid precursor protein or lipopolysaccharide elevated their expression of IL-1alpha, IL-1beta, and tumor necrosis factor alpha (TNFalpha) mRNA. When such activated microglia were placed in coculture with primary neocortical neurons, a significant increase in the phosphorylation of neuronal tau was accompanied by a decline in synaptophysin levels. Similar effects were evoked by treatment of neurons with recombinant IL-1beta. IL-1 receptor antagonist (IL-1ra) as well as anti-IL-1beta antibody attenuated the influence of activated microglia on neuronal tau and synaptophysin, but anti-TNFalpha antibody was ineffective. Some effects of microglial activation on neurons appear to be mediated by activation of p38 mitogen-activated protein kinase (p38-MAPK), because activated microglia stimulated p38-MAPK phosphorylation in neurons, and an inhibitor of p38-MAPK reversed the influence of IL-1beta on tau phosphorylation and synaptophysin levels. Our results, together with previous observations, suggest that activated microglia may contribute to neurofibrillary pathology in AD through their production of IL-1, activation of neuronal p38-MAPK, and resultant changes in neuronal cytoskeletal and synaptic elements.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2003-03-12,"[{'lastname': 'Li', 'firstname': 'Yuekui', 'initials': 'Y', 'affiliation': 'Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.'}, {'lastname': 'Liu', 'firstname': 'Ling', 'initials': 'L', 'affiliation': None}, {'lastname': 'Barger', 'firstname': 'Steven W', 'initials': 'SW', 'affiliation': None}, {'lastname': 'Griffin', 'firstname': 'W Sue T', 'initials': 'WS', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.23-05-01605.2003,<Element 'PubmedArticle' at 0x7f05dc478450>
210,12581338,"Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.","The total amount of hyperphosphorylated tau protein (p-tau load), present as neurofibrillary tangles (NFTs), neuropil threads or plaque neurites, was quantified in the frontal cortex of 109 cases of sporadic Alzheimer's disease (AD) and 35 cases of familial AD due to missense mutations in the presenilin-1, presenilin-2 and amyloid precursor protein genes. p-tau load was inversely correlated with age at onset of illness in both sporadic and familial AD but not with duration of disease. There was no difference in p-tau load between cases of familial AD and others with sporadic AD, matching the familial cases for apolipoprotein E (APO E) genotype. However, p-tau was greater in cases of familial and sporadic AD in the presence of APO E epsilon4 allele and increased with gene dose. Conversely, p-tau load tended to be lower when epsilon2 allele was present. In sporadic AD, tau load was highly significantly correlated with amyloid beta40 (Abeta40), but not Abeta42(43), load. These data indicate that the burden of pathological tau deposited in the brain in both familial and sporadic AD is favoured in the presence of APO E epsilon4 allele and also related to the amount of Abeta40, this also being higher when epsilon4 allele is present. Abeta40 plaques are rich in microglial cells and it is possible that p-tau pathology in AD is triggered by reaction of microglial cells to the presence of Abeta40 and not this peptide directly.",[],Neuropathology and applied neurobiology,2003-02-13,"[{'lastname': 'Thaker', 'firstname': 'U', 'initials': 'U', 'affiliation': 'Clinical Neuroscience Research Group, Department of Medicine, University of Manchester, Manchester, UK.'}, {'lastname': 'McDonagh', 'firstname': 'A M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Iwatsubo', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Lendon', 'firstname': 'C L', 'initials': 'CL', 'affiliation': None}, {'lastname': 'Pickering-Brown', 'firstname': 'S M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Mann', 'firstname': 'D M A', 'initials': 'DM', 'affiliation': None}]",,,,,10.1046/j.1365-2990.2003.00425.x,<Element 'PubmedArticle' at 0x7f05dc493770>
211,12127879,CD40-CD40L interaction in Alzheimer's disease.,"Increasing evidence supports a role of the CD40 receptor-CD40 ligand (CD40-CD40L) interaction in the pathogenesis of Alzheimer's disease (AD). It has previously been shown that this dyad acts synergistically with the Alzheimer amyloid-beta peptide to promote microglial activation. Reactive microglia produce potentially neurotoxic substances such as tumor necrosis factor alpha and the reactive oxygen species nitric oxide, which can induce bystander neuronal injury at high levels. When a transgenic mouse model of AD is crossed with an animal deficient in CD40L, the resulting phenotype is deficient in the gliosis observed in a mouse model of AD in which CD40L is present. Additionally, these crossed animals have complete absence of AD-like neuronal Tau hyperphosphorylation, a marker of the preneuronal tangle pathology in AD patients. This suggests that the CD40-CD40L system is a critical enhancer of microglial activation in an AD transgenic mouse model and that such activation is associated with an increase in a key indicator of neuronal stress. Conversely, the finding that reduced CD40-CD40L interaction is associated with reduced chronic microgliosis and Tau hyperphosphorylation supports the view that, in general, mechanisms that reduce microgliosis will be beneficial in AD.",[],Current opinion in pharmacology,2002-07-20,"[{'lastname': 'Tan', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'The Roskamp Institute, Department of Psychiatry, University of South Florida, 3515 East Fletcher Avenue, Tampa, Florida 33613, USA. jtan@hsc.usf.edu'}, {'lastname': 'Town', 'firstname': 'Terrence', 'initials': 'T', 'affiliation': None}, {'lastname': 'Mullan', 'firstname': 'Mike', 'initials': 'M', 'affiliation': None}]",,,,,10.1016/s1471-4892(02)00180-7,<Element 'PubmedArticle' at 0x7f05dc49cb80>
212,11895040,Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta.,"Familial Danish dementia (FDD) is pathologically characterized by widespread cerebral amyloid angiopathy (CAA), parenchymal protein deposits, and neurofibrillary degeneration. FDD is associated with a mutation of the BRI2 gene located on chromosome 13. In FDD there is a decamer duplication, which abolishes the normal stop codon, resulting in an extended precursor protein and the release of an amyloidogenic fragment, ADan. The aim of this study was to describe the major neuropathological changes in FDD and to assess the distribution of ADan lesions, neurofibrillary pathology, glial, and microglial response using conventional techniques, immunohistochemistry, confocal microscopy, and immunoelectron microscopy. We showed that ADan is widely distributed in the central nervous system (CNS) in the leptomeninges, blood vessels, and parenchyma. A predominance of parenchymal pre-amyloid (non-fibrillary) lesions was found. Abeta was also present in a proportion of both vascular and parenchymal lesions. There was severe neurofibrillary pathology, and tau immunoblotting revealed a triplet electrophoretic migration pattern comparable with PHF-tau. FDD is a novel form of CNS amyloidosis with extensive neurofibrillary degeneration occurring with parenchymal, predominantly pre-amyloid rather than amyloid, deposition. These findings support the notion that parenchymal amyloid fibril formation is not a prerequisite for the development of neurofibrillary tangles. The significance of concurrent ADan and Abeta deposition in FDD is under further investigation.",[],Journal of neuropathology and experimental neurology,2002-03-16,"[{'lastname': 'Holton', 'firstname': 'Janice L', 'initials': 'JL', 'affiliation': 'Department of Molecular Pathogenesis, Queen Square Brain Bank, London, United Kingdom.'}, {'lastname': 'Lashley', 'firstname': 'Tammaryn', 'initials': 'T', 'affiliation': None}, {'lastname': 'Ghiso', 'firstname': 'Jorge', 'initials': 'J', 'affiliation': None}, {'lastname': 'Braendgaard', 'firstname': 'Hans', 'initials': 'H', 'affiliation': None}, {'lastname': 'Vidal', 'firstname': 'Ruben', 'initials': 'R', 'affiliation': None}, {'lastname': 'Guerin', 'firstname': 'Christopher J', 'initials': 'CJ', 'affiliation': None}, {'lastname': 'Gibb', 'firstname': 'Graham', 'initials': 'G', 'affiliation': None}, {'lastname': 'Hanger', 'firstname': 'Diane P', 'initials': 'DP', 'affiliation': None}, {'lastname': 'Rostagno', 'firstname': 'Agueda', 'initials': 'A', 'affiliation': None}, {'lastname': 'Anderton', 'firstname': 'Brian H', 'initials': 'BH', 'affiliation': None}, {'lastname': 'Strand', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ayling', 'firstname': 'Hilary', 'initials': 'H', 'affiliation': None}, {'lastname': 'Plant', 'firstname': 'Gordon', 'initials': 'G', 'affiliation': None}, {'lastname': 'Frangione', 'firstname': 'Blas', 'initials': 'B', 'affiliation': None}, {'lastname': 'Bojsen-Møller', 'firstname': 'Marie', 'initials': 'M', 'affiliation': None}, {'lastname': 'Revesz', 'firstname': 'Tamas', 'initials': 'T', 'affiliation': None}]",,,,,10.1093/jnen/61.3.254,<Element 'PubmedArticle' at 0x7f05dc424040>
213,"11578769
7521944
1376245
10953177
7624036
2529544
7876895
9458167
10959036
10716256
9065483
10217284
10515232
2011243
7635444
10716257
7718619
7535770
11065142
9202310
9056542
10833312
8793994",Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation.,"Activated (phosphorylated) mitogen-activated protein kinase p38 (MAPK-p38) and interleukin-1 (IL-1) have both been implicated in the hyperphosphorylation of tau, a major component of the neurofibrillary tangles in Alzheimer's disease. This, together with findings showing that IL-1 activates MAPK-p38 in vitro and is markedly overexpressed in Alzheimer brain, suggest a role for IL-1-induced MAPK-p38 activation in the genesis of neurofibrillary pathology in Alzheimer's disease. We found frequent colocalization of hyperphosphorylated tau protein (AT8 antibody) and activated MAPK-p38 in neurons and in dystrophic neurites in Alzheimer brain, and frequent association of these structures with activated microglia overexpressing IL-1. Tissue levels of IL-1 mRNA as well as of both phosphorylated and non-phosphorylated isoforms of tau were elevated in these brains. Significant correlations were found between the numbers of AT8- and MAPK-p38-immunoreactive neurons, and between the numbers of activated microglia overexpressing IL-1 and the numbers of both AT8- and MAPK-p38-immunoreactive neurons. Furthermore, rats bearing IL-1-impregnated pellets showed a six- to seven-fold increase in the levels of MAPK-p38 mRNA, compared with rats with vehicle-only pellets (P<0.0001). These results suggest that microglial activation and IL-1 overexpression are part of a feedback cascade in which MAPK-p38 overexpression and activation leads to tau hyperphosphorylation and neurofibrillary pathology in Alzheimer's disease.",[],Neurochemistry international,2001-10-02,"[{'lastname': 'Sheng', 'firstname': 'J G', 'initials': 'JG', 'affiliation': 'The Donald W. Reynolds Department of Geriatrics, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205, USA.'}, {'lastname': 'Jones', 'firstname': 'R A', 'initials': 'RA', 'affiliation': None}, {'lastname': 'Zhou', 'firstname': 'X Q', 'initials': 'XQ', 'affiliation': None}, {'lastname': 'McGinness', 'firstname': 'J M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Van Eldik', 'firstname': 'L J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Mrak', 'firstname': 'R E', 'initials': 'RE', 'affiliation': None}, {'lastname': 'Griffin', 'firstname': 'W S', 'initials': 'WS', 'affiliation': None}]",,,,,10.1016/s0197-0186(01)00041-9,<Element 'PubmedArticle' at 0x7f05dc434540>
214,11173884,Senile dementia of the neurofibrillary tangle type: a comparison with Alzheimer's disease.,"A subset of senile dementia, 'senile dementia (SD) of the neurofibrillary tangle (NFT) type' (SD-NFT), is characterized by numerous NFTs in the hippocampal region and absence or scarcity of senile plaques throughout the brain. To elucidate the pathogenesis of SD-NFT in comparison with Alzheimer's disease (AD), we investigated the hippocampal lesions and analyzed the tau gene. The hippocampal regions from 5 patients with SD-NFT were neuropathologically evaluated in comparison with AD and nondemented control subjects. The tau gene was analyzed in 3 patients with SD-NFT. The densities of NFTs in the CA1/subiculum and entorhinal cortex of SD-NFT were significantly higher than those in AD. However, hippocampal atrophy, neuronal and synaptic loss, and astrocytic and microglial proliferation in SD-NFT were significantly mild compared with AD. There was no significant difference between SD-NFT and AD in the immunoreactivities of NFTs with different anti-tau antibodies. No mutation was found in the tau gene from the SD-NFT patients. Our results indicate that the neurodegenerative process with NFT formation of the hippocampal region in SD-NFT would be different from that in AD.",[],Dementia and geriatric cognitive disorders,2001-02-15,"[{'lastname': 'Yamada', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Neurology, Kanazawa University School of Medicine, Kanazawa, Japan. m-yamada@med.kanazawa-u.ac.jp'}, {'lastname': 'Itoh', 'firstname': 'Y', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Sodeyama', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Suematsu', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Otomo', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Matsushita', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Mizusawa', 'firstname': 'H', 'initials': 'H', 'affiliation': None}]",,,,"Copyright 2001 S. Karger AG, Basel",10.1159/000051245,<Element 'PubmedArticle' at 0x7f05dc44a0e0>
215,"11159188
21610757
2364266
10775542
9928828
10391242
10781099
2011243
7681101
1826835
5432063
2436433
7509849
4090943
3987847
2531851
1357663
7086452
7086450
2765920
2464938
9690671
8506352
7533559
8181568
1705753
1759558
9546672
1922961
7789457
10392577
9736023
10526337
8469374
1724335
1575018
10570203
1439760
9180278
9786340
9546792
11079548
4037751
2197973",Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia.,"Familial British dementia (FBD), pathologically characterized by cerebral amyloid angiopathy (CAA), amyloid plaques, and neurofibrillary degeneration, is associated with a stop codon mutation in the BRI gene resulting in the production of an amyloidogenic fragment, amyloid-Bri (ABri). The aim of this study was to assess the distribution of ABri fibrillar and nonfibrillar lesions and their relationship to neurofibrillary pathology, astroglial and microglial response using immunohistochemistry, confocal microscopy, and immunoelectron microscopy in five cases of FBD. Abnormal tau was studied with immunoblotting. We present evidence that ABri is deposited throughout the central nervous system in blood vessels and parenchyma where both amyloid (fibrillar) and pre-amyloid (nonfibrillar) lesions are formed. Ultrastructurally amyloid lesions appear as bundles of fibrils recognized by an antibody raised against ABri, whereas Thioflavin S-negative diffuse deposits consist of amorphous electron-dense material with sparse, dispersed fibrils. In contrast to nonfibrillar lesions, fibrillar ABri is associated with a marked astrocytic and microglial response. Neurofibrillary tangles and neuropil threads occurring mainly in limbic structures, are found in areas affected by all types of ABri lesions whereas abnormal neurites are present around amyloid lesions. Immunoblotting for tau revealed a triplet electrophoretic migration pattern. Our observations confirm a close link between ABri deposition and neurodegeneration in FBD.",[],The American journal of pathology,2001-02-13,"[{'lastname': 'Holton', 'firstname': 'J L', 'initials': 'JL', 'affiliation': 'Department of Neuropathology, Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Ghiso', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Lashley', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Rostagno', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Guerin', 'firstname': 'C J', 'initials': 'CJ', 'affiliation': None}, {'lastname': 'Gibb', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Houlden', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Ayling', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Martinian', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Anderton', 'firstname': 'B H', 'initials': 'BH', 'affiliation': None}, {'lastname': 'Wood', 'firstname': 'N W', 'initials': 'NW', 'affiliation': None}, {'lastname': 'Vidal', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Plant', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Frangione', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Revesz', 'firstname': 'T', 'initials': 'T', 'affiliation': None}]",,,,,10.1016/S0002-9440(10)63993-4,<Element 'PubmedArticle' at 0x7f05dc455a40>
216,10997291,Strategies to delay the onset of Alzheimer's disease.,"Several processes are implicated in the neuropathology of Alzheimer's disease (AD), such as the deposition of amyloid, the formation of paired helical filaments and the proinflammatory activation of microglial and astroglial cells. Proinflammatory activation of glial cells has been a focus of research for a mere ten years now. However, the availability of and broad experience with anti-inflammatory drugs has led to several ongoing clinical trials to verify the capacity of anti-inflammatory drugs to ameliorate the deterioration in AD. The enzymatic cleavage of the amyloid-precursor-protein or the hyperphosphorylation of tau as well as the subsequent aggregation of the resulting products are further targets for drugs intended to delay the neuropathological destruction observed in AD.",[],EXS,2000-09-21,"[{'lastname': 'Hüll', 'firstname': 'M H', 'initials': 'MH', 'affiliation': 'Dept. of Psychiatry, University of Freiburg, Germany.'}, {'lastname': 'Fiebich', 'firstname': 'B L', 'initials': 'BL', 'affiliation': None}, {'lastname': 'Lieb', 'firstname': 'K', 'initials': 'K', 'affiliation': None}]",,,,,10.1007/978-3-0348-8393-1_13,<Element 'PubmedArticle' at 0x7f05dc3f48b0>
217,10961430,Genetically altered transgenic models of Alzheimer's disease.,"Abnormal processing and aggregation of synaptic proteins might play an important role in the pathogenesis of neurodegenerative disorders. Among them, amyloid precursor protein (APP) has been clearly associated with Alzheimer's disease (AD) and various transgenic (tg) animal models have been developed where mutant APP is overexpressed under the regulatory control of neuronal promoters. These studies have shown that AD-like pathology (namely plaques and synapse damage) begins to develop at 6-8 months of age in mice expressing human APP under Thy1, platelet-derived growth factor (B-chain) or protease-resistant prion protein promoters, provided that levels of APP are higher than 5-7 fold of endogenous levels. None of these models have shown the presence of tangles; however, tau-immunoreactive neurites in plaques and astroglial/microglial activation are observed after 12 months of age. Neuronal loss and alterations of synaptic function and connectivity are found in the CA1 region in the PDAPP tg mice lacking the Swiss Webster background. Co-expression of other genes associated with AD modify this phenotype, for example, mutant presenilin 1 accelerates the onset of plaque formation, transforming growth factor beta enhances vascular amyloidosis, and apolipoprotein E decreases amyloid deposition. In conclusion, tg mice which are capable of mimicking some aspects of AD (provided that high enough levels of expression are achieved) can potentially be used to test novel drugs for the treatment of neurodegenerative disorders.",[],Journal of neural transmission. Supplementum,2000-08-29,"[{'lastname': 'Masliah', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Neurosciences and Pathology, University of California, San Diego School of Medicine, La Jolla 92093-0624, USA.'}, {'lastname': 'Rockenstein', 'firstname': 'E', 'initials': 'E', 'affiliation': None}]",,,,,10.1007/978-3-7091-6781-6_20,<Element 'PubmedArticle' at 0x7f05dc3fd310>
218,10654103,Investigations on oxidative stress and therapeutical implications in dementia.,"Alzheimer's disease (AD) is a progressive dementia affecting a large proportion of the aging population. The histopathological changes in AD include neuronal cell death and formation of amyloid plaques and neurofibrillary tangles (NFTs) NFTs are composed of hyperphosphorylated tau protein, and senile plaques contain aggregates of the beta-peptide. There is also evidence that brain tissue in patients with AD is exposed to oxidative stress during the course of the disease. Advanced glycation endproducts (AGEs), which are formed by a non-enzymatic reaction of glucose with long-lived protein deposits, are potentially toxic to the cell, are present in brain plaques in AD, and its extracellular accumulation in AD may be caused by an accelerated oxidation of glycated proteins. The microtubuli-associated protein tau is also subject to intracellular AGE formation. AGEs participate in neuronal death causing direct (chemical) radical production: Glycated proteins produce nearly 50-fold more radicals than non-glycated proteins, and indirect (cellular) radical production: Interaction of AGEs with cells increases oxidative stress. During aging cellular defence mechanisms weaken and the damages to cell constituents accumulate leading to loss of function and finally cell death. The development of drugs for the treatment of AD remains at a very unsatisfying state. However, pharmacological approaches which break the vicious cycles of oxidative stress and neurodegeneration offer new opportunities for the treatment of AD. Theses approaches include AGE-inhibitors, antioxidants, and anti-inflammatory substances, which prevent radical production. AGE inhibitors might be able to stop formation of AGE-modified beta-amyloid deposits, antioxidants are likely to scavenge intracellular and extracellular superoxide radicals and hydrogen peroxide before these radicals damage cell constituents or activate microglia, and anti-inflammatory drugs attenuating microglial radical and cytokine production.",[],European archives of psychiatry and clinical neuroscience,2000-02-02,"[{'lastname': 'Durany', 'firstname': 'N', 'initials': 'N', 'affiliation': 'Department of Psychiatry, University of Würzburg, Germany. nerk124@mail.uni-wuerzburg.de'}, {'lastname': 'Münch', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Michel', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Riederer', 'firstname': 'P', 'initials': 'P', 'affiliation': None}]",,,,,10.1007/pl00014177,<Element 'PubmedArticle' at 0x7f05dc402950>
219,10192210,Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology.,"In terminal Alzheimer's disease (AD) the frequency of plaques was found to be reduced in single cases. To test this finding in a larger sample, and in order to determine whether the number of plaques labeled with different markers and the distribution of neurofibrillary tangles are correlated positively to each other and to the degree of dementia, a sample of 134 autopsy brains with and 15 without AD-related pathology has been examined. All of the cases were staged according to Braak and Braak. Both the frequency of plaques immunopositive for beta-amyloid, amyloid precursor protein, and apolipoprotein E and that of microglial cells in the cortex and in the white matter were determined semiquantitatively. The content and distribution of PHF-tau was ascertained by ELISA and immunohistochemistry. Both the clinical dementia rating and the global deterioration scale were used as clinical parameters retrospectively. Correlation coefficients were calculated for all parameters and differences were evaluated statistically. With progressive distribution of neurofibrillary tangles and increasing content of PHF-tau the plaque stages and the degree of cortical microglia reaction increased up to the Braak-stages IV and V, thereafter showing a slightly decreasing tendency in the investigated regions. In end-stage AD resorption of beta-amyloid seems to surpass its deposition. The microglial reaction in the white matter correlated neither with the Braak-stage nor with the accumulation of amyloid. With regard to the degree of dementia, both scales correlated well with the pathological changes. Our data show that neuronal cytoskeletal alterations progressively increase with progressive dementia until the end stage of AD in contrast to the frequencies of plaques and cortical microglial cells, and are therefore preferable for staging purposes.",[],Neurobiology of aging,1999-04-07,"[{'lastname': 'Thal', 'firstname': 'D R', 'initials': 'DR', 'affiliation': 'Department of Neuropathology, Institute of Pathology, University of Leipzig, Germany.'}, {'lastname': 'Arendt', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Waldmann', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Holzer', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Zedlick', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Rüb', 'firstname': 'U', 'initials': 'U', 'affiliation': None}, {'lastname': 'Schober', 'firstname': 'R', 'initials': 'R', 'affiliation': None}]",,,,,10.1016/s0197-4580(98)00090-6,<Element 'PubmedArticle' at 0x7f05dc40eb30>
220,10071053,Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease.,"Experimental studies indicate that overactivation of the DNA repair protein poly(ADP-ribose) polymerase (PARP) in response to oxidative damage to DNA can cause cell death due to depletion of NAD+. Oxidative damage to DNA and other macromolecules has been reported to be increased in the brains of patients with Alzheimer's disease. In the present study we sought evidence of PARP activation in Alzheimer's disease by immunostaining sections of frontal and temporal lobe from autopsy material of 20 patients and 10 controls, both for PARP itself and for its end-product, poly(ADP-ribose). All of the brains had previously been subjected to detailed neuropathological examination to confirm the diagnosis of Alzheimer's disease or, in the controls, to exclude Alzheimer's disease-type pathology. Double immunolabelling for poly(ADP-ribose) and microtubule-associated protein 2 (MAP2), glial fibrillary-acidic protein (GFAP), CD68, A beta-protein or tau was used to assess the identity of the cells with poly(ADP-ribose) accumulation and their relationship to plaques and neurofibrillary tangles. Both PARP- and poly(ADP-ribose)-immunolabelled cells were detected in a much higher proportion of Alzheimer's disease (20 out of 20) brains than of control brains (5 out of 10) (P = 0.0018). Double-immunolabelling for poly(ADP-ribose) and markers of neuronal, astrocytic and microglial differentiation (MAP2, GFAP and CD68, respectively) showed many of the cells containing poly(ADP-ribose) to be neurons. Most of these were small pyramidal neurons in cortical laminae 3 and 5. A few of the cells containing poly(ADP-ribose) were astrocytes. No poly(ADP-ribose) accumulation was detected in microglia. Double-immunolabelling for poly(ADP-ribose) and tau or A beta-protein indicated that the cells with accumulation of poly(ADP-ribose) did not contain tangles and relatively few occurred within plaques. Our findings indicate that there is enhanced PARP activity in Alzheimer's disease and suggest that pharmacological interventions aimed at inhibiting PARP may have a role in slowing the progression of the disease.",[],Brain : a journal of neurology,1999-03-10,"[{'lastname': 'Love', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Department of Neuropathology, Frenchay Hospital, Bristol, UK. seth.love@bris.ac.uk'}, {'lastname': 'Barber', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Wilcock', 'firstname': 'G K', 'initials': 'GK', 'affiliation': None}]",,,,,10.1093/brain/122.2.247,<Element 'PubmedArticle' at 0x7f05dc416950>
221,9600680,An immunohistochemical study of centenarian brains: a comparison.,"To evaluate the pathology of centenarian brains, which would reflect the ultimate stage of the aging process, 13 centenarians (M:F=1:12; mean+/-SD, 101.5+/-1.5 years) from the consecutive autopsy series were studied. None had severe dementia compatible with Alzheimer's disease (AD). As younger controls, 20 nondemented (ND) individuals (79.8+/-3.2 years) and 20 AD patients (80.8+/-3.0 years) were selected. In addition to the routine examination including methenamine-Bodian staining, an immunohistochemical study was performed, using antibodies to amyloid beta protein, tau, ubiquitin, glial fibrillary acidic protein (GFAP), synaptophysin, and Ki-MIP (a marker of the microglial and perivascular cells). No centenarian subjects satisfied the neuropathological criteria for definite AD. The densities of senile plaques and neurofibrillary tangles (NFTs) were significantly lower in almost all examined subdivisions than the AD patients, and tended to be higher than the ND subjects. Cerebral amyloid angiopathy of the centenarian was less severe than the AD patients, as well as the proliterations of GFAP-positive astrocytes and Ki-MIP-positive microglial cells, and the loss of synaptic terminal density. The relative mildness of the age-related morphological changes in the centenarians compared with the AD patients supports the idea that AD would not be the ultimate condition of the aging process, but would develop through the switching to the pathological process.",[],Journal of the neurological sciences,1998-05-26,"[{'lastname': 'Itoh', 'firstname': 'Y', 'initials': 'Y', 'affiliation': 'Department of Internal Medicine, Yokufukai Geriatric Hospital, Tokyo, Japan.'}, {'lastname': 'Yamada', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Suematsu', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Matsushita', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Otomo', 'firstname': 'E', 'initials': 'E', 'affiliation': None}]",,,,,10.1016/s0022-510x(98)00050-1,<Element 'PubmedArticle' at 0x7f05dc3a3630>
222,9461057,"Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects.","To examine the time course of the histopathological effects of bilateral injections of amyloid-beta 25-35 (A beta) and to determine if these effects are associated with a reduction in choline acetyltransferase activity and behavioral impairments, we injected A beta (5.0 nmol) into the amygdala of young male Fischer rats. Control rats received vehicle infusions. For histological analysis, animals were sacrificed at 8, 32, 64, 96, and 128 days postoperatively (n = 21-33 per timepoint). A beta induced neuronal tau-2 staining in the right, but not the left amygdala and hippocampus. A beta also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus and amygdala, respectively. As with tau-2, these same brain regions within the left hemisphere in the A beta-treated rats were significantly less affected. In addition, A beta appeared to induce microglial and neuronal interleukin-1beta staining. The histopathological effects of A beta peaked at 32 days postoperatively but were not associated with a reduction in amygdaloid choline acetyltransferase activity. In a separate experiment, behavioral effects of bilateral intra-amygdaloid injections of A beta were analyzed at 34-52 days postoperatively. In an open field test, the treatment groups differed only in the numbers of rears emitted (p = 0.016). There was no effect of A beta in the Morris water maze or in the acquisition and retention of a one-way conditioned avoidance response. These data suggest a laterality in the histopathological effects of A beta and that the effects of single injections are in part transient. These findings also suggest a direct association between plaque and tangle formation in Alzheimer's disease, and support the use of this rat model to screen drugs that may alter the initial pathological events associated with Alzheimer's disease, that occur before the manifestations of extensive behavioral impairments become evident.",[],Neurobiology of aging,1998-02-14,"[{'lastname': 'Sigurdsson', 'firstname': 'E M', 'initials': 'EM', 'affiliation': 'Department of Pharmacology, Loyola University of Chicago Medical Center, Maywood, IL 60153, USA.'}, {'lastname': 'Lee', 'firstname': 'J M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Dong', 'firstname': 'X W', 'initials': 'XW', 'affiliation': None}, {'lastname': 'Hejna', 'firstname': 'M J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Lorens', 'firstname': 'S A', 'initials': 'SA', 'affiliation': None}]",,,,,10.1016/s0197-4580(97)00154-1,<Element 'PubmedArticle' at 0x7f05dc3af2c0>
223,9220460,Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus.,"To identify whether the process of apoptosis bears a topographic relationship to selected aspects of Alzheimer's disease (AD) pathology, we used an in situ nick translation method (TUNEL) to map DNA fragmentation in hippocampal sections immunostained for abnormally phosphorylated tau, which exists in the neurofibrillary tangles (NFTs) and in the dystrophic neurites associated with senile plaques. To ascertain associations of DNA fragmentation with glia, TUNEL was combined with immunohistochemistry for the astrocyte marker, glial fibrillary acidic protein (GFAP), or the microglial antigen OX-42. Consistent with previous reports, the incidence of putative DNA fragmentation detected by TUNEL was much higher in the AD brain, compared to non-demented subjects. While most TUNEL-positive cells did not exhibit any systematic topographic relationship to senile plaques, which were visualized by immunostain of abnormally phosphorylated tau for dystrophic neurites, DNA fragmentation was found frequently within cells containing NFTs. In hippocampal sections prepared to visualize glia, DNA fragmentation was not observed in GFAP-positive astrocytes, but some OX-42-positive microglia exhibited TUNEL signals. Other TUNEL-positive cells were found frequently in proximity to glia. The data suggest that cells compromised by the deposition of NFTs are prone to initiate the process of apoptosis. Furthermore, some glial populations appear to be apoptotic in the AD brain.",[],Neurochemistry international,1997-08-01,"[{'lastname': 'Sugaya', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Department of Pharmacology, Mayo Clinic, Jacksonville 32224, USA. sugaya@mayo.edu'}, {'lastname': 'Reeves', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'McKinney', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,,10.1016/s0197-0186(96)00158-1,<Element 'PubmedArticle' at 0x7f05dc3b8ae0>
224,"9094983
7876895
8159737
7635444
7485389
7479875
8558064
8580716
8605932
8613691
8692878
8866675
8940121
2864910
3780919
2381508
2150888
1827266
1370450
8004671
7527448
1740675
1839072
1386275
1643627
1382099
1407609
1281554
8422590
8229081
8304236
7624036",Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease.,"Cytokines mediate inflammatory responses through their receptors in the hematopoietic system. In a search for potential mediators of inflammatory responses in Alzheimer's disease, we examined brain for cytokine receptors. Herein we describe interleukin-8 receptor B (IL-8RB, also termed CXCR2) immunoreactivity in the central nervous system. Strong IL-8RB immunoreactivity is present in both Alzheimer's disease and control brains. Neurons, dendrites, and axons are clearly immunoreactive. In Alzheimer's disease, IL-8RB immunoreactivity is also present in some swollen dystrophic neurites of neuritic plaques. Double staining and confocal microscopic analysis reveals that these IL-8RB-positive neurites in plaques are neurofilament positive and are distinct from astrocytic or microglial processes. In general, these IL-8RB-positive neurities do not co-localize with PHF-1 or AT8 (hyperphosphorylated tau) immunoreactive neurites but instead co-localize with beta PP-positive neurites. These results demonstrate for the first time IL-8RB immunoreactivity in the central nervous system and imply a new role for this receptor outside the hematopoietic system. The strong presence of IL-8RB on neurons and the potential of glial cells to produce IL-8 suggest that this system might mediate neuronal-glial interactions.",[],The American journal of pathology,1997-04-01,"[{'lastname': 'Xia', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Cambridge, USA.'}, {'lastname': 'Qin', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'McNamara', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Mackay', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Hyman', 'firstname': 'B T', 'initials': 'BT', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05dc3c0450>
225,8176406,Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease.,"The mechanisms by which human immunodeficiency virus (HIV) infection provokes progressive neurodegeneration and dementia in acquired immunodeficiency syndrome (AIDS) remain obscure. In HIV-infected (HIV+) individuals, we found that the brain cells preferentially infected by HIV, viz. the microglia, were abundant, activated, and intensely immunopositive for interleukin-1 alpha (IL-1 alpha), an immune response-generated cytokine that increases the synthesis and processing of beta-amyloid precursor proteins (beta-APP) and promotes proliferation and activation of astroglia. We also found an increase in the number of activated astroglia expressing elevated levels of S100 beta, a cytokine that increases intraneuronal calcium levels and promotes excessive growth of neuronal processes (neurites). These glial changes were accompanied by increased expression of beta-APP immunoreaction product in neurons and overgrown (dystrophic) neurites. In addition, some neurons contained monoclonal antibody Tau-2 immunopositive, neurofibrillary tangle-like structures. Our findings provide evidence that glial activation with increased expression of IL-1 alpha and S100 beta may be important in the neuropathogenesis of AIDS dementia. We propose that HIV infection promotes excessive microglial IL-1 alpha expression with consequent astrogliosis and increased expression of S100 beta. Overexpression of these two cytokines may then be involved in AIDS neuropathogenesis by inducing gliosis, growth of dystrophic neurites, and calcium-mediated neuronal cell loss in AIDS.",[],Journal of neuropathology and experimental neurology,1994-05-01,"[{'lastname': 'Stanley', 'firstname': 'L C', 'initials': 'LC', 'affiliation': 'Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.'}, {'lastname': 'Mrak', 'firstname': 'R E', 'initials': 'RE', 'affiliation': None}, {'lastname': 'Woody', 'firstname': 'R C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Perrot', 'firstname': 'L J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Marshak', 'firstname': 'D R', 'initials': 'DR', 'affiliation': None}, {'lastname': 'Nelson', 'firstname': 'S J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Griffin', 'firstname': 'W S', 'initials': 'WS', 'affiliation': None}]",,,,,10.1097/00005072-199405000-00003,<Element 'PubmedArticle' at 0x7f05dc3d0220>
226,"7522013
6791762
7295008
2806455
1679596
2347768
3399080
14188276
6625538
6117978
2251906
1685040
2675530
1684265
8337941
3221978
14281440
7194369
1669713
2500619
2097581
2579335
1644932
1686132
1963537
3041312
2117395
5877505
4131236
6418385
5689462
3289400
2540611
4925567
3112659
1669714
2550852
2239149
2750476
2405952
1690364
1744690
7368898
13171903
1684757
1557954
2808689
7198888
2082650
1414277
6360030
1557945
2551122
5099604
2082651
2477140
3604576
13992648
1739122
3562457
7038052
3470778
4925307
7195134
2249835
6171990
7445983
2160182",Transmissible cerebral amyloidoses as a model for Alzheimer's disease. An ultrastructural perspective.,"Alzheimer's disease, a prototypic nontransmissible cerebral amyloidosis, has no adequate experimental model. Several pathogenetic events, however, may be modeled and accurately studied in the transmissible cerebral amyloidoses of kuru, Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and scrapie. The common neuropathological denominator in both types of cerebral amyloidoses is the presence of stellate kuru plaques, senile plaques, and pure neuritic plaques. These amyloid plaques consist of amyloid fibers, dystrophic neurites, and reactive astrocytes in different proportions. Microglial cells, which are regarded as amyloid producer/processor cells in Alzheimer's disease, may play the same function in the transmissible cerebral amyloidoses. In both transmissible and nontransmissible amyloidoses, the impairment of axonal transport leads to accumulation of abnormally phosphorylated cytoskeleton proteins (such as neurofilament proteins and microtubule-associated protein tau), which eventually produce dystrophic neurites observed as parts of plaque or as isolated pathological structures.",[],Molecular neurobiology,1994-02-01,"[{'lastname': 'Liberski', 'firstname': 'P P', 'initials': 'PP', 'affiliation': 'Department of Oncology, Medical Academy Lodz, Poland.'}]",,,,,10.1007/BF02778009,<Element 'PubmedArticle' at 0x7f05dc3da770>
227,"1557959
2444063
14107684
2974227
4743882
4646725
1831952
6612148
2555999
2085097
6107328
3149122
4040308
2459498
419938
3408241
2400911
2853854
2082650
6682611
1713394
2553231
2596262
2609933
2447008
506687
2495152
2467503
3681409
3993325
929036",Immunohistochemical study of a case with progressive supranuclear palsy without ophthalmoplegia.,"A case of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome; PSP) with parkinsonism and absence of gaze palsy or mental changes is reported. Neuropathological examination, apart from typical changes, showed, lack of midbrain tegmentum demyelination, marked loss of Purkinje cells and presence of hyalin-like bodies in individual neurons of the substantia nigra. Immunostaining against tau-1 protein revealed the prevalence of a diffuse reaction in locus coeruleus neurons; reflecting either different ability of these cells to accumulate straight filaments, or a various time sequence of neurofibrillary tangles formation. Ferritin immunohistochemistry demonstrated widespread microglial cell proliferation, confirming further the generalized character of CNS pathology in PSP.",[],Acta neuropathologica,1992-01-01,"[{'lastname': 'Kida', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Neuropathology, Medical Research Centre, Polish Academy of Sciences, Warszawa.'}, {'lastname': 'Barcikowska', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Niemczewska', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,,10.1007/BF00296797,<Element 'PubmedArticle' at 0x7f05dc373900>
